



РЕПУБЛИКА БЪЛГАРИЯ

Национален център за  
информация и документация

класификация на информацията:  
ниво 1, TLP-GREEN



НАЦИД

Рег №: 94-05-61

Дата: 27.05.2024

## СПРАВКА

В резултат на извършеното издирване на цитиранията на публикациите на **Иво Спасов Петров** за периода **1995 - 2024 г.** са намерени общо **2805 бр.** цитирания.


Справката е изготвена от базите данни на WEB OF SCIENCE, SCOPUS и други бази данни.

**Приложение:** *Списък на цитирания на публикации*

**КРАСИМИРА ИЛИЕВА**

*Директор на дирекция*

*„Научно-техническа и педагогическа библиотека“*



**СПИСКЪ С ЦИТИРАНИЯ НА ПУБЛИКАЦИИТЕ  
НА ПРОФ. Д-Р ИВО ПЕТРОВ, ДМН.**

**2023**

Plinio CIRILLO, Luigi DI SERAFINO, Habib GAMRA, Marco ZIMARINO, Emanuele BARBATO, Carlo BRIGUORI, Ignatio J. AMAT-SANTOS, Alaide CHIEFFO, Andrejs ERGLIS, Robert J. GIL, Sasko A. KEDEV, **Ivo PETROV**, Francesco RADICO, Tullio NIGLIO, Sunao NAKAMURA, Ricardo A. COSTA, Vojko KANIC, Matteo PERFETTI, Mariano PELLICANO, Kristina MARIC, Tullio TESORIO, Vladan VUKCEVIC, Giovanni ESPOSITO, Goran STANKOVIC. Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry, Panminerva Medica, ISSN 0031-0808, 2023, 65(1), p. 1-12, DOI10.23736/S0031-0808.22.04604-3.

**Cited by:**

1. **Han, Y., Li, Y.** Techniques and Evidence for Percutaneous Coronary Intervention for Coronary Bifurcation Lesions: An Ongoing Journey. // *Cardiology Discovery*, 2, 2022, № 3, p. 131-133. ISSN 2096-952X. DOI 10.1097/CD9.0000000000000075.

Iris Q. Grunwald, Klaus Mathias, Stefan Bertog, Kenneth V. Snyder, Horst Sievert, Adnan Siddiqui, Piotr Musialek, Marius Hornung, Panagiotes Papanagiotou, Simone Comelli, Sanjay Pillai, Helen Routledge, Rafal T. Nizankowski, Ian Ewart, Klaus Fassbender, Anna L. Kühn, Carlos A. Alvarez, Bagrat Alekryan, Dmitry Skrypnik, Maria Politi, Lukasz Tekieli, Thomas Haldis, Shailesh Gaikwad, John Graeme Houston, Helen Donald-Simspon, Paul Guyler, **Ivo Petrov**, Christine Roffe, Mark Abelson, David Hargroves, Sunithi Mani, Anna Podlasek, Adam Witkowski, Kolja Sievert, Krzysztof Pawlowski, Artur Dziadkiewicz, Nelson L. Hopkins  
World Federation for Interventional Stroke Treatment (WIST) multispecialty training guidelines for endovascular stroke intervention, Cardiovascular Revascularization Medicine, ISSN 1553-8389, ISSN-L:1878-0938, 2023, 53, p. 67-72, DOI10.1016/j.carrev.2023.03.004.

**Cited by:**

2. **Cameron, A.** WIST guidelines: a global solution to increase interventional stroke treatment. // *Postepy w Kardiologii Interwencyjnej*, 19, 2023, № 1, p. 4-5. ISSN 1734-9338. DOI 10.5114/aic.2023.126403.
3. **Lenthall, R., Flynn, P., White, P.** World federation for interventional stroke treatment (WIST) multispecialty training guidelines for endovascular stroke intervention: UK neurointerventional group (UKNG) commentary. // *Clinical Radiology*, 78, 2023, № 11, p. 848-850. ISSN 0009-9260. DOI 10.1016/j.crad.2023.08.002.
4. **Mortimer, A.M., White, P., Lenthall, R.** Update on the Royal College of Radiologists sponsored credential Mechanical Thrombectomy for Acute Ischaemic Stroke: thoughts about implementation in an under-resourced environment. // *Clinical Radiology*, 78, 2023, № 11, p. 856-860. ISSN 0009-9260. DOI 10.1016/j.crad.2023.08.004.

5. **Rosenfield, K., Szolkiewicz, M., Alvarez Iorio, C.J., Kovac, J.** Making endovascular stroke treatment possible: training to save brains (and lives). // *Postepy w Kardiologii Interwencyjnej*, 19, 2023, № 1, p. 1-3. ISSN 1734-9338. DOI 10.5114/aic.2023.126461.

## **2022**

Ralf Langhoff, **Ivo Petrov**, Sasko Kedev, Zoran Milosevic, Andrej Schmidt, Dierk Scheinert, Joachim Schofer, Horst Sievert, Gerald Sedgewick, Elizabeth Saylors, Ravish Sachar, Alberto Cremonesi, Antonio Micar, PERFORMANCE 1 study: Novel carotid stent system with integrated post-dilation balloon and embolic protection device, *Catheter Cardiovasc Interv*, ISSN 1522--1946, 2022, 100(6), p. 1090-1099, DOI10.1002/ccd.30410.

### **Cited by:**

6. **Fioretti, V., Gerardi, D., Luzzi, G., Stabile, E.** Proximal versus distal protection: dissecting clinical trials. // *Minerva Cardiology and Angiology*, 70, 2022, № 6, p. 727-737. ISSN 2724-5683. DOI 10.23736/S2724-5683.22.06233-0.
7. **Wang, C., Han, J., Lu, L., Qiu, J., Fu, Y., Zheng, J.** The efficacy of different types of cerebral embolic protection device during transcatheter aortic valve implantation: a meta-analysis. // *Frontiers in Cardiovascular Medicine*, 11, 2024, art. no. 1205943. ISSN 2297-055X. DOI 10.3389/fcvm.2024.1205943.

Jeremie Abtan, Deepak L Bhatt, Yedid Elbez, Gregory Ducrocq, Shinya Goto, Sidney C Smith Jr, E Magnus Ohman, Kim A Eagle, Kim Fox, Robert A Harrington, Lawrence A Leiter, Shamir R Mehta, Tabassome Simon, **Ivo Petrov**, Peter R Sinnaeve, Prem Pais, Eli Lev, Héctor Bueno, Peter Wilson, Philippe Gabriel Steg, External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. *International Journal of Cardiology*, ISSN 0167-5273, 2023, Volume 370, p. 51-57, DOI10.1016/j.ijcard.2022.10.132.

### **Cited by:**

8. **Gupta, R., Mares, A.C.** REACHing conclusions on the external applicability of the THEMIS into clinical practice. // *International Journal of Cardiology*, 375, 2023, p. 9-11. ISSN 0167-5273. DOI 10.1016/j.ijcard.2022.12.050.

S. Vasilev, **I. Petrov**, Z. Stankov, L. Janevska, G. Adam, Infrared Thermography Imaging as a diagnostic tool in the case of acute lower limb ischemia, *Bulgarian Cardiology*, ISSN 1310-7488 (print), ISSN 2683-1015 (online), 2022, 28(3), p. 106-110, DOI 10.3897/bgcardio.28.e91048.

### **Cited by:**

9. **Childs, C., Nwaizu, H., Bullivant, E., Willmott, J., Davies, M., Ousey, K., Soltani, H., Jacques, R.** Cutaneous Perfusion Dynamics of the Lower Abdomen in Healthy Normal Weight, Overweight and Obese Women: Methods Development Using Infrared Thermography with Applications for Future Wound Management after Caesarean Section. // *International Journal of Environmental Research and Public Health*, 20, 2023, № 6, art. no. 5100. ISSN 1661-7827. DOI 10.3390/ijerph20065100.

Jannis Papathanasiou, **Ivo Petrov**, Yana Kashilska, Kosta Kostov, Nigyar Dzhafer, Is telerehabilitation a top priority for the Bulgarian healthcare system in the post COVID-19 era?, *Health Policy and Technology*, ISSN 2211-8837 (Print), ISSN 2211-8845 (Online), 2022 Dec, 11(4), 100664, p. 1-3, [https:// DOI.org/10.1016/j.hlpt.2022.100664](https://doi.org/10.1016/j.hlpt.2022.100664).

#### Cited by:

10. **Ndwabe, H., Basu, A., Mohammed, J.** Post pandemic analysis on comprehensive utilization of telehealth and telemedicine. // *Clinical eHealth*, 7, 2024, p. 5-14. ISSN 2588-9141. DOI 10.1016/j.ceh.2023.12.002.
11. **Stavrou, V.T., Vavougios, G.D., Kalogiannis, P., Tachoulas, K., Touloudi, E., Astara, K., Mysiris, D.S., Tsirimona, G., Papayianni, E., Boutlas, S., Hassandra, M., Daniil, Z., Theodorakis, Y., Gourgoulialis, K.I.** Breathlessness and exercise with virtual reality system in long-post-coronavirus disease 2019 patients. // *Frontiers in Public Health*, 11, 2023, art. no. 1115393. ISSN 2296-2565. DOI 10.3389/fpubh.2023.1115393.

WINDECKER, Stephan; LATIB, Azeem; KEDHI, Elvin; KIRTANE, Ajay J.; KANDZARI, David E.; MEHRAN, Roxana; PRICE, Matthew J.; ABIZAID, Alexandre FMUSP-HC; I, Daniel Simon; WORTHLEY, Stephen G.; ZAMAN, Azfar; HUDEC, Martin; POLIACIKOVA, Petra; GHAPAR, Abdul Kahar bin Abdul; SELVARAJ, Kamaraj; **PETROV, Ivo**; MYLOTTE, Darren; PINAR, Eduardo; MORENO, Raul; FABBIOCCHI, Franco; PASUPATI, Sanjeevan; KIM, Hyo-Soo; AMINIAN, Adel; TIE, Charles; WLODARCZAK, Adrian; HUR, Seung-Ho; MARX, Steven O.; ALI, Ziad A.; PARKE, Maria; LUNG, Te-Hsin; STONE, Gregg W., Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE, *JACC: Cardiovascular Interventions*, ISSN 1876--7605, 2022, Vol. 15, Iss. 11, p. 1153-1163. DOI 10.1016/j.jcin.2022.04.010.

#### Cited by:

12. **Baber, U.** Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. // *JACC: Cardiovascular Interventions*, 15, 2022, № 11, p. 1164-1166. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.04.043.
13. **Fluder-Wlodarczyk, J., Pawłowski, S., Chuchra, P.J., Pawłowski, T., Wojakowski, W., Gasior, P.** Importance of Short-Term Neointimal Coverage of Drug-Eluting Stents in the Duration of Dual Antiplatelet Therapy. // *Journal of Clinical Medicine*, 13, 2024, № 6, art. no. 1730. ISSN 2077-0383. DOI 10.3390/jcm13061730.



14. **Jurado-Román, A., Freixa, X., Cid-Álvarez, A.B., Cruz-González, I.** Selection of the best of 2022 in percutaneous coronary interventions. [Selección de lo mejor del año 2022 en intervencionismo coronario percutáneo]. // *REC: CardioClinics*, 58, 2023, p. S15-S20. ISSN 2605-1532. DOI 10.1016/j.rccl.2022.11.003.
15. **Lazar, F.-L., Onea, H.-L., Olinic, D.-M., Cortese, B.** A 2024 scientific update on the clinical performance of drug-coated balloons. // *AsiaIntervention*, 10, 2024, № 1, p. 15-25. ISSN 2426-3958. DOI 10.4244/AIJ-D-23-00010.
16. **Piccolo, R., Calabrò, P., Varricchio, A., Baldi, C., Napolitano, G., De Simone, C., Mauro, C., Stabile, E., Caiazzo, G., Tesorio, T., Boccalatte, M., Tuccillo, B., Bottiglieri, G., Russolillo, E., Di Lorenzo, E., Carrara, G., Cassese, S., Leonardi, S., Biscaglia, S., Costa, F., McFadden, E., Heg, D., Franzone, A., Stefanini, G.G., Capodanno, D., Esposito, G.** Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI. // *American Heart Journal*, 265, 2023, p. 153-160. ISSN 0002-8703. DOI 10.1016/j.ahj.2023.08.001.
17. **Saito, S., Bennett, J., Nef, H.M., Webster, M., Namiki, A., Takahashi, A., Kakuta, T., Yamazaki, S., Shibata, Y., Scott, D., Vrolix, M., Menon, M., Möllmann, H., Werner, N., Neylon, A., Mehmedbegovic, Z., Smits, P.C., Morice, M.-C., Verheye, S., BIOADAPTOR-RCT Collaborators.** First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT. // *eClinicalMedicine*, 65, 2023, art. no. 102304. ISSN 2589-5370. DOI 10.1016/j.eclinm.2023.102304.
18. **Tam, C.-C., Tse, H.-F.** Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. // *Journal of Clinical Medicine*, 11, 2022, № 24, art. no. 7440. ISSN 2077-0383. DOI 10.3390/jcm11247440.
19. **Zhang, J., Chen, Z., He, Y.** Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (TAILOR-BIRISK): Individualized Management and Genotype-Guided De-escalation. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 12, art. no. rcm2412343. ISSN 1530-6550. DOI 10.31083/j.rcm2412343.
20. **Zhang, J., He, S., Chen, Z., Li, Y., Guo, Y., He, Y.** The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk. // *Current Cardiology Reports*, 25, 2023, № 7, p. 669-680. ISSN 1523-3782. DOI 10.1007/s11886-023-01893-8.

**Ivo Petrov, Zoran Stankov, Georgi Dobrev, Petar Polomsk,** COVID-19 infection complicated with acute pulmonary embolism treated with percutaneous pulmonary artery thrombectomy: a case report. *European Heart Journal - Case Reports*, EISSN 2514-2119, 2022, Vol. 6, Iss. 7, p. 1-4, ytac227, Published 2022 Jun 10, DOI10.1093/ehjcr/ytac227.

**Cited by:**

21. **Casipit, B., Tito, S., Ogunmola, I., Idowu, A., Patil, S., Lo, K., Bozorgnia, B.** Outcomes among heart failure patients hospitalized for acute pulmonary embolism and COVID-19 infection: Insight from the National Inpatient Sample. // *Pulmonary Circulation*, 13, 2023, № 2, art. no. e12229. ISSN 2045-8932. DOI 10.1002/pul2.12229.
22. **Cote, O., Varma, S., Vakili, A., Wells, B.** Management and Prevention of Venous Thromboembolism in Patients with COVID-19. // *Current Treatment Options in Cardiovascular Medicine*, 25, 2023, № 10, p. 515-524. ISSN 1092-8464. DOI 10.1007/s11936-023-01008-0.

Jannis V. PAPATHANASIOU, Ivo PETROV, Dorothea TSEKOURA, Yannis DIONYSSIOTIS, Arthur S. FERREIRA, Agnaldo J. LOPES, Concetta LJOKA, Calogero FOTI, Does group-based high-intensity aerobic interval training improve the inflammatory status in patients with chronic heart failure?, *European Journal of Physical and Rehabilitation Medicine*, ISSN 1973-9087 (Print), ISSN 1973-9095 (Online), 2022, 58(2), p. 242-250, DOI10.23736/S1973-9087.21.06894-5.

#### Cited by:

23. **Milosevic, M., Dopsaj, M., Jourkesh, M., Milosevic, M., Seyhan, S.** Super High-Intensity Continuous Training: A New Approach to Aerobic Training with Huge Effects on Elite Team Handball Players. // *Journal of Science in Sport and Exercise*, 2023. ISSN 2096-6709. DOI 10.1007/s42978-023-00253-w.
24. **Pan, Y., Yang, H., Quan, L., Wang, S., Xu, Y., Chen, Y.** Effects of full-body exercise-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis protocol. // *BMJ Open*, 12, 2022, № 12, art. no. e064212. ISSN 2044-6055. DOI 10.1136/bmjopen-2022-064212.
25. **Taylor, A.G., Ignaszewski, A.I., Bredin, S.S.D., Hill, J.S., Shellington, E.M., Warburton, D.E.R.** High Intensity Interval Training Leads to Similar Inflammatory Activation as Seen With Traditional Training in Chronic Heart Failure. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 752531. ISSN 2297-055X. DOI 10.3389/fcvm.2021.752531.
26. **Xue, J., Zhang, Z., Sun, Y., Jin, D., Guo, L., Li, X., Zhao, D., Feng, X., Qi, W., Zhu, H.** Research Progress and Molecular Mechanisms of Endothelial Cells Inflammation in Vascular-Related Diseases. // *Journal of Inflammation Research*, 16, 2023, p. 3593-3617. ISSN 1178-7031. DOI 10.2147/JIR.S418166.

Robbert J. de Winter, Azfar Zaman, Hironori Hara, Chao Gao, Masafumi Ono, Scot Garg, Pieter C. Smits, Pim A.L. Tonino, Sjoerd H. Hofma, Raul Moreno, Anirban Choudhury, Ivo Petrov, Angel Cequier, Antonio Colombo, Upendra Kaul, Yoshinobu Onuma, Patrick W. Serruys, Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial, *EuroIntervention*, ISSN 1774-024X, ISSN 1969-6213 (Online), 2022, 18(6), p. 492-502, DOI10.4244/EIJ-D-21-00766.

#### Cited by:

27. **de Filippo, O., Bruno, F., Pinxterhuis, T.H., Gąsior, M., Perl, L., Gaido, L., Tuttolomondo, D., Greco, A., Verardi, R., Lo Martire, G., Iannaccone, M., Leone, A., Liccardo, G., Caglioni, S., González Ferreiro, R., Rodinò, G., Musumeci, G., Patti, G., Borzillo, I., Tarantini, G., Wańha, W., Casella, B., Ploumen, E.H., Pyka, Ł., Kornowski, R., Gagnor, A., Piccolo, R., Roubin, S.R., Capodanno, D., Zocca, P., Conrotto, F., De Ferrari, G.M., von Birgelen, C., D'Ascenzo, F., ULTRA Collaborators.** Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry. // *Catheterization and Cardiovascular Interventions*, 102, 2023, № 2, p. 221-232. ISSN 1522-1946. DOI 10.1002/ccd.30696.
28. **Hammami, R., Boughariou, A., Jdidi, J., Cheikhrouhou, A., Abdelmoula, Y., Thabet, H., Gribaa, R., Kacem, M., Mrad, I.B., Belkahla, N., Abdesslem, A.B., Ameur, Z.B., Hejri, E., Kraiem, S., Naffeti, I., Abid, L.** Immediate, medium- and long-term outcomes of percutaneous coronary intervention with very long drug eluting stent : An observational multicentric study. [Les résultats immédiats, à moyen et à long terme de l'angioplastie coronaire par stent actif très long : à propos d'une étude multicentrique observationnelle]. // *Annales de Cardiologie et d'Angéiologie*, 72, 2023, № 1, p. 8-15. ISSN 0003-3928. DOI 10.1016/j.ancard.2022.11.006.
29. **Han, Y., Wang, G., Li, Y., Zheng, M., Cao, R., Zhang, R., Chen, S., Wang, J., Ma, Y., Sun, Z., Li, X., Su, X., Lu, W., Xu, Y., Spitzer, E., Li, X., Sun, F.** Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 1, 2022, № 6, art. no. 100511. ISSN 2772-9303. DOI 10.1016/j.jscai.2022.100511.
30. **Leone, A., Simonetti, F., Avvedimento, M., Angellotti, D., Immobile Molaro, M., Franzone, A., Esposito, G., Piccolo, R.** Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1378. ISSN 2075-4426. DOI 10.3390/jpm12091378.
31. **Li, F., Wang, S., Wang, Y., Wei, C., Wang, Y., Liu, X., Sun, S., Zhao, W., Guo, P., Wu, X.** Long-term safety of ultrathin bioabsorbable-polymer sirolimus-eluting stents versus thin durable-polymer drug-eluting stents in acute coronary syndrome: A systematic review and meta-analysis. // *Clinical Cardiology*, 46, 2023, № 12, p. 1465-1473. ISSN 0160-9289. DOI 10.1002/clc.24139.
32. **Polavarapu, R.S., Pamidimukkala, V., Polavarapu, A., Siripuram, Y., Ravella, K.C., Rachaputi, M.B.R., Polavarapu, N., Pulivarthi, K.C., Byrapaneni, S., Gangasani, S., Noronha, M., Chinta, S.R.** Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents. // *Indian Heart Journal*, 75, 2023, № 4, p. 279-284. ISSN 0019-4832. DOI 10.1016/j.ihj.2023.03.006.

Jannis Papathanasiou, Yana Kashilska, Hristo Bozov, **Ivo Petrov**, Stefano Masiero, The outbreak of the SARS-CoV-2 Omicron variant make imperative the adoption of telerehabilitation in the Bulgarian health care system, *European Journal of Translational Myology*, ISSN 2037-7452(Print), ISSN 2037-7460 (Online), 2022, 32(1), 10355, p. 1-3, DOI10.4081/ejtm.2022.10355.

**Cited by:**

33. **Rochester, C.L.** Does Telemedicine Promote Physical Activity? // *Life*, 12, 2022, № 3, art. no. 425. ISSN 2075-1729. DOI 10.3390/life12030425.
34. **Stavrou, V.T., Vavougiou, G.D., Kalogiannis, P., Tachoulas, K., Touloudi, E., Astara, K., Mysiris, D.S., Tsirimona, G., Papayianni, E., Boutlas, S., Hassandra, M., Daniil, Z., Theodorakis, Y., Gourgoulialis, K.I.** Breathlessness and exercise with virtual reality system in long-post-coronavirus disease 2019 patients. // *Frontiers in Public Health*, 11, 2023, art. no. 1115393. ISSN 2296-2565. DOI 10.3389/fpubh.2023.1115393.
35. **Tsekoura, M., Fousekis, K., Billis, E., Dionyssiotis, Y., Tsepis, E.** Cross-cultural adaptation of the Greek version of post-COVID-19 Functional Status Scale: assessment of non-hospitalised post-COVID-19 survivors. // *European Journal of Translational Myology*, 33, 2023, № 2, art. no. 11328. ISSN 2037-7452. DOI 10.4081/ejtm.2023.11328.
36. **Valverde-Martínez, M.Á., López-Liria, R., Martínez-Cal, J., Benzo-Iglesias, M.J., Torres-Álamo, L., Rocamora-Pérez, P.** Telerehabilitation, A Viable Option in Patients with Persistent Post-COVID Syndrome: A Systematic Review. // *Healthcare (Switzerland)*, 11, 2023, № 2, art. no. 187. ISSN 2227-9032. DOI 10.3390/healthcare11020187.
37. **Zhong, W., Jiang, X., Yang, X., Feng, T., Duan, Z., Wang, W., Sun, Z., Chen, L., Nie, X., Zhu, C., Zhang, W., Li, Y.** The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial. // *Frontiers in Medicine*, 9, 2022, art. no. 980002. ISSN 2296-858X. DOI 10.3389/fmed.2022.980002.

Garyfallia Pepera, Marina-Sofia Tribali, Ladislav Batalik, **Ivo Petrov**, Jannis Papathanasiou, Epidemiology, risk factors and prognosis of cardiovascular disease in the Coronavirus Disease 2019 (COVID-19) pandemic era: a systematic review, *Reviews in Cardiovascular Medicine*, Print ISSN 1530--6550, Electronic ISSN 2153--8174, 2022, 23(1), 028, p. 1-9, DOI10.31083/j.rcm2301028

**Cited by:**

38. **Argyriadis, A., Vlachou, C., Argyriadi, A.** Quality of life for cardiovascular patients: Promoting health at home. // *Review of Clinical Pharmacology and Pharmacokinetics, International Edition*, 37, 2023, № 2, p. 75-81. ISSN 1011-6583. DOI 10.5281/zenodo.8402443.
39. **Baddah, W., Qasem, H.A., Alsabry, A., Hussein Obaid, A.M., Abdo Mohammed, A., Hanash, F.E.** Predicting Heart Disease Using Machine Learning Techniques on Electronic Health Records Data. – In: *2023 3rd International Conference on Emerging Smart Technologies and Applications, eSmarTA 2023*. ISBN 9798350305333. DOI 10.1109/eSmarTA59349.2023.10293622.

40. **Boriani, G., Imberti, J.F., Leyva, F., Casado-Arroyo, R., Chun, J., Braunschweig, F., Zylla, M.M., Duncker, D., Farkowski, M.M., Pürerfellner, H., Merino, J.L.** Length of hospital stay for elective electrophysiological procedures: a survey from the European Heart Rhythm Association. // *Europace*, 25, 2023, № 10. ISSN 1099-5129. DOI 10.1093/europace/euad297.
41. **de Almeida, J.C., Paiva, N.S., Gibson, G., Bastos, L.S., Medronho, R.A., Bloch, K.V.** Registration with Primary Health Care and COVID-19 mortality: cohort of diabetics from five administrative health regions in the city of Rio de Janeiro, Brazil, 2020–2021. [Cadastro na Atenção Primária e mortalidade por COVID-19: coorte de diabéticos de cinco regiões administrativas de saúde do município do Rio de Janeiro, 2020–2021]. // *Revista Brasileira de Epidemiologia*, 26, 2023, art. no. e230039. ISSN 1415-790X. DOI 10.1590/1980-549720230039.
42. **Del Valle, M.F., Valenzuela, J., Marzuca-Nassr, G.N., Cabrera-Inostroza, C., Del Sol, M., Lizana, P.A., Escobar-Cabello, M., Muñoz-Cofre, R.** Eight Weeks of Supervised Pulmonary Rehabilitation Are Effective in Improving Resting Heart Rate and Heart Rate Recovery in Severe COVID-19 Patient Survivors of Mechanical Ventilation. // *Medicina (Lithuania)*, 58, 2022, № 4, art. no. 514. ISSN 1010-660X. DOI 10.3390/medicina58040514.
43. **Denton, F., Waddell, A., Kite, C., Hesketh, K., Atkinson, L., Cocks, M., Jones, H., Randeva, H., Davenport, N., Powell, R., Clark, C., Kyrou, I., Harwood, A.E., McGregor, G.** Remote maintenance cardiac rehabilitation (MAINTAIN): A protocol for a randomised feasibility study. // *Digital Health*, 9, 2023. ISSN 2055-2076. DOI 10.1177/20552076231152176.
44. **DeSouza, A., Wang, D., Wong, J.J., Furlan, A.D., Hogg-Johnson, S., Macedo, L., Mior, S., Côté, P.** Prevalence of Unmet Rehabilitation Needs Among Canadians Living With Long-term Conditions or Disabilities During the First Wave of the COVID-19 Pandemic. // *Archives of Physical Medicine and Rehabilitation*, 105, 2024, № 2, p. 268-279. ISSN 0003-9993. DOI 10.1016/j.apmr.2023.07.010.
45. **Domnicu, A., Mogoi, M., Manea, A., Boia, E.R., Boia, M.** Clinical Factors Associated with COVID-19 Severity in Chronic Hospitalized Infants and Toddlers: Data from a Center in the West Part of Romania. // *Healthcare (Switzerland)*, 10, 2022, № 5, art. no. 808. ISSN 2227-9032. DOI 10.3390/healthcare10050808.
46. **Gao, Y., Wang, N., Zhang, L., Liu, N.** Effectiveness of home-based cardiac telerehabilitation in patients with heart failure: A systematic review and meta-analysis of randomised controlled trials. // *Journal of Clinical Nursing*, 32, 2023, № 21/22, p. 7661-7676. ISSN 0962-1067. DOI 10.1111/jocn.16726.
47. **Grundler, F., Mesnage, R., Cerrada, A., Wilhelmi de Toledo, F.** Improvements during long-term fasting in patients with long COVID – a case series and literature review. // *Frontiers in Nutrition*, 10, 2023, art. no. 1195270. ISSN 2296-861X. DOI 10.3389/fnut.2023.1195270.
48. **Haji-Jafari, S., Tafti, S.H.A., Azizi-Fini, I., Rezaei, M., Atoof, F.** The Effect of Rewarming on the Cognitive Status of Patients After Open-heart Surgery: A Randomized Clinical Trial. // *Journal of Client-Centered Nursing Care*, 9, 2023, № 1, p. 25-34. ISSN 2476-4124. DOI 10.32598/JCCNC.9.1.305.5.



49. **Hammer, P., Tari, A.R., Franklin, B.A., Wen, C.-P., Wisløff, U., Nauman, J.** Personal Activity Intelligence and Ischemic Heart Disease in a Healthy Population: China Kadoorie Biobank Study. // *Journal of Clinical Medicine*, 11, 2022, № 21, art. no. 6552. ISSN 2077-0383. DOI 10.3390/jcm11216552.
50. **Hogberg, H.T., Lam, A., Ohayon, E., Shahbaz, M.A., Clerbaux, L.-A., Bal-Price, A., Coecke, S., Concha, R., De Bernardi, F., Edrosa, E., Hargreaves, A.J., Kanninen, K.M., Munoz, A., Pistollato, F., Saravanan, S., Garcia-Reyero, N., Wittwehr, C., Sachana, M.** The Adverse Outcome Pathway Framework Applied to Neurological Symptoms of COVID-19. // *Cells*, 11, 2022, № 21, art. no. 3411. ISSN 2073-4409. DOI 10.3390/cells11213411.
51. **Ishwarya, K., Arunadevi, R., Nandhini, G., Gurumoorthy, S., Abinaya, K.** Corona Virus Chest CT Scan Classification Using Deep Learning. – In: *International Conference on Applied Intelligence and Sustainable Computing, ICAISC 2023*. DOI 10.1109/ICAISC58445.2023.10199981. ISBN 9798350323795.
52. **Kaihara, T., Hansen, D., Sankaran, S., Scherrenberg, M., Falter, M., Xu, L., Coninx, K., Dendale, P.** Do we need to rethink the determination of exercise-related energy expenditure in cardiac telerehabilitation interventions? // *Journal of Telemedicine and Telecare*, 2023. ISSN 1357-633X. DOI: 10.1177/1357633X231166159.
53. **Karadavut, S., Cetin, M., Sahin, O.** The effect of COVID-19 on the thromboembolic outcomes in atrial fibrillation patients in the long run. // *Acta Cardiologica*, 2023. ISSN 0001-5385. DOI 10.1080/00015385.2023.2286421.
54. **Kemerley, A., Gupta, A., Thirunavukkarasu, M., Maloney, M., Burgwardt, S., Maulik, N.** COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19. // *Current Issues in Molecular Biology*, 46, 2024, № 3, p. 1904-1920. ISSN 1467-3037. DOI 10.3390/cimb46030124.
55. **Lee, K.C.S., Breznen, B., Ukhova, A., Koehler, F., Martin, S.S.** Virtual healthcare solutions for cardiac rehabilitation: a literature review. // *European Heart Journal - Digital Health*, 4, 2023, № 2, p. 99-111. ISSN 2634-3916. DOI 10.1093/ehjdh/ztad005.
56. **Liu, J., Li, C., Mei, W., Qin, H.** The research progress and research trends in acute coronary syndrome nursing: A review of visual analysis based on the Web of Science database. // *Medicine (United States)*, 103, 2024, № 7, p. E35849. ISSN 0025-7974. DOI 10.1097/MD.00000000000035849.
57. **Lushington, G.H., Linde, A., Melgarejo, T.** Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog. // *BioTech*, 12, 2023, № 4, art. no. 61. ISSN 2673-6284. DOI 10.3390/biotech12040061.
58. **Maulana, S., Trisyani, Y., Mirwanti, R., Amirah, S., Kohar, K., Priyatmoko Putri, A.I., Novianti, E.** The Potential of Cardiac Telerehabilitation as Delivery Rehabilitation Care Model in Heart Failure during COVID-19 and Transmissible Disease Outbreak: A Systematic Scoping Review of the Latest RCTs. // *Medicina (Lithuania)*, 58, 2022, № 10, art. no. 1321. ISSN 1010-660X. DOI 10.3390/medicina58101321.



59. **Mirmira, R.G., Kulkarni, R.N., Xu, P., Drossos, T., Varady, K., Knutson, K.L., Reutrakul, S., Martyn-Nemeth, P., Sargis, R.M., Wallia, A., Tuchman, A.M., Weissberg-Benchell, J., Danielson, K.K., Oakes, S.A., Thomas, C.C., Layden, B.T., May, S.C., Burbea Hoffmann, M., Gatta, E., Solway, J., Philipson, L.H.** Stress and human health in diabetes: A report from the 19th Chicago Biomedical Consortium symposium. // *Journal of Clinical and Translational Science*, 7, 2023, № 1, art. no. e263. ISSN 2059-8661. DOI 10.1017/cts.2023.646.
60. **Mousa, S.I., Nyberg, F., Hajiebrahimi, M., Bertilsson, R., Nåtman, J., Santosa, A., Wettermark, B.** Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden. // *Basic and Clinical Pharmacology and Toxicology*, 131, 2022, № 3, p. 196-204. ISSN 1742-7835. DOI 10.1111/bcpt.13766.
61. **Mugnai, G., Ferrero, V., Tomasi, L., Bolzan, B., Vassanelli, F., Ribichini, F.L.** The implementation of telemedicine in the follow-up after catheter ablation of arrhythmias: Do we still need in-office consultations? // *Journal of Cardiovascular Medicine*, 24, 2023, № 11, p. 790-792. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001545.
62. **Orlando, L., Bagnato, G., Ioppolo, C., Franzè, M.S., Perticone, M., Versace, A.G., Sciacqua, A., Russo, V., Cicero, A.F.G., De Gaetano, A., Dattilo, G., Fogacci, F., Tringali, M.C., Di Micco, P., Squadrito, G., Imbalzano, E.** Natural Course of COVID-19 and Independent Predictors of Mortality. // *Biomedicines*, 11, 2023, № 3, art. no. 939. ISSN 2227-9059. DOI 10.3390/biomedicines11030939.
63. **Razmy, A.M., Rahman, A.L.F., Lazarus, E.R., Rajab, T.R., Ilahi, M.M.M.** Risk of COVID-19 among patients with respiratory illnesses and comorbidities at Eastern Province of Sri Lanka: A retrospective study. // *International Journal of Nutrition, Pharmacology, Neurological Diseases*, 14, 2024, № 1, p. 43-51. ISSN 2231-0738. DOI 10.4103/ijnpnd.ijnpnd\_73\_23.
64. **Samokhina, L.M., Rudyk, Iu.S.** Features of heart failure in patients who have contracted a coronavirus infection. // *Fiziologichnyi Zhurnal*, 68, 2022, № 6, p. 90-99. ISSN 2522-9028. DOI 10.15407/fz68.06.090.
65. **Tian, P., Liu, Y., Wang, J., Xing, L., Liu, P.** Psycho-Cardiological Disease in COVID-19 Era. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 8, art. no. 239. ISSN 1530-6550. DOI 10.31083/j.rcm2408239.
66. **Ukolova, E., Burcin, B.** What can multiple causes of death tell about cardiovascular mortality during COVID-19 pandemic in the United States? // *Journal of Public Health (United Kingdom)*, 46, 2024, № 1, p. 97-106. ISSN 1741-3842. DOI 10.1093/pubmed/fdad278.
67. **Wada, H., Shiraki, K., Shimpo, H., Shimaoka, M., Iba, T., Suzuki-Inoue, K.** Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019. // *International Journal of Molecular Sciences*, 24, 2023, № 9, art. no. 7975. ISSN 1661-6596. DOI 10.3390/ijms24097975.

68. **Warren-Gash, C., Davidson, J.A., Strongman, H., Herrett, E., Smeeth, L., Breuer, J., Banerjee, A.** Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. // *The Lancet Regional Health - Europe*, 27, 2023, art. no. 100604. ISSN 2666-7762. DOI 10.1016/j.lanepe.2023.100604.
69. **Xanthopoulos, A., Bourazana, A., Giamouzis, G., Skoularigki, E., Dimos, A., Zagouras, A., Papamichalis, M., Leventis, I., Magouliotis, D.E., Triposkiadis, F., Skoularigis, J.** COVID-19 and the heart. // *World Journal of Clinical Cases*, 10, 2022, № 28, p. 9970-9984. ISSN 2307-8960. DOI 10.12998/wjcc.v10.i28.9970.
70. **Yang, M.L., Wang, J.Y., Zong, X.Y., Guan, L., Li, H.Z., Xiong, Y.B., Liu, Y.Q., Li, T., Ji, X.Y., Shang, X.Y., Zhang, H.F., Guo, Y., Gong, Z.Y., Zhang, L., Tong, L., Chen, R.B., Fan, Y.P., Qin, J., Wang, F., Lin, G., Shi, N.N., Wang, Y.P., Ma, Y.** Treatment Outcomes in COVID-19 Patients with Brucellosis: Case Series in Heilongjiang and Systematic Review of Literature. // *Biomedical and Environmental Sciences*, 36, 2023, № 10, p. 930-939. ISSN 0895-3988. DOI 10.3967/bes2023.035.
71. **Zuin, M., Malagù, M., Vitali, F., De Raffe, M., Balla, C., Bertini, M.** Trends in age- and sex-specific atrial fibrillation/flutter mortality in Italy between 2003 and 2017. // *Journal of Cardiovascular Medicine*, 24, 2023, № 9, p. 604-611. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001519.

## **2021**

**Petrov, I., Stankov, Z., Boychev, D., (2021).** Valve cracking before valve-in-valve transcatheter aortic valve implantation to treat severe paravalvular leak. *J Am Coll Cardiol Case Rep.*, ahead of print, available on print June 2021, DOI 10.1016/j.jaccas.2020.12.042.

## **Cited by:**

72. **Dvir, D., Harari, E.** Expanding Bioprosthetic Ring Fracture Indications: Cracking the Walls Will Tear the House Down? // *JACC: Case Reports*, 3, 2021, № 6, p. 882-883. ISSN 2666-0849. DOI 10.1016/j.jaccas.2021.03.022.

**Ivo Petrov, Zoran Stankov, Damyan Boychev, Valentin Balabanski, Marko Klissurski (2021)** Basilar Artery Occlusion. Clinical Evaluation and Contemporary Methods of Treatment. *J. Clinical Cardiology and Cardiovascular Interventions*, 4(1); DOI 10.31579/2641-0419/117 Valgimigli, M.; Mehran, R.; Franzone, A.; da Costa, B. R.; Baber, U.; Piccolo, R.; McFadden, E. P.; Vranckx, P.; Angiolillo, D. J.; Leonardi, S.; Cao, D.; Dangas, G. D.; Mehta, S. R.; Serruys, P. W.; Gibson, C. M.; Steg, G. P.; Sharma, S. K.; Hamm, C.; Shlofmitz, R.; Liebetrau, C.; Briguori, C.; Janssens, L.; Huber, K.; Ferrario, M.; Kunadian, V.; Cohen, D. J.; Zurakowski, A.; Oldroyd, K. G.; Yaling, H.; Dudek, D.; Sartori, S.; Kirkham, B.; Escaned, J.; Heg, D.; Windecker, S.; Pocock, S.; Jüni, P.; Serruys, P.; Mehta, S.; Gibson, M. C.; Kastrati, A.; Krucoff, M.; Ohman, M. E.; Gurbel, P.; Henry, T. D.; Moliterno, D.; Heg, D.; McFadden, E.; Marx, S. O.; Darrow, B.; Corvaja, N.; DeStefano, D.; Ghodsi, N.; Meller, J.; Franklin-Bond, T.; Cha, J. Y.; Waseem, Z.; Weisz, G.; Kornowski, R.; Oldroyd, K.; Kaul, U.; Witenbichler, B.; Dzavik, V.; Gil, R.; Sardella, G.; Benit, E.; Diletti, R.; Dominici, M.; Slagboom, T.; Buszman, P.; Bolognese, L.; Tumscitz, C.; Bryniarski, K.; Aminian, A.; Vrolix, M.; **Petrov, I.**; Garg, S.; Naber, C.; Prokopcuk, J.; Steg, P. G., Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. *JACC: Cardiovascular Interventions* 2021, 14 (4), 444-456.

**Cited by:**

73. **Condello, F., Sturla, M., Terzi, R., Polimeni, A., Stefanini, G.G.** Walking the line with ticagrelor: Meta-analysis comparing the safety and efficacy of ticagrelor monotherapy after a short course of ticagrelor-based dual antiplatelet therapy versus standard therapy in complex percutaneous coronary intervention. // *Journal of Clinical Medicine*, 10, 2021, № 23, art. no. 5506. ISSN 2077-0383. DOI 10.3390/jcm10235506.
74. **Landi, A., Caglioni, S., Valgimigli, M.** De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options. // *European Journal of Internal Medicine*, 110, 2023, p. 16-18. ISSN 0953-6205. DOI 10.1016/j.ejim.2023.02.006.
75. **Landi, A., Valgimigli, M.** Antithrombotic therapy in patients with established atherosclerotic coronary disease. // *Heart*, 109, 2023, № 13, p. 1034-1043. ISSN 1355-6037. DOI 10.1136/heartjnl-2022-321603.
76. **Leonardi, G.R., Lescano, C.H., Costa, J.L., Mazetto, B., Orsi, F.A., Monica, F.Z.** Adenosine diphosphate-induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t-PAPS): Role of P2Y12-cAMP signaling pathway. // *Journal of Thrombosis and Haemostasis*, 20, 2022, № 7, p. 1699-1711. ISSN 1538-7933. DOI 10.1111/jth.15724.
77. **Meskauskaitė, U., Andruskeviciute, S., Ciapiene, I., Giedraitiene, A., Lesauskaite, V., Tatarunas, V.** Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival. // *Drug Design, Development and Therapy*, 16, 2022, p. 2559-2568. ISSN 1177-8881. DOI 10.2147/DDDT.S357985.
78. **Obayashi, Y., Watanabe, H., Morimoto, T., Yamamoto, K., Natsuaki, M., Domei, T., Yamaji, K., Suwa, S., Isawa, T., Watanabe, H., Yoshida, R., Sakamoto, H., Akao, M., Hata, Y., Morishima, I., Tokuyama, H., Yagi, M., Suzuki, H., Wakabayashi, K., Suematsu, N., Inada, T., Tamura, T., Okayama, H., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., STOPDAPT-2 and STOPDAPT-2 ACS Investigators.** Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. // *Circulation: Cardiovascular Interventions*, 15, 2022, № 8, p. E012004. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.122.012004.
79. **Rezek, M., Moravcová, H.** Ticagrelor monotherapy after percutaneous coronary intervention in comparison with dual-antiplatelet therapy. [Monoterapie ticagrelorem po perkutánní koronární intervenci v porovnání s duální protidestičkovou léčbou]. // *Intervenci a Akutní Kardiologie*, 21, 2022, № 1, p. 35-40. ISSN 1213-807X. DOI 10.36290/KAR.2022.001.
80. **Shoji, S., Kuno, T., Ueyama, H., Takagi, H., Briasoulis, A., Kim, H.-S., Koo, B.-K., Kang, J., Watanabe, H., Kimura, T., Kohsaka, S.** Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials. // *Journal of Cardiology*, 83, 2024, № 5, p. 338-347. ISSN 0914-5087. DOI 10.1016/j.jjcc.2023.08.001.

81. **Sibbing, D., Cassese, S.** Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 457-460. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.039.
82. **Tsigkas, G., Apostolos, A., Trigka, A., Chlorogiannis, D., Katsanos, K., Toutouzias, K., Alexopoulos, D., Brilakis, E.S., Davlouros, P.** Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis. // *American Journal of Cardiovascular Drugs*, 23, 2023, № 1, p. 35-46. ISSN 1175-3277. DOI 10.1007/s40256-022-00559-0.
83. **Voudris, K.V., Feldman, D.N.** Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. // *Current Treatment Options in Cardiovascular Medicine*, 25, 2023, № 5, p. 127-141. ISSN 1092-8464. DOI 10.1007/s11936-023-00981-w.
84. **Wang, H., Xie, X., Zu, Q., Lu, M., Chen, R., Yang, Z., Gao, Y., Tang, Z.** Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis. // *Diabetes Therapy*, 14, 2023, № 1, p. 47-61. ISSN 1869-6953. DOI 10.1007/s13300-022-01350-9.
85. **Xiang, F., Lin, Y., Chen, B.** Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials. // *Perfusion (United Kingdom)*, 38, 2023, № 4, p. 698-705. ISSN 0267-6591. DOI 10.1177/02676591221076284.
86. **Yamamoto, K., Watanabe, H., Morimoto, T., Obayashi, Y., Natsuaki, M., Domei, T., Yamaji, K., Suwa, S., Isawa, T., Watanabe, H., Yoshida, R., Sakamoto, H., Akao, M., Hata, Y., Morishima, I., Tokuyama, H., Yagi, M., Suzuki, H., Wakabayashi, K., Suematsu, N., Inada, T., Tamura, T., Okayama, H., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., STOPDAPT-2 and STOPDAPT-2 ACS Investigators.** Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. // *JACC: Asia*, 3, 2023, № 1, p. 31-46. ISSN 2772-3747. DOI 10.1016/j.jacasi.2022.09.011.

Gao C, Kogame N, Sharif F, Smits PC, Tonino P, Hofma S, Moreno R, Choudhury A, **Petrov I**, Cequier A, Colombo A, Kaul U, Zaman A, de Winter RJ, Onuma Y, Serruys PW. Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex: Two-Year Outcomes of the TALENT Trial. *Circ Cardiovasc Interv*. 2021 Mar;14(3):e010312. DOI 10.1161/CIRCINTERVENTIONS.120.010312. Epub 2021 Mar 9. PMID: 33685213.

#### Cited by:

87. **Ahmad, Y., Howard, J.P., Madhavan, M.V., Bangalore, S., Stone, G.W.** Reporting data from meta-analysis: snapshot of a moving target. // *European Heart Journal*, 43, 2022, № 7, p. 699-700. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab681.
88. **Berry, C.** Meta-analyses of moving targets. // *European Heart Journal*, 42, 2021, № 27, p. 2655-2656. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab359.

89. **Grundeken, M.J., Beijk, M.A.M.** A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? // *Heart International*, 15, 2021, № 2. ISSN 1826-1868.
90. **Leone, A., Simonetti, F., Avvedimento, M., Angellotti, D., Immobile Molaro, M., Franzone, A., Esposito, G., Piccolo, R.** Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1378. ISSN 2075-4426. DOI 10.3390/jpm12091378.
91. **Madhavan, M.V., Howard, J.P., Naqvi, A., Ben-Yehuda, O., Redfors, B., Prasad, M., Shahim, B., Leon, M.B., Bangalore, S., Stone, G.W., Ahmad, Y.** Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: A systematic review and meta-analysis of randomized controlled trials. // *European Heart Journal*, 42, 2021, № 27, p. 2643-2654. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab280.
92. **Sinha, S.K., Kumar, P., Pandey, U., Aggarwal, P., Razi, M., Sharma, A.K., Jha, M., Sachan, M., Shukla, P., Thakur, R., Krishna, V., Mukherjee, P., Karmakar, S., Bhattacharjee, P., Ray, S.** Twelve-month clinical outcomes of “nano-crush technique” for the treatment of bifurcation lesions using ultra-thin (60 µm) sirolimus-eluting coronary stents. // *Minerva Cardiology and Angiology*, 71, 2023, № 1, p. 51-60. ISSN 2724-5683. DOI 10.23736/S2724-5683.21.05875-0.

Leonardi S, Branca M, Franzone A, McFadden E, Piccolo R, Jüni P, Vranckx P, Steg PG, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, **Petrov I**, Garg S, Naber C, Prokopczuk J, Hamm C, Heg D, Windecker S, Valgimigli M. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. *Circ Cardiovasc Qual Outcomes*. 2021 Feb;14(2):e006581. DOI 10.1161/CIRCOUTCOMES.120.006581. Epub 2021 Feb 4. PMID: 33535773.

#### Cited by:

93. **Dhruva, S.S.** GLASS(Y) Half-Full: Moving Towards Greater Pragmatism in Outcome Ascertainment for Clinical Trials. // *Circulation: Cardiovascular Quality and Outcomes*, 14, 2021, № 2, p. E007690. ISSN 1941-7713. DOI 10.1161/CIRCOUTCOMES.120.007690.
94. **Guo, Q., Feng, X., Zhang, B., Zhai, G., Yang, J., Liu, Y., Liu, Y., Shi, D., Zhou, Y.** Influence of the Triglyceride-Glucose Index on Adverse Cardiovascular and Cerebrovascular Events in Prediabetic Patients With Acute Coronary Syndrome. // *Frontiers in Endocrinology*, 13, 2022, art. no. 843072. ISSN 1664-2392. DOI 10.3389/fendo.2022.843072.
95. **Ma, Y., Tian, T., Wang, T., Wang, J., Guan, H., Yuan, J., Song, L., Yang, W., Qiao, S.** Predictive Value of Plasma Big Endothelin-1 in Adverse Events of Patients With Coronary Artery Restenosis and Diabetes Mellitus: Beyond Traditional and Angiographic Risk Factors. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 854107. ISSN 2297-055X. DOI 10.3389/fcvm.2022.854107.



96. **Marx, C.E., Schenker, C., Xu, Y., Salvatore, S.P., Kahn, S.R., Garcia, D., Delluc, A., Kraaijpoel, N., Langlois, N., Girard, P., Le Gal, G., Tritschler, T.** Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort. // *Journal of Thrombosis and Haemostasis*, 21, 2023, № 10, p. 2908-2912. ISSN 1538-7933. DOI 10.1016/j.jtha.2023.07.015.
97. **Spirito, A., Sticchi, A., Praz, F., Gräni, C., Messerli, F., Siontis, G.C.** Impact of design characteristics among studies comparing coronary computed tomography angiography to noninvasive functional testing in chronic coronary syndromes. // *American Heart Journal*, 256, 2023, p. 104-116. ISSN 0002-8703. DOI 10.1016/j.ahj.2022.10.087.
98. **Sun, M., Cui, W., Li, L.** Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 818215. ISSN 2297-055X. DOI 10.3389/fcvm.2021.818215.

Klissurski, M., **Petrov, I.**, Tasheva, I., Penev, L., & Grozdinski, L. (2021). A rare case of non-conventional risk factors for ischemic stroke: A long pathogenic sequence, neurointervention combined with IV acetylsalicylic acid and secondary prevention. *Interdisciplinary Neurosurgery*, 23, 100909. DOI 10.1016/j.inat.2020.100909

**Petrov, I.**, Postadzhian, A., Vasilev, D., Kasabov, R., Tokmakova, M., & Nikolov, F. et al. (2021). Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation. *Advances In Therapy*. DOI 10.1007/s12325-020-01608-3.

#### Cited by:

99. **Al-Alawy, K., Sayegh, K.A., Moonesar, I.A.** Optimizing interventional cardiology services. // *Future Cardiology*, 19, 2023, № 14, p. 695-705. ISSN 1479-6678. DOI 10.2217/fca-2023-0053.
100. **Griffith, N., Bigham, G., Sajja, A., Gluckman, T.J.** Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients. // *Current Cardiology Reports*, 24, 2022, № 10, p. 1387-1396. ISSN 1523-3782. DOI 10.1007/s11886-022-01767-5.
101. **Jones, L.K., Walters, N., Brangan, A., Ahmed, C.D., Gatusky, M., Campbell-Salome, G., Ladd, I.G., Sheldon, A., Gidding, S.S., McGowan, M.P., Rahm, A.K., Sturm, A.C.** Acceptability, appropriateness, and feasibility of automated screening approaches and family communication methods for identification of familial hypercholesterolemia: Stakeholder engagement results from the impact-fh study. // *Journal of Personalized Medicine*, 11, 2021, № 6, art. no. 587. ISSN 2075-4426. DOI 10.3390/jpm11060587.
102. **Persson Lindell, O., Karlsson, L.O., Nilsson, S., Charitakis, E., Hagström, E., Muhr, T., Nilsson, L., Henriksson, M., Janzon, M.** Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care. // *American Heart Journal*, 247, 2022, p. 132-148. ISSN 0002-8703. DOI 10.1016/j.ahj.2022.02.005.



Gao, C.; Kogame, N.; Sharif, F.; Smits, P. C.; Tonino, P.; Hofma, S.; Moreno, R.; Choudhury, A.; **Petrov, I.**; Cequier, A.; Colombo, A.; Kaul, U.; Zaman, A.; de Winter, R. J.; Onuma, Y.; Serruys, P. W., Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex. *Circulation: Cardiovascular Interventions* 2021, 14 (3), e010312.

**Cited by:**

103. **Ahmad, Y., Howard, J.P., Madhavan, M.V., Bangalore, S., Stone, G.W.** Reporting data from meta-analysis: snapshot of a moving target. // *European Heart Journal*, 43, 2022, № 7, p. 699-700. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab681.
104. **Berry, C.** Meta-analyses of moving targets. // *European Heart Journal*, 42, 2021, № 27, p. 2655-2656. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab359.
105. **Grundeken, M.J., Beijk, M.A.M.** A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? // *Heart International*, 15, 2021, № 2. ISSN 1826-1868.
106. **Leone, A., Simonetti, F., Avvedimento, M., Angellotti, D., Immobile Molaro, M., Franzone, A., Esposito, G., Piccolo, R.** Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1378. ISSN 2075-4426. DOI 10.3390/jpm12091378.
107. **Madhavan, M.V., Howard, J.P., Naqvi, A., Ben-Yehuda, O., Redfors, B., Prasad, M., Shahim, B., Leon, M.B., Bangalore, S., Stone, G.W., Ahmad, Y.** Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: A systematic review and meta-analysis of randomized controlled trials. // *European Heart Journal*, 42, 2021, № 27, p. 2643-2654. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab280.
108. **Sinha, S.K., Kumar, P., Pandey, U., Aggarwal, P., Razi, M., Sharma, A.K., Jha, M., Sachan, M., Shukla, P., Thakur, R., Krishna, V., Mukherjee, P., Karmakar, S., Bhattacharjee, P., Ray, S.** Twelve-month clinical outcomes of “nano-crush technique” for the treatment of bifurcation lesions using ultra-thin (60 µm) sirolimus-eluting coronary stents. // *Minerva Cardiology and Angiology*, 71, 2023, № 1, p. 51-60. ISSN 2724-5683. DOI 10.23736/S2724-5683.21.05875-0.

**Petrov I,** Stankov Z, Boychev D, Klissurski M. Use of coronary stent grafts for the treatment of high-flow carotid cavernous fistula. *BMJ Case Rep.* 2021;14(11):e245922. Published 2021 Nov 11. DOI 10.1136/bcr-2021-245922

**Cited by:**

109. **Han, J.W., Lee, J.I., Hwangbo, L.** Endovascular Treatment for Head and Neck Trauma. [두경부 외상의 인터벤션.] // *Journal of the Korean Society of Radiology*, 84, 2023, № 4, p. 792-808. ISSN 2951-0805. DOI 10.3348/jksr.2023.0034.

110. **Morsi, R.Z., Thind, S., Chahine, A., Zakaria, J., Desai, H., Kothari, S.A., Shah, A.P., Nathan, S., Coleman, E., Mendelson, S., Siegler, J.E., Prabhakaran, S., Mansour, A., Kass-Hout, T.** The use of PK Papyrus covered coronary stent for carotid reconstruction: an initial institutional experience. // *Journal of NeuroInterventional Surgery*, 2024, art. no. jnis-2023-021226. ISSN 1759-8478. DOI 10.1136/jnis-2023-021226.

D. Boychev, N. Zlatareva, **I. Petrov**. Cardiovascular system and COVID-19. DOI 10.3897/bgcardio.27.e67571.

**Cited by:**

111. **Gruev, I., Tzanova, V.** How COVID-19 affected the control of hypertension and comorbidities in one cardiological outpatient practice in Bulgaria? // *Bulgarian Cardiology*, 29, 2023, № 3, p. 20-24. ISSN 1310-7488. DOI 10.3897/bgcardio.29.e109781.

Nardai S, Lanzer P, Abelson M, **Ivo Petrov**, et al. Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment. Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention [published correction appears in Eur Heart J. 2021 Jan 21;42(4):307]. Eur Heart J. 2021;42(4):298-307. DOI10.1093/eurheartj/ehaa833.

**Cited by:**

112. **Crea, F.** Management of ischaemic stroke, prognostic impact of procedural myocardial injury, and antiplatelet treatment: The many facets of interventional cardiology. // *European Heart Journal*, 42, 2021, № 4, p. 289-291. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab001.
113. **Dervishi, M., Al-Natour, M., Thomas, J.P., Harth, K.** Multidisciplinary Approach to Venous Disease: Enhancing Patient Care and Trainee Education Through Collaboration. // *Techniques in Vascular and Interventional Radiology*, 26, 2023, № 2, art. no. 100902. ISSN 1089-2516. DOI 10.1016/j.tvir.2023.100902.
114. **Fiehler, J., Shelesko, A.** New online tools to speed-up training of neurointerventionalists: An example in Central Asia. // *Journal of NeuroInterventional Surgery*, 16, 2024, № 2, p. 111-112. ISSN 1759-8478. DOI 10.1136/jnis-2023-021401.
115. **Lin, M., Hu, L., Shen, S., Liu, J., Liu, Y., Xu, Y., Chen, H., Sugimoto, K., Li, J., Kamitsukasa, I., Hiwasa, T., Wang, H., Xu, A.** Atherosclerosis-related biomarker PABPC1 predicts pan-cancer events. // *Stroke and Vascular Neurology*, 2023, art. no. svn-2022-002246. ISSN 2059-8688. DOI 10.1136/svn-2022-002246.
116. **Pawłowski, K., Dziadkiewicz, A., Klaudel, J., Mączkowiak, A., Szolkiewicz, M.** Acute ischemic stroke treatment model for Poland in the mechanical thrombectomy era – which way to go? // *Postępy w Kardiologii Interwencyjnej*, 18, 2022, № 1, p. 4-13. ISSN 1734-9338. DOI 10.5114/aic.2022.115269.

117. **Pracoń, R., Zieliński, K., Bangalore, S., Konka, M., Kruk, M., Kępa, C., Trochimiuk, P., Dębski, M., Przyłuski, J., Kaczmarek, E., Dzielińska, Z., Kurowski, A., Witkowski, A., Demkow, M.** Residual stroke risk after left atrial appendage closure in patients with prior oral anticoagulation failure. // *International Journal of Cardiology*, 354, 2022, p. 17-21. ISSN 0167-5273. DOI 10.1016/j.ijcard.2022.02.030.
118. **Watanabe, T., Kobara, S., Amisaki, R., Yamamoto, K.** Primary percutaneous coronary intervention for cardio-cerebral infarction: a case report. // *Frontiers in Cardiovascular Medicine*, 10, 2023, art. no. 1165735. ISSN 2297-055X. DOI 10.3389/fcvm.2023.1165735.
119. **Widimský, P., Kucera, D.** Stroke thrombectomy ( $\pm$  thrombolysis), and not thrombolysis alone, should be the gold standard for stroke treatment. // *EuroIntervention*, 17, 2022, № 17, p. E1367-E1368. ISSN 1774-024X. DOI 10.4244/EIJ-E-22-00002.
120. **Wita, K., Kulach, A., Wilkosz, K., Wybraniec, M., Wojakowski, W., Kuczmik, W., Lelek, M., Tomalski, W., Ochala, A., Uchwat, U., Lasek-Bal, A.** Mechanical Thrombectomy in Acute Ischemic Stroke—The Role of Interventional Cardiologists: A Prospective Single-Center Study. // *JACC: Cardiovascular Interventions*, 15, 2022, № 5, p. 550-558. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.11.041.
121. **Zhang, L., Shu, Y., Han, C., Liu, J.** Correlation Between Family Functioning and Health Beliefs in Patients with Stroke in Beijing, China. // *Journal of Multidisciplinary Healthcare*, 16, 2023, p. 1067-1074. ISSN 1178-2390. DOI 10.2147/JMDH.S394396.

**Ivo Petrov.** EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet*. 2021;398(10312):1713-1725. DOI 10.1016/S0140-6736(21)01122-3.

#### **Cited by:**

122. **Arnold, N., Koenig, W.** Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 8, art. no. 236. ISSN 1530-6550. DOI 10.31083/j.rcm2408236.
123. **Arrobas Velilla, T., Brea, A., Valdivielso, P.** Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study. // *Frontiers in Genetics*, 13, 2022, art. no. 971651. ISSN 1664-8021. DOI 10.3389/fgene.2022.971651.
124. **Bassareo, P.P., O'Brien, S.T., Dunne, E., Duignan, S., Martino, E., Martino, F., McMahon, C.J.** Does Ischaemic Heart Disease Exist in Paediatric Age as Well? // *Children*, 9, 2022, № 7, art. no. 982. ISSN 2227-9067. DOI 10.3390/children9070982.
125. **Bellows, B.K., Khera, A.V., Zhang, Y., Ruiz-Negrón, N., Stoddard, H.M., Wong, J.B., Kazi, D.S., De Ferranti, S.D., Moran, A.E.** Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in

126. **Brandts, J., Tittel, S.R., Bramlage, P., Danne, T., Brix, J.M., Zimny, S., Heyer, C.H.J., Holl, R.W., Müller-Wieland, D.** Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry. // *Diabetes, Obesity and Metabolism*, 25, 2023, № 12, p. 3700-3708. ISSN 1462-8902. DOI 10.1111/dom.15264.
127. **Brinck, J., Hagström, E., Nätman, J., Franzén, S., Eeg-Olofsson, K., Nathanson, D., Eliasson, B.** Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study. // *Diabetes Care*, 45, 2022, № 12, p. 3040-3049. ISSN 0149-5992. DOI 10.2337/dc22-1025.
128. **Chai, M., He, Y., Zhao, W., Han, X., Zhao, G., Ma, X., Qiao, P., Shi, D., Liu, Y., Han, W., An, P., Li, H., Yan, S., Ma, Q., Deng, H., Qian, L., Zhou, Y., on behalf of CREDIT-2 investigators.** Efficacy and safety of tfolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). // *BMC Medicine*, 21, 2023, № 1, art. no. 77. ISSN 1741-7015. DOI 10.1186/s12916-023-02797-8.
129. **Constantin, A.T., Streat, I., Covăcescu, M.S., Riza, A.L., Roșca, I., Delia, C., Tudor, L.M., Dorobanțu, Ș., Dragoș, A., Ristea, D., Ioana, M., Gherghina, I.** Genetic Testing for Familial Hypercholesterolemia in a Pediatric Group: A Romanian Showcase. // *Diagnostics*, 13, 2023, № 12, art. no. 1988. ISSN 2075-4418. DOI 10.3390/diagnostics13121988.
130. **Cuchel, M., McGowan, M.P.** Familial hypercholesterolaemia: too many lost opportunities. // *The Lancet*, 398, 2021, № 10312, p. 1667-1668. ISSN 0140-6736. DOI 10.1016/S0140-6736(21)01372-6.
131. **Dai, H., Yan, S.** Research progress in genetic diagnosis of familial hypercholesterolemia. [家族性高胆固醇血症的基因诊断研究进展]. // *Journal of Clinical Cardiology*, 39, 2023, № 5, p. 348-354. ISSN 1001-1439. DOI 10.13201/j.issn.1001-1439.2023.05.006.
132. **Daniels, S.R.** What Is the Optimum Approach to Screening for Familial Hypercholesterolemia in Children? // *JAMA Pediatrics*, 177, 2023, № 6, p. 565. ISSN 2168-6203. DOI 10.1001/jamapediatrics.2023.0771.
133. **Dobrowolski, P., Kabat, M., Kępka, C., Januszewicz, A., Prejbisz, A.** Atherosclerotic cardiovascular disease burden in patients with familial hypercholesterolemia: interpretation of data on involvement of different vascular beds. // *Polish Archives of Internal Medicine*, 132, 2022, № 4, art. no. 16248. ISSN 0032-3772. DOI 10.20452/pamw.16248.
134. **Durand, A., Morgan, C.L., Tinsley, S., Hughes, E., McCormack, T., Bitchell, C.L., Lahoz, R.** Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition. // *British Journal of General Practice*, 74, 2024, № 740, p. e174-e182. ISSN 0960-1643. DOI 10.3399/BJGP.2023.0010.

135. **Farias, F.I., Kim, S.M., Shapiro, M.D.** Familial hypercholesterolaemia and emerging therapeutics. // *Heart*, 109, 2023, № 19, p. 1486-1493. ISSN 1355-6037. DOI 10.1136/heartjnl-2022-321917.
136. **Figorilli, F., Mannarino, M.R., Sahebkar, A., Pirro, M.** Lipid profile screening and ASCVD prevention. // *Expert Review of Cardiovascular Therapy*, 21, 2023, № 7, p. 463-471. ISSN 1477-9072. DOI 10.1080/14779072.2023.2218087.
137. **Gijón-Conde, T., Ferré Sánchez, C., Ibáñez Delgado, I., Rodríguez Jiménez, B., Banegas, J.R.** Clinical profile of severe hypercholesterolemia in 156,000 adults in primary care. [Perfil clínico de la hipercolesterolemia severa en 156.000 adultos en atención primaria]. // *Clinica e Investigacion en Arteriosclerosis*, 36, 2024, № 1, p. 1-11. ISSN 0214-9168. DOI 10.1016/j.arteri.2023.08.002.
138. **Gratton, J., Futema, M., Humphries, S.E., Hingorani, A.D., Finan, C., Schmidt, A.F.** A Machine Learning Model to Aid Detection of Familial Hypercholesterolemia. // *JACC: Advances*, 2, 2023, № 4, art. no. 100333. ISSN 2772-963X. DOI 10.1016/j.jacadv.2023.100333.
139. **Gratton, J., Humphries, S.E., Futema, M.** Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank - Brief Report. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 43, 2023, № 9, p. 1737-1742. ISSN 1079-5642. DOI 10.1161/ATVBAHA.123.319438.
140. **Hermel, M., Lieberman, M., Slipczuk, L., Rana, J.S., Virani, S.S.** Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. // *Pharmaceutics*, 15, 2023, № 2, art. no. 459. ISSN 1999-4923. DOI 10.3390/pharmaceutics15020459.
141. **Hu, J., Ji, Y., Lang, X., Zhang, X.-Y.** Prevalence and clinical correlates of abnormal lipid metabolism in first-episode and drug-naïve patients with major depressive disorder: A large-scale cross-sectional study. // *Journal of Psychiatric Research*, 163, 2023, p. 55-62. ISSN 0022-3956. DOI 10.1016/j.jpsychires.2023.05.016.
142. **Ide, V., De Cock, D., Pazmino, S., Vangoitsenhoven, R., Van der Schueren, B., Mertens, A.** A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic. // *Acta Cardiologica*, 79, 2024, № 1, p. 58-67. ISSN 0001-5385. DOI 10.1080/00015385.2023.2266647.
143. **Jiménez, A., Viñals, C., Marco-Benedí, V., González, P., Domenech, M., Suárez-Tembra, M., Pinto, X., Ortega, E.** Sex Disparities in Familial Hypercholesterolemia. // *Journal of the American College of Cardiology*, 81, 2023, № 2, p. 203-205. ISSN 0735-1097. DOI 10.1016/j.jacc.2022.10.023.
144. **Junna, N., Ruotsalainen, S., Ripatti, P., FinnGen, Ripatti, S., Widén, E.** Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease. // *Atherosclerosis*, 386, 2023, art. no. 117327. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2023.117327.
145. **Kakehi, E., Kotani, K.** The Necessity of Collaboration With Doctors Involved in Annual Medical Checkups in the Identification of Familial Hypercholesterolemia in Japan. // *Journal of Clinical Medicine Research*, 14, 2022, № 6, p. 244-245. ISSN 1918-3003. DOI 10.14740/jocmr4740.



146. **Laufs, U., Blüher, M., Isermann, B.** Third generation PCSK9-inhibitors. // *European Heart Journal*, 44, 2023, № 40, p. 4281-4283. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad566.
147. **Le, A., Peng, H., Golinsky, D., Di Scipio, M., Lali, R., Paré, G.** What Causes Premature Coronary Artery Disease? // *Current Atherosclerosis Reports*, 2024. ISSN 1523-3804. DOI 10.1007/s11883-024-01200-y.
148. **Lee, C.J., Yoon, M., Kang, H.-J., Kim, B.J., Choi, S.H., Jeong, I.-K., Lee, S.-H., Task Force Team for Familial Hypercholesterolemia Korean Society of Lipid Atherosclerosis.** 2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. // *Journal of Lipid and Atherosclerosis*, 11, 2022, № 3, p. 213-228. ISSN 2287-2892. DOI 10.12997/jla.2022.11.3.213.
149. **Lee, C.J., Yoon, M., Kang, H.-J., Kim, B.J., Choi, S.H., Jeong, I.-K., Lee, S.-H., Task Force Team for Familial Hypercholesterolemia Korean Society of Lipid Atherosclerosis.** 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. // *Korean Journal of Internal Medicine*, 37, 2022, № 5, p. 931-944. ISSN 1226-3303. DOI 10.3904/kjim.2022.121.
150. **Lee, R.G., Mazzola, A.M., Braun, M.C., Platt, C., Vafai, S.B., Kathiresan, S., Rohde, E., Bellinger, A.M., Khera, A.V.** Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. // *Circulation*, 147, 2023, № 3, p. 242-253. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.122.062132.
151. **Liu, W., Yao, M., Jing, G., Yan, C., Yan, H.** Interpretation of Screening for Lipid Disorders in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement. [2023 年美国预防临床服务指南工作组《儿童和青少年血脂异常筛查推荐声明》解读]. // *Chinese General Practice*, 27, 2024, № 15, p. 1796-1801. ISSN 1007-9572. DOI 10.12114/j.issn.1007-9572.2024.0002.
152. **Mahdi, A., Wodaje, T., Kövamees, O., Tengbom, J., Zhao, A., Jiao, T., Henricsson, M., Yang, J., Zhou, Z., Nieminen, A.I., Levin, M., Collado, A., Brinck, J., Pernow, J.** The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia. // *Journal of Internal Medicine*, 293, 2023, № 2, p. 228-245. ISSN 0954-6820. DOI 10.1111/joim.13580.
153. **Martino, F., Barilla, F., Martino, E., Calcaterra, G., Fanos, V., Bassareo, P.P.** Familial Hypercholesterolaemia in Children and Adolescents: Current and Future Perspectives. // *Current Pediatric Reviews*, 19, 2023, № 3, p. 234-241. ISSN 1573-3963. DOI 10.2174/1573396318666220921155314.
154. **McGowan, M.P., Cuchel, M.** Universal paediatric screening for familial hypercholesterolaemia. // *The Lancet*, 403, 2024, № 10421, p. 6-8. ISSN 0140-6736. DOI 10.1016/S0140-6736(23)02182-7.
155. **Mercuro, G., Cadeddu Dessalvi, C., Deidda, M.** To be or not to be resilient in familial hypercholesterolaemia: implications for the management. // *European Journal of Preventive Cardiology*, 29, 2022, № 5, p. 793-794. ISSN 2047-4873. DOI 10.1093/eurjpc/zwab197.



156. **Motkowski, R., Abramowicz, P., Kubalska, J., Mikolúć, B., Konstantynowicz, J.** Efficacy and Safety of Statin Treatment in Children with Familial Hypercholesterolemia: Outcomes of 20 Years of Experience. // *Journal of Clinical Medicine*, 12, 2023, № 23, art. no. 7197. ISSN 2077-0383. DOI 10.3390/jcm12237197.
157. **Mulder, J.W.C.M., Galema-Boers, A.M.H., Roeters van Lennep, J.E.** First clinical experiences with inclisiran in a real-world setting. // *Journal of Clinical Lipidology*, 17, 2023, № 6, p. 818-827. ISSN 1933-2874. DOI 10.1016/j.jacl.2023.09.005.
158. **Mülverstedt, S., Prescott, E.I.B., Jørgensen, H., Heitmann, M.** Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study. // *BMJ Open*, 14, 2024, № 2, art. no. e082075. ISSN 2044-6055. DOI 10.1136/bmjopen-2023-082075.
159. **Nolan, J., Buchanan, J., Taylor, J., Almeida, J., Bedenham, T., Blair, E., Broadgate, S., Butler, S., Cazeaux, A., Craft, J., Cranston, T., Crawford, G., Forrest, J., Gabriel, J., George, E., Gillen, D., Haeger, A., Hastings Ward, J., Hawkes, L., Hodgkiss, C., Hoffman, J., Jones, A., Karpe, F., Kasperaviciute, D., Kovacs, E., Leigh, S., Limb, E., Lloyd-Jani, A., Lopez, J., Lucassen, A., McFarlane, C., O'Rourke, A.W., Pond, E., Sherman, C., Stewart, H., Thomas, E., Thomas, S., Thomas, T., Thomson, K., Wakelin, H., Walker, S., Watson, M., Williams, E., Ormondroyd, E.** Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure. // *Genetics in Medicine*, 26, 2024, № 3, art. no. 101051. ISSN 1098-3600. DOI 10.1016/j.gim.2023.101051.
160. **Noto, D., Spina, R., Giammanco, A., Barbagallo, C.M., Ganci, A., Scrimali, C., Brucato, F., Misiano, G., Ciaccio, M., Caldarella, R., Cefalù, A.B., Aversa, M.** Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. // *Atherosclerosis*, 347, 2022, p. 63-67. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2022.03.012.
161. **Piccioni, A., Niccolai, E., Rozzi, G., Spaziani, G., Zanza, C., Candelli, M., Covino, M., Gasbarrini, A., Franceschi, F., Amedei, A.** Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers. // *Pathogens*, 12, 2023, № 4, art. no. 627. ISSN 2076-0817. DOI 10.3390/pathogens12040627.
162. **Qiu, H.-R., Zhang, L., Zhu, Z.-J.** Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia. // *Medicina (Lithuania)*, 58, 2022, № 10, art. no. 1430. ISSN 1010-660X. DOI 10.3390/medicina58101430.
163. **Revankar, S., Park, J.K., Satish, P., Agarwala, A.** Is there a role for earlier use of combination therapy? // *American Journal of Preventive Cardiology*, 17, 2024, art. no. 100639. ISSN 2666-6677. DOI 10.1016/j.ajpc.2024.100639.
164. **Romero-Jiménez, M.J., Mansilla-Rodríguez, M.E., Gutiérrez-Cortizo, E.N.** Predictors of cardiovascular risk in familial hypercholesterolemia. // *Current Opinion in Lipidology*, 34, 2023, № 6, p. 272-277. ISSN 0957-9672. DOI 10.1097/MOL.0000000000000903.

165. **Stock, J.K.** Global Familial Hypercholesterolaemia Studies Collaboration (FHSC). // *Atherosclerosis*, 337, 2021, p. 57-58. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2021.09.021.
166. **Stock, J.K.** Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed. // *Atherosclerosis*, 346, 2022, p. 84-85. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2022.02.008.
167. **Tokgozoglul, L., Orringer, C., Ginsberg, H.N., Catapano, A.L.** The year in cardiovascular medicine 2021: dyslipidaemia. // *Cardiologia Hungarica*, 52, 2022, № 4, p. 279-291. ISSN 0133-5596.
168. **van den Bosch, S.E., Corpeleijn, W.E., Hutten, B.A., Wiegman, A.** How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. // *Genes*, 14, 2023, № 3, art. no. 669. ISSN 2073-4425. DOI 10.3390/genes14030669.
169. **Wei, N., Hu, Y., Li, S., Liu, G., Zhang, N., Jia, Q., Shi, J., Yuan, G., Zhai, H.** Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 5, art. no. 151. ISSN 1530-6550. DOI 10.31083/J.RCM2305151.
170. **Wodaje, T., Mahdi, A., Venkateshvaran, A., Häbel, H., Zenlander, R., Gaylard, B., Angelin, B., Pernow, J., Brinck, J.** Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia. // *Atherosclerosis*, 389, 2024, art. no. 117439. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2023.117439.
171. **Zamora, A., Ramos, R., Comas-Cufi, M., García-Gil, M., Martí-Lluch, R., Plana, N., Alves-Cabrata, L., Ponjoan, A., Rodríguez-Borjabad, C., Ibarretxe, D., Roman-Degano, I., Marrugat, J., Elosua, R., Martín-Urda, A., Masana, L.** Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men. // *Scientific Reports*, 13, 2023, № 1, art. no. 1492. ISSN 2045-2322. DOI 10.1038/s41598-023-27963-z.
172. **Zhang, Y., Ju, J., Jiao, L., Yang, B.** Bioactive Components of Chinese Herbal Medicines in the Treatment of Glucose and Lipid Metabolism Disorders: Evidence and Potential Mechanisms. // *Engineering*, 29, 2023, p. 73-82. ISSN 2095-8099. DOI 10.1016/j.eng.2023.03.004.

**Petrov IS, Stankov ZI, Boychev DB, Samardjieva M.** Endovascular closure of MINOCA-caused ventricular septal defect (VSD). *BMJ Case Rep.* 2021;14(9):e242303. Published 2021 Sep 3. DOI10.1136/bcr-2021-242303.

#### **Cited by:**

173. **Bil, J., Buller, P., Gil, R.J., Gromadziński, L., Onichimowski, D., Jalali, R., Kern, A.** Acute Complications in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries: A Systematic Review with Special Focus on Mechanical Complications. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 12, art. no. 393. ISSN 1530-6550. DOI 10.31083/j.rcm2312393.

174. **Firuzi, A., Shekarchizadeh, M., Yadollahi, M., Mohamadifar, A., Ferasati, E., Shekarchizadeh-Esfahani, M.** Relationship between Complete Revascularization and Survival after Post-Infarction Ventricular Septal Rupture. // *ARYA Atherosclerosis*, 19, 2023, № 3, p. 80-86. ISSN 1735-3955. DOI 10.48305/arya.2022.11857.2539.
175. **Jolobe, O.M.P.** A new dimension to the STEMI-related mortality risk seen in the COVID-19 pandemic era. // *American Journal of Emergency Medicine*, 60, 2022, p. 189-192. ISSN 0735-6757. DOI 10.1016/j.ajem.2022.06.028.
176. **Kafkas, N., Dragasis, S., Mantis, C., Floros, G.** Myocardial infarction with non obstructive coronary arteries complicated with ventricular septal rupture: A case report and literature review. // *Catheterization and Cardiovascular Interventions*, 99, 2022, № 4, p. 1125-1128. ISSN 1522-1946. DOI 10.1002/ccd.30028.

**Petrov IS, Stankov ZI, Boychev DB.** Use of ASD closure device for the sealing of false lumen entry in the ascending aorta after dissection Type A surgical repair. *BMJ Case Rep.* 2021;14(8):e242304. Published 2021 Aug 13. DOI10.1136/bcr-2021-242304.

#### Cited by:

177. **Wang, Q., Wei, H., He, C., Liu, Y.** Atrial septal defect occluder combined with stent graft for the management of post-dissection aortic aneurysm previously treated with unsuccessful coils: a case report. // *CVIR Endovascular*, 6, 2023, № 1, art. no. 58. ISSN 2520-8934. DOI 10.1186/s42155-023-00405-7.

#### 2020

Гарвански И, **Петров И**, Симова Я (2020) Препоръки за проследяване на пациенти със сърдечно-съдови заболявания при прилагане на потенциално ефективни медикаменти за лечение на COVID-19 с оглед на редуциране на риска от удължаване на QT-интервала и внезапна сърдечна смърт. *Българска Кардиология* 26(2): 21-26. <https://DOI.org/10.3897/bgcardio.26.e52960>.

#### Cited by:

178. **Gruev, I., Tsanova, V.** How COVID-19 affected the control of hypertension and comorbidities in one cardiological outpatient practice in Bulgaria? // *Bulgarian Cardiology*, 29, 2023, № 3, p. 20-24. ISSN 1310-7488. DOI 10.3897/bgcardio.29.e109781.
179. **Monsuez, J.-J., Gatzov, P., Agoston, G., Aschermann, M., Badran, H.M., Böhm, M., Buendia-Hernandez, A., Cardim, N., De La Torre, J.-M., Erol, C., Heusch, G., Huber, K., Juillière, Y., Shlyakhto, E., Undas, A., Ural, D., Alfonso, F., Ferreira-Gonzalez, I., Editors' Network of the National Societies of Cardiology Journals (NSCJ).** COVID-19 and the heart: insights from the National Societies of Cardiology Journals. // *European Heart Journal*, 42, 2021, № 39, p. 4003-4005. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab262.

Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Abdul Ghapar AKB, Selvaraj K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbicocchi F, Pasupati S, Kim HS, Aminian A, Tie C, Wlodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW; **ONYX ONE Investigators**. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. 2020 Mar 26;382(13):1208-1218. DOI 10.1056/NEJMoa1910021. Epub 2020 Feb 12. PMID: 32050061.

**Cited by:**

180. **Aguilar, L.E.** Biomaterial science: Anatomy and physiology aspects. – In: *Biomaterial Science: Anatomy and Physiology Aspects*, 2022, p. 1-458. ISBN 9783110655377; 9783110655353. DOI 10.1515/9783110655377.
181. **Ahmed, T., Grigorian, A.Y., Messerli, A.W.** Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis. // *American Journal of Cardiovascular Drugs*, 22, 2022, № 1, p. 55-67. ISSN 1175-3277. DOI 10.1007/s40256-021-00478-6.
182. **Al-abcha, A., Radwan, Y., Blais, D., Mazzaferri, E.L., Jr., Boudoulas, K.D., Essa, E.M., Gumina, R.J.** Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 850028. ISSN 2297-055X. DOI 10.3389/fcvm.2022.850028.
183. **Alfonso, F., Gonzalo, N., Rivero, F., Escaned, J.** The year in cardiovascular medicine 2020: Interventional cardiology. // *European Heart Journal*, 42, 2021, № 10, p. 985-1003. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa1096.
184. **Alkhalil, M., Kuzemczak, M., Bell, A., Stern, S., Welsford, M., Cantor, W.J., Goodman, S.G.** A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes [Approche pratique à la prescription des antiplaquettaires chez les patients atteints de syndromes coronariens]. // *CMAJ*, 194, 2022, № 17, p. E620-E631. ISSN 0820-3946. DOI 10.1503/cmaj.202863-f.
185. **Alkhalil, M., Kuzemczak, M., Bell, A., Stern, S., Welsford, M., Cantor, W.J., Goodman, S.G.** A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes. // *CMAJ*, 194, 2022, № 6, p. E205-E215. ISSN 0820-3946. DOI 10.1503/cmaj.202863.
186. **Ameri, P., Canepa, M., López-Fernández, T., Nohria, A., Bertero, E., Vergallo, R., Lombardi, M., Lyon, A.R., Porto, I.** Ischaemic heart disease in patients with cancer. // *European Heart Journal*, 45, 2024, № 14, p. 1209-1223. ISSN 0195-668X. DOI 10.1093/eurheartj/ehae047.
187. **Asad, Z.U.A., Baber, U.** The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. // *Interventional Cardiology Clinics*, 9, 2020, № 4, p. 489-498. ISSN 2211-7458. DOI 10.1016/j.iccl.2020.06.003.
188. **Baber, U.** Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. // *JACC: Cardiovascular Interventions*, 15, 2022, № 11, p. 1164-1166. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.04.043.

189. **Baber, U., Angiolillo, D.J.** Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? // *JACC: Cardiovascular Interventions*, 13, 2020, № 19, p. 2263-2265. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.07.005.
190. **Badescu, M.C., Ciocoiu, M., Rezus, E., Badulescu, O.V., Tanase, D.M., Ouatu, A., Dima, N., Ganceanu-Rusu, A.R., Popescu, D., Isac, P.N.S., Genes, T.-M., Rezus, C.** Current therapeutic approach to acute myocardial infarction in patients with congenital hemophilia. // *Life*, 11, 2021, № 10, art. no. 1072. ISSN 2075-1729. DOI 10.3390/life11101072.
191. **Bainey, K.R., Marquis-Gravel, G., Belley-Côté, E., Turgeon, R.D., Ackman, M.L., Babadagli, H.E., Bewick, D., Boivin-Proulx, L.-A., Cantor, W.J., Fremes, S.E., Graham, M.M., Lordkipanidzé, M., Madan, M., Mansour, S., Mehta, S.R., Potter, B.J., Shavadia, J., So, D.F., Tanguay, J.-F., Welsh, R.C., Yan, A.T., Bagai, A., Bagur, R., Bucci, C., Elbarouni, B., Geller, C., Lavoie, A., Lawler, P., Liu, S., Mancini, J., Wong, G.C., Primary Panel, Secondary Panel.** Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. // *Canadian Journal of Cardiology*, 40, 2024, № 2, p. 160-181. ISSN 0828-282X. DOI 10.1016/j.cjca.2023.10.013.
192. **Bainey, K.R., Marquis-Gravel, G., MacDonald, B.J., Bewick, D., Yan, A., Turgeon, R.D.** Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis. // *PLoS ONE*, 18, 2023, art. no. e0291061. ISSN 1932-6203. DOI 10.1371/journal.pone.0291061.
193. **Benenati, S., Crimi, G., Canale, C., Pescetelli, F., De Marzo, V., Vergallo, R., Galli, M., Della Bona, R., Canepa, M., Ameri, P., Crea, F., Porto, I.** Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: A network meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 1, p. 56-64. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa127.
194. **Brami, P., Fischer, Q., Pham, V., Seret, G., Varenne, O., Picard, F.** Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents. // *Journal of Clinical Medicine*, 12, 2023, № 21, art. no. 6711. ISSN 2077-0383. DOI 10.3390/jcm12216711.
195. **Breen, T.J., Raphael, C.E., Ingraham, B., Lane, C., Huxley, S., Roger, V.L., Jaffe, A., Lewis, B., Sandoval, Y.B., Prasad, A., Rihal, C.S., Gulati, R., Singh, M.** Incidence and outcomes of high bleeding risk patients with type 1 and type 2 myocardial infarction in a community-based cohort: Application of the Academic Research Consortium High Bleeding Risk Criteria. // *International Journal of Cardiology*, 396, 2024, art. no. 131565. ISSN 0167-5273. DOI 10.1016/j.ijcard.2023.131565.
196. **Brilakis, E.** Manual of Chronic Total Occlusion Percutaneous Coronary Interventions: A Step-by-Step Approach, Thrid Edition. – In: *Manual of Chronic Total Occlusion Percutaneous Coronary Interventions: A Step-by-Step Approach*, Thrid Edition, 2023, p. 1-831. ISBN 9780323917872; 9780323918046. DOI 10.1016/C2021-0-01316-X.



197. **Buiten, R.A., Zocca, P., Birgelen, C.V.** Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents. // *Current Opinion in Cardiology*, 35, 2020, № 6, p. 705-711. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000786.
198. **Burlacu, A., Genovesi, S., Basile, C., Ortiz, A., Mitra, S., Kirmizis, D., Kanbay, M., Davenport, A., van der Sande, F., Covic, A., on behalf of the EUDIAL Working Group of ERA-EDTA.** Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. // *Journal of Nephrology*, 34, 2021, № 1, p. 39-51. ISSN 1121-8428. DOI 10.1007/s40620-020-00758-5.
199. **Calderaro, D., Bichuette, L.D., Maciel, P.C., Cardozo, F.A.M., Ribeiro, H.B., Gualandro, D.M., Baracioli, L.M., De Matos Soeiro, A., Serrano, C.V., Da Costa, R.A., Caramelli, B.** Update of the Brazilian Society of Cardiology's Perioperative Cardiovascular Assessment Guideline: Focus on Managing Patients with Percutaneous Coronary Intervention – 2022. // *Arquivos Brasileiros de Cardiologia*, 118, 2022, № 2, p. 536-547. ISSN 0066-782X. DOI 10.36660/abc.20220039.
200. **Calvo-Fernández, A., Gómez-Lara, J., Elosua, R., Durán, X., Cubero-Gallego, H., Tizón-Marcos, H., Salvatella, N., Negrete, A., Millán, R., Ivern, C., Díez, J.L., Sánchez-Carpintero, A., Farré, N., de la Torre Hernández, J.M., Vaquerizo, B.** High rate of uncovered struts in latest generation drug-eluting stents with durable, biodegradable polymer or lack of it 1 month after implantation [Alta tasa de struts no cubiertos en stents de última generación con polímero persistente, absorbible o sin polímero a un mes del implante]. // *REC: Interventional Cardiology*, 5, 2023, № 1, p. 20-28. ISSN 2604-7306. DOI 10.24875/RECICE.M22000343.
201. **Capodanno, D.** Another Coronary Stent for Patients at High Bleeding Risk. // *JACC: Cardiovascular Interventions*, 14, 2021, № 17, p. 1884-1887. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.07.028.
202. **Capodanno, D.** Evolving Landscapes in Coronary Stents for Patients at High Bleeding Risk. // *Circulation: Cardiovascular Interventions*, 14, 2021, № 3, p. E010591. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.121.010591.
203. **Capranzano, P.** The stent in the high-bleeding risk patient: antiplatelet monotherapy? // *European Heart Journal, Supplement*, 24, 2022, p. I54-I56. ISSN 1520-765X. DOI 10.1093/eurheartjsupp/suac074.
204. **Carrillo-Estrada, M., Bobrowski, D., Carrasco, R., Nadler, M.B., Kalra, S., Thavendiranathan, P., Abdel-Qadir, H.** Coronary artery disease in patients with cancer: Challenges and opportunities for improvement. // *Current Opinion in Cardiology*, 36, 2021, № 5, p. 597-608. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000878.
205. **Chansoria, P., Rütsche, D., Wang, A., Liu, H., D'Angella, D., Rizzo, R., Hasenauer, A., Weber, P., Qiu, W., Ibrahim, N.B.M., Korshunova, N., Qin, X.-H., Zenobi-Wong, M.** Synergizing Algorithmic Design, Photoclick Chemistry and Multi-Material Volumetric Printing for Accelerating Complex Shape Engineering. // *Advanced Science*, 10, 2023, № 26, art. no. 2300912. ISSN 2198-3844. DOI 10.1002/advs.202300912.

206. **Chen, Y.-W., Chen, W.-J., Tseng, M.-S., Lo, H.-C., Shih, M.-Y., Chen, Y.-J., Lee, W.-L., Wang, J.-D.** Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor. // *Haemophilia*, 27, 2021, № 3, p. e385-e388. ISSN 1351-8216. DOI 10.1111/hae.14165.
207. **Chiabrando, J.G., Vescovo, G.M., Del Buono, M.G., Lombardi, M., Camilli, M., Ravindra, K., Montone, R.A., Niccoli, G., Biondi-Zoccai, G.** Optimal stent design for high bleeding risk patients: Evidence from a network meta-analysis. // *Journal of Invasive Cardiology*, 33, 2021, № 3, p. E182-E190. ISSN 1042-3931.
208. **Colleran, R., Byrne, R.A.** Polymer-Free Drug-Eluting Stents: The Importance of the Right Control. // *Circulation*, 141, 2020, № 25, p. 2064-2066. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.119.040556.
209. **Corballis, N.H., Nyi, T.H., Vassiliou, V.S., Eccleshall, S.C.** Drug-coated Balloons or Drug-eluting Stents - Determining an Optimum Strategy for Patients with High Bleeding Risk. // *Heart International*, 14, 2020, № 2, p. 100-104. ISSN 1826-1868. DOI 10.17925/HI.2020.14.2.100.
210. **Córdoba-Soriano, J.G., Gutiérrez-Díez, A., Del Blanco, B.G., Núñez, J., Amat-Santos, I.J., Oteo, J.F., Romaguera, R., Gallardo-López, A., Lozano Ruiz-Poveda, F., Baello, P., Aguar, P., Jerez-Valero, M., Jiménez-Díaz, V.A., Serra, B., Cascon, J.D., Morales-Ponce, F.J., Portero-Portaz, J.J., Melehi El Assali, D., Cerrato-García, P., Jiménez-Mazuecos, J.** Bioactive or Drug-Eluting Stents in 75 Years or Older Patients: The BIODS-75 Registry. // *Cardiovascular Revascularization Medicine*, 42, 2022, p. 114-120. ISSN 1553-8389. DOI 10.1016/j.carrev.2022.02.001.
211. **Cornelissen, A., Sakamoto, A., Sato, Y., Kawakami, R., Mori, M., Kawai, K., Kutyna, M., Fernandez, R., Ghosh, S., Barakat, M., Virmani, R., Finn, A.** COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies? // *Future Cardiology*, 18, 2022, № 3, p. 207-217. ISSN 1479-6678. DOI 10.2217/fca-2021-0057.
212. **Cortese, B., Serruys, P.W.** Single-Antiplatelet Treatment After Coronary Angioplasty With Drug-Coated Balloon. // *Journal of the American Heart Association*, 12, 2023, № 6, art. no. e028413. ISSN 2047-9980. DOI 10.1161/JAHA.122.028413.
213. **Costa, F., Garcia-Ruiz, V., Licordari, R., Fimiani, L.** The High Bleeding Risk Patient with Coronary Artery Disease. // *Cardiology Clinics*, 38, 2020, № 4, p. 481-490. ISSN 0733-8651. DOI 10.1016/j.ccl.2020.06.002.
214. **Costa, F., Valgimigli, M.** Competing risks in the duration of dual antiplatelet therapy- the case for shorter treatment. – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 111-130. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00001-X.
215. **Cutlip, D.E.** On the Bleeding Edge: Device- or Drug-Based Solutions. // *Circulation: Cardiovascular Interventions*, 13, 2020, № 4, p. E009128. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.120.009128.

216. **Cutlip, D.E.** Standing the Test of Time: A Device and Patient Perspective. // *Journal of the American College of Cardiology*, 77, 2021, № 9, p. 1179-1181. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.01.005.
217. **Cutlip, D.E., Jauhar, R., Meraj, P., Garratt, K.N., Novack, V., Novack, L., Maillard, L., Erglis, A., Stoler, R., Barakat, M., Silber, S., PzF SHIELD Trial Investigators.** Five-Year Clinical Outcomes of the COBRA Polyzone F NanoCoated Coronary Stent System. // *Cardiovascular Revascularization Medicine*, 2022, 41, p. 76-80. ISSN 1553-8389. DOI 10.1016/j.carrev.2021.12.030.
218. **Dai, Y., Wang, R., Chen, F., Zhang, Y., Liu, Y., Huang, H., Yang, P., Zhang, R., Zheng, B., Gao, C., Chen, Y., Tao, L.** Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry. // *BMC Cardiovascular Disorders*, 21, 2021, № 1, art. no. 537. ISSN 1471-2261. DOI 10.1186/s12872-021-02356-0.
219. **Doolub, G., Mamas, M.A.** Percutaneous Coronary Angioplasty in Patients with Cancer: Clinical Challenges and Management Strategies. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1372. ISSN 2075-4426. DOI 10.3390/jpm12091372.
220. **Eberli, F.R., Stoll, H.-P., Urban, P., Morice, M.-C., Brunel, P., Maillard, L., Lipiecki, J., Cook, S., Berland, J., Hovasse, T., Carrie, D., Schütte, D., Slama, S.S., Garot, P.** Polymer-free Biolimus-A9 coated thin strut stents for patients at high bleeding risk 1-year results from the LEADERS FREE III study. // *Catheterization and Cardiovascular Interventions*, 99, 2022, № 3, p. 593-600. ISSN 1522-1946. DOI 10.1002/ccd.29869.
221. **Elder, T.A., White, T.G., Woo, H.H., Siddiqui, A.H., Nunna, R., Siddiq, F., Esposito, G., Chang, D., Gonzalez, N.R., Amin-Hanjani, S.** Future of Endovascular and Surgical Treatments of Atherosclerotic Intracranial Stenosis. // *Stroke*, 55, 2024, № 2, p. 344-354. ISSN 0039-2499. DOI 10.1161/STROKEAHA.123.043634.
222. **Ellert-Gregersen, J., Jensen, L.O., Jakobsen, L., Freeman, P.M., Eftekhari, A., Maeng, M., Raungaard, B., Engstroem, T., Kahlert, J., Hansen, H.S., Christiansen, E.H.** Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial. // *EuroIntervention*, 18, 2022, № 2, p. E124-E131. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00874.
223. **Espinoza, C., Mukherjee, D.** Dual antiplatelet therapy in patients with high cardiovascular risk. // *Heart International*, 15, 2021, № 1, p. 26-36. ISSN 1826-1868. DOI 10.17925/HI.2021.15.1.26.
224. **Ferro, E.G., Capodanno, D., Yeh, R.W.** The Need to Standardize Our Language Around Dual Antiplatelet Therapy-A Call to Action. // *JAMA Cardiology*, 7, 2022, № 10, p. 995-996. ISSN 2380-6583. DOI 10.1001/jamacardio.2022.2711.
225. **Fluder-Wlodarczyk, J., Pawłowski, S., Chuchra, P.J., Pawłowski, T., Wojakowski, W., Gasior, P.** Importance of Short-Term Neointimal Coverage of Drug-Eluting Stents in the Duration of Dual Antiplatelet Therapy. // *Journal of Clinical Medicine*, 13, 2024, № 6, art. no. 1730. ISSN 2077-0383. DOI 10.3390/jcm13061730.

226. **Fuchs, O.** Synthetic and natural mtor inhibitors for the treatment of cancer and other diseases caused by over-activation of mtor. – In: *Advances in Health and Disease: Volume 48*, 2021, p. 51-88. ISBN 9781685074005; 9781685073756.
227. **Galli, M., Laborante, R., Andreotti, F., Vergallo, R., Montone, R.A., Iaconelli, A., Trani, C., Burzotta, F., Crea, F., D'Amario, D.** Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 8, art. no. 286. ISSN 1530-6550. DOI: 10.31083/j.rcm2308286.
228. **García-Blas, S., Cordero, A., Diez-Villanueva, P., Martinez-Avial, M., Ayesta, A., Ariza-Solé, A., Mateus-Porta, G., Martínez-Sellés, M., Escribano, D., Gabaldon-Perez, A., Bodi, V., Bonanad, C.** Acute coronary syndrome in the older patient. // *Journal of Clinical Medicine*, 10, 2021, № 18, art. no. 4132. ISSN 2077-0383. DOI 10.3390/jcm10184132.
229. **Garot, P., Brunel, P., Dibie, A., Morelle, J.-F., Abdellaoui, M., Levy, R., Carrié, D., Karsenty, B., Robin, C., Berland, J., Copt, S., Sadozai Slama, S., Oldroyd, K., Morice, M.-C., Lipiecki, J., the BioFreedom France Investigators.** Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study. // *Catheterization and Cardiovascular Interventions*, 101, 2023, № 1, p. 60-71. ISSN 1522-1946. DOI: 10.1002/ccd.30481.
230. **Giacoppo, D., Saucedo, J., Scheller, B.** Coronary Drug-Coated Balloons for De Novo and In-Stent Restenosis Indications. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2, 2023, № 3, art. no. 100625. ISSN 2772-9303. DOI 10.1016/j.jscai.2023.100625.
231. **Gîrleanu, I., Trifan, A., Huiban, L., Muzîca, C., Petrea, O.C., Sîngeap, A.M., Cojocariu, C., Chiriac, S., Cuciureanu, T., Costache, I.I., Stanciu, C.** Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. // *Life*, 12, 2022, № 7, art. no. 1036. ISSN 2075-1729. DOI 10.3390/life12071036.
232. **Gorgulko, A.P., Baranov, A.A., Khelimskii, D.A., Krestyaninov, O.V., Badoyan, A.G.** Optimal time of dual antiplatelet therapy in patients with coronary heart disease (literature review) [Оптимальный режим двойной антиагрегантной терапии у пациентов с хронической ишемической болезнью сердца (обзор литературы)]. // *Siberian Journal of Clinical and Experimental Medicine*, 38, 2023, № 4, p. 70-76. ISSN 2713-2927. DOI 10.29001/2073-8552-2023-38-4-70-76.
233. **Halvorsen, S., Mehilli, J., Cassese, S., Hall, T.S., Abdelhamid, M., Barbato, E., De Hert, S., De Laval, I., Geisler, T., Hinterbuchner, L., Ibanez, B., Lenarczyk, R., Mansmann, U.R., McGreavy, P., Mueller, C., Muneretto, C., Niessner, A., Potpara, T.S., Ristić, A., Sade, L.E., Schirmer, H., Schüpke, S., Sillesen, H., Skulstad, H., Torracca, L., Tutarel, O., Van Der Meer, P., Wojakowski, W., Zacharowski, K.** 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. // *European Heart Journal*, 43, 2022, № 39, p. 3826-3924. ISSN 0195-668X. DOI 10.1093/eurheartj/ehac270.
234. **Han, J., Attar, N.** Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era. // *World Journal of Cardiology*, 13, 2021, № 8, p. 243-253. ISSN 1949-8462. DOI 10.4330/wjc.v13.i8.243.

235. **Hansen, K.N., Maeng, M., Antonsen, L., Maehara, A., Jakobsen, L., Ellert, J., Terkelsen, C.J., Ahlehoff, O., Thim, T., Fallesen, C.O., Noori, M., Veien, K.T., Jensen, L.O., Christiansen, E.H.** Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. // *Coronary Artery Disease*, 33, 2022, № 3, p. 196-205. ISSN 0954-6928. DOI 10.1097/MCA.0000000000001113.
236. **Hennigan, B.W., Good, R., Adamson, C., Parker, W.A.E., Martin, L., Anderson, L., Campbell, M., Serruys, P.W., Storey, R.F., Oldroyd, K.G.** Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. // *Platelets*, 33, 2022, № 1, p. 141-146. ISSN 0953-7104. DOI 10.1080/09537104.2020.1863937.
237. **Hink, U., Voigtländer, T.** Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. // *Visceral Medicine*, 36, 2020, № 4, p. 264-273. ISSN 2297-4725. DOI 10.1159/000509896.
238. **Ho Yun, K., Lee, S.-Y., Cho, B.R., Jang, W.J., Bin Song, Y., Oh, J.-H., Chun, W.J., Park, Y.H., Im, E.-S., Jeong, J.-O., Kyu Oh, S., Cho, D.-K., Lee, J.-Y., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Soo Lee, W., Jun Yoon, H., Uk Lee, S., Cho, J.H., Gil Choi, W., Rha, S.-W., Lee, J.M., Kyu Park, T., Yang, J.H., Choi, J.-H., Choi, S.-H., Lee, S.H., Gwon, H.-C., Hahn, J.-Y., Cho, S.C., Hwang, S.-H., Kim, D.-B., Jeon, D.W., Ryu, J.K., Kim, M.-H., Chae, I.-H., Kim, S.-H., Kim, H.-L., Kyu Jin, D., Woo Suh, I., Park, J.S., Shin, E.-S., Kim, S.-J., Cheong, S.-S., Yun Lee, S., Chae, J.K., Mo Yang, Y., SMART-CHOICE Investigators.** Safety of 3-month dual antiplatelet therapy after implantation of ultrathin sirolimus-eluting stents with biodegradable polymer (Orsiro): Results from the SMART-CHOICE trial. // *Journal of the American Heart Association*, 10, 2021, № 1, art. no. e018366, p. 1-9. ISSN 2047-9980. DOI 10.1161/JAHA.120.018366.
239. **Hong, S.-J., Hong, M.-K.** Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances. // *Expert Opinion on Drug Delivery*, 19, 2022, № 3, p. 269-280. ISSN 1742-5247. DOI 10.1080/17425247.2022.2044784.
240. **Hong, S.-J., Kim, J.-S., Hong, S.J., Lim, D.-S., Lee, S.-Y., Yun, K.H., Park, J.-K., Kang, W.C., Kim, Y.H., Yoon, H.-J., Won, H., Nam, C.-M., Ahn, C.-M., Kim, B.-K., Ko, Y.-G., Choi, D., Jang, Y., Hong, M.-K., One-Month DAPT Investigators.** 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial. // *JACC: Cardiovascular Interventions*, 14, 2021, № 16, p. 1801-1811. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.06.003.
241. **Ishida, M., Takahashi, F., Goto, I., Niiyama, M., Saitoh, H., Sakamoto, T., Maegawa, Y., Osaki, T., Nishiyama, O., Endo, H., Sakamoto, R., Kojima, T., Koeda, Y., Kimura, T., Itoh, T., Morino, Y., REIWA investigators.** Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 4, p. 398-404. ISSN 1868-4300. DOI 10.1007/s12928-020-00694-y.



242. **Istanbuly, S., Matetic, A., Mohamed, M.O., Panaich, S., Velagapudi, P., Elgendy, I.Y., Paul, T.K., Alkhouli, M., Mamas, M.A.** Comparison of Outcomes of Patients With Versus Without Chronic Liver Disease Undergoing Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 156, 2021, p. 32-38. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.06.044.
243. **Jang, W.J., Lee, J.B., Song, Y.B., Choi, K.H., Choi, S.-H., Chun, W.J., Oh, J.H., Park, I.H., Doh, J.-H., Jeong, J.-O., Park, J.-S., Gwon, H.-C., Hahn, J.-Y.** A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: A pre-specified analysis of the SMART-DATE trial. // *EuroIntervention*, 17, 2021, № 5, p. 411-417. ISSN 1774-024X. DOI 10.4244/EIJ-D-20-00556.
244. **Jinnouchi, H., Sato, Y., Cheng, Q., Janifer, C., Kutyna, M., Cornelissen, A., Wijeratne, R., Sakamoto, A., Guo, L., Kolodgie, F.D., Tunev, S., Virmani, R., Finn, A.V.** Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. // *International Journal of Cardiology*, 327, 2021, p. 52-57. ISSN 0167-5273. DOI 10.1016/j.ijcard.2020.11.030.
245. **Karimanasseri, C.** Design Considerations for Coronary Stents and Their Efficacy: A Review. // *Critical Reviews in Biomedical Engineering*, 49, 2021, № 4, p. 15-28. ISSN 0278-940X. DOI: 10.1615/CritRevBiomedEng.2022040249.
246. **Kassimis, G., Karamasis, G.V., Katsikis, A., Abramik, J., Kon-Togiannis, N., Didagelos, M., Petroglou, D., Papadopoulos, C.E., Poulimenos, L., Vassilikos, V., Kanonidis, I., Raina, T., Ziakas, A.** Should percutaneous coronary intervention be the standard treatment strategy for significant coronary artery disease in all octogenarians? // *Current Cardiology Reviews*, 17, 2021, № 3, p. 314-329. ISSN 1573-403X. DOI 10.2174/1573403X16666200903153823.
247. **Knijnik, L., Fernandes, M., Rivera, M., Cardoso, R., Goyal, A., Liberman, H., Sperling, L.S., McDaniel, M.C.** Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting. // *American Journal of Cardiology*, 151, 2021, p. 25-29. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.04.014.
248. **Kornowski, R., Konigstein, M., Jonas, M., Assali, A., Vaknin-Assa, H., Segev, A., Danenberg, H., Halabi, M., Roguin, A., Kerner, A., Lev, E., Karamasis, G.V., Johnson, T.W., Anderson, R., Blaxill, J., Jadhav, S., Hoole, S., Witberg, G., Issever, M.O., Ben-Yehuda, O., Baumbach, A.** Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk. // *Journal of the American Heart Association*, 13, 2024, № 2, art. no. e029051. ISSN 2047-9980. DOI 10.1161/JAHA.122.029051.
249. **Kovacevic, M., Pompei, G., Kunadian, V.** Tailoring antiplatelet therapy in older patients with coronary artery disease. // *Platelets*, 34, 2023, № 1, art. no. 2285446. ISSN 0953-7104. DOI 10.1080/09537104.2023.2285446.
250. **Kwok, C.S., Wong, C.W., Kontopantelis, E., Barac, A., Brown, S.-A., Velagapudi, P., Hilliard, A.A., Bharadwaj, A.S., Chadi Alraies, M., Mohamed, M., Bhatt, D.L., Mamas, M.A.** Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding

in the USA. // *European Heart Journal*, 42, 2021, № 10, p. 1019-1034. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa1032.

251. **Kwon, O., Park, D.-W.** Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. // *JACC: Asia*, 2, 2022, № 1, p. 1-18. ISSN 2772-3747. DOI 10.1016/j.jacasi.2021.12.005.
252. **Lafont, A., Sinnaeve, P.R., Cuisset, T., Cook, S., Sideris, G., Kedev, S., Carrie, D., Hovasse, T., Garot, P., El Mahmoud, R., Spaulding, C., Helft, G., Diaz Fernandez, J.F., Brugaletta, S., Pinar-Bermudez, E., Ferre, J.M., Commeau, P., Teiger, E., Bogaerts, K., Sabate, M., Morice, M.C., Varenne, O., for the SENIOR investigators.** Two-year outcomes after percutaneous coronary intervention with drug-eluting stents or bare-metal stents in elderly patients with coronary artery disease. // *Catheterization and Cardiovascular Interventions*, 97, 2021, № 5, p. E607-E613. ISSN 1522-1946. DOI 10.1002/ccd.29159.
253. **Lange, S.A., Reinecke, H.** Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences. // *Cancers*, 14, 2022, № 2, art. no. 434. ISSN 2072-6694. DOI 10.3390/cancers14020434.
254. **Lee, Y.-J., Cho, J.Y., Yun, K.H., Lee, S.-J., Hong, S.-J., Ahn, C.-M., Kim, B.-K., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y., Kim, J.-S.** Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. // *EuroIntervention*, 18, 2022, № 6, p. 471-481. ISSN 1774-024X. DOI 10.4244/EIJ-D-22-00135.
255. **Leedy, D., Tiwana, J.K., Mamas, M., Hira, R., Cheng, R.** Coronary revascularisation outcomes in patients with cancer. // *Heart*, 108, 2022, № 7, p. 507-516. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-318531.
256. **Leening, M.J.G., Mahmoud, K.D.** Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. // *European Journal of Epidemiology*, 36, 2021, № 11, p. 1103-1109. ISSN 0393-2990. DOI 10.1007/s10654-021-00820-x.
257. **Linden, K., Mailey, J., Kearney, A., Menown, I.B.A.** Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. // *Advances in Therapy*, 37, 2020, № 6, p. 2620-2645. ISSN 0741-238X. DOI 10.1007/s12325-020-01355-5.
258. **Lopes, R.D., Fanaroff, A.C.** Dropping P2Y12inhibitors in patients with AF undergoing PCI? Not yet a SAFE bet. // *EuroIntervention*, 16, 2020, № 2, p. E109-E111. ISSN 1774-024X. DOI 10.4244/EIJV16I2A18.
259. **Lucà, F., Parrini, I., Abrignani, M.G., Rao, C.M., Piccioni, L., Di Fusco, S.A., Ceravolo, R., Bisceglia, I., Riccio, C., Gelsomino, S., Colivicchi, F., Gulizia, M.M., Management Quality Working Group ANMCO.** Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It. // *Journal of Clinical Medicine*, 11, 2022, № 7, art. no. 1792. ISSN 2077-0383. DOI 10.3390/jcm11071792.

260. **Machanahalli Balakrishna, A., Ismayl, M., Butt, D.N., Niu, F., Latif, A., Arouni, A.J.** Trends, outcomes, and management of acute myocardial infarction in patients with chronic viral hepatitis. // *Hospital Practice*, 50, 2022, № 3, p. 236-243. ISSN 2154-8331. DOI 10.1080/21548331.2022.2072314.
261. **Magnus Ohman, E.** The evolving post-PCI antithrombotic therapies. // *New England Journal of Medicine*, 385, 2021, № 18, p. 1712-1714. ISSN 0028-4793. DOI 10.1056/NEJMe2112747.
262. **Mahowald, M.K., Locker, C.L., Singh, M., Frye, R.L.** Treatment Strategies in Patients with Diabetes Mellitus and Ischemic Heart Disease. – In: *Clinical Dilemmas in Diabetes: Second Edition*, 2021, p. 228-237. ISBN 9781119603207; 9781119603160. DOI 10.1002/9781119603207.ch19.
263. **Marenzi, G., Cosentino, N., Cardinale, D.** Ischaemic and bleeding risk in cancer patients undergoing PCI: Another brick in the wall. // *European Heart Journal*, 42, 2021, № 10, p. 1035-1037. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa1109.
264. **Marquis-Gravel, G., Ohman, E.M.** Towards a better standard for defining high bleeding risk patients: Can we now translate this into a better practice? // *European Heart Journal*, 41, 2020, № 38), p. 3750-3752. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa699.
265. **Matetic, A., Contractor, T., Mohamed, M.O., Bhardwaj, R., Aneja, A., Myint, P.K., Rakoski, M.O., Zieroth, S., Paul, T.K., Mamas, M.A.** Trends, management and outcomes of acute myocardial infarction in chronic liver disease. // *International Journal of Clinical Practice*, 75, 2021, № 4, art. no. e13841. ISSN 1368-5031. DOI 10.1111/ijcp.13841.
266. **Mauler-Wittwer, S., Garot, P.** The Biolimus A9-coated BioFreedom™stent: From clinical efficacy to real-world evidence. // *Future Cardiology*, 17, 2021, № 2, p. 239-255. ISSN 1479-6678. DOI 10.2217/fca-2020-0069.
267. **Milazzo, V., Cosentino, N., Campodonico, J., Lucci, C., Cardinale, D., Cipolla, C.M., Marenzi, G.** Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. // *Journal of Clinical Medicine*, 9, 2020, № 11, art. no. 3642, p. 1-15. ISSN 2077-0383. DOI 10.3390/jcm9113642.
268. **Milder, D.A., Kam, P.C.A.** Perioperative implications of newer generation drug-eluting coronary stents: A narrative review. // *Anaesthesia and Intensive Care*, 49, 2021, № 5, p. 338-348. ISSN 0310-057X. DOI 10.1177/0310057X20984792.
269. **Mori, M., Sakamoto, A., Sato, Y., Kawakami, R., Kawai, K., Cornelissen, A., Abebe, B., Ghosh, S., Romero, M.E., Kolodgie, F.D., Virmani, R., Finn, A.V.** Overcoming challenges in refining the current generation of coronary stents. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 11, p. 1013-1028. ISSN 1477-9072. DOI 10.1080/14779072.2021.2013810.
270. **Murasato, Y.** Optimal duration of dual antiplatelet therapy after two-stent treatment in coronary bifurcation lesions. // *Circulation Journal*, 85, 2021, № 11, p. 1956-1958. ISSN 1346-9843. DOI 10.1253/circj.CJ-21-0456.
271. **Nakamura, M., Kadota, K., Nakao, K., Nakagawa, Y., Shite, J., Yokoi, H., Kozuma, K., Tanabe, K., Akasaka, T., Shinke, T., Ueno, T., Hirayama, A.,**

- Uemura, S., Harada, A., Kuroda, T., Takita, A., Iijima, R., Murakami, Y., Saito, S.** Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary intervention patients with high bleeding risk. // *Circulation Journal*, 85, 2021, № 6, p. 785-793. ISSN 1346-9843. DOI 10.1253/circj.CJ-20-1058.
272. **Natsuaki, M., Kimura, T.** Antiplatelet Therapy after Percutaneous Coronary Intervention — Past, Current and Future Perspectives —. // *Circulation Journal*, 86, 2022, № 5, p. 741-747. ISSN 1346-9843. DOI 10.1253/circj.CJ-21-0751.
273. **Natsuaki, M., Sonoda, S., Yoshioka, G., Hongo, H., Kaneko, T., Kashiya, K., Yokoi, K., Hikichi, Y., Node, K.** Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. // *Cardiovascular Intervention and Therapeutics*, 37, 2022, № 2, p. 255-263. ISSN 1868-4300. DOI 10.1007/s12928-022-00847-1.
274. **Ng, A.K.-Y., Ng, P.Y., Ip, A., Lam, L.T., Siu, C.-W.** Trade-off of major bleeding versus myocardial infarction on mortality after percutaneous coronary intervention. // *Open Heart*, 9, 2022, № 1, art. no. e001861. ISSN 2398-595X. DOI 10.1136/openhrt-2021-001861.
275. **Ng, A.K.-Y., Ng, P.Y., Ip, A., Ling, I.W.-H., Lam, L.-T., Siu, C.-W.** Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients. // *JACC: Asia*, 2, 2022, p. 341-350. ISSN 2772-3747. DOI 10.1016/j.jacasi.2021.12.009.
276. **Occhiuzzi, M.A., Lico, G., Ioele, G., De Luca, M., Garofalo, A., Grande, F.** Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents. // *European Journal of Medicinal Chemistry*, 246, 2023, art. no. 114971. ISSN 0223-5234. DOI 10.1016/j.ejmech.2022.114971.
277. **Oliveri, F., Tua, L., Camporotondo, R., Gritti, V., Leonardi, S.** Cangrelor in a challenging scenario of concomitant ischaemic stroke, pulmonary embolism, and ST-elevation myocardial infarction: a case report. // *European Heart Journal - Case Reports*, 8, 2024, № 2, art. no. ytae066. ISSN 2514-2119. DOI 10.1093/ehjcr/ytae066.
278. **Ostojic, Z., Ostojic, A., Bulum, J., Mrzljak, A.** Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. // *World Journal of Cardiology*, 13, 2021, № 11, p. 599-607. ISSN 1949-8462. DOI 10.4330/WJC.V13.I11.599.
279. **Otaegui Irurueta, I., García del Blanco, B., Martí Aguasca, G.** Ultrashort 1- to 3-month double antiplatelet therapy after drug-eluting stent implantation or the conquest of the South Pole [La pauta ultracorta de tratamiento antiagregante plaquetario doble de 1-3 meses tras el implante de stent liberador de fármacos o la conquista del polo sur]. // *Revista Espanola de Cardiologia*, 74, 2021, № 2, p. 126-128. ISSN 0300-8932. DOI 10.1016/j.recesp.2020.08.026.
280. **Paradies, V., Maurina, M., Tonino, P., Hofma, S.H., Vos, J., van Kuijk, J.-P., Oemrawsingh, R.M., Mafragi, A.A., Spano, F., Pisters, R., Polad, J., Ijsselmuiden, S., Cambero, M.M., Smits, P.C.** Comparison of Supraflex Cruz 60 µm Versus Ultimaster Tansei 80 µm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial. // *American Journal of*

281. **Parikh, P.B.** Dual Antiplatelet Duration After DES: Is it Time to Say Goodbye to 1-Year DAPT? // *Journal of the American College of Cardiology*, 78, 2021, № 20, p. 1987-1989. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.08.071.
282. **Park, K., Bortnick, A.E., Lindley, K.J., Sintek, M., Sethi, S., Choi, C., Davis, M.B., Walsh, M.N., Voeltz, M., Bello, N.A., Saw, J., Ahmed, M.M., Smilowitz, N.R., Vidovich, M.I., American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group.** Interventional Cardiac Procedures and Pregnancy. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 1, 2022, № 5, art. no. 100427. ISSN 2772-9303. DOI 10.1016/j.jscai.2022.100427.
283. **Pathan, S.** Immune Thrombocytopenic Purpura and Intracranial Stenting. // *Journal of Pharmacy Practice*, 2024. ISSN 0897-1900. DOI 10.1177/08971900241236121.
284. **Piccolo, R., Esposito, G.** Device Comparisons in the New-Generation Drug-Eluting Stent Era: Continued Refinements in Stent Technology. // *JACC: Cardiovascular Interventions*, 13, 2020, № 9, p. 1110-1111. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.02.041.
285. **Pivato, C.A., Reimers, B., Testa, L., Pacchioni, A., Briguori, C., Musto, C., Esposito, G., Piccolo, R., Lucisano, L., De Luca, L., Conrotto, F., De Marco, A., Franzone, A., Presbitero, P., Ferrante, G., Condorelli, G., Paradies, V., Sardella, G., Indolfi, C., Condorelli, G., Stefanini, G.G.** One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. // *Journal of the American Heart Association*, 11, 2022, № 6, art. no. e023454. ISSN 2047-9980. DOI 10.1161/JAHA.121.023454.
286. **Ploumen, E.H., von Birgelen, C.** Novel DES Aims at Full Thromboresistance: Another Promising Player on the Field? // *Cardiovascular Revascularization Medicine*, 32, 2021, p. 25-26. ISSN 1553-8389. DOI 10.1016/j.carrev.2021.07.029.
287. **Ragosta, M.** Bare Metal Stents Are Obsolete and No Longer Have a Role in PCI. Stop Using Them! // *Cardiovascular Revascularization Medicine*, 23, 2021, p. 50-51. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.11.005.
288. **Rahim, H., Shea, N.J., George, I.** The Management of Stable Coronary Artery Disease and Transcatheter Aortic Valve Replacement. // *Structural Heart*, 5, 2021, № 5, p. 439-445. ISSN 2474-8706. DOI 10.1080/24748706.2021.1942600.
289. **Rao, S.V., Wegermann, Z.K.** Validation of the Academic Research Consortium Definition of High Bleeding Risk: Not Academic Anymore. // *Journal of the American College of Cardiology*, 75, 2020, № 21, p. 2723-2725. ISSN 0735-1097. DOI 10.1016/j.jacc.2020.04.024.
290. **Räsänen, A., Kärkkäinen, J.M., Eranti, A., Eränen, J., Rissanen, T.T.** Percutaneous coronary intervention with drug-coated balloon-only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel concept. // *Catheterization and Cardiovascular Interventions*, 101, 2023, № 3, p. 569-578. ISSN 1522-1946. DOI 10.1002/ccd.30558.



291. **Richardt, G., Abdelghani, M., Allali, A., Toelg, R., Abdellaoui, M., Krackhardt, F., Wiseth, R., Morice, M.-C., Copt, S., Stoll, H.-P., Urban, P.** Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. // *Clinical Research in Cardiology*, 110, 2021, № 2, p. 162-171. ISSN 1861-0684. DOI 10.1007/s00392-020-01672-3.
292. **Roccalvalva, F., Ferrante, G.** Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: How short can we go? // *Minerva Cardioangiologica*, 68, 2020, № 5, p. 436-450. ISSN 0026-4725. DOI 10.23736/S0026-4725.20.05196-8.
293. **Samuel, R., Alfadhel, M., McAlister, C., Nestelberger, T., Saw, J.** Coronary Events in the Pregnant Patient: Who Is at Risk and How Best to Manage? // *Canadian Journal of Cardiology*, 37, 2021, № 12, p. 2026-2034. ISSN 0828-282X. DOI 10.1016/j.cjca.2021.09.009.
294. **Santoro, C., Capone, V., Canonico, M.E., Gargiulo, G., Esposito, R., Sanna, G.D., Parodi, G., Esposito, G.** Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. // *Seminars in Thrombosis and Hemostasis*, 47, 2021, № 8, p. 950-961. ISSN 0094-6176. DOI 10.1055/s-0041-1726298.
295. **Sato, Y., Jinnouchi, H., Kolodgie, F.D., Cheng, Q., Janifer, C., Kutyna, M., Sakamoto, A., Cornelissen, A., Mori, M., Kawakami, R., Kawai, K., Fernandez, R., Ghosh, S.K.B., Romero, M.E., Perkins, L.E.L., Virmani, R., Finn, A.V.** Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. // *International Journal of Cardiology*, 338, 2021, p. 42-49. ISSN 0167-5273. DOI 10.1016/j.ijcard.2021.06.034.
296. **Scheller, B., Rissanen, T.T., Farah, A., Ohlow, M.-A., Mangner, N., Wöhrle, J., Möbius-Winkler, S., Weilenmann, D., Leibundgut, G., Cuculi, F., Gilgen, N., Coslovsky, M., Mahfoud, F., Jeger, R.V.** Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. // *Circulation: Cardiovascular Interventions*, 15, 2022, № 4, p. E011569. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.121.011569.
297. **Shah, M.U., Muhammad, A., Davison, B., Naqvi, S.Y.** Invasive management of non-ST elevation myocardial infarction (NSTEMI) in a patient with severe thrombocytopenia secondary to adult-onset immune thrombocytopenic purpura. // *BMJ Case Reports*, 15, 2022, № 12, art. no. e253140. ISSN 1757-790X. DOI 10.1136/bcr-2022-253140.
298. **Sharma, V., Abdul, F., Haider, S.T., Din, J., Talwar, S., O'Kane, P., Varma, C., Kodoth, V.** Rotablation in the Very Elderly – Safer than We Think? // *Cardiovascular Revascularization Medicine*, 22, 2021, p. 36-41. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.06.035.
299. **Shiraishi, J., Ito, F., Yoshimura, J., Kirii, Y., Kataoka, E., Ozawa, T., Ito, D., Kojima, A., Kimura, M., Kishita, E., Nakagawa, Y., Hyogo, M., Sawada, T.** Stentless Interventional Procedure Using Rotational Atherectomy and Drug-Coated Balloon for Noncalcified De Novo Lesions. // *CJC Open*, 3, 2021, № 6, p. 714-722. ISSN 2589-790X. DOI 10.1016/j.cjco.2021.01.004.

300. **Shroff, G.R., Bangalore, S., Bhawe, N.M., Chang, T.I., Garcia, S., Mathew, R.O., Rangaswami, J., Ternacle, J., Thourani, V.H., Pibarot, P.** Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association. // *Circulation*, 143, 2021, № 25, p. E1088-E1114. ISSN 0009-7322. DOI 10.1161/CIR.0000000000000979.
301. **Simonato, M., Ben-Yehuda, O., Vincent, F., Zhang, Z., Redfors, B.** Consequences of Inaccurate Assumptions in Coronary Stent Noninferiority Trials: A Systematic Review and Meta-analysis. // *JAMA Cardiology*, 7, 2022, № 3, p. 320-327. ISSN 2380-6583. DOI 10.1001/jamacardio.2021.5724.
302. **Sinha, N., Balayla, G., Braghiroli, J.** Coronary artery disease in lung transplant patients. // *Clinical Transplantation*, 34, 2020, № 11, art. no. e14078. ISSN 0902-0063. DOI 10.1111/ctr.14078.
303. **Soh, R.Y.-H., Sia, C.-H., Djohan, A.H., Lau, R.-H., Ho, P.-Y., Neo, J.W.-H., Ho, J.S.-Y., Sim, H.-W., Yeo, T.-C., Tan, H.-C., Chan, M.Y.-Y., Loh, J.P.-Y.** Clinical Characteristics and Long-Term Outcomes of Patients With Differing Haemoglobin Levels Undergoing Semi-Urgent and Elective Percutaneous Coronary Intervention in an Asian Population. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 687555. ISSN 2297-055X. DOI 10.3389/fcvm.2022.687555.
304. **Sotomi, Y., Kozuma, K., Kashiwabara, K., Higuchi, Y., Ando, K., Morino, Y., Ako, J., Tanabe, K., Muramatsu, T., Nakazawa, G., Hikoso, S., Sakata, Y.** Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: A study protocol of the OPTIMA-AF trial. // *BMJ Open*, 11, 2021, № 12, art. no. e048354. ISSN 2044-6055. DOI 10.1136/bmjopen-2020-048354.
305. **Spione, F., Brugaletta, S.** Second generation drug-eluting stents: a focus on safety and efficacy of current devices. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 2, p. 107-127. ISSN 1477-9072. DOI 10.1080/14779072.2021.1874352.
306. **Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K.G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Vanassche, T., Potpara, T., Camm, A.J., Heidbüchel, H., Lip, G.Y.H., Deneke, T., Dagres, N., Boriani, G., Chao, T.-F., Choi, E.-K., Hills, M.T., Santos, I.D.S., Lane, D.A., Atar, D., Joung, B., Cole, O.M., Field, M.** 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. // *Europace*, 23, 2021, № 10, p. 1612-1676. ISSN 1099-5129. DOI 10.1093/europace/euab065.
307. **Tam, C.-C., Tse, H.-F.** Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. // *Journal of Clinical Medicine*, 11, 2022, № 24, art. no. 7440. ISSN 2077-0383. DOI 10.3390/jcm11247440.
308. **Tang, K.S., Banerjee, S., Tang, G., Patel, P.M., Frangieh, A.H.** Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review. // *Interventional Cardiology: Reviews, Research, Resources*, 18, 2023, art. no. e31. ISSN 1756-1477. DOI 10.15420/icr.2023.19.
309. **Tersalvi, G., Biasco, L., Cioffi, G.M., Pedrazzini, G.** Acute coronary syndrome, antiplatelet therapy, and bleeding: A clinical perspective. // *Journal of Clinical*

310. **Theodoropoulos, K.C., Vakalopoulou, S., Oikonomou, M., Stavropoulos, G., Ziakas, A., Kanonidis, I., Kassimis, G.** How to manage a patient with haemophilia and acs requiring pci: A battle between bleeding and thrombosis. // *Medicina (Lithuania)*, 57, 2021, № 4, art. no. 352. ISSN 1010-660X. DOI 10.3390/medicina57040352.
311. **Thomas, A., Gitto, M., Shah, S., Saito, Y., Tirziu, D., Chieffo, A., Stefanini, G.G., Lansky, A.J.** Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2, 2023, № 3, art. no. 100607. ISSN 2772-9303. DOI 10.1016/j.jscai.2023.100607.
312. **Towashiraporn, K., Krittayaphong, R.** Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. // *International Journal of General Medicine*, 15, 2022, p. 2397-2414. ISSN 1178-7074. DOI 10.2147/IJGM.S289295.
313. **Ullah, W., Zghouzi, M., Ahmad, B., Suleiman, A.-R.M., Zahid, S., Faisaluddin, M., Alabdalrazzak, M., Sattar, Y., Kalra, A., Kapadia, S., Fischman, D.L., Brilakis, E.S., Mamas, M.A., Alraies, M.C.** Safety and efficacy of the polymer-free and polymer-coated drug-eluting stents in patients undergoing percutaneous coronary intervention. // *Catheterization and Cardiovascular Interventions*, 98, 2021, № 6, p. E802-E813. ISSN 1522-1946. DOI 10.1002/ccd.29953.
314. **Vachiat, A., Ntsekhe, M., Hellig, F.** Hybrid rotablation and drug-eluting balloon strategy. // *Cardiovascular Journal of Africa*, 32, 2021, № 1, p. 28-32. ISSN 1995-1892. DOI 10.5830/CVJA-2020-050.
315. **Varlamos, C., Lianos, I., Benetou, D.-R., Alexopoulos, D.** Left main disease and bifurcation percutaneous coronary intervention: Focus on antithrombotic therapy. // *US Cardiology Review*, 15, 2021, art. no. e11. ISSN 1758-3896. DOI 10.15420/usc.2020.34.
316. **Voudris, K.V., Feldman, D.N.** Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. // *Current Treatment Options in Cardiovascular Medicine*, 25, 2023, № 5, p. 127-141. ISSN 1092-8464. DOI 10.1007/s11936-023-00981-w.
317. **Waksman, R., Yerasi, C.** High bleeding risk patients: One size does not fit all. // *EuroIntervention*, 17, 2021, № 3, p. 189-191. ISSN 1774-024X. DOI 10.4244/EIJV17I3A35.
318. **Watanabe, H., Morimoto, T., Ogita, M., Suwa, S., Natsuaki, M., Suematsu, N., Koeda, Y., Morino, Y., Nikaido, A., Hata, Y., DOI, M., Hibi, K., Kimura, K., Yoda, S., Kaneko, T., Nishida, K., Kawai, K., Yamaguchi, K., Wakatsuki, T., Tonoike, N., Yamamoto, M., Shimizu, S., Shimohama, T., Ako, J., Kimura, T., STOPDAPT-2 Investigators.** Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. // *Cardiovascular Intervention and Therapeutics*, 36, 2021, № 4, p. 403-415. ISSN 1868-4300. DOI 10.1007/s12928-020-00719-6.

319. Weiss, A.J., Lorente-Ros, M., Correa, A., Barman, N., Tamis-Holland, J.E. Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events? // *Current Atherosclerosis Reports*, 24, 2022, № 9, p. 731-744. ISSN 1523-3804. DOI 10.1007/s11883-022-01049-z.
320. White, T.G., Shah, K.A., Koul, P., Link, T., Dehdashti, A.R., Katz, J.M., Patsalides, A., Woo, H.H. The resolute Onyx drug eluting stent for neurointervention: A technical series. // *Interventional Neuroradiology*, 30, 2024, № 1, p. 14-21. ISSN 1591-0199. DOI 10.1177/15910199221084398.
321. Wongsalap, Y., Kengkla, K., Wilairat, P., Ratworawong, K., Saokaew, S., Wanlapakorn, C. Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis. // *Chronic Diseases and Translational Medicine*, 9, 2023, № 4, p. 299-308. ISSN 2095-882X. DOI 10.1002/cdt3.85.
322. Xu, K., Fu, G., Tong, Q., Liu, B., Han, X., Zhang, J., Ma, G., Yang, Q., Li, H., Zhou, Y., Jing, Q., Li, Y., Han, Y. Biolimus-Coated Balloon in Small-Vessel Coronary Artery Disease: The BIO-RISE CHINA Study. // *JACC: Cardiovascular Interventions*, 15, 2022, № 12, p. 1219-1226. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.03.024.
323. Yerasi, C., Case, B.C., Forrestal, B.J., Torguson, R., Weintraub, W.S., Garcia-Garcia, H.M., Waksman, R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 135, 2020, p. 154-165. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.07.061.
324. Yerasi, C., Case, B.C., Forrestal, B.J., Waksman, R. Review of CRT 2020 Late-breaking Trials. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 6, p. 707-711. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.04.003.
325. Yerasi, C., Forrestal, B.J., Case, B.C., Ben-Dor, I., Satler, L.F., Rogers, T., Mintz, G.S., Waksman, R. Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. // *American Journal of Cardiology*, 149, 2021, p. 57-63. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.03.010.
326. Zeitouni, M., Guedeney, P. Aspirin-Free Strategies in ACS: Is It the Drug or the Stent? // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 441-443. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.040.
327. Zhang, J., Chen, Z., He, Y. Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (TAILOR-BIRISK): Individualized Management and Genotype-Guided De-escalation. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 12, art. no. rcm2412343. ISSN 1530-6550. DOI 10.31083/j.rcm2412343.
328. Zhang, J., He, S., Chen, Z., Li, Y., Guo, Y., He, Y. The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk. // *Current Cardiology Reports*, 25, 2023, № 7, p. 669-680. ISSN 1523-3782. DOI 10.1007/s11886-023-01893-8.
329. Zhang, Y., Zhang, Y., Liu, Z., Zhang, B., Liu, G., Chen, K. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-

risk patients with acute coronary syndrome in contemporary practice. // *Biomedicine and Pharmacotherapy*, 130, 2020, art. no. 110758. ISSN 0753-3322. DOI 10.1016/j.biopha.2020.110758.

Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, **Petrov I**, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. *Eur Heart J Cardiovasc Pharmacother*. 2020 Sep 17:pvaa106. DOI 10.1093/ehjcvp/pvaa106. Epub ahead of print. PMID: 32941620.

**Cited by:**

330. **Agewall, S.** A tailor-made suit always fits best. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 9, 2023, № 3, p. 199-200. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvad024.
331. **Agewall, S.** Focus on prevention in diabetes mellitus and lipid disorder. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 9, 2023, № 4, p. 295-296. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvad037.
332. **Agewall, S.** The search for the perfect antiplatelet treatment continues. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 9, 2023, № 8, p. 671-672. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvad079.
333. **Agewall, S.** Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 7, p. 645-647. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvac048.
334. **Agewall, S.** Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 1, p. 1-3. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvab078.
335. **Bono, J.O.E., Ricarte Bratti, J.P.** It is time to rethink the dual antiplatelet therapy indication in revascularization surgery [Es tiempo de repensar la indicación de terapia antiplaquetaria dual en la cirugía de revascularización]. // *Revista de la Federacion Argentina de Cardiologia*, 52, 2023, № 1, p. 5-7. ISSN 0326-646X.
336. **Boudreau, R., Fu, A.Y.N., Barry, Q.S., Clifford, C.R., Chow, A., Tran, U., Simard, T., Labinaz, M., Dick, A., Glover, C., Froeschl, M., Hibbert, B., Russo, J., Chong, A.Y., Le May, M., So, D.Y.F., CAPITAL Investigators.** Outcomes in Patients Stratified by PRECISE-DAPT Versus DAPT Scores After Percutaneous Coronary Interventions. // *American Journal of Cardiology*, 161, 2021, p. 19-25. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.08.055.
337. **Capranzano, P., Moliterno, D., Capodanno, D.** Aspirin-free antiplatelet strategies after percutaneous coronary interventions. // *European Heart Journal*, 45, 2024, № 8, p. 572-585. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad876.



338. **Cha, J.-J., Hyoung Park, J., Joo, H.J., Hong, S.J., Hoon Ahn, T., Kim, B.K., Shin, W., Ahn, S.G., Yoon, J., Kim, Y.H., cho, Y.-H., Kang, W.C., Kim, W., Lim, Y.-H., Cheol Gwon, H., Gil Choi, W., Lim, D.-S.** Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients. // *Aging*, 13, 2021, № 5, p. 6506-6517. ISSN 1945-4589. DOI 10.18632/aging.202799.
339. **De Servi, S., Landi, A., Savonitto, S., De Luca, L., De Luca, G., Morici, N., Montalto, C., Crimi, G., Cattaneo, M.** Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. // *Journal of Cardiovascular Medicine*, 24, 2023, № 2, p. 77-86. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001399.
340. **De Servi, S., Landi, A., Savonitto, S., Morici, N., De Luca, L., Montalto, C., Crimi, G., De Rosa, R., De Luca, G.** Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field. // *Journal of Clinical Medicine*, 12, 2023, № 5, art. no. 2082. ISSN 2077-0383. DOI 10.3390/jcm12052082.
341. **Dong, L., Lu, C., Wensen, C., Fuzhong, C., Khalid, M., Xiaoyu, D., Guangjuan, L., Yanxia, Q., Yufeng, Z., Xinjian, L., Leilei, C., Junhong, W.** Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 910805. ISSN 2297-055X. DOI 10.3389/fcvm.2022.910805.
342. **Doolub, G., Mamas, M.A.** Percutaneous Coronary Angioplasty in Patients with Cancer: Clinical Challenges and Management Strategies. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1372. ISSN 2075-4426. DOI 10.3390/jpm12091372.
343. **Geisler, T., Branch, K., Nikol, S.** Clinical experience with dual pathway inhibition therapy: Case series and mini review. // *European Heart Journal - Case Reports*, 6, 2022, № 7, art. no. ytac201. ISSN 2514-2119. DOI 10.1093/ehjcr/ytac201.
344. **He, W., Xu, C., Wang, X., Lei, J., Qiu, Q., Hu, Y., Luo, D.** Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention. // *BMC Cardiovascular Disorders*, 21, 2021, № 1, art. no. 435. ISSN 1471-2261. DOI 10.1186/s12872-021-02255-4.
345. **Lyu, S.-Q., Zhu, J., Wang, J., Wu, S., Zhang, H., Shao, X.-H., Yang, Y.-M.** Performance of the REACH, PARIS, BleeMACS, and PRECISE-DAPT scores for predicting 1-year bleeding events in patients undergoing coronary drug-eluting stent implantation. // *Platelets*, 33, 2022, № 5, p. 719-726. ISSN 0953-7104. DOI 10.1080/09537104.2021.1981847.
346. **Ngew, K.Y., Tay, H.Z., Yusof, A.K.M.** Development and validation of a predictive models for predicting the cardiac events within one year for patients underwent percutaneous coronary intervention procedure at IJN. // *BMC Cardiovascular Disorders*, 23, 2023, № 1, art. no. 545. ISSN 1471-2261. DOI 10.1186/s12872-023-03536-w.
347. **Steiner-Gager, G.M., Siller-Matula, J.M.** Abbreviated dual antiplatelet therapy after acute coronary syndrome. // *The Lancet*, 2024. ISSN 0140-6736. DOI 10.1016/S0140-6736(24)00586-5.

348. **Yang, Y.-S., Xi, D.-Y., Duan, Y., Yu, M., Liu, K., Meng, Y.-K., Hu, C.-F., Han, S.-G., Xu, K.** A nomogram model for predicting intramyocardial hemorrhage post-PCI based on SYNTAX score and clinical features. // *BMC Cardiovascular Disorders*, 24, 2024, № 1, art. no. 179. ISSN 1471-2261. DOI 10.1186/s12872-024-03847-6.
349. **Zhang, S., Wu, Y., Lv, C., Liu, H., Wang, Y., Dong, L., Liu, Y., Wang, S., Jia, J., Yin, T.**  $\beta$ 1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention. // *Hellenic Journal of Cardiology*, 2023. ISSN 1109-9666. DOI 10.1016/j.hjc.2023.09.017.

Papathanasiou JV, **Petrov I**, Tokmakova MP, Dimitrova DD, Spasov L, Dzhafer NS, Tsekoura D, Dionyssiotis Y, Ferreira AS, Lopes AJ, Rosulescu E, Foti C. Group-based cardiac rehabilitation interventions. A challenge for physical and rehabilitation medicine physicians: a randomized controlled trial. *Eur J Phys Rehabil Med*. 2020 Aug;56(4):479-488. DOI 10.23736/S1973-9087.20.06013-X. Epub 2020 Jan 23. PMID: 31976639.

#### Cited by:

350. **Bakhshayesh, S., Hoseini, B., Bergquist, R., Nabovati, E., Gholoobi, A., Mohammad-Ebrahimi, S., Eslami, S.** Cost-utility analysis of home-based cardiac rehabilitation as compared to usual post-discharge care: systematic review and meta-analysis of randomized controlled trials. // *Expert Review of Cardiovascular Therapy*, 18, 2020, № 11, p. 761-776. ISSN 1477-9072. DOI 10.1080/14779072.2020.1819239.
351. **Batalik, L., Winnige, P., Dosbaba, F., Vlazna, D., Janikova, A.** Home-based aerobic and resistance exercise interventions in cancer patients and survivors: A systematic review. // *Cancers*, 13, 2021, № 8, art. no. 1915. ISSN 2072-6694. DOI 10.3390/cancers13081915.
352. **Cai, H., Cao, P., Zhou, W., Sun, W., Zhang, X., Li, R., Shao, W., Wang, L., Zou, L., Zheng, Y.** Effect of early cardiac rehabilitation on prognosis in patients with heart failure following acute myocardial infarction. // *BMC Sports Science, Medicine and Rehabilitation*, 13, 2021, № 1, art. no. 139. ISSN 2052-1847. DOI 10.1186/s13102-021-00368-z.
353. **Callum, K., Swinton, P., Gorely, T., Crabtree, D., Leslie, S.** Physiological and psychological outcomes of high intensity interval training in patients with heart failure compared to moderate continuous training and usual care: A systematic review with meta analysis. // *Heart and Lung*, 64, 2024, p. 117-127. ISSN 0147-9563. DOI 10.1016/j.hrtlng.2023.12.002.
354. **Collados-Gutiérrez, A., Gutiérrez-Vilahú, L.** Effectiveness of High Intensity Interval Training versus Moderate Intensity Continuous Training in patients with chronic heart failure with reduced ejection fraction, in relation to aerobic capacity, left ventricular ejection fraction and quality of life. Systematic review [Eficacia del entrenamiento interválico de alta intensidad versus entrenamiento continuo moderado en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida, en relación a la capacidad aeróbica, la fracción de eyección del ventrículo

355. **Fraga, I.B., Caballero, L.G., Lago, P.D., de Oliveira, J.L.C., Scherer, M., Haeffner, M.P., Rabelo-Silva, E.R.** Perceived dyspnea and experience of hospitalized patients with acute decompensated heart failure undergoing an early MOBilization protocol with immersive Virtual rEality: MOVE study protocol for a parallel superiority randomized clinical trial. // *Trials*, 24, 2023, № 1, art. no. 751. ISSN 1745-6215. DOI 10.1186/s13063-023-07786-z.
356. **Giallauria, F.** Editorial to 'The effect of high-intensity interval training on exercise capacity in post-myocardial infarction patients: A systematic review and meta-Analysis'. // *European Journal of Preventive Cardiology*, 29, 2022, № 3, p. 473-474. ISSN 2047-4873. DOI 10.1093/eurjpc/zwab072.
357. **Gore, S., Khanna, H., Kumar, A.** Effects of Comprehensive Outpatient Cardiac Rehabilitation on Exercise Capacity, Functional Status, and Quality of Life in People With Heart Failure: A Systematic Review and Meta-Analysis. // *Physical Therapy*, 103, 2023, № 11, art. no. pzad119. ISSN 0031-9023. DOI 10.1093/ptj/pzad119.
358. **Gu, S., Du, X., Wang, D., Yu, Y., Guo, S.** Effects of high intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure: A systematic review and meta-analysis. // *PLoS ONE*, 18, 2023, art. no. e0290362. ISSN 1932-6203. DOI 10.1371/journal.pone.0290362.
359. **Jacobsson, R.J., Oikarinen, A., Krogell, J., Kankkunen, P.** Group-based cardiac telerehabilitation interventions and health outcomes in coronary patients: A scoping review. // *Clinical Rehabilitation*, 38, 2024, № 2, p. 184-201. ISSN 0269-2155. DOI 10.1177/02692155231202855.
360. **Kirwan, R., Perez de Heredia, F., McCullough, D., Butler, T., Davies, I.G.** Impact of COVID-19 lockdown restrictions on cardiac rehabilitation participation and behaviours in the United Kingdom. // *BMC Sports Science, Medicine and Rehabilitation*, 14, 2022, № 1, art. no. 67. ISSN 2052-1847. DOI 10.1186/s13102-022-00459-5.
361. **Li, D., Chen, P., Zhu, J.** The effects of interval training and continuous training on cardiopulmonary fitness and exercise tolerance of patients with heart failure—a systematic review and meta-analysis. // *International Journal of Environmental Research and Public Health*, 18, 2021, № 13, art. no. 6761. ISSN 1661-7827. DOI 10.3390/ijerph18136761.
362. **McDonagh, S.T.J., Dalal, H., Moore, S., Clark, C.E., Dean, S.G., Jolly, K., Cowie, A., Afzal, J., Taylor, R.S.** Home-based versus centre-based cardiac rehabilitation. // *Cochrane Database of Systematic Reviews*, 2023, № 10, art. no. CD007130. ISSN 1465-1858. DOI 10.1002/14651858.CD007130.pub5.
363. **Nelson, R.K., Solomon, R., Hosmer, E., Zuhl, M.** Cardiac rehabilitation utilization, barriers, and outcomes among patients with heart failure. // *Heart Failure Reviews*, 28, 2023, № 6, p. 1239-1249. ISSN 1382-4147. DOI 10.1007/s10741-023-10309-2.
364. **Yang, C., Zhang, L., Cheng, Y., Zhang, M., Zhao, Y., Zhang, T., Dong, J., Xing, J., Zhen, Y., Wang, C.** High intensity interval training vs. moderate intensity continuous training on aerobic capacity and functional capacity in patients with heart

failure: a systematic review and meta-analysis. // *Frontiers in Cardiovascular Medicine*, 11, 2024, art. no. 1302109. ISSN 2297-055X. DOI 10.3389/fcvm.2024.1302109.

365. **Yu, H., Zhao, X., Wu, X., Yang, J., Wang, J., Hou, L.** High-intensity interval training versus moderate-intensity continuous training on patient quality of life in cardiovascular disease: a systematic review and meta-analysis. // *Scientific Reports*, 13, 2023, № 1, art. no. 13915. ISSN 2045-2322. DOI 10.1038/s41598-023-40589-5.

**Petrov, I., Stankov, Z., Tasheva, I., & Stanilov, P.** (2020). Safety and Efficacy of Transbrachial Access for Endovascular Procedures: A Single-Center Retrospective Analysis. *Cardiovascular Revascularization Medicine*, 21(10), 1269-1273. DOI 10.1016/j.carrev.2020.02.023.

#### Cited by:

366. **Guo, W., Chen, L., Li, X., Zhu, L., Zhang, H., Wu, B., Lu, Q., Xia, S., Ding, Z., Zhang, L.** A comparative study on the transbrachial and transfemoral approaches for the treatment of superior mesenteric artery lesions. // *Journal of Vascular Access*, 2024. ISSN 1129-7298. DOI 10.1177/11297298231225679.
367. **Koziarz, A., Kennedy, S.A., El-Karim, G.A., Tan, K.T., Oreopoulos, G.D., Jaber, A., Rajan, D.K., Mafeld, S.** The Use of Vascular Closure Devices for Brachial Artery Access: A Systematic Review and Meta-Analysis. // *Journal of Vascular and Interventional Radiology*, 34, 2023, № 4, p. 677-684.e5. ISSN 1051-0443. DOI 10.1016/j.jvir.2022.12.022.
368. **Nasr, B., Carret, M., Pluchon, K., Yven, C., Bezon, E., Gouëffic, Y.** Perioperative adverse events in percutaneous versus open brachial access. // *Journal of Vascular Surgery*, 77, 2023, № 3, p. 864-869. ISSN 0741-5214. DOI 10.1016/j.jvs.2022.10.010.
369. **Sliman, H., Eitan, A., Shiran, A., Zafrir, B., Jaffe, R.** Transbrachial Secondary Vascular Access in Transcatheter Aortic Valve Replacement Procedures: A Single-Centre Retrospective Analysis. // *Heart Lung and Circulation*, 31, 2022, № 7, p. 1023-1028. ISSN 1443-9506. DOI 10.1016/j.hlc.2022.01.013.
370. **Wu, J., Xu, J., Yu, Q., Chen, C., Xiao, Y., Bao, J., Yuan, L.** Transbrachial Artery as Single or Combined Approach for Complex Interventions in Patients with Peripheral Artery Disease. // *Annals of Vascular Surgery*, 102, 2024, p. 209-215. ISSN 0890-5096. DOI 10.1016/j.avsg.2023.09.093.

#### 2019

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, Valgimigli M; **GLASSY Investigators**. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. *J Am Coll Cardiol*. 2019 Nov 5;74(18):2223-2234. DOI 10.1016/j.jacc.2019.08.1038. PMID: 31672177.

**Cited by:**

371. **Al-Obaidi, F.R., Hutchings, H.A., Yong, A.S.C., Alrubaiy, L., Al-Farhan, H., Al-Ali, M.H., Al-Kinani, T., Al-Myahi, M., Al-Ken-zawi, H., Al-Sudani, N.** Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. // *Current Cardiology Reviews*, 17, 2021, № 6, art. no. e051121190712. ISSN 1573-403X. DOI 10.2174/1573403X17666210126104053.
372. **Andò, G., De Santis, G.A., Greco, A., Pistelli, L., Francaviglia, B., Capodanno, D., De Caterina, R., Capranzano, P.** P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis. // *JACC: Cardiovascular Interventions*, 15, 2022, № 22, p. 2239-2249. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.08.009.
373. **Asano, T., Ono, M., Dai, Z., Saito, A., Kanie, T., Takaoka, Y., Mizuno, A., Yoneoka, D., Komiyama, N.** Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials. // *EuroIntervention*, 17, 2022, № 16, p. 1318-1329. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00192.
374. **Avanzas, P., de la Torre, J.M.** Seeking precision in percutaneous coronary revascularization: The best stent for each setting. // *International Journal of Cardiology*, 389, 2023, art. no. 131222. ISSN 0167-5273. DOI 10.1016/j.ijcard.2023.131222.
375. **Calderone, D., Ingala, S., Mauro, M.S., Angiolillo, D.J., Capodanno, D.** Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 12, p. 1097-1117. ISSN 1477-9072. DOI 10.1080/14779072.2021.2020100.
376. **Capranzano, P., Angiolillo, D.J.** Antithrombotic Management of Elderly Patients With Coronary Artery Disease. // *JACC: Cardiovascular Interventions*, 14, 2021, № 7, p. 723-738. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.01.040.
377. **Capranzano, P., Moliterno, D., Capodanno, D.** Aspirin-free antiplatelet strategies after percutaneous coronary interventions. // *European Heart Journal*, 45, 2024, № 8, p. 572-585. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad876.
378. **Carlin, S., Eikelboom, J.** Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease? // *Expert Review of Cardiovascular Therapy*, 21, 2023, № 5, p. 305-309. ISSN 1477-9072. DOI 10.1080/14779072.2023.2199155.
379. **Cepas-Guillén, P.L., Laffond, A., Lozano Granero, C., López Lluva, M.T.** III CardioMIR: The Congress of Young Cardiologists [III CardioMIR: el Congreso de los Jóvenes Cardiólogos]. // *REC: CardioClinics*, 57, 2022, p. S28-S36. ISSN 2605-1532. DOI 10.1016/j.rccl.2022.10.010.
380. **Cohen, M., Andries, G.** DAPT Duration: When Less Is More. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 12, p. 1507-1508. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.09.018.



381. **Elzanaty, A.M., Nazir, S., Awad, M.T., Elsheikh, E., Ahuja, K.R., Donato, A., Eltahawy, E.A.** Meta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 12, p. 1500-1506. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.05.012.
382. **Galli, M., Capodanno, D., Andreotti, F., Crea, F., Angiolillo, D.J.** Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions. // *Expert Opinion on Drug Safety*, 20, 2021, № 1, p. 9-21. ISSN 1474-0338. DOI 10.1080/14740338.2021.1850691.
383. **Garg, A., Rout, A., Sharma, A., Sargsyan, D., Beavers, T., Tantry, U., Gurbel, P., Rao, S.V., Kostis, J.B., Cohen, M.** Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. // *Progress in Cardiovascular Diseases*, 63, 2020, № 3, p. 243-248. ISSN 0033-0620. DOI 10.1016/j.pcad.2020.03.018.
384. **Gargiulo, G., Esposito, G.** Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient [Opportunità cliniche e impatto sul sistema sanitario di un trattamento ottimale del paziente post-sindrome coronarica acuta]. // *Global and Regional Health Technology Assessment*, 9, 2022, p. 17-26. ISSN 2284-2403. DOI 10.33393/grhta.2022.2391.
385. **Gerstein, N.S., Albrechtsen, C.L., Mercado, N., Cigarroa, J.E., Schulman, P.M.** A Comprehensive Update on Aspirin Management During Noncardiac Surgery. // *Anesthesia and Analgesia*, 131, 2020, № 4, p. 1111-1123. ISSN 0003-2999. DOI 10.1213/ANE.0000000000005064.
386. **Gragnano, F., Calabrò, P., Mehran, R., Valgimigli, M., PANTHER Collaboration.** Reply: Unconvinced by Data or Resistance to Change? // *Journal of the American College of Cardiology*, 83, 2024, № 1, p. e11-e12. ISSN 0735-1097. DOI 10.1016/j.jacc.2023.10.027.
387. **Greco, A., Finocchiaro, S., Angiolillo, D.J., Capodanno, D.** Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. // *Expert Opinion on Pharmacotherapy*, 24, 2023, № 4, p. 453-471. ISSN 1465-6566. DOI 10.1080/14656566.2023.2171788.
388. **Greco, A., Mauro, M.S., Capodanno, D., Angiolillo, D.J.** P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 10, art. no. 348. ISSN 1530-6550. DOI 10.31083/j.rcm2310348.
389. **Guedeney, P., Mesnier, J., Sorrentino, S., Abcha, F., Zeitouni, M., Lattuca, B., Silvain, J., De Rosa, S., Indolfi, C., Collet, J.-P., Kerneis, M., Montalescot, G.** Review early aspirin discontinuation following acute coronary syndrome or percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials. // *Journal of Clinical Medicine*, 9, 2020, № 3, art. no. 680. ISSN 2077-0383. DOI 10.3390/jcm9030680.
390. **Guimarães, P.O., Franken, M., Tavares, C.A.M., Silveira, F.S., Antunes, M.O., Bergo, R.R., Joaquim, R.M., Hirai, J.C.S., Andrade, P.B., Pitta, F.G., Mariani,**

- J., Jr., Nascimento, B.R., de Paula, J.E.T., Silveira, M.S., Costa, T.A.O., Dall'Orto, F.T.C., Serpa, R.G., Sampaio, F.B.A., Ohe, L.N., Mangione, F.M., Furtado, R.H.M., Sarmento-Leite, R., Monfardini, F., Assis, S.R.L., Nicolau, J.C., Sposito, A.C., Lopes, R.D., Onuma, Y., Valgimigli, M., Angiolillo, D.J., Serruys, P.W., Berwanger, O., Bacal, F., Lemos, P.A. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. // *EuroIntervention*, 19, 2023, № 4, p. E323-E329. ISSN 1774-024X. DOI 10.4244/EIJ-D-23-00125.
391. Ho, A.-C., Egolum, U., Parker, S., Dimmel, J., Hawkins, A., Ling, H. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis. // *Clinical Drug Investigation*, 40, 2020, № 9, p. 799-808. ISSN 1173-2563. DOI 10.1007/s40261-020-00947-x.
392. Hong, S.-J., Lee, S.-J., Suh, Y., Yun, K.H., Kang, T.S., Shin, S., Kwon, S.W., Lee, J.-W., Cho, D.-K., Park, J.-K., Bae, J.-W., Kang, W.C., Kim, S., Lee, Y.-J., Ahn, C.-M., Kim, J.-S., Kim, B.-K., Ko, Y.-G., Choi, D., Jang, Y., Hong, M.-K. Stopping Aspirin Within 1 Month after Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial. // *Circulation*, 149, 2024, № 8, p. 562-573. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.123.066943.
393. Hui, J., Bai, T., Liang, L., He, Q., Tian, N., Li, X., Yang, R., Zhu, L. Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. // *Journal of Cardiovascular Pharmacology*, 80, 2022, № 5, p. 700-708. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001348.
394. Ishida, M., Takahashi, F., Goto, I., Niiyama, M., Saitoh, H., Sakamoto, T., Maegawa, Y., Osaki, T., Nishiyama, O., Endo, H., Sakamoto, R., Kojima, T., Koeda, Y., Kimura, T., Itoh, T., Morino, Y., REIWA investigators. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 4, p. 398-404. ISSN 1868-4300. DOI 10.1007/s12928-020-00694-y.
395. Jones, D., Nicolas, J., Beerkens, F., Satish, M., Feldman, D., Cao, D., Spirito, A., Mehran, R. Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 6. ISSN 1530-6550. DOI 10.31083/j.rcm2306207.
396. Ke, B., Gong, R., Shen, A., Qiu, H., Chen, H., Zhang, Z., Li, W., Xie, Y., Li, H. Risk stratification algorithm for clinical outcomes in anemic patients undergoing percutaneous coronary intervention. // *Annals of Medicine*, 55, 2023, № 2, art. no. 2249200. ISSN 0785-3890. DOI 10.1080/07853890.2023.2249200.
397. Khan, S.U., Singh, M., Valavoor, S., Khan, M.U., Lone, A.N., Khan, M.Z., Khan, M.S., Mani, P., Kapadia, S.R., Michos, E.D., Stone, G.W., Kalra, A., Bhatt, D.L. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. // *Circulation*,

398. **Landi, A., Valgimigli, M.** Antithrombotic therapy in patients with established atherosclerotic coronary disease. // *Heart*, 109, 2023, № 13, p. 1034-1043. ISSN 1355-6037. DOI 10.1136/heartjnl-2022-321603.
399. **Leening, M.J.G., Mahmoud, K.D.** Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. // *European Journal of Epidemiology*, 36, 2021, № 11, p. 1103-1109. ISSN 0393-2990. DOI 10.1007/s10654-021-00820-x.
400. **Leonardi, G.R., Lescano, C.H., Costa, J.L., Mazetto, B., Orsi, F.A., Monica, F.Z.** Adenosine diphosphate-induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t-PAPS): Role of P2Y12-cAMP signaling pathway. // *Journal of Thrombosis and Haemostasis*, 20, 2022, № 7, p. 1699-1711. ISSN 1538-7933. DOI 10.1111/jth.15724.
401. **Linden, K., Mailey, J., Kearney, A., Menown, I.B.A.** Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. // *Advances in Therapy*, 37, 2020, № 6, p. 2620-2645. ISSN 0741-238X. DOI 10.1007/s12325-020-01355-5.
402. **Liuzzo, G., Patrono, C.** Aspirin-free antiplatelet strategies: Is the evidence supporting a paradigm shift? // *European Heart Journal*, 42, 2021, № 39, p. 4011-4012. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab573.
403. **Mehran, R., Cao, D., Baber, U.** Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? // *Journal of the American College of Cardiology*, 74, 2019, № 18, p. 2235-2237. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.08.1037.
404. **Nicolas, J., Goel, R., Claessen, B., Mehran, R.** Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade-why it could be a novel paradigm? – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 167-191. ISBN: 9780128205365. DOI: 10.1016/B978-0-12-820536-5.00008-2.
405. **Occhipinti, G., Capodanno, D.** Reflections after TWILIGHT study: a new era in secondary prevention without aspirin? // *European Heart Journal, Supplement*, 23, 2021, p. E45-E50. ISSN 1520-765X. DOI: 10.1093/eurheartj/suab087.
406. **O'Donoghue, M.L., Murphy, S.A., Sabatine, M.S.** The safety and efficacy of aspirin discontinuation on a background of a P2Y12inhibitor in patients after percutaneous coronary intervention: A systematic review and meta-analysis. // *Circulation*, 142, 2020, № 6, p. 538-545. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.046251.
407. **Olivier, C.B., Bode, C., Dürschmied, D.** Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen. // *Klinikerzt*, 49, 2020, № 3, p. 57-61. ISSN 0341-2350. DOI 10.1055/a-1110-6764.
408. **Otieno, B., Ibecheozor, C., Williams, M.S.** What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease? // *Current*

409. **Park, D.Y., An, S., Kumar, A., Malhotra, S., Jolly, N., Kaur, A., Kattoor, A., Doukky, R., Kalra, A., Vij, A.** Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. // *American Journal of Cardiovascular Drugs*, 22, 2022, № 6, p. 633-645. ISSN 1175-3277. DOI 10.1007/s40256-022-00541-w.
410. **Park, D.Y., Hu, J.-R., Campbell, G., Goldwag, K., Kelsey, M.D., Altin, S.E., Gallegos-Kattán, C., Nanna, M.G.** Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2024, art. no. 101859. ISSN 2772-9303. DOI 10.1016/j.jscai.2024.101859.
411. **Park, D.Y., Hu, J.-R., Jamil, Y., Kelsey, M.D., Jones, W.S., Frampton, J., Kochar, A., Aronow, W.S., Damluji, A.A., Nanna, M.G.** Shorter Dual Antiplatelet Therapy for Older Adults after Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis. // *JAMA Network Open*, 7, 2024, № 3, p. E244000. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2024.4000.
412. **Rangé, G., Hakim, R., Etienne, C.S., Deballon, R., Dechery, T., Souteyrand, G., Bar, O., Albert, F., Canville, A., Gamet, A., Beygui, F., Viallard, L., Bonnet, P., Durand, E., Lesault, P.-F., Boiffard, E., Koning, R., Benamer, H., Commeau, P., Cayla, G., Motreff, P.** Stent thrombosis: A won battle ? (data from the France PCI registry) [Thrombose de stent: une bataille gagnée ? (Données du registre France PCI)]. // *Annales de Cardiologie et d'Angéiologie*, 70, 2021, № 6, p. 388-394. ISSN 0003-3928. DOI 10.1016/j.ancard.2021.10.001.
413. **Roccalvalva, F., Ferrante, G.** Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: How short can we go? // *Minerva Cardioangiologica*, 68, 2020, № 5, p. 436-450. ISSN 0026-4725. DOI 10.23736/S0026-4725.20.05196-8.
414. **Rymer, J.A., Wegermann, Z.K., Kaltenbach, L.A., Webb, L.E., Peterson, E.D., Wang, T.Y.** Challenge in Predicting Persistence to P2Y<sub>12</sub> Inhibitors: A Perspective From the ARTEMIS Trial. // *Journal of the American Heart Association*, 12, 2023, № 12, art. no. e029063. ISSN 2047-9980. DOI 10.1161/JAHA.122.029063.
415. **Saint Croix, G., Lacy, S.C., Gazzhal, A., Ibrahim, M., Gjergjindrea, M., Perez, J., Shehadeh, M., Vedantam, K., Torres, C., Beohar, N., Escolar, E.** Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review. // *Journal of Interventional Cardiology*, 2022, art. no. 3111840. ISSN 0896-4327. DOI 10.1155/2022/3111840.
416. **Sandner, S., Kastrati, A., Niessner, A., Böning, A., Zeymer, U., Conradi, L., Danner, B., Zimpfer, D., Färber, G., Manville, E., Schunkert, H., von Scheidt, M., Grothusen, C., Cremer, J., Attmann, T., Friedrich, I., Oberhoffer, M., Knosalla, C., Walther, T., Wimmer-Greinecker, G., Siepe, M., Grubitzsch, H., Joost, A., Schaefer, A., Misfeld, M., Laufer, G., Wiedemann, D., Englberger, L., Hambrecht, R., TiCAB Investigators.** Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified

subgroup analysis of the TiCAB trial. // *International Journal of Cardiology*, 370, 2023, p. 129-135. ISSN 0167-5273. DOI 10.1016/j.ijcard.2022.10.166.

417. **Sandner, S.E., Schunkert, H., Kastrati, A., Milojevic, M., Böning, A., Zimpfer, D., Zellmer, S., Wiedemann, D., Laufer, G., von Scheidt, M., TiCAB Investigators.** Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. // *Annals of Thoracic Surgery*, 113, 2022, № 2, p. 554-562. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2021.03.061.
418. **Sibbing, D., Cassese, S.** Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 457-460. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.039.
419. **Sinnaeve, P.R., Adriaenssens, T.** Dual Antiplatelet Therapy De-escalation Strategies. // *American Journal of Cardiology*, 144, 2021, p. S23-S31. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.12.020.
420. **Spirito, A., Cao, D., Sartori, S., Sharma, A., Smith, K.F., Vogel, B., Kamaleldin, K., Koshy, A.N., Feng, Y., Power, D., Baber, U., Krishnamoorthy, P., Dangas, G., Kini, A., Sharma, S.K., Mehran, R.** Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 10, 2024, № 1, p. 11-19. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvad069.
421. **Tam, C.-C., Tse, H.-F.** Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. // *Journal of Clinical Medicine*, 11, 2022, № 24, art. no. 7440. ISSN 2077-0383. DOI 10.3390/jcm11247440.
422. **Tang, C., Zhu, Y., Yang, X., Xu, B., Ye, C., Yang, Y., Zhong, J., Zhao, Q., Yu, L.** Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. // *Journal of Gastroenterology and Hepatology (Australia)*, 35, 2020, № 10, p. 1720-1730. ISSN 0815-9319. DOI 10.1111/jgh.15030.
423. **Tizón-Marcos, H., Toloba, A., Subirana Cachinero, I., Elosua, R., Sionis, A., Fernández-Avilés, F., Bueno, H., Carrillo, A., Bayés, A., Sánchez, P.L., Roqué, M., Milà, L., Elorriaga, A., Vaquero, J., Fernández-Bergés, D., Bosch, D., Alameda, J., Martí Almor, J., Jiménez-Navarro, M., Martínez, L., Sanchis, J., Sánchez, E., Rubert, C., Ruiz-Valdepeñas, L., Rodríguez, M., Lozano, Í., Abu-Assi, E., González, V.B., Marrugat, J.** Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients [Pronóstico a largo plazo de la extensión de la TAPD en una cohorte consecutiva de pacientes con IAMCEST]. // *Revista Espanola de Cardiologia*, 76, 2023, № 7, p. 548-554. ISSN 0300-8932. DOI 10.1016/j.recesp.2022.11.016.
424. **Voudris, K.V., Feldman, D.N.** Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. // *Current Treatment Options in Cardiovascular Medicine*, 25, 2023, № 5, p. 127-141. ISSN 1092-8464. DOI 10.1007/s11936-023-00981-w.
425. **Wang, H., Xie, X., Zu, Q., Lu, M., Chen, R., Yang, Z., Gao, Y., Tang, Z.** Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A



426. **Yeh, R., Mihatov, N.** Clinical risk scores: A tool to understand bleeding and thrombotic risk. – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 145-166. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00010-0.
  427. **Yeh, R.W., Mihatov, N.** The DAPT Score Uncouples Bleeding and Ischemic Risk...Again. // *JACC: Cardiovascular Interventions*, 13, 2020, № 5, p. 647-650. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.01.211.
  428. **Yerasi, C., Case, B.C., Forrestal, B.J., Torguson, R., Weintraub, W.S., Garcia-Garcia, H.M., Waksman, R.** Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 135, 2020, p. 154-165. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.07.061.
  429. **Yu, Y., Pan, D., Bai, R., Luo, J., Tan, Y., Duan, W., Shi, D.** P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. // *Frontiers in Cardiovascular Medicine*, 10, 2023, art. no. 1197161. ISSN 2297-055X. DOI 10.3389/fcvm.2023.1197161.
  430. **Zhang, W.-B., Liu, L.-N., Liu, Y., Wang, Z.** Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis. // *Medicine (United States)*, 100, 2021, № 20, p. E26070. ISSN 0025-7974. DOI 10.1097/MD.00000000000026070.
- Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; **THEMIS Steering Committee and Investigators**. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet*. 2019 Sep 28;394(10204):1169-1180. DOI 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1. PMID: 31484629.
- Adik-Patha, L., Shirodkar, S., Gupta, A.** Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome. // *Journal of Association of Physicians of India*, 70, 2022, № 8, p. 84-88. ISSN 0004-5772. DOI 10.5005/japi-11001-0073.
432. **Akhtar, K.H., Baber, U.** Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? // *Medical Clinics of North America*, 108, 2024, № 3, p. 539-551. ISSN 0025-7125. DOI 10.1016/j.mcna.2023.12.003.
  433. **Alhazzani, A., Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Munisamy, M., Sekaran, M., Kumar, A.** Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review. // *Frontiers in Neurology*, 12, 2021, art. no. 667234. ISSN 1664-2295. DOI 10.3389/fneur.2021.667234.

434. **American Diabetes Association Professional Practice Committee.** 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. // *Diabetes Care*, 45, 2022, p. S144-S174. ISSN 0149-5992. DOI 10.2337/dc22-S010.
435. **Armstrong, P.W.** Extending the Product Label for Ticagrelor: Looking under the FDA Hood. // *Circulation*, 144, 2021, № 8, p. 583-585. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.121.055907.
436. **Arrarte, V., Campuzano, R., Carro, A., Castro, A., Dalmau, R., Sandín, M., Velasco, E., Valle, A.** Selection of the best of 2019 in vascular risk and cardiac rehabilitation [Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardíaca]. // *REC: CardioClinics*, 55, 2020, p. 18-24. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.10.015.
437. **Avogaro, A., Barilla, F., Cavalot, F., Consoli, A., Federici, M., Mancone, M., Paolillo, S., Pedrinelli, R., Perseghin, G., Perrone Filardi, P., Scicali, R., Sinagra, G., Spaccarotella, C., Indolfi, C., Purrello, F.** Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. // *Nutrition, Metabolism and Cardiovascular Diseases*, 31, 2021, № 6, p. 1671-1690. ISSN 0939-4753. DOI 10.1016/j.numecd.2021.02.029.
438. **Bai, X., Shen, C., Zhang, W., Yu, T., Jiang, J.** Efficacy and risks of drug-coated balloon treatment for coronary artery disease: A meta-analysis. // *Heliyon*, 9, 2023, № 11, art. no. e22224. ISSN 2405-8440. DOI 10.1016/j.heliyon.2023.e22224.
439. **Bálint, A., Tornyos, D., El Alaoui El Abdallaoui, O., Kupó, P., Komócsi, A.** Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. // *Stroke*, 52, 2021, № 9, p. 2809-2816. ISSN 0039-2499. DOI 10.1161/STROKEAHA.120.032670.
440. **Bates, E.R.** Net Adverse Clinical Events with Antiplatelet Therapy in Acute Coronary Syndromes. // *JAMA - Journal of the American Medical Association*, 324, 2020, № 16, p. 1613-1615. ISSN 0098-7484. DOI 10.1001/jama.2020.16238.
441. **Bendary, A., Zarif, B., Badran, H.M., Shokry, K., Kabil, H.** Boosting protection for patients with non-acute cardiovascular disease: a focus on antithrombotic regimen (a consensus expert opinion from the Egyptian Society of Cardiology working group of thrombosis and prevention). // *Egyptian Heart Journal*, 75, 2023, № 1, art. no. 40. ISSN 1110-2608. DOI 10.1186/s43044-023-00364-3.
442. **Bertolone, D.T., Gallinoro, E., Esposito, G., Paolisso, P., Bermpeis, K., De Colle, C., Fabbriatore, D., Mileva, N., Valeriano, C., Munhoz, D., Belmonte, M., Vanderheyden, M., Bartunek, J., Sonck, J., Wyffels, E., Collet, C., Mancusi, C., Morisco, C., De Luca, N., De Bruyne, B., Barbato, E.** Contemporary Management of Stable Coronary Artery Disease. // *High Blood Pressure and Cardiovascular Prevention*, 29, 2022, № 3, p. 207-219. ISSN 1120-9879. DOI 10.1007/s40292-021-00497-z.
443. **Birnbaum, Y., Chen, H., Tran, D., Nylander, S., Ye, Y.** Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. // *Cardiovascular Drugs and Therapy*, 36, 2022, № 5, p. 829-840. ISSN 0920-3206. DOI 10.1007/s10557-021-07222-x.

444. **Blin, P., Darmon, P., Henry, P., Guiard, E., Bernard, M.-A., Dureau-Pournin, C., Maizi, H., Thomas-Delecourt, F., Lassalle, R., Droz-Perroteau, C., Moore, N.** Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database. // *Cardiovascular Diabetology*, 20, 2021, № 1, art. no. 229. ISSN 1475-2840. DOI 10.1186/s12933-021-01416-1.
445. **Bono, J.O., Liberman, F., Bratti, J.P.R.** Interactions in antithrombotic and hypoglycemic therapy. [INTERACCIONES EN EL TRATAMIENTO ANTITROMBÓTICO E HIPOGLUCEMIANTE]. // *Medicina (Argentina)*, 82, 2022, № 6, p. 934-942. ISSN 0025-7680.
446. **Buxing, C.** Antiplatelet therapy for patients with coronary artery disease following percutaneous coronary intervention [冠心病经皮冠状动脉介入术后的抗血小板治疗]. // *Chinese Journal of General Practitioners*, 21, 2022, № 5, p. 497-500. ISSN 1671-7368. DOI 10.3760/cma.j.cn114798-20220127-00061.
447. **Camm, A.J., Sabbour, H., Schnell, O., Summaria, F., Verma, A.** Managing thrombotic risk in patients with diabetes. // *Cardiovascular Diabetology*, 21, 2022, № 1, art. no. 160. ISSN 1475-2840. DOI 10.1186/s12933-022-01581-x.
448. **Campos-Martins, A., Bragança, B., Correia-de-Sá, P., Fontes-Sousa, A.P.** Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. // *Frontiers in Pharmacology*, 12, 2021, art. no. 724320. ISSN 1663-9812. DOI 10.3389/fphar.2021.724320.
449. **Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D'ascenzo, F., Marquis-Gravel, G., Giustino, G., Costa, F.** Antithrombotic therapy for percutaneous cardiovascular interventions: From coronary artery disease to structural heart interventions. // *Journal of Clinical Medicine*, 8, 2019, № 11, art. no. 2016. ISSN 2077-0383. DOI 10.3390/jcm8112016.
450. **Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024.** // *Diabetes Care*, 47, 2024, p. S179-S218. ISSN 0149-5992. DOI 10.2337/dc24-S010.
451. **Cardiovascular disease and risk management: Standards of medical care in diabetesd 2021.** // *Diabetes Care*, 44, 2021, p. S125-S150. ISSN 0149-5992. DOI 10.2337/dc21-S010.
452. **Cassese, S., Kastrati, A.** Long-term ticagrelor versus prasugrel pharmacodynamics in patients with st-segment–elevation myocardial infarction. // *Journal of the American Heart Association*, 9, 2020, № 5, art. no. e015726. ISSN 2047-9980. DOI 10.1161/JAHA.120.015726.
453. **Chandiramani, R., Spirito, A., Johnson, J.W., Mehta, A., Vogel, B., Faillace, R.T., Mehran, R.** Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. // *Expert Review of Cardiovascular Therapy*, 21, 2023, № 5, p. 311-328. ISSN 1477-9072. DOI 10.1080/14779072.2023.2201437.
454. **Chen, C., Kan, Y., Shi, Z., Guo, D., Fu, W., Li, Y., Lv, Q., Li, X., Si, Y.** Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and

455. **Chen, D.-Q., Guo, Y., Li, X., Zhang, G.-Q., Li, P.** Small molecules as modulators of regulated cell death against ischemia/reperfusion injury. // *Medicinal Research Reviews*, 42, 2022, № 6, p. 2067-2101. ISSN 0198-6325. DOI 10.1002/med.21917.
456. **Chen, H., Sun, Q., Li, H., Tian, T., Song, J., Li, Y.** Observation of Bleeding and MACCE Events in Patients with Liver Cirrhosis Complicated with Acute Coronary Syndrome after Antiplatelet Therapy. // *Journal of the College of Physicians and Surgeons Pakistan*, 33, 2023, № 8, p. 927-931. ISSN 1022-386X. DOI 10.29271/jcpsp.2023.08.927.
457. **Chen, H., Tran, D., Yang, H.-C., Nylander, S., Birnbaum, Y., Ye, Y.** Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay. // *Cardiovascular Drugs and Therapy*, 34, 2020, № 4, p. 443-461. ISSN 0920-3206. DOI 10.1007/s10557-020-06978-y.
458. **Choi, Y., Kang, D.-Y., Lee, J., Lee, J., Kim, M., Kim, H., Park, J., Cho, S., Lee, J., Cha, S.J., Kim, T.O., Lee, P.H., Ahn, J.-M., Park, S.-J., Park, D.-W., TICA KOREA Investigators.** Ticagrelor Versus Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus. // *JACC: Asia*, 2, 2022, № 6, p. 666-674. ISSN 2772-3747. DOI 10.1016/j.jacasi.2022.07.005.
459. **Chyrchel, B., Kruszelnicka, O., Surdacki, A.** Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study. // *Cardiovascular Diabetology*, 21, 2022, № 1, art. no. 249. ISSN 1475-2840. DOI 10.1186/s12933-022-01685-4.
460. **Cui, K., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, R., Wang, H., Cai, Z., Feng, L., Dou, K.** How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention? // *Journal of the American Heart Association*, 11, 2022, № 9, art. no. e023578. ISSN 2047-9980. DOI 10.1161/JAHA.121.023578.
461. **Dang, W., Wang, J., Zhang, Q., Liu, N., Li, W., Yao, Z.** Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function: A one-center retrospective cohort study. // *Medicine (United States)*, 100, 2021, № 16, p. E25601. ISSN 0025-7974. DOI 10.1097/MD.00000000000025601.
462. **Deng, T., Huang, L., You, Z.** Advances in Intensified Antithrombotic Therapies in Acute Coronary Syndrome [急性冠脉综合征患者强化抗栓治疗研究进展]. // *Chinese General Practice*, 26, 2023, № 9, p. 1131-1135. ISSN 1007-9572. DOI 10.12114/j.issn.1007-9572.2022.0444.
463. **Dhindsa, D.S., Sandesara, P.B., Shapiro, M.D., Wong, N.D.** The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. // *Frontiers in Cardiovascular Medicine*, 7, 2020, art. no. 88. ISSN 2297-055X. DOI 10.3389/fcvm.2020.00088.

464. **Dillinger, J.-G., Henry, P.** Benefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors: A Complex Equation. // *Journal of the American College of Cardiology*, 77, 2021, № 19, p. 2378-2381. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.03.319.
465. **Ding, J.-W., Chen, Y., Yu, Z.-Z., Zhao, Y.-B., Fan, K.-P., Yao, X.-D., Hu, L.-L., Liao, Y.-H., Deng, T.-H., Xia, Y., Liao, H.-H., Yang, R.-Q.** De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y<sub>12</sub> Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 11, art. no. 360. ISSN 1530-6550. DOI 10.31083/j.rcm2311360.
466. **Dobesh, P.P., Finks, S.W., Trujillo, T.C.** Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. // *Clinical Therapeutics*, 42, 2020, № 10, p. 2084-2097. ISSN 0149-2918. DOI 10.1016/j.clinthera.2020.08.003.
467. **Drapkina, O.M., Kontsevaya, A.V., Kalinina, A.M., Avdeev, S.N., Agaltsov, M.V., Alexandrova, L.M., Antsiferova, A.A., Aronov, D.M., Akhmedzhanov, N.M., Balanova, Yu.A., Balakhonova, T.V., Berns, S.A., Bochkarev, M.V., Bochkareva, E.V., Bubnova, M.G., Budnevsky, A.V., Gambaryan, M.G., Gorbunov, V.M., Gorny, B.E., Gorshkov, A.Yu., Gumanova, N.G., Dadaeva, V.A., Drozdova, L.Yu., Egorov, V.A., Eliashevich, S.O., Ershova, A.I., Ivanova, E.S., Imaeva, A.E., Ipatov, P.V., Kaprin, A.D., Karamnova, N.S., Kobalava, Zh.D., Konradi, A.O., Kopylova, O.V., Korostovtseva, L.S., Kotova, M.B., Kulikova, M.S., Lavrenova, E.A., Lischenko, O.V., Lopatina, M.V., Lukina, Yu.V., Lukyanov, M.M., Mayev, I.V., Mamedov, M.N., Markelova, S.V., Martsevich, S.Yu., Metelskaya, V.A., Meshkov, A.N., Milushkina, O.Yu., Mukaneeva, D.K., Myrzamatova, A.O., Nebieridze, D.V., Orlov, D.O., Poddubskaya, E.A., Popovich, M.V., Popovkina, O.E., Potievskaya, V.I., Prozorova, G.G., Rakovskaya, Yu.S., Rotar, O.P., Rybakov, I.A., Sviryaev, Yu.V., Skripnikova, I.A., Skoblina, N.A., Smirnova, M.I., Starinsky, V.V., Tolpygina, S.N., Usova, E.V., Khailova, Zh.V., Shalnova, S.A., Shepel, R.N., Shishkova, V.N., Yavelov, I.S., Mardanov, B.U., Russian Society for the Prevention of Non-Communicable Diseases, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation.** 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines [Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022]. // *Cardiovascular Therapy and Prevention (Russian Federation)*, 21, 2022, № 4, art. no. 3235. ISSN 1728-8800. DOI 10.15829/1728-8800-2022-3235.
468. **Galougahi, K.K., Petrossian, G., Stone, G.W., Ali, Z.A.** The year in review: Advances in interventional cardiology in 2019. // *Current Opinion in Cardiology*, 35, 2020, № 4, p. 325-331. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000752.
469. **Gatto, L., Prati, F.** How should the ticagrelor be used? The point after the TWILIGHT and THEMIS-PCI studies. // *European Heart Journal, Supplement*, 22, 2020, p. L72-L76. ISSN 1520-765X. DOI 10.1093/EURHEARTJ/SUAA139.
470. **Giubilato, S., Lucà, F., Abrignani, M.G., Gatto, L., Rao, C.M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., Di Matteo, I., Di Nora, C., Favilli, S., Pilleri, A., Pozzi, A., Temporelli, P.L., Zuin, M., Amico, A.F., Riccio,**



- C., Grimaldi, M., Colivicchi, F., Oliva, F., Gulizia, M.M.** Management of Residual Risk in Chronic Coronary Syndromes. Clinical Pathways for a Quality-Based Secondary Prevention. // *Journal of Clinical Medicine*, 12, 2023, № 18, art. no. 5989. ISSN 2077-0383. DOI 10.3390/jcm12185989.
471. **González-Juanatey, C., Anguita-Sánchez, M., Barrios, V., Núñez-Gil, I., Gómez-Doblas, J.J., García-Moll, X., Lafuente-Gormaz, C., Rollán-Gómez, M.J., Peral-Disdie, V., Martínez-Dolz, L., Rodríguez-Santamarta, M., Viñolas-Prat, X., Soriano-Colomé, T., Muñoz-Aguilera, R., Plaza, I., Curcio-Ruigómez, A., Orts-Soler, E., Segovia, J., Maté, C., Cequier, Á.** Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing. // *PLoS ONE*, 17, 2022, art. no. e0263277. ISSN 1932-6203. DOI 10.1371/journal.pone.0263277.
472. **Han, Y., Yuan, Z., Yang, Y., Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Interventional Cardiology Working Group of Chinese Society of Cardiology, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, Specialty Committee on Coronary Artery Disease and Atherosclerosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology.** Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease [冠心病双联抗血小板治疗中国专家共识]. // *Chinese Journal of Cardiology*, 49, 2021, № 5, p. 432-454. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210125-00088.
473. **He, W., Cao, M., Li, Z.** Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). // *Drug Development Research*, 81, 2020, № 5, p. 551-556. ISSN 0272-4391. DOI 10.1002/ddr.21651.
474. **Hommels, T.M., Hermanides, R.S., Fabris, E., Kedhi, E.** Exploring new insights in coronary lesion assessment and treatment in patients with diabetes mellitus: the impact of optical coherence tomography. // *Cardiovascular Diabetology*, 22, 2023, № 1, art. no. 123. ISSN 1475-2840. DOI 10.1186/s12933-023-01844-1.
475. **Huynh, K.** Ticagrelor reduces ischaemic risk in patients with CAD and diabetes. // *Nature Reviews Cardiology*, 16, 2019, № 11, p. 648. ISSN 1759-5002. DOI 10.1038/s41569-019-0281-3.
476. **Januszek, R., Bil, J., Gilis-Malinowska, N., Staszczak, B., Figatowski, T., Milewski, M., Mielczarek, M., Dylewski, Ł., Wybraniec, M., Tomasiewicz, B., Kübler, P., Walczak, T., Hrymniak, B., Desperak, P., Niezgoda, P., Wolny, R., Chudzik, M., Smolka, G., Ciećwierz, D., Reczuch, K., Gruchala, M., Kubica, J., Gil, R.J., Kedhi, E., D'Ascenzo, F., Balan, R., Pawlik, A., Kuźma, Ł., Dobrzycki, S., Hudziak, D., Bartuś, S., Gaśior, M., Ochala, A., Witkowski, A., Jaguszewski, M., Wojakowski, W., Wańha, W.** Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry). // *Postępy w Kardiologii Interwencyjnej*, 18, 2022, № 1, p. 14-26. ISSN 1734-9338. DOI 10.5114/aic.2022.115631.

477. Januszek, R., Zabojszcz, M., Cyran-Stemplewska, S., Kręcis, B., Bartuś, S., Siudak, Z. Impact of psoriasis on ticagrelor platelet activity versus clopidogrel in patients with chronic coronary syndromes treated via percutaneous coronary intervention. // *Polish Archives of Internal Medicine*, 131, 2021, № 10, art. no. 16105. ISSN 0032-3772. DOI 10.20452/pamw.16105.
478. Kalashnikov, V.Iu., Michurova, M.S. New opportunities of antithrombotic therapy in patients with type 2 diabetes mellitus and stable coronary heart disease for reducing the cardiovascular risk and cardiovascular complications: THEMIS, THEMIS-PCI trials [новые возможности антитромботической терапии у больных с сахарным диабетом 2-го типа и стабильной ишемической болезнью сердца с целью снижения риска сердечно-сосудистых осложнений: Исследования THEMIS, THEMIS-ЧЭИ]. // *Terapevticheskii Arkhiv*, 94, 2022, № 10, p. 1204-1210. ISSN 0040-3660. DOI 10.26442/00403660.2022.10.201911.
479. Khakimova, M.B., Komarov, A.L., Krivosheeva, E.N., Mironov, V.M., Kurbanov, S.K., Kuzyakina, S.O., Yarovaya, E.B., Panchenko, E.P. Factors determining the prognosis after elective myocardial revascularization in patients with coronary artery disease with multifocal atherosclerosis [Факторы, определяющие прогноз после плановой реваскуляризации миокарда у больных ишемической болезнью сердца с мультифокальным атеросклеротическим поражением]. // *Cardiovascular Therapy and Prevention (Russian Federation)*, 22, 2023, № 9, p. 14-24. ISSN 1728-8800. DOI 10.15829/1728-8800-2023-3689.
480. Kim, S., Han, D., Choi, J.H., Park, E.-J., Shin, D.G., Kang, M.-K., Choi, S., Lee, N., Cho, J.R. Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy. // *Korean Journal of Internal Medicine*, 36, 2021, p. S80-S89. ISSN 1226-3303. DOI 10.3904/KJIM.2020.085.
481. Koch, T., Lenz, T., Joner, M., Xhepa, E., Koppa, T., Wiebe, J., Coughlan, J.J., Aytekin, A., Ibrahim, T., Kessler, T., Cassese, S., Laugwitz, K.-L., Schunkert, H., Kastrati, A., Kufner, S., Mehilli, J., Hausleiter, J., Byrne, R.A., Kufner, S., for the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial. // *Clinical Research in Cardiology*, 110, 2021, № 10, p. 1586-1598. ISSN 1861-0684. DOI 10.1007/s00392-021-01854-7.
482. Kongyong, C., Dong, Y., Lei, F., Chenggang, Z., Weihua, S., Hongjian, W., Lei, J., Dong, Z., Sheng, Y., Shaoyu, W., Jining, H., Zheng, Q., Kefei, D. Benefits and risks of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent in patients with stable coronary artery disease and diabetes [稳定性冠心病合并糖尿病患者药物洗脱支架置入术后延长双联抗血小板治疗的获益与风险]. // *Chinese Journal of Cardiology*, 50, 2022, № 5, p. 458-465. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20220114-00034.
483. Koshy, A.N., Giustino, G., Sartori, S., Kyaw, H., Yadav, M., Zhang, Z., Hooda, A., Farooq, A., Krishnamoorthy, P., Sweeny, J.M., Khera, S., Serrao, G.W., Sharma, R., Suleman, J., Dangas, G., Kini, A.S., Mehran, R., Sharma, S.K. Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing

Percutaneous Coronary Intervention. // *JACC: Cardiovascular Interventions*, 15, 2022, № 22, p. 2270-2280. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.09.021.

484. **Ku, C.H.C.** Vascular complications in type 2 diabetes. – In: *Obesity and Diabetes: Scientific Advances and Best Practice*, 2020, p. 509-525. ISBN 9783030533700; 9783030533694. DOI 10.1007/978-3-030-53370-0\_37.
485. **Li, J., Zhu, P., Tang, X., Jiang, L., Li, Y., Yan, K., Yang, W., Qiao, S., Yang, Y., Gao, R., Xu, B., Yuan, J., Zhao, X.** Combined effect of D-dimer, hs-CRP, and Lp(a) on 5-year clinical outcomes after percutaneous coronary intervention: A large real-world study in China. // *iScience*, 26, 2023, № 7, art. no. 107030. ISSN 2589-0042. DOI 10.1016/j.isci.2023.107030.
486. **Li, Y., Cui, J., Liu, Y., Chen, K., Huang, L., Liu, Y.** Development and Validation of Risk Prediction Model for New-Onset Diabetes After Percutaneous Coronary Intervention (NODAP): A Study Protocol for a Retrospective, Multicenter Analysis. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 748256. ISSN 2297-055X. DOI 10.3389/fcvm.2021.748256.
487. **Liang, X.-Y., Li, Y., Qiao, X., Zhang, W.-J., Wang, Z.-L.** Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 655718. ISSN 2297-055X. DOI 10.3389/fcvm.2021.655718.
488. **Liu, L., Zhang, Y., Du, Y., Li, H., Wang, M., Lv, J.** The therapeutic effect and targets of cellulose polysaccharide on coronary heart disease (CHD) and the construction of a prognostic signature based on network pharmacology. // *Frontiers in Nutrition*, 9, 2022, art. no. 986639. ISSN 2296-861X. DOI 10.3389/fnut.2022.986639.
489. **Liu, M., Zhuang, X., Chen, X., Zhang, S., Yang, D., Zhong, X., Xiong, Z., Lin, Y., Zhou, H., Fan, Y., Xie, P., Huang, Y., Wang, L., Liao, X.** Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal. // *Journal of Diabetes Investigation*, 12, 2021, № 1, p. 99-108. ISSN 2040-1116. DOI 10.1111/jdi.13324.
490. **Liu, Z., Tian, R., Wang, Y., Chen, Q., Li, J., Xu, L., Zhang, S.** Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes. // *Thrombosis and Haemostasis*, 120, 2020, № 8, p. 1221-1229. ISSN 0340-6245. DOI 10.1055/s-0040-1713375.
491. **Loganath, K., Adamson, P.D., Moss, A.J.** Ticagrelor in the management of coronary artery disease. // *Future Cardiology*, 17, 2021, № 4, p. 561-571. ISSN 1479-6678. DOI 10.2217/fca-2020-0108.
492. **Maggioni, A.P., Dondi, L., Andreotti, F., Ronconi, G., Calabria, S., Piccinni, C., Pedrini, A., Esposito, I., Martini, N.** Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. // *Therapeutic Advances in Chronic Disease*, 12, 2021. ISSN 2040-6223. DOI 10.1177/20406223211026390.

493. **Makhdoum, A., Dhingra, N.K., Kirubaharan, A., Eikelboom, R., Luc, J., Dagher, O., Bierer, J., Cartier, A., Vaillancourt, O., Vo, T.X., Forgie, K., Bisleri, G., Yau, T.M., Verma, S., Yanagawa, B.** Ticagrelor use and practice patterns among Canadian cardiac surgeons. // *Journal of Cardiac Surgery*, 36, 2021, № 8, p. 2793-2801. ISSN 0886-0440. DOI 10.1111/jocs.15636.
494. **Na, K., Qiu, M., Ma, S., Li, Y., Li, J., Liu, R., Zhang, J., Han, Y.** Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA2DS2-VASc Score. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 808571. ISSN 2297-055X. DOI 10.3389/fcvm.2022.808571.
495. **Nan, W., Hui, W., Jie, Z., Xiao-Xia, H., Gui-Min, Z., Yun-Wen, T., Wen-Sheng, L.** Research progress of low-dose ticagrelor combined with aspirin for acute and stable coronary heart disease [不同低剂量替格瑞洛联合阿司匹林治疗急、慢性冠心病的研究进展]. // *Drugs and Clinic*, 36, 2021, № 6, p. 1330-1335. ISSN 1674-5515. DOI 10.7501/j.issn.1674-5515.2021.06.045.
496. **Nicolas, J., Razuk, V., Giustino, G., Mehran, R.** Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. // *Future Cardiology*, 17, 2021, № 3, p. 521-534. ISSN 1479-6678. DOI 10.2217/fca-2021-0014.
497. **Ning, C., Ling, F., Liu, D., Zhi, Z.** Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials. // *BMC Cardiovascular Disorders*, 24, 2024, № 1, art. no. 166. ISSN 1471-2261. DOI 10.1186/s12872-024-03836-9.
498. **Nusca, A., Viscusi, M.M., Piccirillo, F., De Filippis, A., Nenna, A., Spadaccio, C., Nappi, F., Chello, C., Mangiacapra, F., Grigioni, F., Chello, M., Ussia, G.P.** In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. // *Life*, 12, 2022, № 3, art. no. 393. ISSN 2075-1729. DOI 10.3390/life12030393.
499. **Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K., Vogel, B., Mehran, R.** Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review. // *Pharmacogenomics and Personalized Medicine*, 16, 2023, p. 973-990. ISSN 1178-7066. DOI 10.2147/PGPM.S391400.
500. **Olivier, C.B., Bode, C., Dürschmied, D.** Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen. // *Klinikerzt*, 49, 2020, № 3, p. 57-61. ISSN 0341-2350. DOI 10.1055/a-1110-6764.
501. **Otieno, B., Ibecheozor, C., Williams, M.S.** What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease? // *Current Atherosclerosis Reports*, 25, 2023, № 7, p. 343-350. ISSN 1523-3804. DOI 10.1007/s11883-023-01108-z.
502. **Passacquale, G., Sharma, P., Perera, D., Ferro, A.** Antiplatelet therapy in cardiovascular disease: Current status and future directions. // *British Journal of Clinical Pharmacology*, 88, 2022, № 6, p. 2686-2699. ISSN 0306-5251. DOI 10.1111/bcp.15221.

503. **Patel, K.V., Vaduganathan, M.** Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. // *Current Opinion in Cardiology*, 35, 2020, № 5, p. 517-523. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000762.
504. **Patel, P.P., Fanaroff, A.C.** Optimal Medical Therapy for Chronic Coronary Disease in 2024: Focus on Antithrombotic Therapy. // *Medical Clinics of North America*, 108, 2024, № 3, p. 489-507. ISSN 0025-7125. DOI 10.1016/j.mcna.2023.11.004.
505. **Pham, V., Moroni, A., Gall, E., Benedetti, A., Zivelonghi, C., Picard, F.** Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. // *Journal of Clinical Medicine*, 12, 2023, № 8, art. no. 2833. ISSN 2077-0383. DOI 10.3390/jcm12082833.
506. **Pocock, S.J., Rossello, X., Owen, R., Collier, T.J., Stone, G.W., Rockhold, F.W.** Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. // *Journal of the American College of Cardiology*, 78, 2021, № 8, p. 827-839. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.06.024.
507. **Pujade, I., Perino, J., Mathieu, C., Arnaud, M., Raschi, E., Gatti, M., Bezin, J., Salvo, F.** Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. // *Pharmacological Research*, 160, 2020, art. no. 105089. ISSN 1043-6618. DOI 10.1016/j.phrs.2020.105089.
508. **Rydén, L., Ferrannini, G., Mellbin, L.** Risk factor reduction in type 2 diabetes demands a multifactorial approach. // *European Journal of Preventive Cardiology*, 26, 2019, Suppl. № 2, p. 81-91. ISSN 2047-4873. DOI 10.1177/2047487319872015.
509. **Sabouret, P., Savage, M.P., Fischman, D., Costa, F.** Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 1, p. 21-34. ISSN 1175-3277. DOI 10.1007/s40256-020-00414-0.
510. **Sagar, R.C., Naseem, K.M., Ajjan, R.A.** Antiplatelet therapies in diabetes. // *Diabetic Medicine*, 37, 2020, № 5, p. 726-734. ISSN 0742-3071. DOI 10.1111/dme.14291.
511. **Sharma, R., Kumar, P., Prashanth, S.P., Belagali, Y.** Dual Antiplatelet Therapy in Coronary Artery Disease. // *Cardiology and Therapy*, 9, 2020, № 2, p. 349-361. ISSN 2193-8261. DOI 10.1007/s40119-020-00197-0.
512. **Siasos, G., Skotsimara, G., Oikonomou, E., Sagris, M., Vasilikichara, M., Bletsas, E., Stampouloulou, P., Theofilis, P., Charalampous, G., Tousoulis, D.** Antithrombotic treatment in diabetes mellitus: A review of the literature about antiplatelet and anticoagulation strategies used for diabetic patients in primary and secondary prevention. // *Current Pharmaceutical Design*, 26, 2020, № 23, p. 2780-2788. ISSN 1381-6128. DOI 10.2174/1381612826666200417145605.
513. **Sibbing, D., Cassese, S.** Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 457-460. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.039.



514. **Sidhu, M.S., Lyubarova, R., Bangalore, S., Bonaca, M.P.** Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. // *American Heart Journal*, 246, 2022, p. 44-64. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.12.005.
515. **Tam, C.-C.F., Chan, Y.-H., Wong, Y.-K., Li, Z., Zhu, X., Su, K.-J., Ganguly, A., Hwa, K., Ling, X.B., Tse, H.-F.** Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 42, 2022, № 6, p. 789-798. ISSN 1079-5642. DOI 10.1161/ATVBAHA.121.317513.
516. **Tan, J.W.C., Chew, D.P., Tsui, K.L., Tan, D., Duplyakov, D., Hammoudeh, A., Bo, Z., Yi, L., Kai, X., Ong, P.J., Firman, D., Gamra, H., Almahmeed, W., Dalal, J., Tan, L., Steg, G., Nguyen, Q.N., Ako, J., Al Suwaidi, J.A., Chan, M., Sobhy, M., Shehab, A., Buddhari, W., Zulu, W., Fong, A.Y.Y., Karadag, B., Kim, B.-K., Baber, U., Chin, C.T., Yaling, H.** 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific Region: Special populations [2021 亚太心脏病学会 P2Y12 受体拮抗剂应用于亚太特殊人群的共识]. // *Chinese Journal of Cardiology*, 51, 2023, № 1, p. 19-31. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20220729-00588.
517. **Valgimigli, M., Manavifar, N.** Ticagrelor in patients with diabetes and previous PCI. // *The Lancet*, 394, 2019, № 10204, p. 1118-1120. ISSN 0140-6736. DOI 10.1016/S0140-6736(19)31957-9.
518. **Virk, H.U.H., Escobar, J., Rodriguez, M., Bates, E.R., Khalid, U., Jneid, H., Birnbaum, Y., Levine, G.N., Smith, S.C., Jr., Krittanawong, C.** Dual Antiplatelet Therapy: A Concise Review for Clinicians. // *Life*, 13, 2023, № 7, art. no. 1580. ISSN 2075-1729. DOI 10.3390/life13071580.
519. **Wang, H.-Y., Cai, Z.-X., Yin, D., Yang, Y.-J., Song, W.-H., Dou, K.-F.** Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. // *American Journal of Cardiology*, 142, 2021, p. 14-24. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.11.043.
520. **Wang, Z., Yang, B.** Polypharmacology: Principles and methodologies. – In: *Polypharmacology: Principles and Methodologies*, 2022, p. 1-856. ISBN 9783031049989. DOI 10.1007/978-3-031-04998-9
521. **Wittbrodt, E., Bhalla, N., Andersson Sundell, K., Gao, Q., Dong, L., Cavender, M.A., Hunt, P., Wong, N.D., Mellström, C.** Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. // *Endocrinology, Diabetes and Metabolism*, 3, 2020, № 3, art. no. e00133. ISSN 2398-9238. DOI 10.1002/edm2.133.
522. **Wittbrodt, E., Bhalla, N., Sundell, K.A., Hunt, P., Wong, N.D., Kuster, M., Mellström, C.** Assessment of The High risk and unmet Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. // *Journal of Diabetes and its Complications*, 35, 2021, № 4, art. no. 107859. ISSN 1056-8727. DOI 10.1016/j.jdiacomp.2021.107859.

523. **Wu, B., Shi, L.** Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 6, p. 529-538. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa082.
524. **Xu, Y., Shen, Y., Chen, D., Zhao, P., Jiang, J.** Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. // *Journal of Interventional Cardiology*, 2021, art. no. 9934535. ISSN 0896-4327. DOI 10.1155/2021/9934535.
525. **Yan, K., Zhao, X.** Research progress of double antithrombotic therapy in cardiovascular diseases [双通道抑制的抗栓策略在心血管疾病中的研究进展]. // *Chinese Journal of Cardiology*, 51, 2023, № 12, p. 1290-1294. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20231019-00344.
526. **Yao, F., Wang, C.** Plasma Concentration Detection of Aminophylline with Multi-Walled Carbon Nanotube-Modified Electrodes in the Treatment of Ticagrelor-Related Dyspnea. // *Cellular and Molecular Biology*, 68, 2022, № 3, p. 294-303. ISSN 0145-5680. DOI 10.14715/cmb/2022.68.1.32.
527. **Yap, J., Chew, D.P., Stone, G.W., Tan, J.W.C.** Pharmacotherapy in stable coronary artery disease: Historical perspectives and new insights from the ISCHEMIA trial. // *European Cardiology Review*, 16, 2021, art. no. :e04. ISSN 1758-3756. DOI 10.15420/ECR.2020.48.
528. **Yuan, D., Shi, X., Gao, L., Wan, G., Zhang, H., Yang, Y., Zhao, Y., Sun, D.** Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population. // *Pharmacogenomics and Personalized Medicine*, 15, 2022, p. 29-43. ISSN 1178-7066. DOI 10.2147/PGPM.S338287.
529. **Zhang, J., Chen, Z., Cai, Y., Li, C., He, Y.** Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. // *Cardiovascular Therapeutics*, 2023, art. no. 5446271. ISSN 1755-5914. DOI 10.1155/2023/5446271.
530. **Zhang, Z., Chen, O.** Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. // *Journal of Cardiovascular Pharmacology*, 77, 2021, № 5, p. 536-543. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000995.
531. **Zheng, B., Huo, Y., Lee, S.W.L., Sawhney, J.P.S., Kim, H.-S., Krittayaphong, R., Pocock, S.J., Nhan, V.T., Alonso Garcia, A., Chin, C.T., Jiang, J., Jan, S., Vega, A.M., Hayashi, N., Ong, T.K.** Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. // *Clinical Cardiology*, 43, 2020, № 9, p. 999-1008. ISSN 0160-9289. DOI 10.1002/clc.23400.
532. **Zheng, Y.-Y., Wu, T.-T., Yang, Y., Hou, X.-G., Chen, Y., Ma, X., Ma, Y.-T., Zhang, J.-Y., Xie, X.** Diabetes and Outcomes Following Personalized Antiplatelet Therapy in Coronary Artery Disease Patients Who Have Undergone PCI. // *Journal of Clinical Endocrinology and Metabolism*, 107, 2022, № 1, p. E214-E223. ISSN 0021-972X. DOI 10.1210/clinem/dgab612.

533. **Zhou, Z.** Purinergic interplay between erythrocytes and platelets in diabetes-associated vascular dysfunction. // *Purinergic Signalling*, 17, 2021, № 4, p. 705-712. ISSN 1573-9538. DOI 10.1007/s11302-021-09807-5.
534. **Zhu, H., Xu, X., Fang, X., Ying, F., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., Huang, J.** Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: A network meta-analysis of randomized controlled trials. // *Journal of the American Heart Association*, 10, 2021, № 6, art. no. e019184. ISSN 2047-9980. DOI 10.1161/JAHA.120.019184.
535. **Zou, Y., Yang, S., Wang, S., Lv, B., Xiu, L., Li, L., Lee, S.W.L., Chin, C.T., Pocock, S.J., Huo, Y., Yu, B.** Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia. // *Clinical Cardiology*, 43, 2020, № 4, p. 346-354. ISSN 0160-9289. DOI 10.1002/clc.23322.

Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang CC, Modolo R, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Buszman P, Bolognese L, Tumscitz C, Źmudka K, Aminian A, Vrolix M, **Petrov I**, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Onuma Y, Valgimigli M, Windecker S, Vranckx P, Garg S, Serruys PW. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. *Clin Res Cardiol*. 2020 Jul;109(7):918-929. DOI 10.1007/s00392-019-01585-w. Epub 2019 Dec 11. PMID: 31828504.

#### Cited by:

536. **Gaba, P., Bhatt, D.L.** Recruitment practices in multicenter randomized clinical trials: Time for a relook. // *Journal of the American Heart Association*, 10, 2021, № 22, art. no. e023673. ISSN 2047-9980. DOI 10.1161/JAHA.121.023673.
537. **Ndrepepa, G., Neumann, F.-J., Menichelli, M., Bernlochner, I., Richardt, G., Wöhrle, J., Witzenbichler, B., Mayer, K., Cassese, S., Gewalt, S., Xhepa, E., Kufner, S., Sager, H.B., Joner, M., Ibrahim, T., Laugwitz, K.-L., Schunkert, H., Schüpke, S., Kastrati, A.** Assessment of impact of patient recruitment volume on risk profile, outcomes, and treatment effect in a randomized trial of ticagrelor versus prasugrel in acute coronary syndromes. // *Journal of the American Heart Association*, 10, 2021, № 22, art. no. e021418. ISSN 2047-9980. DOI 10.1161/JAHA.121.021418.

**Petrov I**, Tasheva I, Garvanski I, Stankov Z, Simova I. Comparison of standard renal denervation procedure versus novel distal and branch vessel procedure with brachial arterial access. *Cardiovasc Revasc Med*. 2019;20(1):38-42. DOI10.1016/j.carrev.2018.05.011.

#### Cited by:

538. **Cheng, Y.-Y., Liu, H.-X., Zhang, M., Liu, Y.-J., Nan, Q.** Computational Modeling of Catheter-based Radiofrequency Renal Denervation with Patient-specific Model. – In: *Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, 2021, EMBS, p. 4289-4292. ISSN 1557-170X. ISBN 9781728111797. DOI 10.1109/EMBC46164.2021.9630677.

539. **de Prado, A.P., Pérez-Martínez, C., Regueiro-Purriños, M., Cuellas-Ramón, C., López-Benito, M., Gonzalo-Orden, J.M., Estévez-Loureiro, R., Cortina-Rivero, A.I., Viñuela-Baragaño, D., Altonaga, J.R., Tellez, A., Fernández-Vázquez, F.** Development and evaluation of a disease large animal model for preclinical assessment of renal denervation therapies. // *Animals*, 10, 2020, № 9, art. no. 1446, p. 1-15. ISSN 2076-2615. DOI 10.3390/ani10091446.
540. **Fezzi, S., Castaldi, G., Widmann, M., Marin, F., Ribichini, F.** The return of renal denervation for the treatment of hypertension: An update on new evidence and clinical indications [Il ritorno della denervazione renale nella cura dell'ipertensione arteriosa: nuove evidenze e indicazioni cliniche]. // *Giornale Italiano di Cardiologia*, 22, 2021, № 3, p. 17S-24S. ISSN 1827-6806. DOI 10.1714/3578.35630.
541. **Fischell, T.A.** Continued Momentum in Catheter-Based Renal Denervation: The More the Merrier-Better Denervation Wins Again. // *Cardiovascular Revascularization Medicine*, 20, 2019, № 1, p. 2-3. ISSN 1553-8389. DOI 10.1016/j.carrev.2018.12.009.
542. **Kandzari, D.E., Mahfoud, F., Bhatt, D.L., Böhm, M., Weber, M.A., Townsend, R.R., Hettrick, D.A., Schmieder, R.E., Tsioufis, K., Kario, K.** Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. // *Hypertension*, 76, 2020, № 5, p. 1410-1417. ISSN 0194-911X. DOI 10.1161/HYPERTENSIONAHA.120.15745.
543. **Lauder, L., Böhm, M., Mahfoud, F.** The current status of renal denervation for the treatment of arterial hypertension. // *Progress in Cardiovascular Diseases*, 65, 2021, p. 76-83. ISSN 0033-0620. DOI 10.1016/j.pcad.2021.02.005.
544. **Patel, N.J., Mhatre, A.U., Heuser, R.R.** Changing the paradigm in renal denervation: Is trans-urethral access the key to effective blood pressure reduction? // *Cardiovascular Revascularization Medicine*, 20, 2019, № 1, p. 83-85. ISSN 1553-8389. DOI 10.1016/j.carrev.2018.10.012.
545. **Patel, N.J., Mhatre, A.U., Heuser, R.R.** It's what's inside that matters: Getting to the source in renal denervation. // *Catheterization and Cardiovascular Interventions*, 93, 2019, № 3, p. 503-505. ISSN 1522-1946. DOI 10.1002/ccd.28061.
546. **Pisano, A., Iannone, L.F., Leo, A., Russo, E., Coppolino, G., Bolignano, D.** Renal denervation for resistant hypertension. // *Cochrane Database of Systematic Reviews*, 2021, № 11, art. no. CD011499. ISSN 1465-1858. DOI 10.1002/14651858.CD011499.pub3.
547. **Tochev, S., Rifai, N., Finkov, B., Postadzhian, A.** Long term effect of renal denervation on 24 hour abpm blood pressure variability and blood pressure load parameters. // *Bulgarian Cardiology*, 29, 2023, № 3, p. 40-47. ISSN 1310-7488. DOI 10.3897/bgcardio.29.e110119.
548. **Townsend, R.R., Sobotka, P.A.** Catheter-Based Renal Denervation for Hypertension. // *Current Hypertension Reports*, 20, 2018, № 11, art. no. 93. ISSN 1522-6417. DOI 10.1007/s11906-018-0896-5.
549. **Townsend, R.R., Walton, A., Hettrick, D.A., Hickey, G.L., Weil, J., Sharp, A.S.P., Blankestijn, P.J., Böhm, M., Mancía, G.** Review and meta-analysis of renal

artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. // *EuroIntervention*, 16, 2021, № 1, p. 89-96. ISSN 1774-024X. DOI 10.4244/eij-d-19-00902.

550. **Versaci, F., Sciarretta, S., Scappaticci, M., Di Pietro, R., Calcagno, S., Del Prete, A., Gaspardone, C., Biondi Zoccai, G.** Renal arteries denervation: From the treatment of resistant hypertension to the treatment of atrial fibrillation. // *European Heart Journal, Supplement*, 23, 2021, p. E177-E183. ISSN 1520-765X. DOI 10.1093/eurheartj/suab117.
551. **Wang, T.-D., Lee, Y.-H., Chang, S.-S., Tung, Y.-C., Yeh, C.-F., Lin, Y.-H., Pan, C.-T., Hsu, C.-Y., Huang, C.-Y., Wu, C.-K., Sung, P.-H., Chiang, L.-T., Wang, Y.-C., Tsai, W.-C., Lin, T.-T., Lin, C.-P., Chen, W.-J., Hwang, J.-J.** 2019 consensus statement of the Taiwan hypertension society and the Taiwan society of cardiology on renal denervation for the management of arterial hypertension. // *Acta Cardiologica Sinica*, 35, 2019, № 3, p. 199-230. ISSN 1011-6842. DOI 10.6515/ACS.201905\_35(3).20190415A.

**Petrov I, Tasheva I, Stankov Z, Polomski P, Georgieva G, Marinov K.** Uneventful Follow-Up 2 Years after Endovascular Treatment of a High-Flow Iatrogenic Aortocaval Fistula Causing Pulmonary Hypertension and Right Heart Failure. *Methodist Debaquey Cardiovasc J.* 2019;15(2):152-155. DOI10.14797/mdcj-15-2-152.

#### Cited by:

552. **McDonald, M., Robinson, E., Singh, H.** Staged triple endovascular approach for repair of aortocaval fistula secondary to ruptured abdominal aortic aneurysm. // *Journal of Vascular Surgery Cases, Innovations and Techniques*, 9, 2023, № 4, art. no. 101335. ISSN 2468-4287. DOI 10.1016/j.jvscit.2023.101335.
553. **Naouli, H., Jiber, H., Bouarhroum, A.** Iliac arteriovenous fistula following lumbar disc surgery. A case report. // *JMV-Journal de Medecine Vasculaire*, 47, 2022, № 4, p. 199-202. ISSN 2542-4513. DOI 10.1016/j.jdmv.2022.09.004.
554. **Rabtsun, A., Lejay, A., Saaya, S., Bugurov, S., Chakfé, N., Karpenko, A.** Post-Traumatic Arteriovenous Fistulas Leading to Heart Failure. // *EJVES Vascular Forum*, 53, 2021, p. 14-16. ISSN 2666-688X. DOI 10.1016/j.ejvsf.2021.09.001.

Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, **Petrov I**, Cequier A, Kukreja N, Hoyer A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. *Lancet*. 2019 Mar 9;393(10175):987-997. DOI 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28. PMID: 30827782.

#### Cited by:.



555. **Araujo, G.N.D., Machado, G.P., Moura, M., Silveira, A.D., Bergoli, L.C., Fuchs, F.C., Wainstein, R.V., Goncalves, S.C., Lemos, P.A., Quadros, A.S.D., Wainstein, M.V.** Clinical outcomes with biodegradable versus durable polymer drug-eluting stents in patients with ST-elevation myocardial infarction. // *Cardiovascular Revascularization Medicine*, 2024. ISSN 1553-8389. DOI 10.1016/j.carrev.2024.02.023.
556. **Asano, T., Ono, M., Dai, Z., Saito, A., Kanie, T., Takaoka, Y., Mizuno, A., Yoneoka, D., Komiyama, N.** Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials. // *EuroIntervention*, 17, 2022, № 16, p. 1318-1329. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00192.
557. **Berry, C.** Meta-analyses of moving targets. // *European Heart Journal*, 42, 2021, № 27, p. 2655-2656. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab359.
558. **Buiten, R.A., Zocca, P., Birgelen, C.V.** Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents. // *Current Opinion in Cardiology*, 35, 2020, № 6, p. 705-711. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000786.
559. **Chen, J., Wang, S., Wu, Z., Wei, Z., Zhang, W., Li, W.** Anti-CD34-Grafted Magnetic Nanoparticles Promote Endothelial Progenitor Cell Adhesion on an Iron Stent for Rapid Endothelialization. // *ACS Omega*, 4, 2019, № 21, p. 19469-19477. ISSN 2470-1343. DOI 10.1021/acsomega.9b03016.
560. **Dahal, K., Mosleh, W., Almnajam, M., Khaddr, M., Adeel, M.Y., Vashist, A., Robinson, P., Azrin, M., Lee, J.** NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 10, p. 1202-1208. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.03.012.
561. **de Filippo, O., Bruno, F., Pinxterhuis, T.H., Gąsior, M., Perl, L., Gaido, L., Tuttolomondo, D., Greco, A., Verardi, R., Lo Martire, G., Iannaccone, M., Leone, A., Liccardo, G., Caglioni, S., González Ferreiro, R., Rodinò, G., Musumeci, G., Patti, G., Borzillo, I., Tarantini, G., Wańha, W., Casella, B., Ploumen, E.H., Pyka, Ł., Kornowski, R., Gagnor, A., Piccolo, R., Roubin, S.R., Capodanno, D., Zocca, P., Conrotto, F., De Ferrari, G.M., von Birgelen, C., D'Ascenzo, F., ULTRA Collaborators.** Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry. // *Catheterization and Cardiovascular Interventions*, 102, 2023, № 2, p. 221-232. ISSN 1522-1946. DOI 10.1002/ccd.30696.
562. **G Toth, G., Lansky, A., Baumbach, A., Kelbæk, H., van Royen, N., Holmvang, L., Janssens, L., Brugaletta, S., Barbato, E., Maillard, L., Kiemeneij, F., Naber, C.K., Pucher, F., Laursen, P.N., Ameloot, K., Robles, C., Milkas, A., Sevilla, J., Jensen, C., Wijns, W.** Validation of the all-comers design: Results of the TARGET-AC substudy. // *American Heart Journal*, 221, 2020, p. 148-154. ISSN 0002-8703. DOI 10.1016/j.ahj.2019.10.019.
563. **Gherasie, F.-A., Valentin, C., Busnatu, S.-S.** Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?

564. **Grajek, S., Olasińska-Wisniewska, A., Michalak, M., Ritter, S.S.** Triple versus double antithrombotic therapy in patients with atrial fibrillation and stent implantation: A meta-analysis of randomized trials. // *Kardiologia Polska*, 77, 2019, № 9, p. 837-845. ISSN 0022-9032. DOI 10.33963/KP.14899.
565. **Grundeken, M.J., Beijik, M.A.M.** A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? // *Heart International*, 15, 2021, № 2. ISSN 1826-1868.
566. **Hussain, Y., Gaston, S., Kluger, J., Shah, T., Yang, Y., Tirziu, D., Lansky, A.** Long term outcomes of ultrathin versus standard thickness second-generation drug eluting stents: Meta-analysis of randomized trials. // *Catheterization and Cardiovascular Interventions*, 99, 2022, № 3, p. 563-574. ISSN 1522-1946. DOI 10.1002/ccd.29866.
567. **Iglesias, J.F., Degrauwe, S., Cimci, M., Chatelain, Q., Roffi, M., Windecker, S., Pilgrim, T.** Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes. // *JACC: Cardiovascular Interventions*, 14, 2021, № 22, p. 2461-2473. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.09.028.
568. **Iglesias, J.F., Heg, D., Roffi, M., Tüller, D., Noble, S., Muller, O., Moarof, I., Cook, S., Weilenmann, D., Kaiser, C., Cuculi, F., Häner, J., Jüni, P., Windecker, S., Pilgrim, T.** Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients with Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. // *Circulation: Cardiovascular Interventions*, 12, 2019, № 8, art. no. e008024. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.119.008024.
569. **Joner, M., Cassese, S.** Novel Stent Technologies in Search of a TARGET: Balancing Needs for Patient and Market? // *JACC: Cardiovascular Interventions*, 12, 2019, № 17, p. 1688-1690. ISSN 1936-8798. DOI 10.1016/j.jcin.2019.05.005.
570. **Kimura, T.** Can ultra-thin strut drug-eluting stents improve outcomes? // *The Lancet*, 393, 2019, № 10175, p. 961-962. ISSN 0140-6736. DOI 10.1016/S0140-6736(19)30286-7.
571. **Kirk, S.G., Samavati, L., Liu, Y.** MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response. // *Life Sciences*, 241, 2020, art. no. 117157. ISSN 0024-3205. DOI 10.1016/j.lfs.2019.117157.
572. **Klashami, Z.N., Mostafavi, A., Roudbordeh, M.G., Abbasi, A., Ebrahimi, P., Asadi, M., Amoli, M.M.** Investigating the relationship between the VNTR variant of the interleukin-1 receptor antagonist gene and coronary in-stent restenosis. // *Molecular Biology Reports*, 50, 2023, № 10, p. 8575-8587. ISSN 0301-4851. DOI 10.1007/s11033-023-08759-w.
573. **Kobo, O., Roguin, A.** Orsiro: Ultrathin bioabsorbable polymer sirolimus-eluting stent. // *Future Cardiology*, 15, 2019, № 4, p. 295-300. ISSN 1479-6678. DOI 10.2217/fca-2019-0001.

574. **Leening, M.J.G., Mahmoud, K.D.** Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. // *European Journal of Epidemiology*, 36, 2021, № 11, p. 1103-1109. ISSN 0393-2990. DOI 10.1007/s10654-021-00820-x.
575. **Leone, A., Simonetti, F., Avvedimento, M., Angellotti, D., Immobile Molaro, M., Franzone, A., Esposito, G., Piccolo, R.** Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1378. ISSN 2075-4426. DOI 10.3390/jpm12091378.
576. **Liao, C., Liao, S., Liu, M., Xu, R., Peng, J., Wei, Y., Zhang, W.** Angiographic and clinical outcomes of patients implanted with ultrathin, biodegradable polymer sirolimus-eluting stents versus durable polymer drug-eluting stents for percutaneous coronary intervention: An updated meta-analysis based on randomized controlled trials. // *Journal of Cardiovascular Surgery*, 62, 2021, № 2, p. 175-187. ISSN 0021-9509. DOI 10.23736/S0021-9509.20.11620-3.
577. **Linden, K., Mailey, J., Kearney, A., Menown, I.B.A.** Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. // *Advances in Therapy*, 37, 2020, № 6, p. 2620-2645. ISSN 0741-238X. DOI 10.1007/s12325-020-01355-5.
578. **Madhavan, M.V., Howard, J.P., Naqvi, A., Ben-Yehuda, O., Redfors, B., Prasad, M., Shahim, B., Leon, M.B., Bangalore, S., Stone, G.W., Ahmad, Y.** Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: A systematic review and meta-analysis of randomized controlled trials. // *European Heart Journal*, 42, 2021, № 27, p. 2643-2654. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab280.
579. **Mattke, S., Hanson, M., Bentele, M., Kandzari, D.E.** Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 7, p. 835-842. ISSN 1553-8389. DOI 10.1016/j.carrev.2019.12.018.
580. **Nathani, S., Raheem, A., Sanadhya, H., Purohit, P.C., Patel, R., Alane, P.K., Agarwal, D., Sinha, R.** Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients. // *Anatolian Journal of Cardiology*, 24, 2020, № 6, p. 364-369. ISSN 2149-2263. DOI 10.14744/AnatolJCardiol.2020.98452.
581. **Pamidimukkala, V., Polavarapu, A.R., Polavarapu, N.R., Gangasani, S., Gali, D., Bolinera, S.V., Byrapaneni, S., Polavarapu, R.S.** Impact of ultra-long sirolimus-eluting stents on coronary artery lesions: One-year results of real-world FLeX-LONG Study. // *Minerva Medica*, 111, 2021, № 6, p. 529-535. ISSN 0026-4806. DOI 10.5007/1808-1711.2020V24N3P477.
582. **Park, H., Ahn, J.-M., Kang, D.-Y., Lee, J.-B., Park, S., Ko, E., Cho, S.-C., Lee, P.H., Park, D.-W., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Lee, C.W., Park, S.-W., Park, S.-J.** Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation. // *JACC: Cardiovascular Interventions*, 13, 2020, № 12, p. 1403-1413. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.03.023.

583. **Pilgrim, T., Rothenbühler, M., Siontis, G.C., Kandzari, D.E., Iglesias, J.F., Asami, M., Lefèvre, T., Piccolo, R., Koolen, J., Saito, S., Slagboom, T., Muller, O., Waksman, R., Windecker, S.** Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. // *American Heart Journal*, 235, 2021, p. 140-148. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.02.009.
584. **Polavarapu, R.S., Pamidimukkala, V., Polavarapu, A., Siripuram, Y., Ravella, K.C., Rachaputi, M.B.R., Polavarapu, N., Pulivarthi, K.C., Byrapaneni, S., Gangasani, S., Noronha, M., Chinta, S.R.** Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents. // *Indian Heart Journal*, 75, 2023, № 4, p. 279-284. ISSN 0019-4832. DOI 10.1016/j.ihj.2023.03.006.
585. **Pothineni, R.B., Vijan, V., Potdar, A., Inamdar, M.K., Pathak, A., Mantravadi, S.S., Ajmera, P.** Clinical outcomes of ultrathin biodegradable polymer-coated sirolimus-eluting stents in an all-comer population: One-year results from the T-FLEX registry including high-risk subgroups. // *Anatolian Journal of Cardiology*, 25, 2021, № 10, p. 706-715. ISSN 2149-2263. DOI 10.5152/AnatolJCardiol.2021.78291.
586. **Saha, S., Kerkar, P., Gogtay, N.J.** A critical analysis of the noninferiority design of the TALENT trial. // *Indian Heart Journal*, 72, 2020, № 1, p. 52-54. ISSN 0019-4832. DOI 10.1016/j.ihj.2020.02.002.
587. **Sanz-Sánchez, J., Chiarito, M., Gill, G.S., van der Heijden, L.C., Piña, Y., Cortese, B., Alfonso, F., von Birgelen, C., Diez Gil, J.L., Waksman, R., Garcia-Garcia, H.M.** Small Vessel Coronary Artery Disease: Rationale for Standardized Definition and Critical Appraisal of the Literature. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 1, 2022, № 5, art. no. 100403. ISSN 2772-9303. DOI 10.1016/j.jscai.2022.100403.
588. **Schulz, S., Harzheim, L., Hübner, C., Lorke, M., Jünger, S., Woopen, C.** Patient-centered empirical research on ethically relevant psychosocial and cultural aspects of cochlear, glaucoma and cardiovascular implants – a scoping review. // *BMC Medical Ethics*, 24, 2023, № 1, art. no. 68. ISSN 1472-6939. DOI 10.1186/s12910-023-00945-6.
589. **Selvakumar, P.P., Rafuse, M.S., Johnson, R., Tan, W.** Applying Principles of Regenerative Medicine to Vascular Stent Development. // *Frontiers in Bioengineering and Biotechnology*, 10, 2022, art. no. 826807. ISSN 2296-4185. DOI 10.3389/fbioe.2022.826807.
590. **Sinha, S.K., Aggarwal, P., Pandey, U., Razi, M., Kumar, A., Krishna, V.** Ultrathin (60 µm), ultralong (≤40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients. // *Anatolian Journal of Cardiology*, 25, 2021, № 2, p. 111-118. ISSN 2149-2263. DOI 10.14744/AnatolJCardiol.2020.40909.
591. **Sinha, S.K., Kumar, P., Pandey, U., Aggarwal, P., Razi, M., Sharma, A.K., Jha, M., Sachan, M., Shukla, P., Thakur, R., Krishna, V., Mukherjee, P., Karmakar, S., Bhattacharjee, P., Ray, S.** Twelve-month clinical outcomes of “nano-crush technique” for the treatment of bifurcation lesions using ultra-thin (60 µm) sirolimus-

eluting coronary stents. // *Minerva Cardiology and Angiology*, 71, 2023, № 1, p. 51-60. ISSN 2724-5683. DOI 10.23736/S2724-5683.21.05875-0.

592. **Spione, F., Brugaletta, S.** Second generation drug-eluting stents: a focus on safety and efficacy of current devices. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 2, p. 107-127. ISSN 1477-9072. DOI 10.1080/14779072.2021.1874352.
593. **Su, Y.-M., Zhang, R., Xu, R.-F., Wang, H.-L., Geng, H.-H., Pan, M., Qu, Y.-Y., Zuo, W.-J., Ji, Z.-J., Ma, G.-S.** Triglyceride to high-density lipoprotein cholesterol ratio as a risk factor of repeat revascularization among patients with acute coronary syndrome after first-time percutaneous coronary intervention. // *Journal of Thoracic Disease*, 11, 2019, № 12, p. 5087-5095. ISSN 2072-1439. DOI 10.21037/jtd.2019.12.26.
594. **Talimi, R., Rabbani, S., Mehryab, F., Haeri, A.** Perivascular application of sirolimus multilayer nanofibrous mat for prevention of vascular stenosis: Preparation, In vitro characterization, and In vivo efficacy evaluation. // *Journal of Drug Delivery Science and Technology*, 77, 2022, art. no. 103816. ISSN 1773-2247. DOI 10.1016/j.jddst.2022.103816.
595. **Vallejo-Zamora, J.A., Vega-Cantu, Y.I., Rodriguez, C., Cordell, G.A., Rodriguez-Garcia, A.** Drug-Eluting, Bioresorbable Cardiovascular Stents-Challenges and Perspectives. // *ACS Applied Bio Materials*, 2022. ISSN 2576-6422. DOI 10.1021/acsabm.2c00551.
596. **Waliszewski, M., Rosenberg, M., Rittger, H., Breul, V., Krackhardt, F.** Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description. // *Therapeutic Advances in Cardiovascular Disease*, 14, 2020. ISSN 1753-9447. DOI 10.1177/1753944720911329.
597. **Weiss, A.J., Lorente-Ros, M., Correa, A., Barman, N., Tamis-Holland, J.E.** Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events? // *Current Atherosclerosis Reports*, 24, 2022, № 9, p. 731-744. ISSN 1523-3804. DOI 10.1007/s11883-022-01049-z.
598. **Wu, J.J., Way, J.A.H., Brieger, D.** A review of the ultrathin orsiro biodegradable polymer drug-eluting stent in the treatment of coronary artery disease. // *Heart International*, 13, 2019, № 2, p. 17-24. ISSN 1826-1868. DOI 10.17925/hi.2019.13.2.17.
599. **Zimmermann, F.M., Pijls, N.H.J., Gould, K.L., Johnson, N.P.** Stenting “Vulnerable” But Fractional Flow Reserve–Negative Lesions: Potential Statistical Limitations of Ongoing and Future Trials. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 461-467. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.05.036.

Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, Steg PG; **THEMIS Steering Committee**. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. *Clin Cardiol*. 2019 May;42(5):498-505. DOI 10.1002/clc.23164. Epub 2019 Apr 9. PMID: 30788847; PMCID: PMC6522985.

**Cited by:.**



600. **Calderone, D., Capodanno, D., Angiolillo, D.J.** An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. // *Expert Review of Cardiovascular Therapy*, 2020, p. 449-464. ISSN 1477-9072. DOI 10.1080/14779072.2020.1792293.
601. **De Luca, L.** The THEMIS trial [Lo studio THEMIS]. // *Giornale Italiano di Cardiologia*, 21, 2020, № 2, p. 89-92. ISSN 1827-6806. DOI 10.1714/3300.32699.
602. **Dillinger, J.-G., Henry, P.** DAPT in the diabetic patient with CAD [La DAPT chez le patient diabétique coronarien]. // *Archives of Cardiovascular Diseases Supplements*, 11, 2019, p. S3-S7. ISSN 1878-6480. DOI 10.1016/S1878-6480(19)30959-0.
603. **Gatto, L., Prati, F.** How should the ticagrelor be used? The point after the TWILIGHT and THEMIS-PCI studies. // *European Heart Journal, Supplement*, 22, 2020, p. L72-L76. ISSN 1520-765X. DOI 10.1093/EURHEARTJ/SUAA139.
604. **Kunadian, V., Wilson, N., Stocken, D.D., Ali, H., McColl, E., Burns, G., Howe, N., Fisher, A., De Soyza, A.** Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: A randomised controlled proof-of-concept trial. // *ERJ Open Research*, 5, 2019, № 3, art. no. 00110-2019. ISSN 2312-0541. DOI 10.1183/23120541.00110-2019.
605. **Larina, V.N., Gaydina, T.A., Mkrtychev, D.S., Kuznetsova, V.A., Snezhko, Z.V.** Primary Prevention of Chronic non-Communicable Diseases and Acetylsalicylic Acid: Ambiguity of Opinions [Первичная профилактика хронических неинфекционных заболеваний и ацетилсалициловая кислота: неоднозначность мнений]. // *Kardiologiya*, 60, 2020, № 3, p. 96-101. ISSN 0022-9040. DOI 10.18087/cardio.2020.3.n928.
606. **Li, Z., Cheng, G.** Effect of Sodium-glucose Co-transporter 2 Inhibitor on Ventricular Remodeling [钠-葡萄糖共转运蛋白2抑制剂对心室重构的影响]. // *Chinese General Practice*, 24, 2021, № 3, p. 267-271. ISSN 1007-9572. DOI 10.12114/j.issn.1007-9572.2020.00.638.
607. **Rosenson, R.S., Chen, Q., Najera, S.D., Krishnan, P., Lee, M.L., Cho, D.J.** Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: The Hema-kinesis clinical trial. // *Cardiovascular Diabetology*, 18, 2019, № 1, art. no. 77. ISSN 1475-2840. DOI 10.1186/s12933-019-0882-5.
608. **Wang, C.-A., Hsieh, Y.-C., Huang, C.-Y., Liu, J.-C., Hsieh, M.-H., Lin, Y.-K., Yeh, J.-S.** Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry. // *Medicine (United States)*, 99, 2020, № 19, p. E19969. ISSN 0025-7974. DOI 10.1097/MD.00000000000019969.
609. **Wittbrodt, E., Bhalla, N., Andersson Sundell, K., Gao, Q., Dong, L., Cavender, M.A., Hunt, P., Wong, N.D., Mellström, C.** Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. //

610. **Wittbrodt, E., Bhalla, N., Sundell, K.A., Hunt, P., Wong, N.D., Kuster, M., Mellström, C.** Assessment of The High risk and unmet Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. // *Journal of Diabetes and its Complications*, 35, 2021, № 4, art. no. 107859. ISSN 1056-8727. DOI 10.1016/j.jdiacomp.2021.107859.

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; **AUGUSTUS Investigators**. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. *N Engl J Med*. 2019 Apr 18;380(16):1509-1524. DOI 10.1056/NEJMoa1817083. Epub 2019 Mar 17. PMID: 30883055.

#### Cited by:

611. **Abadie, B.Q., Cannon, C.P., Cavender, M.A.** Novel Oral Anticoagulants following Percutaneous Coronary Intervention. // *Circulation: Cardiovascular Interventions*, 13, 2020, № 7, art. no. e008465. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.119.008465.
612. **Abdelnabi, M., Benjanuwattra, J., Okasha, O., Almaghraby, A., Saleh, Y., Gerges, F.** Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! // *Egyptian Heart Journal*, 74, 2022, № 1, art. no. 18. ISSN 1110-2608. DOI 10.1186/s43044-022-00259-9.
613. **Abdulrahman, B., Jabbour, R.J., Curzen, N.** Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation? // *Interventional Cardiology: Reviews, Research, Resources*, 18, 2023, art. no. 40. ISSN 1756-1477. DOI 10.15420/ICR.2022.40.
614. **Abe, K., Kitahara, H., Suzuki, S., Hiraga, T., Yamazaki, T., Ohno, Y., Harada, J., Fukushima, K., Asano, T., Ishio, N., Uchiyama, R., Miyahara, H., Okino, S., Sano, M., Kuriyama, N., Yamamoto, M., Sakamoto, N., Kanda, J., Kobayashi, Y.** Prognosis of anemic patients with atrial fibrillation undergoing percutaneous coronary intervention. // *International Journal of Cardiology*, 2024, art. no. 131989. ISSN 0167-5273. DOI 10.1016/j.ijcard.2024.131989.
615. **Abe, M., Masunaga, N., Ishii, M., DOI, K., Ishigami, K., Ikeda, S., Aono, Y., An, Y., Iguchi, M., Esato, M., Tsuji, H., Wada, H., Hasegawa, K., Ogawa, H., Akao, M., for the Fushimi AF Registry investigators.** Current status of percutaneous coronary intervention in patients with atrial fibrillation: The Fushimi AF Registry. // *Journal of Cardiology*, 75, 2020, № 5, p. 513-520. ISSN 0914-5087. DOI 10.1016/j.jjcc.2019.09.014.
616. **Abramson, B.L., Al-Omran, M., Anand, S.S., Albalawi, Z., Coutinho, T., de Mestral, C., Dubois, L., Gill, H.L., Greco, E., Guzman, R., Herman, C., Hussain, M.A., Huckell, V.F., Jetty, P., Kaplovitch, E., Karlstedt, E., Kayssi, A., Lindsay, T., Mancini, G.B.J., McClure, G., McMurtry, M.S., Mir, H., Nagpal, S., Nault,**

- P., Nguyen, T., Petrasek, P., Rannelli, L., Roberts, D.J., Roussin, A., Saw, J., Srivaratharajah, K., Stone, J., Szalay, D., Wan, D., Cox, H., Verma, S., Virani, S., **Primary Panel, Secondary Panel.** Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. // *Canadian Journal of Cardiology*, 38, 2022, № 5, p. 560-587. ISSN 0828-282X. DOI 10.1016/j.cjca.2022.02.029.
617. **Acconcia, M.C., Caretta, Q., Chiarotti, F., Tanzilli, G., Torromeo, C., Pannarale, G., Gaudio, C.** Dual vs. triple antithrombotic treatment after percutaneous coronary intervention in patients with non-valvular atrial fibrillation: a meta-analysis on current evidence. // *European Review for Medical and Pharmacological Sciences*, 27, 2023, № 21, p. 10716-10729. ISSN 1128-3602. DOI 10.26355/eurrev\_202311\_34352.
618. **Agasthi, P., Lee, J.Z., Pujari, S.H., Tseng, A.S., Shipman, J., Almader-Douglas, D., Ashraf, H., Mookadam, F., Fortuin, F.D., Beohar, N., Arsanjani, R., Mulpuru, S.** Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis. // *Journal of Arrhythmia*, 36, 2020, № 2, p. 271-279. ISSN 1880-4276. DOI 10.1002/joa3.12292.
619. **Agasthi, P., Tseng, A., Mulpuru, S.K.** Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention. // *European Heart Journal*, 41, 2020, № 17, p. 1700. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa081.
620. **Al Said, S., Ellscheid, M., Beltsios, E.T., Frey, N.** Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease. // *Hamostaseologie*, 42, 2022, № 3, p. 201-209. ISSN 0720-9355. DOI 10.1055/a-1606-7523.
621. **Al Said, S., Katus, H.A., Alabed, S.** Cochrane corner: NOACs in atrial fibrillation patients post-percutaneous coronary intervention. // *Heart*, 106, 2020, № 17, p. 1293-1295. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-316726.
622. **Al-abcha, A., Radwan, Y., Blais, D., Mazzaferri, E.L., Jr., Boudoulas, K.D., Essa, E.M., Gumina, R.J.** Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 850028. ISSN 2297-055X. DOI 10.3389/fcvm.2022.850028.
623. **Alban, S.** Anticoagulation with DOAC - An update [Antikoagulation mit DOAK - ein Update]. // *Medizinische Monatsschrift für Pharmazeuten*, 42, 2019, № 8, p. 284-294. ISSN 0342-9601.
624. **Alegría Ezquerro, E., Agra Bermejo, R., Alonso Perez, L.J., Fernández Fernández, M.Á., Vázquez Rodríguez, J.M., Díaz Castro, Ó., Bravo Amaro, M., Ríos Vázquez, R., Martí-Almor, J.** Atrial fibrillation and ischemic heart disease: beyond stroke prevention [Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus]. // *Revista Española de Cardiología Suplementos*, 20, 2020, p. 11-20. ISSN 1131-3587. DOI 10.1016/S1131-3587(20)30012-1.
625. **Alexopoulos, D.** In the search of the ‘sweet spot’ for aspirin discontinuation time in AF patients post PCI. // *International Journal of Cardiology*, 362, 2022, p. 55-56. ISSN 0167-5273. DOI 10.1016/j.ijcard.2022.04.082.

626. Alexopoulos, D., Dragona, V.-M., Varlamos, C., Ktenas, D., Lianos, I., Patsilina-kos, S., Sionis, D., Zarifis, I., Bampali, T., Poulimenos, L., Skolidis, E., Pissimis, E., Trikas, A., Tsiafoutis, I., Kafkas, N., Olympios, C., Tziakas, D., Ziakas, A., Voudris, V., Kanakakis, I., Tsioufis, C., Davlourous, P., Benetou, D.-R. One-Year Outcomes in Anticoagulated Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the Greek Antiplatelet Atrial Fibrillation Registry. // *Journal of Cardiovascular Pharmacology*, 81, 2023, № 2, p. 141-149. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001389.
627. Alexopoulos, D., Mpahara, A., Kassimis, G. Omitting aspirin in PCI patients: Myth or reality? // *Cardiovascular Drugs and Therapy*, 33, 2019, № 6, p. 711-724. ISSN 0920-3206. DOI 10.1007/s10557-019-06916-7.
628. Alimova, Z.A., Bykova, A.A., Salpagarova, Z.K., Chashkina, M.I., Mesitskaya, D.F., Novikova, A.I., Novikova, N.A., Terekhova, A.V. In-hospital anticoagulation in patients with acute coronary syndrome and atrial fibrillation. // *Kardiologiya i Serdechno-Sosudistaya Khirurgiya*, 16, 2023, № 4, p. 390-397. ISSN 1996-6385. DOI 10.17116/kardio202316041390.
629. Alkhalil, M., Kuzemczak, M., Bell, A., Stern, S., Welsford, M., Cantor, W.J., Goodman, S.G. A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes [Approche pratique à la prescription des antiplaquettaires chez les patients atteints de syndromes coronariens]. // *CMAJ*, 194, 2022, № 17, p. E620-E631. ISSN 0820-3946. DOI 10.1503/cmaj.202863-f.
630. Alkhalil, M., Kuzemczak, M., Bell, A., Stern, S., Welsford, M., Cantor, W.J., Goodman, S.G. A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes. // *CMAJ*, 194, 2022, № 6, p. E205-E215. ISSN 0820-3946. DOI 10.1503/cmaj.202863.
631. Alkhezi, O.S., Buckley, L.F., Fanikos, J. Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020. // *American Journal of Cardiovascular Drugs*, 2024. ISSN 1175-3277. DOI 10.1007/s40256-024-00638-4.
632. Al-Obaidi, F.R., Hutchings, H.A., Yong, A.S.C., Alrubaiy, L., Al-Farhan, H., Al-Ali, M.H., Al-Kinani, T., Al-Myahi, M., Al-Ken-zawi, H., Al-Sudani, N. Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. // *Current Cardiology Reviews*, 17, 2021, № 6, art. no. e051121190712. ISSN 1573-403X. DOI 10.2174/1573403X17666210126104053.
633. Alshahrani, A., O’Nunain, S. Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article. // *Egyptian Heart Journal*, 75, 2023, № 1, art. no. 74. ISSN 1110-2608. DOI 10.1186/s43044-023-00402-0.
634. AlShoaibi, N., Al Harbi, M., Modaimagh, H., Al Qubbany, A., Al Saif, S., Connolly, D.L., Kharabsheh, S., Fathy, M., Hegazy, Y., Tarcha, N., Al Fagih, A. Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 3, p. 221-236. ISSN 1477-9072. DOI 10.1080/14779072.2021.1878878.

635. **Altoukhi, R.M., Alshouimi, R.A., Al Rammah, S.M., Alzahrani, M.Y., Almutairi, A.R., Alshehri, A.M., Alfayez, O.M., Al Yami, M.S., Almohammed, O.A.** Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: A systematic review and network meta-analysis. // *BMJ Open*, 10, 2020, № 9, art. no. e036138. ISSN 2044-6055. DOI 10.1136/bmjopen-2019-036138.
636. **Amin, A.P., Frogge, N., Kulkarni, H., Ridolfi, G., Ewald, G., Miller, R., Hall, B., Rogers, S., Gluckman, T., Curtis, J., Masoudi, F.A., Rao, S.V.** The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention. // *American Heart Journal*, 243, 2022, p. 221-231. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.08.021.
637. **Anchan, R., Cifu, A.S., Paul, J.** Management of Acute Coronary Syndromes in Patients without Persistent ST-Segment Elevation. // *JAMA - Journal of the American Medical Association*, 325, 2021, № 15, p. 1556-1557. ISSN 0098-7484. DOI 10.1001/jama.2021.2744.
638. **Andò, G., Costa, F.** Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. // *International Journal of Cardiology*, 302, 2020, p. 95-102. ISSN 0167-5273. DOI 10.1016/j.ijcard.2019.12.054.
639. **Andrade, J.G., Aguilar, M., Atzema, C., Bell, A., Cairns, J.A., Cheung, C.C., Cox, J.L., Dorian, P., Gladstone, D.J., Healey, J.S., Khairy, P., Leblanc, K., McMurtry, M.S., Mitchell, L.B., Nair, G.M., Nattel, S., Parkash, R., Pilote, L., Sandhu, R.K., Sarrazin, J.-F., Sharma, M., Skanes, A.C., Talajic, M., Tsang, T.S.M., Verma, A., Verma, S., Whitlock, R., Wyse, D.G., Macle, L., Members of the Secondary Panel.** The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. // *Canadian Journal of Cardiology*, 36, 2020, № 12, p. 1847-1948. ISSN 0828-282X. DOI 10.1016/j.cjca.2020.09.001.
640. **Angiolillo, D.J., Galli, M., Collet, J.-P., Kastrati, A., O'Donoghue, M.L.** Antiplatelet therapy after percutaneous coronary intervention. // *EuroIntervention*, 17, 2022, № 17, p. E1371-E1396. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00904.
641. **Antoniou, C.-K., Manolakou, P., Arsenos, P., Dilaveris, P., Gatzoulis, K., Tousoulis, D.** Antithrombotic treatment after atrial fibrillation ablation. // *Current Pharmaceutical Design*, 26, 2020, № 23, p. 2703-2714. ISSN 1381-6128. DOI 10.2174/1381612826666200407154329.
642. **Arana-Rueda, E., Frutos, M., Gómez-Pulido, F., Durán-Guerrero, J.M., Sánchez-Brotons, J.A., Acosta, J., Arce-León, Á., Pedrote, A.** Selection of the best of 2019 in cardiac arrhythmias and pacing [Selección de lo mejor del año 2019 en arritmias y estimulación cardíaca]. // *REC: CardioClinics*, 55, 2020, p. 31-37. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.10.007.
643. **Arrarte, V., Campuzano, R., Carro, A., Castro, A., Dalmau, R., Sandín, M., Velasco, E., Valle, A.** Selection of the best of 2019 in vascular risk and cardiac rehabilitation [Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardíaca]. // *REC: CardioClinics*, 55, 2020, p. 18-24. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.10.015.



644. **Atti, V., Turagam, M.K., Garg, J., Velagapudi, P., Patel, N.J., Basir, M.B., Muger, M.T.P., Rayamajhi, S., Abela, G.S., Koerber, S., Gopinnathanair, R., Lakireddy, D.** Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis. // *Journal of Cardiovascular Electrophysiology*, 30, 2019, № 11, p. 2460-2472. ISSN 1045-3873. DOI 10.1111/jce.14132.
645. **Auer, J., Schmalzer, F., Badea, C., Engel, J., Primus, C.** Antithrombotic treatment after percutaneous coronary intervention [Antithrombotische Behandlung nach perkutaner Koronarintervention]. // *Tagliche Praxis*, 65, 2022, № 4, p. 559-574. ISSN 0494-464X.
646. **Auer, J., Schmalzer, F., Badea, C., Engel, J., Primus, C.** Antithrombotic treatment after percutaneous coronary intervention [Antithrombotische Behandlung nach perkutaner Koronarintervention]. // *Internistische Praxis*, 64, 2021, № 3, p. 387-402. ISSN 0020-9570.
647. **Aznaouridis, K., Tselegkidi, M.-E., Kanakakis, I., Alexopoulos, D.** Dual Antithrombotic Therapy in Atrial Fibrillation Patients undergoing Percutaneous Coronary Angioplasty: The Impact of Bleeding Risk Score on Outcome. // *Thrombosis and Haemostasis*, 121, 2021, № 6, p. 845-847. ISSN 0340-6245. DOI 10.1055/s-0040-1721777.
648. **Baber, U.** The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how? [Antiagregación plaquetaria en monoterapia tras intervención coronaria percutánea: qué, quién, dónde, cuándo, por qué y cómo]. // *Revista Espanola de Cardiologia*, 75, 2022, № 2, p. 115-118. ISSN 0300-8932. DOI 10.1016/j.recesp.2021.08.015.
649. **Badescu, M.C., Sorodoc, V., Lionte, C., Ouatu, A., Haliga, R.E., Costache, A.D., Buliga-Finis, O.N., Simon, I., Sorodoc, L., Costache, I.-I., Rezus, C.** Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus. // *Journal of Personalized Medicine*, 13, 2023, № 1, art. no. 158. ISSN 2075-4426. DOI 10.3390/jpm13010158.
650. **Badreldin, H.A., Bin Saleh, K., Al Yami, M.** Major cardiovascular advances: Highlights from the 2019 American college of cardiology annual scientific session. // *US Cardiology Review*, 13, 2019, № 2, p. 105-109. ISSN 1758-3896. DOI 10.15420/usc.2019.11.2.
651. **Baldus, S., Beyer-Westendorf, J., Möllmann, H., Rottbauer, W., Beyerlein, E., Goette, A.** Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design. // *Scientific Reports*, 13, 2023, № 1, art. no. 18215. ISSN 2045-2322. DOI 10.1038/s41598-023-44345-7.
652. **Barcelona, R.** Best Practices in Pharmacotherapy for Acute Coronary Syndromes. // *US Cardiology Review*, 16, 2022, art. no. e16. ISSN 1758-3896. DOI 10.15420/usc.2022.05.
653. **Barnes, G.D.** Combining antiplatelet and anticoagulant therapy in cardiovascular disease. // *Hematology (United States)*, 20, 2020, № 1, p. 642-648. ISSN 1520-4391. DOI 10.1182/HEMATOLOGY.2020000151.

654. **Barrios, V., Vivas, D., Fernández, F.A., Ángel Arias, M., Diaz Simón, R., Sánchez Purificación, A., Barón-Esquivias, G.** Patients with a high cardiovascular risk and atrial fibrillation: the role of rivaroxaban [Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán]. // *Revista Espanola de Cardiologia Suplementos*, 20, 2020, p. 30-38. ISSN 1131-3587. DOI 10.1016/S1131-3587(20)30014-5.
655. **Barry, A.R., Babadagli, H.E., Boswell, R., Chen, J.W., Dawson, E.L., Lopaschuk, D.G., McMillan, C.L., Nguyen, B.V., Omar, M.A., Pollmann, D.M., Zhou, J.S., Ackman, M.L.** Review of the top 5 cardiology studies of 2019-20. // *Canadian Pharmacists Journal*, 154, 2021, № 6, p. 388-393. ISSN 1715-1635. DOI 10.1177/17151635211029328.
656. **Bas, H.A., Aksoy, F., Bagci, A., Varol, E., Altinbas, A.** Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. // *Revista da Associacao Medica Brasileira*, 66, 2020, № 6, p. 800-805. ISSN 0104-4230. DOI 10.1590/1806-9282.66.6.800.
657. **Bass, M.E., Kiser, T.H., Page, R.L., II, McIlvennan, C.K., Allen, L.A., Wright, G., Shakowski, C.** Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. // *Journal of Thrombosis and Thrombolysis*, 52, 2021, № 2, p. 517-522. ISSN 0929-5305. DOI 10.1007/s11239-020-02371-6.
658. **Baumbach, A., Bourantas, C.V., Serruys, P.W., Wijns, W.** The year in cardiology: coronary interventions. // *Cardiologia Hungarica*, 50, 2020, № 4, p. 219-230. ISSN 0133-5596.
659. **Baumbach, A., Bourantas, C.V., Serruys, P.W., Wijns, W.** The year in cardiology: Coronary interventions: The year in cardiology 2019. // *European Heart Journal*, 41, 2020, № 3, p. 394-405. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz947.
660. **Beaulieu, M.-C., Boivin-Proulx, L.-A., Matteau, A., Mansour, S., Gobeil, J.-F., Potter, B.J.** Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake. // *CJC Open*, 3, 2021, № 8, p. 1025-1032. ISSN 2589-790X. DOI 10.1016/j.cjco.2021.04.002.
661. **Behm, P., Nührenberg, T., Bönner, F., Neumann, F.-J.** Update ESC-Guideline: Myocardial Revascularization [Update ESC-Leitlinie: Myokardiale Revaskularisation]. // *Deutsche Medizinische Wochenschrift*, 144, 2019, № 20, p. 1417-1422. ISSN 0012-0472. DOI 10.1055/a-0867-5426.
662. **Bell, S.P., Rich, M.W.** Cardiovascular Disease. – In: *Geriatrics for Specialists*, Second Edition, 2021, p. 239-260. ISBN 9783030762711; 9783030762704. DOI 10.1007/978-3-030-76271-1\_19.
663. **Ben, H., Changsheng, M., Shulin, W.** 2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation. // *PACE - Pacing and Clinical Electrophysiology*, 45, 2022, № 4, p. 535-555. ISSN 0147-8389. DOI 10.1111/pace.14448.
664. **Benetou, D.-R., Varlamos, C., Ktenas, D., Tsiafoutis, I., Koutouzis, M., Bampali, T., Mantis, C., Zarifis, J., Skolidis, E., Aravantinos, D., Varvarousis, D., Lianos,**

- I., Kanakakis, J., Pisimisis, E., Ziakas, A., Davlourous, P., Alexopoulos, D., on behalf of GRAPE-AF investigators.** Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GREEK-AntiPlatelet Atrial Fibrillation (GRAPE-AF) Registry. // *Cardiovascular Drugs and Therapy*, 35, 2021, № 1, p. 11-20. ISSN 0920-3206. DOI 10.1007/s10557-020-07090-x.
665. **Benetou, D.-R., Varlamos, C., Mpahara, A., Alexopoulos, D.** Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 1, p. 11-20. ISSN 1175-3277. DOI 10.1007/s40256-020-00403-3.
666. **Benetou, D.-R., Vlachakis, P.K., Varlamos, C., Alexopoulos, D.** Antithrombotic therapy in complex percutaneous coronary intervention patients requiring chronic anticoagulation. // *US Cardiology Review*, 15, 2021, art. no. e09. ISSN 1758-3896. DOI 10.15420/usc.2020.31.
667. **Bening, C., Leyh, R., Frantz, S., Hofmann, U.** Anticoagulation and inhibition of platelet aggregation in cardiac surgery patients: Up to date review [Antikoagulation und Thrombozytenaggregationshemmung beim herzchirurgischen Patienten: Aktueller Überblick]. // *Zeitschrift für Herz-, Thorax- und Gefäßchirurgie*, 34, 2020, № 3, p. 157-167. ISSN 0930-9225. DOI 10.1007/s00398-020-00369-z.
668. **Bergmark, B.A., Zelniker, T.A., Kim, M., Mehra, M.R., Stewart, G.C., Page, D.S., Woodcome, E.L., Givertz, M.M.** Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. // *Clinical Transplantation*, 35, 2021, № 10, art. no. e14424. ISSN 0902-0063. DOI 10.1111/ctr.14424.
669. **Berteotti, M., Gori, A.M., Giusti, B., Fortini, A., Grossi, G., Ciardetti, N., Migliorini, A., Lotti, E., Valenti, R., Di Mario, C., Marchionni, N., Marcucci, R.** Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy. // *Journal of Thrombosis and Thrombolysis*, 55, 2023, № 4, p. 667-679. ISSN 0929-5305. DOI 10.1007/s11239-023-02784-z.
670. **Bethel, M., Arora, V.** Anticoagulation Management for Mechanical Valves in the On-X Era. – In: *Heart Valves: From Design to Clinical Implantation*, 2023, p. 383-407. ISBN 9783031255410; 9783031255403. DOI 10.1007/978-3-031-25541-0\_14.
671. **Bhogal, S., Alkhouli, M., White, C.J., Bailey, S., Mamas, M., Haddad, E., Paul, T.K.** Is There a Role for Triple Therapy After ACS? // *Current Cardiology Reports*, 24, 2022, № 3, p. 191-200. ISSN 1523-3782. DOI 10.1007/s11886-022-01634-3.
672. **Bixby, A.L., Lichvar, A.B., Salerno, D., Park, J.M.** Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review. // *Pharmacotherapy*, 41, 2021, № 1, p. 28-43. ISSN 0277-0008. DOI 10.1002/phar.2485.
673. **Bocchino, P.P., Angelini, F., Toso, E.** Atrial fibrillation and coronary artery disease: A review on the optimal use of oral anticoagulants. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 3, p. 635-648. ISSN 1530-6550. DOI 10.31083/J.RCM2203074.

674. **Boivin-Proulx, L.-A., Deneault-Marchand, A., Matteau, A., Mansour, S., Gobeil, F., Camm, J.A., Fox, K.A.A., Potter, B.J.** Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. // *Clinical Cardiology*, 43, 2020, № 3, p. 216-221. ISSN 0160-9289. DOI 10.1002/clc.23316.
675. **Boivin-Proulx, L.-A., Potter, B.J., Dorais, M., Perreault, S.** Evolution of and Evidence-Practice Gaps in Antithrombotic Management of Atrial Fibrillation Patients After Percutaneous Coronary Intervention. // *CJC Open*, 5, 2023, № 1, p. 15-23. ISSN 2589-790X. DOI 10.1016/j.cjco.2022.10.004.
676. **Bolliger, D., Fassl, J., Erdoes, G.** How to Manage the Perioperative Patient on Combined Anticoagulant and Antiplatelet Therapy: Comments on the 2020 ACC Consensus Decision Pathway. // *Journal of Cardiothoracic and Vascular Anesthesia*, 35, 2021, № 6, p. 1561-1564. ISSN 1053-0770. DOI 10.1053/j.jvca.2021.01.042.
677. **Bonanad Lozano, C., Díez-Villanueva, P., Blas, S.G., Ayesta, A., Ibars, S., Ariza-Solé, A., Ferreira, J.L., Moreno, R., Roldán, I., Marín, F., Carol Ruiz, A., García Pardo, H., Sanchís, J., Cruz-González, I., Anguita, M., Cequier, Á., Ruiz García, J., Martínez-Sellés, M.** Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischaemic heart disease. Atrial Fibrillation and Ischemic Heart Disease in the Elderly [Impacto del tratamiento antitrombótico y los síndromes geriátricos en octogenarios con fibrilación auricular y cardiopatía isquémica. Fibrilación Auricular y Cardiopatía Isquémica en Longevos (FACIL)]. // *Revista Espanola de Geriatria y Gerontologia*, 55, 2020, № 6, p. 338-342. ISSN 0211-139X. DOI 10.1016/j.regg.2020.05.008.
678. **Bonanad Lozano, C., García-Pardo, H., Carol Ruiz, A., Esteban-Fernández, A., Gallego González, E., Martín-Sánchez, F.J., Ariza-Solé, A., Díez-Villanueva, P.** Selection of the best of 2019 in geriatric cardiology [Selección de lo mejor del año 2019 en cardiología geriátrica]. // *REC: CardioClinics*, 55, 2020, p. 3-9. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.09.008.
679. **Bor, W.L., Wilhelmina de Veer, A.J., Olie, R.H., Rikken, S.A.O.F., Chan Pin Yin, D.R.P.P., Herrman, J.P.R., Vrolix, M., Meuwissen, M., Vandendriessche, T., van Mieghem, C., Magro, M., Bennaghmouch, N., Hermanides, R., Adriaenssens, T., Dewilde, W.J.M., ten Berg, J.M.** Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study. // *EuroIntervention*, 18, 2022, № 4, p. 303-313. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00703.
680. **Boriani, G., Imberti, J.F., Vitolo, M.** From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. // *European Journal of Internal Medicine*, 77, 2020, p. 27-29. ISSN 0953-6205. DOI 10.1016/j.ejim.2020.04.040.
681. **Boris, A., Luigi, B., Serena, M., Stefano, S., Alessandra, C., Elena, P., Tiziano, M., Marco, M., Catherine, K., Giovanni, P.** Prognostic role of atrial fibrillation in acute coronary syndromes: a real-life, contemporary analysis. // *Cardiovascular Medicine*, 23, 2020, № 5, art. no. w02123. ISSN 1664-2031. DOI 10.4414/cvm.2020.02123.

682. **Borovkova, N.Yu., Buyanova, M.V.** Multidisciplinary approach to safety of antithrombotic therapy: focus on the gastrointestinal tract. // *Clinical Review for General Practice*, 2, 2021, № 4, p. 51-59. ISSN 2713-2552. DOI 10.47407/kr2021.2.4.00060.
683. **Botto, G., Ameri, P., Cappellari, M., Dentali, F., Ferri, N., Parrini, I., Porto, I., Squizzato, A., Camporese, G.** Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. // *Advances in Therapy*, 38, 2021, № 6, p. 2891-2907. ISSN 0741-238X. DOI 10.1007/s12325-021-01769-9.
684. **Boyanpally, A., Cutting, S., Furie, K.** Acute Ischemic Stroke Associated with Myocardial Infarction: Challenges and Management. // *Seminars in Neurology*, 41, 2021, № 4, p. 331-339. ISSN 0271-8235. DOI 10.1055/s-0041-1726333.
685. **Boyd, R.L., Tasseff, N., Xu, B.** Contemporary review on the management of oral anticoagulation and anti-platelet therapies in patients undergoing percutaneous coronary intervention with concurrent atrial fibrillation. // *AME Medical Journal*, 6, 2021, art. no. 31. ISSN 2520-0518. DOI 10.21037/amj-21-9.
686. **Breuckmann, F., Settelmeier, S., Rassaf, T., Post, F., Haerer, W., Bauersachs, J., Mudra, H., Voigtländer, T., Senges, J., Münzel, T., Giannitsis, E.** Survey of clinical practice pattern in Germany's certified chest pain units: Adherence to the European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndrome [Versorgungsanalyse unter den deutschen zertifizierten Chest Pain Units: Klinische Umsetzung der Leitlinien der Europäischen Gesellschaft für Kardiologie zum akuten Koronarsyndrom ohne ST-Strecken-Hebung]. // *Herz*, 47, 2022, № 6, p. 543-552. ISSN 0340-9937. DOI 10.1007/s00059-021-05079-2.
687. **Brunetti, N.D., Tricarico, L., De Gennaro, L., Correale, M., Santoro, F., Ieva, R., Iacoviello, M., Di Biase, M.** Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? // *IJC Heart and Vasculature*, 29, 2020, art. no. 100569. ISSN 2352-9067. DOI 10.1016/j.ijcha.2020.100569.
688. **Buccheri, S., Angiolillo, D.J., Capodanno, D.** Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. // *Therapeutic Advances in Cardiovascular Disease*, 13, 2019. ISSN 1753-9447. DOI 10.1177/1753944719891688.
689. **Buccheri, S., Capodanno, D., James, S., Angiolillo, D.J.** Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. // *Expert Opinion on Drug Safety*, 18, 2019, № 12, p. 1171-1189. ISSN 1474-0338. DOI 10.1080/14740338.2019.1680637.
690. **Camaj, A., Miller, M.S., Halperin, J.L., Giustino, G.** Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Cardiology Clinics*, 38, 2020, № 4, p. 551-561. ISSN 0733-8651. DOI 10.1016/j.ccl.2020.07.006.
691. **Camarero, T.G., de la Torre Hernández, J.M.** Antithrombotic treatment after coronary intervention: Agreement and controversy. // *European Cardiology Review*, 15, 2020, art. no. e07. ISSN 1758-3756. DOI 10.15420/ecr.2019.25.2.



692. **Camm, A.J., Sabbour, H., Schnell, O., Summaria, F., Verma, A.** Managing thrombotic risk in patients with diabetes. // *Cardiovascular Diabetology*, 21, 2022, № 1, art. no. 160. ISSN 1475-2840. DOI 10.1186/s12933-022-01581-x.
693. **Cannon, C.P.** Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. // *American Journal of Cardiology*, 144, 2021, p. S32-S39. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.12.017.
694. **Capodanno, D.** Triple Therapy, Dual Therapy, and Modulation of Anticoagulation Intensity. // *JACC: Cardiovascular Interventions*, 14, 2021, № 7, p. 781-784. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.02.039.
695. **Capodanno, D., Angiolillo, D.J.** Dual antithrombotic therapy for atrial fibrillation and PCI. // *The Lancet*, 394, 2019, № 10206, p. 1300-1302. ISSN 0140-6736. DOI 10.1016/S0140-6736(19)31954-3.
696. **Capranzano, P., Angiolillo, D.J.** Antithrombotic Management of Elderly Patients With Coronary Artery Disease. // *JACC: Cardiovascular Interventions*, 14, 2021, № 7, p. 723-738. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.01.040.
697. **Capranzano, P., Angiolillo, D.J.** Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD. // *JACC: Cardiovascular Interventions*, 12, 2019, № 16, p. 1562-1565. ISSN 1936-8798. DOI 10.1016/j.jcin.2019.06.032.
698. **Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D'ascenzo, F., Marquis-Gravel, G., Giustino, G., Costa, F.** Antithrombotic therapy for percutaneous cardiovascular interventions: From coronary artery disease to structural heart interventions. // *Journal of Clinical Medicine*, 8, 2019, № 11, art. no. 2016. ISSN 2077-0383. DOI 10.3390/jcm8112016.
699. **Carciotto, G., Costa, F., Garcia-Ruiz, V., Galli, M., Soraci, E., Magliarditi, A., Teresi, L., Nasso, E., Carerj, S., Di Bella, G., Micari, A., De Luca, G.** Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review. // *Journal of Clinical Medicine*, 12, 2023, № 22, art. no. 7144. ISSN 2077-0383. DOI 10.3390/jcm12227144.
700. **Casado-Arroyo, R., Abugattas De Torres, J.-P.** Augustus or the dilemma of hemorrhagic and ischemic risk in patients with atrial fibrillation [Augustus ou le dilemme du risque hémorragique et ischémique chez les patients atteints d'une fibrillation auriculaire]. // *Revue Medicale de Bruxelles*, 41, 2020, № 3, p. 175-176. ISSN 0035-3639. DOI 10.30637/2020.19-089.
701. **Casula, M., Fortuni, F., Ferlini, M., Fabris, F., Oltrona Visconti, L., Leonardi, S.** Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 2, p. 231-240. ISSN 1175-3277. DOI 10.1007/s40256-020-00436-8.
702. **Cepas-Guillén, P.L., Laffond, A., Lozano Granero, C., López Lluva, M.T.** III CardioMIR: The Congress of Young Cardiologists [III CardioMIR: el Congreso de los Jóvenes Cardiólogos]. // *REC: CardioClinics*, 57, 2022, p. S28-S36. ISSN 2605-1532. DOI 10.1016/j.rccl.2022.10.010.

703. **Cequier, Á.** Introduction [Introducción]. // *Revista Espanola de Cardiologia Suplementos*, 18, 2019, p. 1-2. ISSN 1131-3587. DOI 10.1016/S1131-3587(19)30027-5.
704. **Cequier, Á.** Study Findings and Recommendations for Practice [Conclusiones y recomendaciones prácticas]. // *Revista Espanola de Cardiologia Suplementos*, 18, 2019, p. 34-40. ISSN 1131-3587. DOI 10.1016/S1131-3587(19)30033-0.
705. **Ceresetto, J.M., Tajer, C., Duboscq, C., Bottaro, F., Casais, P., Korin, J., Fondevila, C., Giumelli, C., Scazzioti, A., Rossi, A., Botto, F., Ariscancela, M.E., Martinuzzo, M., Zaidel, E., Maurice, M.F., Bahit, C., Vazquez, F., Molnar, S., Saizberg, S., Aranguren, P.N., Rosa, C., Fedele, J.L., Comignani, P., Pombo, G., Raña, P., Adamczuk, Y., Martí, A., Charask, A., Penchasky, D., Riveros, D., Mariani, J., Puente, D., Celebrin, L., Bosio, M., Brodsky, A., Lucero, A.S., Costa, Y.C., Hirschson, A., Arbesú, G., Viñuales, S., Kazelian, L., Maneyro, A., Gutierrez, V., Rios, M.C., Gagliardi, J., Lescano, A., Repetto, F.** Recommendations for the practical management of the direct oral anticoagulants anti Xa and anti IIa [Recomendaciones de manejo de los anticoagulantes orales directos (doacs) anti Xa y anti IIa]. // *Medicina (Argentina)*, 82, 2022, № 2, p. 1-55. ISSN 0025-7680.
706. **Chan, N.C., Weitz, J.I.** Response by Chan and Weitz to Letter Regarding Article, "antithrombotic Agents: New Directions in Antithrombotic Therapy". // *Circulation Research*, 124, 2019, № 12, p. e119. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.119.315235.
707. **Changsheng, M., Shulin, W., Shaowen, L., Yaling, H.** Chinese guidelines on diagnosis and management of atrial fibrillation [心房颤动诊断和治疗中国指南]. // *Chinese Journal of Cardiology*, 51, 2023, № 6, p. 572-618. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20230416-00221.
708. **Chatterjee, S., Ad, N., Badhwar, V., Gillinov, A.M., Alexander, J.H., Moon, M.R.** Anticoagulation for atrial fibrillation after cardiac surgery: Do guidelines reflect the evidence? // *Journal of Thoracic and Cardiovascular Surgery*, 167, 2024, № 2, p. 694-700. ISSN 0022-5223. DOI 10.1016/j.jtcvs.2023.03.026.
709. **Chen, A., Stecker, E., Warden, B.A.** Direct oral anticoagulant use: A practical guide to common clinical challenges. // *Journal of the American Heart Association*, 9, 2020, № 13, art. no. e017559. ISSN 2047-9980. DOI 10.1161/JAHA.120.017559.
710. **Chen, C.-Y., Lee, C.-H.** Current Evidence of Combining Antithrombotic and Antiplatelet Therapy on Patient with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention [心房颤动患者在接受冠状动脉支架后抗血栓药物选择的最新证据]. // *Journal of Internal Medicine of Taiwan*, 32, 2021, № 5, p. 305-312. ISSN 1016-7390. DOI 10.6314/JIMT.202110\_32(5).01.
711. **Chen, Y., Zhu, M., Wang, K., Xu, Q., Ma, J.** Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombus: An Updated Meta-Analysis of Cohort Studies and Randomized Controlled Trials. // *Journal of Cardiovascular Pharmacology*, 79, 2022, № 6, p. 935-940. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001270.
712. **Chernatska, O.** Prescribing patterns of new oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: A narrative review. // *Ukrainian Journal of*

713. **Chhabra, N., Blech, B., Fortuin, D., Wilansky, S., Demaerschalk, B.M., Dumitrascu, O.M.** Embolic Stroke in Setting of Iliac Vein Stenosis in an Avid Cyclist. // *Neurohospitalist*, 12, 2022, № 2, p. 413-416. ISSN 1941-8744. DOI 10.1177/19418744211067910.
714. **Chilbert, M.R., Woodruff, A.E., Saber, M., Goriacko, P., Sinnet, M., Jacobs, D.** Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens. // *Blood Coagulation and Fibrinolysis*, 34, 2023, № 6, p. 370-376. ISSN 0957-5235. DOI 10.1097/MBC.0000000000001238.
715. **Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology.** Antithrombotic management of patients with atrial fibrillation and coronary artery disease: expert consensus document of Chinese Society of Cardiology [冠心病合并心房颤动患者抗栓管理中国专家共识]. // *Chinese Journal of Cardiology*, 48, 2020, № 7, p. 552-564. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20200328-00257.
716. **Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology.** 2019 Chinese Society of Cardiology (CSC) expert consensus statement on left atrial appendage closure in the prevention of stroke in patients with atrial fibrillation [中国左心耳封堵预防心房颤动卒中专家共识 (2019)]. // *Chinese Journal of Cardiology*, 47, 2019, № 12, p. 937-955. ISSN 0253-3758. DOI 10.3760/cma.j.issn.0253-3758.2019.12.002.
717. **Cho, I.Y.** Using non-vitamin K oral anticoagulants in specific patient populations: A study of Korean cases. // *Therapeutics and Clinical Risk Management*, 15, 2019, p. 1183-1206. ISSN 1176-6336. DOI 10.2147/TCRM.S204377.
718. **Cho, M.S., Kang, D.-Y., Oh, Y.-S., Lee, C.H., Choi, E.-K., Lee, J.H., Kwon, C.H., Park, G.-M., Park, H.W., Park, K.-H., Park, K.-M., Hwang, J., Yoo, K.-D., Cho, Y.-R., Kim, Y.R., Hwang, K.W., Jin, E.S., Kim, P.-J., Kim, K.H., Park, D.-W., Nam, G.-B.** Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial. // *American Heart Journal*, 247, 2022, p. 123-131. ISSN 0002-8703. DOI 10.1016/j.ahj.2022.01.014.
719. **Choi, E.-K.** Cardiovascular research using the Korean national health information database. // *Korean Circulation Journal*, 50, 2020, № 9, art. no. 0171. ISSN 1738-5520. DOI 10.4070/KCJ.2020.0171.
720. **Choi, Y., Lee, Y., Kim, S.-H., Kim, S., Kim, J.Y., Kim, T.-S., Hwang, Y., Kim, J.-H., Jang, S.-W., Lee, M.Y., Oh, Y.-S.** Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. // *Heart*, 108, 2022, № 4, p. 285-291. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-318750.
721. **Choxi, R., Kapoor, K., MacKman, N., Jovin, I.S.** Direct Oral Anticoagulants and Coronary Artery Disease. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 42, 2022, № 5, p. 553-564. ISSN 1079-5642. DOI 10.1161/ATVBAHA.121.317171.

722. **Chua, S.-K., Chen, L.-C., Shyu, K.-G., Cheng, J.-J., Hung, H.-F., Chiu, C.-Z., Lin, C.-M.** Antithrombotic strategies in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and network meta-analysis of randomized controlled trials. // *Journal of Clinical Medicine*, 9, 2020, № 4, art. no. 1062. ISSN 2077-0383. DOI 10.3390/jcm9041062.
723. **Chueh, H.-H., Huang, S.-T., Chang, S.-H., Lin, S.-Y., Hsiao, F.-Y.** Comparative Effectiveness and Safety of Different Combinations of Antithrombotic Regimens in Atrial Fibrillation Patients With Stent Insertions. // *Clinical Pharmacology and Therapeutics*, 2022. ISSN 0009-9236. DOI 10.1002/cpt.2684.
724. **Chutisira, P., Wongpraparut, N., Chotinaiwattarakul, C., Phankingthongkum, R., Tungsubutra, W., Chunhamaneewat, N., Towashiraporn, K., Phichaphop, A., Panchavinin, P., Pongakasira, R.** Direct oral anticoagulants (doacs)-based versus warfarin-based antithrombotic regimens in patients with atrial fibrillation underwent successful coronary stenting at siriraj hospital. // *Journal of the Medical Association of Thailand*, 104, 2021, № 10. ISSN 0125-2208. DOI 10.35755/jmedassoc-thai.2021.10.12821.
725. **Cingel, M., Focko, B., Nagy, N., Péč, M., Jurica, J., Bolek, T., Samoš, M., Mokáň, M.** Direct oral anticoagulants in the treatment of left ventricular thrombosis [Priame orálne antikoagulanty v liečbe trombózy ľavej komory srdca]. // *Cardiology Letters*, 32, 2023, № 4, p. 262-270. ISSN 1338-3655. DOI 10.4149/Cardiol\_2023\_4\_4.
726. **Cohen, M., Visveswaran, G.** Defining and managing patients with non-ST-elevation myocardial infarction: Sorting through type 1 vs other types. // *Clinical Cardiology*, 43, 2020, № 3, p. 242-250. ISSN 0160-9289. DOI 10.1002/clc.23308.
727. **Cojocar, C., Vişniac, A.-E., Gheorghe-Fronea, O., Mohaiu, T., Itu, L., Dorobanţu, M.** Nine-Year Trends in Atrial Fibrillation Prevalence among Romanian Adult Hypertensives: A Post-Hoc Analysis of SEPHAR II-IV Surveys. // *International Journal of Environmental Research and Public Health*, 19, 2022, № 15, art. no. 9250. ISSN 1661-7827. DOI 10.3390/ijerph19159250.
728. **Colleran, R., Byrne, R.A., Ndrepepa, G., Alvarez-Covarrubias, H.A., Mayer, K., Kuna, C., Rai, H., Kastrati, A., Cassese, S.** Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. // *Cardiovascular Revascularization Medicine*, 36, 2022, p. 99-106. ISSN 1553-8389. DOI 10.1016/j.carrev.2021.05.013.
729. **Cordero, A., Ferreira, J.L., Bertomeu-González, V., Rodríguez-Mañero, M., Fácila, L., Escribano, D., Sanchez-Recalde, A., Zuazola, P., Ruiz-Nodar, J.M., González-Juanatey, J.R.** Direct Oral Anticoagulants Versus Vitamin-K Antagonist after PCIs in Patients with AF: A Meta-analysis of Cardiac Ischemic Events. // *Journal of Cardiovascular Pharmacology*, 77, 2021, № 2, p. 164-169. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000938.
730. **Corsini, A., Ferri, N.** Drug-drug interaction with DOACs. – In: *Direct Oral Anticoagulants: From Pharmacology to Clinical Practice*, 2021, p. 41-69. ISBN 9783030744625; 9783030744618. DOI 10.1007/978-3-030-74462-5\_4.

731. **Cosin-Sales, J., Ortiz Cortés, C., Torres Llergo, J., Huelmos, A., Barrios, V., Escobar, C., López Fernández, T., Gámez, J.M.** Selection of the best of 2019 in clinical cardiology [Selección de lo mejor del año 2019 en cardiología clínica]. // *REC: CardioClinics*, 55, 2020, p. 51-57. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.10.012.
732. **Costa, F., Valgimigli, M.** Competing risks in the duration of dual antiplatelet therapy-the case for shorter treatment. – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 111-130. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00001-X.
733. **Crawley, R.M., Anderson, R.L.** Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. // *Drugs*, 80, 2020, № 13, p. 1293-1308. ISSN 0012-6667. DOI 10.1007/s40265-020-01345-5.
734. **Cruz Rodriguez, J.B., Mishra, K., Siddiqui, T.** Antithrombotic / antiplatelet therapy in patients with stable coronary artery disease and after acute coronary syndrome. // *Cardiovascular and Hematological Agents in Medicinal Chemistry*, 19, 2021, № 2, p. 187-200. ISSN 1871-5257. DOI 10.2174/1871525718666201207201552.
735. **Dager, W.E., Ansell, J., Barnes, G.D., Burnett, A., Deitelzweig, S., Minichiello, T., Triller, D., Kaatz, S.** “Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy”: Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. // *Joint Commission Journal on Quality and Patient Safety*, 46, 2020, № 3, p. 173-180. ISSN 1553-7250. DOI 10.1016/j.jcjq.2019.12.004.
736. **Dahal, K., Mosleh, W., Almnajam, M., Khaddr, M., Adeel, M.Y., Vashist, A., Robinson, P., Azrin, M., Lee, J.** NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 10, p. 1202-1208. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.03.012.
737. **Dahiya, D.S., Kichloo, A., Amir, R., Wani, F.** When should antithrombotic therapy be resumed after gastrointestinal bleeding? // *Cleveland Clinic Journal of Medicine*, 89, 2022, № 11, p. 630-633. ISSN 0891-1150. DOI 10.3949/ccjm.89a.20189.
738. **Dalgaard, F., Jones, W.S., Piccini, J.P.** Atrial Fibrillation and Percutaneous Coronary Intervention: Time to Turn the Page. // *Circulation: Cardiovascular Interventions*, 12, 2019, № 8, art. no. e008269. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.119.008269.
739. **Darmon, A., Ducrocq, G.** Ischaemic and bleeding risk assessment after myocardial infarction: Combination is the key. // *Heart*, 105, 2019, № 15, p. 1138-1139. ISSN 1355-6037. DOI 10.1136/heartjnl-2019-315050.
740. **Das, S., Deb, A., Pal, T.** Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. // *Medical Principles and Practice*, 30, 2021, № 5, p. 412-421. ISSN 1011-7571. DOI 10.1159/000516471.



741. **Davanzo, R.H., Alarcón, A.F., Calquín, J.Q., Varela, P.S., Sepúlveda, A.M., Her-  
reros, R.C., Patel, S., Rodríguez, G.M.** Antiplatelet therapy and percutaneous cor-  
onary interventions. // *Current Cardiology Reviews*, 17, 2021, № 3, p. 302-313. ISSN  
1573-403X. DOI 10.2174/1573403X16666200615144423.
742. **Dawson, L.P., Dinh, D., Duffy, S.J., Clark, D., Reid, C.M., Brennan, A., Andria-  
nopoulos, N., Hiew, C., Freeman, M., Oqueli, E., Chan, W., Ajani, A.E., Mel-  
bourne Interventional Group (MIG) Investigators.** Temporal Trends in Patient  
Risk Profile and Clinical Outcomes Following Percutaneous Coronary Intervention.  
// *Cardiovascular Revascularization Medicine*, 31, 2021, p. 10-16. ISSN 1553-8389.  
DOI 10.1016/j.carrev.2020.12.019.
743. **Dawwas, G.K., Barnes, G.D., Dietrich, E., Cuker, A., Leonard, C.E., Genuardi,  
M.V., Lewis, J.D.** Cardiovascular and major bleeding outcomes with antiplatelet and  
direct oral anticoagulants in patients with acute coronary syndrome and atrial fibril-  
lation: A population-based analysis. // *American Heart Journal*, 242, 2021, p. 71-81.  
ISSN 0002-8703. DOI 10.1016/j.ahj.2021.08.014.
744. **De Caterina, R.** Dibattito sulla monoterapia antiplastrinica: Perché non lasciare la  
buona vecchia aspirina per clopidogrel o ticagrelor in monoterapia nella sindrome  
coronarica cronica dopo un'angioplastica coronarica. // *Giornale Italiano di Cardio-  
logia*, 24, 2023, № 4, p. 16S-18S. ISSN 1827-6806. DOI 10.1714/4035.40100.
745. **de Groot, J.R.** Stroke prevention in patients with atrial fibrillation and comorbidities:  
evidence and common sense. // *Netherlands Heart Journal*, 28, 2020, № 10, p. 501-  
503. ISSN 1568-5888. DOI 10.1007/s12471-020-01491-1.
746. **de la Torre Hernandez, J.M., Ferreiro, J.L., Lopez-Palop, R., Ojeda, S., Marti,  
D., Avanzas, P., Linares, J.A., Diego, A., Amat, I.J., Telleria, M., Cid, B.,  
Otaegui, I., Lozano, I., Serrano, D., Pinar, E., González-Manzanares, R., Con-  
cepción-Suárez, R., Pascual, I., Urbano, C., Sadaba, M., Garcia-Guimaraes, M.,  
Andres-Cordon, J.F., Hernandez, F., Sanchez-Recalde, A., Garilleti, C., Perez  
de Prado, A.** Antithrombotic strategies in elderly patients with atrial fibrillation re-  
vascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry. // *Interna-  
tional Journal of Cardiology*, 338, 2021, p. 63-71. ISSN 0167-5273. DOI  
10.1016/j.ijcard.2021.05.036.
747. **De Luca, L., Bolognese, L., Rubboli, A., Vetrano, A., Callera, M., Rivetti, L.,  
Gonzini, L., Gabrielli, D., Di Lenarda, A., Gulizia, M.M.** Combinations of an-  
tithrombotic therapies prescribed after percutaneous coronary intervention in patients  
with acute coronary syndromes and atrial fibrillation: Data from the nationwide  
MATADOR-PCI registry. // *European Heart Journal - Cardiovascular Pharma-  
cotherapy*, 7, 2021, № 3, p. E45-E47. ISSN 2055-6837. DOI  
10.1093/ehjcvp/pvaa088.
748. **De Luca, L., Mistrulli, R., Veneziano, F.A., Grigioni, F., Volpe, M., Musumeci,  
F., Gabrielli, D.** Antithrombotic Strategies in Patients with Atrial Fibrillation and  
Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. // *Journal of Clinical Medicine*, 11, 2022, № 3, art. no. 512. ISSN 2077-0383. DOI  
10.3390/jcm11030512.
749. **De Luca, L., Rubboli, A., Bolognese, L., Gonzini, L., Urbinati, S., Murrone, A.,  
Scotto Di Uccio, F., Ferrari, F., Lucà, F., Caldarola, P., Lucci, D., Gabrielli, D.,  
Di Lenarda, A., Gulizia, M.M.** Antithrombotic management of patients with acute

coronary syndrome and atrial fibrillation undergoing coronary stenting: A prospective, observational, nationwide study. // *BMJ Open*, 10, 2020, № 12, art. no. e041044. ISSN 2044-6055. DOI 10.1136/bmjopen-2020-041044.

750. **De Luca, L., Rubboli, A., Lettino, M., Tubaro, M., Leonardi, S., Casella, G., Valente, S., Rossini, R., Sciahbasi, A., Natale, E., Trambaiolo, P., Navazio, A., Cipriani, M., Corda, M., De Nardo, A., Francese, G.M., Napoletano, C., Tizzani, E., Nardi, F., Roncon, L., Caldarola, P., Riccio, C., Gabrielli, D., Oliva, F., Massimo Gulizia, M., Colivicchi, F.** ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. // *European Heart Journal, Supplement*, 24, 2022, p. C254-C271. ISSN 1520-765X. DOI 10.1093/eurheartj/suac020.
751. **De Luca, L., Rubboli, A., Lettino, M., Tubaro, M., Leonardi, S., Casella, G., Valente, S., Rossini, R., Sciahbasi, A., Natale, E., Trambaiolo, P., Navazio, A., Cipriani, M., Corda, M., De Nardo, A., Francese, G.M., Napoletano, C., Tizzani, E., Roncon, L., Caldarola, P., Riccio, C., Gabrielli, D., Oliva, F., Gulizia, M.M., Colivicchi, F.** ANMCO Position paper: Antithrombotic treatment of patients with atrial fibrillation and acute or chronic coronary syndromes undergoing coronary angioplasty with stent implantation [Position paper ANMCO: Trattamento antitrombotico nei pazienti con fibrillazione atriale e sindromi coronariche acute o croniche sottoposti ad angioplastica coronarica con impianto di stent]. // *Giornale Italiano di Cardiologia*, 23, 2022, № 5, p. 379-395. ISSN 1827-6806. DOI 10.1714/3796.37818.
752. **De Rosa, S., Sabatino, J., Polimeni, A., Sorrentino, S., Indolfi, C.** Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis. // *PLoS ONE*, 15, 2020, art. no. e0235511. ISSN 1932-6203. DOI 10.1371/journal.pone.0235511.
753. **de Servi, S., Sciatti, E., Temporelli, P.L., de Caterina, R., Prati, F., Zito, G.B., Carugo, S., de Biase, L., Senni, M., Rossini, R.** Grey zones on dual antiplatelet therapy. Expert opinion [Grey zones sulla duplice terapia antiplastrinica. opinioni degli esperti]. // *Giornale Italiano di Cardiologia*, 21, 2020, № 7, p. 530-536. ISSN 1827-6806. DOI 10.1714/3386.33642.
754. **de Veer, A.J.W.M., Bennaghmouch, N., Bor, W.L., Herrman, J.P.R., Vrolix, M., Meuwissen, M., Vandendriessche, T., Adriaenssens, T., de Bruyne, B., Magro, M., Dewilde, W.J.M., ten Berg, J.M.** The WOEST 2 registry: A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention. // *Netherlands Heart Journal*, 30, 2022, № 6, p. 302-311. ISSN 1568-5888. DOI 10.1007/s12471-022-01664-0.
755. **de Veer, A.J.W.M., Bennaghmouch, N., Dewilde, W.J.M., ten Berg, J.M.** How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. // *Netherlands Heart Journal*, 29, 2021, № 3, p. 135-141. ISSN 1568-5888. DOI 10.1007/s12471-020-01500-3.
756. **De Vriese, A.S., Heine, G.** Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. // *Nephrology Dialysis Transplantation*, 37, 2022, № 11, p. 2072-2079. ISSN 0931-0509. DOI 10.1093/ndt/gfab060.

757. **Deaconu, A., Deaconu, S., Gatej, A., Dorobantu, M.** Triple antithrombotic therapy in patients with acute coronary syndrome and atrial fibrillation – Balancing risks and benefits. // *Medicina Moderna*, 28, 2021, № 1, p. 63-69. ISSN 1223-0472. DOI 10.31689/rmm.2021.28.1.63.
758. **Deaconu, A., Deaconu, S., Radu, A., Dorobantu, M.** Pharmacological treatment of tachyarrhythmias in acute myocardial infarction - a review. // *Revista Romana de Cardiologie*, 31, 2021, № 2, p. 311-317. ISSN 1220-658X. DOI 10.47803/rjc.2021.31.2.311.
759. **Deng, L., Jia, H.-Z., Li, M.-C., Zhu, W.** Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. // *Kaohsiung Journal of Medical Sciences*, 37, 2021, № 11, p. 1010-1015. ISSN 1607-551X. DOI 10.1002/kjm2.12421.
760. **Desai, A., Escamilla-Ocanas, C., Dilip, D., Saber, H., Damani, R.** Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 4, art. no. 105654. ISSN 1052-3057. DOI 10.1016/j.jstrokecerebrovasdis.2021.105654.
761. **Dharma, S.** Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. // *International Journal of Angiology*, 29, 2020, № 2, p. 81-87. ISSN 1061-1711. DOI 10.1055/s-0040-1702208.
762. **Di Odoardo, L.A.F., Bianco, M., Gil, I.J.N., Motolese, I.G., Chinaglia, A., Vicenzi, M., Carugo, S., Stefanini, G.G., Cerrato, E.** Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review. // *Cardiovascular Drugs and Therapy*, 2022. ISSN 0920-3206. DOI 10.1007/s10557-022-07417-w.
763. **Diep, R., Garcia, D.** Does aspirin prevent venous thromboembolism? // *Hematology (United States)*, 20, 2020, № 1, p. 634-641. ISSN 1520-4391. DOI 10.1182/HEMATOLOGY.2020000150.
764. **Díez-Delhoyo, F., Elízaga, J.** Novel oral anticoagulants, diagnostic catheterization, and coronary intervention: Another step forward towards the optimal strategy. // *REC: Interventional Cardiology*, 1, 2019, № 3, p. 147-149. ISSN 2604-7306. DOI 10.24875/RECICE.M19000051.
765. **Dillinger, J.-G., Henry, P.** DAPT in the diabetic patient with CAD [La DAPT chez le patient diabétique coronarien]. // *Archives of Cardiovascular Diseases Supplements*, 11, 2019, p. S3-S7. ISSN 1878-6480. DOI 10.1016/S1878-6480(19)30959-0.
766. **Dillinger, J.-G., Laine, M., Bouajila, S., Paganelli, F., Henry, P., Bonello, L.** Antithrombotic strategies in elderly patients with acute coronary syndrome [Traitements antithrombotiques chez les patients âgés avec un syndrome coronaire aigu]. // *Archives of Cardiovascular Diseases*, 114, 2021, № 3, p. 232-245. ISSN 1875-2136. DOI 10.1016/j.acvd.2020.12.002.

767. **Dimitriadis, K., Soulaïdopoulos, S., Doundoulakis, I., Iliakis, P., Tsiachris, D., Tsioufis, P., Beneki, E., Sakalidis, A., Pagkalidou, E., Tsiamis, E., Tsioufis, K.** A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding. // *Hellenic Journal of Cardiology*, 73, 2023, p. 69-72. ISSN 1109-9666. DOI 10.1016/j.hjc.2023.04.004.
768. **Disdier Moulder, M.P.A., Hendricks, A.K., Ou, N.N.** Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take? // *Clinical Cardiology*, 43, 2020, № 2, p. 137-144. ISSN 0160-9289. DOI 10.1002/clc.23304.
769. **Doherty, J.U.** Combined antiplatelet and anticoagulant therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: Navigating between scylla and charybdis. // *Annals of Internal Medicine*, 172, 2020, № 7, p. 495-496. ISSN 0003-4819. DOI 10.7326/M20-0572.
770. **Domínguez-Erquicia, P., Raposeiras-Roubín, S., Abu-Assi, E., Lizancos-Castro, A., Parada-Barcia, J.A., González-García, A., Ledo-Piñeiro, A., Noriega-Caro, V., Iglesias-Otero, C., Íñiguez-Romo, A.** Predictive value of bleeding risk scores in elderly patients with atrial fibrillation and oral anticoagulation. // *Journal of Geriatric Cardiology*, 20, 2023, № 9, p. 684-692. ISSN 1671-5411. DOI 10.26599/1671-5411.2023.09.002.
771. **Dos Anjos, F., Simões, J.L.B., Assmann, C.E., Carvalho, F.B., Bagatini, M.D.** Potential therapeutic role of purinergic receptors in cardiovascular disease mediated by SARS-CoV-2. // *Journal of Immunology Research*, 2020, art. no. 8632048. ISSN 2314-8861. DOI 10.1155/2020/8632048.
772. **Dryden, L., Kertland, H.** For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy? // *Canadian Journal of Hospital Pharmacy*, 72, 2019, № 6, p. 464-465. ISSN 0008-4123. DOI 10.4212/cjhp.v72i6.2947.
773. **Dürschmied, D., Goette, A., Hardt, R., Kleinschnitz, C., Kämmerer, W., Lembens, C., Schmitt, W., Bode, C.** Interdisciplinary aspects of oral anticoagulation with NOACs in atrial fibrillation [Interdisziplinäre Aspekte der oralen Antikoagulation mit NOAKs bei Vorhofflimmern]. // *Deutsche Medizinische Wochenschrift*, 146, 2021, p. S2-S16. ISSN 0012-0472. DOI 10.1055/a-1472-3188.
774. **Earle, W., Abdallah, G., Meagher, S., Shen, K., Gibson, C.M., Ho, K.K.L., Secemsky, E.A.** Reducing use of triple therapy after percutaneous coronary intervention: Results from a hospital-wide quality improvement initiative. // *Catheterization and Cardiovascular Interventions*, 100, 2022, № 6, p. 941-947. ISSN 1522-1946. DOI 10.1002/ccd.30412.
775. **Eberhardt, T.E., Bungard, T.J., Graham, M.M., Picard, M., Wang, G.T., Ackman, M.L.** Effect of New Evidence on Antithrombotic Therapies in Atrial Fibrillation Patients Who Undergo Percutaneous Coronary Intervention in Alberta, Canada. // *CJC Open*, 4, 2022, № 4, p. 378-382. ISSN 2589-790X. DOI 10.1016/j.cjco.2021.12.007.
776. **Eikelboom, J.W., Bhatt, D.L., Fox, K.A.A., Bosch, J., Connolly, S.J., Anand, S.S., Avezum, A., Berkowitz, S.D., Branch, K.R.H., Dagenais, G.R., Félix, C., Guzik,**

- T.J., Hart, R.G., Maggioni, A.P., Muehlhofer, E., Sharma, M., Shestakovska, O., Yusuf, S.** Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. // *Journal of the American College of Cardiology*, 78, 2021, № 1, p. 14-23. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.04.083.
777. **El- Khidir, I.Y., Elnour, A.A., Al Amoodi, A., Alrashdi, A.A., Almansour, H.H., Almarwani, T.A., Alrowaili, S.F., Al Khudhairi, S.L., Alshammari, A.F., Sadeq, A., Al Mazrouei, N., Al-Kubaisi, K.A., El Khidir, H.Y., Alkaabi, M., Ashoor, A.** Protocol for systematic review and meta-analysis on randomized clinical trials for direct oral anticoagulant in subjects with acute coronary syndrome. // *Pharmacy Practice*, 21, 2023, № 2, art. no. 2811. ISSN 1885-642X. DOI: 10.18549/PharmPract.2023.2.2811.
778. **El-Armouche, A., Kirchhof, P.** Comedication in treatment with direct oral anticoagulants [Begleitmedikation bei Therapie mit direkten oralen Antikoagulanzen]. // *Kardiologe*, 14, 2020, № 1, p. 29-31. ISSN 1864-9718. DOI 10.1007/s12181-019-00365-0.
779. **Erbay, M.I., Pyrpyris, N., Susarla, S., Ulsan, S., Mares, A.C., Wilson, T.P., Lee, D., Sood, A., Gupta, R.** Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Expert Opinion on Drug Safety*, 23, 2024, № 2, p. 149-160. ISSN 1474-0338. DOI 10.1080/14740338.2024.2305367.
780. **Ergene, O., Aras, D., Kaymaz, C., Arsava, E.M., Gonen, C., Gurkaş, E., Arslan, U., Cağırıcı, G., Cay, S., Kilickap, M., Kanat, S., Ozpelit, E., Vatansever, F., Kilickesmez, K.** The Role of Non-Vitamin K Antagonist Oral Anticoagulants (NO-ACs) in Atrial Fibrillation: Treatment Management Based on Patient and Drug Characteristics. // *Türk Kardiyoloji Dernegi Arsivi*, 50, 2022, № 5, p. 356-370. ISSN 1016-5169. DOI 10.5543/tkda.2022.21191.
781. **Escobar-Cervantes, C., Díez-Villanueva, P., Bonanad Lozano, C., Reino, A.P., Almendro-Delia, M., Facila, L., Valle, A., Suárez, C.** Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation. // *Expert Review of Cardiovascular Therapy*, 2023. ISSN 1477-9072. DOI 10.1080/14779072.2023.2276893.
782. **Esenboga, K., Sahin, E., Özyünc, N., Tan, T.S., Atmaca, Y.** Apixaban for massive intracoronary thrombosis: A case series. // *Anatolian Journal of Cardiology*, 25, 2021, № 9, p. 661-664. ISSN 2149-2263. DOI 10.5152/AnatolJCardiol.2021.32746.
783. **Espinola-Klein, C.** When and How to Combine Antiplatelet and Anticoagulant Drugs? // *Hamostaseologie*, 42, 2022, № 1, p. 73-79. ISSN 0720-9355. DOI 10.1055/a-1724-4922.
784. **Essa, H., Sankaranarayanan, R., Walker, L.** Triple antithrombotic therapy and dual therapy – What is the evidence base? // *British Journal of Clinical Pharmacology*, 88, 2022, № 7, p. 3009-3012. ISSN 0306-5251. DOI 10.1111/bcp.15257.
785. **Essien, U.R., Kornej, J., Johnson, A.E., Schulson, L.B., Benjamin, E.J., Magnani, J.W.** Social determinants of atrial fibrillation. // *Nature Reviews Cardiology*, 18, 2021, № 11, p. 763-773. ISSN 1759-5002. DOI 10.1038/s41569-021-00561-0.



786. **Eyileten, C., Postula, M., Jakubik, D., Toma, A., Mirowska-Guzel, D., Patti, G., Renda, G., Siller-Matula, J.M.** Non-vitamin k oral anticoagulants (Noac) versus vitamin k antagonists (vka) for atrial fibrillation with elective or urgent percutaneous coronary intervention: A meta-analysis with a particular focus on combination type. // *Journal of Clinical Medicine*, 9, 2020, № 4, art. no. 1120. ISSN 2077-0383. DOI 10.3390/jcm9041120.
787. **Fahed, A.C., Chae, C.U.** Stable Ischemic Heart Disease. – In: *MGH Cardiology Board Review: Second Edition*, 2020, p. 125-154. ISBN 9783030457921; 9783030457914. DOI 10.1007/978-3-030-45792-1\_6.
788. **Falanga, A., Leader, A., Ambaglio, C., Bagoly, Z., Castaman, G., Elalamy, I., Lecumberri, R., Niessner, A., Pabinger, I., Szmit, S., Trincherro, A., Cate, H.T., Rocca, B.** EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. // *HemaSphere*, 6, 2022, № 8, art. no. e750. ISSN 2572-9241. DOI 10.1097/HS9.0000000000000750.
789. **Fang, S., Zhu, B.-Z., Yang, F., Wang, Z., Xiang, Q., Gong, Y.-J.** Direct Oral Anti-coagulants Compared with Vitamin K Antagonists for Left Ventricular Thrombus: A Systematic Review and Meta-analysis. // *Current Pharmaceutical Design*, 28, 2022, № 23, p. 1902-1910. ISSN 1381-6128. DOI 10.2174/1381612828666220408120832.
790. **Feit, F.** How un-popular is bleeding in patients with TAVI? // *New England Journal of Medicine*, 382, 2020, № 18, p. 1761-1763. ISSN 0028-4793. DOI 10.1056/NEJMe2003031.
791. **Fernández-Ruiz, I.** Tailoring antithrombotic strategies for high-risk AF populations. // *Nature Reviews Cardiology*, 16, 2019, № 6, p. 321. ISSN 1759-5002. DOI 10.1038/s41569-019-0195-0.
792. **Fernando, H., McFadyen, J.D., Palasubramaniam, J., Shaw, J., Wang, X., Stub, D., Peter, K.** Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. // *Thrombosis and Haemostasis*, 120, 2020, № 10, p. 1352-1356. ISSN 0340-6245. DOI 10.1055/s-0040-1714212.
793. **Fernando, H., McFadyen, J.D., Wang, X., Shaw, J., Stub, D., Peter, K.** P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 854813. ISSN 2297-055X. DOI 10.3389/fcvm.2022.854813.
794. **Ferrari, F., da Silveira, A.D., Martins, V.M., Franzoni, L.T., Zimmerman, L.I., Stein, R.** Direct-Acting Oral Anticoagulants in Atrial Fibrillation What's New in the Literature. // *Cardiology in Review*, 29, 2021, № 3, p. 120-130. ISSN 1061-5377. DOI 10.1097/CRD.0000000000000312.
795. **Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., Corsini, A.** Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. // *Pharmaceutics*, 14, 2022, № 6, art. no. 1120. ISSN 1999-4923. DOI 10.3390/pharmaceutics14061120.
796. **Festa, M.C., Rasasingam, S., Sharma, A., Mavrakanas, T.A.** Early Discontinuation of Aspirin Among Patients with Chronic Kidney Disease Undergoing Percuta-

neous Coronary Intervention with a Drug-Eluting Stent: A Meta-Analysis. // *Kidney360*, 4, 2023, № 9, p. E1245-E1256. ISSN 2641-7650. DOI 10.34067/KID.0000000000000223.

797. **Fleddermann, A.M., Hayes, C., Magalski, A., Main, M.L.** Authors' Reply to "Underlying Differences in the Treatment of Left Ventricular Thrombus With Non-Vitamin K Antagonist Oral Anticoagulants". // *American Journal of Cardiology*, 124, 2019, № 9, p. 1489-1491. ISSN 0002-9149. DOI 10.1016/j.amjcard.2019.08.021.
798. **Frampton, J., Ortengren, A.R., Zeitler, E.P.** Arrhythmias After Acute Myocardial Infarction. // *Yale Journal of Biology and Medicine*, 96, 2023, № 1, p. 83-94. ISSN 0044-0086. DOI 10.59249/LSWK8578.
799. **Franchi, F., Rollini, F., Garcia, E., Rivas Rios, J., Rivas, A., Agarwal, M., Kureti, M., Nagaraju, D., Wali, M., Briceno, M., Moon, J.Y., Kairouz, V., Yaranov, D., Been, L., Suryadevara, S., Soffer, D., Zenni, M.M., Bass, T.A., Angiolillo, D.J.** Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. // *Thrombosis and Haemostasis*, 120, 2020, № 1, p. 83-93. ISSN 0340-6245. DOI 10.1055/s-0039-1695772.
800. **Franchi, F., Rollini, F., Kairouz, V., Rivas Rios, J., Rivas, A., Agarwal, M., Briceno, M., Wali, M., Nawaz, A., Silva, G., Shaikh, Z., Maaliki, N., Been, L., Piraino, J., Pineda, A.M., Suryadevara, S., Soffer, D., Zenni, M.M., Jennings, L.K., Bass, T.A., Angiolillo, D.J.** Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study. // *JACC: Basic to Translational Science*, 4, 2019, № 7, p. 763-775. ISSN 2452-302X. DOI 10.1016/j.jacbts.2019.07.011.
801. **Franchina, A.G., Capodanno, D.** Strategie farmacologiche pre- e post-angioplastica coronarica nel contesto delle sindromi coronariche acute nei pazienti in terapia anti-coagulante orale. // *Giornale Italiano di Cardiologia*, 21, 2020, № 2, p. 26S-33S. ISSN 1827-6806. DOI 10.1714/3311.32818.
802. **Frederiksen, T.C., Dahm, C.C., Preis, S.R., Lin, H., Trinquart, L., Benjamin, E.J., Kornej, J.** The bidirectional association between atrial fibrillation and myocardial infarction. // *Nature Reviews Cardiology*, 20, 2023, № 9, p. 631-644. ISSN 1759-5002. DOI 10.1038/s41569-023-00857-3.
803. **Friede, K.A., Myers, R.A., Gales, J., Zhbannikov, I., Ortel, T.L., Shah, S.H., Kraus, W.E., Ginsburg, G.S., Voora, D.** An antiplatelet response gene expression signature is associated with bleeding. // *Cardiovascular Research*, 119, 2023, № 2, p. 551-560. ISSN 0008-6363. DOI 10.1093/cvr/cvac079.
804. **Fukamachi, D., Okumura, Y., Matsumoto, N., Tachibana, E., Oiwa, K., Ichikawa, M., Haruta, H., Nomoto, K., Arima, K., Hirayama, A.** Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease. // *Journal of Interventional Cardiology*, 2022, art. no. 5905022. ISSN 0896-4327. DOI: 10.1155/2022/5905022.
805. **Fukaya, H., Ako, J., Yasuda, S., Kaikita, K., Akao, M., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., Matsui, K., Ogawa,**

- H.** Aspirin versus P2Y<sub>12</sub> inhibitors with anticoagulation therapy for atrial fibrillation. // *Heart*, 107, 2021, № 21, p. 1731-1738. ISSN 1355-6037. DOI 10.1136/heartjnl-2021-319321.
806. **Fumagalli, S.** Beyond anticoagulant therapy. The not benign impact of atrial fibrillation on patients' outcomes in a real world 'scenario'. // *European Journal of Internal Medicine*, 74, 2020, p. 40-41. ISSN 0953-6205. DOI 10.1016/j.ejim.2020.03.013.
807. **Gaede, L., Möllmann, H.** The elderly patient with acute coronary syndrome [Der alte Patient mit akutem Koronarsyndrom - Konservative oder interventionelle Therapie?]. // *Deutsche Medizinische Wochenschrift*, 146, 2021, № 1, p. 48-57. ISSN 0012-0472. DOI 10.1055/a-1212-9393.
808. **Galli, M., Andreotti, F., D'Amario, D., Porto, I., Crea, F.** Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation—ACS/PCI Trials. // *Journal of the American College of Cardiology*, 75, 2020, № 14, p. 1727-1728. ISSN 0735-1097. DOI 10.1016/j.jacc.2020.01.054.
809. **Galli, M., Andreotti, F., D'Amario, D., Vergallo, R., Montone, R.A., Niccoli, G., Crea, F.** Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. // *IJC Heart and Vascular*, 28, 2020, art. no. 100524. ISSN 2352-9067. DOI 10.1016/j.ijcha.2020.100524.
810. **Galli, M., Andreotti, F., D'Amario, D., Vergallo, R., Montone, R.A., Porto, I., Crea, F.** Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 6, 2020, № 2, p. 128-129. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz030.
811. **Galli, M., Andreotti, F., Porto, I., Crea, F.** Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: A meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. // *Europace*, 22, 2020, № 4, p. 538-546. ISSN 1099-5129. DOI 10.1093/europace/euz345.
812. **Galli, M., Angiolillo, D.J.** Antiplatelet therapy in percutaneous coronary intervention: Latest evidence from randomized controlled trials. // *Current Opinion in Cardiology*, 36, 2021, № 4, p. 390-396. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000879.
813. **Galli, M., Capodanno, D., Andreotti, F., Crea, F., Angiolillo, D.J.** Safety and efficacy of P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions. // *Expert Opinion on Drug Safety*, 20, 2021, № 1, p. 9-21. ISSN 1474-0338. DOI 10.1080/14740338.2021.1850691.
814. **Galli, M., Ortega-Paz, L., Franchi, F., Rollini, F., Angiolillo, D.J.** Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. // *Pharmacogenomics*, 23, 2022, № 13, p. 723-737. ISSN 1462-2416. DOI 10.2217/pgs-2022-0057.
815. **Galougahi, K.K., Petrossian, G., Stone, G.W., Ali, Z.A.** The year in review: Advances in interventional cardiology in 2019. // *Current Opinion in Cardiology*, 35, 2020, № 4, p. 325-331. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000752.

816. **Gamvroulas, E.M., Jones, A.E., Saunders, J.A., Jones, T.L., Witt, D.M.** Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients. // *BMC Cardiovascular Disorders*, 23, 2023, № 1, art. no. 117. ISSN 1471-2261. DOI 10.1186/s12872-023-03161-7.
817. **Gao, C., Wang, R., Sharif, F., Takahashi, K., Ono, M., Hara, H., Tomaniak, M., Kawashima, H., Modolo, R., Van Geuns, R.-J., Capodanno, D., Byrne, R., Wijns, W., Onuma, Y., Serruys, P.W.** The year in review: Coronary interventions. // *EuroIntervention*, 15, 2020, № 17, p. 1534-1547. ISSN 1774-024X. DOI 10.4244/EIJ-D-19-01124.
818. **Gao, F., Rahman, F.** DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. // *Current Atherosclerosis Reports*, 24, 2022, № 6, p. 457-469. ISSN 1523-3804. DOI 10.1007/s11883-022-01022-w.
819. **García-Ropero, Á., Vargas-Delgado, A.P., Santos-Gallego, C.G., Badimon, J.J.** Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era? // *Journal of Cardiovascular Pharmacology*, 75, 2020, № 4, p. 269-275. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000795.
820. **Gargiulo, G., Goette, A., Tijssen, J., Eckardt, L., Lewalter, T., Vranckx, P., Valgimigli, M.** Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-Vitamin K antagonist oral anticoagulant-based randomized clinical trials. // *European Heart Journal*, 40, 2019, № 46, p. 3757-3767. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz732.
821. **Garst, C., Pitliya, A., Iannetti, M., Caccamo, M.** Things We Do for No Reason™: Routine use of triple anticoagulant therapy in patients with both nonvalvular atrial fibrillation and percutaneous coronary intervention. // *Journal of Hospital Medicine*, 17, 2022, № 11, p. 917-920. ISSN 1553-5592. DOI 10.1002/jhm.12831.
822. **Gatto, M.C., Cipollone, L., Galardo, G., Bresciani, E., Alessandroni, M., Mancone, M., Lavalle, C., Pugliese, F., Fedele, F.** The choice of antithrombotic therapy in a patient with new-onset atrial fibrillation and high coronary thrombotic risk. // *Journal of Atrial Fibrillation*, 12, 2019, № 3. ISSN 1941-6911.
823. **Ghafoor, H., Sharma, N.K., Venkataramanan, S.V.A., Hadley, M.** Post PCI severe gastrointestinal bleeding in the setting of idiopathic thrombocytopenic purpura: A treatment dilemma. // *BMJ Case Reports*, 14, 2021, № 6, art. no. e243706. ISSN 1757-790X. DOI: 10.1136/bcr-2021-243706.
824. **Gill, K., Servati, N., Flahive, J., Fraielli, K.** Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 26, 2021, № 6, p. 625-629. ISSN 1074-2484. DOI 10.1177/10742484211031436.
825. **Gimbel, M.E., Tavenier, A.H., Bor, W., Hermanides, R.S., de Vrey, E., Heestermans, T., Gin, M.T.J., Waalewijn, R., Hofma, S., Den Hartog, F., Jukema, W., von Birgelen, C., Voskuil, M., Kelder, J., Deneer, V., Ten Berg, J.M.** Ticagrelor versus clopidogrel in older patients with nste-acs using oral anticoagulation: A sub-

analysis of the popular age trial. // *Journal of Clinical Medicine*, 9, 2020, № 10, art. no. 3249, p. 1-9. ISSN 2077-0383. DOI 10.3390/jcm9103249.

826. **Giubilato, S., Lucà, F., Pozzi, A., Caretta, G., Cornara, S., Pilleri, A., Di Nora, C., Amico, F., Di Matteo, I., Favilli, S., Rossini, R., Riccio, C., Colivicchi, F., Gulizia, M.M., on behalf of Management and Quality Working Group ANMCO.** A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series. // *Journal of Clinical Medicine*, 11, 2022, № 14, art. no. 4089. ISSN 2077-0383. DOI 10.3390/jcm11144089.
827. **Gjermeni, D., Anfang, V., Vetter, H., Szabó, S., Hesselbarth, D., Gauchel, N., Siegel, P.M., Kaier, K., Kille, A., Franke, K., Leggewie, S., Trenk, D., Duerschmied, D., Bode, C., Westermann, D., Olivier, C.B.** Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study. // *Journal of Thrombosis and Thrombolysis*, 57, 2024, № 3, p. 361-369. ISSN 0929-5305. DOI 10.1007/s11239-023-02937-0.
828. **Gjermeni, D., Vetter, H., Szabó, S., Anfang, V., Leggewie, S., Hesselbarth, D., Duerschmied, D., Trenk, D., Olivier, C.B.** Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Journal of Clinical Medicine*, 11, 2022, № 14, art. no. 4237. ISSN 2077-0383. DOI 10.3390/jcm11144237.
829. **Godino, C., Pivato, C.A., Rubino, C., Russi, A., Cera, M., Margonato, A.** Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. // *American Journal of Cardiology*, 129, 2020, p. 122-124. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.05.012.
830. **Godtfredsen, S.J., Kragholm, K.H., Kristensen, A.M.D., Bekfani, T., Sørensen, R., Sessa, M., Torp-Pedersen, C., Bhatt, D.L., Pareek, M.** Ticagrelor or prasugrel vs. clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention for myocardial infarction. // *European Heart Journal Open*, 4, 2024, № 1, art. no. oead134. ISSN 2752-4191. DOI 10.1093/ehjopen/oead134.
831. **Goel, R., Baber, U.** Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. // *Current Opinion in Cardiology*, 34, 2019, № 4, p. 315-322. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000640.
832. **Goette, A., Eckardt, L., Valgimigli, M., Lewalter, T., Laeis, P., Reimitz, P.-E., Smolnik, R., Zierhut, W., Tijssen, J.G., Vranckx, P.** Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. // *Clinical Research in Cardiology*, 110, 2021, № 6, p. 831-840. ISSN 1861-0684. DOI 10.1007/s00392-020-01760-4.
833. **Goette, A., Vranckx, P.** Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants. // *European Heart Journal, Supplement*, 22, 2020, p. I22-I31. ISSN 1520-765X. DOI 10.1093/EURHEART/SUAA101.
834. **Gong, X., Hua, R., Bai, J., Wu, T., Wang, Q., Zhang, J., Zhang, W., Ying, L., Ke, Y., Wang, X., Zhang, X., Liu, K., Chen, Y., Zhang, B., Dong, P., Xiao, J., Li, C.,**



- Zhu, L., Li, C.** Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPTimal management of anTithroMbotic Agents (OPTIMA)-4 trial. // *Clinical Cardiology*, 46, 2023, № 7, p. 777-784. ISSN 0160-9289. DOI 10.1002/clc.24025.
835. **Gonzalez, V.L., Gonzalez, M.D.** Is oral anticoagulation plus antiplatelet therapy superior to oral anticoagulation alone in patients with atrial fibrillation and stable coronary artery disease? // *Journal of Interventional Cardiac Electrophysiology*, 66, 2023, № 5, p. 1031-1032. ISSN 1383-875X. DOI 10.1007/s10840-022-01379-7.
836. **Gorczyca, I., Jelonek, O., Michalska, A., Chrapek, M., Walek, P., Wożakowska-Kapłon, B.** Stroke prevention and guideline adherent antithrombotic treatment in elderly patients with atrial fibrillation: A real-world experience. // *Medicine (United States)*, 99, 2020, № 29, p. E21209. ISSN 0025-7974. DOI 10.1097/MD.00000000000021209.
837. **Gower, M.N., Ratner, L.R., Williams, A.K., Rossi, J.S., Stouffer, G.A., Lee, C.R.** Clinical utility of cyp2c19 genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: A review of emerging evidence. // *Pharmacogenomics and Personalized Medicine*, 13, 2020, p. 239-252. ISSN 1178-7066. DOI 10.2147/PGPM.S231475.
838. **Gragnano, F., Capolongo, A., Micari, A., Costa, F., Garcia-Ruiz, V., De Sio, V., Terracciano, F., Cesaro, A., Moscarella, E., Coletta, S., Raucci, P., Fimiani, F., De Luca, L., Gargiulo, G., Andò, G., Calabrò, P.** Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Journal of Clinical Medicine*, 13, 2024, № 1, art. no. 98. ISSN 2077-0383. DOI 10.3390/jcm13010098.
839. **Grajek, S., Kalużna-Oleksy, M.** Do non-vitamin K antagonist oral anticoagulants increase the risk of myocardial infarction? // *Kardiologia Polska*, 80, 2022, № 1, p. 16-24. ISSN 0022-9032. DOI 10.33963/KP.a2022.0017.
840. **Grajek, S., Kalużna-Oleksy, M., Siller-Matula, J.M., Grajek, M., Michalak, M.** Non-vitamin k antagonist oral anticoagulants and risk of myocardial infarction in patients with atrial fibrillation with or without percutaneous coronary interventions: A meta-analysis. // *Journal of Personalized Medicine*, 11, 2021, № 10, art. no. 1013. ISSN 2075-4426. DOI 10.3390/jpm11101013.
841. **Grajek, S., Ołasińska-Wisniewska, A., Michalak, M., Ritter, S.S.** Triple versus double antithrombotic therapy in patients with atrial fibrillation and stent implantation: A meta-analysis of randomized trials. // *Kardiologia Polska*, 77, 2019, № 9, p. 837-845. ISSN 0022-9032. DOI 10.33963/KP.14899.
842. **Greco, A., Capodanno, D.** Therapeutic uncertainties: first finding of atrial fibrillation in acute coronary syndrome. // *European Heart Journal, Supplement*, 24, 2022, p. 143-146. ISSN 1520-765X. DOI 10.1093/eurheartjsupp/suac072.
843. **Greco, A., Finocchiaro, S., Angiolillo, D.J., Capodanno, D.** Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. // *Expert Opinion on Pharmacotherapy*, 24, 2023, № 4, p. 453-471. ISSN 1465-6566. DOI 10.1080/14656566.2023.2171788.

844. **Greco, A., Laudani, C., Rochira, C., Capodanno, D.** Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective. // *Interventional Cardiology: Reviews, Research, Resources*, 18, 2023, art. no. e05. ISSN 1756-1477. DOI 10.15420/icr.2021.30.
845. **Greco, A., Mauro, M.S., Capodanno, D., Angiolillo, D.J.** P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 10, art. no. 348. ISSN 1530-6550. DOI 10.31083/j.rcm2310348.
846. **Gremmel, T., Sulzgruber, P., Niessner, A.** Critical appraisal of the AUGUSTUS trial. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 5, 2019, № 4, p. 187-188. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz017.
847. **Grilz, E., Posch, F., Nopp, S., Königsbrügge, O., Lang, I.M., Klimek, P., Thurner, S., Pabinger, I., Ay, C.** Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer - A nationwide analysis. // *European Heart Journal*, 42, 2021, № 23, p. 2299-2307. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab171.
848. **Grymonprez, M., Capiiau, A., Steurbaut, S., Boussey, K., Mehuys, E., Somers, A., Petrovic, M., De Backer, T.L., Lahousse, L.** Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study. // *Cardiovascular Drugs and Therapy*, 2023. ISSN 0920-3206. DOI 10.1007/s10557-023-07521-5.
849. **Guedeney, P., Collet, J.-P.** Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. // *Thrombosis and Haemostasis*, 121, 2021, № 7, p. 854-866. ISSN 0340-6245. DOI 10.1055/s-0040-1722188.
850. **Guedeney, P., Collet, J.-P.** Diagnosis and management of acute coronary syndrome: What is new and why? insight from the 2020 european society of cardiology guidelines. // *Journal of Clinical Medicine*, 9, 2020, № 11, art. no. 3474, p. 1-16. ISSN 2077-0383. DOI 10.3390/jcm9113474.
851. **Guedeney, P., Collet, J.-P., Ecollan, P., Montalescot, G.** NSTEMI : What's new in ESC 2020 guidelines [Prise en charge du syndrome coronaire aigu sans élévation du segment ST, nouveautés des recommandations ESC 2020]. // *Journal Europeen des Urgences et de Reanimation*, 33, 2021, № 2, p. 82-87. ISSN 2211-4238. DOI 10.1016/j.jeurea.2021.04.004.
852. **Guedeney, P., Mesnier, J., Sorrentino, S., Abcha, F., Zeitouni, M., Lattuca, B., Silvain, J., De Rosa, S., Indolfi, C., Collet, J.-P., Kerneis, M., Montalescot, G.** Review early aspirin discontinuation following acute coronary syndrome or percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials. // *Journal of Clinical Medicine*, 9, 2020, № 3, art. no. 680. ISSN 2077-0383. DOI 10.3390/jcm9030680.
853. **Guo, K., Wang, G., Zhang, L., Feng, Z., Xia, X., Sun, X., Yan, Z., Jiao, Z., Feng, D.** Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study. // *Expert Opinion on Drug Safety*, 23, 2024, № 4, p. 487-495. ISSN 1474-0338. DOI 10.1080/14740338.2024.2327502.

854. **Guo, W., Chen, X., Hao, Y., Liu, Q., Peng, C., Zhao, L., Feng, Z., Wang, X., Ruan, H., Li, L.** Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: A meta-analysis. // *Aging*, 12, 2020, № 13, p. 12930-12942. ISSN 1945-4589. DOI 10.18632/aging.103359.
855. **Gupta, K., Prejean, S.P., Vaduganathan, M., Golwala, H., Watts, T.E., Aryal, S.R., von Mering, G., Booker, O.J., Ahmed, M.I., Bajaj, N.S.** Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events? // *IJC Heart and Vasculature*, 24, 2019, art. no. 100404. ISSN 2352-9067. DOI 10.1016/j.ijcha.2019.100404.
856. **Gupta, R., Malik, A.H., Gupta, R., Ranchal, P., Yandrapalli, S., Patel, B., Frishman, W.H., Aronow, W.S., Garg, J.** Dual Versus Triple Therapy in Patients with Acute Coronary Syndrome and an Anticoagulation Indication: A Systematic Review with Meta-Analysis and Trial-Sequential Analysis. // *Cardiology in Review*, 29, 2021, № 5, p. 245-252. ISSN 1061-5377. DOI 10.1097/CRD.0000000000000320.
857. **Gurevitz, C., Eisen, A., Lev, E., Itzhaki Ben Zadok, O., Perl, L., Samara, A., Nissenholtz, A., Rozovski, U., Elis, A., Kornowski, R., Raanani, P., Ziv, E., Spectre, G.** Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Cardiology (Switzerland)*, 146, 2021, № 2, p. 222-227. ISSN 0008-6312. DOI 10.1159/000512435.
858. **Gusdon, A.M., Farrokh, S., Grotta, J.C.** Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. // *Seminars in Neurology*, 41, 2021, № 4, p. 365-387. ISSN 0271-8235. DOI 10.1055/s-0041-1726331.
859. **Ha, H.S., Kim, J., Lee, Y.S., Kim, T.-H., Lee, J.M., Park, J., Park, J.-K., Kang, K.-W., Shim, J., Uhm, J.-S., Park, H.W., Cha, M.-J., Choi, E.-K., Kim, J., Kim, J.-B., Kim, C., Joung, B.** Current anticoagulant usage patterns and determinants in Korean patients with nonvalvular atrial fibrillation. // *Yonsei Medical Journal*, 61, 2020, № 2, p. 120-128. ISSN 0513-5796. DOI 10.3349/ymj.2020.61.2.120.
860. **Habhab, M.N., Torabi, A.J., Clary, J.M., Revtyak, G.E.** Spontaneous duodenal hematoma: a rare complication of triple antithrombotic therapy case report. // *Future Cardiology*, 19, 2023, № 2, p. 71-76. ISSN 1479-6678. DOI 10.2217/fca-2021-0078.
861. **Hajjar, L.A., Fonseca, S.M.R., Machado, T.I.V.** Atrial Fibrillation and Cancer. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 590768. ISSN 2297-055X. DOI 10.3389/fcvm.2021.590768.
862. **Hajra, A., Ujjawal, A., Ghalib, N., Chowdhury, S., Biswas, S., Balasubramanian, P., Gupta, R., Aronow, W.S.** Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence. // *Current Problems in Cardiology*, 49, 2024, № 1, art. no. 102017. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2023.102017.
863. **Han, Y., Yuan, Z., Yang, Y., Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Interventional Cardiology Working Group of Chinese Society of Cardiology, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians,**

**Specialty Committee on Coronary Artery Disease and Atherosclerosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology.** Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease [冠心病双联抗血小板治疗中国专家共识]. // *Chinese Journal of Cardiology*, 49, 2021, № 5, p. 432-454. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210125-00088.

864. **Hanna, E.B.** Practical Cardiovascular Medicine. – In: *Practical Cardiovascular Medicine*, 2022, p. 1-963. ISBN 9781119832737; 9781119832713. DOI 10.1002/9781119832737.
865. **Hara, H., Serruys, P.W., O'Leary, N., Gao, C., Murray, A., Breslin, E., Garg, S., Bureau, C., Reiber, J.H., Barbato, E., Aminian, A., Janssens, L., Rosseel, L., Benit, E., Campo, G., Guiducci, V., Casella, G., Santarelli, A., Franzè, A., Diaz, V.A.J., Iñiguez, A., Brugaletta, S., Sabate, M., Amat-Santos, I.J., Amoroso, G., Wykrzykowska, J., von Birgelen, C., Somi, S., Liu, T., Hofma, S.H., Curzen, N., Trillo, R., Ocaranza, R., Mathur, A., Smits, P.C., Escaned, J., Baumbach, A., Wijns, W., Sharif, F., Onuma, Y., PIONEER IV trial investigator.** Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. // *American Heart Journal*, 246, 2022, p. 32-43. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.12.018.
866. **Hardy, M., Dupuis, C., Dincq, A.-S., Jacqmin, H., Lecompte, T., Mullier, F., Les-sire, S.** Reduction of preoperative waiting time before urgent surgery for patients on P2Y12 inhibitors using multiple electrode aggregometry: A retrospective study. // *Journal of Clinical Medicine*, 9, 2020, № 2, art. no. 424. ISSN 2077-0383. DOI 10.3390/jcm9020424.
867. **He, B., Jiang, L.** A brief discussion: the impact of "2019 Chinese Society of Cardiology (CSC) expert consensus statement on left atrial appendage closure in the prevention of stroke in patients with atrial fibrillation" on the evolution of technical development of LAAC in China [浅谈《中国左心耳封堵预防心房颤动卒中专家共识(2019)》对我国左心耳封堵技术发展的影响]. // *Chinese Journal of Cardiology*, 49, 2021, № 3, p. 212-216. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210131-00113.
868. **Hink, U., Voigtländer, T.** Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. // *Visceral Medicine*, 36, 2020, № 4, p. 264-273. ISSN 2297-4725. DOI 10.1159/000509896.
869. **Hoedemaker, N.P.G., de Winter, R.J., Hof, A., Kolkman, E., Damman, P.** Optimal Medical Therapy Prescription in Patients with Acute Coronary Syndrome in the Netherlands: A Multicenter Pilot Registry. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 2, p. 219-229. ISSN 1175-3277. DOI 10.1007/s40256-020-00427-9.
870. **Hofer, F., Kazem, N., Hammer, A., El-Hamid, F., Koller, L., Niessner, A., Sulzgruber, P.** Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: The impact of anti-thrombotic treatment strategies. // *European Heart*

871. **Hohmann, C., Ludwig, M., Walker, J., Iliadis, C., Schipper, J.-H., Baldus, S., Pfister, R.** Real-world anticoagulatory treatment after percutaneous mitral valve repair using MitraClip: a retrospective, observational study on 1300 patients. // *Clinical Research in Cardiology*, 111, 2022, № 8, p. 889-899. ISSN 1861-0684. DOI 10.1007/s00392-022-01988-2.
872. **Hohmann, C., Ludwig, M., Walker, J., Wienemann, H., Baldus, S., Pfister, R.** Real-World Anticoagulatory Treatment After Transcatheter Aortic Valve Replacement: A Retrospective, Observational Study on 4,800 Patients. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 780762. ISSN 2297-055X. DOI 10.3389/fcvm.2021.780762.
873. **Holm, A., Henriksson, M., Alfredsson, J., Janzon, M., Johansson, T., Swahn, E., Vial, D., Lawesson, S.S.** Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy-An observational study. // *PLoS ONE*, 16, 2021, art. no. e0248359. ISSN 1932-6203. DOI 10.1371/journal.pone.0248359.
874. **Hong, K.-S.** Non-vitamin K antagonist oral anticoagulants in medical conditions at high risk of thromboembolism beyond atrial fibrillation. // *Journal of Stroke*, 21, 2019, № 3, p. 259-275. ISSN 2287-6391. DOI 10.5853/jos.2019.01970.
875. **Horie, K., Matsumoto, T., Mizutani, Y., Tada, N., Osai, N., Isawa, T., Taguri, M., Kato, S., Honda, T., Ootomo, T., Inoue, N.** A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 2, p. 150-161. ISSN 1868-4300. DOI 10.1007/s12928-019-00589-7.
876. **Horiguchi, A., Fukaya, H., Oikawa, J., Shirakawa, Y., Kobayashi, S., Arakawa, Y., Nishinarita, R., Nakamura, H., Ishizue, N., Igarashi, G., Satoh, A., Kishihara, J., Niwano, S., Ako, J.** Real-world antithrombotic therapy in atrial fibrillation patients with a history of percutaneous coronary intervention. // *International Heart Journal*, 60, 2019, № 6, p. 1321-1327. ISSN 1349-2365. DOI 10.1536/ihj.19-127.
877. **Hoshi, T., Sato, A., Hiraya, D., Watabe, H., Takeyasu, N., Nogami, A., Ohigashi, T., Goshō, M., Ieda, M., Aonuma, K., the SAFE-A Investigators.** Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: Results of the SAFE - A study. // *EuroIntervention*, 16, 2021, № 2, p. E164-E172. ISSN 1774-024X. DOI 10.4244/eij-d-19-00920.
878. **Hotsuki, Y., Sato, Y., Yoshihisa, A., Watanabe, K., Kimishima, Y., Kiko, T., Yokokawa, T., Misaka, T., Sato, T., Kaneshiro, T., Oikawa, M., Kobayashi, A., Yamaki, T., Kunii, H., Nakazato, K., Takeishi, Y.** Glasgow-blatchford score predicts post-discharge gastrointestinal bleeding in hospitalized patients with heart failure. // *Journal of Clinical Medicine*, 9, 2020, № 12, art. no. 4083, p. 1-9. ISSN 2077-0383. DOI 10.3390/jcm9124083.
879. **Huang, L., Tan, Y., Pan, Y.** Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. // *ESC Heart Failure*, 9, 2022, № 5, p. 3519-3532. ISSN 2055-5822. DOI 10.1002/ehf2.14084.



880. **Huang, Y.-C., Huang, Y.-C., Cheng, Y.-C., Chen, M.** Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study. // *Scientific Reports*, 12, 2022, № 1, art. no. 1417. ISSN 2045-2322. DOI 10.1038/s41598-022-05546-8.
881. **Huisman, M.V.** Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention. // *Netherlands Heart Journal*, 29, 2021, № 3, p. 119-120. ISSN 1568-5888. DOI 10.1007/s12471-021-01546-x.
882. **Huseynov, A., Reinhardt, J., Chandra, L., Dürschmied, D., Langer, H.F.** Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease-A Translational Perspective. // *International Journal of Molecular Sciences*, 24, 2023, № 7, art. no. 6280. ISSN 1661-6596. DOI 10.3390/ijms24076280.
883. **Hussein, A.A., Alvarez, P., Reed, G., Heresi, G.A.** Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardiopulmonary Disease. // *Chest*, 161, 2022, № 5, p. 1360-1369. ISSN 0012-3692. DOI 10.1016/j.chest.2022.01.033.
884. **Hwang, Y.J., Chang, H.-Y., Metkus, T., Andersen, K.M., Singh, S., Alexander, G.C., Mehta, H.B.** Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. // *Drug Safety*, 47, 2024, № 3, p. 251-260. ISSN 0114-5916. DOI 10.1007/s40264-023-01388-z.
885. **Ioannou, M., Leonidou, E., Chaziri, I., Mouzarou, A.** Direct Oral Anticoagulants: Navigating Through Clinical Challenges. // *Cardiovascular Drugs and Therapy*, 2023. ISSN 0920-3206. DOI 10.1007/s10557-023-07499-0.
886. **Iqbal, H., Straw, S., Craven, T.P., Stirling, K., Wheatcroft, S.B., Witte, K.K.** Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. // *ESC Heart Failure*, 7, 2020, № 5, p. 2032-2041. ISSN 2055-5822. DOI 10.1002/ehf2.12718.
887. **Iskaros, O., Ahuja, T., Arnouk, S., Toy, B., Lewis, T., Altshuler, D., Smith, D., Papadopoulos, J., Merchan, C.** Antithrombotic management for Impella® temporary ventricular assist devices: An analysis of an academic health-system experience. // *International Journal of Artificial Organs*, 45, 2022, № 6, p. 550-559. ISSN 0391-3988. DOI 10.1177/03913988221082686.
888. **Jacobsen, A.P., Raber, I., McCarthy, C.P., Blumenthal, R.S., Bhatt, D.L., Cusack, R.W., Serruys, P.W.J.C., Wijns, W., Mcevoy, J.W.** Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted? // *Circulation*, 142, 2020, № 16, p. 1579-1590. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.045695.
889. **Javalkar, V., Kuybu, O., Amireh, A., Kelley, R.E.** Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. // *Southern Medical Journal*, 113, 2020, № 11, p. 585-592. ISSN 0038-4348. DOI 10.14423/SMJ.0000000000001173.
890. **Jeong, Y.-H., Kim, Y.-L., Tantry, U., Gurbel, P.A.** Antithrombotic treatment strategies after PCI. // *The Lancet*, 395, 2020, № 10227, p. 866-867. ISSN 0140-6736. DOI 10.1016/S0140-6736(20)30030-1.

891. **Jiang, X., Zeng, J., Zhong, L., Zhu, W., Li, J.** Preliminary study on the safety and efficacy of one-stop treatment of percutaneous LAAO combined with coronary intervention for higher risk of bleeding in patients with AF complicated with CHD. // *Heart Surgery Forum*, 24, 2021, № 30, p. E474-E478. ISSN 1098-3511. DOI 10.1532/hcf.3701.
892. **Jilek, C., Lewalter, T.** Anticoagulation and comorbidities [Antikoagulation unter erschwerten Bedingungen]. // *MMW-Fortschritte der Medizin*, 162, 2020, № 5, p. 36-44. ISSN 1438-3276. DOI 10.1007/s15006-020-0261-x.
893. **Jilek, C., Lewalter, T.** Atrial fibrillation and anticoagulation [Antikoagulation bei Vorhofflimmern]. // *MMW-Fortschritte der Medizin*, 161, 2019, p. 22-31. ISSN 1438-3276. DOI 10.1007/s15006-019-0026-6.
894. **Jin, C., Cui, C., Seplowe, M., Lee, K.-I., Vegunta, R., Li, B., Frishman, W.H., Iwai, S.** Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. // *Cardiology in Review*, 32, 2024, № 2, p. 131-139. ISSN 1061-5377. DOI 10.1097/CRD.0000000000000489.
895. **Juárez Fernández, M., Uribarri, A., Sousa-Casasnovas, I., Alzola Martínez de Antoñana, E., Jorge Pérez, P., Martín-Asenjo, R., Ariza Solé, A., López-de-Sá, E.** Selection of the best of 2019 in ischaemic heart disease and critical cardiovascular care [Selección de lo mejor del año 2019 en cardiopatía isquémica y cuidados críticos cardiovasculares]. // *REC: CardioClinics*, 55, 2020, p. 38-43. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.10.010.
896. **Jung, J., Seo, Y., Her, S.-H., Lee, J.-H., Lee, K., Yoo, K.-D., Moon, K.-W., Moon, D., Lee, S.-N., Jang, W.-Y., Choi, I.-J., Lee, J.-H., Lee, S.-R., Lee, S.-W., Yun, K.-H., Lee, H.-J.** Prognostic Impact of Atrial Fibrillation in Patients with Heavily Calcified Coronary Artery Disease Receiving Rotational Atherectomy. // *Medicina (Lithuania)*, 59, 2023, № 10, art. no. 1808. ISSN 1010-660X. DOI 10.3390/medicina59101808.
897. **Juriscic, S., Patriki, D., Beer, J.H.** Dual antiplatelet therapy after percutaneous coronary intervention over time: one size does not fit all. // *Cardiovascular Medicine*, 24, 2021, № 5, p. 155-162. ISSN 1664-2031. DOI: 10.4414/cvm.2021.02175.
898. **Kaddoura, R., Orabi, B., Yassin, M.A., Omar, A.S.** Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 6, art. no. 180. ISSN 1530-6550. DOI 10.31083/j.rcm2406180.
899. **Kalich, B.A.** Complex management of atrial fibrillation. // *JACCP Journal of the American College of Clinical Pharmacy*, 2, 2019, № 6, p. 702-706. ISSN 2574-9870. DOI 10.1002/jac5.1186.
900. **Kanorsky, S.G., Mamedov, M.N., Oganov, R.G.** Congress of the American college of cardiology (New Orleans, 2019): Clinical findings. // *Cardiovascular Therapy and Prevention (Russian Federation)*, 18, 2019, № 4, p. 129-136. ISSN 1728-8800. DOI 10.15829/1728-8800-2019-4-129-136.
901. **Kao, T.-W., Liao, P.-J.** Phenotype-directed clinically driven low-dose direct oral anticoagulant for atrial fibrillation. // *Future Cardiology*, 19, 2023, № 8, p. 405-417. ISSN 1479-6678. DOI 10.2217/fca-2022-0109.

902. **Kaplinskiy, V., Gelfand, E.V.** Management of Atrial Fibrillation in the Outpatient Setting. – In: *Handbook of Outpatient Cardiology*, 2022, p. 387-408. ISBN 9783030889531; 9783030889524. DOI 10.1007/978-3-030-88953-1\_23.
903. **Karcioglu, O., Yilmaz, S., Afacan, G., Ersan, E., Abuşka, D., Zengin, S., Ozkaya, B., Hosseinzadeh, M., Yeniocak, S.** An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs). // *Cardiovascular and Hematological Agents in Medicinal Chemistry*, 20, 2022, № 2, p. 114-124. ISSN 1871-5257. DOI 10.2174/1871525719666210914112402.
904. **Kawakami, S., Yasuda, S., Ogawa, H.** Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a “less is more” concept regimen. // *Journal of Cardiology*, 76, 2020, № 1, p. 35-43. ISSN 0914-5087. DOI 10.1016/j.jcc.2020.03.001.
905. **Kayani, W.T., Khan, M.R., Deshotels, M.R., Jneid, H.** Challenges and Controversies in the Management of ACS in Elderly Patients. // *Current Cardiology Reports*, 22, 2020, № 7, art. no. 51. ISSN 1523-3782. DOI 10.1007/s11886-020-01298-x.
906. **Kazem, N., Sulzgruber, P., Niessner, A.** Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: A focus on the net clinical benefit. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 5, p. E83-E84. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvab058.
907. **Kerley, R.N., Fitzgerald, G., Coughlan, J.J., Kelly, C., Waters, M., Reynolds, A., Mulcahy, D., Moore, D.P., Loo, B., Curtin, R.** Real World Prescribing Strategies for Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 26, 2021, № 1, p. 67-74. ISSN 1074-2484. DOI 10.1177/1074248420947280.
908. **Khan, S.U., Osman, M., Khan, M.U., Khan, M.S., Zhao, D., Mamas, M.A., Savji, N., Al-Abdoh, A., Hasan, R.K., Michos, E.D.** Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention a systematic review and meta-analysis. // *Annals of Internal Medicine*, 172, 2020, № 7, p. 474-483. ISSN 0003-4819. DOI 10.7326/M19-3763.
909. **Kharazov, A.F., Basirova, N.M., Markov, A.A.** Discontinuation of antiplatelet and anticoagulant therapy before surgery [Отмена антиагрегантной и антикоагулянтной терапии перед оперативным вмешательством]. // *Clinical and Experimental Surgery*, 10, 2022, № 2, p. 112-119. ISSN 2308-1198. DOI 10.33029/2308-1198-2022-10-2-112-119.
910. **Kheiri, B., Osman, M., Bakhit, A., Radaideh, Q., Abdalla, A., Barbarawi, M., Zayed, Y., Ahmed, S., Bachuwa, G., Hassan, M.** Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. // *Journal of Thrombosis and Thrombolysis*, 48, 2019, № 3, p. 511-513. ISSN 0929-5305. DOI 10.1007/s11239-019-01874-1.
911. **Kichloo, A., Aljadah, M.M., Wani, F., Ananthaneni, S.** Q: Should we give triple therapy to patients with atrial fibrillation after percutaneous intervention? // *Cleveland Clinic Journal of Medicine*, 87, 2020, № 10, p. 599-601. ISSN 0891-1150. DOI 10.3949/CCJM.87A.19115.

912. **Kido, K., Ghaffar, Y.A., Lee, J.C., Bianco, C., Shimizu, M., Shiga, T., Hashiguchi, M.** Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. // *PLoS ONE*, 16, 2021, art. no. e0252549. ISSN 1932-6203. DOI 10.1371/journal.pone.0252549.
913. **Kietaibl, S., Ferrandis, R., Godier, A., Llau, J., Lobo, C., MacFarlane, A.J.R., Schlomp, C.J., Vandermeulen, E., Volk, T., Von Heymann, C., Wolmarans, M., Afshari, A.** Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. // *European Journal of Anaesthesiology*, 39, 2022, № 2, p. 100-132. ISSN 0265-0215. DOI 10.1097/EJA.0000000000001600.
914. **Kim, B.G., Hong, S.-J., Kim, B.-K., Lee, S.-J., Ahn, C.-M., Shin, D.-H., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. // *Journal of the American Heart Association*, 10, 2021, № 24, art. no. e022700. ISSN 2047-9980. DOI 10.1161/JAHA.121.022700.
915. **Kim, G.O., Heo, J.B., Park, D.H., Song, G.Y., Bae, J.-S.** Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa. // *Pharmaceuticals*, 16, 2023, № 4, art. no. 588. ISSN 1424-8247. DOI 10.3390/ph16040588.
916. **Kim, J.-T., Lee, J.S., Kim, B.J., Park, J.-M., Kang, K., Lee, S.J., Kim, J.G., Cha, J.-K., Kim, D.-H., Park, T.H., Park, S.-S., Lee, K.B., Lee, J., Hong, K.-S., Cho, Y.-J., Park, H.-K., Lee, B.-C., Yu, K.-H., Oh, M.S., Kim, D.-E., Ryu, W.-S., Choi, J.C., Kwon, J.-H., Kim, W.-J., Shin, D.-I., Sohn, S.I., Hong, J.-H., Park, M.-S., Choi, K.-H., Cho, K.-H., Lee, J., Gorelick, P.B., Bae, H.-J.** Effectiveness of Adding Antiplatelets to Oral Anticoagulants in Patients with Acute Ischemic Stroke with Atrial Fibrillation and Concomitant Large Artery Steno-Occlusion. // *Translational Stroke Research*, 11, 2020, № 6, p. 1322-1331. ISSN 1868-4483. DOI 10.1007/s12975-020-00822-z.
917. **Kim, T.J., Lee, J.S., Yoon, J.S., Oh, M.S., Kim, J.-W., Park, S.-H., Jung, K.-H., Kim, H.Y., Kwon, J.-H., Choi, H.-Y., Kim, H.Y., Eah, K.Y., Han, S.W., Oh, H.-G., Kim, Y.-J., Shin, B.-S., Kim, C.H., Kim, C.K., Park, J.-M., Lee, K.B., Park, T.H., Lee, J., Park, M.-S., Choi, J.C., Kim, C., Shin, D.-I., Lee, S.J., Kim, D.-E., Cha, J.-K., Kim, E.-G., Yu, K.-H., Hong, K.-S., Lee, Y.-S., Lee, J.-H., Sohn, S.I., Bae, H.-J., Lee, Y.-B., Lee, J.H., Rha, J.-H., Lee, B.-C., Chang, D.-I., Ko, S.-B., Yoon, B.-W.** Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis. // *International Journal of Stroke*, 18, 2023, № 7, p. 812-820. ISSN 1747-4930. DOI 10.1177/17474930231158211.
918. **Kim, Y., Johnson, T.W., Jeong, Y.-H.** To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention. // *Cardiology Journal*, 27, 2020, № 1, p. 1-3. ISSN 1897-5593. DOI 10.5603/CJ.2020.0012.
919. **Kitahara, H., Tateishi, K., Shiko, Y., Inaba, Y., Kobayashi, Y., Inoue, T.** Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention. // *PLoS ONE*, 17, 2022, art. no. e0272140. ISSN 1932-6203. DOI 10.1371/journal.pone.0272140.

920. Kitahara, H., Yamashita, D., Sato, T., Suzuki, S., Hiraga, T., Yamazaki, T., Matsumoto, T., Kobayashi, T., Ohno, Y., Harada, J., Fukushima, K., Asano, T., Ishio, N., Uchiyama, R., Miyahara, H., Okino, S., Sano, M., Kuriyama, N., Yamamoto, M., Sakamoto, N., Kanda, J., Kobayashi, Y. Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention. // *Journal of Cardiology*, 82, 2023, № 3, p. 207-214. ISSN 0914-5087. DOI 10.1016/j.jjcc.2023.06.002.
921. Kitano, D., Migita, S., Li, Y., Takahashi, R., Taniguchi, Y., Kurosawa, T., Sudo, M., Haruta, H., Hiro, T., Takayama, T., Mitsumata, M., Matsumoto, T., Okumura, Y., Hirayama, A. Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. // *Journal of Atherosclerosis and Thrombosis*, 29, 2022, № 1, p. 69-81. ISSN 1340-3478. DOI 10.5551/jat.56549.
922. Knecht, S., Schmidt-Wilcke, T. Second look: practical diagnostic and therapeutic checks in neurorehabilitation [Der zweite Blick: praktische diagnostische und therapeutische Checks in der rehabilitativen Neurologie]. // *Nervenarzt*, 91, 2020, № 4, p. 324-336. ISSN 0028-2804. DOI 10.1007/s00115-020-00887-z.
923. Knijnik, L., Rivera, M., Blumer, V., Cardoso, R., Fernandes, A., Fernandes, G., Ferreira, T., Romano, J.G., Lambrakos, L.K., Cohen, M.G. Prevention of Stroke in Atrial Fibrillation after Coronary Stenting: Systematic Review and Network Meta-Analysis. // *Stroke*, 50, 2019, № 8, p. 2125-2132. ISSN 0039-2499. DOI 10.1161/STROKEAHA.119.026078.
924. Kochetkov, A.I., Ostroumova, O.D. Optimization of pharmacotherapy with direct oral anticoagulants: The need to choose the right dosage regimen [Оптимизация фармакотерапии прямыми оральными антикоагулянтами: необходимость правильного выбора режима дозирования]. // *Rational Pharmacotherapy in Cardiology*, 15, 2019, № 4, p. 593-603. ISSN 1819-6446. DOI 10.20996/1819-6446-2019-15-4-593-603.
925. Kook, H., Kim, H.-D., Shim, J., Kim, Y.-H., Kim, J.-S., Pak, H.-N., Lee, H.-J., Choi, R.-K., Kang, W.-C., Shin, E.-S., Park, J.-W., Yu, C.W., Lim, D.-S. Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. // *PLoS ONE*, 16, 2021, art. no. e0244723. ISSN 1932-6203. DOI 10.1371/journal.pone.0244723.
926. Kosiński, M., Rejszel-Baranowska, J., Młodawska, E., Siller-Matula, J.M., Tomaszuk-Kazberuk, A. Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Postępy w Kardiologii Interwencyjnej*, 16, 2020, № 2, p. 127-137. ISSN 1734-9338. DOI 10.5114/aic.2020.96055.
927. Krestyaninov, O.V., Ba DOIan, A.G., Baystrukov, V.I., Naydenov, R.A. Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary interventions [Антитромботическая терапия у пациентов с фибрилляцией предсердий после чрескожных коронарных вмешательств]. // *Complex Issues of Cardiovascular Diseases*, 11, 2022, № 1, p. 98-106. ISSN 2306-1278. DOI 10.17802/2306-1278-2022-11-1-98-106.



928. **Krishnaswamy, A., Wazni, O., Kapadia, S.R.** Left Atrial Appendage Occlusion for Patients with Transcatheter Aortic Valve Replacement, MitraClip, Percutaneous Coronary Intervention, and Ablation for Atrial Fibrillation: Optimizing Long-Term Patient Outcomes. // *Cardiac Electrophysiology Clinics*, 12, 2020, № 1, p. 117-124. ISSN 1877-9182. DOI 10.1016/j.ccep.2019.11.006.
929. **Krucoff, M.W., Urban, P., Tanguay, J.-F., Mcandrew, T., Zhang, Y., Rao, S.V., Morice, M.-C., Price, M.J., Cohen, D.J., Abdel-Wahab, M., Mehta, S.R., Faurie, B., McLaurin, B., Diaz, C., Stoll, H.-P., Pocock, S., Leon, M.B.** Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. // *Circulation: Cardiovascular Interventions*, 13, 2020, № 4, p. E008603. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.119.008603.
930. **Kühne, M., Krisai, P., Coslovsky, M., Rodondi, N., Müller, A., Beer, J.H., Ammann, P., Auricchio, A., Moschovitis, G., Hayoz, D., Kobza, R., Shah, D., Stephan, F.P., Schläpfer, J., Di Valentino, M., Aeschbacher, S., Ehret, G., Eken, C., Monsch, A., Roten, L., Schwenkglenks, M., Springer, A., Sticherling, C., Reichlin, T., Zuern, C.S., Meyre, P.B., Blum, S., Sinnecker, T., Würfel, J., Bonati, L.H., Conen, D., Osswald, S.** Silent brain infarcts impact on cognitive function in atrial fibrillation. // *European Heart Journal*, 43, 2022, № 22, p. 2127-2135. ISSN 0195-668X. DOI 10.1093/eurheartj/ehac020.
931. **Kuno, T., Ueyama, H., Ando, T., Briasoulis, A., Takagi, H.** Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; Insights from a meta-analysis. // *Coronary Artery Disease*, 2020, p. 31-35. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000900.
932. **Kuno, T., Ueyama, H., Takagi, H., Ando, T., Numasawa, Y., Briasoulis, A., Fox, J., Bangalore, S.** Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 125, 2020, № 4, p. 521-527. ISSN 0002-9149. DOI 10.1016/j.amjcard.2019.11.022.
933. **Kuno, T., Ueyama, H., Takagi, H., Bangalore, S.** The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials. // *Scandinavian Cardiovascular Journal*, 56, 2022, № 1, p. 1-3. ISSN 1401-7431. DOI 10.1080/14017431.2021.2025264.
934. **Lacoste, J.L., Hansen, C.L.** Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. // *American Journal of Health-System Pharmacy*, 76, 2019, № 18, p. 1395-1402. ISSN 1079-2082. DOI 10.1093/ajhp/zxz152.
935. **Laffond, A., Borrego, J., González-Calle, D., Cepas-Guillén, P.** IV CardioMIR: the Congress of Young Cardiologists [IV CardioMIR: el Congreso de los Jóvenes Cardiólogos]. // *REC: CardioClinics*, 58, 2023, p. S32-S42. ISSN 2605-1532. DOI 10.1016/j.rccl.2023.11.001.
936. **Laine, M., Canault, M., Bonello, L.** Letter by Laine et al Regarding Article, "antithrombotic Agents: New Directions in Antithrombotic Therapy". // *Circulation Research*, 124, 2019, № 12, p. e117-e118. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.119.315213.

937. **Lancini, D., Prasad, A., Thomas, L., Atherton, J., Martin, P., Prasad, S.** Predicting new onset atrial fibrillation post acute myocardial infarction: Echocardiographic assessment of left atrial size. // *Echocardiography*, 40, 2023, № 6, p. 456-463. ISSN 0742-2822. DOI 10.1111/echo.15574.
938. **Landi, A., Massucci, M., Scotti, A., Basis, G.** Use of direct oral anticoagulants after percutaneous coronary intervention. – In: *Direct Oral Anticoagulants: From Pharmacology to Clinical Practice*, 2021, p. 255-270. ISBN 9783030744625; 9783030744618. DOI 10.1007/978-3-030-74462-5\_16.
939. **Lasica, R., Djukanovic, L., Popovic, D., Savic, L., Mrdovic, I., Radovanovic, N., Radovanovic, M.R., Polovina, M., Stojanovic, R., Matic, D., Uscumlic, A., Asanin, M.** Use of Anticoagulant Therapy in Patients with Acute Myocardial Infarction and Atrial Fibrillation. // *Medicina (Lithuania)*, 58, 2022, № 3, art. no. 338. ISSN 1010-660X. DOI 10.3390/medicina58030338.
940. **Leblanc, K., MacGillivray, J., Carroccia, A., Macle, L., Andrade, J.G.** The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways. // *Canadian Pharmacists Journal*, 155, 2022, № 2, p. 107-118. ISSN 1715-1635. DOI 10.1177/17151635211058160.
941. **Lee, C.-C., Chang, C.-H., Hung, Y., Lin, C.-S., Yang, S.-P., Cheng, S.-M., Yu, F.-H., Lin, W.-S., Lin, W.-Y.** Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study. // *Thrombosis Journal*, 19, 2021, № 1, art. no. 100. ISSN 1477-9560. DOI 10.1186/s12959-021-00353-z.
942. **Lee, S.-H., Lee, S.-J., Heo, J.H., Ahn, S.G., Doh, J.-H., Shin, S., Shim, J., Her, A.-Y., Kim, B.G., Lim, S.W., Kwon, T.-G., Lee, K.-H., Kim, D., Lee, Y.-J., Yu, H.T., Kim, T.-H., Shin, D.-H., Pak, H.-N., Kim, J.-S.** Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial. // *American Heart Journal*, 271, 2024, p. 48-54. ISSN 0002-8703. DOI 10.1016/j.ahj.2024.02.014.
943. **Leening, M.J.G., Mahmoud, K.D.** Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. // *European Journal of Epidemiology*, 36, 2021, № 11, p. 1103-1109. ISSN 0393-2990. DOI 10.1007/s10654-021-00820-x.
944. **Leschke, M.** Antithrombotische Therapie des chronischen Koronarsyndroms. // *Kliniker*, 49, 2020, № 3, p. 97-101. ISSN 0341-2350. DOI 10.1055/a-1118-1330.
945. **Lettino, M., Mascherbauer, J., Nordaby, M., Ziegler, A., Collet, J.P., Derumeaux, G., Hohnloser, S.H., Leclercq, C., O'Neill, D.E., Visseren, F., Weidinger, F., Richard-Lordereau, I.** Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology - Cardiovascular Round Table. // *European Journal of Preventive Cardiology*, 29, 2022, № 10, p. 1412-1424. ISSN 2047-4873. DOI 10.1093/eurjpc/zwac033.
946. **Li, W., Gao, R., Zhao, J., Ren, Y., Chen, G., Zhu, J., Jin, K., Zhu, L., Ruan, Z.** Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion. // *Annals of Palliative Medicine*, 11, 2022, № 1, p. 201-209. ISSN 2224-5820. DOI 10.21037/apm-21-3654.

947. **Liang, B., Zhu, Y.-C., Gu, N.** Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 832164. ISSN 2297-055X. DOI 10.3389/fcvm.2022.832164.
948. **Lianos, I., Varlamos, C., Benetou, D.-R., Mantis, C., Kintis, K., Dragona, V.-M., Kanakakis, I., Sionis, D., Patsilinos, S., Alexopoulos, D.** Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention. // *Journal of Thrombosis and Thrombolysis*, 55, 2023, № 1, p. 42-50. ISSN 0929-5305. DOI 10.1007/s11239-022-02723-4.
949. **Liao, Y.W.B., Wang, T.K.M.** Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: A meta-analysis of randomized trials. // *Coronary Artery Disease*, 2020, p. 260-265. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000785.
950. **Liedtke, J.-P., Ahrens, I.** Antiplatelet therapy and anticoagulation in patients with coronary heart disease [Antithrombozytäre Therapie und Antikoagulation bei Patienten mit koronarer Herzerkrankung]. // *Deutsche Medizinische Wochenschrift*, 146, 2021, № 16, p. 1041-1050. ISSN 0012-0472. DOI 10.1055/a-1241-6676.
951. **Limbruno, U., de Sensi, F., Cresti, A., Picchi, A., Lena, F., de Caterina, R.** Optimal antithrombotic treatment of patients with atrial fibrillation early after an acute coronary syndrome—triple therapy, dual antithrombotic therapy with an anticoagulant ... or, rather, temporary dual antiplatelet therapy? // *Journal of Clinical Medicine*, 9, 2020, № 8, art. no. 2673, p. 1-11. ISSN 2077-0383. DOI 10.3390/jcm9082673.
952. **Limbruno, U., Goette, A., De Caterina, R.** Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. // *International Journal of Cardiology*, 318, 2020, p. 82-85. ISSN 0167-5273. DOI 10.1016/j.ijcard.2020.05.024.
953. **Lin, D.S.-H., Lo, H.-Y., Huang, K.-C., Lin, T.-T., Lee, J.-K.** Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials. // *Journal of the American Heart Association*, 12, 2023, № 23, art. no. e030380. ISSN 2047-9980. DOI 10.1161/JAHA.123.030380.
954. **Linden, K., Mailey, J., Kearney, A., Menown, I.B.A.** Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. // *Advances in Therapy*, 37, 2020, № 6, p. 2620-2645. ISSN 0741-238X. DOI 10.1007/s12325-020-01355-5.
955. **Liu, H., Han, Y.** Recent advances in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention [冠心病介入抗栓治疗相关最新进展概要]. // *Chinese Journal of Cardiology*, 49, 2021, № 2, p. 108-110. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20201222-01010.
956. **Liu, J., Jin, M.** The Antithrombotic Effect of Dabigatran Etxilate Combined with Ningxinbao Capsules on Non-Valvular Atrial Fibrillation Patients after Percutaneous Coronary Intervention. // *Latin American Journal of Pharmacy*, 41, 2022, № 6, p. 1184-1188. ISSN 0326-2383.

957. **Liu, J., Zhong, Z., Ou, S., Peng, K.** Application effect of evidence-based nursing in perioperative period of acute coronary syndrome. // *American Journal of Translational Research*, 13, 2021, № 4, p. 2653-2661. ISSN 1943-8141.
958. **Liu, L., Lei, H., Hu, J., Tang, Y., Xu, D.** Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. // *Drugs*, 81, 2021, № 17, p. 2003-2016. ISSN 0012-6667. DOI 10.1007/s40265-021-01637-4.
959. **Liu, X., Wang, L., Zhou, M., Feng, L.** Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Contemporary Clinical Trials*, 104, 2021, art. no. 106365. ISSN 1551-7144. DOI 10.1016/j.cct.2021.106365.
960. **Loganath, K., Adamson, P.D., Moss, A.J.** Ticagrelor in the management of coronary artery disease. // *Future Cardiology*, 17, 2021, № 4, p. 561-571. ISSN 1479-6678. DOI 10.2217/fca-2020-0108.
961. **López-Fernández, T., Martín-García, A., Roldán Rabadán, I., Mitroi, C., Mazón Ramos, P., Díez-Villanueva, P., Escobar Cervantes, C., Alonso Martín, C., Alonso Salinas, G.L., Arenas, M., Arrarte Esteban, V.I., Ayala de La Peña, F., Castro Fernández, A., García Pardo, H., García-Sanz, R., González Porras, J.R., López de Sá, E., Lozano, T., Marco Vera, P., Martínez Marín, V., Mesa Rubio, D., Montero, Á., Oristrell, G., Pérez de Prado, A., Velasco del Castillo, S., Virizuela Echaburu, J.A., Zatarain-Nicolás, E., Anguita Sánchez, M., Tamargo Menéndez, J., Marín, F., López-Sendón, J.L., Zamorano, J.L., Revisores expertos.** Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations [Abordaje de la fibrilación auricular en pacientes con cáncer activo. Documento de consenso de expertos y recomendaciones]. // *Revista Espanola de Cardiologia*, 72, 2019, № 9, p. 749-759. ISSN 0300-8932. DOI 10.1016/j.recesp.2019.03.017.
962. **Losik, D., Romanov, A., Grazhdankin, I., Shabanov, V., Ponomarev, D., Mikhchenko, I., Peregudov, I., Filippenko, A., Bondar, N., Boersma, L., Steinberg, J.S.** Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study. // *Heart and Vessels*, 38, 2023, № 7, p. 881-888. ISSN 0910-8327. DOI 10.1007/s00380-023-02236-x.
963. **Lu, W., Wang, Y., Chen, L., Li, Y., Zhang, R., Chen, Z., Yan, J., Yang, M., Han, B., Wang, Z., He, S., Chen, L., Wu, X., Zeng, H., Ma, L., Shi, G., Yin, J., Chen, J., Ma, G.** Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 745549. ISSN 2297-055X. DOI 10.3389/fcvm.2021.745549.
964. **Lucà, F., Caretta, G., Vagnarelli, F., Marini, M., Iorio, A., Di Fusco, S.A., Pozzi, A., Gabrielli, D., Colivicchi, F., De Luca, L., Gulizia, M.M.** Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: Real-world data from two nationwide registries in Italy. // *Journal of Cardiovascular Medicine*, 21, 2020, № 2, p. 99-105. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000911.

965. **Lucà, F., Giubilato, S., Fusco, S.A.D., Leone, A., Poli, S., Rao, C.M., Iorio, A., Gelsomino, S., Gabrielli, D., Colivicchi, F., De Luca, L., Gulizia, M.M.** The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 25, 2020, № 5, p. 391-398. ISSN 1074-2484. DOI 10.1177/1074248420923528.
966. **Lucà, F., Oliva, F., Abrignani, M.G., Di Fusco, S.A., Parrini, I., Canale, M.L., Giubilato, S., Cornara, S., Nesti, M., Rao, C.M., Pozzi, A., Binaghi, G., Maloberti, A., Ceravolo, R., Bisceglia, I., Rossini, R., Temporelli, P.L., Amico, A.F., Calvanese, R., Gelsomino, S., Riccio, C., Grimaldi, M., Colivicchi, F., Gulizia, M.M.** Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. // *Journal of Clinical Medicine*, 12, 2023, № 18, art. no. 5955. ISSN 2077-0383. DOI 10.3390/jcm12185955.
967. **Lucà, F., Parrini, I., Abrignani, M.G., Rao, C.M., Piccioni, L., Di Fusco, S.A., Ceravolo, R., Bisceglia, I., Riccio, C., Gelsomino, S., Colivicchi, F., Gulizia, M.M., Management Quality Working Group ANMCO.** Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It. // *Journal of Clinical Medicine*, 11, 2022, № 7, art. no. 1792. ISSN 2077-0383. DOI 10.3390/jcm11071792.
968. **Luo, C.-F., Mo, P., Li, G.-Q., Liu, S.-M.** Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: Results of a meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 218-224. ISSN 2055-837. DOI 10.1093/ehjcvp/pvaa016.
969. **Lupercio, F., Giancaterino, S., Villablanca, P.A., Han, F., Hoffmayer, K., Ho, G., Raissi, F., Krummen, D., Birgersdotter-Green, U., Feld, G., Reeves, R., Mahmud, E., Hsu, J.C.** P2Y<sub>12</sub> inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: A systematic review and meta-analysis. // *Heart*, 106, 2020, № 8, p. 575-583. ISSN 1355-6037. DOI 10.1136/heartjnl-2019-315963.
970. **Lüscher, T.F., Davies, A., Beer, J.H., Valgimigli, M., Nienaber, C.A., Camm, J.A., Baumgartner, I., Diener, H.-C., Konstantinides, S.V.** Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. // *European Heart Journal*, 43, 2022, № 10, p. 940-958. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab642.
971. **Lyu, S.-Q., Zhu, J., Wang, J., Wu, S., Zhang, H., Shao, X.-H., Yang, Y.-M.** Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. // *Platelets*, 33, 2022, № 6, p. 900-910. ISSN 0953-7104. DOI 10.1080/09537104.2021.2007870.
972. **Lyu, S.-Q., Zhu, J., Wang, J., Wu, S., Zhang, H., Shao, X.-H., Yang, Y.-M.** Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. // *Thrombosis Research*, 209, 2022, p. 16-22. ISSN 0049-3848. DOI 10.1016/j.thromres.2021.11.015.



973. **Ma, C.-S., Wu, S.-L., Liu, S.-W., Han, Y.-L.** Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation. // *Journal of Geriatric Cardiology*, 21, 2024, № 3, p. 251-314. ISSN 1671-5411. DOI 10.26599/1671-5411.2024.03.009.
974. **Ma, F., Xu, W., Chen, J., Zhang, J.** Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis. // *European Journal of Clinical Pharmacology*, 79, 2023, № 8, p. 1013-1022. ISSN 0031-6970. DOI 10.1007/s00228-023-03520-5.
975. **Madsen, J.M., Jacobsen, M.R., Sabbah, M., Topal, D.G., Jabbari, R., Glinge, C., Køber, L., Torp-Pedersen, C., Pedersen, F., Sørensen, R., Holmvang, L., Engstrøm, T., Lønborg, J.T.** Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction. // *American Heart Journal*, 238, 2021, p. 89-99. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.04.012.
976. **Mahmood, H., Shahid, F., Egred, M., Farag, M.** Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report. // *European Heart Journal - Case Reports*, 6, 2022, № 6, art. no. ytac224. ISSN 2514-2119. DOI 10.1093/ehjcr/ytac224.
977. **Maillard, L., de Labriolle, A., Brasselet, C., Faurie, B., Durel, N., de Poli, F., Bosle, S., Madiot, H., Berland, J., Belle, L.** Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study. // *Catheterization and Cardiovascular Interventions*, 98, 2021, № 1, p. 45-54. ISSN 1522-1946. DOI 10.1002/ccd.29065.
978. **Mainka, F.F., Ferreira, V.L., Mendes, A.M., Marques, G.L., Fernandez-Llimos, F., Tonin, F.S., Pontarolo, R.** Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 25, 2020, № 5, p. 399-408. ISSN 1074-2484. DOI 10.1177/1074248420930136.
979. **Marazzato, J., Verdecchia, P., Golino, M., Blasi, F., Crippa, M., De Ponti, R., Angeli, F.** An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here? // *Expert Opinion on Pharmacotherapy*, 22, 2021, № 15, p. 2033-2051. ISSN 1465-6566. DOI 10.1080/14656566.2021.1937119.
980. **Marisol Lugo, L., Luis Ferreiro, J.** Dual Versus Triple Antithrombotic Therapy [Tratamiento antitrombótico doble frente a triple]. // *Revista Espanola de Cardiologia Suplementos*, 18, 2019, p. 27-33. ISSN 1131-3587. DOI 10.1016/S1131-3587(19)30032-9.
981. **Martinez-Sanchez, J., Castrillo, L., Jerez, D., Torramade-Moix, S., Palomo, M., Mendieta, G., Zafar, M.U., Moreno-Castaño, A.B., Sanchez, P., Badimon, J.J., Diaz-Ricart, M., Escolar, G., Roqué, M.** Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens. // *Scientific Reports*, 13, 2023, № 1, art. no. 22969. ISSN 2045-2322. DOI 10.1038/s41598-023-50347-2.

982. **Maruhashi, T., Higashi, Y.** Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan. // *Expert Opinion on Pharmacotherapy*, 21, 2020, № 17, p. 2115-2124. ISSN 1465-6566. DOI 10.1080/14656566.2020.1799976.
983. **Mas-Llado, C., Gonzalez-Del-Hoyo, M., Siquier-Padilla, J., Blaya-Peña, L., Coughlan, J.J., de la Villa, B.G., Peral, V., Rossello, X.** Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines. // *European Heart Journal - Quality of Care and Clinical Outcomes*, 9, 2023, № 8, p. 796-805. ISSN 2058-5225. DOI 10.1093/ehjqcc/qcad007.
984. **Massussi, M., Scotti, A., Landi, A., Basis, G.** Direct oral anticoagulants and left ventricular thrombosis: The evidence for a good therapeutic approach. – In: *Direct Oral Anticoagulants: From Pharmacology to Clinical Practice*, 2021, p. 271-280. ISBN 9783030744625; 9783030744618. DOI 10.1007/978-3-030-74462-5\_17.
985. **Masunaga, N., Ogawa, H., Minami, K., Ishigami, K., Ikeda, S., DOI, K., Hamatani, Y., Yoshizawa, T., Ide, Y., Fujino, A., Ishii, M., Iguchi, M., Wada, H., Hasegawa, K., Tsuji, H., Esato, M., Abe, M., Akao, M., Shinagawa, T., Mitamura, M., Fukahori, M., Kimura, M., Fukuyama, M., Kamata, C., Nishiyama, N., the Fushimi AF Registry Investigators.** Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation — The Fushimi AF Registry. // *Circulation Journal*, 86, 2022, № 8, p. 1252-1262. ISSN 1346-9843. DOI 10.1253/circj.CJ-22-0180.
986. **Matsuura, Y., Moribayashi, K., Kaikita, K.** Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. // *Journal of Atherosclerosis and Thrombosis*, 29, 2022, № 10, p. 1409-1420. ISSN 1340-3478. DOI 10.5551/jat.RV17066.
987. **Matthias, N.P., Jürg, B.H.** Very low-dose direct oral anticoagulants combined with platelet inhibitors in coronary artery disease: ready for widespread use? // *Cardiovascular Medicine*, 22, 2019, № 5, art. no. w02062. ISSN 1664-2031. DOI 10.4414/cvm.2019.02062.
988. **Mauler-Wittwer, S., Garot, P.** The Biolimus A9-coated BioFreedom™stent: From clinical efficacy to real-world evidence. // *Future Cardiology*, 17, 2021, № 2, p. 239-255. ISSN 1479-6678. DOI 10.2217/fca-2020-0069.
989. **Mauro, V.M.** Antithrombotic treatment in acute coronary syndrome and atrial fibrillation [Tratamiento antitrombótico en los síndromes coronarios agudos y fibrilación auricular]. // *Revista Argentina de Cardiología*, 88, 2020, № 1, p. 68-71. ISSN 0034-7000. DOI 10.7775/rac.v88.i1.12469.
990. **McCallum, C.J., Raja, D.C., Pathak, R.K.** Atrial fibrillation: An update on management. // *Australian Prescriber*, 42, 2019, № 6, p. 186-191. ISSN 0312-8008. DOI 10.18773/austprescr.2019.067.
991. **Meador, S., Dyke, S., Togami, J., Kuskov, B., Burnett, A.E.** Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. // *Journal of Thrombosis and Thrombolysis*, 53, 2022, № 2, p. 436-445. ISSN 0929-5305. DOI 10.1007/s11239-021-02551-y.

992. **Meah, M.M.N., Joseph, T., Ding, W.Y., Shaw, M., Hasleton, J., Palmer, N.D., Velavan, P., Aggarwal, S.K.** Primary percutaneous coronary intervention in nonagenarians: is it worthwhile? // *BMC Cardiovascular Disorders*, 21, 2021, № 1, art. no. 30. ISSN 1471-2261. DOI 10.1186/s12872-020-01833-2.
993. **Mehta, S.R.** Refining antithrombotic therapy for atrial fibrillation and acute coronary syndromes or PCI. // *New England Journal of Medicine*, 380, 2019, № 16, p. 1580-1581. ISSN 0028-4793. DOI 10.1056/NEJMe1902214.
994. **Meier, D., Fournier, S., Barras, N., Regamey, J., Rosset, S., Pavon, A.-G., Kamani, C.H., Deliniere, A., Domenichini, G., Graf, D., Hullin, R., Pascale, P., Girod, G., Eeckhout, É., Schwitter, J., Prior, J.O., Pruvot, É., Bouchardy, J., Monney, P., Muller, O., Rutz, T.** Cardiology [Cardiologie]. // *Revue Medicale Suisse*, 16, 2020, № 676/677, p. 16-22. ISSN 1660-9379.
995. **Menditto, A., Antonicelli, R.** Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? // *Journal of Geriatric Cardiology*, 17, 2020, № 1, p. 51-57. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2020.01.004.
996. **Menown, I.B.A., Giugliano, R., Zeymer, U.** Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. // *Cardiology and Therapy*, 9, 2020, № 1. ISSN 2193-8261. DOI 10.1007/s40119-020-00166-7.
997. **Meuli, L., Stadlbauer, T., Stähli, B.E., Espinola-Klein, C., Zimmermann, A., on behalf of the PATENT Study Collaborators.** Preventing Lower Limb Graft Thrombosis after Infrainguinal Arterial Bypass Surgery with Antithrombotic Agents (PATENT Study): An International Expert Based Delphi Consensus. // *Journal of Clinical Medicine*, 12, 2023, № 9, art. no. 3223. ISSN 2077-0383. DOI 10.3390/jcm12093223.
998. **Miller, E.J., Patell, R., Uhlmann, E.J., Ren, S., Southard, H., Elavalakanar, P., Weber, G.M., Neuberg, D., Zwicker, J.I.** Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. // *Blood Advances*, 6, 2022, № 5, p. 1559-1565. ISSN 2473-9529. DOI 10.1182/bloodadvances.2021006470.
999. **Mitchell, A., Watson, M.C., Welsh, T., McGrogan, A.** Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: A systematic review and meta-analyses of observational studies. // *Journal of Clinical Medicine*, 8, 2019, № 4, art. no. 554. ISSN 2077-0383. DOI 10.3390/jcm8040554.
1000. **Miura, K., Shimada, T., Ohya, M., Murai, R., Amano, H., Kubo, S., Tada, T., Tanaka, H., Fuku, Y., Goto, T., Kadota, K.** Long-term incidence and details of bleeding events after everolimus-eluting stent implantation – 7-8-year outcomes. // *Circulation Journal*, 83, 2019, № 11, p. 2242-2249. ISSN 1346-9843. DOI 10.1253/circj.CJ-19-0494.
1001. **Miyamoto, S., Ikeda, T., Ogawa, S., Kitazono, T., Nakagawara, J., Minematsu, K., Murakawa, Y., Iwashiro, S., Takeichi, M., Kidani, Y., Okayama, Y., Sunaya, T., Sato, S., Yamanaka, S.** Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in

1002. **Mo, R., Wang, H.-Y., Yang, Y.-M., Zhang, H., Suo, N., Wang, J.-Y.** Implications of bleeding on subsequent cardiovascular events in patients with atrial fibrillation after acute coronary syndrome or PCI. // *Thrombosis Research*, 229, 2023, p. 243-251. ISSN 0049-3848. DOI 10.1016/j.thromres.2023.08.002.
1003. **Möllmann, H., Leistner, D.M., Schulze, P.C., Sechtem, U., Bauersachs, J.** Comments on the guidelines (2019) of the ESC on chronic coronary syndrome [Kommentar zu den Leitlinien (2019) der ESC zum chronischen Koronarsyndrom]. // *Kardiologie*, 14, 2020, № 6, p. 482-491. ISSN 1864-9718. DOI 10.1007/s12181-020-00408-x.
1004. **Mori, H., Fukui, K., Maeda, A., Akashi, Y., Ako, J., Ikari, Y., Ebina, T., Tamura, K., Namiki, A., Michishita, I., Kimura, K., Suzuki, H.** Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry. // *Journal of Cardiology*, 79, 2022, № 6, p. 768-775. ISSN 0914-5087. DOI 10.1016/j.jjcc.2022.02.007.
1005. **Morici, N., De Servi, S., De Luca, L., Crimi, G., Montalto, C., De Rosa, R., De Luca, G., Rubboli, A., Valgimigli, M., Savonitto, S.** Management of acute coronary syndromes in older adults. // *European Heart Journal*, 43, 2022, № 16, p. 1542-1553. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab391.
1006. **Mourikis, P., Polzin, A.** Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short? // *Journal of the American Heart Association*, 12, 2023, № 2, art. no. e028775. ISSN 2047-9980. DOI 10.1161/JAHA.122.028775.
1007. **M'Pembale, R., Ahlbrecht, S., Helten, C., Mourikis, P., Naguib, D., Zako, S., Trojovský, K., Huhn, R., Petzold, T., Hohlfeld, T., Zeus, T., Kelm, M., Dannenberg, L., Polzin, A.** High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel. // *Pharmacology*, 108, 2023, № 1, p. 83-89. ISSN 0031-7012. DOI 10.1159/000527816.
1008. **Mulder, B.A., ten Berg, J., ten Cate, H., van Es, N., Hemels, M.E.W., Kappelle, L.J., Bearda Bakker, H.B., de Borst, G.J., Drenth, D.J., Geersing, G.J., Rienstra, M.** Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. // *Netherlands Heart Journal*, 28, 2020, № 10, p. 504-513. ISSN 1568-5888. DOI 10.1007/s12471-020-01424-y.
1009. **Mumoli, N., Amellone, C., Antonelli, G., Augello, G., Cloro, C., D'Alleva, A., Ascenzo, L.D., Imbalzano, E., Masala, R., Riccioni, G., Romeo, E., Rossi, L., Santoro, G., Sciatti, E., Tondo, A., Toso, E., Venturini, E., Vizzardì, E., Mascioli, G.** Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. // *CJC Open*, 2, 2020, № 6, p. 641-651. ISSN 2589-790X. DOI 10.1016/j.cjco.2020.07.016.
1010. **Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., Yasuda, S., Akasaka, T., Kohsaka, S., Haze, K., Hirayama, A.** JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. // *Circulation Journal*, 84, 2020, № 5, p. 831-865. ISSN 1346-9843. DOI 10.1253/circj.CJ-19-1109.

1011. Nakamura, M., Yamashita, T., Hayakawa, A., Matsumoto, T., Takita, A., Hasegawa, C., Uchino, K., Sekine, T., Iizuka, T., Tanabe, H., Kogure, S. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study. // *Journal of Cardiology*, 77, 2021, № 2, p. 186-194. ISSN 0914-5087. DOI 10.1016/j.jjcc.2020.08.008.
1012. Nanna, M.G., Wang, S.Y., Damluji, A.A. Management of Stable Angina in the Older Adult Population. // *Circulation: Cardiovascular Interventions*, 16, 2023, № 4, p. E012438. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.122.012438.
1013. Naqvi, S.H.R., Tun, H.N., Cader, F.A., Sabatino, J., Fatima, M. Novel oral anti-coagulants in cardiovascular practice. // *Pakistan Heart Journal*, 56, 2023, № 4, p. 250-255. ISSN 0048-2706. DOI 10.47144/phj.v56i4.2618.
1014. Natsuaki, M., Sonoda, S., Yoshioka, G., Hongo, H., Kaneko, T., Kashiya, K., Yokoi, K., Hikichi, Y., Node, K. Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. // *Cardiovascular Intervention and Therapeutics*, 37, 2022, № 2, p. 255-263. ISSN 1868-4300. DOI 10.1007/s12928-022-00847-1.
1015. Nauffal, V., Trinquart, L., Osho, A., Sundt, T.M., Lubitz, S.A., Ellinor, P.T. Non-Vitamin K Antagonist Oral Anticoagulant vs Warfarin for Post Cardiac Surgery Atrial Fibrillation. // *Annals of Thoracic Surgery*, 112, 2021, № 5, p. 1392-1401. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2020.12.031.
1016. Nef, H.M., Achenbach, S., Birkemeyer, R., Bufe, A., Dörr, O., Elsässer, A., Gaede, L., Gori, T., Hoffmeister, H.M., Hofmann, F.J., Katus, H.A., Liebetrau, C., Massberg, S., Pauschinger, M., Schmitz, T., Süselbeck, T., Voelker, W., Wiebe, J., Zahn, R., Hamm, C., Zeiher, A.M., Möllmann, H. Manual of the working group on interventional cardiology (AGIK) of the German Cardiac Society (DGK): Part 2: "Performance of percutaneous coronary interventions" [Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK): Teil 2: „Durchführung der perkutanen Koronarintervention“]. // *Kardiologie*, 15, 2021, № 6, p. 542-584. ISSN 1864-9718. DOI 10.1007/s12181-021-00504-6.
1017. Ng, A.K.-Y., Ng, P.Y., Ip, A., Ling, I.W.-H., Lam, L.-T., Siu, C.-W. Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients. // *JACC: Asia*, 2, 2022, № 3P2, p. 341-350. ISSN 2772-3747. DOI 10.1016/j.jacasi.2021.12.009.
1018. Nicolas, J., Dangas, G. Combination antiplatelet/antithrombotic regimens after stenting: Are we forcing too much in this decision? // *Catheterization and Cardiovascular Interventions*, 97, 2021, № 4, p. 589-590. ISSN 1522-1946. DOI 10.1002/ccd.29574.
1019. Nii, K., Takemura, Y., Inoue, R., Morinaga, Y., Mitsutake, T., Higashi, T. Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. // *Journal of Stroke and Cerebrovascular Diseases*, 29, 2020, № 7, art. no. 104899. ISSN 1052-3057. DOI 10.1016/j.jstrokecerebrovasdis.2020.104899.



1020. **Nobre Menezes, M., Tavares da Silva, M., Magalhães, A., Melica, B., Toste, J.C., Calé, R., Almeida, M., Fiuza, M., Infante de Oliveira, E.** Interventional cardiology in cancer patients: A position paper from the Portuguese Cardiovascular Intervention Association and the Portuguese Cardio-Oncology Study Group of the Portuguese Society of Cardiology [Cardiologia de intervenção em doentes oncológicos: um documento de posição da Associação Portuguesa de Intervenção Cardiovascular e do Grupo de Estudo de Cardio-Oncologia da Sociedade Portuguesa de Cardiologia]. // *Revista Portuguesa de Cardiologia*, 43, 2024, № 1, p. 35-48. ISSN 0870-2551. DOI 10.1016/j.repc.2023.04.013.
1021. **Numasawa, Yohei, Sawano, Mitsuaki, Fukuoka, Ryoma, Ejiri, Kentaro, Kuno, Toshiki, Shoji, Satoshi, Kohsaka, Shun.** Antithrombotic strategy for patients with acute coronary syndrome: A perspective from east asia. // *Journal of Clinical Medicine*, 9, 2020, № 6, art. no. 1963, p. 1-19. ISSN 2077-0383. DOI 10.3390/jcm9061963.
1022. **Nomura, K., Suda, S., Abe, A., Iguchi, Y., Yagita, Y., Kanzawa, T., Okubo, S., Fujimoto, S., Kimura, K., on behalf of the PASTA study group.** Vitamin K antagonists but not non-vitamin K antagonists in addition on antiplatelet therapy should be associated with increase of hematoma volume and mortality in patients with intracerebral hemorrhage: A sub-analysis of PASTA registry study. // *Journal of the Neurological Sciences*, 448, 2023, art. no. 120643. ISSN 0022-510X. DOI 10.1016/j.jns.2023.120643.
1023. **Noubiap, J.J., Agbaedeng, T.A., Nyaga, U.F., Lau, D.H., Worthley, M.I., Nicholls, S.J., Sanders, P.** Atrial fibrillation incidence, prevalence, predictors, and adverse outcomes in acute coronary syndromes: A pooled analysis of data from 8 million patients. // *Journal of Cardiovascular Electrophysiology*, 33, 2022, № 3, p. 414-422. ISSN 1045-3873. DOI 10.1111/jce.15351.
1024. **Numasawa, Y., Sawano, M., Fukuoka, R., Ejiri, K., Kuno, T., Shoji, S., Kohsaka, S.O. Kiviniemi, T.** Evolving Field of Long-term Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation. // *American Journal of the Medical Sciences*, 358, 2019, № 2, p. 91-92. ISSN 0002-9629. DOI 10.1016/j.amjms.2019.04.029.
1025. **Oancea, A.F., Jigoranu, R.A., Morariu, P.C., Miftode, R.-S., Trandabat, B.A., Iov, D.E., Cojocaru, E., Costache, I.I., Baroi, L.G., Timofte, D.V., Tanase, D.M., Floria, M.** Atrial Fibrillation and Chronic Coronary Ischemia: A Challenging Vicious Circle. // *Life*, 13, 2023, № 6, art. no. 1370. ISSN 2075-1729. DOI 10.3390/life13061370.
1026. **O'Donoghue, M.L., Murphy, S.A., Sabatine, M.S.** The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub>inhibitor in patients after percutaneous coronary intervention: A systematic review and meta-analysis. // *Circulation*, 142, 2020, № 6, p. 538-545. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.046251.
1027. **Okumura, Y., Nagashima, K.** Editorial to the “safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic review and meta-analysis”. // *Journal of Arrhythmia*, 36, 2020, № 2, p. 280-281. ISSN 1880-4276. DOI 10.1002/joa3.12317.

1028. **Olie, R.H., Winckers, K., Rocca, B., ten Cate, H.** Oral Anticoagulants Beyond Warfarin. // *Annual Review of Pharmacology and Toxicology*, 64, 2024, p. 551-575. ISSN 0362-1642. DOI 10.1146/annurev-pharmtox-032823-122811.
1029. **Olivier, C.B., Bode, C., Dürschmied, D.** Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen. // *Klinikerzt*, 49, 2020, № 3, p. 57-61. ISSN 0341-2350. DOI 10.1055/a-1110-6764.
1030. **Olivier, C.B., Fan, J., Askari, M., Mahaffey, K.W., Heidenreich, P.A., Perino, A.C., Leef, G.C., Ho, P.M., Harrington, R.A., Turakhia, M.P.** Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients after Percutaneous Coronary Intervention: Findings from the Veterans Health Administration. // *Circulation: Cardiovascular Interventions*, 12, 2019, № 8, art. no. e007604. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.118.007604.
1031. **Ono, K., Iwasaki, Y.-K., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., Sumitomo, N., Takahashi, N., Niwano, S., Hagiwara, N., Hisatome, I., Furukawa, T., Honjo, H., Maruyama, T., Murakawa, Y., Yasaka, M., Watanabe, E., Aiba, T., Amino, M., Itoh, H., Ogawa, H., Okumura, Y., Aoki-Kamiya, C., Kishihara, J., Kodani, E., Komatsu, T., Sakamoto, Y., Satomi, K., Shiga, T., Shinohara, T., Suzuki, A., Suzuki, S., Sekiguchi, Y., Nagase, S., Hayami, N., Harada, M., Fujino, T., Makiyama, T., Maruyama, M., Miake, J., Muraji, S., Murata, H., Morita, N., Yokoshiki, H., Yoshioka, K., Yodogawa, K., Inoue, H., Okumura, K., Kimura, T., Tsutsui, H., Shimizu, W., the Japanese Circulation Society and, Japanese Heart Rhythm Society Joint Working Group.** JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. // *Journal of Arrhythmia*, 38, 2022, № 6, p. 833-973. ISSN 1880-4276. DOI 10.1002/joa3.12714.
1032. **Ono, K., Iwasaki, Y.-K., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., Sumitomo, N., Takahashi, N., Niwano, S., Hagiwara, N., Hisatome, I., Furukawa, T., Honjo, H., Maruyama, T., Murakawa, Y., Yasaka, M., Watanabe, E., Aiba, T., Amino, M., Itoh, H., Ogawa, H., Okumura, Y., Aoki-Kamiya, C., Kishihara, J., Kodani, E., Komatsu, T., Sakamoto, Y., Satomi, K., Shiga, T., Shinohara, T., Suzuki, A., Suzuki, S., Sekiguchi, Y., Nagase, S., Hayami, N., Harada, M., Fujino, T., Makiyama, T., Maruyama, M., Miake, J., Muraji, S., Murata, H., Morita, N., Yokoshiki, H., Yoshioka, K., Yodogawa, K., Inoue, H., Okumura, K., Kimura, T., Tsutsui, H., Shimizu, W., Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group.** JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. // *Circulation Journal*, 86, 2022, № 11, p. 1790-1924. ISSN 1346-9843. DOI 10.1253/circj.CJ-20-1212.
1033. **Osman, M., Kheiri, B., Munir, M.B., Moreland, J.A., Balla, S., Kapadia, S.** The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis. // *Journal of Thrombosis and Thrombolysis*, 48, 2019, № 3, p. 516-518. ISSN 0929-5305. DOI 10.1007/s11239-019-01896-9.
1034. **Ozaki, Y., Hara, H., Onuma, Y., Katagiri, Y., Amano, T., Kobayashi, Y., Muramatsu, T., Ishii, H., Kozuma, K., Tanaka, N., Matsuo, H., Uemura, S., Kadota, K., Hikichi, Y., Tsujita, K., Ako, J., Nakagawa, Y., Morino, Y., Hamanaka, I., Shiode, N., Shite, J., Honye, J., Matsubara, T., Kawai, K., Igarashi, Y., Okamura, A., Ogawa, T., Shibata, Y., Tsuji, T., Yajima, J., Iwabuchi, K., Komatsu,**

N., Sugano, T., Yamaki, M., Yamada, S., Hirase, H., Miyashita, Y., Yoshimachi, F., Kobayashi, M., Aoki, J., Oda, H., Katahira, Y., Ueda, K., Nishino, M., Nakao, K., Michishita, I., Ueno, T., Inohara, T., Kohsaka, S., Ismail, T.F., Serruys, P.W., Nakamura, M., Yokoi, H., Ikari, Y., The Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT). CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. // *Cardiovascular Intervention and Therapeutics*, 37, 2022, № 1. ISSN 1868-4300. DOI 10.1007/s12928-021-00829-9.

1035. Paciaroni, M., Caso, V., Agnelli, G., Mosconi, M.G., Giustozzi, M., Seiffge, D.J., Engelter, S.T., Lyrer, P., Polymeris, A.A., Kriemler, L., Zietz, A., Putaala, J., Strbian, D., Tomppo, L., Michel, P., Strambo, D., Salerno, A., Remillard, S., Buehrer, M., Bavaud, O., Vanacker, P., Zuurbier, S., Yperzeele, L., Loos, C.M.J., Cappellari, M., Emiliani, A., Zedde, M., Abdul-Rahim, A., Dawson, J., Cronshaw, R., Schirinzi, E., Del Sette, M., Stretz, C., Kala, N., Reznik, M., Schomer, A., Grory, B.M., Jayaraman, M., McTaggart, R., Yaghi, S., Furie, K.L., Masotti, L., Grifoni, E., Toni, D., Risitano, A., Falcou, A., Petraglia, L., Lotti, E.M., Padroni, M., Pavolucci, L., Lochner, P., Silvestrelli, G., Ciccone, A., Alberti, A., Venti, M., Traballi, L., Urbini, C., Kargiotis, O., Rocco, A., Diomedì, M., Marcheselli, S., Caliendo, P., Zauli, A., Reale, G., Antonenko, K., Rota, E., Tassinari, T., Saia, V., Palmerini, F., Aridon, P., Arnao, V., Monaco, S., Cottone, S., Baldi, A., D'Amore, C., Ageno, W., Pegoraro, S., Ntaios, G., Sagris, D., Gianopoulos, S., Kosmidou, M., Ntais, E., Romoli, M., Pantoni, L., Rosa, S., Bertora, P., Chiti, A., Canavero, I., Saggese, C.E., Plocco, M., Giorli, E., Palaiodimou, L., Bakola, E., Tsiygoulis, G., Bandini, F., Gasparro, A., Terruso, V., Mannino, M., Pezzini, A., Ornello, R., Sacco, S., Popovic, N., Scoditti, U., Genovese, A., Denti, L., Flomin, Y., Mancuso, M., Ferrari, E., Caselli, M.C., Ulivi, L., Giannini, N., De Marchis, G.M. Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. // *Stroke*, 53, 2022, № 8, p. 2620-2627. ISSN 0039-2499. DOI 10.1161/STROKEAHA.121.038239.
1036. Panahi, L., Udeani, G., Horseman, M., Weston, J., Samuel, N., Joseph, M., Mora, A., Bazan, D. Review of medical therapies for the management of pulmonary embolism. // *Medicina (Lithuania)*, 57, 2021, № 2, art. no. 110, p. 1-21. ISSN 1010-660X. DOI 10.3390/medicina57020110.
1037. Panchenko, E.P. Apixaban in patients with atrial fibrillation and acute coronary syndrome in elective percutaneous coronary intervention: what did the subanalysis of the AUGUSTUS trial add to our understanding? [Апиксабан у больных фибрилляцией предсердий с острым коронарным синдромом и при плановом чрескожном коронарном вмешательстве: что добавили к нашим представлениям субанализы исследования AUGUSTUS?]. // *Meditsinskiy Sovet*, 17, 2023, № 16, p. 41-45. ISSN 2079-701X. DOI 10.21518/ms2023-286.
1038. Panov, A.V. Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention [Антитромботическая терапия у пациентов с фибрилляцией предсердий при чрескожных коронарных вмешательствах]. // *Rational Pharmacotherapy in Cardiology*, 17, 2021, № 4, p. 628-637. ISSN 1819-6446. DOI 10.20996/1819-6446-2021-07-02.

1039. **Paolillo, S., Ruocco, G., Filardi, P.P., Palazzuoli, A., Tocchetti, C.G., Nodari, S., Lombardi, C., Metra, M., Correale, M., on behalf of “Right and Left Heart Failure Study Group” of the Italian Society of Cardiology.** Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. // *Heart Failure Reviews*, 27, 2022, № 1, p. 135-145. ISSN 1382-4147. DOI 10.1007/s10741-020-09994-0.
1040. **Papazoglou, A.S., Moysidis, D.V., Kartas, A., Bekiaridou, A., Samaras, A., Giannakoulas, G.** Oral anticoagulation challenges and therapeutic dilemmas in the very elderly: to treat and how to treat octogenarians and nonagenarians? // *Polish Archives of Internal Medicine*, 133, 2023, № 6, art. no. 16508. ISSN 0032-3772. DOI 10.20452/pamw.16508.
1041. **Pardo-Galiana, B., Medina-Rodriguez, M., Millan-Vazquez, M., Cabezas-Rodriguez, J.A., Lebrato-Hernandez, L., Ainz-Gomez, L., Zapata-Arriaza, E., Ortega, J., de Albóniga-Chindurza, A., Montaner, J., Gonzalez, A., Moniche, F.** Antithrombotic Treatment after Carotid Stenting in Patients with Concomitant Atrial Fibrillation. // *American Journal of Neuroradiology*, 43, 2022, № 5, p. 727-730. ISSN 0195-6108. DOI 10.3174/ajnr.A7482.
1042. **Parfrey, S., Teh, A.W., Roberts, L., Brennan, A., Clark, D., Duffy, S.J., Ajani, A.E., Reid, C.M., Freeman, M.** The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Coronary Artery Disease*, 32, 2021, № 4, p. 288-294. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000987.
1043. **Pasquale, G.D., Iacovoni, A., Filardi, P.P., Giustozzi, M., De Ponti, R., Falanga, A., Botto, G.L., De Filippo, P., Gavazzi, A., Sciatti, E., Senni, M., Porcu, M.** Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti]. // *Giornale Italiano di Cardiologia*, 21, 2020, № 2, p. 103-110. ISSN 1827-6806. DOI 10.1714/3300.32703.
1044. **Passacquale, G., Sharma, P., Perera, D., Ferro, A.** Antiplatelet therapy in cardiovascular disease: Current status and future directions. // *British Journal of Clinical Pharmacology*, 88, 2022, № 6, p. 2686-2699. ISSN 0306-5251. DOI 10.1111/bcp.15221.
1045. **Patrono, C., Rocca, B.** Aspirin at 120: Retiring, recombining, or repurposing? // *Research and Practice in Thrombosis and Haemostasis*, 5, 2021, № 4, art. no. e12516. ISSN 2475-379. DOI 10.1002/rth2.12516.
1046. **Pauley, E.D., Doorey, A.J., Stouffer, G.A.** Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in PCI. // *JACC: Cardiovascular Interventions*, 12, 2019, № 18, p. 1867. ISSN 1936-8798. DOI 10.1016/j.jcin.2019.07.011.
1047. **Pereverzeva, K.G., Yakushin, S.S., Yakushina, M.S., Ezhova, A.V., Bogdanovich, I.A., Simkova, L.A.** Changes in prescribing antithrombotic therapy in patients with atrial fibrillation and myocardial infarction in 2016-2019. // *Russian Journal of Cardiology*, 25, 2020, № 7, art. no. 3908, p. 144-149. ISSN 1560-4071. DOI 10.15829/1560-4071-2020-3908.



1048. **Peterson, B.E., Bhatt, D.L.** Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention. // *Journal of Thrombosis and Thrombolysis*, 49, 2020, № 4, p. 522-526. ISSN 0929-5305. DOI 10.1007/s11239-020-02081-z.
1049. **Pivato, C.A., Margonato, A., Godino, C.** Antithrombotic therapy: Less is more or the more the better? // *Europace*, 22, 2020, № 7. ISSN 1099-5129. DOI 10.1093/europace/eaab073.
1050. **Pocock, S.J., Collier, T.J.** Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. // *Journal of the American College of Cardiology*, 73, 2019, № 21, p. 2740-2755. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.03.484.
1051. **Poirier, C.M., Carter, A.A., Kwan, Y., Koo, J., Westlund, J.M., Alkass, F., Leblanc, K.** Experiences of Patients With Atrial Fibrillation With Combination Antithrombotic Therapy Post-Percutaneous Coronary Intervention. // *CJC Open*, 5, 2023, № 11, p. 846-858. ISSN 2589-790X. DOI 10.1016/j.cjco.2023.08.007.
1052. **Pollack, C.V., Amin, A., Wang, T., Deitelzweig, S., Cohen, M., Slattery, D., Fanikos, J., DiLascia, C., Tuder, R., Kaatz, S.** Contemporary NSTEMI management: the role of the hospitalist. // *Hospital Practice*, 48, 2020, № 1, p. 1-11. ISSN 2154-8331. DOI 10.1080/21548331.2020.1701329.
1053. **Polzin, A., Dannenberg, L., Thienel, M., Orban, M., Wolff, G., Hohlfeld, T., Zeus, T., Kelm, M., Petzold, T.** Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. // *Thrombosis and Haemostasis*, 121, 2021, № 2, p. 122-130. ISSN 0340-6245. DOI 10.1055/s-0040-1716750.
1054. **Pomero, F., Dentali, F., Mumoli, N., Salomone, P., Tangianu, F., Desideri, G., Mastroiacovo, D.** The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. // *Acta Diabetologica*, 56, 2019, № 12, p. 1247-1258. ISSN 0940-5429. DOI 10.1007/s00592-019-01426-2.
1055. **Pop, C., Tint, D., Petris, A.** Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 3, p. 659-675. ISSN 1530-6550. DOI 10.31083/J.RCM2203076.
1056. **Pradhan, A., Bhandari, M., Vishwakarma, P., Salimei, C., Iellamo, F., Sethi, R., Perrone, M.A.** Anticoagulation for Left Ventricle Thrombus—Case Series and Literature Review for Use of Direct Oral Anticoagulants. // *Journal of Cardiovascular Development and Disease*, 10, 2023, № 2, art. no. 41. ISSN 2308-3425. DOI 10.3390/jcdd10020041.
1057. **Qiu, M., Liu, S.-Y., Zhou, H.-R.** Double antithrombotic therapy for prevention of bleeding and ischemic events after percutaneous coronary intervention in patients with atrial fibrillation: A meta-analysis. // *Medicine (United States)*, 100, 2021, № 1, p. E24188. ISSN 0025-7974. DOI 10.1097/MD.00000000000024188.
1058. **Qu, P., Liu, S., Ma, C., Xue, Y., Lei, X., Han, Y., Huang, L., Li, S., Li, Y., Qi, X., Wang, Z., Wu, S., Yuan, Z., Chen, J., Fu, G., Gao, C., Gao, W., Jia, S., Jiang, C., Li, Y., Liu, Q., Liu, X., Liu, Y., Lou, D., Lu, Z., Luo, Y., Sun, Y., Tang, Y., Wu, Y., Xu, Y., Yang, L., Yang, X., Yang, Y., Yin, Y., Yuan, J., Zhang, P.,**



**Zhang, R., Zhang, S., Zhang, Z., Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology.** Antithrombotic Management of Atrial Fibrillation Patients Presenting with Coronary Artery Disease: A Consensus Document of the Chinese Society of Cardiology. // *Cardiology Discovery*, 1, 2021, № 1, p. 15-28. ISSN 2096-952X. DOI 10.1097/CD9.0000000000000020.

1059. **Rao, K., Bhindi, R.** Underusage of Oral Anticoagulation in Atrial Fibrillation: Can We Prevent More Strokes? // *Heart Lung and Circulation*, 30, 2021, № 8, p. 1107-1109. ISSN 1443-9506. DOI 10.1016/j.hlc.2021.05.081.
1060. **Räsänen, A., Kärkkäinen, J.M., Eranti, A., Eränen, J., Rissanen, T.T.** Percutaneous coronary intervention with drug-coated balloon-only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel concept. // *Catheterization and Cardiovascular Interventions*, 101, 2023, № 3, p. 569-578. ISSN 1522-1946. DOI 10.1002/ccd.30558.
1061. **Ravi, V., Pulipati, P., Vij, A., Kodumuri, V.** Meta-Analysis Comparing Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease. // *American Journal of Cardiology*, 125, 2020, № 1, p. 19-28. ISSN 0002-9149. DOI 10.1016/j.amjcard.2019.09.045.
1062. **Registry of patients with acute coronary syndrome and atrial fibrillation taking rivaroxaban:** Observation results. [Реестр пациентов с острым коронарным синдромом и фибрилляцией предсердий, принимающих ривароксабан: Результаты наблюдения]. // *Kardiologiya*, 61, 2021, № 6, p. 52-58. ISSN 0022-9040. DOI 10.18087/cardio.2021.6.n1630.
1063. **Reiff, T., Ringleb, P.A.** Secondary prevention of cerebral infarction. [Sekundärprophylaxe der zerebralen Ischämie]. // *Nervenheilkunde*, 39, 2020, № 10, p. 644-650. ISSN 0722-1541. DOI 10.1055/a-1239-0344.
1064. **Ricceri, S., Salazar, J.W., Vu, A.A., Vittinghoff, E., Moffatt, E., Tseng, Z.H.** Factors Predisposing to Survival After Resuscitation for Sudden Cardiac Arrest. // *Journal of the American College of Cardiology*, 77, 2021, № 19, p. 2353-2362. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.03.299.
1065. **Ricottini, E., Nenna, A., Melfi, R., Giannone, S., Lusini, M., Sciascio, G.D., Chello, M., Ussia, G.P., Grigioni, F.** Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence. // *European Journal of Internal Medicine*, 77, 2020, p. 44-51. ISSN 0953-6205. DOI 10.1016/j.ejim.2020.02.004.
1066. **Riddle, M., McCallum, R., Ojha, C.P., Paul, T.K., Gupta, V., Baran, D.A., Prakash, B.V., Misra, A., Mares, A.C., Abedin, M., Kedar, A., Mulukutla, V., Ibrahim, A., Nagarajao, H.** Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: A review of current recommendations. // *Journal of Investigative Medicine*, 68, 2020, № 8, p. 1317-1333. ISSN 1081-5589. DOI 10.1136/jim-2020-001500.
1067. **Rivolo, S., Di Fusco, M., Polanco, C., Kang, A., Dhanda, D., Savone, M., Skandamis, A., Kongnakorn, T., Soto, J.** Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

1068. **Rodriguez, F., Harrington, R.A.** Management of antithrombotic therapy after acute coronary syndromes. // *New England Journal of Medicine*, 384, 2021, № 5, p. 452-460. ISSN 0028-4793. DOI 10.1056/NEJMra1607714.
1069. **Romiti, G.F., Corica, B., Proietti, M.** A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: A 10-year-long story. // *Future Cardiology*, 17, 2021, № 2, p. 215-226. ISSN 1479-6678. DOI 10.2217/fca-2020-0084.
1070. **Rubboli, A.** And now we have the AUGUSTUS ... How will it impact on antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention? // *European Journal of Internal Medicine*, 65, 2019, p. 1-3. ISSN 0953-6205. DOI 10.1016/j.ejim.2019.05.019.
1071. **Rubboli, A.** The ENTRUST-AF PCI trial [Lo studio ENTRUST-AF PCI]. // *Giornale Italiano di Cardiologia*, 20, 2019, № 10, p. 541-542. ISSN 1827-6806. DOI 10.1714/3228.32052.
1072. **Rubboli, A., Barbaresi, E., Rocca, B.** From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. // *Cardiovascular Drugs and Therapy*, 34, 2020, № 1, p. 143-144. ISSN 0920-3206. DOI 10.1007/s10557-019-06903-y.
1073. **Rubboli, A., Collet, J.-P.** Double vs. triple antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: does clinical presentation matter? // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № F11, p. F61-F62. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa121.
1074. **Rubboli, A., Lisi, M.** After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention? // *Cardiovascular Drugs and Therapy*, 33, 2019, № 4, p. 499-500. ISSN 0920-3206. DOI 10.1007/s10557-019-06886-w.
1075. **Ruiz-Nodar, J.M., Ferreira, J.L.** Antithrombotic therapy after percutaneous revascularization in patients on chronic oral anticoagulation treatment. // *REC: Interventional Cardiology*, 1, 2019, № 1, p. 41-50. ISSN 2604-7306. DOI 10.24875/RECICE.M19000010.
1076. **Ruiz-Nodar, J.M., Torres Mezcúa, F., Cambra Poveda, C.** Percutaneous Coronary Intervention and Oral Anticoagulation [Intervención coronaria percutánea y anticoagulantes orales]. // *Revista Espanola de Cardiologia Suplementos*, 18, 2019, p. 21-26. ISSN 1131-3587. DOI 10.1016/S1131-3587(19)30031-7.
1077. **Ruzina, E.V., Berdibekov, B.Sh., Bulaeva, N.I., Kubova, M.Ch., Golukhova, E.Z.** Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions [Сравнение различных режимов антитромботической терапии у пациентов с клапанными пороками сердца и ишемической болезнью]

сердца после хирургических и интервенционных вмешательств]. // *Kardiologiya*, 63, 2023, № 7, p. 47-53. ISSN 0022-9040. DOI 10.18087/cardio.2023.7.n2132.

1078. **Ruzina, E.V., Golukhova, E.Z.** Review of modern concepts of triple and double antiplatelet therapy in patients with atrial fibrillation and coronary artery disease [Обзор современных концепций тройной и двойной антитромбоцитарной терапии у больных с фибрилляцией предсердий в сочетании с ишемической болезнью сердца]. // *Creative Cardiology*, 13, 2019, № 4, p. 308-319. ISSN 1997-3187. DOI 10.24022/1997-3187-2019-13-4-308-319.
1079. **Ryan, D., Girotra, T., Feng, W.** Choice and Timing of Antithrombotic after Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis. // *CNS and Neurological Disorders - Drug Targets*, 23, 2024, № 2, p. 135-152. ISSN 1871-5273. DOI 10.2174/1871527322666230309100626.
1080. **Sadat, B., Al Taii, H., Sabayon, M., Narayanan, C.A.** Atrial Fibrillation Complicating Acute Myocardial Infarction: Prevalence, Impact, and Management Considerations. // *Current Cardiology Reports*, 2024. ISSN 1523-3782. DOI 10.1007/s11886-024-02040-7.
1081. **Saglietto, A., D'Ascenzo, F., Errigo, D., Leonardi, S., Dewilde, W.J., Conrotto, F., Omedè, P., Montefusco, A., Angelini, F., De Filippo, O., Bianco, M., Gallone, G., Bruno, F., Zaccaro, L., Giannini, F., Latib, A., Colombo, A., Costa, F., De Ferrari, G.M.** Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. // *Catheterization and Cardiovascular Interventions*, 97, 2021, № 4, p. 581-588. ISSN 1522-1946. DOI 10.1002/ccd.29192.
1082. **Sagris, M., Theofilis, P., Papanikolaou, A., Antonopoulos, A.S., Tsioufis, C., Tousoulis, D.** Direct Oral Anticoagulants use in Patients with Stable Coronary Artery Disease, Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. // *Current Pharmaceutical Design*, 29, 2023, № 35, p. 2787-2794. ISSN 1381-6128. DOI 10.2174/0113816128259508231118141831.
1083. **Saito, Y., Kobayashi, Y.** Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 1, p. 44-51. ISSN 1868-4300. DOI 10.1007/s12928-019-00600-1.
1084. **Saito, Y., Kobayashi, Y.** Update on antithrombotic therapy after percutaneous coronary intervention. // *Internal Medicine*, 59, 2020, № 3, p. 311-321. ISSN 0918-2918. DOI 10.2169/internalmedicine.3685-19.
1085. **Saito, Y., Kobayashi, Y., Tanabe, K., Ikari, Y.** Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 1, p. 19-29. ISSN 1868-4300. DOI 10.1007/s12928-019-00633-6.
1086. **Saito, Y., Nazif, T., Baumbach, A., Tchétché, D., Latib, A., Kaple, R., Forrest, J., Prendergast, B., Lansky, A.** Adjunctive Antithrombotic Therapy for Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. // *JAMA Cardiology*, 5, 2020, № 1, p. 92-101. ISSN 2380-6583. DOI 10.1001/jamacardio.2019.4367.

1087. **Sambola, A., Bueno, H., Miranda, B., Hernandez, A.V., Limeres, J., del Blanco, B.G., García-Dorado, D.** Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI. // *Cardiovascular Drugs and Therapy*, 33, 2019, № 4, p. 425-433. ISSN 0920-3206. DOI 10.1007/s10557-019-06889-7.
1088. **Santoro, C., Capone, V., Canonico, M.E., Gargiulo, G., Esposito, R., Sanna, G.D., Parodi, G., Esposito, G.** Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. // *Seminars in Thrombosis and Hemostasis*, 47, 2021, № 8, p. 950-961. ISSN 0094-6176. DOI 10.1055/s-0041-1726298.
1089. **Scanavacca, M., Wu, T.C.** Clinical management of patients with first-episode atrial fibrillation detected in the acute phase of myocardial infarction [Manuseio clínico de pacientes com primeiro episódio de fibrilação atrial detectado na fase aguda do infarto do miocárdio]. // *Arquivos Brasileiros de Cardiologia*, 113, 2019, № 5, p. 958-959. ISSN 0066-782X. DOI 10.36660/abc.20190733.
1090. **Scavée, C.** Direct oral anticoagulants: How to choose? [Anticoagulants oraux directs, comment choisir?]. // *Louvain Medical*, 139, 2019, № 5, p. 279-285. ISSN 0024-6956.
1091. **Schäfer, A., Bauersachs, J.** Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions [Orale Antikoagulation und anti-thrombozytäre Therapie bei Patienten mit Vorhofflimmern nach Koronarintervention]. // *Herz*, 44, 2019, № 4, p. 365-378. ISSN 0340-9937. DOI 10.1007/s00059-019-4811-x.
1092. **Schäfer, A., Flierl, U., Bauersachs, J.** Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. // *Clinical Research in Cardiology*, 110, 2021, № 6, p. 759-774. ISSN 1861-0684. DOI 10.1007/s00392-020-01708-8.
1093. **Schäfer, A., Flierl, U., Bauersachs, J.** Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 6, 2020, № 1, p. 57-68. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz032.
1094. **Schäfer, A., Flierl, U., Berliner, D., Bauersachs, J.** Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. // *Cardiovascular Drugs and Therapy*, 34, 2020, № 4, p. 555-568. ISSN 0920-3206. DOI 10.1007/s10557-020-06981-3.
1095. **Schirmer, C.M., Bulsara, K.R., Al-Mufti, F., Haranhalli, N., Thibault, L., Hetts, S.W.** Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update. // *Journal of NeuroInterventional Surgery*, 15, 2023, № 11, p. 1155-1162. ISSN 1759-8478. DOI 10.1136/jnis-2022-019844.
1096. **Schmode, A., Ackman, M., Bungard, T.J.** Antiplatelet, anticoagulant or both? A tool for pharmacists. // *Canadian Pharmacists Journal*, 152, 2019, № 5, p. 291-300. ISSN 1715-1635. DOI 10.1177/1715163519866232.
1097. **Sciahbasi, A., Gargiulo, G., Talarico, G.P., Cesaro, A., Zilio, F., De Rosa, S., Talanas, G., Tebaldi, M., Andò, G., Rigattieri, S., Misuraca, L., Cortese, B., Imperadore, F., Lucci, V., Guiducci, V., Renda, G., Zezza, L., Versaci, F., Gianico, M.B., Caruso, M., Spaccarotella, C., Calabrò, P., Esposito, G., Tarantini,**

- G., Musumeci, G., Rubboli, A.** Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent. // *Journal of Cardiovascular Medicine*, 23, 2022, № 11, p. 738-743. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001372.
1098. **Seelig, J., Pisters, R., Hemels, M.E., Huisman, M.V., Cate, H.T., Alings, M.** When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics. // *Vascular Health and Risk Management*, 15, 2019, p. 399-408. ISSN 1176-6344. DOI 10.2147/VHRM.S187656.
1099. **Seiler, T., Vasiliauskaite, E., Grüter, D., Young, M., Attinger-Toller, A., Madanchi, M., Cioffi, G.M., Tersalvi, G., Müller, G., Stämpfli, S.F., de Boeck, B., Suter, Y., Nossen, J., Toggweiler, S., Willemin, W.A., Cuculi, F., Kobza, R., Bossard, M.** Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi—Insights from a Swiss Multicenter Registry. // *American Journal of Cardiology*, 194, 2023, p. 113-121. ISSN 0002-9149. DOI 10.1016/j.amjcard.2023.01.018.
1100. **Selvarajah, A., Tavenier, A.H., Fabris, E., van Leeuwen, M.A.H., Hermanides, R.S.** Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. // *Journal of Clinical Medicine*, 11, 2022, № 19, art. no. 5605. ISSN 2077-0383. DOI 10.3390/jcm11195605.
1101. **Serrao, A., Lucani, B., Assanto Manfredi, G., Fiori, L., Baldacci, E., Aprile, S.M., Chistolini, A.** Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. // *Journal of Thrombosis and Thrombolysis*, 50, 2020, № 3, p. 718-723. ISSN 0929-5305. DOI 10.1007/s11239-020-02070-2.
1102. **Shah, R., Labroo, A., Davis, D.A., Le, F.K.** Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta-analysis. // *Catheterization and Cardiovascular Interventions*, 98, 2021, № 3, p. E490-E492. ISSN 1522-1946. DOI 10.1002/ccd.29205.
1103. **Shah, S., Shah, K., Turagam, M.K., Sharma, A., Natale, A., Lakkireddy, D., Garg, J.** Direct oral anticoagulants to treat left ventricular thrombus—A systematic review and meta-analysis: ELECTRAM investigators. // *Journal of Cardiovascular Electrophysiology*, 32, 2021, № 6, p. 1764-1771. ISSN 1045-3873. DOI 10.1111/jce.15016.
1104. **Shahandeh, N., Harrell, J., Yang, E.H., Parikh, R.V.** A Cautionary Tale of Triple Therapy. // *JACC: Case Reports*, 3, 2021, № 5, p. 789-794. ISSN 2666-0849. DOI 10.1016/j.jaccas.2021.03.013.
1105. **Sherwood, M.W., Piccini, J.P., Holmes, D.N., Pieper, K.S., Steinberg, B.A., Fonarow, G.C., Allen, L.A., Naccarelli, G.V., Kowey, P.R., Gersh, B.J., Mahaffey, K.W., Singer, D.E., Ansell, J.E., Freeman, J.V., Chan, P.S., Reiffel, J.A., Blanco, R., Peterson, E.D., Rao, S.V.** Outcomes of Cardiac Catheterization in Patients with Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. // *Circulation: Cardiovascular Interventions*, 13, 2020, № 5, art. no. e008274. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.119.008274.



1106. **Shibahashi, E., Abe, T., Kamishima, K., Ebihara, S., Moriyama, T., Shimazaki, K., Saito, K., Uchigata, Y., Jujo, K.** Direct Oral Anticoagulants Affect Activated Clotting Time During and Bleeding Events After Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 204, 2023, p. 1-8. ISSN 0002-9149. DOI 10.1016/j.amjcard.2023.07.092.
1107. **Shlofmitz, E., Shlofmitz, R., Lee, M.S.** The role of novel oral anticoagulants and antiplatelet therapy after percutaneous coronary intervention: Individualizing therapy to optimize outcomes. // *Korean Circulation Journal*, 49, 2019, № 8, p. 645-656. ISSN 1738-5520. DOI 10.4070/kcj.2019.0185.
1108. **Shrivastava, A., Agrawal, A., Moscote-Salazar, L.R.** Re: Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. // *Journal of Stroke and Cerebrovascular Diseases*, 29, 2020, № 9, art. no. 105028. ISSN 1052-3057. DOI 10.1016/j.jstrokecerebrovasdis.2020.105028.
1109. **Shurrab, M., Danon, A., Alnasser, S., Glover, B., Kaoutskaia, A., Henderson, M., Newman, D., Crystal, E., Ko, D.** Dual-Antithrombotic Therapy With DOACs After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. // *Canadian Journal of Cardiology*, 36, 2020, № 1, p. 135-142. ISSN 0828-282X. DOI 10.1016/j.cjca.2019.11.005.
1110. **Siasos, G., Tsigkou, V., Bletsas, E., Stampouloulou, P.K., Oikonomou, E., Kallogeris, K., Katsarou, O., Pesiridis, T., Vavuranakis, M., Tousoulis, D.** Antithrombotic Treatment in Coronary Artery Disease. // *Current Pharmaceutical Design*, 29, 2023, № 35, p. 2764-2779. ISSN 1381-6128. DOI 10.2174/1381612829666230830105750.
1111. **Siddiqi, R., Yamani, N., Alnaimat, S., Khurshid, A., Siddiqui, S., Khan, M.S., Khan, S.U.** Meta-analysis of antithrombotic therapy with new oral anticoagulants in patients with atrial fibrillation after percutaneous coronary intervention. // *European Journal of Preventive Cardiology*, 27, 2020, № 19, p. 2119-2122. ISSN 2047-4873. DOI 10.1177/2047487319865048.
1112. **Sigamani, A., Gupta, R.** Revisiting secondary prevention in coronary heart disease. // *Indian Heart Journal*, 74, 2022, № 6, p. 431-440. ISSN 0019-4832. DOI 10.1016/j.ihj.2022.11.011.
1113. **Sommer, J., Seeling, A., Rupprecht, H.** Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. // *Drugs and Aging*, 37, 2020, № 5, p. 359-372. ISSN 1170-229X. DOI 10.1007/s40266-020-00747-0.
1114. **Sorbets, E., Steg, P.G.** Direct-acting Anticoagulants in Chronic Coronary Syndromes. // *European Cardiology Review*, 15, 2020, art. no. e10. ISSN 1758-3756. DOI 10.15420/ecr.2018.24.2.
1115. **Sorrentino, S., Salerno, N., Leo, I., Polimeni, A., Sabatino, J., Spaccarotella, C.A.M., Mongiardo, A., De Rosa, S., Indolfi, C.** New Antithrombotic Strategies and Coronary Stent Technologies for Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention. // *Current Vascular Pharmacology*, 20, 2022, № 1, p. 37-45. ISSN 1570-1611. DOI 10.2174/1570161119666210809163404.

1116. **Sotomi, Y., Kozuma, K., Kashiwabara, K., Higuchi, Y., Ando, K., Morino, Y., Ako, J., Tanabe, K., Muramatsu, T., Nakazawa, G., Hikoso, S., Sakata, Y.** Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: A study protocol of the OPTIMA-AF trial. // *BMJ Open*, 11, 2021, № 12, art. no. e048354. ISSN 2044-6055. DOI 10.1136/bmjopen-2020-048354.
1117. **Spaccarotella, C., Indolfi, C.** Focus on relevant aspects of 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [Le novità delle linee guida europee 2020 sulle sindromi coronariche acute senza sopraslivellamento persistente del tratto ST]. // *Giornale Italiano di Cardiologia*, 22, 2021, № 2, p. 107-114. ISSN 1827-6806. DOI 10.1714/3514.35024.
1118. **Spadafora, L., Bernardi, M., Galli, M., Biondi-Zoccai, G., Sabouret, P.** Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies. // *Archives of Medical Science*, 18, 2022, № 6, p. 1689-1692. ISSN 1734-1922. DOI 10.5114/aoms/155411.
1119. **Srinivasan, S., Ajmal, M., Pecci, C., Lassar, T.** Edoxaban in cardiovascular disease management: Review. // *British Journal of Clinical Pharmacology*, 88, 2022, № 2, p. 535-540. ISSN 0306-5251. DOI 10.1111/bcp.15026.
1120. **Steen, D.L.** Highlights from the 2019 American College of Cardiology Scientific Sessions in New Orleans, LA. // *Journal of Thrombosis and Thrombolysis*, 48, 2019, № 1, p. 78-80. ISSN 0929-5305. DOI 10.1007/s11239-019-01870-5.
1121. **Stepanović-Petrović, R., Nastić, K.** Direct oral anticoagulants – a new chapter in anticoagulation therapy [Direktni oralni antikoagulansi – novo poglavlje u antikoagulantnoj terapiji]. // *Arhiv za Farmaciju*, 70, 2020, № 5, p. 249-268. ISSN 0004-1963. DOI 10.5937/arhfarm2005249S.
1122. **Stojanovic, M., Deljanin-Ilic, M., Ilic, S., Ilic, B., Petrovic, D.** Does HAS-BLED risk score underestimate the risk of bleeding in patients with triple antithrombotic therapy? [Czy wskaźnik ryzyka krwawienia zaniża ryzyko krwawienia u chorych otrzymujących potrójną terapię przeciwzakrzepową?]. // *Polski Merkurusz Lekarski*, 48, 2020, № 287, p. 361-364. ISSN 1426-9686.
1123. **Su, M.-I., Cheng, Y.-C., Huang, Y.-C., Liu, C.-W.** The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease. // *Journal of Clinical Medicine*, 11, 2022, № 7, art. no. 1936. ISSN 2077-0383. DOI 10.3390/jcm11071936.
1124. **Sulaica, E.M., Wanat, M.A., Macaulay, T.E.** Clinical Considerations Prior to Transition from Triple Antithrombotic Therapy to Dual Antithrombotic Therapy. // *JAMA Cardiology*, 5, 2020, № 1, p. 111. ISSN 2380-6583. DOI 10.1001/jamacardio.2019.4542.
1125. **Sulzgruber, P., Hofer, F., Kazem, N., Hammer, A., Niessner, A.** Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Cardiovascular Drugs and Therapy*, 35, 2021, № 4, p. 875-876. ISSN 0920-3206. DOI 10.1007/s10557-021-07165-3.

1126. Sulzgruber, P., Wassmann, S., Semb, A.G., Doehner, W., Widimsky, P., Gremmel, T., Kaski, J.C., Savarese, G., Rosano, G.M.C., Borghi, C., Kjeldsen, K., Torp-Pedersen, C., Schmidt, T.A., Lewis, B.S., Drexel, H., Tamargo, J., Atar, D., Agewall, S., Niessner, A. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 5, 2019, № 3, art. no. pvz016, p. 171-180. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz016.
1127. Sumarokov, A.B., Buryachkovskaya, L.I., Docenko, Y.V., Kurochkin, M.S., Lomakin, N.V. Clinical significance of thrombin blockade with low doses (2.5 mg) of rivaroxabane in ischemic heart disease patients [Клиническое значение блокады тромбина с помощью малых (2,5мг) доз ривароксабана у больных ишемической болезнью сердца]. // *Rational Pharmacotherapy in Cardiology*, 16, 2020, № 1, p. 99-107. ISSN 1819-6446. DOI 10.20996/1819-6446-2020-01-03.
1128. Suo, N., Yang, Y.-M., Wang, J., Zhang, H., Shao, X.-H., Wu, S., Zhu, J. Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 846803. ISSN 2297-055X. DOI 10.3389/fcvm.2022.846803.
1129. Sycheva, N.A., Koroleva, L.Y., Nosov, V.P., Volkova, A.T., Kisel, A.M., Kovaleva, G.V. Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study. // *Kardiologiya*, 60, 2020, № 7, p. 53-63. ISSN 0022-9040. DOI 10.18087/cardio.2020.7.n954.
1130. Takeda, T., Dohke, T., Ueno, Y., Mastui, T., Fujii, M., Takayama, T., Dochi, K., Miyamoto, A., Mabuchi, H., Wada, A. Clinical utility of the BIWACO score for patients with atrial fibrillation after percutaneous coronary intervention. // *Heart and Vessels*, 38, 2023, № 1, p. 96-105. ISSN 0910-8327. DOI 10.1007/s00380-022-02128-6.
1131. Tang, K.S., Banerjee, S., Tang, G., Patel, P.M., Frangieh, A.H. Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review. // *Interventional Cardiology: Reviews, Research, Resources*, 18, 2023, art. no. e31. ISSN 1756-1477. DOI 10.15420/icr.2023.19.
1132. Tanner, R., Cronin, M., Macken, L., Murphy, R., Maree, A.O., Ullah, I., Cosgrave, J., O'Connor, S., Daly, C. Real-World Experience with Antiplatelet Agents after Percutaneous Coronary Intervention in Patients with an Indication for an Oral Anticoagulant. // *Journal of Cardiovascular Pharmacology*, 77, 2021, № 4, p. 501-507. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000973.
1133. Tantry, U.S., Chaudhary, R., Gurbel, P.A. In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. // *Kardiologia Polska*, 77, 2019, № 9, p. 817-819. ISSN 0022-9032. DOI 10.33963/KP.14983.
1134. Tao, Q., Xiao, G., Wang, T., Zhang, L., Yu, M., Peng, L., Han, L., Du, X., Han, W., He, S., Lyu, M., Zhu, Y. Identification of linoleic acid as an antithrombotic component of Wenxin Keli via selective inhibition of p-selectin-mediated platelet

activation. // *Biomedicine and Pharmacotherapy*, 153, 2022, art. no. 113453. ISSN 0753-3322. DOI 10.1016/j.biopha.2022.113453.

1135. **Teira Calderón, A., Chiarito, M., Santos, I.A., Cao, D., Vaquerizo Montilla, B., Jurado Román, A., Pulido Garrido, P., Tartaglia, F., García-García, H.M., Díez-Gil, J.L., Sanz-Sánchez, J.** Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design. // *Cardiovascular Revascularization Medicine*, 2024. ISSN 1553-8389. DOI 10.1016/j.carrev.2024.01.013.
1136. **Thiele, H., Jobs, A.** ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation: What is new? [ESC-Leitlinie 2020: akutes Koronarsyndrom ohne persistierende ST-Strecken-Hebungen: Was ist neu?]. // *Herz*, 46, 2021, № 1, p. 3-13. ISSN 0340-9937. DOI 10.1007/s00059-020-05002-1.
1137. **Thomas, A., Gitto, M., Shah, S., Saito, Y., Tirziu, D., Chieffo, A., Stefanini, G.G., Lansky, A.J.** Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2, 2023, № 3, art. no. 100607. ISSN 2772-9303. DOI 10.1016/j.jscai.2023.100607.
1138. **Thomas, M.R., Grove, E.L., Kirchhof, P.** Complex antithrombotic combinations: how to find the perfect blend? // *Heart*, 106, 2020, № 8, p. 557-558. ISSN 1355-6037. DOI 10.1136/heartjnl-2019-316352.
1139. **Thomopoulos, C., Ntalakouras, J., Polyzos, D., Konstantinidis, D., Palaiodimou, L., Tsvigoulis, G., Tsioufis, C.** Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: A meta-analysis of randomized trials. // *Pharmacological Research*, 175, 2022, art. no. 105902. ISSN 1043-6618. DOI 10.1016/j.phrs.2021.105902.
1140. **Tinkham, T.T., Vazquez, S.R., Jones, A.E., Witt, D.M.** Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. // *Journal of Thrombosis and Thrombolysis*, 49, 2020, № 3, p. 492-496. ISSN 0929-5305. DOI 10.1007/s11239-019-01999-3.
1141. **Ton, M.T., Quang Ho, T.H., Nguyen, V.L., Pham, H.M., Van Hoang, S., Vo, N.T., Nguyen, T.Q., Pham, L.T., Mai, T.D., Nguyen, T.H.** Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2. // *European Cardiology Review*, 18, 2023, art. no. e62. ISSN 1758-3756. DOI 10.15420/ecr.2023.25.
1142. **Tonko, J.B., Wright, M.J.** Review of the 2020 esc guidelines for the diagnosis and management of atrial fibrillation-what has changed and how does this affect daily practice. // *Journal of Clinical Medicine*, 10, 2021, № 17, art. no. 3922. ISSN 2077-0383. DOI 10.3390/jcm10173922.
1143. **Towashiraporn, K., Krittayaphong, R.** Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. // *International Journal of General Medicine*, 15, 2022, p. 2397-2414. ISSN 1178-7074. DOI 10.2147/IJGM.S289295.

1144. **Traby, L., Kollars, M., Kaider, A., Siller-Matula, J.M., Steinbrecher, O., Wolzt, M., Kyrle, P.A., Eichinger, S.** Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. // *Clinical Pharmacology and Therapeutics*, 109, 2021, № 6, p. 1546-1554. ISSN 0009-9236. DOI 10.1002/cpt.2106.
1145. **Treatment of Atrial Fibrillation.** // *Medical Letter on Drugs and Therapeutics*, 66, 2024, № 1693, p. 1-8. ISSN 0025-732X. DOI 10.58347/tml.2024.1693a.
1146. **Triska, J., Haddadin, F., Madanat, L., Jabri, A., Daher, M., Birnbaum, Y., Jneid, H.** The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Cardiovascular Drugs and Therapy*, 2022. ISSN 0920-3206. DOI 10.1007/s10557-022-07367-3.
1147. **Tseng, A.S., Shamoun, F.E., Marks, L.A., Agrwal, N.** Antithrombotic therapy for patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention. // *Journal of the American Osteopathic Association*, 120, 2020, № 5, p. 345-349. ISSN 0098-6151. DOI 10.7556/jaoa.2020.053.
1148. **Tseng, A.S., Shamoun, F.E., Marks, L.A., Agrwal, N.** Q: What antithrombotic therapy should I use for my patient with atrial fibrillation who underwent percutaneous coronary intervention or had an acute coronary syndrome? // *Cleveland Clinic Journal of Medicine*, 88, 2021, № 7, p. 389-392. ISSN 0891-1150. DOI 10.3949/CCJM.88A.19081.
1149. **Tsigkas, G., Apostolos, A., Despotopoulos, S., Vasilagkos, G., Papageorgiou, A., Kallergis, E., Leventopoulos, G., Mplani, V., Koniari, I., Velissaris, D., Parissis, J.** Anticoagulation for atrial fibrillation in heart failure patients: Balancing between Scylla and Charybdis. // *Journal of Geriatric Cardiology*, 18, 2021, № 5, p. 352-361. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2021.05.006.
1150. **Tsigkas, G., Vakka, A., Apostolos, A., Bousoula, E., Vythoulkas-Biotis, N., Koufou, E.-E., Vasilagkos, G., Tsiapoutis, I., Hamilos, M., Aminian, A., Davlourous, P.** Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review. // *Journal of Cardiovascular Development and Disease*, 10, 2023, № 4, art. no. 135. ISSN 2308-3425. DOI 10.3390/jcdd10040135.
1151. **Türk, U.Ö., Acar, R.D., Akgün, T., Emren, V., Kanat, S., Karacağlar, E., Kepez, A., Kul, Ş., Özel, E., Şimşek, E., Tülüce, S.Y., Tülüce, K., John Camm, A.** Current clinician perspective on non-Vitamin K antagonist oral anticoagulant use in challenging clinical cases [Zorlu atriyal fibrilasyon olgularında non-Vitamin K antagonisti oral antikoagülan kullanımına güncel klinik yaklaşımlar]. // *Türk Kardiyoloji Dernegi Arsivi*, 48, 2020, № 3, p. 289-303. ISSN 1016-5169. DOI 10.5543/tkda.2020.16359.
1152. **Undas, A., Drabik, L.** Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. // *Cardiologia Hungarica*, 50, 2020, № 4, p. 231-238. ISSN 0133-5596. DOI 10.26430/CHUNGARICA.2020.50.4.231.
1153. **Uskach, T.M., Tereshchenko, A.S.** Modern antiplatelet therapy for percutaneous coronary intervention. How to make the right choice? [Современная антитромбоцитарная терапия при чрескожном коронарном вмешательстве. Как



сделать правильный выбор?]. // *Rational Pharmacotherapy in Cardiology*, 16, 2021, № 6, p. 1017-1023. ISSN 1819-6446. DOI 10.20996/1819-6446-2020-11-12.

1154. **Vahanian, A., Beyersdorf, F.** 2021 ESC/EACTS Guidelines for the management of valvular heart disease. // *European Journal of Cardio-thoracic Surgery*, 60, 2021, № 4, p. 727-800. ISSN 1010-7940. DOI 10.1093/ejcts/ezab389.
1155. **Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., Delgado, V., Freemantle, N., Gilard, M., Haugaa, K.H., Jeppsson, A., Jüni, P., Pierard, L., Prendergast, B.D., Rafael Sádaba, J., Tribouilloy, C., Wojakowski, W., y Grupo de Documentos Científicos de la ESC/EACTS.** 2021 ESC/EACTS Guideline on the diagnosis and treatment of valvular heart disease: Developed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Working Groups on the diagnosis and treatment of valvular heart disease [Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías: Desarrollada por el Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) y la European Association for Cardio-Thoracic Surgery (EACTS) sobre el diagnóstico y tratamiento de las valvulopatías]. // *Revista Espanola de Cardiologia*, 75, 2022, № 6, p. 524.e1-524.e69. ISSN 0300-8932. DOI 10.1016/j.recesp.2021.11.023.
1156. **Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., Delgado, V., Freemantle, N., Gilard, M., Haugaa, K.H., Jeppsson, A., Jüni, P., Pierard, L., Prendergast, B.D., Sádaba, J.R., Tribouilloy, C., Neumann, F.-J., Myers, P., Abdelhamid, M., Achenbach, S., Asteggiano, R., Barili, F., Borger, M.A., Carrel, T., Collet, J.-P., Foldager, D., Habib, G., Hassager, C., Irs, A., Iung, B., Jahangiri, M., Katus, H.A., Koskinas, K.C., Massberg, S., Mueller, C.E., Nielsen, J.C., Pibarot, P., Rakisheva, A., Roffi, M., Rubboli, A., Shlyakhto, E., Siepe, M., Sitges, M., Sondergaard, L., Sousa-Uva, M., Tarantini, G., Zamorano, J.L., ESC/EACTS Scientific Document Group.** 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) [Linee guida ESC/EACTS 2021 per il trattamento delle valvulopatie elaborate dalla Task Force per il trattamento delle valvulopatie della Società Europea di Cardiologia (ESC) e dell'Associazione Europea di Chirurgia Cardio-Toracica (EACTS)]. // *Giornale Italiano di Cardiologia*, 23, 2022, № 5, p. E1-E75. ISSN 1827-6806.
1157. **Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., de Bonis, M., de Paulis, R., Delgado, V., Freemantle, N., Gilard, M., Haugaa, K.H., Jeppsson, A., Jüni, P., Pierard, L., Prendergast, B.D., Sádaba, J.R., Tribouilloy, C., Wojakowski, W., ESC/EACTS Scientific Document Group.** 2021 ESC/EACTS Guidelines for the management of valvular heart disease. // *EuroIntervention*, 17, 2022, № 14, p. E1126-E1196. ISSN 1774-024X. DOI 10.4244/EIJ-E-21-00009.
1158. **Valeriani, E., Bartimoccia, S., Pignatelli, P., Pastori, D.** Aging and Antithrombotic Treatment. // *Antioxidants and Redox Signaling*, 2023. ISSN 1523-0864. DOI 10.1089/ars.2023.0373.
1159. **van der Pals, J., Holmqvist, F., Borgquist, R., Göteborg, M., Nseir, M., Koul, S., Isma, N., Scherstén, F., Tydén, P., Braun, O.Ö., Erlinge, D.** Characteristics and outcomes in patients with atrial fibrillation and acute coronary syndrome treated with

ticagrelor and novel oral anticoagulants. // *Thrombosis Update*, 3, 2021, art. no. 100054. ISSN 2666-5727. DOI 10.1016/j.tru.2021.100054.

1160. **Varvařovský, I.** AUGUSTUS: a major step towards proper treatment after PCI in the setting of atrial fibrillation [AUGUSTUS: velký krok ke správné léčbě po PCI při fibrilaci síní]. // *Journal of Validation Technology*, 18, 2019, № 3, p. 166-168. ISSN 1079-6630.
1161. **Varvarovský, I.** Kontroverze - aspirin po PCI? Aspirin po PCI: proc nepodávat. // *Intervenční a Akutní Kardiologie*, 19, 2020, № 3, p. 182-183. ISSN 1213-807X. DOI 10.36290/kar.2020.040.
1162. **Veitch, A.M., Radaelli, F., Alikhan, R., Dumonceau, J.M., Eaton, D., Jerrome, J., Lester, W., Nylander, D., Thoufeeq, M., Vanbiervliet, G., Wilkinson, J.R., Van Hooft, J.E.** Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. // *Gut*, 70, 2021, № 9, art. no. 325184, p. 1611-1628. ISSN 0017-5749. DOI 10.1136/gutjnl-2021-325184.
1163. **Veitch, A.M., Radaelli, F., Alikhan, R., Dumonceau, J.-M., Eaton, D., Jerrome, J., Lester, W., Nylander, D., Thoufeeq, M., Vanbiervliet, G., Wilkinson, J.R., Van Hooft, J.E.** Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. // *Endoscopy*, 53, 2021, № 9, p. 947-969. ISSN 0013-726X. DOI 10.1055/a-1547-2282.
1164. **Ver DOIa, M., Camaro, C., Kedhi, E., Marcolongo, M., Suryapranata, H., De Luca, G.** Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. // *Cardiovascular Therapeutics*, 2020, art. no. 6495036. ISSN 1755-5914. DOI 10.1155/2020/6495036.
1165. **Ver DOIa, M., Gioscia, R., de Luca, G.** Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. // *Journal of Geriatric Cardiology*, 18, 2021, № 3, p. 210-218. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2021.03.010.
1166. **Virani, S.S., Newby, L.K., Arnold, S.V., Bittner, V., Brewer, L.C., Demeter, S.H., Dixon, D.L., Fearon, W.F., Hess, B., Johnson, H.M., Kazi, D.S., Kolte, D., Kumbhani, D.J., Lofaso, J., Mahtta, D., Mark, D.B., Minissian, M., Navar, A.M., Patel, A.R., Piano, M.R., Rodriguez, F., Talbot, A.W., Taqueti, V.R., Thomas, R.J., Van Diepen, S., Wiggins, B., Williams, M.S.** 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. // *Circulation*, 148, 2023, № 9, p. E9-E119. ISSN 0009-7322. DOI 10.1161/CIR.0000000000001168.
1167. **Virani, S.S., Newby, L.K., Arnold, S.V., Bittner, V., Brewer, L.C., Demeter, S.H., Dixon, D.L., Fearon, W.F., Hess, B., Johnson, H.M., Kazi, D.S., Kolte, D., Kumbhani, D.J., LoFaso, J., Mahtta, D., Mark, D.B., Minissian, M., Navar, A.M., Patel, A.R., Piano, M.R., Rodriguez, F., Talbot, A.W., Taqueti, V.R., Thomas, R.J., van Diepen, S., Wiggins, B., Williams, M.S., Writing Committee Members.** 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart

Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. // *Journal of the American College of Cardiology*, 82, 2023, № 9, p. 833-955. ISSN 0735-1097. DOI 10.1016/j.jacc.2023.04.003.

1168. **Volpe, M., Gallo, G.** Atrial fibrillation and ischaemic heart disease: Should we use acetylsalicylic acid beside anticoagulants? // *European Heart Journal, Supplement*, 22, 2020, p. L166-L169. ISSN 1520-765X. DOI 10.1093/eurheartj/suaa159.
1169. **von Stein, P., Seitz, L., Wienemann, H., Hohmann, C., Baar, T., Baldus, S., Halbach, M.** Early in-hospital discontinuation of aspirin on the first post-procedural day after percutaneous coronary stent implantation in patients on direct oral anticoagulation. // *Frontiers in Cardiovascular Medicine*, 10, 2023, art. no. 1265452. ISSN 2297-055X. DOI 10.3389/fcvm.2023.1265452.
1170. **Vranckx, P., Angiolillo, D.J., Valgimigli, M.** Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter? // *Journal of the American College of Cardiology*, 79, 2022, № 5, p. 428-431. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.11.034.
1171. **Vranckx, P., Valgimigli, M.** Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction! // *EuroIntervention*, 18, 2022, № 4, p. E267-E268. ISSN 1774-024X. DOI 10.4244/EIJ-D-22-00300.
1172. **Waddy, S.P., Solomon, A.J., Becerra, A.Z., Ward, J.B., Chan, K.E., Fwu, C.-W., Norton, J.M., Eggers, P.W., Abbott, K.C., Kimmel, P.L.** Racial/ethnic disparities in atrial fibrillation treatment and outcomes among dialysis patients in the United States. // *Journal of the American Society of Nephrology*, 31, 2020, № 3, p. 637-649. ISSN 1046-6673. DOI 10.1681/ASN.2019050543.
1173. **Wakili, R., Riesinger, L., Fender, A.C., Dobrev, D.** Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease? // *IJC Heart and Vasculature*, 23, 2019, art. no. 100369. ISSN 2352-9067. DOI 10.1016/j.ijcha.2019.100369.
1174. **Walker, J., Cattaneo, M., Badimon, L., Agnelli, G., Chan, A.T., Lanås, A., Rocca, B., Rothwell, P., Patrignani, P., Langley, R., Vilahur, G., Cosentino, F.** Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention. // *Ecancermedicalscience*, 14, 2020, art. no. 998. ISSN 1754-6605. DOI 10.3332/ECANCER.2019.998.
1175. **Wang, K.-L., Chiang, C.-E.** A brave new world. // *Acta Cardiologica Sinica*, 35, 2019, № 5, p. 522-523. ISSN 1011-6842. DOI 10.6515/ACS.201909\_35(5).20190906A.
1176. **Wang, Q., Yang, K.** Dual therapy with an oral non-vitamin K antagonist and a P2Y<sub>12</sub> inhibitor vs triple therapy with aspirin, a P2Y<sub>12</sub> inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis. // *Medicine (United States)*, 100, 2021, № 15, p. E25546. ISSN 0025-7974. DOI 10.1097/MD.00000000000025546.

1177. **Wang, S., Liu, Y., Wang, L., Zuo, H., Tian, Y., Wang, Y., Yin, D., Zhang, H., Tian, Y.** Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A meta-analysis and systematic review. // *IJC Heart and Vasculature*, 36, 2021, art. no. 100850. ISSN 2352-9067. DOI 10.1016/j.ijcha.2021.100850.
1178. **Wang, T., Liu, X., Zhu, Y., Zhang, Y., Zhang, Z., Huang, G., Xu, J.** Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation. // *Frontiers in Cardiovascular Medicine*, 10, 2023, art. no. 1325488. ISSN 2297-055X. DOI 10.3389/fcvm.2023.1325488.
1179. **Wang, T.-F., Billett, H.H., Connors, J.M., Soff, G.A.** Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. // *Oncologist*, 26, 2021, № 1, p. e17-e23. ISSN 1083-7159. DOI 10.1002/onco.13570.
1180. **Wang, X., Sun, M., Qu, A., Wang, W., Lu, M., Guo, X., Chen, C., Hao, C., Xu, L., Xu, C., Kuang, H.** Improved Reactive Oxygen Species Generation by Chiral Co<sub>3</sub>O<sub>4</sub> Supraparticles under Electromagnetic Fields. // *Angewandte Chemie - International Edition*, 60, 2021, № 33, p. 18240-18246. ISSN 1433-7851. DOI 10.1002/anie.202105675.
1181. **Warren, A., Nunn, M.** Acute coronary syndrome: risk factors, diagnosis and treatment. // *Pharmaceutical Journal*, 304, 2020, № 7935. ISSN 0031-6873. DOI 10.1211/PJ.2020.20207744.
1182. **Watanabe, H., Kimura, T.** 1 vs 12 Months of Dual Antiplatelet Therapy for Patients after Percutaneous Coronary Intervention – Reply. // *JAMA - Journal of the American Medical Association*, 322, 2019, № 17, p. 1715-1716. ISSN 0098-7484. DOI 10.1001/jama.2019.14250.
1183. **Watson, R.A., Johnson, D.M., Dharia, R.N., Merli, G.J., Doherty, J.U.** Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. // *Hospital Practice*, 48, 2020, № 4, p. 169-179. ISSN 2154-8331. DOI 10.1080/21548331.2020.1772639.
1184. **Welt, F.G.P.** Atrial Fibrillation, Diabetes, and Percutaneous Coronary Intervention: A Complicated Triad. // *JACC: Cardiovascular Interventions*, 12, 2019, № 23, p. 2356-2358. ISSN 1936-8798. DOI 10.1016/j.jcin.2019.08.004.
1185. **Wernly, B., Lichtenauer, M., Erlinge, D., Jung, C.** Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy? // *Clinical Research in Cardiology*, 109, 2020, № 1, p. 128-130. ISSN 1861-0684. DOI 10.1007/s00392-019-01496-w.
1186. **Wiebe, J., Ndrepepa, G., Kufner, S., Lahmann, A.L., Xhepa, E., Kuna, C., Voll, F., Gosetti, R., Laugwitz, K.-L., Joner, M., Kastrati, A., Cassese, S.** Early aspirin discontinuation after coronary stenting: A systematic review and meta-analysis. // *Journal of the American Heart Association*, 10, 2021, № 2, art. no. e018304, p. 1-10. ISSN 2047-980. DOI 10.1161/JAHA.120.018304.
1187. **Williams, M., Ahuja, T., Raco, V., Papadopoulos, J., Green, D., Yuriditsky, E., Arnouk, S.** Real world prescribing practices of apixaban or rivaroxaban lead-in

doses for the treatment of venous thromboembolism in hospitalized patients. // *Journal of Thrombosis and Thrombolysis*, 54, 2022, № 2, p. 219-229. ISSN 0929-5305. DOI 10.1007/s11239-022-02641-5.

1188. **Wolfes, J., Ellermann, C., Frommeyer, G., Eckardt, L.** Evidence-based treatment of atrial fibrillation around the globe: Comparison of the latest ESC, AHA/ACC/HRS, and CCS guidelines on the management of atrial fibrillation. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 2, art. no. rcm2302056. ISSN 1530-6550. DOI 10.31083/j.rcm2302056.
1189. **Wu, S., Lv, M., Chen, J., Jiang, S., Chen, M., Fang, Z., Zeng, Z., Qian, J., Xu, W., Guan, C., Zhang, J.** Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. // *Supportive Care in Cancer*, 30, 2022, № 12, p. 10407-10420. ISSN 0941-4355. DOI 10.1007/s00520-022-07433-4.
1190. **Xiangbin, P., Yaling, H., Shengshou, H., National Center for Cardiovascular Diseases; National Center for Quality Control of Structural Heart Disease Intervention; Chinese Society of Cardiology; Chinese Society for Thoracic and Cardiovascular Surgery; Joint Expert Group on TAVR Guidelines.** Chinese guideline for the clinical application of transcatheter aortic valve replacement [经导管主动脉 Ⅱ 换术临床实践指南]. // *National Medical Journal of China*, 103, 2023, № 12, p. 886-900. ISSN 0376-2491. DOI 10.3760/cma.j.cn112137-20221106-02332.
1191. **Xu, W., Lv, M., Wu, S., Jiang, S., Zeng, Z., Fang, Z., Qian, J., Chen, M., Chen, J., Zhang, J.** Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. // *Cardiovascular Drugs and Therapy*, 37, 2023, № 2, p. 363-377. ISSN 0920-3206. DOI 10.1007/s10557-021-07232-9.
1192. **Xu, Y., Gomes, T., Wells, P.S., Pequeno, P., Johnson, A., Sholzberg, M.** Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. // *Thrombosis Research*, 213, 2022, p. 57-64. ISSN 0049-3848. DOI 10.1016/j.thromres.2022.02.018.
1193. **Xuan, H., Chen, Y.-M., Dai, Y.-L., Zhou, J., Jiang, Y.-F., Zhou, Y.-F.** Safety and Efficacy of Vitamin K Antagonists vs. Novel Oral Anticoagulants in Patients With Left Ventricular Thrombus: A Meta-Analysis. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 636491. ISSN 2297-055X. DOI 10.3389/fcvm.2021.636491.
1194. **Yakushin, S.S., Pereverzeva, K.G.** Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016–2019 and Associations with Prognosis. // *Medicina (Lithuania)*, 59, 2023, № 9, art. no. 1556. ISSN 1010-660X. DOI 10.3390/medicina59091556.
1195. **Yamamoto, K., Shiomi, H., Morimoto, T., Natsuaki, M., Takeji, Y., Watanabe, H., Yoshikawa, Y., Matsumura-Nakano, Y., Shizuta, S., Tanabe, K., Ando, K., Kadota, K., Morino, Y., Kozuma, K., Nakagawa, Y., Kimura, T.** Effect of Renal Dysfunction on the Risks for Ischemic and Bleeding Events in Patients With Atrial Fibrillation Receiving Percutaneous Coronary Intervention. // *American Journal of*



1196. **Yang, S.-M., Huang, C.-J., Chen, C.-H., Yu, W.-C., Sung, S.-H., Guo, C.-Y., Chuang, S.-Y., Cheng, H.-M., Chiang, C.-E.** Network meta-analysis and trial sequential analysis for atrial fibrillation patients receiving PCI or with ACS. // *Journal of the Chinese Medical Association*, 85, 2022, № 1, p. 59-66. ISSN 1726-4901. DOI 10.1097/JCMA.0000000000000651.
1197. **Yang, Y.G., Han, Y.B., Zou, G.L., Sui, Y.B., Jin, J., Liu, L.** Reporting quality of randomized controlled trials evaluating non-vitamin K oral anticoagulants in atrial fibrillation: a systematic review. // *BMC Cardiovascular Disorders*, 23, 2023, № 1, art. no. 229. ISSN 1471-2261. DOI 10.1186/s12872-023-03258-z.
1198. **Yao-Cheng Ho, C., Lee, M., Nunn, C., White, J., Kerr, A.J.** Atrial fibrillation in acute coronary syndrome: Patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39). // *New Zealand Medical Journal*, 133, 2020, № 1519, p. 41-54. ISSN 0028-8446.
1199. **Yashima, F., Inohara, T., Nishida, H., Shimoji, K., Ueno, K., Noma, S., Yamaji, K., Ishii, H., Tanaka, N., Kohsaka, S., Amano, T., Ikari, Y.** In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry. // *Journal of Cardiovascular Pharmacology*, 78, 2021, № 2, p. 221-227. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001006.
1200. **Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., Matsui, K., Ogawa, H., the AFIRE Investigators.** Antithrombotic therapy for atrial fibrillation with stable coronary disease. // *New England Journal of Medicine*, 381, 2019, № 12, p. 1103-1113. ISSN 0028-4793. DOI 10.1056/NEJMoa1904143.
1201. **Yavelov, I.S.** Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: Universal safety advantage in different categories of patients. // *Meditinskiy Sovet*, 2020, № 14, p. 48-54. ISSN 2079-701X. DOI 10.21518/2079-701X-2020-14-48-54.
1202. **Yilmaz, S., Agac, M.T., Cosansu, K.** Patient outcomes under new oral anticoagulants therapy in daily practice. // *Kuwait Medical Journal*, 54, 2022, № 3, p. 376-384. ISSN 0023-5776.
1203. **Yoshimura, J., Yamakawa, K., Ohta, Y., Nakamura, K., Hashimoto, H., Kawada, M., Takahashi, H., Yamagiwa, T., Kodate, A., Miyamoto, K., Fujimi, S., Morimoto, T.** Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients with Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial. // *JAMA Network Open*, 5, 2022, № 4, p. E226136. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2022.6136.
1204. **Yu, R., Hou, R., Wang, T., Li, T., Han, H., An, J.** Correlation between monocyte to high-density lipoprotein ratio and major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention. // *Pakistan Journal of Medical Sciences*, 37, 2021, № 3, p. 885-889. ISSN 1682-024X. DOI 10.12669/pjms.37.3.3469.

1205. **Zaman, A.G., Aleem, Q.** Pharmacology before, during and after percutaneous coronary intervention. // *Heart*, 107, 2021, № 7, p. 585-592. ISSN 1355-6037. DOI 10.1136/heartjnl-2019-315090.
1206. **Zamin, S.A., Widmer, R.J.** ULISSE – Facilitating the odyssey toward individualized DAPT. // *International Journal of Cardiology*, 290, 2019, p. 81-83. ISSN 0167-5273. DOI 10.1016/j.ijcard.2019.05.013.
1207. **Zarei, M., Sahebi Vaighan, N., Ziai, S.A.** Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. // *Immunopharmacology and Immunotoxicology*, 43, 2021, № 6, p. 633-643. ISSN 0892-3973. DOI 10.1080/08923973.2021.1988102.
1208. **Zekery-Saad, S.A., Lewin, A., Pham, M., Sylvester, K.W., Fanikos, J., Goldhaber, S.Z., Connors, J.M.** Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. // *Journal of Thrombosis and Thrombolysis*, 51, 2021, № 2, p. 405-412. ISSN 0929-5305. DOI 10.1007/s11239-020-02207-3.
1209. **Zhang, H.-H., Liu, Q., Zhao, H.-J., Yu, Y.-N., Tian, L.-Y., Zhang, Y.-Y., Fu, Z.-H., Zheng, L., Zhu, Y., Ma, Y.-H., Li, S., Ma, Y.-Y., Liu, Y.-Q.** Predictive validation of existing bleeding and thromboembolic scores in elderly patients with comorbid atrial fibrillation and acute coronary syndrome. // *Journal of Geriatric Cardiology*, 20, 2023, № 5, p. 330-340. ISSN 1671-5411. DOI 10.26599/1671-5411.2023.05.001.
1210. **Zhang, Z.X., Schroeder-Tanka, J., Stooker, W., Wissen, S., Khorsand, N.** Management of combined oral antithrombotic therapy by an antithrombotic stewardship program: A prospective study. // *British Journal of Clinical Pharmacology*, 88, 2022, № 9, p. 4092-4099. ISSN 0306-5251. DOI 10.1111/bcp.15346.
1211. **Zhao, S., Hong, X., Cai, H., Liu, M., Li, B., Ma, P.** Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 660986. ISSN 2297-055X. DOI 10.3389/fcvm.2021.660986.
1212. **Zhao, S., Hong, X., Cao, J., Cai, H., Du, S., Ma, P.** Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration. // *Frontiers in Pharmacology*, 11, 2020, art. no. 1293. ISSN 1663-9812. DOI 10.3389/fphar.2020.01293.
1213. **Zhou, J., Wang, X., Yu, J., Wu, Y., Li, X., Xie, X., Zhang, X., Cheng, D., Yang, B.** An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions. // *Clinical and Experimental Pharmacology and Physiology*, 50, 2023, № 7, p. 583-593. ISSN 0305-1870. DOI 10.1111/1440-1681.13775.
1214. **Zhu, L., Li, Q., Yu, L., Liu, Y., Chen, Y., Wang, Z., Zhang, S., Li, J., Liu, Y., Zhao, Y., Xi, Y., Pi, L., Sun, Y.** Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study [心房颤动合并 ACS 住院患者抗凝治疗现状和其依从性

及对 1 年预后的影响：一项多中心队列研究]. // *Chinese Journal of Cardiology*, 51, 2023, № 7, p. 731-741. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20230314-00138.

1215. **Zieminski, J.J., Mara, K.C., Wamsley, K.S., Stulak, J.M., Nei, S.D.** A Single-Center Bleeding Comparison of Warfarin Plus Aspirin or Clopidogrel Following Coronary Artery Bypass Grafting and Surgical Valve Replacement. // *Clinical and Applied Thrombosis/Hemostasis*, 29, 2023. ISSN 1076-0296. DOI 10.1177/10760296231156175.
1216. **Zoppellaro, G., Marchese, G.M., Squizzato, A., Denas, G., Patti, G., De Caterina, R., Pengo, V.** Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. // *Internal and Emergency Medicine*, 15, 2020, № 6, p. 1093-1104. ISSN 1828-0447. DOI 10.1007/s11739-020-02402-3.
1217. **Zwart, B., Ten Berg, J.M.** Atrial fibrillation and coronary stenting: Is the augustus trial the end of triple therapy? // *Future Cardiology*, 15, 2019, № 5, p. 319-321. ISSN 1479-6678. DOI 10.2217/fca-2019-0027.
1218. **Zwicker, J.I., Paranagama, D., Lessen, D.S., Colucci, P.M., Grunwald, M.R.** Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. // *Haematologica*, 107, 2022, № 5, p. 1106-1110. ISSN 0390-6078. DOI 10.3324/haematol.2021.279032.

## **2018**

Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; **GLOBAL LEADERS Investigators**. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018 Sep 15;392(10151):940-949. DOI 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27. PMID: 30166073.

## **Cited by:**

1219. **Abusnina, W., Baral, N., Seri, A., Ben-Dor, I., Alkhouli, M., Monteleone, P., Haddad, E., Goldsweig, A.M., Paul, T.K.** Safety and Efficacy of Ultra Short-duration Dual Antiplatelet Therapy After Percutaneous Coronary Interventions: A Meta-analysis of Randomized Controlled Trials. // *Current Problems in Cardiology*, 47, 2022, № 10, art. no. 101295. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2022.101295.
1220. **Agewall, S.** Focus on pharma in acute coronary syndrome. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 6, 2020, № 1, p. 1-2. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz074.

1221. Aggarwal, D., Bhatia, K., Chunawala, Z.S., Furtado, R.H.M., Mukherjee, D., Dixon, S.R., Jain, V., Arora, S., Zelniker, T.A., Navarese, E.P., Mishkel, G.J., Lee, C.J., Banerjee, S., Bangalore, S., Levisay, J.P., Bhatt, D.L., Ricciardi, M.J., Qamar, A. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: Meta-Analysis of randomized trials. // *European Heart Journal Open*, 2, 2022, № 2, art. no. oeac019. ISSN 2752-4191. DOI 10.1093/eh-jopen/oeac019.
1222. Ajjan, R.A., Kietsiriroje, N., Badimon, L., Vilahur, G., Gorog, D.A., Angiolillo, D.J., Russell, D.A., Rocca, B., Storey, R.F. Antithrombotic therapy in diabetes: Which, when, and for how long? // *European Heart Journal*, 42, 2021, № 23, p. 2235-2259. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab128.
1223. Al-Abdoun, A., Abusnina, W., Mhanna, M., Radideh, Q., Alzu'bi, H., Rmilah, A.A., Jabri, A., Barbarawi, M., Obeidat, K., Alabduh, T., Michos, E.D., Alnablsi, T., Paul, T.K. P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis. // *Current Problems in Cardiology*, 47, 2022, № 10, art. no. 101292. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2022.101292.
1224. Alexopoulos, D., Mpahara, A., Kassimis, G. Omitting aspirin in PCI patients: Myth or reality? // *Cardiovascular Drugs and Therapy*, 33, 2019, № 6, p. 711-724. ISSN 0920-3206. DOI 10.1007/s10557-019-06916-7.
1225. Alkhalil, A., Alvarez Villela, M., Kobayashi, Y., Latib, A. Follow-up of left main patients treated with PCI or CABG. – In: *Left Main Coronary Revascularization*, 2022, p. 169-179. ISBN 9783031052651. DOI 10.1007/978-3-031-05265-1\_15.
1226. Alkhalil, M., Džavík, V., Bhatt, D.L., Mehran, R., Mehta, S.R. Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. // *Current Cardiology Reports*, 24, 2022, № 3, p. 277-293. ISSN 1523-3782. DOI 10.1007/s11886-022-01645-0.
1227. Almas, T., Ehtesham, M., Basit, J., Khedro, T., Malik, U., Nagarajan, V.R., Hur, J., Alshareef, N., Fathima, A., Virk, H.U.H., Hameed, A., Li, J. Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials. // *Annals of Medicine and Surgery*, 74, 2022, art. no. 103330. ISSN 2049-0801. DOI 10.1016/j.amsu.2022.103330.
1228. Al-Obaidi, F.R., Hutchings, H.A., Yong, A.S.C., Alrubaiy, L., Al-Farhan, H., Al-Ali, M.H., Al-Kinani, T., Al-Myahi, M., Al-Ken-zawi, H., Al-Sudani, N. Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. // *Current Cardiology Reviews*, 17, 2021, № 6, art. no. e051121190712. ISSN 1573-403X. DOI 10.2174/1573403X17666210126104053.
1229. Ameri, P., Canepa, M., López-Fernández, T., Nohria, A., Bertero, E., Vergallo, R., Lombardi, M., Lyon, A.R., Porto, I. Ischaemic heart disease in patients with cancer. // *European Heart Journal*, 45, 2024, № 14, p. 1209-1223. ISSN 0195-668X. DOI 10.1093/eurheartj/ehae047.

1230. **An, K., Guo, P., Qiu, S., Zhu, W., Cao, W., Shi, J., Wang, S.** Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drug-eluting stent implantation: A Bayesian network meta-analysis. // *Polish Archives of Internal Medicine*, 131, 2021, № 9, p. 781-789. ISSN 0032-3772. DOI 10.20452/pamw.16032.
1231. **Andò, G., Andò, G., Trio, O.** Ticagrelor or Prasugrel for Prevention of Stent Thrombosis? // *American Journal of Cardiology*, 125, 2020, № 5, p. 831-832. ISSN 0002-9149. DOI 10.1016/j.amjcard.2019.12.011.
1232. **Andò, G., Costa, F.** Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. // *International Journal of Cardiology*, 302, 2020, p. 95-102. ISSN 0167-5273. DOI 10.1016/j.ijcard.2019.12.054.
1233. **Andò, G., De Santis, G.A., Greco, A., Pistelli, L., Francaviglia, B., Capodanno, D., De Caterina, R., Capranzano, P.** P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis. // *JACC: Cardiovascular Interventions*, 15, 2022, № 22, p. 2239-2249. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.08.009.
1234. **Anghel, L., Tudurachi, B.-S., Tudurachi, A., Zăvoi, A., Clement, A., Roungos, A., Benchea, L.-C., Zota, I.M., Prisacariu, C., Sascău, R.A., Stătescu, C.** Patient-Related Factors Predicting Stent Thrombosis in Percutaneous Coronary Interventions. // *Journal of Clinical Medicine*, 12, 2023, № 23, art. no. 7367. ISSN 2077-0383. DOI 10.3390/jcm12237367.
1235. **Angiolillo, D.J.** Editorial commentary: Evolving paradigms in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention. // *Trends in Cardiovascular Medicine*, 30, 2020, № 4, p. 203-204. ISSN 1050-1738. DOI 10.1016/j.tcm.2019.06.004.
1236. **Angiolillo, D.J., Galli, M., Collet, J.-P., Kastrati, A., O'Donoghue, M.L.** Antiplatelet therapy after percutaneous coronary intervention. // *EuroIntervention*, 17, 2022, № 17, p. E1371-E1396. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00904.
1237. **Arockiam, S., Staniforth, B., Kepreotis, S., Maznyczka, A., Bulluck, H.** A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. // *International Journal of Molecular Sciences*, 24, 2023, № 13, art. no. 11132. ISSN 1661-6596. DOI 10.3390/ijms241311132.
1238. **Asad, Z.U.A., Baber, U.** The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. // *Interventional Cardiology Clinics*, 9, 2020, № 4, p. 489-498. ISSN 2211-7458. DOI 10.1016/j.iccl.2020.06.003.
1239. **Ashley, K.E., Hillegass, W.B.** Antiplatelet therapy regimen and duration after percutaneous coronary intervention: Combining prediction scores with clinical judgment. // *Catheterization and Cardiovascular Interventions*, 97, 2021, № 4, p. 579-580. ISSN 1522-1946. DOI 10.1002/ccd.29573.



1240. **Ashley, K.E., Hillegass, W.B.** Ticagrelor monotherapy after coronary stenting in patients requiring proton pump inhibitor and prolonged antiplatelet therapy. // *Catheterization and Cardiovascular Interventions*, 100, 2022, № 1, p. 83-84. ISSN 1522-1946. DOI: 10.1002/ccd.30315.
1241. **Ashley, K.E., Hillegass, W.B.** Ticagrelor monotherapy: When is mono-antiplatelet therapy (MAPT) equivalent or better? // *Catheterization and Cardiovascular Interventions*, 96, 2020, № 7, p. 1379-1380. ISSN 1522-1946. DOI 10.1002/ccd.29411.
1242. **Auer, J., Schmalzer, F., Badea, C., Engel, J., Primus, C.** Antithrombotic treatment after percutaneous coronary intervention [Antithrombotische Behandlung nach perkutaner Koronarintervention]. // *Tagliche Praxis*, 65, 2022, № 4, p. 559-574. ISSN 0494-464X.
1243. **Auer, J., Schmalzer, F., Badea, C., Engel, J., Primus, C.** Antithrombotic treatment after percutaneous coronary intervention [Antithrombotische Behandlung nach perkutaner Koronarintervention]. // *Internistische Praxis*, 64, 2021, № 3, p. 387-402. ISSN 0020-9570.
1244. **Averkov, O.V.** Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk. // *Russian Journal of Cardiology*, 26, 2021, № 1, art. no. 4305, p. 128-136. ISSN 1560-4071. DOI 10.15829/1560-4071-2021-4305.
1245. **Ayoub, A., Ayinapudi, K., Al-Ogaili, A., Panhwar, M.S., Dakkak, W., LeJemtel, T.** Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 2, p. 153-163. ISSN 1175-3277. DOI 10.1007/s40256-020-00430-0.
1246. **Baber, U.** The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how? [Antiagregación plaquetaria en monoterapia tras intervención coronaria percutánea: qué, quién, dónde, cuándo, por qué y cómo]. // *Revista Espanola de Cardiologia*, 75, 2022, № 2, p. 115-118. ISSN 0300-8932. DOI 10.1016/j.recesp.2021.08.015.
1247. **Baber, U., Angiolillo, D.J.** Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? // *JACC: Cardiovascular Interventions*, 13, 2020, № 19, p. 2263-2265. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.07.005.
1248. **Baber, U., Mehran, R.** Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? // *EuroIntervention*, 16, 2020, № 8, p. 620-622. ISSN 1774-024X. DOI 10.4244/EIJV16I8A115.
1249. **Bainey, K.R., Marquis-Gravel, G., MacDonald, B.J., Bewick, D., Yan, A., Turgeon, R.D.** Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis. // *PLoS ONE*, 18, 2023, art. no. e0291061. ISSN 1932-6203. DOI 10.1371/journal.pone.0291061.
1250. **Bajraktari, G., Bytyçi, I., Bajraktari, A., Henein, M.Y.** Non-inferiority of 1 month versus longer dual antiplatelet therapy in patients undergoing PCI with drug-eluting

stents: a systematic review and meta-analysis of randomized clinical trials. // *Therapeutic Advances in Chronic Disease*, 13, 2022. ISSN 2040-6223. DOI 10.1177/20406223221093758.

1251. **Barcudi, R.J., Bono, J., Ramos, H.R., Castro, W.Q., Muntaner, J., Macín, S., Zapata, G., Meiriño, A., Hominal, M., Mauro, D., Atencio, L., Amoroso, A., Murga, A.F., Rengel, E., Hasbani, E., Luciardi, H., Zoni, R., Onocko, M., Caruso, O.** Antithrombotic therapy in coronary artery disease. A Statement from the Ischemic Heart Disease Committee of the Argentina Federation of Cardiology [Documento de Consenso sobre terapia antitrombótica en enfermedad coronaria del Comité de Cardiopatía Isquémica de la Federación Argentina de Cardiología]. // *Revista de la Federacion Argentina de Cardiologia*, 51, 2022 p. 4-35. ISSN 0326-646X.
1252. **Baumbach, A.** Advancing the evidence base in interventional cardiology. // *Nature Reviews Cardiology*, 16, 2019, № 2, p. 79-81. ISSN 1759-5002. DOI 10.1038/s41569-018-0142-5.
1253. **Benenati, S., Crimi, G., Canale, C., Pescetelli, F., De Marzo, V., Vergallo, R., Galli, M., Della Bona, R., Canepa, M., Ameri, P., Crea, F., Porto, I.** Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: A network meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 1, p. 56-64. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa127.
1254. **Benenati, S., Galli, M., Marzo, V.D., Pescetelli, F., Toma, M., Andreotti, F., Bona, R.D., Canepa, M., Ameri, P., Crea, F., Porto, I.** Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: A meta-analysis of randomized controlled trials. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 2, p. 86-93. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa001.
1255. **Bergmark, B.A., Mathenge, N., Merlini, P.A., Lawrence-Wright, M.B., Giugliano, R.P.** Acute coronary syndromes. // *The Lancet*, 399, 2022, № 10332, p. 1347-1358. ISSN 0140-6736. DOI 10.1016/S0140-6736(21)02391-6.
1256. **Bhatt, D.L.** Aspirin—still the GLOBAL LEADER in antiplatelet therapy. // *The Lancet*, 392, 2018, № 10151, p. 896-897. ISSN 0140-6736. DOI 10.1016/S0140-6736(18)31884-1.
1257. **Bhattarai, M., Ibrahim, A.M., Salih, M., Tandan, N., Al-Akchar, M., Ayan, M., Kulkarni, A., Hafiz, A.M.** Comprehensive Outcomes Evaluation after Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short-Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis of Randomized Control Trials. // *Journal of Cardiovascular Pharmacology*, 76, 2020, № 5, p. 574-583. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000902.
1258. **Bianco, M., Careggio, A., Destefanis, P., Luciano, A., Perrelli, M.G., Quadri, G., Rossini, R., Campo, G., Vizzari, G., D'Ascenzo, F., Anselmino, M., Biondi-Zoccai, G., Ibáñez, B., Montagna, L., Varbella, F., Cerrato, E.** P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized clinical trials

including 29 089 patients. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 196-205. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa038.

1259. **Blum, M., Cao, D., Mehran, R.** Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy. // *Expert Review of Medical Devices*, 17, 2020, № 4, p. 257-265. ISSN 1743-4440. DOI 10.1080/17434440.2020.1736037.
1260. **Bonanad, C., Esteve-Claramunt, F., García-Blas, S., Ayesta, A., Díez-Villanueva, P., Pérez-Rivera, J.-Á., Ferreiro, J.L., Cánoves, J., López-Fornás, F., Solé, A.A., Raposerias, S., Vivas, D., Blanco, R., Berroterán, D.B., Cordero, A., Núñez, J., Fácila, L., Núñez-Gil, I.J., Górriz, J.L., Bodí, V., Martínez-Selles, M., Nodar, J.M.R., Chorro, F.J.** Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. // *Journal of Clinical Medicine*, 11, 2022, № 11, art. no. 3008. ISSN 2077-0383. DOI 10.3390/jcm11113008.
1261. **Braghieri, L., Badwan, O.Z., Reed, G., Menon, V., Ziada, K., Kapadia, S.R.** Dual Antiplatelet Therapy Duration After Percutaneous Coronary Interventions of Left Main Coronary Artery Disease: A Meta-Analysis. // *American Journal of Cardiology*, 205, 2023, p. 422-424. ISSN 0002-9149. DOI 10.1016/j.amjcard.2023.08.052.
1262. **Brieger, D., Chew, D., Goodman, S., Hammett, C., Lefkovits, J., Farouque, O., Atherton, J., Hyun, K., D'Souza, M.** Balancing the Risks of Recurrent Ischaemic and Bleeding Events in a Stable Post ACS Population. // *Heart Lung and Circulation*, 31, 2022, № 10, p. 1349-1359. ISSN 1443-9506. DOI 10.1016/j.hlc.2022.05.043.
1263. **Briguori, C.** Early P2Y<sub>12</sub> Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin? // *Circulation: Cardiovascular Interventions*, 14, 2021, № 5, p. E010880. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.121.010880.
1264. **Brinza, C., Burlacu, A., Tinica, G., Covic, A., Macovei, L.** A systematic review on bleeding risk scores' accuracy after percutaneous coronary interventions in acute and elective settings. // *Healthcare (Switzerland)*, 9, 2021, № 2, art. no. 148. ISSN 2227-9032. DOI 10.3390/healthcare9020148.
1265. **Buccheri, S., Capodanno, D., James, S., Angiolillo, D.J.** Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. // *Expert Opinion on Drug Safety*, 18, 2019, № 12, p. 1171-1189. ISSN 1474-0338. DOI 10.1080/14740338.2019.1680637.
1266. **Bularga, A., Meah, M.N., Doudesis, D., Shah, A.S.V., Mills, N.L., Newby, D.E., Lee, K.K.** Duration of dual antiplatelet therapy and stability of coronary heart disease: A 60 000-patient meta-analysis of randomised controlled trials. // *Open Heart*, 8, 2021, № 2, art. no. e001707. ISSN 2398-595X. DOI 10.1136/openhrt-2021-001707.
1267. **Busch, L., Stern, M., Dannenberg, L., Mourikis, P., Gröne, M., Özaslan, G., Heinen, Y., Heiss, C., Sansone, R., Polzin, A., Kelm, M.** Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. // *Platelets*, 32, 2021, № 3, p. 391-397. ISSN 0953-7104. DOI 10.1080/09537104.2020.1742314.

1268. **Buske, M., Feistritz, H.-J., Jobs, A., Thiele, H.** Management of acute coronary syndrome: ESC guidelines 2023 [Management des akuten Koronarsyndroms: ESC-Leitlinie 2023]. // *Herz*, 49, 2024, № 1, p. 5-14. ISSN 0340-9937. DOI 10.1007/s00059-023-05222-1.
1269. **Buszman, P.P.** Quitting Prolonged Aspirin Therapy With Potent Antiplatelet Inhibitors—The Time Has Come. // *American Journal of Cardiology*, 212, 2024, p. 133-134. ISSN 0002-9149. DOI 10.1016/j.amjcard.2023.11.021.
1270. **Calderaro, D., Bichuette, L.D., Maciel, P.C., Cardozo, F.A.M., Ribeiro, H.B., Gualandro, D.M., Baracioli, L.M., De Matos Soeiro, A., Serrano, C.V., Da Costa, R.A., Caramelli, B.** Update of the Brazilian Society of Cardiology's Perioperative Cardiovascular Assessment Guideline: Focus on Managing Patients with Percutaneous Coronary Intervention – 2022. // *Arquivos Brasileiros de Cardiologia*, 118, 2022, № 2, p. 536-547. ISSN 0066-782X. DOI 10.36660/abc.20220039.
1271. **Calderone, D., Capodanno, D., Angiolillo, D.J.** An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. // *Expert Review of Cardiovascular Therapy*, 2020, p. 449-464. ISSN 1477-9072. DOI 10.1080/14779072.2020.1792293.
1272. **Calderone, D., Ingala, S., Mauro, M.S., Angiolillo, D.J., Capodanno, D.** Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 12, p. 1097-1117. ISSN 1477-9072. DOI 10.1080/14779072.2021.2020100.
1273. **Camaj, A., Miller, M.S., Halperin, J.L., Giustino, G.** Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. // *Cardiology Clinics*, 38, 2020, № 4, p. 551-561. ISSN 0733-8651. DOI 10.1016/j.ccl.2020.07.006.
1274. **Camarero, T.G., de la Torre Hernández, J.M.** Antithrombotic treatment after coronary intervention: Agreement and controversy. // *European Cardiology Review*, 15, 2020, art. no. e07. ISSN 1758-3756. DOI 10.15420/ecr.2019.25.2.
1275. **Cao, D., Chandiramani, R., Chiarito, M., Claessen, B.E., Mehran, R.** Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: A 40-year journey. // *European Heart Journal*, 42, 2021, № 4, p. 339-351. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa824.
1276. **Capodanno, D., Angiolillo, D.J.** Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients with Coronary Artery Disease and Diabetes Mellitus. // *Circulation*, 142, 2020, № 22, p. 2172-2188. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.045465.
1277. **Capodanno, D., Angiolillo, D.J.** Personalised antiplatelet therapies for coronary artery disease: what the future holds. // *European Heart Journal*, 44, 2023, № 32, p. 3059-3072. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad362.
1278. **Capodanno, D., Angiolillo, D.J.** Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI. // *JACC: Cardiovascular Interventions*, 16, 2023, № 1, p. 1-18. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.10.023.

1279. **Capodanno, D., Angiolillo, D.J.** When less becomes more: Insights on the pharmacodynamic effects of aspirin withdrawal in patients with potent platelet p2y12 inhibition induced by ticagrelor. // *Journal of the American Heart Association*, 9, 2020, № 24, art. no. e019432. ISSN 2047-9980. DOI 10.1161/JAHA.120.019432.
1280. **Capodanno, D., Mehran, R., Angiolillo, D.J.** Aspirin-free antithrombotic management following coronary stenting. Myth or reality? // *REC: Interventional Cardiology*, 1, 2019, № 1, p. 62-66. ISSN 2604-7306. DOI 10.24875/RECICE.M19000016.
1281. **Capranzano, P.** The stent in the high-bleeding risk patient: antiplatelet monotherapy? // *European Heart Journal, Supplement*, 24, 2022, p. I54-I56. ISSN 1520-765X. DOI 10.1093/eurheartjsupp/suac074.
1282. **Capranzano, P., Angiolillo, D.J.** Antithrombotic Management of Elderly Patients With Coronary Artery Disease. // *JACC: Cardiovascular Interventions*, 14, 2021, № 7, p. 723-738. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.01.040.
1283. **Capranzano, P., Moliterno, D., Capodanno, D.** Aspirin-free antiplatelet strategies after percutaneous coronary interventions. // *European Heart Journal*, 45, 2024, № 8, p. 572-585. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad876.
1284. **Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D'ascenzo, F., Marquis-Gravel, G., Giustino, G., Costa, F.** Antithrombotic therapy for percutaneous cardiovascular interventions: From coronary artery disease to structural heart interventions. // *Journal of Clinical Medicine*, 8, 2019, № 11, art. no. 2016. ISSN 2077-0383. DOI 10.3390/jcm8112016.
1285. **Carciotto, G., Costa, F., Garcia-Ruiz, V., Galli, M., Soraci, E., Magliarditi, A., Teresi, L., Nasso, E., Carerj, S., Di Bella, G., Micari, A., De Luca, G.** Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review. // *Journal of Clinical Medicine*, 12, 2023, № 22, art. no. 7144. ISSN 2077-0383. DOI 10.3390/jcm12227144.
1286. **Carlin, S., Eikelboom, J.** Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease? // *Expert Review of Cardiovascular Therapy*, 21, 2023, № 5, p. 305-309. ISSN 1477-9072. DOI 10.1080/14779072.2023.2199155.
1287. **Cassese, S., Ndrepepa, G., Byrne, R.A., Laugwitz, K.-L., Schunkert, H., Fusaro, M., Alfonso, F., Kastrati, A.** Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials. // *American Heart Journal*, 219, 2020, p. 109-116. ISSN 0002-8703. DOI 10.1016/j.ahj.2019.08.020.
1288. **Cepas-Guillén, P.L., Laffond, A., Lozano Granero, C., López Lluva, M.T.** III CardioMIR: The Congress of Young Cardiologists [III CardioMIR: el Congreso de los Jóvenes Cardiólogos]. // *REC: CardioClinics*, 57, 2022, p. S28-S36. ISSN 2605-1532. DOI 10.1016/j.rccl.2022.10.010.
1289. **Chandiramani, R., Spirito, A., Johnson, J.W., Mehta, A., Vogel, B., Failace, R.T., Mehran, R.** Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. // *Expert Review of Cardiovascular Therapy*, 21, 2023, № 5, p. 311-328. ISSN 1477-9072. DOI 10.1080/14779072.2023.2201437.



1290. **Chen, H., Sun, Q., Li, H., Tian, T., Song, J., Li, Y.** Observation of Bleeding and MACCE Events in Patients with Liver Cirrhosis Complicated with Acute Coronary Syndrome after Antiplatelet Therapy. // *Journal of the College of Physicians and Surgeons Pakistan*, 33, 2023, № 8, p. 927-931. ISSN 1022-386X. DOI 10.29271/jcpsp.2023.08.927.
1291. **Chen, P.-W., Feng, W.-H., Ho, M.-Y., Su, C.-H., Huang, S.-W., Cheng, C.-W., Yeh, H.-I., Chen, C.-P., Huang, W.-C., Fang, C.-C., Lin, H.-W., Lin, S.-H., Hsieh, I.-C., Li, Y.-H.** P2y12 inhibitor monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention. // *Journal of Clinical Medicine*, 9, 2020, № 6, art. no. 1657. ISSN 2077-0383. DOI 10.3390/jcm9061657.
1292. **Chen, S., Li, J., Qiu, M., Ma, S., Jiang, Z., Na, K., Qi, Z., Li, Y., Li, Y., Han, Y.** Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention. // *Catheterization and Cardiovascular Interventions*, 99, 2022, № S1, p. 1424-1431. ISSN 1522-1946. DOI 10.1002/ccd.30089.
1293. **Chiarito, M., Sanz-Sánchez, J., Cannata, F., Cao, D., Sturla, M., Panico, C., Godino, C., Regazzoli, D., Reimers, B., De Caterina, R., Condorelli, G., Ferrante, G., Stefanini, G.G.** Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. // *The Lancet*, 395, 2020, № 10235, p. 1487-1495. ISSN 0140-6736. DOI 10.1016/S0140-6736(20)30315-9.
1294. **Cho, J.Y., Lee, S.-Y., Yun, K.H., Kim, B.-K., Hong, S.-J., Ko, J.S., Rhee, S.J., Oh, S.K., Shin, D.-H., Ahn, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Factors related to major bleeding after ticagrelor therapy: Results from the tico trial. // *Journal of the American Heart Association*, 10, 2021, № 7, art. no. e019630. ISSN 2047-9980. DOI 10.1161/JAHA.120.019630.
1295. **Choi, K.H., Park, Y.H., Song, Y.B., Park, T.K., Lee, J.M., Yang, J.H., Choi, J.-H., Choi, S.-H., Oh, J.-H., Chun, W.J., Jang, W.J., Im, E.-S., Jeong, J.-O., Cho, B.R., Oh, S.K., Yun, K.H., Cho, D.-K., Lee, J.-Y., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Lee, W.S., Yoon, H.J., Lee, S.U., Cho, J.H., Choi, W.G., Rha, S.-W., Gwon, H.-C., Hahn, J.-Y.** Long-term Effects of P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial. // *JAMA Cardiology*, 7, 2022, № 11, p. 1100-1108. ISSN 2380-6583. DOI: 10.1001/jamacardio.2022.3203.
1296. **Chong, B., Goh, R.S.J., Kong, G., Sim, F.R.E., Ng, C.H., Teo, X.Y.V., Quek, J.X., Lim, O., Chin, Y.H., Chan, S.-P., Chan, M.Y., Tan, H.-C., Chew, N.W.S., Loh, P.H.** Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients. // *Journal of Thrombosis and Thrombolysis*, 53, 2022, № 3, p. 671-682. ISSN 0929-5305. DOI 10.1007/s11239-021-02628-8.
1297. **Chuang, A., Nguyen, M.T., Kung, W.-M., Lehman, S., Chew, D.P.** High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond. // *Reviews in Cardiovascular Medicine*, 21, 2020, № 2, p. 191-203. ISSN 1530-6550. DOI 10.31083/J.RCM.2020.02.17.

1298. **Collet, J.-P., Montalescot, G., Zeitouni, M.** Aspirin-Free Strategies After PCI: Still Not Out of the Twilight. // *Journal of the American College of Cardiology*, 74, 2019, № 16, p. 2028-2031. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.08.998.
1299. **Costa, I.B.S.D.S., Andrade, F.T.D.A., Carter, D., Seleme, V.B., Costa, M.S., Campos, C.M., Hajjar, L.A.** Challenges and Management of Acute Coronary Syndrome in Cancer Patients. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 590016. ISSN 2297-055X. DOI 10.3389/fcvm.2021.590016.
1300. **Costabel, J.P., Duronto, E., Nani, S., Arazi, H.C., Guetta, J.** Antiplatelet strategies in acute coronary syndromes [Estrategias de antiagregación plaquetaria en síndromes coronarios agudos]. // *Revista Argentina de Cardiología*, 89, 2021, № 2, p. 140-150. ISSN 0034-7000. DOI 10.7775/rac.v89.i2.19703.
1301. **Davanzo, R.H., Alarcón, A.F., Calquín, J.Q., Varela, P.S., Sepúlveda, A.M., Herreros, R.C., Patel, S., Rodríguez, G.M.** Antiplatelet therapy and percutaneous coronary interventions. // *Current Cardiology Reviews*, 17, 2021, № 3, p. 302-313. ISSN 1573-403X. DOI 10.2174/1573403X16666200615144423.
1302. **De Caterina, R.** Dibattito sulla monoterapia antiplastrinica: Perché non lasciare la buona vecchia aspirina per clopidogrel o ticagrelor in monoterapia nella sindrome coronarica cronica dopo un'angioplastica coronarica. // *Giornale Italiano di Cardiologia*, 24, 2023, № 4, p. 16S-18S. ISSN 1827-6806. DOI 10.1714/4035.40100.
1303. **De Filippo, O., Piroli, F., Bruno, F., Bocchino, P.P., Saglietto, A., Franchin, L., Angelini, F., Gallone, G., Alabed, S., Gasparini, M., Ahmad, M., De Ferrari, G.M., D'Ascenzo, F.** De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. // *Cochrane Database of Systematic Reviews*, 2021, № 7, art. no. CD014813. ISSN 1465-1858. DOI 10.1002/14651858.CD014813.
1304. **de Luca, L., Paolucci, L., Nusca, A., Putini, R.L., Mangiacapra, F., Natale, E., Ussia, G.P., Colivicchi, F., Grigioni, F., Musumeci, F., Gabrielli, D.** Current management and prognosis of patients with recurrent myocardial infarction. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 3, p. 731-740. ISSN 1530-6550. DOI 10.31083/J.RCM2203080.
1305. **De Rosa, R., Piscione, F., Galasso, G., De Servi, S., Savonitto, S.** Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. // *Journal of Geriatric Cardiology*, 16, 2019, № 2, p. 103-113. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2019.02.006.
1306. **De Servi, S., Landi, A., Savonitto, S., De Luca, L., De Luca, G., Morici, N., Montalto, C., Crimi, G., Cattaneo, M.** Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. // *Journal of Cardiovascular Medicine*, 24, 2023, № 2, p. 77-86. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001399.
1307. **de Servi, S., Sciatti, E., Temporelli, P.L., de Caterina, R., Prati, F., Zito, G.B., Carugo, S., de Biase, L., Senni, M., Rossini, R.** Grey zones on dual antiplatelet therapy. Expert opinion. [Grey zones sulla duplice terapia antiplastrinica. opinioni degli esperti]. // *Giornale Italiano di Cardiologia*, 21, 2020, № 7, p. 530-536. ISSN 1827-6806. DOI 10.1714/3386.33642.

1308. **Deharo, P., Cuisset, T.** Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. // *Trends in Cardiovascular Medicine*, 30, 2020, № 4, p. 198-202. ISSN 1050-1738. DOI 10.1016/j.tcm.2019.05.008.
1309. **Dillinger, J.-G., Henry, P.** DAPT in the diabetic patient with CAD. [La DAPT chez le patient diabétique coronarien]. // *Archives of Cardiovascular Diseases Supplements*, 11, 2019, p. S3-S7. ISSN 1878-6480. DOI 10.1016/S1878-6480(19)30959-0.
1310. **Ding, J.-W., Chen, Y., Yu, Z.-Z., Zhao, Y.-B., Fan, K.-P., Yao, X.-D., Hu, L.-L., Liao, Y.-H., Deng, T.-H., Xia, Y., Liao, H.-H., Yang, R.-Q.** De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 11, art. no. 360. ISSN 1530-6550. DOI 10.31083/j.rcm2311360.
1311. **Doolub, G., Mamas, M.A.** Percutaneous Coronary Angioplasty in Patients with Cancer: Clinical Challenges and Management Strategies. // *Journal of Personalized Medicine*, 12, 2022, № 9, art. no. 1372. ISSN 2075-4426. DOI 10.3390/jpm12091372.
1312. **Dotto, C., Lombarte Serrat, A., Ledesma, M., Vay, C., Ehling-Schulz, M., Sordelli, D.O., Grunert, T., Buzzola, F.** Salicylic acid stabilizes *Staphylococcus aureus* biofilm by impairing the agr quorum-sensing system. // *Scientific Reports*, 11, 2021, № 1, art. no. 2953. ISSN 2045-2322. DOI 10.1038/s41598-021-82308-y.
1313. **Dudek, D., Dziewierz, A., Stone, G., Wijns, W.** The year in cardiology 2018: Coronary interventions. // *European Heart Journal*, 40, 2019, № 2, p. 195-203. ISSN 0195-668X. DOI 10.1093/eurheartj/ehy882.
1314. **Eggebrecht, H.** TICO study: ASA-free antiplatelet therapy after coronary intervention for acute coronary syndrome—is ticagrelor monotherapy the solution? [TICO-Studie: ASS-freie Thrombozytenaggregationshemmung nach Koronarintervention bei akutem Koronarsyndrom – Ist Ticagrelor-Monotherapie die Alternative?]. // *Kardiologie*, 15, 2021, № 1, p. 6-8. ISSN 1864-9718. DOI 10.1007/s12181-020-00427-8.
1315. **Eid, M.M., Mostafa, M.R., Alabdouh, A., Najim, M., Mohamed, S., Ziada, A.R., Takla, A., Balmer-Swain, M., Baibhav, B., Al-Azizi, K.M., Goldsweig, A.M.** Short duration of dual antiplatelet therapy following complex percutaneous coronary intervention: A systematic review and meta-analysis. // *Cardiovascular Revascularization Medicine*, 61, 2024, p. 8-15. ISSN 1553-8389. DOI 10.1016/j.carrev.2023.11.002.
1316. **Elzanaty, A.M., Nazir, S., Awad, M.T., Elsheikh, E., Ahuja, K.R., Donato, A., Eltahawy, E.A.** Meta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. // *Cardiovascular Revascularization Medicine*, 21, 2020, № 12, p. 1500-1506. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.05.012.
1317. **Espinoza, C., Mukherjee, D.** Dual antiplatelet therapy in patients with high cardiovascular risk. // *Heart International*, 15, 2021, № 1, p. 26-36. ISSN 1826-1868. DOI 10.17925/HI.2021.15.1.26.

1318. **Fan, Z.-G., Tian, N.-L., He, S.-H., Ma, G.-S.** Maintained P2Y12 inhibitor monotherapy after shorter-duration of dual antiplatelet therapy in patients undergoing coronary drug-eluting stents implantation: An updated meta-analysis of randomized trials. // *Journal of Clinical Pharmacy and Therapeutics*, 47, 2022, № 7, p. 860-869. ISSN 0269-4727. DOI 10.1111/jcpt.13626.
1319. **Faria, D., Santos, M., Baptista, S.B., Ferreira, J., Leal, P., Abreu, P.F.E., Moraes, C.** Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. [Elegibilidade para terapêutica anti-trombótica prolongada para prevenção secundária da síndrome coronária aguda]. // *Revista Portuguesa de Cardiologia*, 39, 2020, № 9, p. 493-501. ISSN 0870-2551. DOI 10.1016/j.repc.2020.02.012.
1320. **Feldman, D., Beerkens, F., Nicolas, J., Satish, M., Jones, D., Demirhan, M., Dangas, G.** Defining Key Features of Complex Coronary Lesions: An Evidence Based Review of Clinical Practice. Part II: Chronic Total Occlusions, Graft Interventions, In-Stent Restenosis, and Antithrombotic Strategies. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 6, art. no. 209. ISSN 1530-6550. DOI 10.31083/j.rcm2306209.
1321. **Feng, Q., Tsoi, M.F., Fei, Y., Cheung, C.L., Cheung, B.M.Y.** Use of ticagrelor and the risks of pneumonia and pneumonia-specific death in patients with non-acute coronary syndrome conditions: a population-based cohort study. // *Scientific Reports*, 11, 2021, № 1, art. no. 20468. ISSN 2045-2322. DOI 10.1038/s41598-021-00105-z.
1322. **Feng, W.-H., Chang, Y.-C., Lin, Y.-H., Chen, H.-L., Chang, H.-M., Chu, C.-S.** Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. // *International Journal of Molecular Sciences*, 23, 2022, № 9, art. no. 4549. ISSN 1661-6596. DOI 10.3390/ijms23094549.
1323. **Feng, W.-H., Chang, Y.-C., Lin, Y.-H., Chen, H.-L., Chen, C.-Y., Lin, T.-H., Lin, T.-C., Chang, C.-T., Kuo, H.-F., Chang, H.-M., Chu, C.-S.** P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis. // *Pharmaceuticals*, 16, 2023, № 2, art. no. 232. ISSN 1424-8247. DOI 10.3390/ph16020232.
1324. **Feng, W.-H., Hsieh, I.-C., Li, Y.-H.** P2Y12 inhibitor monotherapy after percutaneous coronary intervention: Is it safe to abandon aspirin? // *Acta Cardiologica Sinica*, 37, 2021, № 1, p. 1-8. ISSN 1011-6842. DOI 10.6515/ACS.202101\_37(1).20200806A.
1325. **Fernando, H., McFadyen, J.D., Palasubramaniam, J., Shaw, J., Wang, X., Stub, D., Peter, K.** Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. // *Thrombosis and Haemostasis*, 120, 2020, № 10, p. 1352-1356. ISSN 0340-6245. DOI 10.1055/s-0040-1714212.
1326. **Fernando, H., McFadyen, J.D., Wang, X., Shaw, J., Stub, D., Peter, K.** P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 854813. ISSN 2297-055X. DOI 10.3389/fcvm.2022.854813.

1327. **Ferreiro, J.L., Vivas, D., De La Hera, J.M., Marcano, A.L., Lugo, L.M., Gómez-Polo, J.C., Silva, I., Tello-Montoliu, A., Marín, F., Roldán, I.** High and low on-treatment platelet reactivity to P2Y<sub>12</sub> inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. // *Thrombosis Research*, 175, 2019, p. 95-101. ISSN 0049-3848. DOI 10.1016/j.thromres.2019.01.021.
1328. **Festa, M.C., Rasasingam, S., Sharma, A., Mavrakanas, T.A.** Early Discontinuation of Aspirin Among Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention with a Drug-Eluting Stent: A Meta-Analysis. // *Kidney360*, 4, 2023, № 9, p. E1245-E1256. ISSN 2641-7650. DOI 10.34067/KID.0000000000000223.
1329. **Filardi, P.P., Caldarola, P., Colivicchi, F., Mugelli, A., Varbella, F., Paolillo, S.** Long-term antithrombotic strategies in post-myocardial infarction patients. [Strategie antitrombotiche a lungo termine nel paziente post-infarto]. // *Giornale Italiano di Cardiologia*, 20, 2019, № 11, p. E1-E11. ISSN 1827-6806. DOI 10.1714/3261.32286.
1330. **Fitchett, D.H., Leiter, L.A., Lin, P., Pickering, J., Welsh, R., Stone, J., Gregoire, J., McFarlane, P., Langer, A., Gupta, A., Goodman, S.G.** Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. // *CJC Open*, 2, 2020, № 5, p. 402-415. ISSN 2589-790X. DOI 10.1016/j.cjco.2020.04.002.
1331. **Frampton, J., Devries, J.T., Welch, T.D., Gersh, B.J.** Modern Management of ST-Segment Elevation Myocardial Infarction. // *Current Problems in Cardiology*, 45, 2020, № 3, art. no. 100393. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2018.08.005.
1332. **Frampton, J., Ortengren, A.R., Zeitler, E.P.** Arrhythmias After Acute Myocardial Infarction. // *Yale Journal of Biology and Medicine*, 96, 2023, № 1, p. 83-94. ISSN 0044-0086. DOI 10.59249/LSWK8578.
1333. **Franchi, F., Rollini, F., Kairouz, V., Rivas Rios, J., Rivas, A., Agarwal, M., Briceño, M., Wali, M., Nawaz, A., Silva, G., Shaikh, Z., Maaliki, N., Been, L., Piraino, J., Pineda, A.M., Suryadevara, S., Soffer, D., Zenni, M.M., Jennings, L.K., Bass, T.A., Angiolillo, D.J.** Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study. // *JACC: Basic to Translational Science*, 4, 2019, № 7, p. 763-775. ISSN 2452-302X. DOI 10.1016/j.jacbts.2019.07.011.
1334. **Galiuto, L., Patrono, C.** Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy? // *European Heart Journal*, 42, 2021, № 30, p. 2883-2884. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab387.
1335. **Galli, M., Capodanno, D., Andreotti, F., Crea, F., Angiolillo, D.J.** Safety and efficacy of P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions. // *Expert Opinion on Drug Safety*, 20, 2021, № 1, p. 9-21. ISSN 1474-0338. DOI 10.1080/14740338.2021.1850691.
1336. **Gao, C., Zhu, B., Liu, J., Jiang, Z., Hu, T., Wang, Q., Liu, Y., Yuan, M., Li, F., Zhang, R., Xia, J., Onuma, Y., Wang, D., Serruys, P., Tao, L., on behalf of the REC-CAGEFREE II Study Group.** Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and



1337. **Gao, X., Bi, X., Yang, J., Cheng, M.** Safety and Efficacy of Short-Term vs. Standard Periods Dual Antiplatelet Therapy After New-Generation Drug-Eluting Stent Implantation: A Meta-analysis. – In: *Lecture Notes in Computer Science* (including subseries *Lecture Notes in Artificial Intelligence* and *Lecture Notes in Bioinformatics*), 13393 LNCS, 2022, p. 701-725. ISSN 0302-9743. ISBN 9783031138690. DOI 10.1007/978-3-031-13870-6\_58.
1338. **Garg, A., Rout, A., Sharma, A., Sargsyan, D., Beavers, T., Tantry, U., Gurbel, P., Rao, S.V., Kostis, J.B., Cohen, M.** Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. // *Progress in Cardiovascular Diseases*, 63, 2020, № 3, p. 243-248. ISSN 0033-0620. DOI 10.1016/j.pcad.2020.03.018.
1339. **Ge, Z., Gao, X.-F., Kan, J., Kong, X.-Q., Zuo, G.-F., Ye, F., Tian, N.-L., Lin, S., Liu, Z.-Z., Shao, Y.-B., He, Y.-Q., Wen, S.-Y., Yang, Q., Xia, Y., Wang, Z.-Z., Xiao, P.-X., Li, F., Zeng, H.-S., Yang, S., Wang, Y., Tao, L., Gao, D.-S., Qu, H., Qian, X.-S., Han, Y.-L., Chen, F., Zhang, J.-J., Chen, S.-L.** Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. // *American Heart Journal*, 236, 2021, p. 49-58. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.02.014.
1340. **Ge, Z., Kan, J., Gao, X., Raza, A., Zhang, J.-J., Mohyidin, B.S., Gao, F., Shao, Y., Wang, Y., Zeng, H., Li, F., Khan, H.S., Mengal, N., Cong, H., Wang, M., Chen, L., Wei, Y., Chen, F., Stone, G.W., Chen, S.-L., Li, X., Anjum, M., Ye, F., Jalal, A., Xie, P., Tao, L., Chen, X., Khan, H.S., Javed, A., Shao, Y., Guo, X., Saghir, T., Nie, S., Qu, H., Qian, X., Yang, S., Chen, J., Gao, D., Liu, L., Liu, F., Xu, T., Liu, Y., Gill, B.U.A., Yang, Q., Guo, N., Wen, S., Hong, L., Sheiban, I., Mintz, G.S., ULTIMATE-DAPT investigators.** Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. // *The Lancet*, 2024. ISSN 0140-6736. DOI 10.1016/S0140-6736(24)00473-2.
1341. **Gelbenegger, G., Erari-Canyurt, U., Grafeneder, J., Jilma, B., Lesiak, M., Komosa, A., de Caterina, R., Postula, M., Siller-Matula, J.M.** Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis. // *Vascular Pharmacology*, 138, 2021, art. no. 106858. ISSN 1537-1891. DOI 10.1016/j.vph.2021.106858.
1342. **Gelbenegger, G., Jilma, B.** Clinical pharmacology of antiplatelet drugs. // *Expert Review of Clinical Pharmacology*, 15, 2022, № 10, p. 1177-1197. ISSN 1751-2433. DOI 10.1080/17512433.2022.2121702.
1343. **Gelbenegger, G., Schoergenhofer, C., Jilma, B., Gager, G.M., Dizdarevic, A.M., Mamas, M.A., Parapid, B., Velagapudi, P., Siller-Matula, J.M.** Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. // *Clinical Pharmacology and Therapeutics*, 110, 2021, № 2, p. 424-431. ISSN 0009-9236. DOI 10.1002/cpt.2226.

1344. **Georges, J.L., Cherif, G., Ajlani, B.** Optimal duration of dual antiplatelet therapy after coronary stent placement or acute coronary syndrome. Is customisation possible? [Durée optimale de la double antiagrégation plaquettaire après angioplastie coronaire ou syndrome coronaire aigu. La personnalisation est-elle possible ?]. // *Annales de Cardiologie et d'Angéiologie*, 68, 2019, № 5, p. 347-357. ISSN 0003-3928. DOI 10.1016/j.ancard.2019.07.011.
1345. **Gerstein, N.S., Albrechtsen, C.L., Mercado, N., Cigarroa, J.E., Schulman, P.M.** A Comprehensive Update on Aspirin Management During Noncardiac Surgery. // *Anesthesia and Analgesia*, 131, 2020, № 4, p. 1111-1123. ISSN 0003-2999. DOI 10.1213/ANE.0000000000005064.
1346. **Giannoni, A., Borrelli, C., Gentile, F., Mirizzi, G., Coceani, M., Paradossi, U., Vergaro, G., Bramanti, F., Iudice, G., Emdin, M., Passino, C.** Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 180-188. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa089.
1347. **Gimbel, M.E., Ten Berg, J.M.** Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome. // *Expert Opinion on Drug Safety*, 20, 2021, № 12, p. 1545-1552. ISSN 1474-0338. DOI 10.1080/14740338.2021.1936498.
1348. **Giubilato, S., Lucà, F., Abrignani, M.G., Gatto, L., Rao, C.M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., Di Matteo, I., Di Nora, C., Favilli, S., Pilleri, A., Pozzi, A., Temporelli, P.L., Zuin, M., Amico, A.F., Riccio, C., Grimaldi, M., Colivicchi, F., Oliva, F., Gulizia, M.M.** Management of Residual Risk in Chronic Coronary Syndromes. Clinical Pathways for a Quality-Based Secondary Prevention. // *Journal of Clinical Medicine*, 12, 2023, № 18, art. no. 5989. ISSN 2077-0383. DOI 10.3390/jcm12185989.
1349. **Goel, R., Baber, U.** Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. // *Current Opinion in Cardiology*, 34, 2019, № 4, p. 315-322. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000640.
1350. **Gonçalves, M., Garcia-Garcia, H.M.** What is the best treatment for patients with myocardial infarction with non-obstructive coronary artery disease? [Qual é o melhor tratamento para os doentes com enfarte do miocárdio com doença coronária não obstrutiva?]. // *Revista Portuguesa de Cardiologia*, 39, 2020, № 12, p. 685-686. ISSN 0870-2551. DOI 10.1016/j.repc.2020.10.004.
1351. **Gorog, D.A., Jeyalan, V., Markides, R.I.L., Navarese, E.P., Jeong, Y.-H., Farag, M.** Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. // *Thrombosis and Haemostasis*, 123, 2023, № 8, p. 773-792. ISSN 0340-6245. DOI 10.1055/s-0043-57030.
1352. **Goryo, Y., Kume, T., Okamoto, H., Kawamura, A., Fukuhara, K., Tamada, T., Koyama, T., Imai, K., Yamada, R., Neishi, Y., Uemura, S.** Influence of dual antiplatelet therapy duration on neointimal condition after second-generation drug-eluting stent implantation. // *Cardiovascular Intervention and Therapeutics*, 37, 2022, № 1, p. 101-108. ISSN 1868-4300. DOI 10.1007/s12928-021-00765-8.

1353. **Grazhdankin, I.O., Baystrukov, V.I., Kretov, E.I., Chernyavskiy, A.M.** Clopidogrel in clinical practice for myocardial revascularisation: from the origins to the latest recommendations [Клопидогрель в клинической практике при реваскуляризации миокарда: от истоков к последним рекомендациям]. // *Patologiya Krovoobrashcheniya i Kardiokhirurgiya*, 26, 2022, № 1, p. 32-43. ISSN 1681-3472. DOI 10.21688/1681-3472-2022-1-32-43.
1354. **Greco, A., Capodanno, D.** Long-term monotherapy with ticagrelor after coronary stenting: The GLOBAL LEADERS study. // *European Heart Journal, Supplement*, 22, 2021, p. E46-E49. ISSN 1520-765X. DOI 10.1093/EURHEARTJ/SUAA058.
1355. **Greco, A., Finocchiaro, S., Angiolillo, D.J., Capodanno, D.** Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. // *Expert Opinion on Pharmacotherapy*, 24, 2023, № 4, p. 453-471. ISSN 1465-6566. DOI 10.1080/14656566.2023.2171788.
1356. **Greco, A., Mauro, M.S., Capodanno, D., Angiolillo, D.J.** P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 10, art. no. 348. ISSN 1530-6550. DOI 10.31083/j.rcm2310348.
1357. **Grines, C.L., Marshall, J.J.** Short DAPT after DES: P2Y12 monotherapy is in, aspirin is out! // *European Heart Journal*, 40, 2019, № 31, p. 2605-2606. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz519.
1358. **Guedeney, P., Collet, J.-P.** Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. // *Thrombosis and Haemostasis*, 121, 2021, № 7, p. 854-866. ISSN 0340-6245. DOI 10.1055/s-0040-1722188.
1359. **Guedeney, P., Collet, J.-P.** Diagnosis and management of acute coronary syndrome: What is new and why? insight from the 2020 european society of cardiology guidelines. // *Journal of Clinical Medicine*, 9, 2020, № 11, art. no. 3474, p. 1-16. ISSN 2077-0383. DOI 10.3390/jcm9113474.
1360. **Guedeney, P., Collet, J.-P., Ecollan, P., Montalescot, G.** NSTEMI : What's new in ESC 2020 guidelines [Prise en charge du syndrome coronaire aigu sans élévation du segment ST, nouveautés des recommandations ESC 2020]. // *Journal Europeen des Urgences et de Reanimation*, 33, 2021, № 2, p. 82-87. ISSN 2211-4238. DOI 10.1016/j.jeurea.2021.04.004.
1361. **Guedeney, P., Mesnier, J., Sorrentino, S., Abcha, F., Zeitouni, M., Lattuca, B., Silvain, J., De Rosa, S., Indolfi, C., Collet, J.-P., Kerneis, M., Montalescot, G.** Review early aspirin discontinuation following acute coronary syndrome or percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials. // *Journal of Clinical Medicine*, 9, 2020, № 3, art. no. 680. ISSN 2077-0383. DOI 10.3390/jcm9030680.
1362. **Guedeney, P., Montalescot, G.** Management of chronic coronary artery disease: Are new guidelines warranted? [Prise en charge de la maladie coronaire chronique: vers de nouvelles recommandations ?]. // *Archives of Cardiovascular Diseases Supplements*, 11, 2019, p. S28-S39. ISSN 1878-6480. DOI 10.1016/S1878-6480(19)30447-1.

1363. **Gurbel, P.A., Navarese, E.P., Tantry, U.S.** The optimal antithrombotic regimen to prevent post-CABG adverse events: An ongoing controversy. // *European Heart Journal*, 40, 2019, № 29, p. 2441-2443. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz263.
1364. **Habib, A., Petrucci, G., Rocca, B.** Pathophysiology of thrombosis in peripheral artery disease. // *Current Vascular Pharmacology*, 18, 2020, № 3, p. 204-214. ISSN 1570-1611. DOI 10.2174/1570161117666190206234046.
1365. **Hahn, J.-Y., Gallus, A.** After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo. // *Annals of Internal Medicine*, 171, 2019, № 10, p. JC53. ISSN 0003-4819. DOI 10.7326/ACPJ201911190-053.
1366. **Hahn, J.-Y., Song, Y.B., Oh, J.-H., Chun, W.J., Park, Y.H., Jang, W.J., Im, E.-S., Jeong, J.-O., Cho, B.R., Oh, S.K., Yun, K.H., Cho, D.-K., Lee, J.-Y., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Lee, W.S., Yoon, H.J., Lee, S.U., Cho, J.H., Choi, W.G., Rha, S.-W., Lee, J.M., Park, T.K., Yang, J.H., Choi, J.-H., Choi, S.-H., Lee, S.H., Gwon, H.-C.** Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. // *JAMA - Journal of the American Medical Association*, 321, 2019, № 24, p. 2428-2437. ISSN 0098-7484. DOI 10.1001/jama.2019.8146.
1367. **Halbach, M., Baldus, S., Nitschmann, S.** Shortening and de-escalation of dual antiplatelet therapy [Verkürzung und Deeskalation der dualen Plättchenhemmung]. // *Internist*, 63, 2022, № 3, p. 341-345. ISSN 0020-9554. DOI 10.1007/s00108-022-01262-7.
1368. **Han, J.-K., Hwang, D., Yang, S., Park, S.-H., Kang, J., Yang, H.-M., Park, K.W., Kang, H.-J., Koo, B.-K., Hur, S.-H., Kim, W., Kim, S.Y., Park, S.-H., Han, S.H., Kim, S.-H., Shin, S., Kim, Y.H., Park, K., Lee, N., Lee, S.J., Kim, J.W., Kim, H.-S.** Comparison of 3-to 6-Month Versus 12-Month Dual Antiplatelet Therapy after Coronary Intervention Using the Contemporary Drug-Eluting Stents with Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial. // *Circulation*, 147, 2023, № 18, p. 1358-1368. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.123.064264.
1369. **Han, Y., Liao, Z., Li, Y., Zhao, X., Ma, S., Bao, D., Qiu, M., Deng, J., Wang, J., Qu, P., Jiang, C., Jia, S., Yang, S., Ru, L., Feng, J., Gao, W., Huang, Y., Tao, L., Han, Y., Yang, K., Wang, X., Zhang, W., Wang, B., Li, Y., Yang, Y., Li, J., Sheng, J., Ma, Y., Cui, M., Ma, S., Wang, X., Li, Z., Stone, G.W.** Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury. // *Journal of the American College of Cardiology*, 79, 2022, № 2, p. 116-128. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.10.028.
1370. **Han, Y., Yuan, X., Hu, X., Fang, Y., Jiang, M., Feng, H., Gao, L.** Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis. // *Cardiology Journal*, 30, 2023, № 4, p. 556-566. ISSN 1897-5593. DOI 10.5603/CJ.A2022.0071.
1371. **Han, Y., Yuan, Z., Yang, Y., Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Interventional Cardiology Working Group of Chinese Society of Cardiology, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular**

**Physicians, Specialty Committee on Coronary Artery Disease and Atherosclerosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology.** Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease [冠心病双联抗血小板治疗中国专家共识]. // *Chinese Journal of Cardiology*, 49, 2021, № 5, p. 432-454. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210125-00088.

1372. **Han, Y.-L.** De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A narrative review. // *Chinese Medical Journal*, 132, 2019, № 2, p. 197-210. ISSN 0366-6999. DOI 10.1097/CM9.000000000000047.
1373. **Ho, A.-C., Egolum, U., Parker, S., Dimmel, J., Hawkins, A., Ling, H.** P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis. // *Clinical Drug Investigation*, 40, 2020, № 9, p. 799-808. ISSN 1173-2563. DOI 10.1007/s40261-020-00947-x.
1374. **Ho, M.-Y., Chen, P.-W., Feng, W.-H., Su, C.-H., Huang, S.-W., Cheng, C.-W., Yeh, H.-I., Chen, C.-P., Huang, W.-C., Fang, C.-C., Lin, H.-W., Lin, S.-H., Hsieh, I.C., Li, Y.-H.** Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. // *PLoS ONE*, 16, 2021, art. no. e0251109. ISSN 1932-6203. DOI 10.1371/journal.pone.0251109.
1375. **Hoedemaker, N.P.G., de Winter, R.J., Hof, A., Kolkman, E., Damman, P.** Optimal Medical Therapy Prescription in Patients with Acute Coronary Syndrome in the Netherlands: A Multicenter Pilot Registry. // *American Journal of Cardiovascular Drugs*, 21, 2021, № 2, p. 219-229. ISSN 1175-3277. DOI 10.1007/s40256-020-00427-9.
1376. **Hong, S.-J., Ahn, C.-M., Kim, J.-S., Kim, B.-K., Ko, Y.-G., Choi, D., Jang, Y., Hong, M.-K.** Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: A systematic review and meta-analysis of randomized trials including 26 143 patients. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 1, p. 48-55. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa119.
1377. **Hong, S.-J., Hong, M.-K.** Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances. // *Expert Opinion on Drug Delivery*, 19, 2022, № 3, p. 269-280. ISSN 1742-5247. DOI 10.1080/17425247.2022.2044784.
1378. **Hong, S.-J., Kim, J.-S., Hong, S.J., Lim, D.-S., Lee, S.-Y., Yun, K.H., Park, J.-K., Kang, W.C., Kim, Y.H., Yoon, H.-J., Won, H., Nam, C.-M., Ahn, C.-M., Kim, B.-K., Ko, Y.-G., Choi, D., Jang, Y., Hong, M.-K., One-Month DAPT Investigators.** 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial. // *JACC: Cardiovascular Interventions*, 14, 2021, № 16, p. 1801-1811. ISSN 1936-8798. DOI 10.1016/j.jcin.2021.06.003.
1379. **Hong, S.-J., Lee, S.-J., Suh, Y., Yun, K.H., Kang, T.S., Shin, S., Kwon, S.W., Lee, J.-W., Cho, D.-K., Park, J.-K., Bae, J.-W., Kang, W.C., Kim, S., Lee, Y.-J., Ahn, C.-M., Kim, J.-S., Kim, B.-K., Ko, Y.-G., Choi, D., Jang, Y., Hong, M.-K.**



Stopping Aspirin Within 1 Month after Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial. // *Circulation*, 149, 2024, № 8, p. 562-573. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.123.066943.

1380. **Hu, M., Gao, X., Yang, J., Yang, Y.** The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent. // *Journal of Clinical Medicine*, 11, 2022, № 15, art. no. 4465. ISSN 2077-0383. DOI 10.3390/jcm11154465.
1381. **Huang, S.-W., Chen, P.-W., Feng, W.-H., Hsieh, I.-C., Ho, M.-Y., Cheng, C.-W., Yeh, H.-I., Chen, C.-P., Huang, W.-C., Fang, C.-C., Lin, H.-W., Lin, S.-H., Tsai, C.-F., Su, C.-H., Li, Y.-H.** Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 772820. ISSN 2297-055X. DOI 10.3389/fcvm.2021.772820.
1382. **Hudzik, B., Blachut, A., Lesiak, M., Kubica, J., Wojakowski, W., Gašior, M.** Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions. // *Kardiologia Polska*, 80, 2022, № 10, p. 974-989. ISSN 0022-9032. DOI 10.33963/KP.a2022.0198.
1383. **Hui, J., Bai, T., Liang, L., He, Q., Tian, N., Li, X., Yang, R., Zhu, L.** Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. // *Journal of Cardiovascular Pharmacology*, 80, 2022, № 5, p. 700-708. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001348.
1384. **Huo, Y., Jeong, Y.-H., Gong, Y., Wang, D., He, B., Chen, J., Fu, G., Chen, Y., Li, J., Li, Y., Goto, S., Tantry, U.S., Gurbel, P.A., Ahn, J.-H., Kim, H.-S., Ho Jeong, M., Han, Y., Smith, S.C., Jr., Ge, J.** 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. // *Science Bulletin*, 64, 2019, № 3, p. 166-179. ISSN 2095-9273. DOI 10.1016/j.scib.2018.12.020.
1385. **Ibanez, B., Roque, D., Price, S.** The year in cardiovascular medicine 2020: Acute coronary syndromes and intensive cardiac care. // *European Heart Journal*, 42, 2021, № 9, p. 884-895. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa1090.
1386. **Ishida, M., Takahashi, F., Goto, I., Niiyama, M., Saitoh, H., Sakamoto, T., Maegawa, Y., Osaki, T., Nishiyama, O., Endo, H., Sakamoto, R., Kojima, T., Koeda, Y., Kimura, T., Itoh, T., Morino, Y., REIWA investigators.** Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 4, p. 398-404. ISSN 1868-4300. DOI 10.1007/s12928-020-00694-y.
1387. **Iuliano, G., Citro, R.** ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: a practical guide for clinicians. // *Heart, Vessels and Transplantation*, 7, 2023, № 3. ISSN 1694-7886. DOI 10.24969/hvt.2023.393.

1388. **Jang, J.-Y., Lee, B.-K., Kim, J.-S., Shin, D.-H., Hong, S.-J., Ahn, C.-M., Kim, B.-K., Ko, Y.-G., Choi, D., Hong, M.-K., Woo Park, K., Gwon, H.-C., Kim, H.-S., Kwon, H.M., Jang, Y.** Efficacy and safety of guideline-recommended risk score-directed dual antiplatelet therapy after 2nd-generation drug-eluting stents. // *Circulation Journal*, 84, 2020, № 2, p. 161-168. ISSN 1346-9843. DOI 10.1253/circj.CJ-19-0667.
1389. **Jia, Y., Tian, Y., Tian, J.** The clinical progresses in interventional therapy of coronary heart disease. // *Zhongguo Dongmai Yinghua Zazhi*, 29, 2021, № 6, p. 461-467. ISSN 1007-3949.
1390. **Jin, Y., Huang, H., Shu, X., Chen, S., Lu, L., Gao, X., Wu, Z.** P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials. // *Thrombosis Research*, 198, 2021, p. 115-121. ISSN 0049-3848. DOI 10.1016/j.thromres.2020.11.038.
1391. **Johnson, T.W., Baos, S., Collett, L., Hutchinson, J.L., Nkai, M., Molina, M., Aungraheeta, R., Reilly-Stitt, C., Bowles, R., Reeves, B.C., Rogers, C.A., Mundell, S.J., Baumbach, A., Mumford, A.D.** Pharmacodynamic comparison of ticagrelor monotherapy versus ticagrelor and aspirin in patients after percutaneous coronary intervention: The template (ticagrelor monotherapy and platelet reactivity) randomized controlled trial. // *Journal of the American Heart Association*, 9, 2020, № 24, art. no. e016495. ISSN 2047-9980. DOI 10.1161/JAHA.120.016495.
1392. **Jones, D., Nicolas, J., Beerkens, F., Satish, M., Feldman, D., Cao, D., Spirito, A., Mehran, R.** Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 6. ISSN 1530-6550. DOI 10.31083/j.rcm2306207.
1393. **Jourdi, G., Marquis-Gravel, G., Martin, A.-C., Lordkipanidzé, M., Godier, A., Gaussem, P.** Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. // *Frontiers in Pharmacology*, 13, 2022, art. no. 878416. ISSN 1663-9812. DOI 10.3389/fphar.2022.878416.
1394. **Juriscic, S., Patriki, D., Beer, J.H.** Dual antiplatelet therapy after percutaneous coronary intervention over time: one size does not fit all. // *Cardiovascular Medicine*, 24, 2021, № 5, p. 155-162. ISSN 1664-2031. DOI 10.4414/cvm.2021.02175.
1395. **Kanenawa, K., Yamaji, K., Tashiro, H., Domei, T., Ando, K., Watanabe, H., Kimura, T.** Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Corner Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial. // *Circulation: Cardiovascular Interventions*, 14, 2021, № 2, p. E010007. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.120.010007.
1396. **Kang, S.J., Tae, C.H., Bang, C.S., Shin, C.M., Jeong, Y.-H., Choi, M., Hwang, J.H., Saito, Y., Chiu, P.W.Y., Rerknimitr, R., Khor, C., Khien, V.V., Choi, K.D., Shim, K.-N., Song, G.A., Lee, O.Y., The Korean Society of Gastrointestinal Endoscopy Task Force on Clinical Practice Guidelines.** International Digestive Endoscopy Network consensus on the management of antithrombotic agents in patients undergoing gastrointestinal endoscopy. // *Clinical Endoscopy*, 57, 2024, № 2, p. 141-157. ISSN 2234-2400. DOI 10.5946/ce.2024.002.

1397. **Kaul, P., Kandzari, D.E.** Intracoronary imaging and stent implantation technique: Have we lost focus? // *Circulation: Cardiovascular Interventions*, 11, 2018, № 12, art. no. e007453. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.118.007453.
1398. **Kearney, A., Linden, K., Savage, P., Menown, I.B.A.** Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. // *Advances in Therapy*, 38, 2021, № 5, p. 2170-2200. ISSN 0741-238X. DOI 10.1007/s12325-021-01711-z.
1399. **Khakimova, M.B., Komarov, A.L., Dobrovolskiy, A.B., Panchenko, E.P.** Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future. // *Russian Cardiology Bulletin*, 17, 2022, № 4, p. 5-15. ISSN 2077-6764. DOI 10.17116/Cardiobulletin2022170415.
1400. **Khan, M.S., Moustafa, A., Azhar, A.Z., Khan, A.R., Ikram, S.** Aspirin-free strategy versus standard term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. // *European Journal of Preventive Cardiology*, 28, 2021, № 12, p. E25-E28. ISSN 2047-4873. DOI 10.1177/2047487320925623.
1401. **Khan, M.S., Usman, M.S., Van Spall, H.G.C., Greene, S.J., Baqal, O., Felker, G.M., Bhatt, D.L., Januzzi, J.L., Butler, J.** Endpoint adjudication in cardiovascular clinical trials. // *European Heart Journal*, 44, 2023, № 46, p. 4835-4846. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad718.
1402. **Khan, S.U., Khan, M.Z., Khan, M.S., Mahmood, A., Kalra, A., Kaluski, E., Michos, E.D., Alkhouli, M.** De-escalation of antiplatelets after percutaneous coronary intervention: A Bayesian network meta-analysis of various de-escalation strategies. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 209-215. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa025.
1403. **Khan, S.U., Osman, M., Khan, M.U., Khan, M.S., Zhao, D., Mamas, M.A., Savji, N., Al-Abdoun, A., Hasan, R.K., Michos, E.D.** Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention a systematic review and meta-analysis. // *Annals of Internal Medicine*, 172, 2020, № 7, p. 474-483. ISSN 0003-4819. DOI 10.7326/M19-3763.
1404. **Khan, S.U., Singh, M., Valavoor, S., Khan, M.U., Lone, A.N., Khan, M.Z., Khan, M.S., Mani, P., Kapadia, S.R., Michos, E.D., Stone, G.W., Kalra, A., Bhatt, D.L.** Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. // *Circulation*, 142, 2020, № 15, p. 1425-1436. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.046308.
1405. **Kheiri, B., Simpson, T.F., Osman, M., Golwala, H., Radaideh, Q., Kumar, K., Rahmouni, H., Divanji, P., Cigarroa, J.E., Zahr, F.** Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. // *Journal of Thrombosis and Thrombolysis*, 50, 2020, № 4, p. 867-873. ISSN 0929-5305. DOI 10.1007/s11239-020-02069-9.
1406. **Kim, B.G., Hong, S.-J., Kim, B.-K., Lee, S.-J., Ahn, C.-M., Shin, D.-H., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular

Events: A Post Hoc Analysis of the TICO Randomized Trial. // *Journal of the American Heart Association*, 10, 2021, № 24, art. no. e022700. ISSN 2047-9980. DOI 10.1161/JAHA.121.022700.

1407. **Kim, B.-K., Hong, S.-J., Cho, Y.-H., Yun, K.H., Kim, Y.H., Suh, Y., Cho, J.Y., Her, A.-Y., Cho, S., Jeon, D.W., Yoo, S.-Y., Cho, D.-K., Hong, B.-K., Kwon, H., Ahn, C.-M., Shin, D.-H., Nam, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Effect of Ticagrelor Monotherapy vs Ticagrelor with Aspirin on Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndrome: The TICO Randomized Clinical Trial. // *JAMA - Journal of the American Medical Association*, 323, 2020, № 23, p. 2407-2416. ISSN 0098-7484. DOI 10.1001/jama.2020.7580.
1408. **Kim, C., Hong, S.-J., Shin, D.-H., Kim, B.-K., Ahn, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. // *American Heart Journal*, 212, 2019, p. 45-52. ISSN 0002-8703. DOI 10.1016/j.ahj.2019.02.015.
1409. **Kim, C.J., Park, M.-W., Kim, M.C., Choo, E.-H., Hwang, B.-H., Lee, K.Y., Choi, Y.S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Shin, E.-S., Jeong, Y.-H., Seung, K.-B., Jeong, M.H., Yim, H.W., Ahn, Y., Chang, K., Jeong, Y.-H., Jeon, M.H., Oh, J.-H., Ha, S.J., Baek, J.Y., Jung, K.T., Doh, J.-H., Kim, W., Kim, D.-B., Cha, K.S., Yoon, M.-H., Hur, S.-H., Lee, S.-H., Cho, B.-R., Park, J.-S., Koh, J.S., Kim, S.-H., Cho, J.H., Shim, B.J., Kim, S.W., Jang, J.-S., Kim, K.-S., Shin, W.-Y., Sung, K.-C., TALOS-AMI investigators.** Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. // *The Lancet*, 398, 2021, № 10308, p. 1305-1316. ISSN 0140-6736. DOI 10.1016/S0140-6736(21)01445-8.
1410. **Kim, J., Jang, W.J., Lee, W.S., Choi, K.H., Lee, J.M., Park, T.K., Yang, J.H., Choi, J.-H., Song, Y.B., Choi, S.-H., Gwon, H.-C., Lee, S.H., Oh, J.-H., Chun, W.J., Park, Y.H., Im, E.-S., Jeong, J.-O., Cho, B.R., Oh, S.K., Yun, K.H., Cho, D.-K., Lee, J.-Y., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Yoon, H.J., Lee, S.U., Cho, J.H., Choi, W.G., Rha, S.-W., Hahn, J.-Y.** P2Y<sub>12</sub> inhibitor monotherapy after coronary stenting according to type of P2Y<sub>12</sub> inhibitor. // *Heart*, 107, 2021, № 13, p. 1077-1083. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-318821.
1411. **Kim, M.C., Ahn, S.G., Cho, K.H., Sim, D.S., Hong, Y.J., Kim, J.H., Jeong, M.H., Lee, J.-W., Youn, Y.-J., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Shin, E.-S., Jeong, Y.-H., Chang, K., Ahn, Y.** De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. // *EuroIntervention*, 19, 2023, № 10, p. E832-E843. ISSN 1774-024X. DOI 10.4244/EIJ-D-23-00427.
1412. **Kinlay, S., Young, M.M., Sherrod, R., Gagnon, D.R.** Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study. // *Journal of the American Heart Association*, 12, 2023, № 2, art. no. e027055. ISSN 2047-9980. DOI 10.1161/JAHA.122.027055.

1413. **Kleiman, N.S.** Is This a Good Time to Revisit the Tropics?: Platelet Function Testing in Patients With Acute Coronary Syndromes. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 428-430. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.041.
1414. **Knijnik, L., Fernandes, M., Rivera, M., Cardoso, R., Goyal, A., Liberman, H., Sperling, L.S., McDaniel, M.C.** Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting. // *American Journal of Cardiology*, 151, 2021, p. 25-29. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.04.014.
1415. **Koh, L., Heon, K.J., Yin, D.T.S., Qi, L.W., Imran, S.S., Leng, L.K., Loong, E.W.W.** Switching from ticagrelor to clopidogrel in asian patients with ST-elevated myocardial infarction – A time dependent analysis study. // *Acta Cardiologica Sinica*, 36, 2020, № 1, p. 8-15. ISSN 1011-6842. DOI 10.6515/ACS.202001\_36(1).20190627A.
1416. **Kohsaka, S., Ejiri, K., Takagi, H., Watanabe, I., Gatate, Y., Fukushima, K., Nakano, S., Hirai, T.** Diagnostic and Therapeutic Strategies for Stable Coronary Artery Disease Following the ISCHEMIA Trial. // *JACC: Asia*, 3, 2023, № 1, p. 15-30. ISSN 2772-3747. DOI 10.1016/j.jacasi.2022.10.013.
1417. **Kovacevic, M., Pompei, G., Kunadian, V.** Tailoring antiplatelet therapy in older patients with coronary artery disease. // *Platelets*, 34, 2023, № 1, art. no. 2285446. ISSN 0953-7104. DOI 10.1080/09537104.2023.2285446.
1418. **Kozuma, K., Kinoshita, Y., Hioki, H., Nanasato, M., Ito, Y., Yamaguchi, J., Shiode, N., Hibi, K., Tanabe, K., Ako, J., Morino, Y., Hirohata, A., Sonoda, S., Nakagawa, Y., Ikari, Y.** 1-year safety of 3-month dual antiplatelet therapy followed by aspirin or P2Y12 receptor inhibitor monotherapy using a bioabsorbable polymer sirolimus-eluting stent. // *Circulation Journal*, 85, 2021, № 1, p. 19-26. ISSN 1346-9843. DOI 10.1253/circj.CJ-20-0644.
1419. **Krittanawong, C., Virk, H.U.H., Isath, A., Wang, Z., Naidu, S.S., Mehran, R., Birnbaum, Y., Levine, G.N., Jneid, H.** Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 174, 2022, p. 182-184. ISSN 0002-9149. DOI 10.1016/j.amjcard.2022.03.045.
1420. **Kumar, A., Shariff, M., Doshi, R., Vaz, I.P.** Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months' Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials. // *American Journal of Cardiovascular Drugs*, 20, 2020, № 4, p. 355-361. ISSN 1175-3277. DOI 10.1007/s40256-019-00390-0.
1421. **Kuno, T., Ueyama, H., Takagi, H., Bangalore, S.** P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials. // *American Heart Journal*, 227, 2020, p. 82-90. ISSN 0002-8703. DOI 10.1016/j.ahj.2020.06.008.
1422. **Kuno, T., Ueyama, H., Takagi, H., Fox, J., Bangalore, S.** Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients



With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials. // *Cardiovascular Revascularization Medicine*, 28, 2021, p. 50-56. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.07.039.

1423. **Kwon, O., Park, D.-W.** Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. // *JACC: Asia*, 2, 2022, № 1, p. 1-18. ISSN 2772-3747. DOI 10.1016/j.jacasi.2021.12.005.
1424. **Laborante, R., Borovac, J.A., Galli, M., Rodolico, D., Ciliberti, G., Restivo, A., Cappannoli, L., Arcudi, A., Vergallo, R., Zito, A., Princi, G., Leone, A.M., Aurigemma, C., Romagnoli, E., Montone, R.A., Burzotta, F., Trani, C., D'Amario, D.** Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome? // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 1009475. ISSN 2297-055X. DOI 10.3389/fcvm.2022.1009475.
1425. **Lahu, S., Bristot, P., Gewalt, S., Goedel, A., Giacoppo, D., Schüpke, S., Schunkert, H., Kastrati, A., Sarafoff, N.** Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y12 Inhibitor Thereafter. // *Journal of Atherosclerosis and Thrombosis*, 29, 2022, № 7, p. 1001-1019. ISSN 1340-3478. DOI 10.5551/jat.63000.
1426. **Larsen, M.L., Grove, E.L., Kristensen, S.D., Hvas, A.-M.** Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery Disease. // *Seminars in Thrombosis and Hemostasis*, 46, 2020, № 4, p. 446-456. ISSN 0094-6176. DOI 10.1055/s-0039-3399567.
1427. **Lattuca, B., Cayla, G.** Which strategy should be the global leader in antithrombotic therapy decision making in older patients? // *EuroIntervention*, 15, 2020, № 18, p. E1560-E1563. ISSN 1774-024X. DOI 10.4244/EIJV15I18A285.
1428. **Lawton, J.S., Tamis-Holland, J.E., Bangalore, S., Bates, E.R., Beckie, T.M., Bischoff, J.M., Bittl, J.A., Cohen, M.G., Dimaio, J.M., Don, C.W., Fremes, S.E., Gaudino, M.F., Goldberger, Z.D., Grant, M.C., Jaswal, J.B., Kurlansky, P.A., Mehran, R., Metkus, T.S., Nnacheta, L.C., Rao, S.V., Sellke, F.W., Sharma, G., Yong, C.M., Zwischenberger, B.A.** 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. // *Circulation*, 145, 2022, № 3, p. E18-E114. ISSN 0009-7322. DOI 10.1161/CIR.0000000000001038.
1429. **Lawton, J.S., Tamis-Holland, J.E., Bangalore, S., Bates, E.R., Beckie, T.M., Bischoff, J.M., Bittl, J.A., Cohen, M.G., DiMaio, J.M., Don, C.W., Fremes, S.E., Gaudino, M.F., Goldberger, Z.D., Grant, M.C., Jaswal, J.B., Kurlansky, P.A., Mehran, R., Metkus, T.S., Jr., Nnacheta, L.C., Rao, S.V., Sellke, F.W., Sharma, G., Yong, C.M., Zwischenberger, B.A., Writing Committee Members.** 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. // *Journal of the American College of Cardiology*, 79, 2022, № 2, p. e21-e129. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.09.006.
1430. **Le Bras, A.** Ticagrelor not superior to DAPT after PCI. // *Nature Reviews Cardiology*, 15, 2018, № 11, p. 655. ISSN 1759-5002. DOI 10.1038/s41569-018-0099-4.

1431. **Lee, B., Lee, S.-J., Kim, B.-K., Lee, Y.-J., Hong, S.-J., Ahn, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Sex Differences in Outcomes of Ticagrelor Therapy with or Without Aspirin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 43, 2023, № 6, p. E218-E226. ISSN 1079-5642. DOI 10.1161/ATVBAHA.122.318725.
1432. **Lee, C.H., Angiolillo, D.J.** Platelet physiology and pharmacology-relevant considerations for patient care. – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 15-45. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00005-7.
1433. **Lee, M., Byun, S., Lim, S., Choo, E.H., Lee, K.Y., Moon, D., Choi, I.J., Hwang, B.-H., Kim, C.J., Park, M.-W., Choi, Y.S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Yim, H.W., Chang, K., the TALOS-AMI Investigators.** Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial. // *JAMA Cardiology*, 9, 2024, № 2, p. 125-133. ISSN 2380-6583. DOI 10.1001/jamacardio.2023.4587.
1434. **Lee, S.H., Lee, S.Y., Chun, W.J., Song, Y.B., Choi, S.-H., Jeong, J.-O., Oh, S.K., Yun, K.H., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Gwon, H.-C., Hahn, J.-Y.** Clopidogrel monotherapy in patients with and without ontreatment high platelet reactivity: A SMART-CHOICE substudy. // *EuroIntervention*, 17, 2021, № 11, p. E888-E897. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00223.
1435. **Lee, S.-J., Cho, J.Y., Kim, B.-K., Yun, K.H., Suh, Y., Cho, Y.-H., Kim, Y.H., Her, A.-Y., Cho, S., Jeon, D.W., Yoo, S.-Y., Cho, D.-K., Hong, B.-K., Kwon, H.M., Hong, S.-J., Ahn, C.-M., Shin, D.-H., Nam, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y., TICO Investigators.** Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 431-440. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.11.036.
1436. **Lee, S.-J., Lee, Y.-J., Kim, B.-K., Hong, S.-J., Ahn, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y.** Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events. // *Circulation: Cardiovascular Interventions*, 14, 2021, № 8, p. E010812. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.121.010812.
1437. **Lee, S.-Y., Jeong, Y.-H., Yun, K.H., Cho, J.Y., Gorog, D.A., Angiolillo, D.J., Kim, J.W., Jang, Y.** P2Y<sub>12</sub> Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study. // *JACC: Cardiovascular Interventions*, 16, 2023, № 15, p. 1845-1855. ISSN 1936-8798. DOI 10.1016/j.jcin.2023.05.035.
1438. **Lee, Y.-J., Cho, J.Y., Yun, K.H., Lee, S.-J., Hong, S.-J., Ahn, C.-M., Kim, B.-K., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y., Kim, J.-S.** Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. // *EuroIntervention*, 18, 2022, № 6, p. 471-481. ISSN 1774-024X. DOI 10.4244/EIJ-D-22-00135.

1439. **Leedy, D., Tiwana, J.K., Mamas, M., Hira, R., Cheng, R.** Coronary revascularisation outcomes in patients with cancer. // *Heart*, 108, 2022, № 7, p. 507-516. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-318531.
1440. **Li, J., He, K., Ge, J., Li, C., Jing, Z.** Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. // *International Journal of Clinical Practice*, 75, 2021, № 7, art. no. e13938. ISSN 1368-5031. DOI 10.1111/ijcp.13938.
1441. **Li, J., Sheng, Z., Tan, Y., Liu, C., Zhou, P., Zhou, J., Chen, R., Chen, Y., Song, L., Zhao, H., Yan, H.** Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. // *Platelets*, 31, 2020, № 6, p. 788-794. ISSN 0953-7104. DOI 10.1080/09537104.2019.1680825.
1442. **Li, J., Wang, Q., Wu, C., Qu, X., Zhang, L., He, X., Ma, S., Qiu, M., Wang, X.** Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. // *Cardiology (Switzerland)*, 148, 2023, № 4, p. 363-373. ISSN 0008-6312. DOI 10.1159/000530602.
1443. **Li, Y., Jing, Q., Wang, B., Wang, X., Li, J., Qiao, S., Chen, S., Angiolillo, D.J., Han, Y.** Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. // *American Heart Journal*, 228, 2020, p. 1-7. ISSN 0002-8703. DOI 10.1016/j.ahj.2020.07.005.
1444. **Liang, X.-Y., Li, Y., Qiao, X., Zhang, W.-J., Wang, Z.-L.** Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 655718. ISSN 2297-055X. DOI 10.3389/fcvm.2021.655718.
1445. **Lin, L., Xuefeng, D., Xiangzhen, F., Kui, L., Li, C.** Efficacy and safety of antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis [经皮冠脉药物洗脱支架术后抗血小板治疗策略疗效和安全性的网状 Meta 分析]. // *Chinese Journal of Evidence-Based Medicine*, 20, 2020, № 12, p. 1403-1412. ISSN 1672-2531. DOI 10.7507/1672-2531.202004141.
1446. **Lin, M., Su, Z., Huang, J., Li, J., Luo, N., Wang, J.** Eosinophilic granulomatosis with polyangiitis presenting with repetitive acute coronary syndrome, refractory coronary vasospasm, and spontaneous coronary dissection: a case report. // *Journal of International Medical Research*, 50, 2022, № 3. ISSN 0300-0605. DOI 10.1177/03000605221089516.
1447. **Linden, K., McQuillan, C., Brennan, P., Menown, I.B.A.** Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. // *Advances in Therapy*, 36, 2019, № 7, p. 1549-1573. ISSN 0741-238X. DOI 10.1007/s12325-019-00962-1.

1448. **Liuzzo, G., Patrono, C.** Aspirin-free antiplatelet strategies: Is the evidence supporting a paradigm shift? // *European Heart Journal*, 42, 2021, № 39, p. 4011-4012. ISSN 0195-668X. DOI 10.1093/eurheartj/ehab573.
1449. **Loganath, K., Adamson, P.D., Moss, A.J.** Ticagrelor in the management of coronary artery disease. // *Future Cardiology*, 17, 2021, № 4, p. 561-571. ISSN 1479-6678. DOI 10.2217/fca-2020-0108.
1450. **Lozano, Í., Vegas, J.M.** Onyx ONE trial: A new option in patients at high risk of bleeding. // *REC: Interventional Cardiology*, 2, 2020, № 1, p. 55-58. ISSN 2604-7306. DOI 10.24875/RECICE.M19000080.
1451. **Lugo, L.M., Ferreiro, J.L.** Ticagrelor in patients with myocardial infarction: Is the treatment strategy crystal clear? // *European Heart Journal - Cardiovascular Pharmacotherapy*, 5, 2019, № 4, p. 207-209. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz023.
1452. **Luo, L., Fu, M., Li, Y., Chen, Z., Yu, J., Luo, J., Hu, S., Tu, L., Xu, X.** The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. // *Clinical Cardiology*, 43, 2020, № 3, p. 235-241. ISSN 0160-9289. DOI 10.1002/clc.23305.
1453. **Lüscher, T.F.** Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting. // *European Heart Journal*, 40, 2019, № 31, p. 2549-2552. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz590.
1454. **Mackman, N., Bergmeier, W., Stouffer, G.A., Weitz, J.I.** Therapeutic strategies for thrombosis: new targets and approaches. // *Nature Reviews Drug Discovery*, 19, 2020, № 5, p. 333-352. ISSN 1474-1776. DOI 10.1038/s41573-020-0061-0.
1455. **Magrum, B.G., Pickworth, K.K.** Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. // *American Journal of Health-System Pharmacy*, 77, 2020, № 2, p. 123-127. ISSN 1079-2082. DOI 10.1093/ajhp/zxz276.
1456. **Mahajan, K., Batra, A.** Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era. // *Indian Heart Journal*, 72, 2020, № 3, p. 209-211. ISSN 0019-4832. DOI 10.1016/j.ihj.2020.05.009.
1457. **Malik, A.H., Yandrapalli, S., Shetty, S.S., Aronow, W.S., Cooper, H.A., Panza, J.A.** Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 127, 2020, p. 25-29. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.04.027.
1458. **Mansournia, M.A., Nazemipour, M., Etminan, M.** P-value, compatibility, and S-value. // *Global Epidemiology*, 4, 2022, art. no. 100085. ISSN 2590-1133. DOI 10.1016/j.gloepi.2022.100085.
1459. **Maqsood, M.H., Levine, G.N., Kleiman, N.D., Hasdai, D., Uretsky, B.F., Birnbaum, Y.** Do We Still Need Aspirin in Coronary Artery Disease? // *Journal of Clinical Medicine*, 12, 2023, № 24, art. no. 7534. ISSN 2077-0383. DOI 10.3390/jcm12247534.

1460. **Marquis-Gravel, G., Robert-Halabi, M., Bainey, K.R., Tanguay, J.-F., Mehta, S.R.** The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. // *Canadian Journal of Cardiology*, 38, 2022, № 10, p. S79-S88. ISSN 0828-282X. DOI 10.1016/j.cjca.2022.02.022.
1461. **Marquis-Gravel, G., Stebbins, A., Wruck, L.M., Roe, M.T., Effron, M.B., Hammill, B.G., Whittle, J., Vanwormer, J.J., Robertson, H.R., Alikhaani, J.D., Kripalani, S., Farrehi, P.M., Girotra, S., Benziger, C.P., Polonsky, T.S., Merritt, J.G., Gupta, K., McCormick, T.E., III, Knowlton, K.U., Jain, S.K., Kochar, A., Rothman, R.L., Harrington, R.A., Hernandez, A.F., Jones, W.S.** Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. // *Journal of the American Heart Association*, 13, 2024, № 4, art. no. e026921. ISSN 2047-9980. DOI 10.1161/JAHA.122.026921.
1462. **Martí, D., Sanmartín, M.** Dyspnoea in the GLOBAL LEADERS trial. // *The Lancet*, 393, 2019, № 10189, p. 2393. ISSN 0140-6736. DOI 10.1016/S0140-6736(19)30697-X.
1463. **Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R.A., Antunes, M.J., Christodorescu, R.M., Crawford, C., Di Angelantonio, E., Eliasson, B., Espinola-Klein, C., Fauchier, L., Halle, M., Herrington, W.G., Kautzky-Willer, A., Lambrinou, E., Lesiak, M., Lettino, M., McGuire, D.K., Mullens, W., Rocca, B., Sattar, N., ESC Scientific Document Group.** Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici: Elaborate dalla task force per il trattamento delle malattie cardiovascolari nei pazienti diabetici della Società Europea di Cardiologia (ESC). // *Giornale Italiano di Cardiologia*, 25, 2024, № 1, p. E1-E103. ISSN 1827-6806. DOI 10.1714/4162.41558.
1464. **Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R.A., Antunes, M.J., Christodorescu, R.M., Crawford, C., Di Angelantonio, E., Eliasson, B., Espinola-Klein, C., Fauchier, L., Halle, M., Herrington, W.G., Kautzky-Willer, A., Lambrinou, E., Lesiak, M., Lettino, M., McGuire, D.K., Mullens, W., Rocca, B., Sattar, N.** 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. // *European Heart Journal*, 44, 2023, № 39, p. 4043-4140. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad192.
1465. **Matthias, N.P., Jürg, B.H.** Very low-dose direct oral anticoagulants combined with platelet inhibitors in coronary artery disease: ready for widespread use? // *Cardiovascular Medicine*, 22, 2019, № 5, art. no. w02062. ISSN 1664-2031. DOI 10.4414/cvm.2019.02062.
1466. **McClure, J.D., Ramsay, J.C., Berry, C.** Pooled analysis of bleeding, major adverse cardiovascular events, and all-cause mortality in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention. // *Journal of the American Heart Association*, 9, 2020, № 16, art. no. e017109. ISSN 2047-9980. DOI 10.1161/JAHA.120.017109.
1467. **Mehran, R., Cao, D., Baber, U.** Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? // *Journal of the American College of Cardiology*, 74, 2019, № 18, p. 2235-2237. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.08.1037.



1468. **Meyer, B.M., Campos, J.K., Collard de Beaufort, J.C., Chen, I., Khan, M.W., Amin, G., Zarrin, D.A., Lien, B.V., Coon, A.L.** Trends in Dual Antiplatelet Therapy Use for Neurointerventional Procedures for the Management of Intracranial Aneurysms. // *Biomedicines*, 11, 2023, № 8, art. no. 2234. ISSN 2227-9059. DOI 10.3390/biomedicines11082234.
1469. **Min, P.-K., Kang, T.S., Cho, Y.-H., Cheong, S.-S., Kim, B.-K., Kwon, S.W., Park, W.J., Lee, J.-H., Kim, W., Lee, W.-S., Yoon, Y.W., Lee, B.K., Kwon, H.M., Hong, B.-K.** P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy after Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial. // *JAMA Network Open*, 7, 2024, № 3, p. E240877. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2024.0877.
1470. **Mohamed, M.M.G., Shaikh, S., Osman, M., Kheiri, B.** Meta-Analysis of One-Month Dual Antiplatelet Therapy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 166, 2022, p. 138-140. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.11.035.
1471. **Montalescot, G.** A farewell to aspirin in primary prevention? // *Nature Reviews Cardiology*, 16, 2019, № 2, p. 76-77. ISSN 1759-5002. DOI 10.1038/s41569-018-0148-z.
1472. **Montarello, N.J., Nelson, A.J., Verjans, J., Nicholls, S.J., Psaltis, P.J.** The role of intracoronary imaging in translational research. // *Cardiovascular Diagnosis and Therapy*, 10, 2020, № 5, p. 1480-1507. ISSN 2223-3652. DOI 10.21037/cdt-20-1.
1473. **Mori, M., Sakamoto, A., Sato, Y., Kawakami, R., Kawai, K., Cornelissen, A., Abebe, B., Ghosh, S., Romero, M.E., Kolodgie, F.D., Virmani, R., Finn, A.V.** Overcoming challenges in refining the current generation of coronary stents. // *Expert Review of Cardiovascular Therapy*, 19, 2021, № 11, p. 1013-1028. ISSN 1477-9072. DOI 10.1080/14779072.2021.2013810.
1474. **Moss, A.J., Dweck, M.R., Doris, M.K., Andrews, J.P.M., Bing, R., Forsythe, R.O., Carlidge, T.R., Pawade, T.A., Daghem, M., Raftis, J.B., Williams, M.C., van Beek, E.J.R., Forsyth, L., Lewis, S.C., Lee, R.J., Shah, A.S.V., Mills, N.L., Newby, D.E., Adamson, P.D.** Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque. // *JACC: Cardiovascular Imaging*, 13, 2020, № 7, p. 1549-1560. ISSN 1936-878X. DOI 10.1016/j.jcmg.2019.05.023.
1475. **Mourikis, P., Polzin, A.** Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short? // *Journal of the American Heart Association*, 12, 2023, № 2, art. no. e028775. ISSN 2047-9980. DOI 10.1161/JAHA.122.028775.
1476. **M'Pembele, R., Ahlbrecht, S., Helten, C., Mourikis, P., Naguib, D., Zako, S., Trojovský, K., Huhn, R., Petzold, T., Hohlfeld, T., Zeus, T., Kelm, M., Dannenberg, L., Polzin, A.** High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel. // *Pharmacology*, 108, 2023, № 1, p. 83-89. ISSN 0031-7012. DOI 10.1159/000527816.
1477. **Muramatsu, T., Kozuma, K., Tanabe, K., Morino, Y., Ako, J., Nakamura, S., Yamaji, K., Kohsaka, S., Amano, T., Kobayashi, Y., Ikari, Y., Kadota, K., Nakamura, M., The Task Force of the Japanese Association of Cardiovascular Intervention, Therapeutics (CVIT).** Clinical expert consensus document on drug-coated

balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. // *Cardiovascular Intervention and Therapeutics*, 38, 2023, № 2, p. 166-176. ISSN 1868-4300. DOI 10.1007/s12928-023-00921-2.

1478. **Murphy, T., Jones, D.A., Friebe, R., Uchegbu, I., Mohiddin, S.A., Petersen, S.E.** A Cost Analysis of Cardiac Magnetic Resonance Imaging in the Diagnostic Pathway of Patients Presenting With Unexplained Acute Myocardial Injury and Culprit-Free Coronary Angiography. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 749668. ISSN 2297-055X. DOI 10.3389/fcvm.2021.749668.
1479. **Naganawa, H., Ito, A., Saiki, S., Nishi, D., Takamatsu, S., Ito, Y., Suzuki, T.** The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome. // *Cardiology Research and Practice*, 2023, art. no. 4594818. ISSN 2090-8016. DOI 10.1155/2023/4594818.
1480. **Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., Yasuda, S., Akasaka, T., Kohsaka, S., Haze, K., Hirayama, A.** JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. // *Circulation Journal*, 84, 2020, № 5, p. 831-865. ISSN 1346-9843. DOI 10.1253/circj.CJ-19-1109.
1481. **Nakamura, M., Kitazono, T., Kozuma, K., Sekine, T., Nakamura, S., Shiosakai, K., Tanabe, A., Iizuka, T.** Prasugrel for Japanese patients with ischemic heart disease in long-term clinical practice (PRASFIT-Practice II) - Final 2-year follow-up results of a postmarketing observational study. // *Circulation Journal*, 84, 2020, № 11, p. 1981-1989. ISSN 1346-9843. DOI 10.1253/circj.CJ-20-0253.
1482. **Natale, P., Palmer, S.C., Saglimbene, V.M., Ruospo, M., Razavian, M., Craig, J.C., Jardine, M.J., Webster, A.C., Strippoli, G.F.M.** Antiplatelet agents for chronic kidney disease. // *Cochrane Database of Systematic Reviews*, 2022, № 2, art. no. CD008834. ISSN 1465-1858. DOI 10.1002/14651858.CD008834.pub4.
1483. **Natsuaki, M., Kimura, T.** Antiplatelet Therapy after Percutaneous Coronary Intervention - Past, Current and Future Perspectives. // *Circulation Journal*, 86, 2022, № 5, p. 741-747. ISSN 1346-9843. DOI 10.1253/circj.CJ-21-0751.
1484. **Natsuaki, M., Morimoto, T., Shiomi, H., Kadota, K., Tada, T., Takeji, Y., Matsumura-Nakano, Y., Yoshikawa, Y., Watanabe, H., Yamamoto, K., Imada, K., Domei, T., Yamaji, K., Kaneda, K., Taniguchi, R., Ehara, N., Nawada, R., Toyofuku, M., Shinoda, E., Suwa, S., Tamura, T., Inada, T., Matsuda, M., Aoyama, T., Sato, Y., Furukawa, Y., Ando, K., Nakagawa, Y., Kimura, T., for the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators.** Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk after Percutaneous Coronary Intervention. // *Circulation Journal*, 85, 2021, № 11, p. 1928-1941. ISSN 1346-9843. DOI 10.1253/circj.CJ-21-0016.
1485. **Natsuaki, M., Morimoto, T., Watanabe, H., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Hanaoka, K.I., Morino, Y., Kozuma, K., Kadota, K., Kimura, T.** Clopidogrel Monotherapy vs. Aspirin Monotherapy following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation. // *Circulation Journal*, 84, 2020, № 9, p. 1483-1492. ISSN 1346-9843. DOI 10.1253/circj.CJ-20-0298.

1486. Natsuaki, M., Morimoto, T., Yamamoto, E., Watanabe, H., Furukawa, Y., Abe, M., Nakao, K., Ishikawa, T., Kawai, K., Yunoki, K., Shimizu, S., Akao, M., Miki, S., Yamamoto, M., Okada, H., Hoshino, K., Kadota, K., Morino, Y., Hanaoka, K.I., Tanabe, K., Kozuma, K., Kimura, T., Nakao, K., Miyamoto, S., Kimura, T., Natsuaki, M., Yamamoto, E., Ishikawa, T., Tsutsumi, J., Kawai, K., Seki, S., Yunoki, K., Itoh, A., Shimizu, S., Akao, M., Ishii, M., Miki, S., Mizoguchi, T., Kato, M., Yamamoto, M., Okada, H., Hoshino, K., Hirokami, M., Suwa, S., Muramatsu, T., Kobayashi, N., Tarutani, Y., Inada, T., Hayashi, F., Morino, Y., Ishikawa, Y., Ito, M., Tanigawa, T., Sawai, T., Kadota, K., Tanaka, H., Ike-Guchi, S., Okada, M., Inuzuka, Y., Serikawa, T., Kozai, T., Natsuaki, M., Tanabe, K., Hashimoto, T., Urasawa, K., Koshida, R., Yamashita, T., Maeno, T., Kimura, K., Hibi, K., Fujita, H., Isodono, K., Kitaguchi, S., Morikami, Y., Kobayashi, M., Sato, T., Kinoshita, M., Igarashi, K., Furuya, J., Nakagawa, Y., Tamura, T., Kishi, K., Tobaru, T., Takamisawa, I., Takatsu, Y., Taniguchi, R., Seino, Y., Shimizu, Y., Ando, K., Yamaji, K., Kinoshita, N., Yajima, J., Murata, N., Sugano, T., Ogawa, H., Kiyokuni, M., Tamura, T., Takahashi, K., Sonoda, S., Kashiya, K., Kyono, H., Takebayashi, H., Kikuta, Y., Yasuda, S., Sakamoto, H., Asaumi, Y., Yoshiyama, M., Hasegawa, T., Iguchi, T., Akasaka, T., Yamaguchi, T., Miyauchi, K., Okazaki, S., Shiota, K., Kataoka, T., Sakamoto, Y., Miyazaki, S., Yasuda, M., Kato, A., Saji, K., Suzuki, T., Kinoshita, Y., Amano, T., Takashima, H., Watanabe, K., Shigemi, S., Nishikawa, H., Suzuki, H., Yamaguchi, J., Kamishima, K., Ako, J., Katayama, T., Hiroshi, W., Hiraoka, H., Yasuga, Y., STOPDAPT trial investigators. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. // *PLoS ONE*, 15, 2020, № 3, art. no. e0227612. ISSN 1932-6203. DOI 10.1371/journal.pone.0227612.
1487. Natsuaki, M., Node, K. Is it time to shift the monotherapy after percutaneous coronary intervention from aspirin to P2Y12 inhibitors? - New normal in the new-generation era. // *Circulation Journal*, 85, 2021, № 6, p. 794-796. ISSN 1346-9843. DOI 10.1253/circj.CJ-21-0026.
1488. Nicolas, J., Baber, U., Mehran, R. Twilight: A randomized trial of ticagrelor monotherapy versus ticagrelor plus aspirin beginning at 3 months in High-risk patients undergoing percutaneous coronary intervention. // *US Cardiology Review*, 14, 2020, № 1, art. no. e03. ISSN 1758-3896. DOI 10.15420/usc.2019.02.
1489. Nicolas, J., Dangas, G., Chiarito, M., Pivato, C.A., Spirito, A., Cao, D., Giustino, G., Beerkens, F., Camaj, A., Vogel, B., Sartori, S., Yamamoto, K., Kimura, T., Kim, B.-K., Baber, U., Mehran, R. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 9, 2023, № 3, p. 240-250. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvac071.
1490. Nicolas, J., Goel, R., Claessen, B., Mehran, R. Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade-why it could be a novel paradigm? – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 167-191. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00008-2.
1491. Nicolas, J., Razuk, V., Giustino, G., Mehran, R. Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. //

1492. **Novikova, T.N.** Ticagrelor in patients with stable coronary artery disease: A role in improving prognosis. // *Russian Journal of Cardiology*, 25, 2020, # s3, art. no. 4094, p. 50-54. ISSN 1560-4071. DOI 10.15829/1560-4071-2020-4094.
1493. **Obayashi, Y., Watanabe, H., Morimoto, T., Yamamoto, K., Natsuaki, M., Domei, T., Yamaji, K., Suwa, S., Isawa, T., Watanabe, H., Yoshida, R., Sakamoto, H., Akao, M., Hata, Y., Morishima, I., Tokuyama, H., Yagi, M., Suzuki, H., Wakabayashi, K., Suematsu, N., Inada, T., Tamura, T., Okayama, H., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., STOPDAPT-2 and STOPDAPT-2 ACS Investigators.** Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. // *Circulation: Cardiovascular Interventions*, 15, 2022, № 8, p. E012004. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.122.012004.
1494. **Occhipinti, G., Capodanno, D.** Reflections after TWILIGHT study: a new era in secondary prevention without aspirin? // *European Heart Journal, Supplement*, 23, 2021, p. E45-E50. ISSN 1520-765X. DOI: 10.1093/eurheartj/suab087.
1495. **O'Donoghue, M.L., Murphy, S.A., Sabatine, M.S.** The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub>inhibitor in patients after percutaneous coronary intervention: A systematic review and meta-analysis. // *Circulation*, 142, 2020, № 6, p. 538-545. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.046251.
1496. **O'Fee, K., Deych, E., Ciani, O., Brown, D.L.** Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. // *JAMA Internal Medicine*, 181, 2021, № 12, p. 1575-1587. ISSN 2168-6106. DOI 10.1001/jamainternmed.2021.5726.
1497. **Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K., Vogel, B., Mehran, R.** Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review. // *Pharmacogenomics and Personalized Medicine*, 16, 2023, p. 973-990. ISSN 1178-7066. DOI 10.2147/PGPM.S391400.
1498. **Olivier, C.B., Bode, C., Dürschmied, D.** Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen. // *Klinikerzt*, 49, 2020, № 3, p. 57-61. ISSN 0341-2350. DOI 10.1055/a-1110-6764.
1499. **Osman, M., Farjo, P.D., Osman, K., Radaideh, Q., Munir, M.B., Kheiri, B., Balla, S.** The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials. // *Journal of Thrombosis and Thrombolysis*, 49, 2020, № 2, p. 184-191. ISSN 0929-5305. DOI 10.1007/s11239-019-01997-5.
1500. **Otaegui Irurueta, I., García del Blanco, B., Martí Aguasca, G.** Ultrashort 1- to 3-month double antiplatelet therapy after drug-eluting stent implantation or the conquest of the South Pole [La pauta ultracorta de tratamiento antiagregante plaquetario doble de 1-3 meses tras el implante de stent liberador de fármacos o la conquista del



1501. **Otieno, B., Ibecheozor, C., Williams, M.S.** What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease? // *Current Atherosclerosis Reports*, 25, 2023, № 7, p. 343-350. ISSN 1523-3804. DOI 10.1007/s11883-023-01108-z.
1502. **Palmerini, T., Bruno, A.G., Gasparini, M., Rizzello, G., Kim, H.-S., Kang, J., Park, K.-W., Hahn, J.-Y., Song, Y.B., Gwon, H.-C., Choo, E.H., Park, M.-W., Kim, C.J., Chang, K., Cuisset, T., Taglieri, N., Kim, B.-K., Jang, Y., Nardi, E., Saia, F., Orzalkiewicz, M., Chietera, F., Ghatti, G., Galiè, N., Stone, G.W.** Reduced Mortality with Antiplatelet Therapy Deescalation after Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis. // *Circulation: Cardiovascular Interventions*, 15, 2022, № 11, p. 906-914. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.122.012245.
1503. **Parfrey, S., Abdelrahman, A., Blackman, D., Blaxill, J.M., Cunningham, M.S., Greenwood, J.P., Malkin, C.J., Mozid, A.M., Rossington, J.A., Veerasamy, M., Wassef, N., Wheatcroft, S.B., Bulluck, H.** Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials. // *BMC Cardiovascular Disorders*, 22, 2022, № 1, art. no. 450. ISSN 1471-2261. DOI 10.1186/s12872-022-02900-6.
1504. **Park, D.-W., Park, S.-J.** Response by Park and Park to Letter Regarding Article, "clinically Significant Bleeding with Ticagrelor Versus Clopidogrel in Korean Patients with Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial". // *Circulation*, 141, 2020, № 14, p. E741-E742. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.120.045963.
1505. **Park, D.Y., Hu, J.-R., Campbell, G., Goldwag, K., Kelsey, M.D., Altin, S.E., Gallegos-Kattán, C., Nanna, M.G.** Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2024, art. no. 101859. ISSN 2772-9303. DOI 10.1016/j.jscai.2024.101859.
1506. **Park, K.-H., Jeong, M.H., Kim, H.K., Ki, Y.-J., Kim, S.S., Choi, D.-H., Koh, Y.-Y., Ahn, Y., Kim, H.-S., Gwon, H.-C., Rha, S.-W., Hwang, J.-Y., on behalf of the KAMIR-NIH registry investigators.** Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk. // *Journal of Korean Medical Science*, 36, 2021, № 42, p. 1-16. ISSN 1011-8934. DOI 10.3346/JKMS.2021.36.E268.
1507. **Parker, W.A.E., Orme, R.C., Hanson, J., Stokes, H.M., Bridge, C.M., Shaw, P.A., Sumaya, W., Thorneycroft, K., Petrucci, G., Porro, B., Judge, H.M., Ajjan, R.A., Rocca, B., Storey, R.F.** Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. // *Platelets*, 30, 2019, № 2, p. 148-157. ISSN 0953-7104. DOI 10.1080/09537104.2019.1572880.
1508. **Parker, W.A.E., Storey, R.F.** Novel approaches to P2Y12 inhibition and aspirin dosing. // *Platelets*, 32, 2021, № 1, p. 7-14. ISSN 0953-7104. DOI 10.1080/09537104.2020.1714574.



1509. **Passacquale, G., Sharma, P., Perera, D., Ferro, A.** Antiplatelet therapy in cardiovascular disease: Current status and future directions. // *British Journal of Clinical Pharmacology*, 88, 2022, № 6, p. 2686-2699. ISSN 0306-5251. DOI 10.1111/bcp.15221.
1510. **Patrono, C.** Aspirin. – In: *Platelets*, 2019, p. 921-936. ISBN 9780128134566. DOI 10.1016/B978-0-12-813456-6.00050-3.
1511. **Patrono, C., Rocca, B.** Aspirin at 120: Retiring, recombining, or repurposing? // *Research and Practice in Thrombosis and Haemostasis*, 5, 2021, № 4, art. no. e12516. ISSN 2475-0379. DOI 10.1002/rth2.12516.
1512. **Patti, G., Fattirolli, F., De Luca, L., Renda, G., Marcucci, R., Parodi, G., Perna, G.P., Andreotti, F., Ghiglieno, C., Fedele, F., Marchionni, N.** Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. // *Biomedicine and Pharmacotherapy*, 140, 2021, art. no. 111783. ISSN 0753-3322. DOI 10.1016/j.biopha.2021.111783.
1513. **Pavasini, R., Campo, G.** Ticagrelor and Endothelial Function: An Effect That Persists Far From the Acute Phase and in Monotherapy. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 42, 2022, № 6, p. 799-801. ISSN 1079-5642. DOI 10.1161/ATVBAHA.122.317693.
1514. **Pavasini, R., Maietti, E., Tonet, E., Bugani, G., Tebaldi, M., Biscaglia, S., Cimaglia, P., Serenelli, M., Ruggiero, R., Vitali, F., Galvani, M., Minarelli, M., Rubboli, A., Bernucci, D., Volpato, S., Campo, G.** Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. // *Cardiovascular Drugs and Therapy*, 33, 2019, № 5, p. 523-532. ISSN 0920-3206. DOI 10.1007/s10557-019-06911-y.
1515. **Pelliccia, F., Gaudio, C.** The ACEF score in patients undergoing percutaneous coronary intervention: “Keep it simple and focus on what matters”. // *International Journal of Cardiology*, 286, 2019, p. 54-55. ISSN 0167-5273. DOI 10.1016/j.ijcard.2019.03.023.
1516. **Piccolo, R., Esposito, G.** Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention for bifurcation lesions. // *Catheterization and Cardiovascular Interventions*, 96, 2020, № 1, p. 112-113. ISSN 1522-1946. DOI 10.1002/ccd.29082.
1517. **Pop, C., Tint, D., Petris, A.** Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 3, p. 659-675. ISSN 1530-6550. DOI 10.31083/J.RCM2203076.
1518. **Pordzik, J., Eyileten-Postula, C., Jakubik, D., Czajka, P., Nowak, A., De Rosa, S., Gasecka, A., Cieřlicka-Kaplon, A., Sulikowski, P., Filipiak, K.J., Mirowska-Guzel, D., Siller-Matula, J.M., Postula, M.** Mir-126 is an independent predictor of long-term all-cause mortality in patients with type 2 diabetes mellitus. // *Journal of Clinical Medicine*, 10, 2021, № 11, art. no. 2371. ISSN 2077-0383. DOI 10.3390/jcm10112371.
1519. **Ranard, L.S., Brener, S.J.** Acute coronary syndromes and percutaneous coronary intervention-current recommendations for dual antiplatelet therapy. Are guidelines

reflecting the data? – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 57-77. ISBN 9780128205365. DOI 10.1016/B978-0-12-820536-5.00002-1.

1520. **Rezek, M., Moravcová, H.** Ticagrelor monotherapy after percutaneous coronary intervention in comparison with dual-antiplatelet therapy [Monoterapie ticagrelorem po perkutánní koronární intervenci v porovnání s duální protideštičkovou léčbou]. // *Intervenční a Akutní Kardiologie*, 21, 2022, № 1, p. 35-40. ISSN 1213-807X. DOI 10.36290/KAR.2022.001.
1521. **Rocca, B., Rubboli, A., Zaccardi, F.** Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. // *European Journal of Preventive Cardiology*, 26, 2019, № 2\_suppl, p. 92-105. ISSN 2047-4873. DOI 10.1177/2047487319880045.
1522. **Roccasalva, F., Ferrante, G.** Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: How short can we go? // *Minerva Cardioangiologica*, 68, 2020, № 5, p. 436-450. ISSN 0026-4725. DOI 10.23736/S0026-4725.20.05196-8.
1523. **Rodriguez, F., Harrington, R.A.** Management of antithrombotic therapy after acute coronary syndromes. // *New England Journal of Medicine*, 384, 2021, № 5, p. 452-460. ISSN 0028-4793. DOI 10.1056/NEJMra1607714.
1524. **Rodriguez, J.J., Baron, L.E., Munoz, O.C., Diaz, J.J.** Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis. // *Current Cardiology Reports*, 24, 2022, № 2, p. 87-91. ISSN 1523-3782. DOI 10.1007/s11886-021-01627-8.
1525. **Roh, J.W., Hahn, J.-Y., Oh, J.-H., Chun, W.J., Park, Y.H., Jang, W.J., Im, E.-S., Jeong, J.-O., Cho, B.R., Oh, S.K., Yun, K.H., Cho, D.-K., Lee, J.-Y., Koh, Y.-Y., Bae, J.-W., Choi, J.W., Lee, W.S., Yoon, H.J., Lee, S.U., Cho, J.H., Choi, W.G., Rha, S.-W., Kim, H.-Y., Lee, J.M., Park, T.K., Yang, J.H., Choi, J.-H., Choi, S.-H., Lee, S.H., Gwon, H.-C., Kim, D.-B., Song, Y.B.** P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial. // *Cardiology Journal*, 28, 2021, № 6, art. no. 84704, p. 855-863. ISSN 1897-5593. DOI 10.5603/CJ.A2021.0101.
1526. **Rout, A., Sharma, A., Ikram, S., Garg, A.** Short-term dual antiplatelet therapy for 1–3 months after percutaneous coronary intervention using drug eluting stents: A systematic review and meta-analysis of randomized clinical trials. // *Catheterization and Cardiovascular Interventions*, 101, 2023, № 2, p. 299-307. ISSN 1522-1946. DOI 10.1002/ccd.30521.
1527. **Rubinfeld, G.D., Berger, J.S., Smilowitz, N.R.** Acute Myocardial Infarction Following Hospitalization for Gastrointestinal Bleeding: Incidence, Predictors, Management, and Outcomes. // *American Journal of Medicine*, 135, 2022, № 8, p. e263-e278. ISSN 0002-9343. DOI 10.1016/j.amjmed.2022.03.030.
1528. **Sabouret, P., Angoulvant, D., Pathak, A., Fysekidis, M., Lattera, G., Costa, F., Angelini, F., Bocchino, J.P., Montalescot, G., Biondi-Zoccai, G.** How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators.

1529. **Sabouret, P., Spadafora, L., Fischman, D., Ullah, W., Zeitouni, M., Gulati, M., De Rosa, S., Savage, M.P., Costabel, J.P., Banach, M., Biondi-Zoccai, G., Galli, M.** De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy? // *European Journal of Internal Medicine*, 110, 2023, p. 1-9. ISSN 0953-6205. DOI 10.1016/j.ejim.2022.12.008.
1530. **Sadeghi, M., Kermani-Alghoraishi, M., Khosravi, A., Amerizadeh, A., Sadeghi, M.** Cardiovascular and Bleeding Events of Ticagrelor Monotherapy after Short-term Dual Antiplatelet Therapy (DAPT) in Diabetics and Non-Diabetics Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. // *ARYA Atherosclerosis*, 19, 2023, № 3, p. 105-115. ISSN 1735-3955. DOI 10.22122/arya.2022.26680.2821.
1531. **Saint Croix, G., Lacy, S.C., Gazzhal, A., Ibrahim, M., Gjergjindrea, M., Perez, J., Shehadeh, M., Vedantam, K., Torres, C., Beohar, N., Escolar, E.** Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review. // *Journal of Interventional Cardiology*, 2022, art. no. 3111840. ISSN 0896-4327. DOI 10.1155/2022/3111840.
1532. **Saito, Y., Kobayashi, Y.** Update on antithrombotic therapy after percutaneous coronary intervention. // *Internal Medicine*, 59, 2020, № 3, p. 311-321. ISSN 0918-2918. DOI 10.2169/internalmedicine.3685-19.
1533. **Saito, Y., Kobayashi, Y., Tanabe, K., Ikari, Y.** Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. // *Cardiovascular Intervention and Therapeutics*, 35, 2020, № 1, p. 19-29. ISSN 1868-4300. DOI 10.1007/s12928-019-00633-6.
1534. **Sanderson, N.C., Parker, W.A.E., Storey, R.F.** Ticagrelor: Clinical development and future potential. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 2, p. 373-394. ISSN 1530-6550. DOI 10.31083/j.rcm2202044.
1535. **Sandner, S.E., Schunkert, H., Kastrati, A., Milojevic, M., Böning, A., Zimpfer, D., Zellmer, S., Wiedemann, D., Laufer, G., von Scheidt, M., TiCAB Investigators.** Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. // *Annals of Thoracic Surgery*, 113, 2022, № 2, p. 554-562. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2021.03.061.
1536. **Santos-Gallego, C.G., Requena-Ibanez, J.A., Badimon, J.** Per-Protocol Versus Intention-to-Treat in Clinical Trials: The Example of GLOBAL-LEADERS Trial. // *Journal of the American Heart Association*, 11, 2022, № 10, art. no. e025561. ISSN 2047-9980. DOI 10.1161/JAHA.122.025561.
1537. **Savonitto, S., Morici, N., De Servi, S.** Antiplatelet therapy for elderly patients with Acute Coronary Syndromes. // *Aging*, 10, 2018, № 9, p. 2220-2221. ISSN 1945-4589. DOI 10.18632/aging.101553.
1538. **Schmucker, J., Fach, A., Mata Marin, L.A., Retzlaff, T., Osteresch, R., Kollhorst, B., Hambrecht, R., Pohlabein, H., Wienbergen, H.** Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with st-segment-elevation

myocardial infarctions. // *Journal of the American Heart Association*, 8, 2019, № 18, art. no. e012530. ISSN 2047-9980. DOI 10.1161/JAHA.119.012530.

1539. **Schorr, K.** Acetylsalicylic acid. – In: *Acetylsalicylic Acid*, 2022, p. 1-630. ISBN 9783110746419; 9783110745726. DOI 10.1515/9783110746419.
1540. **Scirica, B.M., Bergmark, B.A., Morrow, D.A., Antman, E.M., Bonaca, M.P., Murphy, S.A., Sabatine, M.S., Braunwald, E., Wiviott, S.D.** Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. // *Journal of the American College of Cardiology*, 75, 2020, № 10, p. 1095-1106. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.12.067.
1541. **Serrao, G., Vinayak, M., Nicolas, J., Subramaniam, V., Lai, A.C., Laskey, D., Kini, A., Seethamraju, H., Scheinin, S.** The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient. // *Journal of Clinical Medicine*, 12, 2023, № 24, art. no. 7644. ISSN 2077-0383. DOI 10.3390/jcm12247644.
1542. **Shah, R., Labroo, A., Davis, D.A., Le, F.K.** Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta-analysis. // *Catheterization and Cardiovascular Interventions*, 98, 2021, № 3, p. E490-E492. ISSN 1522-1946. DOI 10.1002/ccd.29205.
1543. **Shakarami, A.** Incidence of Restenosis Following Rapamycin or Paclitaxeluting Stent in Coronary Stent Implantation. // *Cardiovascular and Hematological Disorders - Drug Targets*, 21, 2021, № 3, p. 196-201. ISSN 1871-529X. DOI 10.2174/1871529X21666211209115126.
1544. **Sharma, R., Kumar, P., Prashanth, S.P., Belagali, Y.** Dual Antiplatelet Therapy in Coronary Artery Disease. // *Cardiology and Therapy*, 9, 2020, № 2, p. 349-361. ISSN 2193-8261. DOI 10.1007/s40119-020-00197-0.
1545. **Shiono, Y., Akasaka, T.** European society of cardiology (ESC) annual congress report from Munich 2018. // *Circulation Journal*, 83, 2019, № 1, p. 18-24. ISSN 1346-9843. DOI 10.1253/circj.CJ-18-1056.
1546. **Shlofmitz, E., Shlofmitz, R., Lee, M.S.** The role of novel oral anticoagulants and antiplatelet therapy after percutaneous coronary intervention: Individualizing therapy to optimize outcomes. // *Korean Circulation Journal*, 49, 2019, № 8, p. 645-656. ISSN 1738-5520. DOI 10.4070/kcj.2019.0185.
1547. **Shoji, S., Kuno, T., Fujisaki, T., Takagi, H., Briasoulis, A., Deharo, P., Cuisset, T., Latib, A., Kohsaka, S.** De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. // *Journal of the American College of Cardiology*, 78, 2021, № 8, p. 763-777. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.06.012.
1548. **Shoji, S., Kuno, T., Ueyama, H., Takagi, H., Briasoulis, A., Kim, H.-S., Koo, B.-K., Kang, J., Watanabe, H., Kimura, T., Kohsaka, S.** Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials. // *Journal of Cardiology*, 83, 2024, № 5, p. 338-347. ISSN 0914-5087. DOI 10.1016/j.jjcc.2023.08.001.
1549. **Shoji, S., Sawano, M., Sandhu, A.T., Heidenreich, P.A., Shiraishi, Y., Ikemura, N., Ueno, K., Suzuki, M., Numasawa, Y., Fukuda, K., Kohsaka, S.** Ischemic and Bleeding Events among Patients with Acute Coronary Syndrome Associated with

Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. // *JAMA Network Open*, 3, 2020, № 4, art. no. e202004. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2020.2004.

1550. **Siasos, G., Tsigkou, V., Bletsas, E., Stampouloulou, P.K., Oikonomou, E., Kallogeris, K., Katsarou, O., Pesiridis, T., Vavuranakis, M., Tousoulis, D.** Antithrombotic Treatment in Coronary Artery Disease. // *Current Pharmaceutical Design*, 29, 2023, № 35, p. 2764-2779. ISSN 1381-6128. DOI 10.2174/1381612829666230830105750.
1551. **Sibbing, D., Cassese, S.** Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 457-460. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.039.
1552. **Sidhu, M.S., Lyubarova, R., Bangalore, S., Bonaca, M.P.** Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. // *American Heart Journal*, 246, 2022, p. 44-64. ISSN 0002-8703. DOI 10.1016/j.ahj.2021.12.005.
1553. **Sinnaeve, P.R., Adriaenssens, T.** Dual Antiplatelet Therapy De-escalation Strategies. // *American Journal of Cardiology*, 144, 2021, p. S23-S31. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.12.020.
1554. **Sone, H., Mori, H., Sato, T., Takei, Y., Tashiro, K., Sasai, M., Suzuki, H.** Angioscopic imaging one month after the implantation of a drug-eluting stent following drug-coated balloon treatment. // *IJC Heart and Vasculature*, 21, 2018, p. 111-112. ISSN 2352-9067. DOI 10.1016/j.ijcha.2018.10.007.
1555. **Song, L., Liu, C., Zhou, P., Zhou, J., Sheng, Z., Li, J., Chen, R., Chen, Y., Zhao, H., Yan, H.** Ticagrelor versus clopidogrel in patients with ST-elevation myocardial infarction: Postdischarge mild bleeding and its clinical impacts. // *Coronary Artery Disease*, 2021, art. no. 917, p. 164-166. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000917.
1556. **Song, P.S., Park, Y.H., Oh, J.-H., Song, Y.B., Choi, S.-H., Gwon, H.-C., Cho, D.-K., Rha, S.-W., Bae, J.-W., Jeong, J.-O., Hahn, J.-Y., for the SMART-DATE and the SMART-CHOICE investigators.** P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. // *American Journal of Cardiology*, 150, 2021, p. 47-54. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.03.053.
1557. **Sorrentino, S., Baber, U., Mehran, R.** Limitations of Current Risk Scoring in Real World Populations: The Importance of External Validation. [Limitación de la aplicación de las puntuaciones de riesgo en la clínica: la importancia de la validación.] // *Revista Española de Cardiología*, 72, 2019, № 3, p. 192-194. ISSN 0300-8932. DOI 10.1016/j.recesp.2018.09.013.
1558. **Sotomi, Y., Hikoso, S., Komukai, S., Kitamura, T., Nakatani, D., Dohi, T., Mizuno, H., Okada, K., Kida, H., Oeun, B., Sunaga, A., Sato, T., Matsuoka, Y., Sakata, Y., Sato, H., Hori, M., Komuro, I., Sakata, Y., Osaka Acute Coronary Insufficiency Study (OACIS) Group.** Individual acute-phase bleeding and thrombotic risk balance assessment in patients undergoing percutaneous coronary intervention for acute myocardial infarction. // *American Heart Journal Plus: Cardiology*



1559. **Spadafora, L., Bernardi, M., Galli, M., Biondi-Zoccai, G., Sabouret, P.** Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies. // *Archives of Medical Science*, 18, 2022, № 6, p. 1689-1692. ISSN 1734-1922. DOI 10.5114/aoms/155411.
1560. **Storey, R.F.** The long journey of individualizing antiplatelet therapy after acute coronary syndromes. // *European Heart Journal*, 41, 2020, № 37, p. 3546-3548. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa644.
1561. **Sulzgruber, P.** Changing paradigms in antiplatelet therapy after coronary intervention. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 206-208. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa043.
1562. **Tam, C.-C., Tse, H.-F.** Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. // *Journal of Clinical Medicine*, 11, 2022, № 24, art. no. 7440. ISSN 2077-0383. DOI 10.3390/jcm11247440.
1563. **Tang, C., Zhu, Y., Yang, X., Xu, B., Ye, C., Yang, Y., Zhong, J., Zhao, Q., Yu, L.** Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. // *Journal of Gastroenterology and Hepatology (Australia)*, 35, 2020, № 10, p. 1720-1730. ISSN 0815-9319. DOI 10.1111/jgh.15030.
1564. **Tang, K.S., Banerjee, S., Tang, G., Patel, P.M., Frangieh, A.H.** Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review. // *Interventional Cardiology: Reviews, Research, Resources*, 18, 2023, art. no. e31. ISSN 1756-1477. DOI 10.15420/icr.2023.19.
1565. **Tasoudis, P.T., Kyriakoulis, I.G., Sagris, D., Diener, H.C., Ntaios, G.** Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. // *Thrombosis and Haemostasis*, 122, 2022, № 11, p. 1879-1887. ISSN 0340-6245. DOI 10.1055/a-1853-2952.
1566. **Tavenier, A.H., Mehran, R., Chiarito, M., Cao, D., Pivato, C.A., Nicolas, J., Beerkens, F., Nardin, M., Sartori, S., Baber, U., Angiolillo, D.J., Capodanno, D., Valgimigli, M., Hermanides, R.S., Van't Hof, A.W.J., Ten Berg, J.M., Chang, K., Kini, A.S., Sharma, S.K., Dangas, G.** Guided and unguided de-escalation from potent P2Y<sub>12</sub>inhibitors among patients with acute coronary syndrome: a meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 5, p. 492-502. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvab068.
1567. **Terrier, J., Daali, Y., Fontana, P., Csajka, C., Reny, J.-L.** Towards Personalized Antithrombotic Treatments: Focus on P2Y<sub>12</sub> Inhibitors and Direct Oral Anticoagulants. // *Clinical Pharmacokinetics*, 58, 2019, № 12, p. 1517-1532. ISSN 0312-5963. DOI 10.1007/s40262-019-00792-y.
1568. **Tersalvi, G., Biasco, L., Cioffi, G.M., Pedrazzini, G.** Acute coronary syndrome, antiplatelet therapy, and bleeding: A clinical perspective. // *Journal of Clinical Medicine*, 9, 2020, № 7, art. no. 2064, p. 1-20. ISSN 2077-0383. DOI 10.3390/jcm9072064.

1569. **Thomas, A., Gitto, M., Shah, S., Saito, Y., Tirziu, D., Chieffo, A., Stefanini, G.G., Lansky, A.J.** Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 2, 2023, № 3, art. no. 100607. ISSN 2772-9303. DOI 10.1016/j.jscai.2023.100607.
1570. **Tian, M.-Y., Wang, X.-Y., Chen, F., Guo, Y.-F.** Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study. // *Journal of Cardiovascular Pharmacology*, 82, 2023, № 4, p. 327-332. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001461.
1571. **Torii, S., Jinnouchi, H., Sakamoto, A., Kutyna, M., Cornelissen, A., Kuntz, S., Guo, L., Mori, H., Harari, E., Paek, K.H., Fernandez, R., Chahal, D., Romero, M.E., Kolodgie, F.D., Gupta, A., Virmani, R., Finn, A.V.** Drug-eluting coronary stents: insights from preclinical and pathology studies. // *Nature Reviews Cardiology*, 17, 2020, № 1, p. 37-51. ISSN 1759-5002. DOI 10.1038/s41569-019-0234-x.
1572. **Towashiraporn, K., Krittayaphong, R.** Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. // *International Journal of General Medicine*, 15, 2022, p. 2397-2414. ISSN 1178-7074. DOI 10.2147/IJGM.S289295.
1573. **Traby, L., Kollars, M., Kaider, A., Siller-Matula, J.M., Wolkersdorfer, M.F., Wolzt, M., Kyrle, P.A., Eichinger, S.** Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. // *Clinical Pharmacology and Therapeutics*, 107, 2020, № 2, p. 415-422. ISSN 0009-9236. DOI 10.1002/cpt.1616.
1574. **Tritschler, T., Patel, A., Kraaijpoel, N., Bhatt, D.L., De Luca, G., Di Santo, P., Feres, F., Costa, R.A., Hibbert, B., Isshiki, T., Le Gal, G., Castellucci, L.A.** Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis. // *Research and Practice in Thrombosis and Haemostasis*, 6, 2022, № 7, art. no. e12834. ISSN 2475-0379. DOI 10.1002/rth2.12834.
1575. **Tscharre, M., Gremmel, T.** Antiplatelet Therapy in Coronary Artery Disease: Now and Then. // *Seminars in Thrombosis and Hemostasis*, 49, 2023, № 3, p. 255-271. ISSN 0094-6176. DOI 10.1055/s-0042-1758821.
1576. **Tsigkas, G., Apostolos, A., Trigka, A., Chlorogiannis, D., Katsanos, K., Toutouzas, K., Alexopoulos, D., Brilakis, E.S., Davlourous, P.** Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis. // *American Journal of Cardiovascular Drugs*, 23, 2023, № 1, p. 35-46. ISSN 1175-3277. DOI 10.1007/s40256-022-00559-0.
1577. **Ueng, K.-C., Chiang, C.-E., Chao, T.-H., Wu, Y.-W., Lee, W.-L., Li, Y.-H., Ting, K.-H., Su, C.-H., Lin, H.-J., Su, T.-C., Liu, T.-J., Lin, T.-H., Hsu, P.-C., Wang, Y.-C., Chen, Z.-C., Jen, H.-L., Lin, P.-L., Ko, F.-Y., Yen, H.-W., Chen, W.-J., Hou, C.J.-Y.** 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome. // *Acta Cardiologica Sinica*, 39, 2023, № 1, p. 4-96. ISSN 1011-6842. DOI 10.6515/ACS.202301\_39(1).20221103A.

1578. **Ullah, W., Zahid, S., Sandhyavenu, H., Faisaluddin, M., Khalil, F., Pasha, A.K., Alraies, M.C., Cuisset, T., Rao, S.V., Sabouret, P., Savage, M.P., Fischman, D.L.** Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bi-variate, influential, and network meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 7, p. 717-727. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvac020.
1579. **Valeriani, E., Bartimoccia, S., Pignatelli, P., Pastori, D.** Aging and Antithrombotic Treatment. // *Antioxidants and Redox Signaling*, 2023. ISSN 1523-0864. DOI 10.1089/ars.2023.0373.
1580. **van der Sangen, N.M.R., Küçük, I.T., Sivanesan, S., Appelman, Y., ten Berg, J.M., Verburg, A., Azzahhafi, J., Arkenbout, E.K., Kikkert, W.J., Pisters, R., Jukema, J.W., Arslan, F., van 't Hof, A., Ilhan, M., Hoebers, L.P., van der Schaaf, R.J., Damman, P., Woudstra, P., van de Hoef, T.P., Bax, M., Anthonio, R.L., Polad, J., Adriaenssens, T., Dewilde, W., Zivelonghi, C., Laanmets, P., Majas, R., Dijkgraaf, M.G.W., Claessen, B.E.P.M., Henriques, J.P.S.** Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study. // *American Heart Journal*, 265, 2023, p. 114-120. ISSN 0002-8703. DOI 10.1016/j.ahj.2023.07.011.
1581. **van der Sangen, N.M.R., Küçük, I.T., ten Berg, J.M., Beijk, M.A.M., Delewi, R., den Hartog, A.W., Appelman, Y., Verouden, N.J.W., Kikkert, W.J., Henriques, J.P.S., Claessen, B.E.P.M.** P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal? // *Expert Review of Cardiovascular Therapy*, 20, 2022, № 8, p. 637-645. ISSN 1477-9072. DOI 10.1080/14779072.2022.2104248.
1582. **Varvarovský, I.** GLOBAL LEADERS-paving the way for better antithrombotic treatment? [GLOBAL LEADERS-naznacení cesty k účinnější antitrombotické léčbě?]. // *Intervenční a Akutní Kardiologie*, 17, 2018, № 4, p. 246-247. ISSN 1213-807X.
1583. **Varvarovský, I.** Kontroverze - aspirin po PCI? Aspirin po PCI: proc nepodávat. // *Intervenční a Akutní Kardiologie*, 19, 2020, № 3, p. 182-183. ISSN 1213-807X. DOI 10.36290/kar.2020.040.
1584. **Ver DOIa, M., Gioscia, R., de Luca, G.** Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. // *Journal of Geriatric Cardiology*, 18, 2021, № 3, p. 210-218. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2021.03.010.
1585. **Ver DOIa, M., Savonitto, S., Dudek, D., Kedhi, E., De Luca, G.** Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. // *Vascular Pharmacology*, 137, 2021, art. no. 106828. ISSN 1537-1891. DOI 10.1016/j.vph.2020.106828.
1586. **Vilain, K.A., Dibattiste, P.M., Schneider, D.J., Cohen, D.J.** Exploring the potential cost-effectiveness of a novel platelet assay for guiding dual antiplatelet therapy duration in acute coronary syndrome patients following percutaneous coronary intervention. // *Coronary Artery Disease*, 34, 2023, № 1, p. 24-33. ISSN 0954-6928. DOI 10.1097/MCA.0000000000001194.

1587. Virani, S.S., Newby, L.K., Arnold, S.V., Bittner, V., Brewer, L.C., Demeter, S.H., Dixon, D.L., Fearon, W.F., Hess, B., Johnson, H.M., Kazi, D.S., Kolte, D., Kumbhani, D.J., Lofaso, J., Mahtta, D., Mark, D.B., Minissian, M., Navar, A.M., Patel, A.R., Piano, M.R., Rodriguez, F., Talbot, A.W., Taqueti, V.R., Thomas, R.J., Van Diepen, S., Wiggins, B., Williams, M.S. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. // *Circulation*, 148, 2023, № 9, p. E9-E119. ISSN 0009-7322. DOI 10.1161/CIR.0000000000001168.
1588. Virani, S.S., Newby, L.K., Arnold, S.V., Bittner, V., Brewer, L.C., Demeter, S.H., Dixon, D.L., Fearon, W.F., Hess, B., Johnson, H.M., Kazi, D.S., Kolte, D., Kumbhani, D.J., LoFaso, J., Mahtta, D., Mark, D.B., Minissian, M., Navar, A.M., Patel, A.R., Piano, M.R., Rodriguez, F., Talbot, A.W., Taqueti, V.R., Thomas, R.J., van Diepen, S., Wiggins, B., Williams, M.S., Writing Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. // *Journal of the American College of Cardiology*, 82, 2023, № 9, p. 833-955. ISSN 0735-1097. DOI 10.1016/j.jacc.2023.04.003.
1589. Virk, H.U.H., Escobar, J., Rodriguez, M., Bates, E.R., Khalid, U., Jneid, H., Birnbaum, Y., Levine, G.N., Smith, S.C., Jr., Krittanawong, C. Dual Antiplatelet Therapy: A Concise Review for Clinicians. // *Life*, 13, 2023, № 7, art. no. 1580. ISSN 2075-1729. DOI 10.3390/life13071580.
1590. Vojáček, J.F. Kontroverze - aspirin po PCI? Aspirin po PCI: proc podávat. // *Intervenci a Akutni Kardiologie*, 19, 2020, № 3, p. 184-186. ISSN 1213-807X. DOI 10.36290/kar.2020.041.
1591. Von Scheidt, M., Bongiovanni, D., Tebbe, U., Nowak, B., Stritzke, J., Zhao, Q., Zhu, Y., Kastrati, A., Cassese, S., Schunkert, H. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: A meta-analysis of randomized controlled trials. // *European Journal of Cardio-thoracic Surgery*, 57, 2020, № 3, p. 520-528. ISSN 1010-7940. DOI 10.1093/ejcts/ezz260.
1592. Voudris, K.V., Feldman, D.N. Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. // *Current Treatment Options in Cardiovascular Medicine*, 25, 2023, № 5, p. 127-141. ISSN 1092-8464. DOI 10.1007/s11936-023-00981-w.
1593. Wakabayashi, H., Ando, H., Nakano, Y., Takashima, H., Waseda, K., Shimoda, M., Ohashi, H., Suzuki, A., Sakurai, S., Amano, T. Temporal changes of incomplete stent apposition during early phase after everolimus-eluting stent implantation: serial optical coherence tomography analyses at 2-week and 4-month. // *International Journal of Cardiovascular Imaging*, 37, 2021, № 2, p. 411-417. ISSN 1569-5794. DOI 10.1007/s10554-020-02023-z.
1594. Walker, J., Cattaneo, M., Badimon, L., Agnelli, G., Chan, A.T., Lanas, A., Rocca, B., Rothwell, P., Patrignani, P., Langley, R., Vilahur, G., Cosentino, F. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention. // *Ecancermedicalscience*, 14, 2020, art. no. 998. ISSN 1754-6605. DOI 10.3332/ECANCER.2019.998.



1595. Wang, G., Ma, G., Tao, L., Yuan, Z., Liu, H., Hu, X., Tong, Q., Yu, Z., Zhou, X., Han, Y. Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials. // *Catheterization and Cardiovascular Interventions*, 95, 2020, № S1, p. 565-571. ISSN 1522-1946. DOI 10.1002/ccd.28713.
1596. Wang, G., Wang, X., Zhao, G., Huang, X., Guo, R., Nie, S. De-escalation of antiplatelet therapy after percutaneous coronary intervention among East Asians and non-East Asians: a meta-analysis of randomized controlled trials. // *BMC Cardiovascular Disorders*, 22, 2022, № 1, art. no. 29. ISSN 1471-2261. DOI 10.1186/s12872-022-02476-1.
1597. Wang, Q., Yang, K., Bundhun, P.K. Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis. // *Diabetes Therapy*, 11, 2020, № 10, p. 2299-2311. ISSN 1869-6953. DOI 10.1007/s13300-020-00909-8.
1598. Wang, Y., Wuyunqidamugai, Zhou, Q. Strategies for intolerance of standard dual antiplatelet therapy after PCI [PCI术后标准双联抗血小板治疗不耐受的处理策略]. // *Journal of Clinical Cardiology*, 37, 2021, № 5, p. 406-410. ISSN 1001-1439. DOI 10.13201/j.issn.1001-1439.2021.05.004.
1599. Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., Hata, Y., Yagi, M., Suematsu, N., Yokomatsu, T., Takamisawa, I., Doi, M., Noda, T., Okayama, H., Seino, Y., Tada, T., Sakamoto, H., Hibi, K., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Hanaoka, K.I., Morino, Y., Kozuma, K., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. // *JAMA - Journal of the American Medical Association*, 321, 2019, № 24, p. 2414-2427. ISSN 0098-7484. DOI 10.1001/jama.2019.8145.
1600. Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Ono, K., Kadota, K., Suwa, S., Morishima, I., Yoshida, R., Hata, Y., Akao, M., Yagi, M., Suematsu, N., Morino, Y., Yokomatsu, T., Takamisawa, I., Noda, T., DOI, M., Okayama, H., Nakamura, Y., Hibi, K., Sakamoto, H., Noguchi, T., Kimura, T., STOPDAPT-2 Investigators. Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention. // *Journal of the American College of Cardiology*, 83, 2024, № 1, p. 17-31. ISSN 0735-1097. DOI 10.1016/j.jacc.2023.10.013.
1601. Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., Tatsushima, S., Watanabe, H., Ohya, M., Tokuyama, H., Tada, T., Sakamoto, H., Mori, H., Suzuki, H., Nishikura, T., Wakabayashi, K., Hibi, K., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T. Comparison of Clopidogrel Monotherapy after 1 to 2 Months of Dual Antiplatelet Therapy with 12 Months of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. //



1602. **Watanabe, H., Morimoto, T., Ogita, M., Suwa, S., Natsuaki, M., Suematsu, N., Koeda, Y., Morino, Y., Nikaido, A., Hata, Y., DOI, M., Hibi, K., Kimura, K., Yoda, S., Kaneko, T., Nishida, K., Kawai, K., Yamaguchi, K., Wakatsuki, T., Tonoike, N., Yamamoto, M., Shimizu, S., Shimohama, T., Ako, J., Kimura, T., STOPDAPT-2 Investigators.** Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. // *Cardiovascular Intervention and Therapeutics*, 36, 2021, № 4, p. 403-415. ISSN 1868-4300. DOI 10.1007/s12928-020-00719-6.
1603. **Welsh, R.C., Peterson, E.D., De Caterina, R., Bode, C., Gersh, B., Eikelboom, J.W.** Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. // *American Heart Journal*, 218, 2019, p. 100-109. ISSN 0002-8703. DOI 10.1016/j.ahj.2019.09.006.
1604. **Wernly, B., Lichtenauer, M., Erlinge, D., Jung, C.** Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy? // *Clinical Research in Cardiology*, 109, 2020, № 1, p. 128-130. ISSN 1861-0684. DOI 10.1007/s00392-019-01496-w.
1605. **Wernly, B., Rezar, R., Gurbel, P., Jung, C.** Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint. // *Journal of Thrombosis and Thrombolysis*, 49, 2020, № 1, p. 173-176. ISSN 0929-5305. DOI 10.1007/s11239-019-01985-9.
1606. **Widimsky, P., Crea, F., Binder, R.K., Lüscher, T.F.** The year in cardiology 2018: Acute coronary syndromes. // *European Heart Journal*, 40, 2019, № 3, p. 271-283. ISSN 0195-668X. DOI 10.1093/eurheartj/ehy904.
1607. **Wiebe, J., Ndrepepa, G., Kufner, S., Lahmann, A.L., Xhepa, E., Kuna, C., Voll, F., Gosetti, R., Laugwitz, K.-L., Joner, M., Kastrati, A., Cassese, S.** Early aspirin discontinuation after coronary stenting: A systematic review and meta-analysis. // *Journal of the American Heart Association*, 10, 2021, № 2, art. no. e018304, p. 1-10. ISSN 2047-9980. DOI 10.1161/JAHA.120.018304.
1608. **Wong, B., Lee, K.-H., El-Jack, S.** Very Elderly Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention. // *Heart Lung and Circulation*, 30, 2021, № 9, p. 1337-1342. ISSN 1443-9506. DOI 10.1016/j.hlc.2021.03.275.
1609. **Wongsalap, Y., Kengkla, K., Wilairat, P., Ratworawong, K., Saokaew, S., Wanlapakorn, C.** Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis. // *Chronic Diseases and Translational Medicine*, 9, 2023, № 4, p. 299-308. ISSN 2095-882X. DOI 10.1002/cdt3.85.
1610. **Wu, X.-T., He, R.-R., Liang, S.-Z., Ye, G.-Y., Ding, S.-B.** Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients

undergoing percutaneous coronary intervention: Systematic review and meta-analysis. // *Minerva Medica*, 111, 2020, № 2, p. 173-180. ISSN 0026-4806. DOI 10.23736/S0026-4806.19.06281-5.

1611. **Xu, K., Xu, B., Guan, C., Jing, Q., Zheng, Q., Li, X., Zhao, X., Wang, H., Zhao, X., Li, Y., Li, J., Yang, Y., Han, Y., Li, X., Yu, P., Zang, H., Wang, Z., Cao, X., Zhang, J., Pang, W., the I-LOVE-IT 2 Investigators.** Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: The final 5-year outcomes of the I-LOVE-IT 2 trial. // *EuroIntervention*, 16, 2021, № 18, p. E1518-E1526. ISSN 1774-024X. DOI 10.4244/EIJ-D-19-00865.
1612. **Xu, S., Liang, Y., Chen, Y., Gao, H., Tan, Z., Wang, Q., Liu, Y., Zhu, B., Tao, F., Wang, Q., Zhao, S., Yang, L., Zhang, Y., Wang, Z., Han, P., Chen, Y., Zhang, A., Li, C., Lian, K.** Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. // *Drugs and Aging*, 2022. ISSN 1170-229X. DOI 10.1007/s40266-022-00971-w.
1613. **Xu, Y., Shen, Y., Chen, D., Zhao, P., Jiang, J.** Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. // *Journal of Interventional Cardiology*, 2021, art. no. 9934535. ISSN 0896-4327. DOI 10.1155/2021/9934535.
1614. **Yamamoto, K., Shiomi, H., Morimoto, T., Miyazawa, A., Watanabe, H., Nakamura, S., Suwa, S., Domei, T., Ono, K., Sakamoto, H., Shigetoshi, M., Taniguchi, R., Okayama, H., Yokomatsu, T., Muto, M., Kawaguchi, R., Kishi, K., Hadase, M., Fujita, T., Nishida, Y., Nishino, M., Otake, H., Natsuaki, M., Watanabe, H., Suematsu, N., Tanabe, K., Abe, M., Hibi, K., Kadota, K., Ando, K., Kimura, T., OPTIVUS-Complex PCI Investigators.** Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention. // *Circulation Journal*, 87, 2023, № 11, p. 1661-1671. ISSN 1346-9843. DOI 10.1253/circj.CJ-23-0141.
1615. **Yamamoto, K., Watanabe, H., Morimoto, T., Domei, T., Ohya, M., Ogita, M., Takagi, K., Suzuki, H., Nikaido, A., Ishii, M., Fujii, S., Natsuaki, M., Yasuda, S., Kaneko, T., Tamura, T., Tamura, T., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Igarashi Hanaoka, K., Morino, Y., Kozuma, K., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T.** Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. // *Circulation: Cardiovascular Interventions*, 14, 2021, № 5, p. E010384. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.120.010384.
1616. **Yamamoto, K., Watanabe, H., Morimoto, T., Obayashi, Y., Natsuaki, M., Domei, T., Yamaji, K., Suwa, S., Isawa, T., Watanabe, H., Yoshida, R., Sakamoto, H., Akao, M., Hata, Y., Morishima, I., Tokuyama, H., Yagi, M., Suzuki, H., Wakabayashi, K., Suematsu, N., Inada, T., Tamura, T., Okayama, H., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., STOPDAPT-2 and STOPDAPT-2 ACS Investigators.** Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. // *JACC: Asia*, 3, 2023, № 1, p. 31-46. ISSN 2772-3747. DOI 10.1016/j.jacasi.2022.09.011.

1617. Yamamoto, K., Watanabe, H., Morimoto, T., Obayashi, Y., Natsuaki, M., Yamaji, K., Domei, T., Ogita, M., Ohya, M., Tatsushima, S., Suzuki, H., Tada, T., Ishii, M., Nikaido, A., Watanabe, N., Fujii, S., Mori, H., Nishikura, T., Suematsu, N., Hayashi, F., Komiyama, K., Shigematsu, T., Isawa, T., Suwa, S., Ando, K., Kimura, T., the STOPDAPT-2 and STOPDAPT-2 ACS Investigators. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. // *JACC: Cardiovascular Interventions*, 16, 2023, № 1, p. 19-31. ISSN 1936-8798. DOI 10.1016/j.jcin.2022.09.053.
1618. Yeh, R., Mihatov, N. Clinical risk scores: A tool to understand bleeding and thrombotic risk. – In: *Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease*, 2021, p. 145-166. ISBN 9780128205365. DOI: 10.1016/B978-0-12-820536-5.00010-0.
1619. Yeh, R.W., Mihatov, N. The DAPT Score Uncouples Bleeding and Ischemic Risk...Again. // *JACC: Cardiovascular Interventions*, 13, 2020, № 5, p. 647-650. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.01.211.
1620. Yerasi, C., Case, B.C., Forrestal, B.J., Torguson, R., Weintraub, W.S., Garcia-Garcia, H.M., Waksman, R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 135, 2020, p. 154-165. ISSN 0002-9149. DOI 10.1016/j.amjcard.2020.07.061.
1621. Yoon, Y.-H., Park, G.-M., Roh, J.-H., Her, S.-H., Lim, S.-H., Kang, T.S., Lee, S.J., Bae, J.-W., Choi, W., Yang, Y.-M., Kim, J., Choi, Y.J., Choi, S.W., Lee, J.-H. Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent. // *Cardiology Research and Practice*, 2022, art. no. 2914385. ISSN 2090-8016. DOI 10.1155/2022/2914385.
1622. Yoshikawa, Y., Shiomi, H., Morimoto, T., Takeji, Y., Matsumura-Nakano, Y., Yamamoto, K., Yamamoto, E., Kato, E.T., Watanabe, H., Saito, N., Domei, T., Tada, T., Nawada, R., Onodera, T., Suwa, S., Tamura, T., Ishii, K., Ando, K., Furukawa, Y., Kadota, K., Nakagawa, Y., Kimura, T., CREDO-Kyoto PCI/CABG Registry Cohort-2 and Cohort-3 Investigators. Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents. // *JACC: Asia*, 1, 2021, № 3, p. 345-356. ISSN 2772-3747. DOI 10.1016/j.jacasi.2021.08.010.
1623. You, S.C., Rho, Y., Bikdeli, B., Kim, J., Siapos, A., Weaver, J., Londhe, A., Cho, J., Park, J., Schuemie, M., Suchard, M.A., Madigan, D., Hripcsak, G., Gupta, A., Reich, C.G., Ryan, P.B., Park, R.W., Krumholz, H.M. Association of Ticagrelor vs Clopidogrel with Net Adverse Clinical Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. // *JAMA - Journal of the American Medical Association*, 324, 2020, № 16, p. 1640-1650. ISSN 0098-7484. DOI 10.1001/jama.2020.16167.
1624. Yu, Y., Pan, D., Bai, R., Luo, J., Tan, Y., Duan, W., Shi, D. P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention:

a meta-analysis of randomized controlled trials. // *Frontiers in Cardiovascular Medicine*, 10, 2023, art. no. 1197161. ISSN 2297-055X. DOI 10.3389/fcvm.2023.1197161.

1625. **Yuan, Z., Xiao, Y.** Research progress of antiplatelet de-escalation strategy in acute coronary syndrome [急性冠状动脉综合征抗血小板降阶治疗策略的研究进展]. // *Journal of Clinical Cardiology*, 38, 2022, № 10, p. 767-770. ISSN 1001-1439. DOI 10.13201/j.issn.1001-1439.2022.10.001.
1626. **Yun, K.H., Cho, J.Y., Lee, S.Y., Rhee, S.J., Kim, B.K., Hong, M.K., Jang, Y., Oh, S.K., the TICO Investigators.** Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial. // *Frontiers in Pharmacology*, 11, 2021, art. no. 620906. ISSN 1663-9812. DOI 10.3389/fphar.2020.620906.
1627. **Zeitouni, M., Guedeney, P.** Aspirin-Free Strategies in ACS: Is It the Drug or the Stent? // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 441-443. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.12.040.
1628. **Zeitouni, M., Silvain, J., Kerneis, M., Montalescot, G., J.-P., C.** Combination of antiplatelet and oral anticoagulation for chronic coronary artery disease: What is the rationale? [Antiagrégant et anticoagulant en association dans la maladie coronaire chronique: rationnel d'une double voie d'inhibition?]. // *Archives of Cardiovascular Diseases Supplements*, 11, 2019, p. S11-S19. ISSN 1878-6480. DOI 10.1016/S1878-6480(19)30445-8.
1629. **Zeng, Y., Xu, J., Deng, Y., Li, X., Chen, W., Tang, Y.** Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis. // *Frontiers in Cardiovascular Medicine*, 11, 2024, art. no. 1288659. ISSN 2297-055X. DOI 10.3389/fcvm.2024.1288659.
1630. **Zhang, C., Wang, X., Cardiovascular Group, Geriatrics Branch of Chinese Medical Association.** Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. // *Aging Medicine*, 6, 2023, № 1, p. 4-24. ISSN 2475-0360. DOI 10.1002/agm2.12234.
1631. **Zhang, D., Li, P., Qiu, M., Liang, Z., He, J., Li, Y., Han, Y.** Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention. // *Atherosclerosis*, 390, 2024, art. no. 117395. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2023.117395.
1632. **Zhang, J., He, S., Chen, Z., Li, Y., Guo, Y., He, Y.** The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk. // *Current Cardiology Reports*, 25, 2023, № 7, p. 669-680. ISSN 1523-3782. DOI 10.1007/s11886-023-01893-8.
1633. **Zhang, W.-B., Liu, L.-N., Liu, Y., Wang, Z.** Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis. // *Medicine (United States)*, 100, 2021, № 20, p. E26070. ISSN 0025-7974. DOI 10.1097/MD.00000000000026070.
1634. **Zhang, W.-J., Qiao, X., Guo, W.-F., Liang, X.-Y., Li, Y., Wang, Z.-L.** Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated

With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 615396. ISSN 2297-055X. DOI 10.3389/fcvm.2021.615396.

1635. **Zhang, W.-J., Qiao, X., Liang, X.-Y., Li, Y., Yang, R.-R., Wang, Z.-L.** Efficacy and safety of short-term 1–3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. // *Platelets*, 2020, p. 1-9. ISSN 0953-7104. DOI 10.1080/09537104.2020.1786039.
1636. **Zhang, X., Zhou, D., Song, S., Huang, X., Ding, Y., Meng, R.** Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis. // *Clinical and Applied Thrombosis/Hemostasis*, 30, 2024. ISSN 1076-0296. DOI 10.1177/10760296241244772.
1637. **Zhao, B., Wu, Q., Wang, L., Liao, C., Dong, Y., Xu, J., Wei, Y., Zhang, W.** Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis. // *Frontiers in Pharmacology*, 11, 2021, art. no. 592116. ISSN 1663-9812. DOI 10.3389/fphar.2020.592116.
1638. **Zhao, Z., Wang, J., Lei, M., Li, Y., Yang, Y., An, L., Sun, X., Li, C., Xue, Z.** Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. // *BMC Cardiovascular Disorders*, 23, 2023, № 1, art. no. 168. ISSN 1471-2261. DOI 10.1186/s12872-023-03152-8.
1639. **Zhu, H., Xu, X., Fang, X., Ying, F., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., Huang, J.** Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: A network meta-analysis of randomized controlled trials. // *Journal of the American Heart Association*, 10, 2021, № 6, art. no. e019184. ISSN 2047-9980. DOI 10.1161/JAHA.120.019184.
1640. **Ziada, K.M., Moliterno, D.J.** Dual Antiplatelet Therapy: Is It Time to Cut the Cord with Aspirin? // *JAMA - Journal of the American Medical Association*, 321, 2019, № 24, p. 2409-2411. ISSN 0098-7484. DOI 10.1001/jama.2019.7025.
1641. **Zimmermann, F.M., Pijls, N.H.J., Gould, K.L., Johnson, N.P.** Stenting “Vulnerable” But Fractional Flow Reserve–Negative Lesions: Potential Statistical Limitations of Ongoing and Future Trials. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 461-467. ISSN 1936-8798. DOI 10.1016/j.jcin.2020.05.036.

Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, **Petrov I**, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). *BMJ Open*. 2019 Mar 9;9(3):e026053. DOI 10.1136/bmjopen-2018-026053. PMID: 30852547; PMCID: PMC6429932.

**Cited by:**



1642. **Alexopoulos, D., Mpahara, A., Kassimis, G.** Omitting aspirin in PCI patients: Myth or reality? // *Cardiovascular Drugs and Therapy*, 33, 2019, № 6, p. 711-724. ISSN 0920-3206. DOI 10.1007/s10557-019-06916-7.
1643. **Bianco, M., Careggio, A., Destefanis, P., Luciano, A., Perrelli, M.G., Quadri, G., Rossini, R., Campo, G., Vizzari, G., D'Ascenzo, F., Anselmino, M., Biondi-Zoccai, G., Ibáñez, B., Montagna, L., Varbella, F., Cerrato, E.** P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized clinical trials including 29 089 patients. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 7, 2021, № 3, p. 196-205. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvaa038.
1644. **Brown, M.T., Bortfeld, K.S., Sperling, L.S., Wenger, N.K.** Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention. // *Current Cardiology Reviews*, 19, 2023, № 6, art. no. e020523216449, p. 9-22. ISSN 1573-403X. DOI 10.2174/1573403X19666230502163828.
1645. **Chen, Y., Lawrence, J., Hung, H.M.J., Stockbridge, N.** Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials. // *Therapeutic Innovation and Regulatory Science*, 55, 2021, № 1, p. 197-211. ISSN 2168-4790. DOI 10.1007/s43441-020-00206-3.
1646. **Clifford, C.R., Boudreau, R., Visintini, S., Orr, N., Fu, A.Y.N., Malhotra, N., Barry, Q., So, D.Y.F.** The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 5, p. 511-518. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvab080.
1647. **Khan, M.S., Usman, M.S., Van Spall, H.G.C., Greene, S.J., Baqal, O., Felker, G.M., Bhatt, D.L., Januzzi, J.L., Butler, J.** Endpoint adjudication in cardiovascular clinical trials. // *European Heart Journal*, 44, 2023, № 46, p. 4835-4846. ISSN 0195-668X. DOI 10.1093/eurheartj/ehad718.
1648. **Li, Y., Jing, Q., Wang, B., Wang, X., Li, J., Qiao, S., Chen, S., Angiolillo, D.J., Han, Y.** Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. // *American Heart Journal*, 228, 2020, p. 1-7. ISSN 0002-8703. DOI 10.1016/j.ahj.2020.07.005.
1649. **Sandner, S.E., Schunkert, H., Kastrati, A., Wiedemann, D., Misfeld, M., Böning, A., Tebbe, U., Nowak, B., Stritzke, J., Laufer, G., Von Scheidt, M.** Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: Insights from the TiCAB trial. // *European Journal of Cardio-thoracic Surgery*, 57, 2020, № 4, p. 732-739. ISSN 1010-7940. DOI 10.1093/ejcts/ezz313.

1650. **Scarsini, R., Banning, A.P.** DEFINE-ing the next steps in interventional cardiology. // *Cardiovascular Research*, 115, 2019, № 8, p. E74-E76. ISSN 0008-6363. DOI 10.1093/cvr/cvz114.
1651. **Zhang, W.-B., Liu, L.-N., Liu, Y., Wang, Z.** Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis. // *Medicine (United States)*, 100, 2021, № 20, p. E26070. ISSN 0025-7974. DOI 10.1097/MD.00000000000026070.

Zimarino M, Briguori C, Amat-Santos IJ, Radico F, Barbato E, Chieffo A, Cirillo P, Costa RA, Erglis A, Gamra H, Gil RJ, Kanic V, Kedev SA, Maddestra N, Nakamura S, Pellicano M, **Petrov I**, Strozzi M, Tesorio T, Vukcevic V, De Caterina R, Stankovic G; EuroBifurcation Club. Mid-term outcomes after percutaneous interventions in coronary bifurcations. *Int J Cardiol*. 2019 May 15;283:78-83. DOI 10.1016/j.ijcard.2018.11.139. Epub 2018 Dec 2. PMID: 30528620.

#### Cited by:

1652. **Calcagno, S., Massaro, G., Romagnoli, E.** "Crushing" the minimum: Nano-Crush technique, a novel approach for coronary bifurcation stenting. // *Minerva Cardiology and Angiology*, 70, 2022, № 4, p. 455-458. ISSN 2724-5683. DOI 10.23736/S2724-5683.22.05979-8.
1653. **Dall'ara, G., Grotti, S., Compagnone, M., Spartà, D., Guerrieri, G., Galvani, M., Tarantino, F.F.** How to deal with vessel diameter mismatch in left main bifurcation stenting. // *Journal of Cardiovascular Medicine*, 23, 2022, № 9, p. 600-607. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001356.
1654. **Gallone, G., Kang, J., Bruno, F., Han, J.-K., De Filippo, O., Yang, H.-M., Doronzo, M., Park, K.-W., Mittone, G., Kang, H.-J., Parma, R., Gwon, H.-C., Cerrato, E., Chun, W.J., Smolka, G., Hur, S.-H., Helft, G., Han, S.H., Muscoli, S., Song, Y.B., Figini, F., Choi, K.H., Boccuzzi, G., Hong, S.-J., Trabattoni, D., Nam, C.-W., Giammaria, M., Kim, H.-S., Conrotto, F., Escaned, J., Di Mario, C., D'Ascenzo, F., Koo, B.-K., de Ferrari, G.M.** Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention. // *American Journal of Cardiology*, 172, 2022, p. 18-25. ISSN 0002-9149. DOI 10.1016/j.amjcard.2022.02.015.
1655. **Kalinin, R.E., Suchkov, I.A., Karpov, A.V., Ilyasov, I.B., Shanaev, I.N.** Reasons and frequency of transition to a double-stent technique when correcting bifurcation lesions of the coronary arteries in patients with acute coronary syndrome. [Причины и частота перехода к двухстентовой методике при коррекции бифуркационных поражений коронарных артерий у пациентов с острым коронарным синдромом]. // *Grekov's Bulletin of Surgery*, 182, 2023, № 2, p. 29-37. ISSN 0042-4625. DOI 10.24884/0042-4625-2023-182-2-29-37.
1656. **Kirat, T.** Fundamentals of percutaneous coronary bifurcation interventions. // *World Journal of Cardiology*, 14, 2022, № 3, p. 108-138. ISSN 1949-8462. DOI 10.4330/wjc.v14.i3.108.
1657. **Mizuno, Y., Sakakura, K., Jinnouchi, H., Taniguchi, Y., Tsukui, T., Watanabe, Y., Yamamoto, K., Seguchi, M., Wada, H., Fujita, H.** Comparison of the Incidence

- of Periprocedural Myocardial Infarction in Bifurcation Lesions Between Medina (1,1,1) and (0,1,1) in Elective Percutaneous Coronary Intervention. // *International Heart Journal*, 63, 2022, № 3, p. 459-465. ISSN 1349-2365. DOI 10.1536/ihj.21-791.
1658. **Rigatelli, G., Zuin, M., Lee, A.** Coronary artery double stenting techniques and their results in complex left main bifurcation disease. // *Future Cardiology*, 16, 2020, № 5, p. 497-504. ISSN 1479-6678. DOI 10.2217/fca-2019-0081.
  1659. **Rigatelli, G., Zuin, M., Nikolov, P., Mileva, N., Vassilev, D.** One- and 3-year outcomes of percutaneous bifurcation left main revascularization with modern drug-eluting stents: a systematic review and meta-analysis. // *Clinical Research in Cardiology*, 110, 2021, № 1. ISSN 1861-0684. DOI 10.1007/s00392-020-01679-w.
  1660. **Rigatelli, G., Zuin, M., Vassilev, D., Dinh, H., Dell'Avvocata, F., Van Tan, N., Nghia, N., Ronco, F., Roncon, L.** Feasibility, safety and long-term outcomes of complex left main bifurcation treatment using the nano-inverted-t stenting: a multicentre prospective registry. // *International Journal of Cardiovascular Imaging*, 37, 2021, № 4, p. 1107-1119. ISSN 1569-5794. DOI 10.1007/s10554-020-02106-x.
  1661. **Rigatelli, G., Zuin, M., Vassilev, D., Rodino', G., Marchese, G., Pasquetto, G.** Technical Complications of Coronary Bifurcation Percutaneous Interventions. // *Journal of Clinical Medicine*, 11, 2022, № 22, art. no. 6801. ISSN 2077-0383. DOI 10.3390/jcm11226801.
  1662. **Serino, F., Di Serafino, L., Caiazzo, G.** Coronary artery bifurcation lesions. – In: *The Interventional Cardiology World: User's Manual of the Cath. Lab. for Students and Apprentices*, 2020, p. 205-247. ISBN 9781536186758; 9781536182491.
  1663. **Suleiman, S., Coughlan, J.J., Touma, G., Szirt, R.** Contemporary management of isolated ostial side branch disease: An evidence-based approach to medina 001 bifurcations. // *Interventional Cardiology: Reviews, Research, Resources*, 16, 2021, art. no. A1. ISSN 1756-1477. DOI 10.15420/ICR.2020.30.
  1664. **Varlamos, C., Lianos, I., Benetou, D.-R., Alexopoulos, D.** Left main disease and bifurcation percutaneous coronary intervention: Focus on antithrombotic therapy. // *US Cardiology Review*, 15, 2021, art. no. e11. ISSN 1758-3896. DOI 10.15420/usc.2020.34.
  1665. **Wang, H.-Y., Dou, K.-F., Guan, C., Xie, L., Huang, Y., Zhang, R., Yang, W., Wu, Y., Yang, Y., Qiao, S., Gao, R., Xu, B.** New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. // *Circulation: Cardiovascular Interventions*, 15, 2022, № 6, p. E011536. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.121.011536.
  1666. **Yurtdaş, M., Asoğlu, R., Özdemir, M., Asoğlu, E.** An upfront two-stent strategy for true coronary bifurcation lesions with a large side branch in acute coronary syndrome: A two-year follow-up study. // *Medicina (Lithuania)*, 56, 2020, № 3, art. no. 102. ISSN 1010-660X. DOI 10.3390/medicina56030102.
  1667. **Zuin, M., Chatzizisis, Y.S., Beier, S., Shen, C., Colombo, A., Rigatelli, G.** Role of secondary flows in coronary artery bifurcations before and after stenting: What is

**Petrov, I.,** Tasheva, I., Garvanski, I., Marzyanov, M., & Adam, G. (2018). Recanalization and stenting of total occlusions of the renal arteries for blood pressure control in resistant to treatment hypertension. *Cardiovascular Revascularization Medicine*. DOI 10.1016/j.carrev.2018.06.026.

**Cited by:**

1668. **Feyen, L., Artzner, C., Paprottka, P., Haage, P., Kröger, K., Alhmid, B., Katoh, M.** Endovascular treatment of renal artery stenosis in Germany: A retrospective analysis of the DEGIR registry 2018-2021. [Endovasculäre Behandlung von Nierenarterienstenosen in Deutschland: Eine retrospektive Analyse der DEGIR Datenbank von 2018-2021]. // *RoFo Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgebenden Verfahren*, 196, 2023, № 3, p. 283-291. ISSN 1438-9029. DOI 10.1055/a-2193-1209.

1669. **Li, P., Niu, G., Yan, Z., Zhang, B., Yang, M.** Case Report: Endovascular Treatment of Chronic Atherosclerotic Renal Artery Total Occlusions with Failed Medical Therapy. // *Frontiers in Surgery*, 9, 2022, art. no. 843568. ISSN 2296-875X. DOI 10.3389/fsurg.2022.843568.

**Petrov IS,** Tasheva IG, Tsonev SN, Stankov Z, Pavlova SA, Grozdisnki LN. Late outcomes after interventional treatment - Successful stenting of Takayasu arteritis lesions. Single center experience in Bulgaria. *Cor Vasa*. 2018;60(2):e114-121. DOI 10.1016/j.crvasa.2017.06.002.

**Cited by:**

1670. **Georgiev, T., Stoilov, R.** Bulgarian rheumatology: science and practice in a cost-constrained environment. // *Rheumatology International*, 39, 2019, № 3, p. 417-429. ISSN 0172-8172. DOI 10.1007/s00296-018-4202-2.

1671. **Kaszczewski, P.K., Ostrowski, T., Maciąg, R., Elwertowski, M., Chudziński, W., Gałazka, Z.** Multiple occlusions in extracranial arteries in patients with aortic arch syndrome: Is minimally invasive treatment still possible? Technical aspects of the treatment based on our own experience and a review of the literature. // *Wideochirurgia I Inne Techniki Maloinwazyjne*, 16, 2021, № 1, p. 183-190. ISSN 1895-4588. DOI 10.5114/WIITM.2020.94517.

**Petrov, I.,** Stankov, Z., Tasheva, I., & Stanilov, P. (2018). Endovascular Treatment of Acute Aortic Dissection Stanford Type A. *JACC: Cardiovascular Interventions*, 11(2), 218-219. DOI 10.1016/j.jcin.2017.10.048.

**Cited by:**

1672. **Bontinis, V., Antonopoulos, C.N., Bontinis, A., Sfyroeras, G.S., Kontopodis, N., Ioannou, C.V., Ktenidis, K., Geroulakos, G.** A systematic review and meta-

analysis of the streamliner multilayer flow modulator stent for treatment of complex aortic lesions. // *Journal of Vascular Surgery*, 74, 2021, № 2, p. 646-656.e9. ISSN 0741-5214. DOI 10.1016/j.jvs.2021.03.031.

1673. **Borulu, F., Birdal, O., Calik, E.S., Usta, H., Erkut, B.** Endovascular aortic repair with Cardiatis® multilayer flow modulator in a patient undergone ascending aortic replacement for type I aortic dissection. // *Turkish Journal of Vascular Surgery*, 32, 2023, № 2, p. 114-117. ISSN 2667-5080. DOI 10.9739/tjvs.2023.02.06.
1674. **Calik, E., Erkut, B.** Endovascular repair of a Stanford Type A dissection with the Cardiatis multilayer flow modulator. // *Interactive Cardiovascular and Thoracic Surgery*, 28, 2019, № 2, p. 321-323. ISSN 1569-9293. DOI 10.1093/icvts/ivy241.
1675. **Kreibich, M., Soekeland, T., Beyersdorf, F., Bavaria, J.E., Schröfel, H., Czerny, M., Rylski, B.** Anatomic feasibility of an endovascular valve-carrying conduit for the treatment of type A aortic dissection. // *Journal of Thoracic and Cardiovascular Surgery*, 157, 2019, № 1, p. 26-34.e1. ISSN 0022-5223. DOI 10.1016/j.jtcvs.2018.05.045.
1676. **Liu, D., Wang, H., Li, Y., Ma, Q., Wang, W., Wang, X., Su, J.** Minimally Invasive Device Repair of Ascending Aortic Pathology in Selected High-risk Patients. // *Annals of Surgery*, 276, 2022, № 1, p. E61-E63. ISSN 0003-4932. DOI 10.1097/SLA.0000000000005333.
1677. **Vasudevan, T.M., Sivakumaran, Y.** “More or less”: management of type A aortic dissections in the endovascular era. // *Indian Journal of Thoracic and Cardiovascular Surgery*, 38, 2022, p. 193-197. ISSN 0970-9134. DOI 10.1007/s12055-021-01316-9.
1678. **Wang, C.** The current status and prospect of catheter-based treatment of ascending aorta and aortic root diseases. [腔内修复术在升主动脉及主动脉根部疾病中的应用.] // *Zhonghua Wai Ke Za Zhi / Chinese Journal of Surgery*, 59, 2021, № 6, p. 443-446. ISSN 0529-5815. DOI 10.3760/cma.j.cn112139-20200910-00693.

Russo, V., Rago, A., De Rosa, M., Papa, A., Simova, I., & **Petrov, I.** et al. (2018). Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. *International Journal Of Cardiology*, 270, 149-153. DOI 10.1016/j.ijcard.2018.06.063.

#### Cited by:

1679. **Brignole, M., Rivasi, G.** New insights in diagnostics and therapies in syncope: A novel approach to non-cardiac syncope. // *Heart*, 107, 2021, № 11, p. 864-873. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-318261.
1680. **Glikson, M., Nielsen, J.C., Kronborg, M.B., Michowitz, Y., Auricchio, A., Barbash, I.M., Barrabés, J.A., Boriani, G., Braunschweig, F., Brignole, M., Burri, H., Coats, A.J.S., Deharo, J.-C., Delgado, V., Diller, G.-P., Israel, C.W., Keren, A., Knops, R.E., Kotecha, D., Leclercq, C., Merkely, B., Starck, C., Thylén, I., Tolosana, J.M., Grupo de Documentos Científicos de la ESC.** 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed



by the Task Force on Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA). [Grupo de trabajo sobre estimulación cardíaca y terapia de resincronización cardíaca de la Sociedad Europea de Cardiología (ESC): Desarrollada en colaboración con la European Heart Rhythm Association (EHRA).] // *Revista Española de Cardiología*, 75, 2022, № 5, p. 430.e1-430.e86. ISSN 0300-8932. DOI 10.1016/j.recesp.2021.10.025.

1681. **Glikson, M., Nielsen, J.C., Kronborg, M.B., Michowitz, Y., Auricchio, A., Barbash, I.M., Barrabes, J.A., Boriani, G., Braunschweig, F., Brignole, M., Burri, H., Coats, A.J.S., Deharo, J.-C., Delgado, V., Diller, G.-P., Israel, C.W., Keren, A., Knops, R.E., Kotecha, D., Leclercq, C., Merkely, B., Starck, C., Thylen, I., Tolosana, J.M., Leyva, F., Linde, C., Abdelhamid, M., Aboyans, V., Arbelo, E., Asteggiano, R., Barón-Esquivias, G., Bauersachs, J., Biffi, M., Birgersdotter-Green, U., Bongiorni, M.G., Borger, M.A., Celutkienė, J., Cikes, M., Daubert, J.-C., Drossart, I., Ellenbogen, K., Elliott, P.M., Fabritz, L., Falk, V., Fauchier, L., Fernández-Aviles, F., Foldager, D., Gadler, F., De Vinuesa, P.G.G., Gorenek, B., Guerra, J.M., Hermann Haugaa, K., Hendriks, J., Kahan, T., Katus, H.A., Konradi, A., Koskinas, K.C., Law, H., Lewis, B.S., Linker, N.J., Løchen, M.-L., Lumens, J., Mascherbauer, J., Mullens, W., Nagy, K.V., Prescott, E., Raatikainen, P., Rakisheva, A., Reichlin, T., Ricci, R.P., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sutton, R., Suwalski, P., Svendsen, J.H., Touyz, R.M., Van Gelder, I.C., Vernooy, K., Waltenberger, J., Whinnett, Z., Witte, K.K.** 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). // *Europace*, 24, 2022, № 1, p. 71-164. ISSN 1099-5129. DOI 10.1093/europace/euab232.
1682. **Ling, L., Feng, T., Xue, X., Ling, Z.** Etiology, risk factors, and prognosis of patients with syncope: A single-center analysis. // *Annals of Noninvasive Electrocardiology*, 26, 2021, № 6, art. no. e12891. ISSN 1082-720X. DOI 10.1111/anec.12891.
1683. **Morillo, C.A., Brignole, M.** Pacing for vasovagal syncope: Tips for use in practice. // *Autonomic Neuroscience: Basic and Clinical*, 241, 2022, art. no. 102998. ISSN 1566-0702. DOI 10.1016/j.autneu.2022.102998.
1684. **Pombo Jiménez, M., Cano Pérez, Ó., Chimeno García, J., Lorente Carreño, D.** Selection of the best of 2019 in cardiac pacing. [Selección de lo mejor del año 2019 en estimulación cardíaca]. // *REC: CardioClinics*, 55, 2020, p. 25-30. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.09.010.
1685. **Táborský, M., Kautzner, J., Fedorco, M., Curila, K., Wünschová, H., Pysko, J., Novák, M., Kozák, M., Válek, M., Polášek, R., Kepřt, P., Kubícková, M., Plášek, J., Gloger, V., Bulava, A., Vancura, V., Skála, T., Parízek, P., Danek, J.** 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. [Doporučené postupy ESC pro kardiostimulaci a srdeční resynchronizační terapii: aktualizace 2021. Preklad dokumentu pripravený Ceskou kardiologickou spolecností]. // *Cor et Vasa*, 64, 2022, p. 7-86. ISSN 0010-8650. DOI 10.33678/cor.2022.024.

1686. **Toon, L.-T., Roberts, P.R.** The Micra Transcatheter Pacing System: past, present and the future. // *Future Cardiology*, 19, 2023, № 15, p. 735-746. ISSN 1479-6678. DOI 10.2217/fca-2023-0093.

## **2017**

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; **CHAMPION Investigators**. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2017 Jan 17;69(2):176-185. DOI 10.1016/j.jacc.2016.10.055. PMID: 28081827.

### **Cited by:**

1687. **Abo-Aly, M., George, B., Shokri, E., Chelvarajan, L., El-Helw, M., Smyth, S.S., Abdel-Latif, A., Ziada, K.** Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction. // *Journal of Thrombosis and Thrombolysis*, 52, 2021, № 3, p. 934-940. ISSN 0929-5305. DOI 10.1007/s11239-020-02345-8.
1688. **Alexopoulos, D., Katogiannis, K., Sfantou, D., Lekakis, J.** Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice? // *Platelets*, 29, 2018, № 3, p. 228-237. ISSN 0953-7104. DOI 10.1080/09537104.2017.1353685.
1689. **Alexopoulos, D., Pappas, C., Sfantou, D., Lekakis, J.** Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 23, 2018, № 1, p. 13-22. ISSN 1074-2484. DOI 10.1177/1074248417715004.
1690. **Brar, S.S.** Cangrelor: The Paradox of Choice. // *Journal of the American College of Cardiology*, 69, 2017, № 2, p. 186-188. ISSN 0735-1097. DOI 10.1016/j.jacc.2016.11.020.
1691. **Bulluck, H., Chan, M.H.H., Bryant, J.A., Chai, P., Chawla, A., Chua, T.S., Chung, Y.-C., Fei, G., Ho, H.H., Ho, A.F.W., Hoe, A.J., Imran, S.S., Lee, C.-H., Lim, S.H., Liew, B.W., Yun, P.L.Z., Hock, M.O.E., Paradies, V., Roe, M.T., Teo, L., Wong, A.S., Wong, E., Wong, P.E., Watson, T., Chan, M.Y., Tan, J.W., Hausenloy, D.J.** Platelet inhibition to target reperfusion injury trial: Rationale and study design. // *Clinical Cardiology*, 42, 2019, № 1, p. 5-12. ISSN 0160-9289. DOI 10.1002/clc.23110.
1692. **Chioncel, O., Parissis, J., Mebazaa, A., Thiele, H., Desch, S., Bauersachs, J., Harjola, V.-P., Antohi, E.-L., Arrigo, M., Gal, T.B., Celutkiene, J., Collins, S.P., DeBacker, D., Ilescu, V.A., Jankowska, E., Jaarsma, T., Keramida, K., Lainscak, M., Lund, L.H., Lyon, A.R., Masip, J., Metra, M., Miro, O., Mortara, A., Mueller, C., Mullens, W., Nikolaou, M., Piepoli, M., Price, S., Rosano, G., Vieillard-Baron, A., Weinstein, J.M., Anker, S.D., Filippatos, G., Ruschitzka, F., Coats, A.J.S., Seferovic, P.** Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology. // *European Journal of Heart Failure*, 22, 2020, № 8, p. 1315-1341. ISSN 1388-9842. DOI 10.1002/ejhf.1922.

1693. **Cohen, M.V., Downey, J.M.** What Are Optimal P2Y<sub>12</sub> Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome? // *Journal of Cardiovascular Pharmacology and Therapeutics*, 25, 2020, № 2, p. 121-130. ISSN 1074-2484. DOI 10.1177/1074248419882923.
1694. **Du, N., Wang, L.-X., Liu, Y.-L., Yin, X.-L., Zhao, J.-S., Yang, L.** Effect of tirofiban in treating patients with progressive ischemic stroke. // *European Review for Medical and Pharmacological Sciences*, 26, 2022, № 6, p. 2098-2105. ISSN 1128-3602. DOI 10.26355/eurev\_202203\_28357.
1695. **Erlinge, D.** Cangrelor for ST-Segment-Elevation Myocardial Infarction: Pharmacodynamic Evidence Is in. // *Circulation*, 139, 2019, № 14, p. 1671-1673. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.119.039253.
1696. **Evoy, K.E., Isch, J., Raber, H.** Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. – In: *Side Effects of Drugs Annual*, 40, 2018, p. 447-461. ISBN 9780444641199. DOI 10.1016/bs.seda.2018.06.012.
1697. **Grimfjärd, P., Lagerqvist, B., Erlinge, D., Varenhorst, C., James, S.** Clinical use of cangrelor: Nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). // *European Heart Journal - Cardiovascular Pharmacotherapy*, 5, 2019, № 3, art. no. pvz002, p. 151-157. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvz002.
1698. **Kelly, M.A.** Neurological complications of cardiovascular drugs. // *Handbook of Clinical Neurology*, 177, 2021, p. 319-344. ISSN 0072-9752. DOI 10.1016/B978-0-12-819814-8.00020-2.
1699. **Kumbhani, D.J., Cannon, C.P., Beavers, C.J., Bhatt, D.L., Cuker, A., Gluckman, T.J., Marine, J.E., Mehran, R., Messe, S.R., Patel, N.S., Peterson, B.E., Rosenfield, K., Spinler, S.A., Thourani, V.H.** 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. // *Journal of the American College of Cardiology*, 77, 2021, № 5, p. 629-658. ISSN 0735-1097. DOI 10.1016/j.jacc.2020.09.011.
1700. **Leonardi, S., Bhatt, D.L.** Practical considerations for cangrelor use in patients with acute coronary syndromes. // *European Heart Journal: Acute Cardiovascular Care*, 8, 2019, № 1, p. 39-44. ISSN 2048-8726. DOI 10.1177/2048872617707960.
1701. **Lim, M.J.R., Zheng, Y., Soh, R.Y.-H., Foo, Q.X.J., Djohan, A.H., Nga Diong Weng, V., Ho, J.S.-Y., Yeo, T.T., Sim, H.-W., Yeo, T.-C., Tan, H.-C., Chan, M.Y.-Y., Loh, J.P.-Y., Sia, C.-H.** Symptomatic intracerebral hemorrhage after non-emergency percutaneous coronary intervention: Incidence, risk factors, and association with cardiovascular outcomes. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 936498. ISSN 2297-055X. DOI 10.3389/fcvm.2022.936498.
1702. **Lu, H., Guan, W., Zhou, Y., Tang, Z., Bao, H.** Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. // *Diabetes Therapy*, 10, 2019, № 3, p. 937-950. ISSN 1869-6953. DOI 10.1007/s13300-019-0593-7.

1703. **Mamas, M.A., Curzen, N.** Hobson's Choice: Platelet Inhibition and Thrombocytopenia. // *Circulation: Cardiovascular Interventions*, 11, 2018, № 4, art. no. e006577. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.118.006577.
1704. **Mostafa, M.R., Eid, M.M., Awad, A.K., Takla, A., Hassan, A.R., Katamesh, B.E., AlBarakat, M.M., Ziada, A.R., Mohamed, S., Al-Azizi, K.M., Goldsweig, A.M.** Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. // *American Journal of Cardiovascular Drugs*, 24, 2024, № 1, p. 71-81. ISSN 1175-3277. DOI 10.1007/s40256-023-00616-2.
1705. **Ratcliffe, F.M., Kharbanda, R., Foëx, P.** Perioperative ST-elevation myocardial infarction: with time of the essence, is there a case for guidelines? // *British Journal of Anaesthesia*, 123, 2019, № 5, p. 548-554. ISSN 0007-0912. DOI 10.1016/j.bja.2019.08.009.
1706. **Rubboli, A., Patti, G.** What is the role for glycoprotein IIB/IIIA inhibitor use in the catheterization laboratory in the current era? // *Current Vascular Pharmacology*, 16, 2018, № 5, p. 451-458. ISSN 1570-1611. DOI 10.2174/1570161116666180117102422.
1707. **Topaz, O., Topaz, A.** Power-sourced mechanical thrombectomy in the management of thrombus-containing atherosclerotic lesions. – In: *Cardiovascular Thrombus: From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions*, 2018, p. 261-283. ISBN 9780128126158; 9780128126165. DOI 10.1016/B978-0-12-812615-8.00018-1.
1708. **van der Sangen, N.M.R., Cheung, H.Y., Verouden, N.J.W., Appelman, Y., Beijik, M.A.M., Claessen, B.E.P.M., Delewi, R., Knaapen, P., Lemkes, J.S., Nap, A., Vis, M.M., Kikkert, W.J., Henriques, J.P.S.** Cangrelor use in routine practice: a two-center experience. // *Journal of Clinical Medicine*, 10, 2021, № 13, art. no. 2829. ISSN 2077-0383. DOI 10.3390/jcm10132829.
1709. **Varvařovský, I.** Cangrelor (KENGREXAL®): A new old acquaintance. [Cangrelor (KENGREXAL®)-Nový starý znám.] // *Intervencni a Akutni Kardiologie*, 19, 2020, № 1, p. 63-66. ISSN 1213-807X. DOI 10.36290/KAR.2020.020.
1710. **Zhao, C., Li, S., Zhang, J., Huang, Y., Zhang, L., Zhao, F., Du, X., Hou, J., Zhang, T., Shi, C., Wang, P., Huo, R., Woodman, O.L., Qin, C.X., Xu, H., Huang, L.** Current state and future perspective of cardiovascular medicines derived from natural products. // *Pharmacology and Therapeutics*, 216, 2020, art. no. 107698. ISSN 0163-7258. DOI 10.1016/j.pharmthera.2020.107698.

Sultan, S.; Kavanagh, E. P.; Stefanov, F.; Sultan, M.; Elhelali, A.; Costache, V.; Diethrich, E.; Hynes, N.; **Petrov, I.**; Grozdinski, L.; Moosdorf, R.; Ramsey-Semmelweis, E.; Mathias, K.; Chocron, S.; Bouayad, M. N., Endovascular management of chronic symptomatic aortic dissection with the Streamliner Multilayer Flow Modulator: Twelve-month outcomes from the global registry. *Journal of Vascular Surgery* **2017**, 65 (4), 940-950.

**Cited by:**

1711. **Baptista-Strazzi, A.P.W., Aun, R., Sincos, I.R., Tobita, A.M., Portugal, M.F.C., de Paula, V.P., Kaufmann, O., Wolosker, N.** Multilayer stents affect the final

- diameter of aortic aneurysms and maintain renal artery patency for a short time in a swine experimental model. // *Clinics*, 76, 2021, art. no. e2812. ISSN 1807-5932. DOI 10.6061/CLINICS/2021/E2812.
1712. **Bhave, N.M., Nienaber, C.A., Clough, R.E., Eagle, K.A.** Multimodality Imaging of Thoracic Aortic Diseases in Adults. // *JACC: Cardiovascular Imaging*, 11, 2018, № 6, p. 902-919. ISSN 1936-878X. DOI 10.1016/j.jcmg.2018.03.009.
  1713. **Dai, Y., Luo, G., Dai, X., Liu, H.** Hemodynamic Effects of Multiple Overlapping Uncovered Stents on Aortic Dissection: Surgical Strategies and Implications for False Lumen Thrombosis. // *Cardiovascular Engineering and Technology*, 11, 2020, № 1, p. 24-35. ISSN 1869-408X. DOI 10.1007/s13239-019-00443-0.
  1714. **Hinojosa, C.A., Anaya-Ayala, J.E., García-Alva, R., Escobar-Preciado, M., Luna-Vargas, L., Cuen-Ojeda, C., López-Peña, G., Arzola, L., Lozano-Corona, R.** Flow diverter and modulator stents in the treatment of aortic pathology. [Stents diversores y moduladores de flujo en el tratamiento de patología aórtica]. // *Revista Mexicana de Angiología*, 47, 2019, № 2, p. 88-95. ISSN 0037-7740.
  1715. **Ibrahim, W., Spanos, K., Gussmann, A., Nienaber, C.A., Tessarek, J., Walter, H., Thalwitzer, J., Debus, S.E., Tsilimparis, N., Kölbel, T.** Early and midterm outcome of Multilayer Flow Modulator stent for complex aortic aneurysm treatment in Germany. // *Journal of Vascular Surgery*, 68, 2018, № 4, p. 956-964. ISSN 0741-5214. DOI 10.1016/j.jvs.2018.01.037.
  1716. **Kankılıç, N., Aydın, M.S.** Results of a three-year follow-up after endovascular therapy with multilayer flow modulator in complex thoracoabdominal aortic aneurysm: A case report. // *Vascular*, 29, 2021, № 1, p. 35-39. ISSN 1708-5381. DOI 10.1177/1708538120933516.
  1717. **Kremer Diniz, B., Sena, M., Henrique Lima, P.** Multilayer Stent for Emergency Treatment of Acute Type B Aortic Dissection: A Case Report. // *Vascular and Endovascular Surgery*, 58, 2024, № 2, p. 205-208. DOI 10.1177/15385744231190448.
  1718. **Makhija, R.R., Mukherjee, D.** Endovascular Therapies for Type B Aortic Dissection. // *Cardiovascular and Hematological Disorders - Drug Targets*, 21, 2021, № 3, p. 167-178. ISSN 1871-529X. DOI 10.2174/1871529X21666210924141446.
  1719. **Mastracci, T.M.** Aneurysms don't have borders. // *Journal of Vascular Surgery*, 67, 2018, № 5, p. 1328-1336. ISSN 0741-5214. DOI 10.1016/j.jvs.2017.12.045.
  1720. **Oderich, G.S.** Evidence of use of multilayer flow modulator stents in treatment of thoracoabdominal aortic aneurysms and dissections. // *Journal of Vascular Surgery*, 65, 2017, № 4, p. 935-937. ISSN 0741-5214. DOI 10.1016/j.jvs.2016.12.092.
  1721. **Rikhtegar Nezami, F., Athanasiou, L.S., Amrute, J.M., Edelman, E.R.** Vascular biology and microcirculation: Multilayer flow modulator enhances vital organ perfusion in patients with type b aortic dissection. // *American Journal of Physiology - Heart and Circulatory Physiology*, 315, 2018, № 5, p. H1182-H1193. ISSN 0363-6135. DOI 10.1152/ajpheart.00199.2018.



1722. **Schafigh, M.J., Kohistani, Z., Schiller, W., Probst, C.** Retrograde Stanford type A dissection caused by a multilayer stent graft in a patient with chronic type B dissection. // *Interactive Cardiovascular and Thoracic Surgery*, 28, 2019, № 4, p. 655-656. ISSN 1569-9293. DOI 10.1093/icvts/ivy313.
1723. **Spanos, K., Kölbel, T.** Role of Endoluminal Techniques in the Management of Chronic Type B Aortic Dissection. // *CardioVascular and Interventional Radiology*, 43, 2020, № 12, p. 1808-1820. ISSN 0174-1551. DOI 10.1007/s00270-020-02566-7.
1724. **Vignau Cano, J.M., Daroca Martínez, T., Gómez Vidal, M., Bermúdez García, A., Macías Rubio, D.** Endovascular management of aortic arch aneurysm using the multilayer flow modulator stent. [Tratamiento endovascular de aneurisma en arco aórtico usando la endoprótesis multicapa moduladora de flujo]. // *Cirugía Cardiovascular*, 26, 2019, № 1, p. 59-61. ISSN 1134-0096. DOI 10.1016/j.circv.2018.08.004.
1725. **Xia, S., Song, C., Zhang, L., Pei, Y., Yuan, L., Li, H., Mao, H., Lu, Q.** Efficacy of endovascular treatment of distal aortic dissection involving abdominal visceral segment with bare-metal stents related technique. [裸支架相关技术腔内治疗涉及分支区的主动脉远端夹层]. // *Chinese Journal of Cardiology*, 49, 2021, № 4, p. 380-386. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210301-00184.
1726. **Yoshida, R.A., Costa, R.F., Cunha, D.O., Palhares, R.M., Jaldin, R.G., Sobreira, M.L., Pimenta, R.E.F., Yoshida, W.B.** Unibody design for aortic disease with a narrow aortic bifurcation: Tips and tricks for success. [Design unimodular para doença da aorta com bifurcação aórtica estreita: Dicas para o sucesso]. // *Jornal Vascular Brasileiro*, 20, 2021, art. no. e20200230. ISSN 1677-5449. DOI 10.1590/1677-5449.200230.
1727. **Zeng, Z., Zhao, Y., Wu, M., Bao, X., Li, T., Feng, J., Feng, R., Jing, Z.** Endovascular strategies for post-dissection aortic aneurysm (PDAA). // *Journal of Cardiothoracic Surgery*, 15, 2020, № 1, art. no. 287. ISSN 1749-8090. DOI 10.1186/s13019-020-01331-8.

## **2016**

Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, Merkely B, Musialek P, Wojakowski W, Andreka P, Horvath IG, Katz A, Dolatabadi D, El Nakadi B, Arandjelovic A, Edes I, Seferovic PM, Obradovic S, Vanderheyden M, Jagic N, **Petrov I**, Atar S, Halabi M, Gelev VL, Shochat MK, Kasprzak JD, Sanz-Ruiz R, Heyndrickx GR, Nyolczas N, Legrand V, Guédès A, Heyse A, Moccetti T, Fernandez-Aviles F, Jimenez-Quevedo P, Bayes-Genis A, Hernandez-Garcia JM, Ribichini F, Gruchala M, Waldman SA, Teerlink JR, Gersh BJ, Povsic TJ, Henry TD, Metra M, Hajjar RJ, Tendera M, Behfar A, Alexandre B, Seron A, Stough WG, Sherman W, Cotter G, Wijns W; CHART Program. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. *Eur Heart J*. 2016 Dec. 1;38(9):648-660. PMID 28025189, DOI 10.1093/eurheartj/ehw543.

**Cited by:**

1728. **Aboulgheit, A., Karbasiafshar, C., Sabra, M., Zhang, Z., Sodha, N., Abid, M.R., Sellke, F.W.** Extracellular vesicles improve diastolic function and substructure in normal and high-fat diet models of chronic myocardial ischemia. // *Journal of Thoracic and Cardiovascular Surgery*, 164, 2022, № 6, p. e371-e384. ISSN 0022-5223. DOI 10.1016/j.jtcvs.2021.07.062.
1729. **Aggarwal, R., Shao, A., Potel, K.N., So, S.W., Swingen, C.M., Wright, C.A., Hocum Stone, L.L., McFalls, E.O., Butterick, T.A., Kelly, R.F.** Stem cell-derived exosome patch with coronary artery bypass graft restores cardiac function in chronically ischemic porcine myocardium. // *Journal of Thoracic and Cardiovascular Surgery*, 166, 2023, № 6, p. e512-e530. ISSN 0022-5223. DOI 10.1016/j.jtcvs.2023.07.014.
1730. **Ayyat, K.S., Argawi, A., Mende, M., Steinhoff, G., Borger, M.A., Deebis, A.M., McCurry, K.R., Garbade, J.** Combined Coronary Artery Bypass Surgery With Bone Marrow Stem Cell Transplantation: Are We There Yet? // *Annals of Thoracic Surgery*, 108, 2019, № 6, p. 1913-1921. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2019.05.094.
1731. **Balkan, W., Banerjee, M., Trapani, J., Hare, J.M.** Marrow-derived stromal cells for cardiac regeneration. – In: *Emerging Technologies for Heart Diseases: Volume 1: Treatments for Heart Failure and Valvular Disorders*, 2020, p. 193-216. ISBN 9780128137062. DOI 10.1016/B978-0-12-813706-2.00010-5.
1732. **Banerjee, M.N., Bolli, R., Hare, J.M.** Clinical studies of cell therapy in cardiovascular medicine recent developments and future directions. // *Circulation Research*, 123, 2018, № 2, p. 266-287. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.118.311217.
1733. **Banovic, M., Poglajen, G., Vrtovec, B., Ristic, A.** Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure. // *Journal of Cardiovascular Development and Disease*, 9, 2022, № 12, art. no. 429. ISSN 2308-3425. DOI 10.3390/jcdd9120429.
1734. **Banovic, M., Pusnik-Vrckovnik, M., Nakou, E., Vardas, P.** Myocardial regeneration therapy in heart failure: Current status and future therapeutic implications in clinical practice. // *International Journal of Cardiology*, 260, 2018, p. 124-130. ISSN 0167-5273. DOI 10.1016/j.ijcard.2018.01.144.
1735. **Bartolucci, J., Verdugo, F.J., González, P.L., Larrea, R.E., Abarzua, E., Goset, C., Rojo, P., Palma, I., Lamich, R., Pedreros, P.A., Valdivia, G., Lopez, V.M., Nazzari, C., Alcayaga-Miranda, F., Cuenca, J., Brobeck, M.J., Patel, A.N., Figueroa, F.E., Khoury, M.** Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). // *Circulation Research*, 121, 2017, № 10, p. 1192-1204. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.117.310712.
1736. **Biagi, D., Fantozzi, E.T., Campos-Oliveira, J.C., Naghetini, M.V., Ribeiro, A.F., Rodrigues, S., Ogusku, I., Vanderlinde, R., Christie, M.L.A., Mello, D.B., de Carvalho, A.C.C., Valadares, M., Cruvinel, E., Dariolli, R.** In situ matured early-stage human-induced pluripotent stem cell-derived cardiomyocytes improve cardiac function by enhancing segmental contraction in infarcted rats. // *Journal of*

1737. **Bolli, R., Solankhi, M., Tang, X.-L., Kahlon, A.** Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. // *Cardiovascular Research*, 118, 2022, № 4, p. 951-976. ISSN 0008-6363. DOI 10.1093/cvr/cvab135.
1738. **Braunwald, E.** Cell-based therapy in cardiac regeneration: An overview. // *Circulation Research*, 123, 2018, № 2, p. 132-137. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.118.313484.
1739. **Broughton, K.M.** Prevalence of comorbidities in heart failure patients and those treated with cellular therapeutics. // *Expert Review of Cardiovascular Therapy*, 17, 2019, № 8, p. 597-604. ISSN 1477-9072. DOI 10.1080/14779072.2019.1653185.
1740. **Broughton, K.M., Sussman, M.A.** Enhancement strategies for cardiac regenerative cell therapy focus on adult stem cells. // *Circulation Research*, 123, 2018, № 2, p. 177-187. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.118.311207.
1741. **Cassani, M., Fernandes, S., Vrbsky, J., Ergir, E., Cavalieri, F., Forte, G.** Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. // *Frontiers in Bioengineering and Biotechnology*, 8, 2020, art. no. 323. ISSN 2296-4185. DOI 10.3389/fbioe.2020.00323.
1742. **Clément, F., Grockowiak, E., Zylbersztejn, F., Fossard, G., Gobert, S., Maguer-Satta, V.** Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence. // *Stem Cell Investigation*, 4, 2017, № 7. ISSN 2306-9759. DOI 10.21037/sci.2017.07.03.
1743. **Constantinides, C.** Is There Preclinical and Clinical Value for 19F MRI in Stem Cell Cardiac Regeneration? // *Cell Transplantation*, 29, 2020. ISSN 0963-6897. DOI 10.1177/0963689720954434.
1744. **Cvetinovic, N., Sekularac, N., Haehling, S.V., Tahirovic, E., Inkrot, S., Lainscak, M., Apostolovic, S., Putnikovic, B., Waagstein, F., Gelbrich, G., Aleksic, A., Loncar, G., Düngen, H.-D.** The  $\beta$ -blocker uptitration in elderly with heart failure regarding biomarker levels: CIBIS-ELD substudy. // *Biomarkers in Medicine*, 12, 2018, № 11, p. 1261-1270. ISSN 1752-0363. DOI 10.2217/bmm-2018-0136.
1745. **De Luca, M., Aiuti, A., Cossu, G., Parmar, M., Pellegrini, G., Robey, P.G.** Advances in stem cell research and therapeutic development. // *Nature Cell Biology*, 21, 2019, № 7, p. 801-811. ISSN 1465-7392. DOI 10.1038/s41556-019-0344-z.
1746. **Descamps, B., Saif, J., Benest, A.V., Biglino, G., Bates, D.O., Chamorro-Jorganes, A., Emanuelli, C.** BDNF (Brain-Derived Neurotrophic Factor) promotes embryonic stem cells differentiation to endothelial cells via a molecular pathway, including MicroRNA-214, EZH2 (Enhancer of Zeste Homolog 2), and eNOS (Endothelial Nitric Oxide Synthase). // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 38, 2018, № 9, p. 2117-2125. ISSN 1079-5642. DOI 10.1161/ATVBAHA.118.311400.

1747. **Desgres, M., Menasché, P.** Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations. // *Cell Stem Cell*, 25, 2019, № 5, p. 594-606. ISSN 1934-5909. DOI 10.1016/j.stem.2019.10.001.
1748. **Diaz-Navarro, R., Urrútia, G., Cleland, J.G.F., Poloni, D., Villagran, F., Acosta-Dighero, R., Bangdiwala, S.I., Rada, G., Madrid, E.** Stem cell therapy for dilated cardiomyopathy. // *Cochrane Database of Systematic Reviews*, 2021, № 7, art. no. CD013433. ISSN 1465-1858. DOI 10.1002/14651858.CD013433.pub2.
1749. **Dolati, S., Yousefi, M., Mahdipour, M., Afrasiabi Rad, A., Pishgahi, A., Nouri, M., Jodati, A.R.** Mesenchymal stem cell and bone marrow mononuclear cell therapy for cardiomyopathy: From bench to bedside. // *Journal of Cellular Biochemistry*, 120, 2019, № 1, p. 45-55. ISSN 0730-2312. DOI 10.1002/jcb.27531.
1750. **Epstein, S.E., Lipinski, M.J., Luger, D.** Persistent inflammation, stem cell-induced systemic anti-inflammatory effects, and need for repeated stem cell injections: Critical concepts influencing optimal stem cell strategies for treating acute myocardial infarction and heart failure. // *Journal of the American Heart Association*, 7, 2018, № 4, art. no. e008524. ISSN 2047-9980. DOI 10.1161/JAHA.118.008524.
1751. **Epstein, S.E., Luger, D., Lipinski, M.J.** Large animal model efficacy testing is needed prior to launch of a stem cell clinical trial: An evidence-lacking conclusion based on conjecture. // *Circulation Research*, 121, 2017, № 5, p. 496-498. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.117.311562.
1752. **Fan, M., Huang, Y., Chen, Z., Xia, Y., Chen, A., Lu, D., Wu, Y., Zhang, N., Qian, J., Ge, J.** Efficacy of mesenchymal stem cell therapy in systolic heart failure: A systematic review and meta-analysis. // *Stem Cell Research and Therapy*, 10, 2019, № 1, art. no. 150. ISSN 1757-6512. DOI 10.1186/s13287-019-1258-1.
1753. **Florea, V., Banerjee, M.N., Bagno, L., Rieger, A.C., Balkan, W., Hare, J.M.** Stem Cells and Myocardial Repair. – In: *Encyclopedia of Tissue Engineering and Regenerative Medicine: Volumes 1-3*, 2019, p. V2-91-V2-113. ISBN 9780128137000; 9780128136997. DOI 10.1016/B978-0-12-801238-3.65454-5.
1754. **Florea, V., Banerjee, M.N., Bagno, L., Rieger, A.C., Balkan, W., Hare, J.M.** Stem cells and myocardial repair. – In: *Encyclopedia of Tissue Engineering and Regenerative Medicine*, 1-3, 2019, p. 91-113. ISBN 9780128136997; 9780128137000. DOI 10.1016/B978-0-12-801238-3.65454-5.
1755. **Florea, V., Rieger, A.C., DiFede, D.L., El-Khorazaty, J., Natsumeda, M., Banerjee, M.N., Tompkins, B.A., Khan, A., Schulman, I.H., Landin, A.M., Mushtaq, M., Golpanian, S., Lowery, M.H., Byrnes, J.J., Hendel, R.C., Cohen, M.G., Valasaki, K., Pujol, M.V., Ghersin, E., Miki, R., Delgado, C., Abuzeid, F., Vidro-Casiano, M., Saltzman, R.G., DaFonseca, D., Caceres, L.V., Ramdas, K.N., Mendizabal, A., Heldman, A.W., Mitrani, R.D., Hare, J.M.** Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT study). // *Circulation Research*, 121, 2017, № 11, p. 1279-1290. ISSN 0009-7330. DOI: 10.1161/CIRCRESAHA.117.311827.
1756. **Gara, E., Kosztin, A., Harding, S.E., Földes, G.** Stem cell therapy to treat heart failure. – In: *Comprehensive Biotechnology*, 2019, p. 286-303. ISBN 9780444640475; 9780444640468. DOI 10.1016/B978-0-444-64046-8.00302-5.

1757. **Ghiroldi, A., Piccoli, M., Cirillo, F., Monasky, M.M., Ciconte, G., Pappone, C., Anastasia, L.** Cell-based therapies for cardiac regeneration: A comprehensive review of past and ongoing strategies. // *International Journal of Molecular Sciences*, 19, 2018, № 10, art. no. 3194. ISSN 1661-6596. DOI 10.3390/ijms19103194.
1758. **Gorecka, J., Dardik, A.** Stem cell therapy to improve acute myocardial infarction remodeling. – In: *Stem Cell Therapy for Vascular Diseases: State of the Evidence and Clinical Applications*, 2020, p. 299-329. ISBN 9783030569549; 9783030569532. DOI 10.1007/978-3-030-56954-9\_14.
1759. **Gubert, F., da Silva, J.S., Vasques, J.F., de Jesus Gonçalves, R.G., Martins, R.S., de Sá, M.P.L., Mendez-otero, R., Zapata-sudo, G.** Mesenchymal stem cells therapies on fibrotic heart diseases. // *International Journal of Molecular Sciences*, 22, 2021, № 14, art. no. 7447. ISSN 1661-6596. DOI 10.3390/ijms22147447.
1760. **Guo, Q.-Y., Yang, J.-Q., Feng, X.-X., Zhou, Y.-J.** Regeneration of the heart: from molecular mechanisms to clinical therapeutics. // *Military Medical Research*, 10, 2023, № 1, art. no. 18. ISSN 2095-7467. DOI 10.1186/s40779-023-00452-0.
1761. **Gyöngyösi, M., Haller, P.M., Blake, D.J., Rendon, E.M.** Meta-analysis of cell therapy studies in heart failure and acute myocardial infarction. // *Circulation Research*, 123, 2018, № 2, p. 301-308. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.117.311302.
1762. **Hatzistergos, K.E., Selem, S., Balkan, W., Hare, J.M.** Cardiac Stem Cells. – In: *Principles of Regenerative Medicine*, 2018, p. 247-272. ISBN 9780128098806; 9780128098936. DOI 10.1016/B978-0-12-809880-6.00017-5.
1763. **He, S.-Y., Long, L.-Y., Wang, Z.-C., Liu, W.-Q., Zhang, W., Hu, C., Wu, X.-F., Dong, R., Fan, H.-S., Qing-Jiang, Tong, Y.-Y., Yang, G.-H., Li-Yang, Wang, Y.-B.** Combining HUMSC secretome and a conductive hydrogel enhances angiogenesis and electrical transmission at myocardial infarct sites to support cardiac repair. // *Chemical Engineering Journal*, 474, 2023, art. no. 145877. ISSN 1385-8947. DOI 10.1016/j.cej.2023.145877.
1764. **He, X., Wang, Q., Zhao, Y., Zhang, H., Wang, B., Pan, J., Li, J., Yu, H., Wang, L., Dai, J., Wang, D.** Effect of Intramyocardial Grafting Collagen Scaffold with Mesenchymal Stromal Cells in Patients with Chronic Ischemic Heart Disease: A Randomized Clinical Trial. // *JAMA Network Open*, 3, 2020, № 9, art. no. e2016236. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2020.16236.
1765. **Henning, R.J.** Current status of stem cells in cardiac repair. // *Future Cardiology*, 14, 2018, № 2, p. 181-192. ISSN 1479-6678. DOI 10.2217/fca-2017-0072.
1766. **Hénon, P.** Key Success Factors for Regenerative Medicine in Acquired Heart Diseases. // *Stem Cell Reviews and Reports*, 16, 2020, № 3, p. 441-458. ISSN 2629-3269. DOI 10.1007/s12015-020-09961-0.
1767. **Hey, C.Y., Barra, S., Duehmke, R., Pettit, S., Levy, W.C., Silva-Cardoso, J., Providência, R.** An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. // *Heart Failure Reviews*, 27, 2022, № 5, p. 1761-1777. ISSN 1382-4147. DOI 10.1007/s10741-022-10216-y.



1768. **Hotham, W.E., Henson, F.M.D.** The use of large animals to facilitate the process of MSC going from laboratory to patient—‘bench to bedside’. // *Cell Biology and Toxicology*, 36, 2020, № 2, p. 103-114. ISSN 0742-2091. DOI 10.1007/s10565-020-09521-9.
1769. **Hyer, J.M., Diaz, A., Pawlik, T.M.** The win ratio: A novel approach to define and analyze postoperative composite outcomes to reflect patient and clinician priorities. // *Surgery (United States)*, 172, 2022, № 5, p. 1484-1489. ISSN 0039-6060. DOI 10.1016/j.surg.2022.07.024.
1770. **Jackson, A.O., Rahman, G.A., Yin, K., Long, S.** Enhancing Matured Stem-Cardiac Cell Generation and Transplantation: A Novel Strategy for Heart Failure Therapy. // *Journal of Cardiovascular Translational Research*, 14, 2021, № 3, p. 556-572. ISSN 1937-5387. DOI 10.1007/s12265-020-10085-6.
1771. **Jane, M.O., Becerra, D.C., Madsen, J.C.** The Future of Heart and Lung Transplantation. – In: *Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease*, 2023, p. 1361-1388. ISBN 9781119633884; 9781119633846. DOI 10.1002/9781119633884.ch96.
1772. **Karbasiarfshar, C., Sellke, F.W., Abid, M.R.** Mesenchymal stem cell-derived extracellular vesicles in the failing heart: Past, present, and future. // *American Journal of Physiology - Heart and Circulatory Physiology*, 320, 2021, № 5, p. H1999-H2010. ISSN 0363-6135. DOI 10.1152/AJPHEART.00951.2020.
1773. **Karel, S., Starigazdová, J., Vágnerová, H., Kulhánek, J., Horáčková, L., Flegel, M., Drašar, P., Brožek, J., Velebný, V.** Hyaluronic Acid Fibres in Solid Phase Peptide Synthesis - Their Properties, Morphology and Stability. // *Fibers and Polymers*, 21, 2020, № 12, p. 2707-2717. ISSN 1229-9197. DOI 10.1007/s12221-020-0075-6.
1774. **Kim, M., Kim, Y.S., Ahn, Y., Eom, G.H., Yoon, S.** PSME4 determines mesenchymal stem cell fate towards cardiac commitment through YAP1 degradation. // *Korean Journal of Physiology and Pharmacology*, 27, 2023, № 4, p. 407-416. ISSN 1226-4512. DOI 10.4196/kjp.2023.27.4.407.
1775. **Kim, Y.S., Kim, M., Cho, D.I., Lim, S.Y., Jun, J.H., Kim, M.R., Kang, B.G., Eom, G.H., Kang, G., Yoon, S., Ahn, Y.** PSME4 Degrades Acetylated YAP1 in the Nucleus of Mesenchymal Stem Cells. // *Pharmaceutics*, 14, 2022, № 8, art. no. 1659. ISSN 1999-4923. DOI 10.3390/pharmaceutics14081659.
1776. **Kir, D., Patel, M.J., Munagala, M.R.** What Is the Status of Regenerative Therapy in Heart Failure? // *Current Cardiology Reports*, 23, 2021, № 10, art. no. 146. ISSN 1523-3782. DOI 10.1007/s11886-021-01575-3.
1777. **Kishino, Y., Fukuda, K.** Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments. // *Biomedicines*, 11, 2023, № 3, art. no. 915. ISSN 2227-9059. DOI 10.3390/biomedicines11030915.
1778. **Kobayashi, K., Suzuki, K.** Mesenchymal stem/stromal cell-based therapy for heart failure — What is the best source? // *Circulation Journal*, 82, 2018, № 9, p. 2222-2232. ISSN 1346-9843. DOI 10.1253/circj.CJ-18-0786.

1779. **Konoplyannikov, M., Kotova, S., Baklaushev, V., Konoplyannikov, A., Kalsin, V., Timashev, P., Troitskiy, A.** Mesenchymal stem cell therapy for ischemic heart disease: Advances and challenges. // *Current Pharmaceutical Design*, 24, 2018, № 26, p. 3132-3142. ISSN 1381-6128. DOI 10.2174/1381612824666180913151059.
1780. **Korpela, H., Järveläinen, N., Siimes, S., Lampela, J., Airaksinen, J., Valli, K., Turunen, M., Pajula, J., Nurro, J., Ylä-Herttuala, S.** Gene therapy for ischaemic heart disease and heart failure. // *Journal of Internal Medicine*, 290, 2021, № 3, p. 567-582. ISSN 0954-6820. DOI 10.1111/joim.13308.
1781. **Krampera, M., Le Blanc, K.** Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. // *Cell Stem Cell*, 28, 2021, № 10, p. 1708-1725. ISSN 1934-5909. DOI 10.1016/j.stem.2021.09.006.
1782. **Lalu, M.M., Mazzarello, S., Zlepniġ, J., Dong, Y.Y.R., Montroy, J., McIntyre, L., Devereaux, P.J., Stewart, D.J., David Mazer, C., Barron, C.C., McIsaac, D.I., Fergusson, D.A.** Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. // *Stem Cells Translational Medicine*, 7, 2018, № 12, p. 857-866. ISSN 2157-6564. DOI 10.1002/sctm.18-0120.
1783. **Landin, A.M., Hare, J.M.** The quest for a successful cell-based therapeutic approach for heart failure. // *European Heart Journal*, 38, 2017, № 9, p. 661-664. ISSN 0195-668X. DOI 10.1093/eurheartj/ehw626.
1784. **Li, L., Guan, Q., Dai, S., Wei, W., Zhang, Y.** Integrin  $\beta 1$  increases stem cell survival and cardiac function after myocardial infarction. // *Frontiers in Pharmacology*, 8, 2017, art. no. 135. ISSN 1663-9812. DOI 10.3389/fphar.2017.00135.
1785. **Liang, P., Ye, F., Hou, C.-C., Pi, L., Chen, F.** Mesenchymal stem cell therapy for patients with ischemic heart fail-ure-past, present, and future. // *Current Stem Cell Research and Therapy*, 16, 2021, № 5, p. 608-621. ISSN 1574-888X. DOI 10.2174/1574888X15666200309144906.
1786. **Liu, Z., Mikrani, R., Zubair, H.M., Taleb, A., Naveed, M., Baig, M.M.F.A., Zhang, Q., Li, C., Habib, M., Cui, X., Sembatya, K.R., Lei, H., Zhou, X.** Systemic and local delivery of mesenchymal stem cells for heart renovation: Challenges and innovations. // *European Journal of Pharmacology*, 876, 2020, art. no. 173049. ISSN 0014-2999. DOI 10.1016/j.ejphar.2020.173049.
1787. **Liwei, Z., Sicheng, Z., Xueqin, L., Manqing, L., Kaiyang, L., Yansong, G.** The application prospect of win ratio in cardiovascular research. [胜出率在心血管病研究中的应用前景]. // *Chinese Journal of Cardiology*, 50, 2022, № 6, p. 619-624. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20210823-00753.
1788. **Lund, L.H., Køber, L., Swedberg, K., Ruschitzka, F.** Kardiológia v roku 2017. [Srdcové zlyhávanie]. // *Cardiology Letters*, 27, 2018, № 4, p. 194-203. ISSN 1338-3655.
1789. **Lund, L.H., Køber, L., Swedberg, K., Ruschitzka, F.** The year in cardiology 2017: Heart failure. // *European Heart Journal*, 39, 2018, № 10, p. 832-839. ISSN 0195-668X. DOI 10.1093/eurheartj/ehx782.

1790. **Lüscher, T.F.** Frontiers in the management of coronary artery disease: Bioabsorbable scaffolds, regenerative medicine, and gene therapy. // *European Heart Journal*, 38, 2017, № 33, p. 2517-2520. ISSN 0195-668X. DOI 10.1093/eurheartj/ehx507.
1791. **Lüscher, T.F.** Frontiers of valvular heart disease: From aortic stenosis to the tricuspid valve and congenital anomalies. // *European Heart Journal*, 38, 2017, № 9, p. 611-614. ISSN 0195-668X. DOI 10.1093/eurheartj/ehx083.
1792. **Lüscher, T.F.** Update on heart failure: Biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal. // *European Heart Journal*, 38, 2017, № 30, p. 2315-2317. ISSN 0195-668X. DOI 10.1093/eurheartj/ehx436.
1793. **Madeddu, P.** Cell therapy for the treatment of heart disease: Renovation work on the broken heart is still in progress. // *Free Radical Biology and Medicine*, 164, 2021, p. 206-222. ISSN 0891-5849. DOI 10.1016/j.freeradbiomed.2020.12.444.
1794. **Malliaras, K., Cokkinos, D.V.** Cell therapy for heart disease: Ready for prime time or lost in translation? – In: *Myocardial Preservation: Translational Research and Clinical Application*, 2019, p. 355-376. ISBN 9783319981864; 9783319981857. DOI 10.1007/978-3-319-98186-4\_17.
1795. **Mazine, A., Rushani, D., Yau, T.M.** Clinical mesenchymal stem cell therapy in ischemic cardiomyopathy. // *JTCVS Open*, 8, 2021, p. 135-141. ISSN 2666-2736. DOI 10.1016/j.xjon.2021.06.030.
1796. **Menasché, P.** Cardiac cell therapy: Current status, challenges and perspectives. [Thérapie cellulaire cardiaque: état des lieux, défis et perspectives.] // *Archives of Cardiovascular Diseases*, 113, 2020, № 4, p. 285-292. ISSN 1875-2136. DOI 10.1016/j.acvd.2020.01.002.
1797. **Menasché, P.** Cell therapy trials for heart regeneration — lessons learned and future directions. // *Nature Reviews Cardiology*, 15, 2018, № 11, p. 659-671. ISSN 1759-5002. DOI 10.1038/s41569-018-0013-0.
1798. **Micheu, M.M.** Moving forward on the pathway of cell-based therapies in ischemic heart disease and heart failure - time for new recommendations? // *World Journal of Stem Cells*, 11, 2019, № 8, p. 445-451. ISSN 1948-0210. DOI 10.4252/wjsc.v11.i8.445.
1799. **Micheu, M.M., Scarlatescu, A.I., Scafa-Udriste, A., Dorobantu, M.** The winding road of cardiac regeneration—Stem cell omics in the spotlight. // *Cells*, 7, 2018, № 12, art. no. 255. ISSN 2073-4409. DOI 10.3390/cells7120255.
1800. **Müller, P., Lemcke, H., David, R.** Stem Cell Therapy in Heart Diseases-Cell Types, Mechanisms and Improvement Strategies. // *Cellular Physiology and Biochemistry*, 48, 2018, № 6, p. 2607-2655. ISSN 1015-8987. DOI 10.1159/000492704.
1801. **Nakamura, K., Murry, C.E.** Function follows form - a review of cardiac cell therapy. // *Circulation Journal*, 83, 2019, № 12, p. 2399-2412. ISSN 1346-9843. DOI: 10.1253/circj.CJ-19-0567.
1802. **Natsumeda, M., Tompkins, B.A., Florea, V., Rieger, A.C., Banerjee, M., Balkan, W., Hare, J.M.** Heart Regeneration with Stem Cell Therapies. – In: *Encyclopedia of*

1803. **Nazari-Shafti, T.Z., Xu, Z., Bader, A.M., Henke, G., Klose, K., Falk, V., Stamm, C.** Mesenchymal stromal cells cultured in serum from heart failure patients are more resistant to simulated chronic and acute stress. // *Stem Cells International*, 2018, art. no. 5832460. ISSN 1687-9678. DOI 10.1155/2018/5832460.
1804. **Neuber, S., Emmert, M.Y., Nazari-Shafti, T.Z.** Hopes and hurdles of employing mesenchymal stromal cells in the treatment of cardiac fibrosis. // *International Journal of Molecular Sciences*, 22, 2021, № 23, art. no. 13000. ISSN 1661-6596. DOI 10.3390/ijms222313000.
1805. **Olatunji, G., Kokori, E., Yusuf, I., Ayanleke, E., Damilare, O., Afolabi, S., Adetunji, B., Mohammed, S., Akinmoju, O., Aboderin, G., Aderinto, N.** Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives. // *Heart Failure Reviews*, 2023. ISSN 1382-4147. DOI: 10.1007/s10741-023-10351-0.
1806. **Parra-Lucare, A., Romero-Hernández, E., Villa, E., Weitz-Muñoz, S., Vizcarra, G., Reyes, M., Vergara, D., Bustamante, S., Llancaqueo, M., Toro, L.** New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside... and Back. // *Biomedicines*, 11, 2023, № 1, art. no. 70. ISSN 2227-9059. DOI 10.3390/biomedicines11010070.
1807. **Pattar, S.S., Fatehi Hassanabad, A., Fedak, P.W.M.** Application of Bioengineered Materials in the Surgical Management of Heart Failure. // *Frontiers in Cardiovascular Medicine*, 6, 2019, art. no. 123. ISSN 2297-055X. DOI 10.3389/fcvm.2019.00123.
1808. **Peng, H., Shindo, K., Donahue, R.R., Abdel-Latif, A.** Cardiac cell therapy: Insights into the mechanisms of tissue repair. // *International Journal of Molecular Sciences*, 22, 2021, № 3, art. no. 1201, p. 1-15. ISSN 1661-6596. DOI 10.3390/ijms22031201.
1809. **Petrosyan, A., Martins, P.N., Solez, K., Uygun, B.E., Gorantla, V.S., Orlando, G.** Regenerative medicine applications: An overview of clinical trials. // *Frontiers in Bioengineering and Biotechnology*, 10, 2022, art. no. 942750. ISSN 2296-4185. DOI 10.3389/fbioe.2022.942750.
1810. **Popandopulo, A.G., Turchyn, V.V., Solopov, M.V., Bushe, V.V.** Problems of clinical trials of cell therapy effectiveness today. // *Sibirskij Nauchnyj Medicinskij Zhurnal*, 41, 2021, № 1, p. 16-32. ISSN 2410-2512. DOI 10.18699/SSMJ20210102.
1811. **Potz, B.A., Parulkar, A.B., Abid, R.M., Sodha, N.R., Sellke, F.W.** Novel molecular targets for coronary angiogenesis and ischemic heart disease. // *Coronary Artery Disease*, 28, 2017, № 7, p. 605-613. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000516.
1812. **Potz, B.A., Scrimgeour, L.A., Pavlov, V.I., Sodha, N.R., Ruhul Abid, M., Sellke, F.W.** Extracellular vesicle injection improves myocardial function and increases angiogenesis in a swine model of chronic ischemia. // *Journal of the American Heart Association*, 7, 2018, № 12, art. no. e008344. ISSN 2047-9980. DOI 10.1161/JAHA.117.008344.

1813. **Povsic, T.J.** Approaching regulatory approval of cardiovascular regenerative therapy. // *Circulation Research*, 122, 2018, № 4, p. 552-554. ISSN 0009-7330. DOI 10.1161/CIRCRESAHA.117.312520.
1814. **Rajab, A.M., Rajab, T.M., AlJundi, S., Haider, K.H.** Bone stem cell therapy in the clinical perspective: A focus on nonrandomized and randomized trials. – In: *Stem Cells: From Myth to Reality and Evolving*, 2019, p. 53-101. ISBN 9783110642438; 9783110642230. DOI: 10.1515/9783110642438-004.
1815. **Raval, A.N., Pepine, C.J.** Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting. // *Cardiovascular Revascularization Medicine*, 22, 2021, p. 100-108. ISSN 1553-8389. DOI 10.1016/j.carrev.2020.06.031.
1816. **Razeghian-Jahromi, I., Matta, A.G., Canitrot, R., Zibaeenezhad, M.J., Razmkhah, M., Safari, A., Nader, V., Roncalli, J.** Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy. // *Stem Cell Research and Therapy*, 12, 2021, № 1, art. no. 361. ISSN 1757-6512. DOI 10.1186/s13287-021-02443-1.
1817. **Redfors, B., Gregson, J., Crowley, A., Mcandrew, T., Ben-Yehuda, O., Stone, G.W., Pocock, S.J.** The win ratio approach for composite endpoints: Practical guidance based on previous experience. // *European Heart Journal*, 41, 2020, № 46, p. 4391-4399. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa665.
1818. **Rheault-Henry, M., White, I., Atoui, R.** Therapeutic Uses of Stem Cells for Heart Failure: Hype or Hope. – In: *Handbook of Stem Cell Therapy: Vol. 1*, 2022, p. 511-544. ISBN 9789811926556; 9789811926549. DOI 10.1007/978-981-19-2655-6\_17.
1819. **Rheault-Henry, M., White, I., Atoui, R.** Unraveling the Mystery of Regenerative Medicine in the Treatment of Heart Failure. – In: *Handbook of Stem Cell Therapy: Volume 1*, 2022, p. 471-509. ISBN 9789811926556; 9789811926549. DOI 10.1007/978-981-19-2655-6\_16.
1820. **Rheault-Henry, M., White, I., Grover, D., Atoui, R.** Stem cell therapy for heart failure: Medical breakthrough, or dead end? // *World Journal of Stem Cells*, 13, 2021, № 4, p. 236-259. ISSN 1948-0210. DOI 10.4252/wjsc.v13.i4.236.
1821. **Sabra, M., Karbasiafshar, C., Aboulgheit, A., Raj, S., Ruhul Abid, M., Sellke, F.W.** Clinical application of novel therapies for coronary angiogenesis: Overview, challenges, and prospects. // *International Journal of Molecular Sciences*, 22, 2021, № 7, art. no. 3722. ISSN 1661-6596. DOI 10.3390/ijms22073722.
1822. **Scrimgeour, L.A., Potz, B.A., Aboul Gheit, A., Shi, G., Stanley, M., Zhang, Z., Sodha, N.R., Ahsan, N., Abid, M.R., Sellke, F.W.** Extracellular Vesicles Promote Arteriogenesis in Chronically Ischemic Myocardium in the Setting of Metabolic Syndrome. // *Journal of the American Heart Association*, 8, 2019, № 15, art. no. e012617. ISSN 2047-9980. DOI 10.1161/JAHA.119.012617.
1823. **Scrimgeour, L.A., Potz, B.A., Gheit, A.A., Liu, Y., Shi, G., Pfeiffer, M., Colantuono, B.J., Sodha, N.R., Ruhul Abid, M., Sellke, F.W.** Intravenous injection of extracellular vesicles to treat chronic myocardial ischemia. // *PLoS ONE*, 15, 2020, art. no. e0238879. ISSN 1932-6203. DOI 10.1371/journal.pone.0238879.



1824. **Selvakumar, D., Clayton, Z.E., Chong, J.J.H.** Robust Cardiac Regeneration: Fulfilling the Promise of Cardiac Cell Therapy. // *Clinical Therapeutics*, 42, 2020, № 10, p. 1857-1879. ISSN 0149-2918. DOI: 10.1016/j.clinthera.2020.08.008.
1825. **Severino, P., D'amato, A., Prosperi, S., Dei Cas, A., Mattioli, A.V., Cevese, A., Novo, G., Prat, M., Pedrinelli, R., Raddino, R., Gallina, S., Schena, F., Poggesi, C., Pagliaro, P., Mancone, M., Fedele, F.** Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity? // *Journal of Clinical Medicine*, 11, 2022, № 3, art. no. 857. ISSN 2077-0383. DOI 10.3390/jcm11030857.
1826. **Sid-Otmane, C., Perrault, L.P., Ly, H.Q.** Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. // *Journal of Translational Medicine*, 18, 2020, № 1, art. no. 336. ISSN 1479-5876. DOI 10.1186/s12967-020-02504-8.
1827. **Sogorkova, J., Zapotocky, V., Cepa, M., Stepankova, V., Vagnerova, H., Batova, J., Pospisilova, M., Betak, J., Nesporova, K., Hermannova, M., Daro, D., Duffy, G., Velebny, V.** Optimization of cell growth on palmitoyl-hyaluronan knitted scaffolds developed for tissue engineering applications. // *Journal of Biomedical Materials Research - Part A*, 106, 2018, № 6, p. 1488-1499. ISSN 1549-3296. DOI 10.1002/jbm.a.36353.
1828. **Soma, Y., Tani, H., Morita-Umei, Y., Kishino, Y., Fukuda, K., Tohyama, S.** Pluripotent stem cell-based cardiac regenerative therapy for heart failure. // *Journal of Molecular and Cellular Cardiology*, 187, 2024, p. 90-100. ISSN 0022-2828. DOI 10.1016/j.yjmcc.2023.12.001.
1829. **Song, Y.-L., Jiang, H., Jiang, N.-G., Jin, Y.-M., Zeng, T.-T.** Mesenchymal Stem Cell-Platelet Aggregates Increased in the Peripheral Blood of Patients with Acute Myocardial Infarction and Might Depend on the Stromal Cell-Derived Factor 1/CXCR4 Axis. // *Stem Cells and Development*, 28, 2019, № 24, p. 1607-1619. ISSN 1547-3287. DOI 10.1089/scd.2019.0154.
1830. **Steinhoff, G., Nesteruk, J., Wolfien, M., Kundt, G., Börgermann, J., David, R., Garbade, J., Große, J., Haverich, A., Hennig, H., Kaminski, A., Lotz, J., Mohr, F.-W., Müller, P., Oostendorp, R., Ruch, U., Sarikouch, S., Skorska, A., Stamm, C., Tiedemann, G., Wagner, F.M., Wolkenhauer, O.** Cardiac Function Improvement and Bone Marrow Response –: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133+ Application After Myocardial Infarction. // *EBioMedicine*, 22, 2017, p. 208-224. ISSN 2352-3964. DOI 10.1016/j.ebiom.2017.07.022.
1831. **Strzelec, M., Detka, J., Mieszczak, P., Sobocińska, M.K., Majka, M.** Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. // *Frontiers in Immunology*, 14, 2023, art. no. 1127704. ISSN 1664-3224. DOI 10.3389/fimmu.2023.1127704.
1832. **Sullivan, K.M., Goldmuntz, E.A., Keyes-Elstein, L., McSweeney, P.A., Pinckney, A., Welch, B., Mayes, M.D., Nash, R.A., Crofford, L.J., Eggleston, B., Castina, S., Griffith, L.M., Goldstein, J.S., Wallace, D., Craciunescu, O., Khanna, D., Folz, R.J., Goldin, J., Clair, E.W., St., Seibold, J.R., Phillips, K., Mineishi, S., Simms, R.W., Ballen, K., Wener, M.H., Georges, G.E., Heimfeld, S., Hosing, C., Forman, S., Kafaja, S., Silver, R.M., Griffing, L., Storek, J., LeClercq, S., Brasington, R., Csuka, M.E., Bredeson, C., Keever-Taylor, C.,**

- Domsic, R.T., Kahaleh, M.B., Medsger, T., Furst, D.E.** Myeloablative autologous stem-cell transplantation for severe scleroderma. // *New England Journal of Medicine*, 378, 2018, № 1, p. 35-47. ISSN 0028-4793. DOI 10.1056/NEJMoa1703327.
1833. **Sundin, A., Ionescu, S.I., Balkan, W., Hare, J.M.** Mesenchymal STRO-1/STRO-3+ precursor cells for the treatment of chronic heart failure with reduced ejection fraction. // *Future Cardiology*, 19, 2023, № 12, p. 567-581. ISSN 1479-6678. DOI 10.2217/fca-2023-0081.
1834. **Sung, P.-H., Yin, T.-C., Wallace, C.G., Chen, K.-H., Shao, P.-L., Lee, F.-Y., Sun, C.-K., Sheu, J.-J., Chen, Y.-L., Omran, M.M., Chung, S.-Y., Wang, C.-J., Lee, M.S., Yip, H.-K.** Extracorporeal shock wave-supported adipose-derived fresh stromal vascular fraction preserved Left Ventricular (LV) function and inhibited LV remodeling in acute myocardial infarction in rat. // *Oxidative Medicine and Cellular Longevity*, 2018, art. no. 7518920. ISSN 1942-0900. DOI 10.1155/2018/7518920.
1835. **Szydlak, R.** Mesenchymal stem cells in ischemic tissue regeneration. // *World Journal of Stem Cells*, 15, 2023, № 2, p. 16-30. ISSN 1948-0210. DOI 10.4252/wjsc.v15.i2.16.
1836. **Tompkins, B.A., Rieger, A.C., Florea, V., Banerjee, M.N., Hare, J.M.** New insights into cell-based therapy for heart failure from the CHART-1 study. // *European Journal of Heart Failure*, 19, 2017, № 11, p. 1530-1533. ISSN 1388-9842. DOI 10.1002/ehf.955.
1837. **Tsujimoto, H., Osafune, K.** Current status and future directions of clinical applications using iPS cells-focus on Japan. // *FEBS Journal*, 289, 2022, № 23, p. 7274-7291. ISSN 1742-464X. DOI 10.1111/febs.16162.
1838. **Turner, D., Rieger, A.C., Balkan, W., Hare, J.M.** Clinical-based cell therapies for heart disease-current and future state. // *Rambam Maimonides Medical Journal*, 11, 2020, № 2, art. no. e0015. ISSN 2076-9172. DOI 10.5041/RMMJ.10401.
1839. **Weatherald, J., Boucly, A., Peters, A., Montani, D., Prasad, K., Psotka, M.A., Zannad, F., Gomberg-Maitland, M., McLaughlin, V., Simonneau, G., Humbert, M., The Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum.** The evolving landscape of pulmonary arterial hypertension clinical trials. // *The Lancet*, 400, 2022, № 10366, p. 1884-1898. ISSN 0140-6736. DOI 10.1016/S0140-6736(22)01601-4.
1840. **Weber, B.N., Kobashigawa, J.A., Givertz, M.M.** Evolving Areas in Heart Transplantation. // *JACC: Heart Failure*, 5, 2017, № 12, p. 869-878. ISSN 2213-1779. DOI 10.1016/j.jchf.2017.10.009.
1841. **Widimsky, P., Crea, F., Binder, R.K., Lüscher, T.F.** The year in cardiology 2018: Acute coronary syndromes. // *European Heart Journal*, 40, 2019, № 3, p. 271-283. ISSN 0195-668X. DOI 10.1093/eurheartj/ehy904.
1842. **Wolint, P., Bopp, A., Woloszyk, A., Tian, Y., Evrova, O., Hilbe, M., Giovanoli, P., Calcagni, M., Hoerstrup, S.P., Buschmann, J., Emmert, M.Y.** Cellular self-assembly into 3D microtissues enhances the angiogenic activity and functional

neovascularization capacity of human cardiopoietic stem cells. // *Angiogenesis*, 22, 2019, № 1, p. 37-52. ISSN 0969-6970. DOI 10.1007/s10456-018-9635-4.

1843. **Wu, R., Hu, X., Wang, J.** Concise Review: Optimized Strategies for Stem Cell-Based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation. // *Stem Cells*, 36, 2018, № 4, p. 482-500. ISSN 1066-5099. DOI 10.1002/stem.2778.
1844. **Xu, C.M., Karbasiafshar, C., Brinck Teixeira, R., Ahsan, N., Blume Corssac, G., Sellke, F.W., Abid, M.R.** Proteomic Assessment of Hypoxia-Pre-Conditioned Human Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicles Demonstrates Promise in the Treatment of Cardiovascular Disease. // *International Journal of Molecular Sciences*, 24, 2023, № 2, art. no. 1674. ISSN 1661-6596. DOI 10.3390/ijms24021674.
1845. **Xu, R., Zhou, C., Zhang, Y., Zhang, S., Xie, J., Yuan, Q.** Challenges of stem-cell-based craniofacial regeneration. // *Current Stem Cell Research and Therapy*, 16, 2021, № 6, p. 670-682. ISSN 1574-888X. DOI 10.2174/1574888X16999210128193910.
1846. **Xu, Z., Neuber, S., Nazari-Shafti, T., Liu, Z., Dong, F., Stamm, C.** Impact of procedural variability and study design quality on the efficacy of cell-based therapies for heart failure - a meta-analysis. // *PLoS ONE*, 17, 2022, art. no. e0261462. ISSN 1932-6203. DOI: 10.1371/journal.pone.0261462.
1847. **Yagyu, T., Yasuda, S., Nagaya, N., DOI, K., Nakatani, T., Satomi, K., Shimizu, W., Kusano, K., Anzai, T., Noguchi, T., Ohgushi, H., Kitamura, S., Kangawa, K., Ogawa, H.** Long-term results of intracardiac mesenchymal stem cell transplantation in patients with cardiomyopathy. // *Circulation Journal*, 83, 2019, № 7, p. 1590-1599. ISSN 1346-9843. DOI 10.1253/circj.CJ-18-1179.
1848. **Yan, W., Xia, Y., Zhao, H., Xu, X., Ma, X., Tao, L.** Stem cell-based therapy in cardiac repair after myocardial infarction: Promise, challenges, and future directions. // *Journal of Molecular and Cellular Cardiology*, 188, 2024, p. 1-14. ISSN 0022-2828. DOI 10.1016/j.yjmcc.2023.12.009.
1849. **Yanamandala, M., Zhu, W., Garry, D.J., Kamp, T.J., Hare, J.M., Jun, H.-W., Yoon, Y.-S., Bursac, N., Prabhu, S.D., Dorn, G.W., II, Bolli, R., Kitsis, R.N., Zhang, J.** Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. // *Journal of the American College of Cardiology*, 70, 2017, № 6, p. 766-775. ISSN 0735-1097. DOI 10.1016/j.jacc.2017.06.012.
1850. **Yaron, J.R., Kwiecien, J.M., Zhang, L., Ambadapadi, S., Wakefield, D.N., Clapp, W.L., Dabrowski, W., Burgin, M., Munk, B.H., McFadden, G., Chen, H., Lucas, A.R.** Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm? // *Trends in Molecular Medicine*, 25, 2019, № 7, p. 626-639. ISSN 1471-4914. DOI 10.1016/j.molmed.2019.04.002.
1851. **Yu, H., Sonntag, P.D., Bream, P.R., Lazarowicz, M.P., Nowakowski, F.S., Woodhead, G.J., Hennemeyer, C.T., Muller, R.D., Navuluri, R., Caoili, E.M., Eifler, A.C., Tominna, B.S., Stavas, J.M.** Safety and Feasibility of a Novel Percutaneous Locoregional Injection Technique of Renal Cellular Therapy for Chronic Kidney Disease of Diabetes. // *Kidney International Reports*, 6, 2021, № 9, p. 2486-2490. ISSN 2468-0249. DOI 10.1016/j.ekir.2021.06.014.

1852. **Zampieri, F.G., Damiani, L.P., Biondi, R.S., Freitas, F.G.R., Veiga, V.C., Figueiredo, R.C., Serpa-Neto, A., Manoel, A.L.O., Miranda, T.A., Corrêa, T.D., Azevedo, L.C.P., Silva, N.B., Machado, F.R., Cavalcanti, A.B., the BRICNet.** Hierarchical endpoint analysis using win ratio in critical care: An exploration using the balanced solutions in intensive care study (BaSICS). // *Journal of Critical Care*, 71, 2022, art. no. 154113. ISSN 0883-9441. DOI 10.1016/j.jcrc.2022.154113.
1853. **Zhong, Z., Tian, Y., Luo, X., Zou, J., Wu, L., Tian, J.** Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells Protect Against DOX-Induced Heart Failure Through the miR-100-5p/NOX4 Pathway. // *Frontiers in Bioengineering and Biotechnology*, 9, 2021, art. no. 703241. ISSN 2296-4185. DOI 10.3389/fbioe.2021.703241.

Staikov I., Stoyanov I., Staneva M., Neykov N., Kirova G., Polonski, P., **Petrov I.**; Diagnostic value of color-coded duplex sonography in patients with ischemic stroke and congenital changes in the circle of Willis; *Cor et Vasa* 58 (2016) e591–e599; DOI 10.1016/j.crvasa.2015.11.008.

#### Cited by:

1854. **Mamytova, E., Kadyrova, A., Turgumbaev, D., Zholdoshev, E., Vityala, Y., Tagaev, T.** Risk factors of ischemic stroke/transient ischemic attack in young women: A case report. // *Biomedicine (India)*, 41, 2021, № 1, p. 160-162. ISSN 0970-2067. DOI 10.51248/v41i1.555.

**I. Petrov, Z. Stankov, S. Stefanov, Tz. Minchev, P. Polonski, H. Stojanov, G. Kozarova, G. Adam;** Minimally invasive treatment of a life threatening ruptured thoracic aortic aneurysm; *Cor et Vasa*, Volume 58, Issue 5, Pages e525-e529, Jan 2016; ISSN 0010-8650. DOI 10.1016/j.crvasa.2015.11.002.

#### Cited by:

1855. **Gil, J., Marmelo, B., Abreu, L., Antunes, H., Gonçalves, L., Moreira, D., Santos, L.F.D., Cabral, J.C.** Case report of an unusual presentation of aortic dissection. // *Cor et Vasa*, 60, 2018, № 5, p. e531-e532. ISSN 0010-8650. DOI 10.1016/j.crvasa.2017.03.011

### 2014

Steen D. Kristensen, Kristina G. Laut, Jean Fajadet, Zuzana Kaifoszova, Petr Kala, Carlo Di Mario, William Wijns, Peter Clemmensen, Vaja Agladze, Loizos Antoniadis, Khalid F. Alhabib, Menko-Jan De Boer, Marc J. Claeys, Dan Deleanu, Dariusz Dudek, Andrejs Erglis, Martine Gilard, Omer Goktekin, Giulio Guagliumi, Thorarinn Gudnason, Kim Wadt Hansen, Kurt Huber, Stefan James, Tomáš Janota, Siobhan Jennings, Olli Kajander, John Kanakakis, Kiril K. Karamfiloff, Sasko Kedev, Ran Kornowski, Peter F. Ludman, Béla Merkely, Davor Milicic, Ruslan Najafov, Francesca A. Nicolini, Marko Noč, Miodrag Ostojic, Hélder Pereira, Dragana Radovanovic, Manel Sabaté, Mohamed Sobhy, Maxim Sokolov, Martin Studencan, Ibrahim Terzic, Steffen Wahler, Petr Widimsky, on behalf of the European Association for Percutaneous Cardiovascular Interventions, Volker Mühlberger, Ruslan

Najafov, V. Legrand, M. Spuzic, R. Hajric, D. Markota, S. Srdic, Julia Jorgova, Vassil Velchev, **Ivo Petrov**, V. Nikolic Heitzler, Z. Babic, Evagoras Nicolaides, Theodoros Christodulides, Panagiota Georgiou, Petr Jansky, Josef Stasek, Christian Juhl Terkelsen, Søren Galatius, Rikke Sørensen, Mohamed Sobhy, Ahmed El Shal, Hannu Romppanen, Alfred Müller, Jörg Rustige, Dimitrios Alexopoulos, Ioannis Kallikazaros, Georgios Papaioannou, David Becker, Imre Ungi, Robert Gabor Kiss, Frida Bjork Skuladottir, Thora K. Bjornsdottir, Brendan Cavanagh, Kathleen Twomey, Kieran Daly, Shlomi Matetzky, Leonardo De Luca, Alberto Cremonesi, Francesco Bovenzi, Ilja Zakke, Aija Maca, Inga Narbute, S. Antov, Karel T. Koch, Jorge Mimoso, Manuel Almeida, Ernesto Pereira, Gabriel Tatu, Dragos Vinereanu, Cinzia D'Angeli, Milan Nedeljkovic, Vladan Vukcevic, Milan Dobric, V. Hricak, F. Kovař, P. Kurray, Vincente Peral, Ricard Tresserras, Ander Regueiro, Paul Erne, Hans Rickli, Stephan Windecker, Omer Kozan, Gokhan Ertas, Umit Kervan, John Birkhead, Yuriy Sokolov, Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. // *European Heart Journal*, Vol. 35, Issue 29, 1 August 2014, Pages 1957–1970, [https:// DOI.org/10.1093/eurheartj/eh529](https://doi.org/10.1093/eurheartj/eh529).

#### Cited by:

1856. **Addo, T., Swanson, N., Gershlick, A.** Primary and rescue PCI in acute myocardial infarction and elements of myocardial conditioning. – In: *Interventional Cardiology: Principles and Practice*, 2016, p. 155-162. ISBN 9781118983652; 9781118976036. DOI 10.1002/9781118983652.
1857. **Al Habib, K.F., Sulaiman, K., Al Suwaidi, J., Almahmeed, W., Alsheikh-Ali, A.A., Amin, H., Al Jarallah, M., Alfaleh, H.F., Panduranga, P., Hersi, A., Kashour, T., Al Aseri, Z., Ullah, A., Altaradi, H.B., Asfina, K.N., Welsh, R.C., Yusuf, S.** Patient and system-related delays of emergency medical services use in acute stlevation myocardial infarction: Results from the third gulf registry of acute coronary events (Gulf RACE-3Ps). // *PLoS ONE*, 11, 2016, № 1, art. no. e0147385. ISSN 1932-6203. DOI 10.1371/journal.pone.0147385.
1858. **Alekyan , B.G., Boytsov, S.A., Manoshkina, E.M., Ganyukov, V.I.** Myocardial revascularization in the Russian Federation for acute coronary syndrome in 2016-2020 [Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016-2020 гг.]. // *Kardiologiya*, 61, 2022, № 12, p. 4-15. ISSN 0022-9040. DOI 10.18087/cardio.2021.12.n1879.
1859. **Alva, D.E., Gómez, M.Y.M., Moreno, J.M.M.** Mechanical complications after myocardial infarction in a National Reference Hospital. [Complicaciones mecánicas posinfarto de miocardio en un hospital de referencia nacional]. // *Archivos Peruanos de Cardiología y Cirugia Cardiovascular*, 3, 2022, № 1, p. 25-32. ISSN 2708-7212. DOI 10.47487/apcyccv.v3i1.200.
1860. **Ariza-Solé, A., Alegre, O., Elola, F.J., Fernández, C., Formiga, F., Martínez-Sellés, M., Bernal, J.L., Segura, J.V., Iñíguez, A., Bertomeu, V., Salazar-Mendiguchía, J., Sánchez Salado, J.C., Lorente, V., Cequier, A.** Management of myocardial infarction in the elderly. Insights from Spanish Minimum Basic Data Set. // *European Heart Journal: Acute Cardiovascular Care*, 8, 2019, № 3, p. 242-251. ISSN 2048-8726. DOI 10.1177/2048872617719651.
1861. **Ascencio-Lemus, M.G., Iglesias-Garriz, I., Minguito-Carazo, C., Del Castillo-García, S., Prieto-Salvador, I., Fernández-Vázquez, F.** Thirty-day mortality after the implantation of a system to provide rapid access to reperfusion therapy acute in



- myocardial infarction. [Mortalidad a 30 días tras la implementación de un sistema para brindar acceso rápido al tratamiento de reperfusión en el infarto agudo de miocardio]. // *REC: CardioClinics*, 55, 2020, № 1, p. 15-22. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.09.007.
1862. **Averkov, O.V., Pavlikova, E.P., Tyulkina, E.E.** The place for systemic thrombolysis in modern reperfusion methods for myocardial infarction. // *Russian Journal of Cardiology*, 113, 2014, № 9, p. 77-83. ISSN 1560-4071. DOI 10.15829/1560-4071-2014-9-77-83.
  1863. **Averkov, O.V., Vechorko, V.I.** Ticagrelor and thrombolysis in myocardial infarction: What does the treat study change? // *Russian Journal of Cardiology*, 23, 2018, № 9, p. 65-70. ISSN 1560-4071. DOI 10.15829/1560-4071-2018-9-65-70.
  1864. **Balen, F., Lhermusier, T., Grolleau, S., Pélissier, F., Dehours, E., Charpentier, S., Azema, O., Lamy, S., RESCAMIP investigators.** Identifying key factors leading to the optimal care pathway for patients with ST-segment elevation myocardial infarction: Results from the RESCAMIP registry. [Facteurs associés à un parcours de soin optimal pour les patients porteurs d'un SC ST+: résultats du registre RESCAMIP]. // *Archives of Cardiovascular Diseases*, 112, 2019, № 6/7, p. 374-380. ISSN 1875-2136. DOI 10.1016/j.acvd.2019.01.004.
  1865. **Barbarash, O.L., Kashtalap, V.V.** The place of pharmacoinvasive management in patients with ST-elevation acute coronary syndrome in Russia. // *Kardiologiia*, 54, 2014, № 9, p. 79-85. ISSN 0022-9040. DOI 10.18565/cardio.2014.9.79-85.
  1866. **Bayer, T., Szüts, S., Fiedler, L., Roithinger, F.X., Trimmel, H.** 3 = 1: cooperative provision of PCI treatment in a rural region. [3 = 1: kooperative PCI-Versorgung einer ländlichen Region]. // *Notfall und Rettungsmedizin*, 23, 2020, № 8, p. 594-603. ISSN 1434-6222. DOI 10.1007/s10049-019-00670-x.
  1867. **Bayes-Genis, A., García, C., de Antonio, M., Fernandez-Nofrerías, E., Domingo, M., Zamora, E., Moliner, P., Lupón, J.** Impact of a 'stent for life' initiative on post-ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience. // *ESC Heart Failure*, 5, 2018, № 1, p. 101-105. ISSN 2055-5822. DOI 10.1002/ehf2.12245.
  1868. **Bayraktarova, I., Trendafilova, E.** Complete Interventional Revascularization Versus Infarct-Related Artery Revascularization only in Stemi Patients – Part I. // *Bulgarian Cardiology*, 26, 2020, № 3, p. 17-25. ISSN 1310-7488. DOI 10.3897/bgcardio.26.e51199.
  1869. **Berti, S., Piccaluga, E., Marchese, A., Varbella, F., Sardella, G., Danzi, G.B., Salvi, A., Cremonesi, A., Merelli, A., Ciarna, L., Magro, B., Bedogni, F.** SICI-GISE position paper on standards and guidelines for diagnostic and catheterization laboratories. [Documento di posizione SICI-GISE sugli standard e linee guida per i laboratori di diagnostica e interventistica cardiovascolare]. // *Giornale Italiano di Cardiologia*, 16, 2015, № 10, p. 590-600. ISSN 1827-6806. DOI 10.1714/2028.22050.
  1870. **Beska, B., Raharjo, D.E., Kunadian, V.** Novel drug-eluting stents to improve coronary endothelial and microvascular function in STEMI patients? [Nuevos stents farmacoactivos para mejorar la función endotelial y microvascular coronaria en el

1871. **Biagioni, C., Tirado-Conte, G., Rodés-Cabau, J., Ryan, N., Cerrato, E., Nazif, T.M., Eltchaninoff, H., Sondergaard, L., Ribeiro, H.B., Barbanti, M., Nietlispach, F., De Jaegere, P., Agostoni, P., Trillo, R., Jiménez-Quevedo, P., D'Ascenzo, F., Wendler, O., Maluenda, G., Chen, M., Tamburino, C., Macaya, C., Leon, M.B., Nombela-Franco, L.** State of transcatheter aortic valve implantation in Spain versus Europe and non-European countries. // *Journal of Invasive Cardiology*, 30, 2018, № 8, p. 301-309. ISSN 1042-3931.
1872. **Blöndal, M., Ainla, T., Eha, J., Lõiveke, P., Marandi, T., Saar, A., Veldre, G., Edfors, R., Lewinter, C., Jernberg, T., Jortveit, J., Halvorsen, S., Becker, D., Csanádi, Z., Ferenci, T., János, A.** Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries. // *European Heart Journal - Quality of Care and Clinical Outcomes*, 8, 2022, № 3, p. 307-314. ISSN 2058-5225. DOI 10.1093/ehjqcco/qcaa098.
1873. **Bonnefoy-Cudraz, E., Bueno, H., Casella, G., De Maria, E., Fitzsimons, D., Halvorsen, S., Hassager, C., Iakobishvili, Z., Magdy, A., Marandi, T., Mimoso, J., Parkhomenko, A., Price, S., Rokyta, R., Roubille, F., Serpytis, P., Shimony, A., Stepinska, J., Tint, D., Trendafilova, E., Tubaro, M., Vrints, C., Walker, D., Zahger, D., Zima, E., Zukermann, R., Lettino, M.** Editor's Choice - Acute Cardiovascular Care Association Position Paper on Intensive Cardiovascular Care Units: An update on their definition, structure, organisation and function. // *European Heart Journal: Acute Cardiovascular Care*, 7, 2018, № 1, p. 80-95. ISSN 2048-8726. DOI 10.1177/2048872617724269.
1874. **Borowicz, A., Nadolny, K., Bujak, K., Cieśla, D., Gąsior, M., Hudzik, B.** Paramedic versus physician-staffed ambulances and prehospital delays in the management of patients with ST-segment elevation myocardial infarction. // *Cardiology Journal*, 28, 2021, № 1, p. 110-117. ISSN 1897-5593. DOI 10.5603/CJ.a2019.0072.
1875. **Burak, C., Süleymanoğlu, M., Gümüşdağ, A., Çap, M., Yildiz, İ., İliş, D., Hamideyin, Ş., Köksal, F., Rencüzoğulları, İ., Karabağ, Y.** The effect of nutritional status on long-term mortality in very elderly patients with ST segment elevation myocardial infarction. // *Türk Geriatri Dergisi*, 24, 2021, № 1, p. 87-94. ISSN 1304-2947. DOI 10.31086/tjgeri.2021.203.
1876. **Burrello, J., Bolis, S., Balbi, C., Burrello, A., Provati, E., Caporali, E., Gauthier, L.G., Peirone, A., D'Ascenzo, F., Monticone, S., Barile, L., Vassalli, G.** An extracellular vesicle epitope profile is associated with acute myocardial infarction. // *Journal of Cellular and Molecular Medicine*, 24, 2020, № 17, p. 9945-9957. ISSN 1582-1838. DOI 10.1111/jcmm.15594.
1877. **Bychowski, J., Michalski, T., Bachorski, W., Jaguszewski, M., Gruchala, M.** Treatment delays and in-hospital outcomes of patients with ST-segment elevation myocardial infarction treated at a tertiary center in Poland. // *Polish Archives of Internal Medicine*, 133, 2024, № 3, art. no. 16695. ISSN 0032-3772. DOI 10.20452/pamw.16695.

1878. **Çap, M., Erdoğan, E., Karagöz, A., Doğan, C., Acar, R.D., Unkun, T., Geçmen, Ç., Özkalaycı, F., Şengör, B.G., Bayram, Z., Kaymaz, C., Ozdemir, N.** The association of left ventricular end-diastolic pressure and acute left ventricular end-diastolic pressure change with myocardial blush grade and ST segment resolution in STEMI patients undergoing primary percutaneous intervention. // *Eastern Journal of Medicine*, 25, 2020, № 2, p. 250-255. ISSN 1301-0883. DOI 10.5505/ejm.2020.60252.
1879. **Capodanno, D., Angiolillo, D.J.** Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. // *Thrombosis and Haemostasis*, 114, 2015, № 5, p. 945-957. ISSN 0340-6245. DOI 10.1160/TH15-03-0204.
1880. **Carbone, F., Crowe, L.A., Roth, A., Burger, F., Lenglet, S., Braunersreuther, V., Brandt, K.J., Quercioli, A., Mach, F., Vallée, J.-P., Montecucco, F.** Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury. // *Journal of Molecular and Cellular Cardiology*, 94, 2016, p. 82-94. ISSN 0022-2828. DOI 10.1016/j.yjmcc.2016.03.013.
1881. **Castaldi, G., Benfari, G., Zivelonghi, C.** Risk stratification in patients with STEMI: is it finally time to look at the left atrium? // *International Journal of Cardiovascular Imaging*, 38, 2022, № 10, p. 2115-2116. ISSN 1569-5794. DOI 10.1007/s10554-022-02650-8.
1882. **Cenko, E., Ricci, B., Bugiardini, R.** STEMI: Prognosis. – In: *Encyclopedia of Cardiovascular Research and Medicine*, 1-4, 2017, p. 489-498. ISBN 9780128051542; 9780128096574. DOI 10.1016/B978-0-12-809657-4.99745-X.
1883. **Cequier, Á., Ariza-Solé, A., Elola, F.J., Fernández-Pérez, C., Bernal, J.L., Segura, J.V., Iñiguez, A., Bertomeu, V.** Impact on Mortality of Different Network Systems in the Treatment of ST-segment Elevation Acute Myocardial Infarction. The Spanish Experience. [Impacto en la mortalidad de diferentes sistemas de asistencia en red para el tratamiento del infarto agudo de miocardio con elevación del segmento ST. La experiencia de España]. // *Revista Espanola de Cardiologia*, 70, 2017, № 3, p. 155-161. ISSN 0300-8932. DOI 10.1016/j.recesp.2016.07.016.
1884. **Cequier, Á., de Prado, A.P., Cid, A.B., Martín-Moreiras, J., Rodríguez-Leor, O., Rumoroso, J.R., Moreno, R., Serrador, A., Raposeiras, S., Ariza, A., de Sá, E.L., Iñiguez, A., Sendón, J.L.L., Delgado, F.J., Pérez, R.G., Jiménez-Alegre, J.J., Vázquez, M.J., Flores, J.M., Bueno, H., Anguita, M.** Requirements and sustainability of primary PCI programs in Spain for the management of patients with STEMI. SEC, AECC, and SEMES consensus document. // *REC: Interventional Cardiology*, 1, 2019, № 2, p. 108-119. ISSN 2604-7306. DOI 10.24875/RECICE.M19000042.
1885. **Chacón-Díaz, M., Hernández-Vásquez, A., Vargas-Fernández, R., Bendezu-Quispe, G.** Study protocol of the Peruvian registry of STsegment elevation myocardial infarction II (PERSTEMI-II) study. // *PLoS ONE*, 16, 2021, art. no. e0257618. ISSN 1932-6203. DOI 10.1371/journal.pone.0257618.
1886. **Chen, M., Kan, J., Zhang, J.-J., Tian, N., Ye, F., Yang, S., Chen, S.-L., On behalf of MOODY Registry study Investigators.** Improvement of clinical outcome in patients with ST-elevation myocardial infarction between 1999 and 2016 in China: The Prospective, Multicentre Registry MOODY study. // *European Journal of Clinical*

1887. **Chen, Y., Chen, S., Han, Y., Xu, Q., Zhao, X.** Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction. // *Diabetes, Metabolic Syndrome and Obesity*, 16, 2023, p. 3501-3512. ISSN 1178-7007. DOI 10.2147/DMSO.S433876.
1888. **Chen, Y., Chen, S., Han, Y., Xu, Q., Zhao, X.** Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio are Important Indicators for Predicting in-Hospital Death in Elderly AMI Patients. // *Journal of Inflammation Research*, 16, 2023, p. 2051-2061. ISSN 1178-7031. DOI 10.2147/JIR.S411086.
1889. **Chen, Y., Xie, K., Han, Y., Xu, Q., Zhao, X.** An Easy-to-Use Nomogram Based on SII and SIRI to Predict in-Hospital Mortality Risk in Elderly Patients with Acute Myocardial Infarction. // *Journal of Inflammation Research*, 16, 2023, p. 4061-4071. ISSN 1178-7031. DOI 10.2147/JIR.S427149.
1890. **Chhikara, S., Datta, R., Rishikanta, N., Tandon, M., Prasad, K., Srivastava, A., Gupta, A.** aVR: The forgotten lead in acute coronary syndrome: A case series. // *Medical Journal Armed Forces India*, 79, 2023, p. S270-S275. ISSN 0377-1237. DOI 10.1016/j.mjafi.2021.06.033.
1891. **Costa, R., Trêpa, M., Oliveira, M., Frias, A., Campinas, A., Luz, A., Santos, M., Torres, S.** Heart Failure Incidence Following ST-Elevation Myocardial Infarction. // *American Journal of Cardiology*, 164, 2022, p. 14-20. ISSN 0002-9149. DOI 10.1016/j.amjcard.2021.10.035.
1892. **Crişan, S., Petriş, A.O., Petrescu, L., Luca, C.T.** Current perspectives in facilitated angioplasty. // *American Journal of Therapeutics*, 26, 2019, № 2, p. E208-E212. ISSN 1075-2765. DOI 10.1097/MJT.0000000000000914.
1893. **Cui, H., Ding, X., Li, W., Chen, H., Li, H.** The neutrophil percentage to albumin ratio as a new predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction. // *Medical Science Monitor*, 25, 2019, p. 7845-7852. ISSN 1234-1010. DOI 10.12659/MSM.917987.
1894. **Daemen, J.** Close, But not close enough. // *Netherlands Heart Journal*, 22, 2014, № 11, p. 510-512. ISSN 1568-5888. DOI 10.1007/s12471-014-0611-3.
1895. **Dal Zotto, B., Barbieri, L., Tumminello, G., Saviano, M., Gentile, D., Lucreziotti, S., Frattini, L., Tarricone, D., Carugo, S.** New Onset Atrial Fibrillation in STEMI Patients: Main Prognostic Factors and Clinical Outcome. // *Diagnostics*, 13, 2023, № 4, art. no. 613. ISSN 2075-4418. DOI 10.3390/diagnostics13040613.
1896. **Danzi, G.B., Olivotti, L., Valenti, R., Bedogni, F., Ciarma, L., Cremonesi, A., Marchese, A., Piccaluga, E., Salvi, A., Sardella, G., Varbella, F., Berti, S.** Trends of percutaneous coronary intervention in Italy in the last 10 years. // *Journal of Cardiovascular Medicine*, 18, 2017, № 3, p. 170-177. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000393.

1897. **Dauerman, H.L.** Anticoagulation Strategies for Primary Percutaneous Coronary Intervention: Current Controversies and Recommendations. // *Circulation: Cardiovascular Interventions*, 8, 2015, № 5, art. no. e001947. ISSN 1941-7640. DOI 10.1161/CIRCINTERVENTIONS.115.001947.
1898. **Dauerman, H.L., Gogo, P.B., Jr., Sobel, B.E.** Reperfusion therapies for acute ST elevation myocardial infarction. – In: *Cardiac Intensive Care*, 2018, p. 103-116.e5. ISBN 9780323529938. DOI 10.1016/B978-0-323-52993-8.00011-4.
1899. **Deharo, P., Rahbi, H., Cuisset, T.** Optimizing adjunctive antithrombotic and anticoagulant therapy in primary PCI for STEMI. // *Minerva Cardioangiologica*, 64, 2016, № 3, p. 238-255. ISSN 0026-4725.
1900. **Dehghani, P., Schmidt, C.W., Garcia, S., Okeson, B., Grines, C.L., Singh, A., Patel, R.A.G., Wiley, J., Htun, W.W., Nayak, K.R., Alraies, M.C., Ghasemzadeh, N., Davidson, L.J., Acharya, D., Stone, J., Alyousef, T., Case, B.C., Dai, X., Hafiz, A.M., Madan, M., Jaffer, F.A., Shavadia, J.S., Garberich, R., Bagai, A., Singh, J., Aronow, H.D., Mercado, N., Henry, T.D.** North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital Mortality. // *Journal of the Society for Cardiovascular Angiography and Interventions*, 1, 2022, № 5, art. no. 100404. ISSN 2772-9303. DOI 10.1016/j.jscai.2022.100404.
1901. **Del Buono, M.G., Damonte, J.I., Trankle, C.R., Bhardwaj, H., Markley, R., Turlington, J., Van Tassell, B.W., Salloum, F.N., Abbate, A.** Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use? // *Journal of Cardiovascular Pharmacology*, 78, 2021, № 3, p. 331-333. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001103.
1902. **Del Buono, M.G., Damonte, J.I., Trankle, C.R., Kadariya, D., Carbone, S., Thomas, G., Turlington, J., Markley, R., Canada, J.M., Biondi-Zoccai, G.G., Kontos, M.C., Van Tassell, B.W., Abbate, A.** Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. // *Scientific Reports*, 12, 2022, № 1, art. no. 1254. ISSN 2045-2322. DOI 10.1038/s41598-022-05374-w.
1903. **Del Buono, M.G., Garmendia, C.M., Seropian, I.M., Gonzalez, G., Berrocal, D.H., Biondi-Zoccai, G., Trankle, C.R., Bucciarelli-Ducci, C., Thiele, H., Lavie, C.J., Crea, F., Abbate, A.** Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. // *Current Problems in Cardiology*, 48, 2023, № 8, art. no. 101215. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2022.101215.
1904. **Devon, H.A., Daya, M.R., Knight, E., Brecht, M.-L., Su, E., Zègre-Hemsey, J., Mirzaei, S., Frisch, S., Rosenfeld, A.G.** Unusual Fatigue and Failure to Utilize EMS Are Associated With Prolonged Prehospital Delay for Suspected Acute Coronary Syndrome. // *Critical Pathways in Cardiology*, 19, 2020, № 4, p. 206-212. ISSN 1535-282X. DOI 10.1097/HPC.0000000000000245.
1905. **Di Fusco, S.A., Di Pasquale, G., Mistrulli, R., Dini, C.S., Gasparetto, N., De Luca, L., Gabrielli, D., Oliva, F., Scherillo, M., Colivicchi, F.** The network for myocardial infarction in Italy: ANMCO role in 20 years of progresses and future prospects. [La rete per l'infarto in Italia: il ruolo dell'ANMCO in 20 anni di progressi e prospettive future]. // *Giornale Italiano di Cardiologia*, 23, 2022, № 11, p. 821-825. ISSN 1827-6806. DOI 10.1714/3900.38820.



1906. **Diana, G., Locorotondo, G., Manfredonia, L., Graziani, F., Lombardo, A., Lanza, G.A., Pedicino, D., Liuzzo, G., Massetti, M., Crea, F.** Subclinical dysfunction of remote myocardium is related to high NT-proBNP and affects global contractility at follow-up, independently of infarct area. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 997821. ISSN 2297-055X. DOI 10.3389/fcvm.2022.997821.
1907. **Diaz-Arocutipa, C., Torres-Valencia, J., Saucedo-Chinchay, J., Cuevas, C.** ST-segment elevation in patients with COVID-19: a systematic review. // *Journal of Thrombosis and Thrombolysis*, 52, 2021, № 3, p. 738-745. ISSN 0929-5305. DOI 10.1007/s11239-021-02411-9.
1908. **Dürig, M., Arroyo, D., Bedossa, M., Commeau, P., Fournier, S., Müller, O., Barragan, P., Le Breton, H., Puricel, S., Cook, S.** Clinical outcomes after unprotected left main coronary artery occlusion: A retrospective multicentre cohort analysis. // *Catheterization and Cardiovascular Interventions*, 101, 2023, № 4, p. 679-686. ISSN 1522-1946. DOI 10.1002/ccd.30585.
1909. **Ehrlikh, A.D., Gratsiansky, N.A.** Registry of acute coronary syndromes «record-3». Characteristics of patients and treatment until discharge during initial hospitalization. // *Kardiologiya*, 56, 2016, № 4, p. 16-24. ISSN 0022-9040. DOI 10.18565/cardio.2016.4.16-24.
1910. **El Khoury, C., Bochaton, T., Flocard, E., Serre, P., Tomasevic, D., Mewton, N., Bonnefoy-Cudraz, E., on behalf of the Observatoire des Syndromes Coronaires Aigus dans RESCUE (OSCAR) Research Team.** Five-year evolution of reperfusion strategies and early mortality in patients with ST-segment elevation myocardial infarction in France. // *European Heart Journal: Acute Cardiovascular Care*, 6, 2017, № 7, p. 573-582. ISSN 2048-8726. DOI 10.1177/2048872615623065.
1911. **Emet, S., Elitok, A., Karaayvaz, E.B., Engin, B., Cevik, E., Tuncozgun, A., Aydogan, M., Mercanoglu, F., Ozcan, M., Oncul, A.** Predictors of left ventricle ejection fraction and early in-hospital mortality in patients with ST-segment elevation myocardial infarction: Single-center data from a tertiary referral university hospital in Istanbul. // *SAGE Open Medicine*, 7, 2019. ISSN 2050-3121. DOI 10.1177/2050312119871785.
1912. **Esina, O.P., Esin, S.G., Nosov, V.P., Koroleva, L., Kovaleva, G.V., Trofimov, N.A.** Heart rate variability in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention and risk of complicated in-hospital period. // *Kardiologiya i Serdechno-Sosudistaya Khirurgiya*, 11, 2018, № 4, p. 20-25. ISSN 1996-6385. DOI 10.17116/kardio201811420.
1913. **Falco, L., Fabris, E., Gregorio, C., Pezzato, A., Milo, M., Massa, L., Lardieri, G., Korcova, R., Cominotto, F., Vitrella, G., Rakar, S., Perkan, A., Sinagra, G.** Early prognostic stratification and identification of irreversibly shocked patients despite primary percutaneous coronary intervention. // *Journal of Cardiovascular Medicine*, 23, 2022, № 4, p. 247-253. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001282.
1914. **Fan, J., Wang, X., Ma, X., Somers, V.K., Nie, S., Wei, Y.** Association of obstructive sleep apnea with Cardiovascular outcomes in patients with acute coronary syndrome. // *Journal of the American Heart Association*, 8, 2019, № 2, art. no. e010826, 10 p. ISSN 2047-9980. DOI 10.1161/JAHA.118.010826.

1915. **Faria, D.C., Santos, M.B., Abreu, P.F.E.** The fall in acute coronary syndrome admissions during the COVID-19 Portuguese lockdown. [A queda das admissões por síndrome coronária aguda durante o estado de emergência português pela COVID-19]. // *Revista Portuguesa de Cardiologia*, 40, 2021, № 3, p. 251. ISSN 0870-2551. DOI 10.1016/j.repc.2020.04.012.
1916. **Farshidi, H., Abdi, A., Boland, A., Moshiri, S., Nicolino, A., Nikparvar, M., Azad, M., Eftekhari, T.E.** Successful implementation of primary percutaneous coronary intervention in an Iranian population: A single-center experience. // *Iranian Heart Journal*, 20, 2019, № 4, p. 46-55. ISSN 1735-7306.
1917. **Feistritzer, H.-J., Desch, S., de Waha, S., Jobs, A., Zeymer, U., Thiele, H.** German contribution to development and innovations in the management of acute myocardial infarction and cardiogenic shock. // *Clinical Research in Cardiology*, 107, 2018, p. 74-80. ISSN 1861-0684. DOI 10.1007/s00392-018-1276-5.
1918. **Fernández-Bergés, D.** Data from the German Chest Pain Unit Registry: The well known gap between knowledge and practice. // *International Journal of Cardiology*, 246, 2017, p. 16-17. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.02.002.
1919. **Fernández-Bergés, D., Degano, I.R., Fernandez, R.G., Subirana, I., Vila, J., Jiménez-Navarro, M., Perez-Fernandez, S., Roqué, M., Bayes-Genis, A., Fernandez-Aviles, F., Mayorga, A., Bertomeu-Gonzalez, V., Sanchis, J., Esteban, M.R., Sanchez-Hidalgo, A., Sanchez-Insa, E., Elorriaga, A., Assi, E.A., Nuñez, A., Ruiz, J.M.G., Valdeolmillos, P.M., Bosch-Portell, D., Lekuona, I., Carrillo-Lopez, A., Zamora, A., Vega-Hernandez, B., Serrano, J.A., Rubert, C., Ruiz-Valdepeñas, L., Quintas, L., Rodríguez-Padial, L., Vaquero, J., Dolz, L.M., Barabes, J.A., Sanchez, P.L., Sionis, A., Martí-Almor, J., Elosua, R., Lidon, R.-M., Garcia-Dorado, D., Marrugat, J., ATHOS investigators.** Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction. // *Open Heart*, 7, 2020, № 2, art. no. e001169. ISSN 2398-595X. DOI 10.1136/openhrt-2019-001169.
1920. **Filipiak, K.J., Wozakowska-Kaplon, B., Witkowski, A., Gierlotka, M., Opolski, G., Mamcarz, A.** Fondaparinux in the treatment of acute coronary syndromes in Poland-from theory to the practice. Experts' group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. [Miejsce fondaparinuxu w terapii ostrych zespołów wieńcowych w Polsce-od teorii do praktyki. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego]. // *Kardiologia Polska*, 73, 2015, № 10, p. 943-948. ISSN 0022-9032. DOI 10.5603/KP.2015.0181.
1921. **Fraticelli, L., Kleitz, O., Claustre, C., Eydoux, N., Peiretti, A., Tazarourte, K., Bonnefoy-Cudraz, E., Dussart, C., El Khoury, C.** Comparison of the pathways of care and life courses between first-time ST-elevation myocardial infarction (STEMI) and STEMI with prior MI: Findings from the OSCAR registry. // *BMJ Open*, 10, 2020, № 11, art. no. e038773. ISSN 2044-6055. DOI 10.1136/bmjopen-2020-038773.
1922. **Gale, C.P.** Inequalities in reperfusion therapy for STEMI. // *European Heart Journal - Quality of Care and Clinical Outcomes*, 2, 2016, № 1, p. 4-5. ISSN 2058-5225. DOI 10.1093/ehjqcco/qcv031.

1923. **Ganyukov, V.I., Protopopov, A.V., Bashkireva, A.L., Alekyan, B.G., Shlyakhto, E.V.** European initiative “Stent for life” in Russia. // *Russian Journal of Cardiology*, 134, 2016, № 6, p. 68-72. ISSN 1560-4071. DOI 10.15829/1560-4071-2016-6-68-72.
1924. **Gao, W., Zhong, X., Ma, Y., Huang, D., Wang, R., Zhao, S., Yang, S., Qian, J., Ge, J.** A randomized multicenter trial to evaluate early invasive strategy for patients with acute ST-segment elevation myocardial infarction presenting 24-48 hours from symptom onset: Protocol of the RESCUE-MI study. // *American Heart Journal*, 251, 2022, p. 54-60. ISSN 0002-8703. DOI 10.1016/j.ahj.2022.05.002.
1925. **Garcia, D.C., Benjo, A.M., White, C.J., Cardoso, R.N., Macedo, F.Y.B., Schob, A.H., El-Hayek, G.E., Nadkarni, G., Aziz, E.F., Patel, R.A.G.** Metaanalysis of multivessel vs culprit artery only percutaneous coronary intervention in st elevation myocardial infarction. // *Ochsner Journal*, 19, 2019, № 2, p. 107-115. ISSN 1524-5012. DOI 10.31486/toj.18.0033.
1926. **García, V., Muñoz-García, A.J., Jiménez-Navarro, M.F.** Diagnostic and therapeutic protocol of acute coronary syndrome with ST segment elevation in the emergency department. [Protocolo diagnóstico y terapéutico del síndrome coronario agudo con elevación del segmento ST en Urgencias]. // *Medicine (Spain)*, 12, 2019, № 89, p. 5249-5252. ISSN 0304-5412. DOI 10.1016/j.med.2019.11.006.
1927. **García-García, C., Ribas, N., Recasens, L.L., Meroño, O., Subirana, I., Fernández, A., Pérez, A., Miranda, F., Tizón-Marcos, H., Martí-Almor, J., Bruguera, J., Elosua, R.** In-hospital prognosis and long-term mortality of STEMI in a reperfusion network. "Head to head" analysis: Invasive reperfusion vs optimal medical therapy. // *BMC Cardiovascular Disorders*, 17, 2017, № 1, art. no. 139. ISSN 1471-2261. DOI 10.1186/s12872-017-0574-6.
1928. **Garcia-Moll, X.** Lights and (some) shadows in the management of acute coronary syndrome in Spain: The DIOCLEES study. [Luces y (algunas) sombras en el manejo del síndrome coronario agudo en España: El estudio DIOCLEES]. // *Revista Espanola de Cardiologia*, 68, 2015, № 2, p. 85-86. ISSN 0300-8932. DOI 10.1016/j.recesp.2014.11.003.
1929. **Gelbenegger, G., Grafeneder, J., Gager, G.M., Siller-Matula, J.M., Schwameis, M., Jilma, B., Schoergenhofer, C.** Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. // *Thrombosis Journal*, 20, 2022, № 1, art. no. 19. ISSN 1477-9560. DOI 10.1186/s12959-022-00377-z.
1930. **Gelbenegger, G., Jilma, B.** Clinical pharmacology of antiplatelet drugs. // *Expert Review of Clinical Pharmacology*, 15, 2022, № 10, p. 1177-1197. ISSN 1751-2433. DOI 10.1080/17512433.2022.2121702.
1931. **Giannakopoulos, G., Noble, S.** Should We Be Using Upstream Beta-Blocker Therapy for Acute Myocardial Infarction? // *Current Cardiology Reports*, 23, 2021, № 6, art. no. 66. ISSN 1523-3782. DOI 10.1007/s11886-021-01494-3.
1932. **Gowdak, L.H.W.** Focus on trimetazidine in acute coronary syndrome. // *Heart and Metabolism*, 2018, № 75, p. 22-27. ISSN 1566-0338. DOI 10.31887/hm.2018.75/gowdak.

1933. **Hall, M., Cenko, E., Bueno, H., Gale, C.P.** Contemporary roles of registries in clinical cardiology: Insights from Western and Eastern European countries. // *International Journal of Cardiology*, 217, 2016, p. S13-S15. ISSN 0167-5273. DOI 10.1016/j.ijcard.2016.06.220.
1934. **Heusch, G., Andreadou, I., Bell, R., Bertero, E., Botker, H.-E., Davidson, S.M., Downey, J., Eaton, P., Ferdinandy, P., Gersh, B.J., Giacca, M., Hausenloy, D.J., Ibanez, B., Krieg, T., Maack, C., Schulz, R., Sellke, F., Shah, A.M., Thiele, H., Yellon, D.M., Di Lisa, F.** Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. // *Redox Biology*, 67, 2023, art. no. 102894. ISSN 2213-2317. DOI 10.1016/j.redox.2023.102894.
1935. **Heusch, G., Gersh, B.J.** The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. // *European Heart Journal*, 38, 2017, № 11, p. 774-784. ISSN 0195-668X. DOI 10.1093/eurheartj/ehw224.
1936. **Hromádka, M., Bernat, I., Seidlerová, J., Jirouš, Š., Dragounová, E., Pechman, V., Tůmová, P., Rokyta, R.** Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: Influence of adjunctive antiplatelet therapy. // *Coronary Artery Disease*, 27, 2016, № 4, p. 267-272. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000352.
1937. **Hua, Y., Shao, M., Wang, Y., Du, J., Tian, J., Wei, K., Chang, J., Zhang, X., Chen, M., Liao, J.** Xuesaitong injection treating acute myocardial infarction A systematic review and meta-Analysis. // *Medicine (United States)*, 100, 2021, № 37, art. no. A113. ISSN 0025-7974. DOI 10.1097/MD.00000000000027027.
1938. **Huang, F., Sun, L., Zhao, C., Qiu, Z., Zhao, Y., Jin, W.** Protein microcapsules integrated hierarchical scaffolds for local treatment of acute myocardial infarction model. // *Applied Materials Today*, 22, 2021, art. no. 100901. ISSN 2352-9407. DOI 10.1016/j.apmt.2020.100901.
1939. **Irawati, S., Dharma, S., Taxis, K., Nguyen, T., Nursyarofah, N., Wilffert, B., Hak, E.** Association between adherence to guideline-recommended preventive medications and in-hospital mortality among non-reperfused ST-elevation myocardial infarction patients admitted to a tertiary care academic center in a developing country. // *Global Heart*, 15, 2020, № 1, art. no. 8. ISSN 2211-8160. DOI 10.5334/GH.394.
1940. **Itoh, T., Nakajima, S., Tanaka, F., Nishiyama, O., Matsumoto, T., Endo, H., Sakai, T., Nakamura, M., Morino, Y.** Impact of the Japan earthquake disaster with massive Tsunami on emergency coronary intervention and in-hospital mortality in patients with acute ST-elevation myocardial infarction. // *European Heart Journal: Acute Cardiovascular Care*, 3, 2014, № 3, p. 195-203. ISSN 2048-8726. DOI 10.1177/2048872614538388.
1941. **Iwama, M., Noda, T., Takagi, K., Tanaka, A., Uemura, Y., Umemoto, N., Shibata, N., Negishi, Y., Ohashi, T., Tanaka, M., Yoshida, R., Shimizu, K., Tashiro, H., Yoshioka, N., Morishima, I., Watarai, M., Tanaka, T., Tatami, Y., Takada, Y., Ishii, H., Murohara, T., on behalf of N-registry investigators.** Impact of right coronary artery dominance on the long-term mortality in the patients with acute total/subtotal occlusion of unprotected left main coronary artery. // *Journal of Cardiology*, 82, 2023, № 3, p. 165-171. ISSN 0914-5087. DOI 10.1016/j.jjcc.2023.04.003.

1942. **Izadpanah, P., Falahati, F., Mokhtari, A.M., Hosseinpour, F., Faham, B., Sheidaee, R., Jalali, S., Zare, H., Hassanipour, S.** The survival rate of patients with ST-Segment elevation myocardial infarction treated with primary percutaneous coronary intervention and thrombolysis. // *Clinical Epidemiology and Global Health*, 8, 2020, № 3, p. 770-774. ISSN 2213-3984. DOI 10.1016/j.cegh.2020.01.017.
1943. **Jensen, R.V., Hjortbak, M.V., Bøtker, H.E.** Ischemic Heart Disease: An Update. // *Seminars in Nuclear Medicine*, 50, 2020, № 3, p. 195-207. ISSN 0001-2998. DOI 10.1053/j.semnuclmed.2020.02.007.
1944. **Jung, C., Elsässer, A.** Update ESC Guideline 2017 - Acute Myocardial Infarction (STEMI). [Update ESC-Leitlinie 2017 - Akuter Myokardinfarkt (STEMI)]. // *Deutsche Medizinische Wochenschrift*, 143, 2018, № 11, p. 797-801. ISSN 0012-0472. DOI 10.1055/a-0494-0341.
1945. **Kalinauskiene, E., Gerviene, D., Bacharova, L., Krivosikova, Z., Naudziunas, A.** Differences in the Selvester QRS score after primary PCI strategy and conservative treatment for STEMI patients with negative T waves. // *Annals of Noninvasive Electrocardiology*, 24, 2019, № 6, art. no. e12684. ISSN 1082-720X. DOI 10.1111/anec.12684.
1946. **Kämpfer, J., Yagensky, A., Zdrojewski, T., Windecker, S., Meier, B., Pavelko, M., Sichkaruk, I., Kasprzyk, P., Gruchala, M., Giacomini, M., Räber, L., Saner, H.** Long-term outcomes after acute myocardial infarction in countries with different socioeconomic environments: An international prospective cohort study. // *BMJ Open*, 7, 2017, № 8, art. no. e012715. ISSN 2044-6055. DOI 10.1136/bmjopen-2016-012715.
1947. **Kang, J.E., Yu, J.M., Choi, J.H., Chung, I.-M., Pyun, W.B., Kim, S.A., Lee, E.K., Han, N.Y., Yoon, J.-H., Oh, J.M., Rhie, S.J.** Development and clinical application of an evidence-based pharmaceutical care service algorithm in acute coronary syndrome. // *Journal of Clinical Pharmacy and Therapeutics*, 43, 2018, № 3, p. 366-376. ISSN 0269-4727. DOI 10.1111/jcpt.12665.
1948. **Kanjanahattakij, N., Rattanawong, P., Riangwiwat, T., Prasitlunkum, N., Limpruttidham, N., Chongsathidkiet, P., Vutthikraivit, W., Crossey, E.** Fragmented QRS and mortality in patients undergoing percutaneous intervention for ST-elevation myocardial infarction: Systematic review and meta-analysis. // *Annals of Noninvasive Electrocardiology*, 23, 2018, № 6, art. no. e12567. ISSN 1082-720X. DOI 10.1111/anec.12567.
1949. **Kaur, K., Singh, N., Dhawan, R.K.** Exploring the role of dimethylarginine dimethylaminohydrolasemediated reduction in tissue asymmetrical dimethylarginine levels in cardio-protective mechanism of ischaemic postconditioning in rats. // *Iranian Journal of Basic Medical Sciences*, 22, 2019, № 12, p. 1415-1423. ISSN 2008-3866. DOI 10.22038/ijbms.2019.14067.
1950. **Kaur, K., Singh, N., Dhawan, R.K.** Potential role of EphrinA2 receptors in post-conditioning induced cardioprotection in rats. // *European Journal of Pharmacology*, 883, 2020, art. no. 173231. ISSN 0014-2999. DOI 10.1016/j.ejphar.2020.173231.
1951. **Kazemi, B., Hajizadeh, R., Ranjbar, A., Sohrabi, B., Vaezi, H.** Evaluation of Tpeak to end/QT and Tpeak to end/QTc ratios in patients with STEMI undergoing



- percutaneous intervention vs. thrombolytic therapy. // *Journal of Electrocardiology*, 58, 2020, p. 160-164. ISSN 0022-0736. DOI 10.1016/j.jelectrocard.2019.12.001.
1952. **Kirtane, A.J., Stone, G.W.** STEMI care in China: A world opportunity. // *The Lancet*, 385, 2015, № 9966, p. 400-401. ISSN 0140-6736. DOI 10.1016/S0140-6736(14)61033-3.
  1953. **Kontsevaya, A., Sabgaida, T., Ivanova, A., Leon, D.A., McKee, M.** How has the management of acute coronary syndrome changed in the Russian Federation during the last 10 years? // *Health Policy*, 121, 2017, № 12, p. 1274-1279. ISSN 0168-8510. DOI 10.1016/j.healthpol.2017.09.018.
  1954. **Kvakkestad, K., Gran, J.M., Halvorsen, S.** Short-and long-term survival after ST-elevation myocardial infarction treated with pharmacoinvasive versus primary percutaneous coronary intervention strategy: a prospective cohort study. // *BMJ Open*, 12, 2022, № 7, art. no. e061590. ISSN 2044-6055. DOI 10.1136/bmjopen-2022-061590.
  1955. **Kwok, C.S., Qureshi, A.I., Will, M., Schwarz, K., Lip, G.Y.H., Borovac, J.A.** Structural Complications Following ST-Elevation Myocardial Infarction: An Analysis of the National Inpatient Sample 2016 to 2020. // *Journal of Cardiovascular Development and Disease*, 11, 2024, № 2, art. no. 59. ISSN 2308-3425. DOI 10.3390/jcdd11020059.
  1956. **Lazar, E., Benedek, T., Korodi, S., Rat, N., Lo, J., Benedek, I.** Stem cell-derived exosomes - An emerging tool for myocardial regeneration. // *World Journal of Stem Cells*, 10, 2018, № 8, p. 106-115. ISSN 1948-0210. DOI 10.4252/wjsc.v10.i8.106.
  1957. **Li, B.-Y., Li, X.-M., Zhang, Y., Wei, Z.-Y., Li, J., Hua, Q.** Effect of coronary artery revascularization on in-hospital outcomes and long-term prognoses in acute myocardial infarction patients with prior ischemic stroke. // *Journal of Geriatric Cardiology*, 13, 2016, № 2, p. 145-151. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2015.06.017.
  1958. **Li, J., Li, X., Ross, J.S., Wang, Q., Wang, Y., Desai, N.R., Xu, X., Nuti, S.V., Masoudi, F.A., Spertus, J.A., Krumholz, H.M., Jiang, L., for the China PEACE Collaborative Group.** Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. // *European Heart Journal: Acute Cardiovascular Care*, 6, 2017, № 3, p. 232-243. ISSN 2048-8726. DOI 10.1177/2048872615626656.
  1959. **Li, M.-F., Wei, Z.-T., Li, S., Feng, Q.-M., Li, J.-B.** Association of Mild Thyroid Dysfunction and Adverse Prognosis Among Chinese Patients With Acute ST Segment Elevation Myocardial Infarction. // *Frontiers in Endocrinology*, 13, 2022, art. no. 879443. ISSN 1664-2392. DOI 10.3389/fendo.2022.879443.
  1960. **Li, S.-Y., Zhou, M.-G., Ye, T., Cheng, L.-C., Zhu, F., Cui, C.-Y., Zhang, Y.-M., Cai, L.** Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: Results from a Southwest Chinese Registry. // *Reviews in Cardiovascular Medicine*, 22, 2021, № 1, p. 239-245. ISSN 1530-6550. DOI 10.31083/J.RCM.2021.01.103.
  1961. **Li, Y.** Diagnostic Model of In-Hospital Mortality in Patients with Acute ST-Segment Elevation Myocardial Infarction Used Artificial Intelligence Methods. // *Cardiology*

1962. **Li, Y., Xiang, Y., Zhang, S., Wang, Y., Yang, J., Liu, W., Xue, F.** Intramyocardial injection of thioredoxin 2-expressing lentivirus alleviates myocardial ischemia-reperfusion injury in rats. // *American Journal of Translational Research*, 9, 2017, № 10, art. no. AJTR0060765, p. 4428-4439. ISSN 1943-8141.
1963. **Liu, J., Huang, L., Shi, X., Gu, C., Xu, H., Liu, S.** Clinical Parameters and Metabolomic Biomarkers That Predict Inhospital Outcomes in Patients With ST-Segment Elevated Myocardial Infarctions. // *Frontiers in Physiology*, 12, 2022, art. no. 820240. ISSN 1664-042X. DOI 10.3389/fphys.2021.820240.
1964. **Llaó, I., Gómez-Hospital, J.A., Aboal, J., Garcia, C., Montero, S., Sambola, A., Ortiz, J., Tomás, C., Bonet, G., Viñas, D., Oliveras, T., Sans-Roselló, J., Cantalapiedra, J., Andrea, R., Hernández, I., Pérez-Rodríguez, M., Gual, M., Cequier, A., Ariza-Solé, A., en representacion de los investigadores del Grup de Treball de Cures Agudes Cardiològiques de la Societat Catalana de Cardiologia.** Risk-adjusted early invasive strategy in patients with non-ST-segment elevation acute coronary syndrome in Intensive Cardiac Care Units. [Estrategia invasiva precoz ajustada al riesgo en pacientes con síndrome coronario agudo sin elevación de segmento ST en Unidades de Cuidados Intensivos Cardiológicos]. // *Medicina Intensiva*, 44, 2020, № 8, p. 475-484. ISSN 0210-5691. DOI 10.1016/j.medin.2019.06.006.
1965. **Longrois, D., Maegele, M., Bersini, H., Crooks, G., Hubloue, I., Nowé, A., Rimensberger, P.C., Sabbe, M., Tilsed, J., Vandemeulebroucke, J., Verhelst, W., Vincent, J.-L.** Streamlining pre- and intra-hospital care for patients with severe trauma: a white paper from the European Critical Care Foundation. // *European Journal of Trauma and Emergency Surgery*, 45, 2019, № 1, p. 39-48. ISSN 1863-9933. DOI 10.1007/s00068-018-1053-1.
1966. **Lozano, I., Suárez-Cuervo, A., Rondán, J., Avanzas, P., Vegas, J.M., Morís, C.** Care network for ST-elevation myocardial infarction: What is the ideal catchment area for primary angioplasty? [Redes de atención al infarto con elevación del ST: ¿cuál es el área idónea de referencia para angioplastia primaria?]. // *Revista Espanola de Cardiologia*, 68, 2015, № 5, p. 444-445. ISSN 0300-8932. DOI 10.1016/j.recesp.2014.12.016.
1967. **Luscher, T.F.** Infections, infarction, and heart failure: Prevention and management. // *European Heart Journal*, 36, 2015, № 44, p. 3033-3035. ISSN 0195-668X. DOI 10.1093/eurheartj/ehv618.
1968. **Luscher, T.F.** Stroke: Cardiac causes and their management. // *European Heart Journal*, 36, 2015, № 35, p. 2339-2341. ISSN 0195-668X. DOI 10.1093/eurheartj/ehv374.
1969. **Lüscher, T.F.** The management of acute coronary syndromes: Towards optimal treatment of STEMI and non-STEMI. // *European Heart Journal*, 37, 2016, № 3, p. 203-205. ISSN 0195-668X. DOI 10.1093/eurheartj/ehv747.
1970. **Malay, L.N., Solokhina, L.V., Bukhonkina, Y.M., Poshatayev, K.E., Garayev, H.B., Letskin, A.Y.** Characteristic features, treatment and hospital outcomes in patients with acute myocardial infarction: Khabarovsk Register data. Part I. // *Rational*

1971. **Mancone, M., van Mieghem, N.M., Zijlstra, F., Diletti, R.** Current and novel approaches to treat patients presenting with ST elevation myocardial infarction. // *Expert Review of Cardiovascular Therapy*, 14, 2016, № 8, p. 895-904. ISSN 1477-9072. DOI 10.1080/14779072.2016.1190642.
1972. **Mehta, S., Grines, C.L., Botelho, R., Fernandez, F., Cade, J., Dusilek, C., Prudente, M., Cavalcanti, R., Campos, C., Alcocer Gamba, M.** STEMI telemedicine for 100 million lives. // *Catheterization and Cardiovascular Interventions*, 98, 2021, № 6, p. 1066-1071. ISSN 1522-1946. DOI 10.1002/ccd.29896.
1973. **Mendes, A.S., Dos Santos Souza Reis, V.R., De Souza Teles Santos, C.A., Mussi, F.C.** Access times to health services in cases of myocardial infarction. [Tempos de acesso a serviços de saúde face ao infarto do miocárdio]. // *ACTA Paulista de Enfermagem*, 29, 2016, № 4, p. 446-453. ISSN 0103-2100. DOI 10.1590/1982-0194201600061.
1974. **Mohl, W., Gangl, C., Jusić, A., Aschacher, T., De Jonge, M., Rattay, F.** PICSO: From myocardial salvage to tissue regeneration. // *Cardiovascular Revascularization Medicine*, 16, 2015, № 1, p. 36-46. ISSN 1553-8389. DOI 10.1016/j.carrev.2014.12.004.
1975. **Montecucco, F., Carbone, F., Schindler, T.H.** Pathophysiology of ST-segment elevation myocardial infarction: Novel mechanisms and treatments. // *European Heart Journal*, 37, 2016, № 16, p. 1268-1283e. ISSN 0195-668X. DOI 10.1093/eurheartj/ehv592.
1976. **Moulin, K., Viallon, M., Romero, W., Chazot, A., Mewton, N., Isaaz, K., Croisille, P.** MRI of reperfused acute myocardial infarction edema: ADC quantification versus T1 and T2 mapping. // *Radiology*, 295, 2020, № 3, p. 542-549. ISSN 0033-8419. DOI 10.1148/radiol.2020192186.
1977. **Moura, F.A., Figueiredo, V.N., Teles, B.S.B.S., Barbosa, M.A., Pereira, L.R., Costa, A.P.R., Carvalho, L.S.F., Cintra, R.M.R., Almeida, O.L.R., Quinaglia e Silva, J.C., Nadruz Junior, W., Sposito, A.C., Brasilia Heart Study.** Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. // *Atherosclerosis*, 243, 2015, № 1, p. 124-130. ISSN 0021-9150. DOI 10.1016/j.atherosclerosis.2015.09.004.
1978. **Mühlberger, V., Kaltenbach, L., Ulmer, H.** Austrian National CathLab Registry (ANCLAR): Cardiac Catheterization, Coronary Angiography (CA) and PCI in Austria during the Year 2014 (Registry Data with Audit including 2015). [Herzkathetereingriffe in Österreich im Jahr 2014 (mit Audit bis 2015)]. // *Journal fur Kardiologie*, 23, 2016, № 1/2, p. 1-10. ISSN 1024-0098.
1979. **Mühlberger, V., Kaltenbach, L., Ulmer, H., Pachinger, O., Österreichischen Herzkatheterzentren.** Austrian National CathLab Registry (ANCLAR): Cardiac catheterization, coronary angiography (CA) and PCI in Austria during the year 2013 (registry data with audit including 2014). [Herzkathetereingriffe in Österreich im Jahr 2013 (mit audit bis 2014)]. // *Journal fur Kardiologie*, 22, 2015, № 1/2, p. 1-11. ISSN 1024-0098.

1980. **Nesterak, R., Vakaliuk, I., Łuniewski, J., Szczegielniak, J.** Clinicohemodynamic and psychocognitive parallels of internal picture of health correction in the process of restorative treatment and rehabilitation of patients with STsegment elevation myocardial infarction. // *Fizjoterapia Polska*, 19, 2019, № 3, p. 158-166. ISSN 1642-0136.
1981. **Ning, C., Zheng, Y., Li, J., Liu, M., Fang, Z., Lawal, I.** Effects of recombinant human brain natriuretic peptide in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis. // *Medicine (United States)*, 99, 2020, № 11, p. E19479. ISSN 0025-7974. DOI 10.1097/MD.00000000000019479.
1982. **Oikonomou, E., Tousoulis, D.** Targeting percutaneous cardiovascular interventions at all who will benefit the most: The reality of the Eastern European countries. // *International Journal of Cardiology*, 217, 2016, p. S47-S48. ISSN 0167-5273. DOI 10.1016/j.ijcard.2016.06.226.
1983. **Oliveira, J.C., Dos Santos Ferreira, G.J., Oliveira, J.C., Munareto Lima, T.C.R., De Carvalho Barreto, I.D., Souza Oliveira, L.C., Maia Arcelino, L.A., Sousa, A.C., Barreto-Filho, J.A.S.** Influence of geographical location on access to reperfusion therapies and mortality of patients with stemi in sergipe: Victim register. // *Arquivos Brasileiros de Cardiologia*, 117, 2021, № 1, p. 120-129. ISSN 0066-782X. DOI 10.36660/abc.20200015.
1984. **Ottani, F., Latini, R., Staszewsky, L., La Vecchia, L., Locuratolo, N., Sicuro, M., Masson, S., Barlera, S., Milani, V., Lombardi, M., Costalunga, A., Mollicelli, N., Santarelli, A., De Cesare, N., Sganzerla, P., Boi, A., Maggioni, A.P., Limbruno, U., CYCLE Investigators.** Cyclosporine A in Reperfused Myocardial Infarction the Multicenter, Controlled, Open-Label CYCLE Trial. // *Journal of the American College of Cardiology*, 67, 2016, № 4, p. 365-374. ISSN 0735-1097. DOI 10.1016/j.jacc.2015.10.081.
1985. **Parkhomenko, O.M., Lutay, Y.M., Bilyi, D.O., Irkin, O.I., Stepura, A.O., Kushnir, S.P., Skarzhevskiy, O.A.** Features of laboratory-diagnostic indicators in patients of different age groups with ST-elevation acute coronary syndrome. // *Ukrainian Journal of Cardiology*, 26, 2019, № 1, p. 31-39. ISSN 1608-635X. DOI 10.31928/1608-635X-2019.1.3139.
1986. **Pryds, K., Hjortbak, M.V., Schmidt, M.R.** Influence of cardiovascular risk factors, comorbidities, medication use and procedural variables on remote ischemic conditioning efficacy in patients with ST-segment elevation myocardial infarction. // *International Journal of Molecular Sciences*, 20, 2019, № 13, art. no. 3246. ISSN 1661-6596. DOI 10.3390/ijms20133246.
1987. **Qiu, Z., Chen, X., Yin, L., Chen, W., Xu, Y., Jiang, B.** Stomatin-like protein-2 relieve myocardial ischemia/reperfusion injury by adenosine 5'-monophosphate-activated protein kinase signal pathway. // *Journal of Cellular Biochemistry*, 120, 2019, № 2, p. 2323-2335. ISSN 0730-2312. DOI 10.1002/jcb.27561.
1988. **Radisauskas, R., Kirvaitiene, J., Bernotiene, G., Virviciūtė, D., Ustinaviciene, R., Tamosiunas, A.** Long-term survival after acute myocardial infarction in Lithuania during transitional period (1996–2015): Data from population-based kaunas ischemic heart disease register. // *Medicina (Lithuania)*, 55, 2019, № 7, art. no. 357. ISSN 1010-660X. DOI 10.3390/medicina55070357.



1989. **Rajkumar, C.A., Ganesanathan, S., Ahmad, Y., Seligman, H., Thornton, G.D., Foley, M., Nowbar, A.N., Howard, J.P., Francis, D.P., Keeble, T.R., Grunwald, I.Q., Al-Lamee, R.K., Malik, I.S., Shun-Shin, M.J.** Mechanical thrombectomy with retrievable stents and aspiration catheters for acute ischaemic stroke: a meta-analysis of randomised controlled trials. // *EuroIntervention*, 17, 2022, № 17, p. E1425-E1434. ISSN 1774-024X. DOI 10.4244/EIJ-D-21-00343.
1990. **Rakowski, T., Dudek, D., van 't Hof, A., Ten Berg, J., Soulat, L., Zeymer, U., Lapostolle, F., Anthopoulos, P., Bernstein, D., Deliargyris, E.N., Steg, P.G.** Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. // *European Heart Journal: Acute Cardiovascular Care*, 7, 2018, № 6, p. 514-521. ISSN 2048-8726. DOI 10.1177/2048872617690888.
1991. **Riehle, L., Gothe, R.M., Ebbinghaus, J., Maier, B., Bruch, L., Röhnisch, J.-U., Schühlen, H., Fried, A., Stockburger, M., Theres, H., Dreger, H., Leistner, D.M., Landmesser, U., Fröhlich, G.M.** Implementation of the ESC STEMI guidelines in female and elderly patients over a 20-year period in a large German registry. // *Clinical Research in Cardiology*, 112, 2023, № 9, p. 1240-1251. ISSN 1861-0684. DOI 10.1007/s00392-023-02165-9.
1992. **Righetti, S., Montemerlo, E., Soffici, F., Sala, D., Bozzano, A., Mauro, A., Maggioni, E., Avalli, L., Camisasca, P., Colombo, V., Achilli, F., Lettino, M., Calchera, I.** Outcomes Related to Antiplatelet Therapy in a High-Risk ST-Segment Elevation Myocardial Infarction Population: A Retrospective Real-World Analysis of an Italian ECMO Center. // *Journal of Cardiovascular Pharmacology and Therapeutics*, 25, 2020, № 3, p. 219-225. ISSN 1074-2484. DOI 10.1177/1074248419896129.
1993. **Rikken, S.A.O.F., Selvarajah, A., Hermanides, R.S., Coller, B.S., Gibson, C.M., Granger, C.B., Lapostolle, F., Postma, S., van de Wetering, H., van Vliet, R.C.W., Montalescot, G., ten Berg, J.M., van 't Hof, A.W.J., CELEBRATE investigators.** Prehospital treatment with zalunfiban (RUC-4) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. // *American Heart Journal*, 258, 2023, p. 119-128. ISSN 0002-8703. DOI 10.1016/j.ahj.2022.12.015.
1994. **Rivero, F., Bastante, T., Cuesta, J., Benedicto, A., Salamanca, J., Restrepo, J.-A., Aguilar, R., Gordo, F., Batlle, M., Alfonso, F.** Factors Associated with Delays in Seeking Medical Attention in Patients with ST-segment Elevation Acute Coronary Syndrome. [Factores asociados al retraso en la demanda de atención médica en pacientes con síndrome coronario agudo con elevación del segmento ST]. // *Revista Espanola de Cardiologia*, 69, 2016, № 3, p. 279-285. ISSN 0300-8932. DOI 10.1016/j.recesp.2015.07.033.
1995. **Rizza, A., de Giorgi, A., Negro, F., Boari, B., Palmieri, C., Berti, S., Manfredini, R.** Sex-related differences and chronobiology of ST-elevation myocardial infarction: findings from a single hub center in Italy. // *European Review for Medical and Pharmacological Sciences*, 27, 2023, № 4, p. 1540-1552. ISSN 1128-3602. DOI 10.26355/eurrev\_202302\_31397.
1996. **Rodriguez-Leor, O., Cid-Álvarez, A.B., Moreno, R., Martín-Moreiras, J., Serrador, A., Jiménez-Alegre, J.J., Raposeiras, S., Rumoroso, J.R., de Prado, A.P., Cequier, Á.** Survey on the needs of primary angioplasty programs in Spain. // *REC:*



1997. **Rosselló, X., Huo, Y., Pocock, S., de Werf, F.V., Chin, C.T., Danchin, N., Lee, S.W.-L., Medina, J., Vega, A., Bueno, H.** Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. // *International Journal of Cardiology*, 245, 2017, p. 27-34. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.07.039.
1998. **Rossello, X., Lobo-Gonzalez, M., Ibanez, B.** Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome. // *European Heart Journal: Acute Cardiovascular Care*, 8, 2019, № 5, p. 443-456. ISSN 2048-8726. DOI 10.1177/2048872619845283.
1999. **Saar, A., Marandi, T., Ainla, T., Fischer, K., Blöndal, M., Eha, J.** Improved treatment and prognosis after acute myocardial infarction in Estonia: Cross-sectional study from a high risk country. // *BMC Cardiovascular Disorders*, 15, 2015, № 1, art. no. 136. ISSN 1471-2261. DOI 10.1186/s12872-015-0129-7.
2000. **Salama, A.M., Khalil, W.A., Al-Zaky, M., Abdallah, S.H., Kandil, N.T., Abdelsabour, A., Shaker, A.M., Hasanein, M.T., Luciani, G.B., Azzazy, H.M.E.** MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. // *Journal of Cardiovascular Translational Research*, 13, 2020, № 6, p. 988-995. ISSN 1937-5387. DOI 10.1007/s12265-020-10020-9.
2001. **Salehi, N., Motevaseli, S., Janjani, P., Bahremand, M., Moghadam, R.H., Rouzbahani, M., Siabani, S., Tadbiri, H., Nalini, M.** Reperfusion therapy and predictors of 30-day mortality after st-segment elevation myocardial infarction in a university medical center in western Iran. // *Archives of Iranian Medicine*, 24, 2021, № 11, p. 796-803. ISSN 1029-2977. DOI 10.34172/aim.2021.119.
2002. **Salzwedel, A., Völler, H., Reibis, R., Bonaventura, K., Behrens, S., Reibis, R.** Regional Aspects in Treatment of Patients with Acute Myocardial Infarction in the North-East of Germany. [Regionale Versorgungsaspekte des akuten Myokardinfarktes im Nordosten Deutschlands]. // *Deutsche Medizinische Wochenschrift*, 143, 2018, № 8, p. e51-e58. ISSN 0012-0472. DOI 10.1055/s-0043-123907.
2003. **Sambola, A., Del Blanco, B.G., Ruiz-Meana, M., Francisco, J., Barrabés, J.A., Figueras, J., Bañeras, J., Otaegui, I., Rojas, A., Vilardosa, Ú., Montaner, J., García-Dorado, D.** Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy. // *Thrombosis and Haemostasis*, 115, 2016, № 6, p. 1129-1137. ISSN 0340-6245. DOI 10.1160/TH15-12-0985.
2004. **Sambola, A., Elola, F.J., Ferreira, J.L., Murga, N., Rodríguez-Padial, L., Fernández, C., Bueno, H., Bernal, J.L., Cequier, Á., Marín, F., Anguita, M.** Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction. [Impacto de las diferencias de sexo y los sistemas de red en la mortalidad hospitalaria de pacientes con infarto agudo de miocardio con elevación del segmento ST]. // *Revista Espanola de Cardiologia*, 74, 2021, № 11, p. 927-934. ISSN 0300-8932. DOI 10.1016/j.recesp.2020.07.031.
2005. **Sánchez-Salado, J.C., Burgos, V., Ariza-Solé, A., Sionis, A., Canteli, A., Bernal, J.L., Fernández, C., Castrillo, C., Ruiz-Lera, M., López-de-Sá, E., Lidón, R.M.,**

- Worner, F., Martínez-Sellés, M., Segovia, J., Viana-Tejedor, A., Lorente, V., Alegre, O., Llaó, I., González-Costello, J., Manito, N., Cequier, Á., Bueno, H., Elola, J.** Trends in cardiogenic shock management and prognostic impact of type of treating center. [Tendencias en el tratamiento del shock cardiogénico e impacto pronóstico del tipo de centros tratantes]. // *Revista Espanola de Cardiologia*, 73, 2020, № 7, p. 546-553. ISSN 0300-8932. DOI 10.1016/j.recesp.2019.10.009.
2006. **Sanz-Sánchez, J., Stefanini, G.G.** Timing and completeness of revascularisation in acute coronary syndromes. // *Heart*, 108, 2022, № 8, p. 648-656. ISSN 1355-6037. DOI 10.1136/heartjnl-2020-316743.
2007. **Saygi, M., Uzman, O., Birdal, O., Karagoz, A., Yumurtas, A.C., Tezen, O., Tanboga, I.H., Karabay, C.Y.** The Relation of Body Mass Index with In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction. // *Metabolic Syndrome and Related Disorders*, 21, 2023, № 2, p. 94-100. ISSN 1540-4196. DOI 10.1089/met.2022.0070.
2008. **Schiele, F., Bassand, J.-P.** Beyond Reperfusion Networks in ST-segment Elevation Myocardial Infarction: Assessment of Quality of Care. [Más allá de las redes asistenciales de reperfusión coronaria en el infarto con elevación del ST: evaluación de la calidad de la asistencia]. // *Revista Espanola de Cardiologia*, 70, 2017, № 3, p. 140-141. ISSN 0300-8932. DOI 10.1016/j.recesp.2016.09.018.
2009. **Schrage, B., Schwarzl, M., Waldeyer, C., Becher, P.M., Sinning, C., Schäfer, U., Seiffert, M., Zengin-Sahm, E., Blankenberg, S., Westermann, D.** Percutaneous coronary intervention for ostial and bifurcation lesions using the Szabo technique: A single center experience. // *Minerva Cardioangiologica*, 65, 2017, № 4, p. 331-335. ISSN 0026-4725. DOI 10.23736/S0026-4725.17.04334-1.
2010. **Shaheen, S., Wafa, A., Mekarab, M., Zareef, B., Bendary, A., Abdelhameed, T., Rashwan, A., Seleem, M., Elmasry, M., Abdelhady, Y., Abdelrazik, G., Ibrahim, A., Ghareeb, M., Aly, K., Saraya, M., Wadie, M., Youssef, M.** Presentation, management, and outcomes of STEMI in Egypt: results from the European Society of Cardiology Registry on ST elevation myocardial infarction. // *Egyptian Heart Journal*, 72, 2020, № 1, art. no. 35. ISSN 1110-2608. DOI 10.1186/s43044-020-00069-x.
2011. **Shaheen, S.M., Saleh, A.K., Okasha, N.K., Abdalhamid, M.A., Fakhry, H.M., Guindy, R.R.** Implementation of a Regional STEMI Network in North Cairo (Egypt): Impact on the Management and Outcome of STEMI Patients. // *Global Heart*, 18, 2023, № 1, art. no. 2. ISSN 2211-8160. DOI 10.5334/gh.1182.
2012. **Shen, C., Li, C., Wang, J., Yin, J., Lou, P., Wang, Z., Lu, Y., Yang, Y., Li, M., Chen, M.** In-depth look into urban and rural disparities in prehospital delay in patients with acute ST-elevation myocardial infarction and its impact on prognosis: a prospective observational study. // *BMJ Open*, 12, 2022, № 11, art. no. e063795. ISSN 2044-6055. DOI 10.1136/bmjopen-2022-063795.
2013. **Shigotarova, E.A., Dushina, E.V., Galinskaya, V.A., Oleynikov, V.E.** Heart rate variability, ventricular late potentials and heart rate turbulence as indicators of coronary reperfusion in ST segment elevation myocardial infarction. // *Rational Pharmacotherapy in Cardiology*, 13, 2017, № 6, p. 787-793. ISSN 1819-6446. DOI 10.20996/1819-6446-2017-13-6-787-793.

2014. **Sia, C.-H., Leow, A.S.-T., Tan, B.Y.-Q., Low, C.J., Kaur, R., Yeo, T.-C., Chan, M.Y.-Y., Tay, E.L.-W., Yeo, L.L.-L., Yap, E.-S., Loh, J.P.-Y.** The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention. // *Thrombosis Research*, 194, 2020, p. 16-20. ISSN 0049-3848. DOI 10.1016/j.thromres.2020.06.003.
2015. **Sokolov, M.Yu., Danylchuk, I.V., Besh, D.I., Klantsa, A.I., Kolesnyk, V.O., Rafalyuk, O.I., Salo, V.M., Salo, S.V., Sorokhtey, L.V., Furkalo, S.M.** Registry of percutaneous coronary interventions: changes over recent years (2010–2022). // *Ukrainian Journal of Cardiology*, 31, 2024, № 1, p. 7-33. ISSN 1608-635X. DOI 10.31928/2664-4479-2024.1.733.
2016. **Song, Y., Li, J., Bian, S., Qin, Z., Song, Y., Jin, J., Zhao, X., Song, M., Chen, J., Huang, L.** Association between Low Free Triiodothyronine Levels and Poor Prognosis in Patients with Acute ST-Elevation Myocardial Infarction. // *BioMed Research International*, 2018, art. no. 9803851. ISSN 2314-6133. DOI 10.1155/2018/9803851.
2017. **Stehli, J., Dagan, M., Dinh, D.T., Lefkovits, J., Dick, R., Oxley, S., Brennan, A.L., Duffy, S.J., Zaman, S.** Differences in outcomes of patients with in-hospital versus out-of-hospital ST-elevation myocardial infarction: A registry analysis. // *BMJ Open*, 12, 2022, № 3, art. no. e052000. ISSN 2044-6055. DOI 10.1136/bmjopen-2021-052000.
2018. **Stehli, J., Dinh, D., Dagan, M., Dick, R., Oxley, S., Brennan, A., Lefkovits, J., Duffy, S.J., Zaman, S.** Sex differences in treatment and outcomes of patients with in-hospital ST-elevation myocardial infarction. // *Clinical Cardiology*, 45, 2022, № 4, p. 427-434. ISSN 0160-9289. DOI 10.1002/clc.23797.
2019. **Stengaard, C., Sørensen, J.T., Rasmussen, M.B., Bøtker, M.T., Pedersen, C.K., Terkelsen, C.J.** Prehospital diagnosis of patients with acute myocardial infarction. // *Diagnosis*, 3, 2016, № 4, p. 155-166. ISSN 2194-8011. DOI 10.1515/dx-2016-0021.
2020. **Strom, J.A., Sand, I.C., Box, L.C.** Optimizing care for ST-elevation myocardial infarction patients: Application of systems engineering. // *Journal of Geriatric Cardiology*, 13, 2016, № 11, p. 883-887. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2016.11.001.
2021. **Takagi, K., Tanaka, A., Morishima, I., Morita, Y., Yoshioka, N., Yoshida, R., Kanzaki, Y., Watanabe, N., Yamauchi, R., Komeyama, S., Sugiyama, H., Shimojo, K., Imaoka, T., Sakamoto, G., Ohi, T., Goto, H., Ishii, H., Murohara, T.** Fifteen-Year Mortality and Cardiac, Thrombotic, and Bleeding Events in Survivors of ST-Elevation Myocardial Infarction. // *Cardiovascular Revascularization Medicine*, 36, 2022, p. 43-50. ISSN 1553-8389. DOI 10.1016/j.carrev.2021.04.023.
2022. **Takagi, K., Tanaka, A., Yoshioka, N., Morita, Y., Yoshida, R., Kanzaki, Y., Watanabe, N., Yamauchi, R., Komeyama, S., Sugiyama, H., Shimojo, K., Imaoka, T., Sakamoto, G., Ohi, T., Goto, H., Ishii, H., Morishima, I., Murohara, T.** In-hospital mortality among consecutive patients with ST-Elevation myocardial infarction in modern primary percutaneous intervention era ~ Insights from 15-year data of single-center hospital-based registry. // *PLoS ONE*, 16, 2021, art. no. e0252503. ISSN 1932-6203. DOI 10.1371/journal.pone.0252503.

2023. **Tang, Y., Liu, S., Shi, Y., He, T., Sun, X., Wu, M., Peng, Z., Gui, F., Yuan, H., Lu, Y., Cai, J., Chen, Y.** Association of blood pressure in the first-week of hospitalization and long-term mortality in patients with acute left ventricular myocardial infarction. // *International Journal of Cardiology*, 349, 2022, p. 18-26. ISSN 0167-5273. DOI 10.1016/j.ijcard.2021.11.045.
2024. **Tarantini, G.** Beyond the guidelines stance: Green light for very early angiography after fibrinolysis. // *JACC: Cardiovascular Interventions*, 8, 2015, № 1, p. 175-177. ISSN 1936-8798. DOI 10.1016/j.jcin.2014.11.009.
2025. **Tateishi, K., Nakagomi, A., Saito, Y., Kitahara, H., Kanda, M., Shiko, Y., Kawasaki, Y., Kuwabara, H., Kobayashi, Y., Inoue, T.** Feasibility of management of hemodynamically stable patients with acute myocardial infarction following primary percutaneous coronary intervention in the general ward settings. // *PLoS ONE*, 15, 2020, № 10, art. no. e0240364. ISSN 1932-6203. DOI 10.1371/journal.pone.0240364.
2026. **Teplova, N.V., Taratukhin, E.O.** The relevance of thrombolytic therapy in st elevation myocardial infarction. // *Russian Journal of Cardiology*, 109, 2014, № 5, p. 109-112. ISSN 1560-4071. DOI 10.15829/1560-4071-2014-5-109-112.
2027. **Tereshchenko, A.S., Uskach, T.M., Kondratova, N.V.** Pharmacoinvasive strategy in the treatment of acute myocardial infarction: Current state-of-the-art. // *Russian Journal of Cardiology*, 26, 2021, № S2, art. no. 4452, p. 48-53. ISSN 1560-4071. DOI 10.15829/1560-4071-2021-4452.
2028. **The Ministry of Healthcare of Russian Federation.** Acute ST elevation myocardial infarction: Aftercare and secondary prevention. National Russian guidelines. // *Russian Journal of Cardiology*, 117, 2015, № 1, p. 6-52. ISSN 1560-4071. DOI 10.15829/1560-4071-2015-1-6-52.
2029. **Thiele, H.** Recommendations of the European Society of Cardiology Guideline 2017—STEMI. [Empfehlungen der Europäischen Gesellschaft für Kardiologie-Leitlinien 2017 – STEMI]. // *Notfall und Rettungsmedizin*, 21, 2018, № 1, p. 22-33. ISSN 1434-6222. DOI 10.1007/s10049-017-0402-7.
2030. **Thiele, H., Desch, S., de Waha, S.** Acute myocardial infarction in patients with ST-segment elevation myocardial infarction: ESC guidelines 2017. [Akuter Myokardinfarkt bei Patienten mit ST-Strecken-Hebungs-Infarkt: ESC-Leitlinien 2017]. *Herz*, 42, 2017, № 8, p. 728-738. ISSN 0340-9937. DOI 10.1007/s00059-017-4641-7.
2031. **Timmis, A., Townsend, N., Gale, C., Grobbee, R., Maniadakis, N., Flather, M., Wilkins, E., Wright, L., Vos, R., Bax, J., Blum, M., Pinto, F., Vardas, P.** European Society of Cardiology: Cardiovascular disease statistics 2017. // *European Heart Journal*, 39, 2018, № 7, p. 508-577. ISSN 0195-668X. DOI 10.1093/eurheartj/ehx628.
2032. **Tofighi, S., Poorhosseini, H., Jenab, Y., Alidoosti, M., Sadeghian, M., Mehrani, M., Tabrizi, Z., Hashemi, P.** Comparison of machine-learning models for the prediction of 1-year adverse outcomes of patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. // *Clinical Cardiology*, 47, 2024, № 1, art. no. e24157. ISSN 0160-9289. DOI 10.1002/clc.24157.

2033. **Tra, J., De Blok, C., Van Der Wulp, I., De Bruijne, M.C., Wagner, C.** Multicentre analysis of current ST-elevation myocardial infarction acute care pathways. // *Open Heart*, 4, 2017, № 1, art. no. e000458. ISSN 2053-3624. DOI 10.1136/openhrt-2016-000458.
2034. **Turen, S., Turen, S.E.V.** Gender differences in early complications after STEMI and their associations with anxiety and depression. // *European Review for Medical and Pharmacological Sciences*, 27, 2023, № 7, p. 2936-2945. ISSN 1128-3602. DOI 10.26355/eurrev\_202304\_31925.
2035. **Valgimigli, M., Bueno, H., Byrne, R.A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., Montalescot, G., Neumann, F.-J., Petricevic, M., Roffi, M., Steg, P.G., Windecker, S., Zamorano, J.L., Levine, G.N.** 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. [Uaktualnione stanowisko ESC dotyczące stosowania podwójnej terapii przeciwplatekowej w chorobie wieńcowej w 2017 roku, przygotowane we współpracy z EACTS]. // *Kardiologia Polska*, 75, 2017, № 12, p. 1217-1299. ISSN 0022-9032. DOI 10.5603/KP.2017.0224.
2036. **Valls-Lacalle, L., Consegal, M., Ruiz-Meana, M., Benito, B., Inserte, J., Barba, I., Ferreira-González, I., Rodríguez-Sinovas, A.** Connexin 43 deficiency is associated with reduced myocardial scar size and attenuated tgfb1 signaling after transient coronary occlusion in conditional knock-out mice. // *Biomolecules*, 10, 2020, № 4, art. no. 651. ISSN 2218-273X. DOI 10.3390/biom10040651.
2037. **Van De Werf, F., Crea, F.** The year in cardiology 2014: Acute coronary syndromes. // *European Heart Journal*, 36, 2015, № 6, p. 342-346. ISSN 0195-668X. DOI 10.1093/eurheartj/ehu488.
2038. **Van Der Wall, E.E.** New guidelines on primary PCI for patients with STEMI: Changing insights. // *Netherlands Heart Journal*, 24, 2016, № 2, p. 93-95. ISSN 1568-5888. DOI 10.1007/s12471-015-0780-8.
2039. **van Hout, G.P.J., van Solinge, W.W., Gijsberts, C.M., Teuben, M.P.J., Leliefeld, P.H.C., Heeres, M., Nijhoff, F., de Jong, S., Bosch, L., de Jager, S.C.A., Huisman, A., Stella, P.R., Pasterkamp, G., Koenderman, L.J., Hoefer, I.E.** Elevated mean neutrophil volume represents altered neutrophil composition and reflects damage after myocardial infarction. // *Basic Research in Cardiology*, 110, 2015, № 6, art. no. 58, 11 p. ISSN 0300-8428. DOI 10.1007/s00395-015-0513-6.
2040. **Vasilyeva, E.Yu., Plavunov, N.F., Kalinskaya, A.I., Sapina, A.I., Wedensky, G.A., Lebedeva, A.Yu., Skrypnyk, D.V., Shpektor, A.V.** Treatment of patients with acute myocardial infarction with ST-Segment elevation. Organization of the Myocardial infarction network in Moscow. // *Kardiologiya*, 56, 2016, № 12, p. 48-53. ISSN 0022-9040. DOI 10.18565/cardio.2016.12.48-53.
2041. **Vriz, O., Minisini, R., Zito, C., Boccato, E., Fimiani, F., Pirisi, M., Facciolo, C., Limongelli, G., Bossone, E., Calabrò, P.** Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on  $\beta_1$  and  $\beta_2$ -adrenergic receptors polymorphisms? // *International Journal of Cardiology*, 199, 2015, p. 189-192. ISSN 0167-5273. DOI 10.1016/j.ijcard.2015.07.054.



2042. **Wang, C.-H., Wang, H.-T., Wu, K.-H., Cheng, F.-J., Cheng, C.-I., Kung, C.-T., Chen, F.-C.** Comparison of Different Risk Scores for Prediction of In-Hospital Mortality in STEMI Patients Treated with PPCI. // *Genetics Research*, 2022, art. no. 5389072. ISSN 1469-5073. DOI 10.1155/2022/5389072.
2043. **Wang, F., Wu, Y.** LncRNA DLX6-AS1 Promotes Myocardial Ischemia-Reperfusion Injury through Mediating the miR-204-5p/FBXW7 Axis. // *Mediators of Inflammation*, 2023, art. no. 9380398. ISSN 0962-9351. DOI 10.1155/2023/9380398.
2044. **Wang, L., Liu, Y., Tian, R., Zuo, W., Qian, H., Wang, L., Yang, X., Liu, Z., Zhang, S.** What do we know about platelets in myocardial ischemia-reperfusion injury and why is it important? // *Thrombosis Research*, 229, 2023, p. 114-126. ISSN 0049-3848. DOI 10.1016/j.thromres.2023.06.022.
2045. **Wang, W., Yang, L., Zhang, J., Xiang, H.** Decreased circulating omega-3 fatty acids increase the risk of myocardial infarction: a two-sample Mendelian randomization study. // *Frontiers in Cardiovascular Medicine*, 11, 2024, art. no. 1328087. ISSN 2297-055X. DOI 10.3389/fcvm.2024.1328087.
2046. **Wang, Y., Chen, Y., Han, Y., Xu, Q., Chen, S., Lyu, Z., Lu, C., Zheng, M., Zhao, X.** Platelet-lymphocyte Ratio Predicts In-hospital Mortality in Elderly Patients with Acute Myocardial Infarction. [血小板 - 淋巴细胞比值可预测老年急性心肌梗死患者住院期间死亡风险]. // *Chinese General Practice*, 26, 2023, № 33, p. 4137-4142. ISSN 1007-9572. DOI 10.12114/j.issn.1007-9572.2023.0116.
2047. **Wein, B., Kaiser, C.** Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts — Response to the letter to the Editor. // *International Journal of Cardiology*, 251, 2018, p. 33. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.10.079.
2048. **Welsh, R.C., Deckert-Sookram, J., Sookram, S., Valaire, S., Brass, N.** Evaluating clinical reason and rationale for not delivering reperfusion therapy in ST elevation myocardial infarction patients: Insights from a comprehensive cohort. // *International Journal of Cardiology*, 216, 2016, p. 99-103. ISSN 0167-5273. DOI 10.1016/j.ijcard.2016.04.075.
2049. **Wu, N., Li, J., Xu, X., Yuan, Z., Yang, L., Chen, Y., Xia, T., Hu, Q., Chen, Z., Li, C., Xiang, Y., Zhang, Z., Zhong, L., Li, Y.** Prediction Model of New Onset Atrial Fibrillation in Patients with Acute Coronary Syndrome. // *International Journal of Clinical Practice*, 2023, art. no. 3473603. ISSN 1368-5031. DOI 10.1155/2023/3473603.
2050. **Xu, H., Yang, Y., Wang, C., Yang, J., Li, W., Zhang, X., Ye, Y., Dong, Q., Fu, R., Sun, H., Yan, X., Gao, X., Wang, Y., Jia, X., Sun, Y., Wu, Y., Zhang, J., Zhao, W., Sabatine, M.S., Wiviott, S.D.** Association of Hospital-Level Differences in Care with Outcomes among Patients with Acute ST-Segment Elevation Myocardial Infarction in China. // *JAMA Network Open*, 3, 2020, № 10, art. no. e2021677. ISSN 2574-3805. DOI 10.1001/jamanetworkopen.2020.21677.
2051. **Xu, W., Yang, Y.-M., Zhu, J., Wu, S., Wang, J., Zhang, H., Shao, X.-H.** Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment eleva-

- tion myocardial infarction: insights from a multi-center observational study. // *Cardiovascular Diabetology*, 21, 2022, № 1, art. no. 48. ISSN 1475-2840. DOI 10.1186/s12933-022-01479-8.
2052. **Yamaji, K., Kohsaka, S., Inohara, T., Numasawa, Y., Ishii, H., Amano, T., Ikari, Y.** Population density analysis of percutaneous coronary intervention for st-segment-elevation myocardial infarction in Japan. // *Journal of the American Heart Association*, 9, 2020, № 15, art. no. e016952. ISSN 2047-9980. DOI 10.1161/JAHA.120.016952.
  2053. **Yang, B., Bai, L., Zhang, Y., Cheng, Y., Zhao, C., Huang, B., Chen, M.** The Value of Different Short-Term Risk Scoring Models in Predicting Long-Term Death of Acute Myocardial Infarction. // *Journal of Clinical Medicine*, 11, 2022, № 17, art. no. 5054. ISSN 2077-0383. DOI 10.3390/jcm11175054.
  2054. **Yang, Y., Zhang, Y., Ren, L.** Prognosis Analysis of Delayed Call Time for Chest Pain in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Direct Percutaneous Coronary Intervention. // *Clinical and Applied Thrombosis/Hemostasis*, 29, 2023. ISSN 1076-0296. DOI 10.1177/10760296231186811.
  2055. **You, Q., Wang, J., Dong, W., Tian, F., Liu, H.-X., Jing, J., Chen, Y.-D.** Protective effect of Danhong injection in patients with acute myocardial infarction at a high risk of no-reflow during primary percutaneous coronary intervention. // *Journal of Geriatric Cardiology*, 16, 2019, № 5, p. 406-413. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2019.05.001.
  2056. **Yuan, Y.Y., Long, R., Li, B., Duan, W.X., Wei, Z.W., Li, J.** Correlation Between Selvester Qrs Score and Major Adverse Cardiovascular Events in Athletic Patients with Acute St-Segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention: Implications for Sports Participation and Physical Impact. // *Revista Internacional de Medicina y Ciencias de la Actividad Fisica y del Deporte*, 22, 2022, № 88.1, p. 388-398. ISSN 1577-0354. DOI 10.15366/rimcafd2022.88.1.027.
  2057. **Zachura, M., Wilczek, K., Janion, M., Gąsior, M., Gierlotka, M., Sadowski, M.** Long-term outcomes in men and women with ST-segment elevation myocardial infarction and incomplete reperfusion after a primary percutaneous coronary intervention: A 2-year follow-up. // *Coronary Artery Disease*, 30, 2019, № 3, p. 171-176. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000703.
  2058. **Zalewski, J., Nowak, K., Furczynska, P., Zalewska, M.** Complicating acute myocardial infarction. Current status and unresolved targets for subsequent research. // *Journal of Clinical Medicine*, 10, 2021, № 24, art. no. 5904. ISSN 2077-0383. DOI 10.3390/jcm10245904.
  2059. **Zandecki, L., Janion, M., Sadowski, M., Kurzawski, J., Polonski, L., Gierlotka, M., Gasior, M.** Associations of changes in patient characteristics and management with decrease in mortality rates of men and women with ST-elevation myocardial infarction - a propensity score-matched analysis. // *Archives of Medical Science*, 16, 2020, № 4, p. 772-780. ISSN 1734-1922. DOI 10.5114/aoms.2020.93458.
  2060. **Zhang, W., Qi, L., Xue, J., Li, X., Du, F., Wang, X., Zhao, H.** Risk factors to assess in-hospital mortality of stemi patients after primary pci fast and effectively. // *Acta Medica Mediterranea*, 36, 2020, № 5, p. 3201-3206. ISSN 0393-6384. DOI 10.19193/0393-6384\_2020\_5\_494.

2061. **Zhang, X., Khan, A.A., Haq, E.U., Rahim, A., Hu, D., Attia, J., Oldmeadow, C., Ma, X., Ding, R., Boyle, A.J.** Increasing mortality from ischaemic heart disease in China from 2004 to 2010: Disproportionate rise in rural areas and elderly subjects. 438 million person-years follow-up. // *European Heart Journal - Quality of Care and Clinical Outcomes*, 3, 2017, № 1, p. 47-52. ISSN 2058-5225. DOI 10.1093/ehjqcco/qcw041.
2062. **Zhou, S., Zhang, Y., Dong, X., Ma, J., Li, N., Shi, H., Smith, S.C., Jr, Jin, Y., Xu, M., Xiang, D., Zheng, Z.-J., Huo, Y.** Regional variations in management and outcomes of patients with acute coronary syndrome in China: Evidence from the National Chest Pain Center Program. // *Science Bulletin*, 2024. ISSN 2095-9273. DOI 10.1016/j.scib.2024.03.010.

## **2013**

Hristova K, Shiue I, Pella D, Singh RB, Chaves H, Basu TK, Ozimek L, Rastogi SS, Takahashi T, Wilson D, DeMeester F, Cheema S, Garg M, Buttar HS, Milovanovic B, Kumar A, Handjiev S, Cornelissen G, **Petrov I.** Prevention strategies for cardiovascular diseases and diabetes mellitus in developing countries: World Conference of Clinical Nutrition 2013. Nutrition. 2014 Sep;30(9):1085-9. DOI 10.1016/j.nut.2013.12.013. Epub 2014 Jan 8. No abstract available.

### **Cited by:**

2063. **Dominguez-Rodriguez, A., Avanzas, P., Abreu-Gonzalez, P., Gonzalez-Gonzalez, J., Del Carmen Garcia-Baute, M., Barrios, P., Martin-Cabeza, M., Jimenez-Sosa, A.** Consumption of 'gofio', a roasted cereal flour from the Canary Islands, is associated with exercise capacity and risk of coronary heart disease in the elderly. // *International Journal of Cardiology*, 187, 2015, № 1, p. 41-43. ISSN 0167-5273. DOI 10.1016/j.ijcard.2015.03.347.
2064. **Esen, S., Esen, İ., Açıkgöz, Y.** Nutritional health in premenopausal women: A cross-sectional study from Turkey. // *International Journal of Preventive Medicine*, 13, 2022, № 1, art. no. 32. ISSN 2008-7802. DOI 10.4103/ijpvm.IJPVM\_141\_20.

Steg PG, Mehta SR, Pollack CV Jr, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, **Petrov I**, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS; TAO Investigators. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013 Sep 18 ;310(11):1145-55. DOI 10.1001/jama.2013.277165. PubMed PMID: 23995608.

### **Cited by:**

2065. **Aggarwal, B., Menon, V.** Recent advances in treatment of acute coronary syndromes. // *F1000Prime Reports*, 5, 2013, art. no. 56. ISSN 2051-7599. DOI 10.12703/P5-56.

2066. **Bainey, K.R., Marquis-Gravel, G., Mehta, S.R., Tanguay, J.-F.** The Evolution of Anticoagulation for Percutaneous Coronary Intervention: A 40-Year Journey. // *Canadian Journal of Cardiology*, 38, 2022, № 10, p. S89-S98. ISSN 0828-282X. DOI 10.1016/j.cjca.2022.07.007.
2067. **Bal Dit Sollier, C., Drouet, L.** Non anticoagulant properties of heparin preparations: Practical considerations. [Les activités non anticoagulantes des héparines: Intérêt pratique]. // *Sang Thrombose Vaisseaux*, 25, 2013, № 6, p. 389-398. ISSN 0999-7385. DOI 10.1684/stv.2013.0807.
2068. **Beleño Acosta, B., Advincula, R.C., Grande-Tovar, C.D.** Chitosan-Based Scaffolds for the Treatment of Myocardial Infarction: A Systematic Review. // *Molecules*, 28, 2023, № 4, art. no. 1920. ISSN 1420-3049. DOI 10.3390/molecules28041920.
2069. **Bhatty, S., Ali, A., Shetty, R., Sumption, K.F., Topaz, O., Jovin, I.S.** Contemporary anticoagulation therapy in patients undergoing percutaneous intervention. // *Expert Review of Cardiovascular Therapy*, 12, 2014, № 4, p. 451-461. ISSN 1477-9072. DOI 10.1586/14779072.2014.885839.
2070. **Budek-Sydor, A., Wierzbowska-Drabik, K., Kasprzak, J.D.** Hot news from the congress of european society of cardiology (ESC) in Amsterdam. [Co nowego? Kongres europejskiego towarzystwa kardiologicznego (ESC) w Amsterdamie]. // *Polski Przegląd Kardiologiczny*, 15, 2013, № 4, p. 290-293. ISSN 1507-5540.
2071. **Capodanno, D.** Emerging strategies for rapid reversal of anticoagulation in patients undergoing catheter-based interventions: Aptamers enter the RADAR. // *EuroIntervention*, 10, 2014, № 4, p. 425-427. ISSN 1774-024X. DOI 10.4244/EIJV10I4A74.
2072. **Capranzano, P., Angiolillo, D.J.** Basics of antiplatelet and anticoagulant therapy for cardiovascular disease. – In: *Interventional Cardiology: Principles and Practice*, 2016, p. 379-388. ISBN 9781118983652; 9781118976036. DOI 10.1002/9781118983652.ch38.
2073. **Choxi, R., Kapoor, K., MacKman, N., Jovin, I.S.** Direct Oral Anticoagulants and Coronary Artery Disease. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 42, 2022, № 5, p. 553-564. ISSN 1079-5642. DOI 10.1161/ATVBAHA.121.317171.
2074. **Clemens, A., Fraessdorf, M., Friedman, J.** Authors' reply. // *Vascular Health and Risk Management*, 10, 2014, p. 47-48. ISSN 1176-6344. DOI 10.2147/VHRM.S57529.
2075. **Damluji, A.A., Otalvaro, L., Cohen, M.G.** Anticoagulation for percutaneous coronary intervention: A contemporary review. // *Current Opinion in Cardiology*, 30, 2015, № 4, p. 311-318. ISSN 0268-4705. DOI 10.1097/HCO.0000000000000182.
2076. **De Luca, G., Suryapranata, H.** Recent advances in optimal adjunctive antithrombotic therapy in STEMI patients undergoing primary angioplasty: An overview. // *Current Vascular Pharmacology*, 13, 2015, № 5, p. 594-615. ISSN 1570-1611. DOI 10.2174/1570161113666141229115302.

2077. **Depta, J.P., Bhatt, D.L.** New approaches to inhibiting platelets and coagulation. // *Annual Review of Pharmacology and Toxicology*, 55, 2015, p. 373-397. ISSN 0362-1642. DOI 10.1146/annurev-pharmtox-010814-124438.
2078. **Dillinger, J.-G., Achkouty, G., Albert, F., Muller, G., Labèque, J.-N., Moisson, L., Morelle, J.-F., Cottin, Y., Pezel, T., Lim, P., Aissaoui, N., Schiele, F., Ferrières, J., Angoulvant, D., Henry, P., Puymirat, E., Simon, T., Danchin, N., FAST-MI investigators.** Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. [Effets synergiques délétères de l'insuffisance cardiaque aiguë et du diabète chez des patients avec syndrome coronarien aigu. Données des registres FAST-MI]. // *Archives of Cardiovascular Diseases*, 115, 2022, № 5, p. 264-275. ISSN 1875-2136. DOI 10.1016/j.acvd.2022.02.004.
2079. **Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S.A., Mander, A.P., Weir, C.J., Koenig, F., Walton, M.K., Nicholl, J.P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M.A., Scott, J.A., Ando, Y., Hind, D., Altman, D.G.** The Adaptive designs CONSORT Extension (ACE) statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. // *The BMJ*, 369, 2020, art. no. m115. ISSN 0959-8146. DOI 10.1136/bmj.m115.
2080. **Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S.A., Mander, A.P., Weir, C.J., Koenig, F., Walton, M.K., Nicholl, J.P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M.A., Scott, J.A., Ando, Y., Hind, D., Altman, D.G., Meurer, W.J., Cates, C., Sydes, M., Jemai, Y., Ashby, D., Yap, C., Waldron-Lynch, F., Roger, J., Marsh, J., Collignon, O., Lawrence, D.J., Bunce, C., Parke, T., Gazzard, G., Hopewell, S.** The adaptive designs CONSORT extension (ACE) statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. // *Trials*, 21, 2020, № 1, art. no. 528. ISSN 1745-6215. DOI 10.1186/s13063-020-04334-x.
2081. **Dong, C.-H., Wang, Z.-M., Chen, S.-Y.** Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: A systematic review and meta-analysis. // *Clinical Biochemistry*, 52, 2018, p. 131-136. ISSN 0009-9120. DOI 10.1016/j.clinbiochem.2017.11.008.
2082. **Gargiulo, G., Moschovitis, A., Windecker, S., Valgimigli, M.** Developing drugs for use before, during and soon after percutaneous coronary intervention. // *Expert Opinion on Pharmacotherapy*, 17, 2016, № 6, p. 803-818. ISSN 1465-6566. DOI 10.1517/14656566.2016.1145666.
2083. **Hamm, C.W., Crea, F.** The year in cardiology 2013: Acute coronary syndromes. // *European Heart Journal*, 35, 2014, № 6, p. 349-352. ISSN 0195-668X. DOI 10.1093/eurheartj/eh548.
2084. **Hattori, T., Mizuno, A., Yoneoka, D., Tam, W.W.S., Kwong, J.S.W.** Direct thrombin inhibitors and factor Xa inhibitors for acute coronary syndromes: a network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2022, № 9, art. no. CD014549. ISSN 1465-1858. DOI 10.1002/14651858.CD014549.
2085. **Hempel, T., Elez, K., Krüger, N., Raich, L., Shrimp, J.H., Danov, O., Jonigk, D., Braun, A., Shen, M., Hall, M.D., Pöhlmann, S., Hoffmann, M., Noé, F.** Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent



protease inhibitors: Pre-clinical assessment of pharmacological and molecular properties. // *Chemical Science*, 12, 2021, № 38, p. 12600-12609. ISSN 2041-6520. DOI 10.1039/d1sc01494c.

2086. **Hernández Hernández, F., Rumoroso Cuevas, J.R., García Del Blanco, B., Trillo Nouche, R.** Update on interventional cardiology 2013. [Actualización en cardiología intervencionista 2013]. // *Revista Espanola de Cardiologia*, 67, 2014, № 4, p. 305-311. ISSN 0300-8932. DOI 10.1016/j.recesp.2013.10.028.
2087. **Iyer, J.K., Koh, C.Y., Kazimirova, M., Roller, L., Jobichen, C., Swaminathan, K., Mizuguchi, J., Iwanaga, S., Nuttall, P.A., Chan, M.Y., Kini, R.M.** Avathrin: A novel thrombin inhibitor derived from a multicopy precursor in the salivary glands of the ixodid tick, *Amblyomma variegatum*. // *FASEB Journal*, 31, 2017, № 7, p. 2981-2995. ISSN 0892-6638. DOI 10.1096/fj.201601216R.
2088. **Kaddoura, R., Orabi, B., Yassin, M.A., Omar, A.S.** Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome. // *Reviews in Cardiovascular Medicine*, 24, 2023, № 6, art. no. 180. ISSN 1530-6550. DOI 10.31083/j.rcm2406180.
2089. **Kiss, R.G.** Direct oral anticoagulants in cardiology. [Direkt orális antikoagulánsok a kardiológiában]. // *Orvosi Hetilap*, 157, 2016, № 38, p. 1507-1510. ISSN 0030-6002. DOI 10.1556/650.2016.30578.
2090. **Kopřiva, K., Neužil, P.** Novel oral anticoagulants in treatment of acute coronary syndrome. [Nová orální antikoagulancia v léčbě akutního koronárního syndromu]. // *Intervencni a Akutni Kardiologie*, 14, 2015, № 1, p. 26-30. ISSN 1213-807X.
2091. **Lee, L., Varma, C.** Lessons from primary PCI practice for the next decade. // *Heart*, 100, 2014, № 21, p. 1667-1672. ISSN 1355-6037. DOI 10.1136/heartjnl-2013-305401.
2092. **Lipinski, M.J., Lee, R.C., Gaglia, M.A., Jr, Torguson, R., Garcia-Garcia, H.M., Pichard, A.D., Satler, L.F., Waksman, R.** Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis. // *Cardiovascular Revascularization Medicine*, 17, 2016, № 8, p. 535-545. ISSN 1553-8389. DOI 10.1016/j.carrev.2016.09.011.
2093. **Lippi, G., Gosselin, R., Favaloro, E.J.** Current and Emerging Direct Oral Anticoagulants: State-of-the-Art. // *Seminars in Thrombosis and Hemostasis*, 45, 2019, № 5, p. 490-501. ISSN 0094-6176. DOI 10.1055/s-0039-1692703.
2094. **Liu, L., Lei, H., Hu, J., Tang, Y., Xu, D.** Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. // *Drugs*, 81, 2021, № 17, p. 2003-2016. ISSN 0012-6667. DOI 10.1007/s40265-021-01637-4.
2095. **McNeice, A.H., McAleavey, N.M., Menown, I.B.A.** Advances in Clinical Cardiology. // *Advances in Therapy*, 31, 2014, № 8, p. 837-860. ISSN 0741-238X. DOI 10.1007/s12325-014-0141-9.
2096. **Nathoe, H.M., Van Klei, W.A., Scott Beattie, W.** Perioperative troponin elevation: Always myocardial injury, but not always myocardial infarction. // *Anesthesia and*

2097. **Onwordi, E.N.C., Gamal, A., Zaman, A.** Anticoagulant therapy for acute coronary syndromes. // *Interventional Cardiology: Reviews, Research, Resources*, 13, 2018, № 2, p. 87-92. ISSN 1756-1477. DOI 10.15420/icr.2017:26:1.
2098. **Roberts, A.** Anticoagulation therapy: Otamixaban fails in NSTEMI-ACS. // *Nature Reviews Cardiology*, 10, 2013, № 11, p. 615. ISSN 1759-5002. DOI 10.1038/nrcardio.2013.134.
2099. **Robinson, A., McCarty, D., Douglas, J.** Novel oral anticoagulants for acute coronary syndrome. // *Therapeutic Advances in Cardiovascular Disease*, 11, 2017, № 1, p. 4-11. ISSN 1753-9447. DOI 10.1177/1753944716671484.
2100. **Romero, P.S., Costanzi, A.P., Hirakata, V.N., Beghetto, M.G., Sauer, J.M., Rabelo-Silva, E.R.** Subsample analysis of the Vascular Complications Risk Score at two public referral centers for interventional cardiology. // *Revista da Escola de Enfermagem*, 53, 2019, art. no. e03438. ISSN 0080-6234. DOI 10.1590/S1980-220X2018005103438.
2101. **Sagris, M., Theofilis, P., Papanikolaou, A., Antonopoulos, A.S., Tsioufis, C., Tousoulis, D.** Direct Oral Anticoagulants use in Patients with Stable Coronary Artery Disease, Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. // *Current Pharmaceutical Design*, 29, 2023, № 35, p. 2787-2794. ISSN 1381-6128. DOI 10.2174/0113816128259508231118141831.
2102. **Santos-Gallego, C.G., Badimon, L., Badimón, J.J.** Perspectives: Direct and specific inhibition of factor Xa: An emerging therapeutic strategy for atherothrombotic disease. // *European Heart Journal, Supplement*, 16, 2014, № Suppl. A, p. A56-A60. ISSN 1520-765X. DOI 10.1093/eurheartj/sut013.
2103. **Schäfer, A., Arntz, H.R., Boudriot, E., Garlich, C., Hoffmann, S., Ince, H., Klingenhöfen, T., Weil, J., Zugck, C., Helms, T.M., Silber, S.** Differentiated antiplatelet therapy for acute coronary syndromes. [Differenzierte antithrombozytäre Therapie bei akutem Koronarsyndrom]. // *Deutsche Medizinische Wochenschrift*, 139, 2014, № 4, p. 152-158. ISSN 0012-0472. DOI 10.1055/s-0033-1359911.
2104. **Shrimp, J.H., Janiszewski, J., Chen, C.Z., Xu, M., Wilson, K.M., Kales, S.C., Sanderson, P.E., Shinn, P., Schneider, R., Itkin, Z., Guo, H., Shen, M., Klumpp-Thomas, C., Michael, S.G., Zheng, W., Simeonov, A., Hall, M.D.** Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. // *ACS Infectious Diseases*, 8, 2022, № 6, p. 1191-1203. ISSN 2373-8227. DOI 10.1021/acsinfectdis.2c00172.
2105. **Tremmel, J.A., Patel, R.A.G., Bhatt, D.L., Cilingiroglu, M., Pinto, D.S., Dean, L.S., Grines, C.L.** Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013. // *Catheterization and Cardiovascular Interventions*, 85, 2015, № 1, p. 95-103. ISSN 1522-1946. DOI 10.1002/ccd.25635.
2106. **Villablanca, P.A., Holmes, D., Mohananey, D., Briceno, D.F., Núñez Gil, I.J., Kargoli, F., Gupta, T., Kizer, J.R., Bortnick, A.E., Wiley, J., Menegus, M.A., Pyo, R., Garcíá, M., Ramakrishna, H., Mookadam, F.** Direct Xa inhibitors in

addition to antiplatelet therapy in acute coronary syndrome: Meta-analysis of randomized trials. // *Coronary Artery Disease*, 28, 2017, № 5, p. 395-405. ISSN 0954-6928. DOI 10.1097/MCA.0000000000000485.

2107. **Yandrapalli, S., Andries, G., Gupta, S., Dajani, A.R., Aronow, W.S.** Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents. // *Expert Opinion on Investigational Drugs*, 28, 2019, № 3, p. 223-234. ISSN 1354-3784. DOI 10.1080/13543784.2019.1559814.
2108. **Yang, H., Lin, X., Yu, Q., Awadasseid, A., Zhang, W.** Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19). // *Pharmazie*, 78, 2023, № 11/12, p. 217-224. ISSN 0031-7144. DOI 10.1691/ph.2023.3578.
2109. **Zalewski, J., Undas, A.** Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. // *Postepy w Kardiologii Interwencyjnej*, 12, 2016, № 4, p. 290-302. ISSN 1734-9338. DOI 10.5114/aic.2016.63626.
2110. **Zatloukalová, A.** New direct oral anticoagulances-new molecules in research. [Nová přímá perorální antikoagulancia – nové molekuly ve výzkumu]. // *Klinická Farmakologie a Farmacie*, 34, 2020, № 2, p. 84-88. ISSN 1212-7973. DOI 10.36290/far.2020.017.

Traykov VB, Kotirkov KI, **Petrov IS.** Pheochromocytoma presenting with bidirectional ventricular tachycardia. *Heart*. 2013 Apr; 99(7):509. DOI 10.1136/heartjnl-2012-303311. Epub 2013 Jan 12. PubMed PMID: 23315606.

#### Cited by:

2111. **Berraa, E., Gonzalezc, M.C., Scavée, C., Vroonene, L., Bersali, A., Pouleura, A.-C., Persua, A.** High prevalence of cardiac electric abnormalities in patients with phaeochromocytomas. // *Journal of Hypertension*, 35, 2017, № 4, p. 899-901. ISSN 0263-6352. DOI 10.1097/HJH.0000000000001235.
2112. **Chapman, M., Hargreaves, M., Schneider, H., Royle, M.** Bidirectional ventricular tachycardia associated with digoxin toxicity and with normal digoxin levels. // *Heart Rhythm*, 11, 2014, № 7, p. 1222-1225. ISSN 1547-5271. DOI 10.1016/j.hrthm.2014.03.050.
2113. **Gorennek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G.Y.H., Mahajan, R., Potpara, T., Ramirez, J.D., Vos, M.A., Marin, F., Blomstrom-Lundqvist, C., Rinaldi, A., Bongiorni, M.G., Sciaraffia, E., Nielsen, J.C., Lewalter, T., Zhang, S., Gutiérrez, O., Fuenmayor, A.** European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). // *Europace*, 20, 2018, № 6, p. 895-896. ISSN 1099-5129. DOI 10.1093/europace/euy051.
2114. **Li, J., Huang, K., Jiang, P., Chen, Y., Gan, H., Su, X.** Recurrent ventricular tachycardia as initial presentation of pheochromocytoma: A case report and literature

review. // *Journal of Electrocardiology*, 59, 2020, p. 112-115. ISSN 0022-0736. DOI 10.1016/j.jelectrocard.2020.02.004.

2115. **Lindow, T., Pahlm, O., Ljungström, E.** Pheochromocytoma – An ECG diagnosis? // *Journal of Electrocardiology*, 58, 2020, p. 7-9. ISSN 0022-0736. DOI 10.1016/j.jelectrocard.2019.09.023.
2116. **Nazari, M.A., Rosenblum, J.S., Haigney, M.C., Rosing, D.R., Pacak, K.** Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week. // *Journal of the American College of Cardiology*, 76, 2020, № 4, p. 451-464. ISSN 0735-1097. DOI 10.1016/j.jacc.2020.04.080.
2117. **Pérez-Riera, A.R., Barbosa-Barros, R., Samesina, N., Pastore, C.A., Scanavacca, M., Daminello-Raimundo, R., De Abreu, L.C., Nikus, K., Brugada, P.** Andersen-Tawil Syndrome: A Comprehensive Review. // *Cardiology in Review*, 29, 2021, № 4, p. 165-177. ISSN 1061-5377. DOI 10.1097/CRD.0000000000000326.

Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozd J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; **Heart Failure Association of the ESC**. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2013 Oct;15(10):1173-84. DOI 10.1093/eurjhf/hft134. Epub 2013 Aug 26. PMID: 23978433.

#### Cited by:

2118. **Abeel, M., Gupta, A., Constance, C.** Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies. // *Advances in Therapy*, 39, 2022, № 1, p. 391-404. ISSN 0741-238X. DOI 10.1007/s12325-021-01958-6.
2119. **Abensur Guillaume, L., Rossignol, P., Lamiral, Z., Girerd, N., Boivin, J.-M.** Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners. // *ESC Heart Failure*, 7, 2020, № 5, p. 2042-2050. ISSN 2055-5822. DOI 10.1002/ehf2.12834.
2120. **Adamantidou, C., Ahn, S., Rousseau, M., Gruson, D.** Performances of a novel chemiluminescence ABEI-based NT-proBNP immunoassay. // *Acta Cardiologica*, 77, 2022, № 2, p. 176-179. ISSN 0001-5385. DOI 10.1080/00015385.2021.1903195.
2121. **Akin, I., Behnes, M., Müller, J., Forner, J., Abumayyaleh, M., Mashayekhi, K., Akin, M., Bertsch, T., Weidner, K., Rusnak, J., Meininghaus, D.G., Kittel, M., Schupp, T.** Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias. // *Journal of Clinical Medicine*, 11, 2022, № 11, art. no. 2987. ISSN 2077-0383. DOI 10.3390/jcm11112987.

2122. **Akkineni, S.S.L., Mohammed, O., Pathiraj, J.P.K., Devasia, T., Chandrababu, R., Kunhikatta, V.** Readmissions and clinical outcomes in heart failure patients: A retrospective study. // *Clinical Epidemiology and Global Health*, 8, 2020, № 2, p. 495-500. ISSN 2213-3984. DOI 10.1016/j.cegh.2019.11.002.
2123. **Al-Aghbari, S., Al-Maqbali, J.S., Alawi, A.M.A., Za'abi, M.A., Al-Zakwani, I.** Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization. // *Pharmacy Practice*, 20, 2022, № 2, art. no. 2642. ISSN 1885-642X. DOI 10.18549/PharmPract.2022.2.2642.
2124. **Albatat, M., Finsberg, H.N., Arevalo, H., Sundnes, J., Bergsland, J., Balasingham, I., Odland, H.H.** Regional Left Ventricular Fiber Stress Analysis for Cardiac Resynchronization Therapy Response. // *Annals of Biomedical Engineering*, 51, 2023, № 2, p. 343-351. ISSN 0090-6964. DOI 10.1007/s10439-022-03030-y.
2125. **Alhabeeb, W., Elasfar, A., AlBackr, H., AlShaer, F., Almasood, A., Alfaleh, H., Kashour, T., Hersi, A., Asfina, K.N., Altaradi, H., AlShaqhaa, W., Alayoubi, F., AlHabib, K.F.** Clinical characteristics, management and outcomes of patients with chronic heart failure: Results from the heart function assessment registry trial in Saudi Arabia (HEARTS-chronic). // *International Journal of Cardiology*, 235, 2017, p. 94-99. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.02.087.
2126. **Allaw, A.B., Mittal, S., Merchant, F.M., Besser, S.A., Beaser, A.D., Aziz, Z., Ozcan, C., Nayak, H.M., Tung, R., Upadhyay, G.A.** Population-Level Impact of the Guidelines Update on Patient Selection and Outcomes After Cardiac Resynchronization Therapy. // *JACC: Clinical Electrophysiology*, 8, 2022, № 5, p. 651-661. ISSN 2405-500X. DOI 10.1016/j.jacep.2022.01.026.
2127. **Ambrosy, A.P., Gheorghiade, M.** Clinical profiles in acute heart failure: one size fits all or not at all? // *European Journal of Heart Failure*, 19, 2017, № 10, p. 1255-1257. ISSN 1388-9842. DOI 10.1002/ejhf.907.
2128. **Ambrosy, A.P., Gheorghiade, M.** Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. // *European Journal of Heart Failure*, 19, 2017, № 11, p. 1424-1426. ISSN 1388-9842. DOI 10.1002/ejhf.915.
2129. **Ambrosy, A.P., Lee, K.K.** Applying data science approaches to identify frequent flyers in heart failure: rise of the machines. // *European Journal of Heart Failure*, 21, 2019, № 3, p. 319-321. ISSN 1388-9842. DOI 10.1002/ejhf.1387.
2130. **Andreenko, E.Y., Lukyanov, M.M., Yakushin, S.S., Vorobyev, A.N., Kudryashov, E.V., Yavelov, I.S., Klyashtorny, V.G., Pereverzeva, K.G., Boytsov, S.A., Drapkina, O.M.** Young ambulatory patients with cardiovascular diseases: Age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). [Больные с ранним развитием сердечно-сосудистых заболеваний в амбулаторной практике: возрастные и гендерные характеристики, коморбидность, медикаментозное лечение и исходы (данные регистра РЕКВАЗА).] // *Cardiovascular Therapy and Prevention (Russian Federation)*, 18, 2019, № 6, p. 99-106. ISSN 1728-8800. DOI 10.15829/1728-8800-2019-6-99-106.



2131. **Andries, G., Yandrapalli, S., Aronow, W.S.** Benefit–risk review of different drug classes used in chronic heart failure. // *Expert Opinion on Drug Safety*, 18, 2019, № 1, p. 37-49. ISSN 1474-0338. DOI 10.1080/14740338.2018.1512580.
2132. **Anguita Sánchez, M., Recio Mayoral, A., Rodríguez Padial, L.** Improving the quality of healthcare. Results of the SEC-Excelente accreditation program in heart failure of the Spanish Society of Cardiology. [Mejorando la calidad de la asistencia desde la Sociedad Española de Cardiología. Resultados del programa SEC-Excelente en insuficiencia cardiaca]. // *Revista Espanola de Cardiologia*, 2024. ISSN 0300-8932. DOI 10.1016/j.recesp.2024.02.001.
2133. **Anker, M.S., von Haehling, S., Papp, Z., Anker, S.D.** ESC Heart Failure receives its first impact factor. // *European Journal of Heart Failure*, 21, 2019, № 12, p. 1490-1503. ISSN 1388-9842. DOI 10.1002/ehjhf.1665.
2134. **Arfsten, H.** MUW researcher of the month. // *Wiener Klinische Wochenschrift*, 132, 2020, № 7/8, p. 219-220. ISSN 0043-5325. DOI 10.1007/s00508-020-01656-3.
2135. **Arfsten, H., Goliash, G., Pavo, N., Ulmer, H., Hülsmann, M., Stefenelli, T.** Prescription bias in the treatment of chronic systolic heart failure. // *Annals of Internal Medicine*, 172, 2020, № 1, p. 70-72. ISSN 0003-4819. DOI 10.7326/M19-0476.
2136. **Arrieta, F., Iglesias, P., Pedro-Botet, J., Tébar, F.J., Ortega, E., Nubiola, A., Pardo, J.L., Maldonado, G.F., Obaya, J.C., Matute, P., Petrecca, R., Alonso, N., Sarabia, E., Sánchez-Margalet, V., Alemán, J.J., Navarro, J., Becerra, A., Duran, S., Aguilar, M., Escobar-Jiménez, F., Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Espanola de Diabetes (SED).** Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015). [Diabetes mellitus y riesgo cardiovascular: Recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015)]. // *Atencion Primaria*, 48, 2016, № 5, p. 325-336. ISSN 0212-6567. DOI 10.1016/j.aprim.2015.05.002.
2137. **Arrieta, F., Iglesias, P., Pedro-Botet, J., Tébar, F.J., Ortega, E., Nubiola, A., Pardo, J.L., Maldonado, G.F., Obaya, J.C., Matute, P., Petrecca, R., Alonso, N., Sarabia, E., Sánchez-Margalet, V., Alemán, J.J., Navarro, J., Becerra, A., Duran, S., Aguilar, M., Escobar-Jiménez, F., y Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Espanola de Diabetes (SED).** Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015). [Diabetes mellitus y riesgo cardiovascular: Recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015)]. // *Clinica e Investigacion en Arteriosclerosis*, 27, 2015, № 4, p. 181-192. ISSN 0214-9168. DOI 10.1016/j.arteri.2014.12.003.
2138. **Artanian, V., Rac, V.E., Ross, H.J., Seto, E.** Impact of remote titration combined with telemonitoring on the optimization of guideline-directed medical therapy for patients with heart failure: Protocol for a randomized controlled trial. // *JMIR Research Protocols*, 9, 2020, № 10, art. no. e19705. ISSN 1929-0748. DOI 10.2196/19705.
2139. **Artanian, V., Ross, H.J., Rac, V.E., O'Sullivan, M., Brahmabhatt, D.H., Seto, E.** Impact of Remote Titration Combined with Telemonitoring on the Optimization of

Guideline-Directed Medical Therapy for Patients with Heart Failure: Internal Pilot of a Randomized Controlled Trial. // *JMIR Cardio*, 4, 2020, № 1, art. no. e21962. ISSN 2561-1011. DOI 10.2196/21962.

2140. **Artanian, V., Ware, P., Rac, V.E., Ross, H.J., Seto, E.** Experiences and perceptions of patients and providers participating in remote titration of heart failure medication facilitated by telemonitoring: Qualitative study. // *JMIR Cardio*, 5, 2021, № 2, art. no. e28259. ISSN 2561-1011. DOI 10.2196/28259.
2141. **Auricchio, A., Leclercq, C.** Cardiac Resynchronization Therapy. – In: *Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy*, 2016, p. 490-522. ISBN 9780323378048; 9780323394840. DOI 10.1016/B978-0-323-37804-8.00018-3.
2142. **Badar, A.A., Perez-Moreno, A.C., Hawkins, N.M., Brunton, A.P.T., Jhund, P.S., Wong, C.M., Solomon, S.D., Granger, C.B., Yusuf, S., Pfeffer, M.A., Swedberg, K., Gardner, R.S., Petrie, M.C., McMurray, J.J.V.** Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. // *European Journal of Heart Failure*, 17, 2015, № 2, p. 196-204. ISSN 1388-9842. DOI 10.1002/ejhf.221.
2143. **Bakhai, A., Palaka, E., Linde, C., Bennett, H., Furuland, H., Qin, L., McEwan, P., Evans, M.** Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. // *Journal of Medical Economics*, 21, 2018, № 12, p. 1172-1182. ISSN 1369-6998. DOI 10.1080/13696998.2018.1518239.
2144. **Baridloghmani, F., Dana, F., Shajari, A., Zare, E., Soltani, M.H.** How Guideline Directed Medical Therapy Is Practiced for Patients with Heart Failure? A Cross-Sectional Study in Yazd, Iran. // *International Cardiovascular Research Journal*, 15, 2021, № 4, art. no. e119179, p. 149-153. ISSN 2251-9130.
2145. **Barisani, J.L.** Management of heart rate in heart failure. [Manejo da frequência cardíaca na insuficiência cardíaca.] [Manejo de la frecuencia cardíaca en la insuficiencia cardíaca]. // *Insuficiencia Cardiaca*, 14, 2019, № 3, p. 88-95. ISSN 1850-1044.
2146. **Barrera-Chimal, J., Bonnard, B., Jaisser, F.** Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. // *Annual Review of Physiology*, 84, 2022, p. 585-610. ISSN 0066-4278. DOI 10.1146/annurev-physiol-060821-013950.
2147. **Barrera-Chimal, J., Gerarduzzi, C., Rossignol, P., Jaisser, F.** The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. // *Clinical Science*, 136, 2022, № 12, p. 1005-1017. ISSN 0143-5221. DOI 10.1042/CS20220212.
2148. **Barrera-Chimal, J., Girerd, S., Jaisser, F.** Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. // *Kidney International*, 96, 2019, № 2, p. 302-319. ISSN 0085-2538. DOI 10.1016/j.kint.2019.02.030.
2149. **Behnes, M., Rusnak, J., Egner-Walter, S., Ruka, M., Dudda, J., Schmitt, A., Forner, J., Mashayekhi, K., Tajti, P., Ayoub, M., Weiß, C., Akin, I., Schupp, T.** Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic

2150. **Behnes, M., Schupp, T., Mashayekhi, K., Akin, I.** ‘Off-pump’ left ventricular reconstruction – A causal and less invasive surgical option for patients with advanced systolic heart failure? // *European Journal of Heart Failure*, 22, 2020, № 4, p. 581-583. ISSN 1388-9842. DOI 10.1002/ejhf.1737.
2151. **Belfiore, A., Palmieri, V.O., Di Gennaro, C., Settimo, E., De Sario, M.G., Lattanzio, S., Fanelli, M., Portincasa, P.** Long-term management of chronic heart failure patients in internal medicine. // *Internal and Emergency Medicine*, 15, 2020, № 1, p. 49-58. ISSN 1828-0447. DOI 10.1007/s11739-019-02024-4.
2152. **Beltrami, M., Fumagalli, C.** Heart failure with preserved ejection fraction in elderly. From pathophysiology to treatment: An unresolved problem. // *Monaldi Archives for Chest Disease*, 89, 2019, № 2, art. no. 1026, p. 11-14. ISSN 1122-0643. DOI 10.4081/monaldi.2019.1026.
2153. **Ben Zadok, O.I., Murninkas, D., Lakobishvili, Z., Jino, H., Yohananov, E., Birkenfeld, S., Hasdai, D.** Characteristics associated with upper-range doses of beta-blockers and angiotensin-renin inhibitors in reduced ejection fraction. // *Israel Medical Association Journal*, 22, 2020, № 7, p. 375-379. ISSN 1565-1088.
2154. **Bennett, A.S.** Management of Cardiovascular Disorders and the Pharmacist's Role: Heart Failure. – In: *Encyclopedia of Pharmacy Practice and Clinical Pharmacy: Volumes 1-3*, 2019, p. V3A-188-V3A-209. ISBN 9780128127360; 9780128127353. DOI 10.1016/B978-0-12-812735-3.00504-5.
2155. **Bennett, A.S.** Management of cardiovascular disorders and the pharmacist's role: Heart failure. – In: *Encyclopedia of Pharmacy Practice and Clinical Pharmacy*, 2019, p. 188-209. ISBN 9780128127353; 9780128127360. DOI 10.1016/B978-0-12-812735-3.00504-5.
2156. **Berliner, D., Bauersachs, J.** Current drug therapy in chronic heart failure - The new guidelines of the European Society of Cardiology (ESC). // *Korean Circulation Journal*, 47, 2017, № 5, p. 543-554. ISSN 1738-5520. DOI 10.4070/kcj.2017.0030.
2157. **Berliner, D., Bauersachs, J.** New drugs: Big changes in conservative heart failure therapy? // *European Journal of Cardio-thoracic Surgery*, 55, 2019, art. no. ezy421, p. I3-I10. ISSN 1010-7940. DOI 10.1093/ejcts/ezy421.
2158. **Berliner, D., Hallbaum, M., Bauersachs, J.** Current drug therapy for heart failure with reduced ejection fraction. [Medikamentöse Therapie der Herzinsuffizienz mit reduzierter systolischer LV-Funktion]. // *Herz*, 43, 2018, № 5, p. 383-391. ISSN 0340-9937. DOI 10.1007/s00059-018-4712-4.
2159. **Bhat, S., Kansal, M., Kondos, G.T., Groo, V.** Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic. // *Annals of Pharmacotherapy*, 52, 2018, № 8, p. 724-732. ISSN 1060-0280. DOI 10.1177/1060028018760568.
2160. **Bianchi, S., Aucella, F., De Nicola, L., Genovesi, S., Paoletti, E., Regolisti, G.** Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. // *Journal of Nephrology*, 32, 2019, № 4, p. 499-516. ISSN 1121-8428. DOI 10.1007/s40620-019-00617-y.

2161. **Bianco, A., Canepa, M., Catapano, G.A., Marvisi, M., Oliva, F., Passantino, A., Sarzani, R., Tarsia, P., Versace, A.G.** Implementation of the Care Bundle for the Management of Chronic Obstructive Pulmonary Disease with/without Heart Failure. // *Journal of Clinical Medicine*, 13, 2024, № 6, art. no. 1621. ISSN 2077-0383. DOI 10.3390/jcm13061621.
2162. **Bitar, S., Agrinier, N., Alla, F., Rossignol, P., Mebazaa, A., Thilly, N.** Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: Results from the EPICAL2 cohort study. // *Pharmacoepidemiology and Drug Safety*, 28, 2019, № 11, p. 1489-1500. ISSN 1053-8569. DOI 10.1002/pds.4868.
2163. **Bitar, S., Thilly, N., Agrinier, N.** Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study. // *European Journal of Clinical Pharmacology*, 77, 2021, № 10, p. 1569-1581. ISSN 0031-6970. DOI 10.1007/s00228-021-03153-6.
2164. **Böhm, M., Tschöpe, C., Wirtz, J.H., Lokies, J., Turgonyi, E., Bramlage, P., Lins, K., Strunz, A.M., Tebbe, U.** Treatment of heart failure in real-world clinical practice: Findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. // *Clinical Cardiology*, 38, 2015, № 4, p. 200-207. ISSN 0160-9289. DOI 10.1002/clc.22375.
2165. **Bohn, B., Schöfl, C., Zimmer, V., Hummel, M., Heise, N., Siegel, E., Karges, W., Riedl, M., Holl, R.W., On behalf of the DPV-initiative.** Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: A German/Austrian DPV-multicenter analysis. // *Cardiovascular Diabetology*, 15, 2016, № 1, art. no. 72. ISSN 1475-2840. DOI 10.1186/s12933-016-0391-8.
2166. **Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vrizz, O., Castello, R., Passantino, A., Campo, M., Modesti, P.A., De Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D'Assante, R., Marra, A.M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M.G., Napoli, R., Matarazzo, M., Stagnaro, F.M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D'Andrea, A., Maddaloni, V., Pacileo, G., Scarafie, R., Belfiore, A., Cimellaro, A., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A.M.R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M.R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., De Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L.M., Bruzzese, D., TOSCA Investigators.** Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.C.A. Registry. // *Internal and Emergency Medicine*, 13, 2018, № 5, p. 661-671. ISSN 1828-0447. DOI 10.1007/s11739-018-1844-8.
2167. **Bouriche, F., Warrak, S., Yvorra, S.** Setting up the Back Home Program for Heart Failure Patients: Perception by Health Professionals and Patients and Outcomes. // *Current Problems in Cardiology*, 46, 2021, № 3, art. no. 100745. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2020.100745.



2168. **Brahmbhatt, D.H., Ross, H.J., O'Sullivan, M., Artanian, V., Mueller, B., Runeckles, K., Steve Fan, C.-P., Rac, V.E., Seto, E., Medly Titrate Study Team.** The Effect of Using a Remote Patient Management Platform in Optimizing Guideline-Directed Medical Therapy in Heart Failure Patients: A Randomized Controlled Trial. // *JACC: Heart Failure*, 12, 2024, № 4, p. 678-690. ISSN 2213-1779. DOI 10.1016/j.jchf.2024.02.008.
2169. **Brankovic, M., Akkerhuis, K.M., van Boven, N., Manintveld, O., Germans, T., Brugts, J., Caliskan, K., Umans, V., Constantinescu, A., Kardys, I.** Real-Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. // *Clinical Pharmacology and Therapeutics*, 104, 2018, № 2, p. 346-355. ISSN 0009-9236. DOI 10.1002/cpt.931.
2170. **Brownell, N.K., Ziaieian, B., Fonarow, G.C.** The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. // *Cardiac Failure Review*, 7, 2021, art. no. e18. ISSN 2057-7540. DOI 10.15420/cfr.2021.18.
2171. **Brugts, J.J., Linssen, G.C.M., Hoes, A.W., Brunner-La Rocca, H.P., van Amerongen, H., Derks, A., Hering, D., Kruik, H.J., Martherus, M., Pluimers, J., Rodijk-Heijmer, C.E.M., Uitzetter, A., Veldhuis, D., Huisman, N.A.M., van der Spank, A., Winter, J., Moons, A.H.M., Smit, M., Oortman, R.M., Aengenend, N., Koornstra-Wortel, H.J.J., Rongen, T., Balhuizen, K.J., Plomp, J., van Drimmelen, A.A.M., Snoek, I., van Anken, A., van Rijn, L., Smeele, F.J.J., van Gent, M.W.F., van Lingen-Koppejan, G.C., Smits, P.A., Trossèl, H.I.S., Schaafsma, H.J., Tuin-v.d. Kolk, G., Vermeulen-v.d. Wetering, H.D., Zimmerman, J., Adema, A., Brakel, J.W., Nagelsmit, M.J., Veenstra, W., Aksoy, I., Meulmeester-Sinke, D.C., Monraats, P.S., Reijnierse-Buitenwerf, H.H., Witkam-Bal, A.H., Boes-van Laar, M., Schoep-Bezemer, H.M.C., Westendorp, P.H.M., van Dieën, A., Viergever, E.P., Vossebelt, E.B., Takens, L.H., de Valk-Bedijn, W.E.H., van der Bolt, C.L.B., Hendrick, R., Kragten, J.A., Stoot, N.P., Barandiaran Aizpurua, M.A., Marcks, N.G.H.M., Merken, J., Corsten, L., Kelder, J.C., van Tooren, R.M., Hillebrink, T., Oosterom, L., Telgt, N., van Dalen, B.M., van Miltenburg, A., Slingerland, N., Sonneveld, B., Bird-Lake, E., Hoek-Verschoor, J., van der Ree, A., Erol-Yilmaz, A., den Hartog-Taai, L., Middelburg-Poldervaart, P., Rademaker, P.C., de Smet, S., de Theije, E.G.M.V., de Wit, T.J., Langerveld, J., Morang-van Drempt, C.J., Vermeulen, M.M., Foolen, Y., Pronk, A.C.B., Szabó, B.M., Valk, L.K., Grosfeld, M.J.W., Aertsen, M., Engelen, D.J.M., Kneijber, V., van Santvoord, J., Eurlings, L.W.M., Geurts, E.J., Hazeleger, R., Koopman-Verhagen, A.M., Maessen, G., Pansters, C.W.A.M., Geerlings, P.R., de Boer, M., Kolkman, A., van der Lee, C., Blonk, R., Krijger, J., Smits, J.P.P., Al-Windy, N.Y.Y., Harmsen, M., CHECK-HF investigators.** Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: Design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. // *Netherlands Heart Journal*, 26, 2018, № 5, p. 272-279. ISSN 1568-5888. DOI 10.1007/s12471-018-1103-7.
2172. **Brunner-La Rocca, H.-P., Linssen, G.C., Smeele, F.J., van Drimmelen, A.A., Schaafsma, H.-J., Westendorp, P.H., Rademaker, P.C., van de Kamp, H.J., Hoes, A.W., Brugts, J.J., CHECK-HF Investigators.** Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF



2173. **Busson, A., Thilly, N., Laborde-Castérot, H., Alla, F., Messikh, Z., Clerc-Urmes, I., Mebazaa, A., Soudant, M., Agrinier, N.** Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study. // *European Journal of Internal Medicine*, 51, 2018, p. 53-60. ISSN 0953-6205. DOI 10.1016/j.ejim.2017.12.005.
2174. **Cai, A., Qiu, W., Zhou, Y., Feng, Y., Chen, J., Xia, S., Li, W., Liao, Y., Li, X., Zhou, J., Wang, H., Jin, W., Zhang, Q., Sun, Z., Chen, M., Wang, J., Kong, H., Zhang, Y., Dong, W., Bai, L., Xu, D., Yuan, J., Liu, C., Jiang, M., Xu, Y., Li, L., Dong, Y., Yang, J.** Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry. // *European Journal of Heart Failure*, 24, 2022, № 11, p. 2048-2062. ISSN 1388-9842. DOI 10.1002/ejhf.2654.
2175. **Cainzos-Achirica, M., Rebordosa, C., Vela, E., Cleries, M., Matsushita, K., Plana, E., Rivero-Ferrer, E., Enjuanes, C., Jimenez-Marrero, S., Garcia-Rodriguez, L.A., Comin-Colet, J., Perez-Gutthann, S.** Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. // *American Heart Journal*, 202, 2018, p. 76-83. ISSN 0002-8703. DOI 10.1016/j.ahj.2018.05.005.
2176. **Carigi, S., Gentile, P., Gori, M., Tinti, D., De Gennaro, L., Leonardi, G., Orso, F., Felici, A.R., Catalano, M.R., Floresta, M., Rizzello, V., Lucci, D., Gonzini, L., De Maria, R., Marini, M., on behalf of IN-HF investigators (appendix).** Clinical characteristics, treatment, trajectories and outcome of patients with dilated cardiomyopathy in a national heart failure registry. // *International Journal of Cardiology*, 2024, art. no. 131986. ISSN 0167-5273. DOI 10.1016/j.ijcard.2024.131986.
2177. **Carr, A., De Iorio, F., Cowie, M.R.** Variability in use of IV nitrates and diuretics in acute HF: A 'virtual patient' clinical decision-making study. // *British Journal of Cardiology*, 25, 2018, № 1. ISSN 0969-6113. DOI 10.5837/bjc.2018.002.
2178. **Carroll, R., Mudge, A., Suna, J., Denaro, C., Atherton, J.** Prescribing and up-titration in recently hospitalized heart failure patients attending a disease management program. // *International Journal of Cardiology*, 216, 2016, p. 121-127. ISSN 0167-5273. DOI 10.1016/j.ijcard.2016.04.084.
2179. **Caruso, N., Terns, P.P., Soricetti, J., Bortman, G., Coronel, M.L., Benavidez, A., Prado, A.H., Arazi, H.C., Fernández, A., Lescano, A.** Heart Failure Treatment at Hospital Discharge. Do we Adhere to Guidelines? A Sub-analysis of the ARGEN-IC Registry. [Tratamiento al alta en insuficiencia cardiaca ¿cumplimos con las guías? Subanálisis del registro ARGEN-IC]. // *Revista Argentina de Cardiología*, 89, 2021, № 6, p. 519-524. ISSN 0034-7000. DOI 10.7775/rac.es.v89.i6.20453.
2180. **Cavallari, I., Crispino, S.P., Segreti, A., Ussia, G.P., Grigioni, F.** Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. // *American Journal of Cardiovascular Drugs*, 23, 2023, № 6, p. 609-621. ISSN 1175-3277. DOI 10.1007/s40256-023-00601-9.

2181. **Chan, D., Doughty, R.N., Lund, M., Lee, M., Kerr, A.J.** Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). // *Heart Lung and Circulation*, 29, 2020, № 9, p. 1386-1396. ISSN 1443-9506. DOI 10.1016/j.hlc.2020.03.013.
2182. **Chan, D., Doughty, R.N., Mazengarb, J., McLachlan, A., Kerr, A.J.** Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48). // *New Zealand Medical Journal*, 133, 2020, № 1516, p. 58-71. ISSN 0028-8446.
2183. **Chan, G.C.-K., Ng, J.K.-C., Chow, K.-M., Szeto, C.-C.** SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. // *Diabetes Research and Clinical Practice*, 195, 2023, art. no. 110200. ISSN 0168-8227. DOI 10.1016/j.diabres.2022.110200.
2184. **Chang, H.-Y., Feng, A.-N., Fong, M.-C., Hsueh, C.-W., Lai, W.-T., Huang, K.-C., Chong, E., Chen, C.-N., Chang, H.-C., Yin, W.-H.** Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. // *Journal of Cardiology*, 74, 2019, № 4, p. 372-380. ISSN 0914-5087. DOI 10.1016/j.jjcc.2019.03.010.
2185. **Chatterjee, N.A., Singh, J.P.** Cardiac resynchronization therapy: Past, present, and future. // *Heart Failure Clinics*, 11, 2015, № 2, p. 287-303. ISSN 1551-7136. DOI 10.1016/j.hfc.2014.12.007.
2186. **Chernyavskaya, T.K., Glezer, M.G.** Clinical characteristics and treatment of outpatients with chronic heart failure in the Moscow Region. // *Almanac of Clinical Medicine*, 49, 2021, № 2, p. 125-131. ISSN 2072-0505. DOI 10.18786/2072-0505-2021-49-023.
2187. **Chivite, D., Franco, J., Formiga, F.** Chronic heart failure in the elderly patient. [Insuficiencia cardíaca crónica en el paciente anciano]. // *Revista Espanola de Geriatria y Gerontologia*, 50, 2015, № 5, p. 237-246. ISSN 0211-139X. DOI 10.1016/j.regg.2015.03.003.
2188. **Chow, S.L., Page, R.L., II, Depre, C.** Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. // *Expert Review of Cardiovascular Therapy*, 16, 2018, № 7, p. 515-526. ISSN 1477-9072. DOI 10.1080/14779072.2018.1489235.
2189. **Christian, M., Klaus, B., Marc, B., Andreas, F.J., Jean-Michel, G., François, M., Giorgio, M., Matthias, P., Andreas, Z., Ellen, H., Bianca, F., Thomas, R.** Roadmap for the treatment of heart failure patients after hospital discharge: An interdisciplinary consensus paper. // *Swiss Medical Weekly*, 150, 2020, № 5/6, art. no. e20159. ISSN 1424-7860. DOI 10.4414/smw.2020.20159.
2190. **Clarisse, D., Deng, L., de Bosscher, K., Lothar, A.** Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor. // *British Journal of Pharmacology*, 179, 2022, № 13, p. 3235-3249. ISSN 0007-1188. DOI 10.1111/bph.15719.

2191. **Coca, A., Kreutz, R., Manolis, A.J., Mancia, G.** A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. // *Journal of Hypertension*, 38, 2020, № 10, p. 1890-1898. ISSN 0263-6352. DOI 10.1097/HJH.0000000000002464.
2192. **Cooper, L.B., Hernandez, A.F.** Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. // *European Journal of Heart Failure*, 20, 2018, № 8, p. 1227-1229. ISSN 1388-9842. DOI 10.1002/ejhf.1221.
2193. **Coutrot, M., Dépret, F., Legrand, M.** Tailoring treatment of hyperkalemia. // *Nephrology Dialysis Transplantation*, 34, 2019, p. III62-III68. ISSN 0931-0509. DOI 10.1093/ndt/gfz220.
2194. **Curtain, J.P., Campbell, R.T., Petrie, M.C., Jackson, A.M., Abraham, W.T., Desai, A.S., Dickstein, K., Køber, L., Rouleau, J.L., Swedberg, K., Zile, M.R., Solomon, S.D., Jhund, P.S., McMurray, J.J.V.** Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. // *JACC: Heart Failure*, 10, 2022, № 6, p. 415-427. ISSN 2213-1779. DOI 10.1016/j.jchf.2022.01.020.
2195. **Cuthbert, J.J., Pellicori, P., Clark, A.L.** Cardiovascular outcomes with sacubitril-valsartan in heart failure: Emerging clinical data. // *Therapeutics and Clinical Risk Management*, 16, 2020, p. 715-726. ISSN 1176-6336. DOI 10.2147/TCRM.S234772.
2196. **Cuthbert, J.J., Pellicori, P., Shah, P., Clark, A.L.** New pharmacological approaches in heart failure therapy: Developments and possibilities. // *Future Cardiology*, 13, 2017, № 2, p. 173-188. ISSN 1479-6678. DOI 10.2217/fca-2016-0068.
2197. **Cvetinovic, N., Loncar, G., Farkas, J.** Heart failure management in the elderly – a public health challenge. // *Wiener Klinische Wochenschrift*, 128, 2016, p. 466-473. ISSN 0043-5325. DOI 10.1007/s00508-016-1138-y.
2198. **D’Amario, D., Rodolico, D., Delvinioti, A., Laborante, R., Iacomini, C., Masciocchi, C., Restivo, A., Ciliberti, G., Galli, M., Paglianiti, A.D., Iaconelli, A., Zito, A., Lenkiewicz, J., Patarnello, S., Cesario, A., Valentini, V., Crea, F.** Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge. // *Journal of the American Heart Association*, 12, 2023, № 13, art. no. e029071. ISSN 2047-9980. DOI 10.1161/JAHA.122.029071.
2199. **D’Onofrio, A., Stabile, G., Capucci, A., Amellone, C., De Simone, A., Leoni, L., Morani, G., Bianchi, V., Campari, M., Valsecchi, S., Buja, G.** Association between remote implantable cardioverter defibrillator monitoring and beta-blocker utilization: An analysis from the EFFECT study. // *Journal of Telemedicine and Telecare*, 22, 2016, № 7, p. 383-390. ISSN 1357-633X. DOI 10.1177/1357633X15613701.
2200. **D’Amario, D., Rodolico, D., Rosano, G.M.C., Dahlström, U., Crea, F., Lund, L.H., Savarese, G.** Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. // *European Journal of Heart Failure*, 24, 2022, № 5, p. 871-884. ISSN 1388-9842. DOI 10.1002/ejhf.2477.

2201. **Dashwood, A., Vale, C., Laher, S., Chui, F., Rheault, H., Gan, J., Wong, Y.W.** Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience. // *Heart Lung and Circulation*, 29, 2020, № 11, p. 1688-1695. ISSN 1443-9506. DOI 10.1016/j.hlc.2020.03.008.
2202. **Dauw, J., Martens, P., Mullens, W.** CRT Optimization: What Is New? What Is Necessary? // *Current Treatment Options in Cardiovascular Medicine*, 21, 2019, № 9, art. no. 45. ISSN 1092-8464. DOI 10.1007/s11936-019-0751-2.
2203. **Davarzani, N., Sanders-van Wijk, S., Maeder, M.T., Rickenbacher, P., Smirnov, E., Karel, J., Suter, T., de Boer, R.A., Block, D., Rolny, V., Zaugg, C., Pfisterer, M.E., Peeters, R., Brunner-La Rocca, H.-P., for the TIME-CHF investigators.** Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine. // *EPMA Journal*, 9, 2018, № 2, p. 161-173. ISSN 1878-5077. DOI 10.1007/s13167-018-0137-7.
2204. **De Nicola, L., Garofalo, C., Provenzano, M., Grosseto, D., Magnani, G., Pulignano, G.** La gestione dell'iperpotassiemia: Nefrologo e cardiologo a confronto. // *Giornale Italiano di Cardiologia*, 20, 2019, № 10, p. 552-558. ISSN 1827-6806. DOI 10.1714/3228.32054.
2205. **De Sutter, J., Pardaens, S., Audenaert, T., Weytjens, C., Vande Kerckhove, B., Willems, A.-M., De Laet, N., Van Camp, G.** Clinical characteristics and short-term outcome of patients admitted with heart failure in Belgium: Results from the BIO-HF registry. // *Acta Cardiologica*, 70, 2015, № 4, p. 375-385. ISSN 0001-5385. DOI 10.1080/ac.70.4.3094645.
2206. **D'Elia, E., Pascale, A., Marchesi, N., Ferrero, P., Senni, M., Govoni, S., Gronda, E., Vanoli, E.** Novel approaches to the post-myocardial infarction/heart failure neural remodeling. // *Heart Failure Reviews*, 19, 2014, № 5, p. 611-619. ISSN 1382-4147. DOI 10.1007/s10741-013-9415-6.
2207. **Devore, A.D., Schulte, P.J., Mentz, R.J., Hardy, N.C., Kelly, J.P., Velazquez, E.J., Maya, J.F., Kielhorn, A., Patel, H.K., Reed, S.D., Hernandez, A.F.** Relation of elevated heart rate in patients with heart failure with reduced ejection fraction to one-year outcomes and costs. // *American Journal of Cardiology*, 117, 2016, № 6, p. 946-951. ISSN 0002-9149. DOI 10.1016/j.amjcard.2015.12.031.
2208. **Diamant, M.J., Virani, S.A., MacKenzie, W.J., Ignaszewski, A., Toma, M., Hawkins, N.M.** Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. // *ESC Heart Failure*, 6, 2019, № 4, p. 774-783. ISSN 2055-5822. DOI 10.1002/ehf2.12454.
2209. **D'Onofrio, A., Palmisano, P., Rapacciuolo, A., Ammendola, E., Calò, L., Ruocco, A., Bianchi, V., Maresca, F., Del Giorno, G., Martino, A., Mauro, C., Campari, M., Valsecchi, S., Accogli, M.** Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: The RESTORE study. // *International Journal of Cardiology*, 236, 2017, p. 290-295. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.02.015.

2210. **Dubrava, J.** "3P (Patient-Pulse-Prognosis) in heart failure" survey: Focus on heart rate. [Prieskum 3P (Pacient - Pulz - Prognóza) pri srdcovom zlyhavani" so zamieraním na srdcovú frekvenciu]. // *Vnitrni Lekarstvi*, 62, 2016, № 1, p. 17-24. ISSN 0042-773X.
2211. **Dubrava, J., Sidlo, R.** EPIT-HF survey of chronic heart failure with reduced, mid-range and preserved ejection fraction in Slovakia. Part 2: Focus on therapy. [EPIT-HF survey chronického srdcového zlyhávania s redukovanou, mid-range a zachovanou ejekčnou frakciou na Slovensku. 2. časť: Terapia]. // *Cardiology Letters*, 27, 2018, № 1, p. 5-19. ISSN 1338-3655.
2212. **Duncker, D., König, T., Hohmann, S., Bauersachs, J., Veltmann, C.** Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-the PROLONG study. // *Journal of the American Heart Association*, 6, 2017, № 1, art. no. e004512. ISSN 2047-9980. DOI 10.1161/JAHA.116.004512.
2213. **Ehling, J., Noblé, H.J., Gysan, D., Möller, M., Goss, F., Haerer, W., Glück, S., Bansmann, P.M.** Are Hospital Admissions (Costs) and Mortality Rate Impacted by Guideline-driven Treatment of Heart Failure?: A Comparison between Participants in the "CorBene" CMP and Standard-care Patients on the Basis of Propensity Score Matching. // *International Journal of Angiology*, 2024. ISSN 1061-1711. DOI 10.1055/s-0044-1779660.
2214. **Elena, K.V., Olga, B.V., Elena, V.V., Maria, M.I.** Cetr RS247616 Polymorphism in Patients with Chronic Heart Failure and Coronary Heart Disease: Traits of Lipid Metabolism and Effectiveness of Statin Therapy. [Полиморфизм RS247616 гена cetr у пациентов с хронической сердечной недостаточностью и ишемической болезнью сердца: особенности липидного обмена и эффективности терапии статинами]. // *Vestnik Sovremennoi Klinicheskoi Mediciny*, 16, 2023, № 6, p. 67-77. ISSN 2071-0240. DOI 10.20969/VSKM.2023.16(6).67-77.
2215. **Emami, A., Ebner, N., von Haehling, S.** Publishing in a heart failure journal—where lies the scientific interest? // *ESC Heart Failure*, 4, 2017, № 4, p. 389-401. ISSN 2055-5822. DOI 10.1002/ehf2.12233.
2216. **Emdin, M., Vergaro, G., Barison, A., Giannoni, A.** Heart & kidney failure: Who's afraid of renin angiotensin system blockade? // *International Journal of Cardiology*, 266, 2018, p. 195-196. ISSN 0167-5273. DOI 10.1016/j.ijcard.2018.04.112.
2217. **Epstein, M.** Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: The widening gap between mandated treatment guidelines and the real-world clinical arena. // *Kidney International Supplements*, 6, 2016, № 1, p. 20-28. ISSN 2157-1724. DOI 10.1016/j.kisu.2016.01.004.
2218. **Epstein, M., Lifschitz, M.D.** Potassium homeostasis and dyskalemiás: The respective roles of renal, extrarenal, and gut sensors in potassium handling. // *Kidney International Supplements*, 6, 2016, № 1, p. 7-15. ISSN 2157-1724. DOI 10.1016/j.kisu.2016.01.006.
2219. **Epstein, M., Lifschitz, M.D.** The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemiás and Interpreting Clinical Trials. // *Kidney International Reports*, 1, 2016, № 1, p. 43-56. ISSN 2468-0249. DOI 10.1016/j.ekir.2016.03.001.



2220. **Epstein, M., Pitt, B.** Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. // *Expert Opinion on Pharmacotherapy*, 17, 2016, № 10, p. 1435-1448. ISSN 1465-6566. DOI 10.1080/14656566.2016.1190333.
2221. **Ezekowitz, J.A., McMullan, C.J., Westerhout, C.M., Piña, I.L., Lopez-Sendon, J., Anstrom, K.J., Hernandez, A.F., Lam, C.S.P., O'Connor, C.M., Pieske, B., Ponikowski, P., Roessig, L., Voors, A.A., Koglin, J., Armstrong, P.W., Butler, J.** Background Medical Therapy and Clinical Outcomes from the VICTORIA Trial. // *Circulation: Heart Failure*, 16, 2023, № 9, p. E010599. ISSN 1941-3289. DOI 10.1161/CIRCHEARTFAILURE.123.010599.
2222. **Fabian, S.** Interdisciplinary and according to guidelines therapy of cardiorenal patients - Focus on iron deficiency and hyperkalemia. [Interdisziplinäre, leitliniengerechte Therapie kardioresnaler Patienten – Eisenmangel und Hyperkaliämie im Fokus]. // *Perfusion (Germany)*, 2019, № 5/6, p. 144-146. ISSN 0935-0020.
2223. **Fang, C.-C., Ng Jao, Y.T.F.** Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. // *Acta Cardiologica Sinica*, 39, 2023, № 2, p. 297-308. ISSN 1011-6842. DOI 10.6515/ACS.202303\_39(2).20220926A.
2224. **Farias, M.C.L., Filho, P.C., Pontes, A.I., Jacobina, U.P.** DNA barcode reveals high cryptic diversity in the commercially important Penaeini shrimps (Decapoda, Penaeidae). // *Organisms Diversity and Evolution*, 23, 2023, № 4, p. 857-869. ISSN 1439-6092. DOI 10.1007/s13127-023-00616-9.
2225. **Feldman, S.F., Lesuffleur, T., Olié, V., Gastaldi-Ménager, C., Juillière, Y., Tuppin, P.** French annual national observational study of 2015 outpatient and inpatient healthcare utilization by approximately half a million patients with previous heart failure diagnosis. [Étude observationnelle annuelle nationale de la consommation de ville et hospitalière en 2015 d'environ un demi-million de patients ayant une insuffisance cardiaque connue antérieurement]. // *Archives of Cardiovascular Diseases*, 114, 2021, № 1, p. 17-32. ISSN 1875-2136. DOI 10.1016/j.acvd.2020.05.009.
2226. **Fomin, I.V., Kraiem, N., Polyakov, D.S., Vinogradova, N.G., Valikulova, F.Yu., Vaysberg, A.R., Shechrbina, E.V.** The notion of CHF course stability: Is it acceptable for Russian practice? // *Kardiologiya*, 58, 2018, p. 55-63. ISSN 0022-9040. DOI 10.18087/cardio.2356.
2227. **Fomin, I.V., Vinogradova, N.G., Polyakov, D.S., Pogrebetskaya, V.A.** Experience of introducing a new form of organization of medical care for patients with heart failure in the Russian Federation. [Опыт внедрения новой формы организации медицинской помощи больным сердечной недостаточностью в Российской Федерации.] // *Kardiologiya*, 61, 2021, № 3, p. 42-51. ISSN 0022-9040. DOI 10.18087/CARDIO.2021.3.N1005.
2228. **Foo, F.S., Lee, M., Poppe, K.K., Clare, G.C., Stiles, M.K., Gavin, A., Webber, M., Jackson, R., Kerr, A.J.** Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). // *Heart Lung and Circulation*, 31, 2022, № 11, p. 1531-1538. ISSN 1443-9506. DOI 10.1016/j.hlc.2022.06.691.

2229. **Franchini, M., Pieroni, S., Passino, C., Emdin, M., Molinaro, S.** The CAR-PEDIEM Algorithm: A Rule-Based System for Identifying Heart Failure Phenotype with a Precision Public Health Approach. // *Frontiers in Public Health*, 6, 2018, art. no. 6. ISSN 2296-2565. DOI 10.3389/fpubh.2018.00006.
2230. **Frigerio, M., Mazzali, C., Paganoni, A.M., Ieva, F., Barbieri, P., Maistrello, M., Agostoni, O., Masella, C., Scalvini, S.** Trends in heart failure hospitalizations, patient characteristics, in-hospital and 1-year mortality: A population study, from 2000 to 2012 in Lombardy. // *International Journal of Cardiology*, 236, 2017, p. 310-314. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.02.052.
2231. **Fu, M., Ahrenmark, U., Berglund, S., Lindholm, C.J., Lehto, A., Broberg, A.M., Tasevska-Dinevska, G., Wikstrom, G., Ågård, A., Andersson, B., All investigators of the HR-HF study, Fu, M., Andersson, B., Hagelind, S.E., Berglund, S., Frisell, J.-E., Borgencrantz, B., Broberg, A.M., Wedén, U., Thorsén, C., Kymle, F., Tasevska, G., Kullberg, A., Ahremark, U., Andersson, L., Ågård, A., Lehto, A., Wagner, N., Wikström, G., Ehrsson, M., Loayza, J., Lindholm, C.-J., Bachus, E.** Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). // *Clinical Research in Cardiology*, 106, 2017, № 12, p. 960-973. ISSN 1861-0684. DOI 10.1007/s00392-017-1146-6.
2232. **Fu, M., Vedin, O., Svennblad, B., Lampa, E., Johansson, D., Dahlström, U., Lindmark, K., Vasko, P., Lundberg, A., Costa-Scharplatz, M., Lund, L.H.** Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. // *ESC Heart Failure*, 7, 2020, № 6, p. 3633-3643. ISSN 2055-5822. DOI 10.1002/ehf2.12883.
2233. **Fudim, M., Grodin, J.L., Mentz, R.J.** Hyperkalemia in heart failure: Probably not O"K". // *Journal of the American Heart Association*, 7, 2018, № 11, art. no. e009429. ISSN 2047-9980. DOI 10.1161/JAHA.118.009429.
2234. **Gabler, M., Picker, N., Geier, S., Ley, L., Aberle, J., Lehrke, M., Martin, S., Riedl, M., Wilke, T.** Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset. // *Diabetes Therapy*, 12, 2021, № 4, p. 1209-1226. ISSN 1869-6953. DOI 10.1007/s13300-021-01024-y.
2235. **Gardner, R.S., D'Onofrio, A., Mark, G., Gras, D., Hu, Y., Veraghtert, S., Garcia-Bolao, I.** Real-world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART- Registry. // *ESC Heart Failure*, 8, 2021, № 2, p. 1675-1680. ISSN 2055-5822. DOI 10.1002/ehf2.13192.
2236. **Garganeeva, A.A., Kuzheleva, E.A., Kuzmichkina, M.A., Ryabov, V.V., Mareev, Yu.V., Mareev, V.Yu.** Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016. // *Kardiologiya*, 58, 2018, p. 18-26. ISSN 0022-9040. DOI 10.18087/cardio.2605.
2237. **Giezeman, M., Arne, M., Theander, K.** Adherence to guidelines in patients with chronic heart failure in primary health care. // *Scandinavian Journal of Primary Health Care*, 35, 2017, № 4, p. 336-343. ISSN 0281-3432. DOI 10.1080/02813432.2017.1397253.

2238. **Girerd, N., Coiro, S., Benson, L., Savarese, G., Dahlström, U., Rossignol, P., Lund, L.H.** Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry. // *European Journal of Heart Failure*, 26, 2024, № 2, p. 359-369. ISSN 1388-9842. DOI 10.1002/ehf.3066.
2239. **Glezer, M.G., Chesnikova, A.I., Gilyarevsky, S.R., Perepech, N.B., Astashkin, E.I., Lopatin, Yu.M., Vasyuk, Yu.A.** Decrease in heart rate in patients with coronary artery disease and chronic heart failure the purpose and means. // *Kardiologiya*, 54, 2014, № 4, p. 109-120. ISSN 0022-9040. DOI 10.18565/cardio.2014.4.109-120.
2240. **Goldberger, J.J., Subačius, H., Marroquin, O.C., Beau, S.L., Simonson, J.** One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction. // *Journal of the American Heart Association*, 10, 2021, № 14, art. no. e019017. ISSN 2047-9980. DOI 10.1161/JAHA.120.019017.
2241. **Gómez-Martínez, L., Orozco-Beltrán, D., Quesada, J.A., Bertomeu-González, V., Gil-Guillén, V.F., López-Pineda, A., Carratalá-Munuera, C.** Trends in Premature Mortality Due to Heart Failure by Autonomous Community in Spain: 1999 to 2013. [Tendencias de mortalidad prematura por insuficiencia cardiaca por comunidades autónomas en España, periodo 1999-2013]. // *Revista Espanola de Cardiologia*, 71, 2018, № 7, p. 531-537. ISSN 0300-8932. DOI 10.1016/j.recesp.2017.09.014.
2242. **González, O.E.O., Mejía, D.C.L., Kaplinsky, E., Barbagelata, A., Perrone, S.** Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. // *Drugs in Context*, 2023, art. no. 2022-6-4. ISSN 1745-1981. DOI 10.7573/dic.2022-6-4.
2243. **González-Pacheco, H., Álvarez-Sangabriel, A., Martínez-Sánchez, C., Briseño-Cruz, J.L., Altamirano-Castillo, A., Mendoza-García, S., Manzur-Sandoval, D., Amezcua-Guerra, L.M., Sandoval, J., Bojalil, R., Araiza-Garaygordobil, D., Sierra-Lara, D., Guiza-Sánchez, C.A., Gopar-Nieto, R., Cruz-Rodríguez, C., Valdivia-Nuño, J.J., Salas-Teles, B., Arias-Mendoza, A.** Clinical phenotypes, aetiologies, management, and mortality in acute heart failure: a single-institution study in Latin-America. // *ESC Heart Failure*, 8, 2021, № 1, p. 423-437. ISSN 2055-5822. DOI 10.1002/ehf2.13092.
2244. **Greene, S.J., Sabbah, H.N., Butler, J., Voors, A.A., Albrecht-Küpper, B.E., Düngen, H.-D., Dinh, W., Gheorghiade, M.** Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. // *Heart Failure Reviews*, 21, 2016, № 1, p. 95-102. ISSN 1382-4147. DOI 10.1007/s10741-015-9522-7.
2245. **Grzešek, G., Stolarek, W., Kasprzak, M., Krzyżanowski, M., Szadujkis-Szadurska, K., Wiciński, M., Grzešek, E.** Therapeutic drug monitoring of digoxin- 20 years of experience. // *Pharmacological Reports*, 70, 2018, № 1, p. 184-189. ISSN 2299-5684. DOI 10.1016/j.pharep.2017.08.014.
2246. **Güder, G., Ertl, G.** Heart failure with preserved ejection fraction (diastolic heart failure). [Die diastolische Herzinsuffizienz]. // *MMW-Fortschritte der Medizin*, 161, 2019, № 9, p. 58-65. ISSN 1438-3276. DOI 10.1007/s15006-019-0015-9.
2247. **Güder, G., Ertl, G., Angermann, C.E.** Diagnostics and treatment of chronic heart failure: Update 2020. [Diagnostik und Therapie der chronischen Herzinsuffizienz:

2248. **Guha, K., Allen, C.J., Chawla, S., Pryse-Hawkins, H., Fallon, L., Chambers, V., Vazir, A., Lyon, A.R., Cowie, M.R., Sharma, R.** Audit of a tertiary heart failure outpatient service to assess compliance with NICE guidelines. // *Clinical Medicine, Journal of the Royal College of Physicians of London*, 16, 2016, № 5, p. 407-411. ISSN 1470-2118. DOI 10.7861/clinmedicine.16-5-407.
2249. **Hanbali, D.A., Hashmi, K.A., Za'abi, M.A., Al-Zakwani, I.** Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman. // *International Journal of Clinical Pharmacy*, 43, 2021, № 4, p. 878-883. ISSN 2210-7703. DOI 10.1007/s11096-020-01190-2.
2250. **Harikrishnan, S., Sanjay, G., Agarwal, A., Kumar, N.P., Kumar, K.K., Bahuleyan, C.G., Vijayaraghavan, G., Viswanathan, S., Sreedharan, M., Biju, R., Rajalekshmi, N., Nair, T., Suresh, K., Jeemon, P.** One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India. // *American Heart Journal*, 189, 2017, p. 193-199. ISSN 0002-8703. DOI 10.1016/j.ahj.2017.03.019.
2251. **Harikrishnan, S., Sanjay, G., Anees, T., Viswanathan, S., Vijayaraghavan, G., Bahuleyan, C.G., Sreedharan, M., Biju, R., Nair, T., Suresh, K., Rao, A.C., Dalus, D., Huffman, M.D., Jeemon, P.** Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: The Trivandrum Heart Failure Registry. // *European Journal of Heart Failure*, 17, 2015, № 8, p. 794-800. ISSN 1388-9842. DOI 10.1002/ejhf.283.
2252. **Harjola, P., Tarvasmäki, T., Barletta, C., Body, R., Capsec, J., Christ, M., Garcia-Castrillo, L., Golea, A., Karamercan, M.A., Martin, P.-L., Miró, Ò., Tolonen, J., van Meer, O., Palomäki, A., Verschuren, F., Harjola, V.-P., Laribi, S., Plaisance, P., Dandachi, G.A., Maignan, M., Pateron, D., Hermand, C., Tessier, C., Roy, P.-M., Bucco, L., Duytsche, N., Garmilla, P., Carbone, G., Cosentini, R., Truță, S., Hrihorișan, N., Cimpoeșu, D., Rotaru, L., Petrica, A., Cojocaru, M., Nica, S., Tudoran, R., Vecerdi, C., Puticiu, M., Schönberger, T., Coolsma, C., Baggelaar, M., Fransen, N., van den Brand, C., Idzenga, D., Maas, M., Franssen, M., Staal, C.M., Schutte, L., de Kubber, M., Mignot-Evers, L., Penninga-Puister, U., Jansen, J., Kuijten, J., Bouwhuis, M., Reuben, A., Smith, J., Ramlakhan, S., Darwent, M., Gagg, J., Keating, L., Bongale, S., Hardy, E., Keep, J., Jarman, H., Crane, S., Lawal, O., Hassan, T., Corfield, A., Reed, M., Geier, F., Smolarsky, Y., Blaschke, S., Kill, C., Jerrentrup, A., Hohenstein, C., Rockmann, F., Brännler, T., Ghuysen, A., Vranckx, M., Ergin, M., Dundar, Z.D., Altuncu, Y.A., Arziman, I., Avcil, M., Katirci, Y., Suurmunne, H., Kokkonen, L., Valli, J., Kiljunen, M., Kaye, S., Mäkelä, M., Metsäniitty, J., Vaula, E., On Behalf of the EURODEM Study Group.** The emergency department arrival mode and its relations to ED management and 30-day mortality in acute heart failure: an ancillary analysis from the EURODEM study. // *BMC Emergency Medicine*, 22, 2022, № 1, art. no. 27. ISSN 1471-227X. DOI 10.1186/s12873-022-00574-z.
2253. **Hesse, K., Bourke, S., Steer, J.** Heart failure in patients with COPD exacerbations: Looking below the tip of the iceberg. // *Respiratory Medicine*, 196, 2022, art. no. 106800. ISSN 0954-6111. DOI 10.1016/j.rmed.2022.106800.



2254. **Hoes, A.W.**  $\beta$  blockers for heart failure. // *BMJ (Online)*, 353, 2016, art. no. i2074. ISSN 0959-8146. DOI 10.1136/bmj.i2074.
2255. **Hu, Y.-R., Hua, W., Jin, H., Gu, M., Fan, X.-H., Niu, H.-X., Ding, L.-G., Wang, J., Zhang, S.** Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center. // *Journal of Geriatric Cardiology*, 16, 2019, № 3, p. 255-262. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2019.03.015.
2256. **Hu, Y.-R., Hua, W., Yang, S.-W., Gu, M., Niu, H.-X., Ding, L.-G., Wang, J., Jing, R., Fan, X.-H., Zhang, S.** Predictors of non-response to cardiac resynchronization therapy implantation in patients with class I indications: The markedly dilated left ventricular end-diastolic dimension and the presence of fragmented QRS. // *Journal of Geriatric Cardiology*, 16, 2019, № 7, p. 514-521. ISSN 1671-5411. DOI 10.11909/j.issn.1671-5411.2019.07.009.
2257. **Hülsmann, M., Preinreich, J.M.** News: Disease management in heart failure. Requirement and challenge. Summary of the Expert Meeting, October 8, 2015, Vienna. [Aktuelles: Disease Management bei Herzinsuffizienz Forderung und Herausforderung Zusammenfassung des Expertentreffens vom 8. Oktober 2015, Wien]. // *Journal fur Kardiologie*, 23, 2016, № 1/2, p. 44-49. ISSN 1024-0098.
2258. **Huntsinger, M.E., Rabara, R., Peralta, I., Doshi, R.N.** Current technology to maximize cardiac resynchronization therapy benefit for patients with symptomatic heart failure. // *AACN Advanced Critical Care*, 26, 2015, № 4, p. 329-340. ISSN 1559-7768. DOI 10.1097/NCI.0000000000000113.
2259. **Iacoviello, M., Pulignano, G., Di Lenarda, A.** Medical training and mini-Delphi approach to implement heart failure treatment with mineralocorticoid receptor antagonists. [Training e mini-Delphi per implementare il trattamento dell'insufficienza cardiaca con gli antagonisti dei recettori dei mineralcorticoidi]. // *Giornale Italiano di Cardiologia*, 23, 2022, № 6, p. 469-476. ISSN 1827-6806.
2260. **Iacovoni, A., D'Elia, E., Gori, M., Oliva, F., Lorini, F.L., Senni, M.** Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. // *Cardiac Failure Review*, 5, 2019, № 2, p. 78-82. ISSN 2057-7540. DOI: 10.15420/cfr.2018.46.2.
2261. **Ibrahim, N.E., Gaggin, H.K., Turchin, A., Patel, H.K., Song, Y., Trebnick, A., Doros, G., Maya, J.F., Cannon, C.P., Januzzi, J.L.** Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 5, 2019, № 1, p. 3-11. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvy011.
2262. **Jackson, J.D.S., Cotton, S.E., Wirta, S.B., Proenca, C.C., Zhang, M., Lahoz, R., Balas, B., Calado, F.J.** Care pathways and treatment patterns for patients with heart failure in China: Results from a cross-sectional survey. // *Drug Design, Development and Therapy*, 12, 2018, p. 2311-2321. ISSN 1177-8881. DOI 10.2147/DDDT.S166277.
2263. **Jairoun, A.A., Al-Hemyari, S.S., Shahwan, M., Zyoud, S.H., Jairoun, M.** Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Palestine: Retrospective clinical audit study. // *Saudi Pharmaceutical Journal*, 32, 2024, № 3, art. no. 101965. ISSN 1319-0164. DOI 10.1016/j.jsps.2024.101965.



2264. **Jariwala, P., Jadhav, K., Punjani, A., Boorugu, H., Mari, A.R.** ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Nepriylsin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial). // *Indian Heart Journal*, 73, 2021, № 5, p. 605-611. ISSN 0019-4832. DOI 10.1016/j.ihj.2021.07.005.
2265. **Jarjour, M., Ducharme, A.** Optimization of GDMT for patients with heart failure and reduced ejection fraction: can physiological and biological barriers explain the gaps in adherence to heart failure guidelines? // *Drugs in Context*, 12, 2023. ISSN 1745-1981. DOI 10.7573/dic.2023-5-6.
2266. **Jhund, P.S.** Implementing the evidence – the true summit of evidence-based care and the false peak of guidelines. // *European Journal of Heart Failure*, 24, 2022, № 11, p. 2090-2092. ISSN 1388-9842. DOI 10.1002/ejhf.2712.
2267. **Jones, N.R., Hobbs, F.D.R., Taylor, C.J.** Prognosis following a diagnosis of heart failure and the role of primary care: A review of the literature. // *BJGP Open*, 1, 2017, № 3, 8 p. ISSN 1849-5435. DOI 10.3399/bjgpopen17X101013.
2268. **Jonsson, A., Viklund, I., Jonsson, A., Valham, F., Bergdahl, E., Lindmark, K., Norberg, H.** Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure. // *ESC Heart Failure*, 7, 2020, № 3, p. 1150-1160. ISSN 2055-5822. DOI 10.1002/ehf2.12643.
2269. **Joseph, P., Swedberg, K., Leong, D.P., Yusuf, S.** The Evolution of  $\beta$ -Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). // *Journal of the American College of Cardiology*, 74, 2019, № 5, p. 672-682. ISSN 0735-1097. DOI 10.1016/j.jacc.2019.04.067.
2270. **Jugdutt, B.I., Jugdutt, B.A.** Oxidative Stress and Heart Failure. – In: *Modulation of Oxidative Stress in Heart Disease*, 2019, p. 257-311. ISBN 9789811389467; 9789811389450. DOI 10.1007/978-981-13-8946-7\_11.
2271. **Kaiser, L.** Treatment of heart failure. How can adherence to beta-blocker therapy be optimized? Summary of the Meeting of Experts, May 5, 2014 in Vienna. [Therapie der Herzinsuffizienz Wie kann die Betablocker-Therapieadhärenz optimiert werden? Zusammenfassung des expertenmeetings vom 5. Mai 2014, Wien]. // *Journal für Kardiologie*, 22, 2015, № 5/6, p. 160. ISSN 1024-0098.
2272. **Kanda, E., Rastogi, A., Murohara, T., Lesén, E., Agiro, A., Arnold, M., Chen, G., Yajima, T., Järbrink, K., Pollack, C.V., Jr.** Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. // *BMC Nephrology*, 24, 2023, № 1, art. no. 18. ISSN 1471-2369. DOI 10.1186/s12882-022-03054-5.
2273. **Kazory, A., Bargman, J.M.** Defining the role of peritoneal dialysis in management of congestive heart failure. // *Expert Review of Cardiovascular Therapy*, 17, 2019, № 7, p. 533-543. ISSN 1477-9072. DOI 10.1080/14779072.2019.1637254.
2274. **Kearney, J., Drozd, M., Walker, A.M.N., Slater, T.A., Straw, S., Gierula, J., Paton, M., Lowry, J., Cole, C., Witte, K.K., Cubbon, R.M., Kearney, M.T.** Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study. // *Diabetes and Vascular Disease Research*, 18, 2021, № 1. ISSN 1479-1641. DOI 10.1177/1479164120984433.

2275. **Khan, M.S., Fonarow, G.C., Ahmed, A., Greene, S.J., Vaduganathan, M., Khan, H., Marti, C., Gheorghiade, M., Butler, J.** Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. // *Circulation: Heart Failure*, 10, 2017, № 8, art. no. e003956. ISSN 1941-3289. DOI 10.1161/CIRCHEARTFAILURE.117.003956.
2276. **Khan, M.S., Siddiqi, T.J., Usman, M.S., Sreenivasan, J., Fugar, S., Riaz, H., Murad, M.H., Mookadam, F., Figueredo, V.M.** Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis. // *International Journal of Cardiology*, 263, 2018, p. 80-87. ISSN 0167-5273. DOI 10.1016/j.ijcard.2018.04.049.
2277. **Kim, H.-Y., Mok, J., Kim, J.-Y., Jeon, D., Her, S.-H., Park, M.W., Kim, D.-B., Park, C.-S., Lee, J.-M., Chang, K., Jung, W.S., Ahn, Y.** Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction with Preserved Left Ventricular Systolic Function. // *Journal of Cardiovascular Pharmacology*, 82, 2023, № 1, p. 52-60. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001427.
2278. **Kim, K.A., Kim, E.-S., Youn, J.-C., Lee, H.S., Jeon, S., Lee, H.-Y., Cho, H.-J., Choi, J.-O., Jeon, E.-S., Lee, S.E., Kim, M.-S., Kim, J.-J., Hwang, K.-K., Cho, M.-C., Chae, S.C., Kang, S.-M., Choi, D.-J., Yoo, B.-S., Kim, K.H., Oh, B.-H., Baek, S.H.** A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study. // *European Heart Journal - Cardiovascular Pharmacotherapy*, 8, 2022, № 6, p. 587-599. ISSN 2055-6837. DOI 10.1093/ehjcvp/pvac002.
2279. **Kleemann, T., Strauss, M., Kouraki, K., Lampropoulou, E., Fendt, A., Werner, N., Zahn, R.** Contemporary benefit-harm profile over two decades in primary prophylactic ICD-therapy. // *Clinical Cardiology*, 42, 2019, № 10, p. 866-872. ISSN 0160-9289. DOI 10.1002/clc.23234.
2280. **Kobalava, Z.D., Galochkin, S.A., Tolkacheva, V.V., Bagmanova, N.Kh.** Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction. // *RUDN Journal of Medicine*, 24, 2020, № 2, p. 125-134. ISSN 2313-0245. DOI 10.22363/2313-0245-2020-24-2-125-134.
2281. **Kocabaş, U., Ergin, I., Kıvrak, T., Yılmaz Öztekin, G.M., Tanık, V.O., Özdemir, İ., Avcı Demir, F., Doğduş, M., Şen, T., Altınsoy, M., Üstündağ, S., Urgun, Ö.D., Sinan, Ü.Y., Uygur, B., Yeni, M., Özçalık, E.** Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. // *ESC Heart Failure*, 10, 2023, № 6, p. 3677-3689. ISSN 2055-5822. DOI 10.1002/ehf2.14559.
2282. **Kocabaş, U., Kıvrak, T., Öztekin, G.M.Y., Tanık, V.O., Özdemir, İ., Kaya, E., Yüce, E.İ., Demir, F.A., Doğduş, M., Altınsoy, M., Üstündağ, S., Özyurtlu, F., Karagöz, U., Karakuş, A., Urgun, Ö.D., Sinan, Ü.Y., Mutlu, İ., Şen, T., Astarcioglu, M.A., Kınık, M., Tok, Ö.Ö., Uygur, B., Yeni, M., Alan, B., Dalgıç, O., Sarıtürk, Ç., Altay, H., Pehlivanoğlu, S.** Adherence to guideline-directed medical and device Therapy in outpatients with heart failure with reduced ejection fraction: The ATA study. // *Anatolian Journal of Cardiology*, 24, 2020, № 1, p. 32-40. ISSN 2149-2263. DOI 10.14744/AnatolJCardiol.2020.91771.
2283. **Kocabaş, U., Kıvrak, T., Yılmaz Öztekin, G.M., Tanık, V.O., Özdemir, İ., Kaya, E., Yüce, E.İ., Avcı Demir, F., Doğduş, M., Altınsoy, M., Üstündağ, S., Özyurtlu,**

- F., Karagöz, U., Karakuş, A., Urgan, O.D., Sinan, Ü.Y., Mutlu, İ., Şen, T., Astarcioglu, M.A., Kınık, M., Özden Tok, Ö., Uygur, B., Yeni, M., Alan, B., Dalgıç, O., Altay, H., Pehlivanoğlu, S. Gender-related clinical and management differences in patients with chronic heart failure with reduced ejection fraction. // *International Journal of Clinical Practice*, 75, 2021, № 3, art. no. e13765. ISSN 1368-5031. DOI 10.1111/ijcp.13765.
2284. **Kohanim, S., Sternberg Jr., P.** Ophthalmic patient data registries: Defining and improving quality and outcomes. // *Ophthalmology*, 121, 2014, № 3, p. 619-621. ISSN 0161-6420. DOI 10.1016/j.ophtha.2013.12.033.
2285. **Kohlmeier, J., Bramlage, P.** Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: A case report. // *Perfusion (United Kingdom)*, 31, 2016, № 8, p. 699-702. ISSN 0267-6591. DOI 10.1177/0267659116660608.
2286. **Kokhan, E.V., Kiyakbaev, G.K., Kobalava, Zh.D.** Frequency of use and indications for beta-blockers in heart failure with preserved ejection fraction. [Частота и обоснованность назначения бета-адреноблокаторов у пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса: анализ динамики данных рандомизированных клинических исследований]. // *Kardiologiya*, 60, 2020, № 6, p. 30-40. ISSN 0022-9040. DOI 10.18087/cardio.2020.6.n1062.
2287. **Konishi, M., von Haehling, S.** The need for re-defining cut-off values in heart failure: From obesity to iron deficiency. // *Experimental Gerontology*, 87, 2017, p. 1-7. ISSN 0531-5565. DOI 10.1016/j.exger.2016.10.010.
2288. **Kruik-Kollöffel, W.J., Linssen, G.C.M., Kruik, H.J., Movig, K.L.L., Heintjes, E.M., van der Palen, J.** Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. // *Heart Failure Reviews*, 2019. ISSN 1382-4147. DOI 10.1007/s10741-019-09777-2.
2289. **Krynský, T., Mayer, O., Jr., Bruthans, J., Bílková, S., Jiráček, J.** Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure. [Dávkování základní farmakoterapie a jeho vliv na prognózu pacientů hospitalizovaných pro srdeční selhání]. // *Vnitřní Lekarství*, 69, 2023, № 2, p. 109-118. ISSN 0042-773X. DOI 10.36290/vnl.2023.018.
2290. **Kumbhani, D.J., Fonarow, G.C., Heidenreich, P.A., Schulte, P.J., Lu, D., Hernandez, A., Yancy, C., Bhatt, D.L.** Association between hospital volume, processes of care, and outcomes in patients admitted with heart failure: Insights from get with the guidelines-heart failure. // *Circulation*, 137, 2018, № 16, p. 1661-1670. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.117.028077.
2291. **Laflamme, É., Vachon, A., Gilbert, S., Boisvert, J., Leclerc, V., Bernier, M., Voisine, P., Sénéchal, M., Bergeron, S.** Usefulness of a titration algorithm for de novo users of sacubitril/valsartan in a tertiary centre heart failure clinic. // *Cardiovascular Journal of Africa*, 29, 2018, № 6, p. 352-356. ISSN 1995-1892. DOI 10.5830/CVJA-2018-039.
2292. **Latif, A., Ahsan, M.J., Lateef, N., Kapoor, V., Tran, A., Abusnina, W., Lundgren, S., Goldsweig, A., Ahsan, M.Z., Mirza, M.** Implementation of Multiple

Evidence-Based Heart Failure Therapies. // *Current Problems in Cardiology*, 47, 2022, № 10, art. no. 101293. ISSN 0146-2806. DOI 10.1016/j.cpcardiol.2022.101293.

2293. **Lauder, L., Ewen, S., Emrich, I.E., Böhm, M., Mahfoud, F.** Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure. [Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz]. // *Herz*, 44, 2019, № 7, p. 611-629. ISSN 0340-9937. DOI 10.1007/s00059-019-04846-6.
2294. **Lee, S.E., Cho, H.-J., Lee, H.-Y., Yang, H.-M., Choi, J.-O., Jeon, E.-S., Kim, M.-S., Kim, J.-J., Hwang, K.-K., Chae, S.C., Seo, S.M., Baek, S.H., Kang, S.-M., Oh, I.-Y., Choi, D.-J., Yoo, B.-S., Ahn, Y., Park, H.-Y., Cho, M.-C., Oh, B.-H.** A multicentre cohort study of acute heart failure syndromes in Korea: Rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. // *European Journal of Heart Failure*, 16, 2014, № 6, p. 700-708. ISSN 1388-9842. DOI 10.1002/ejhf.91.
2295. **Lee, S.E., Lee, H.-Y., Cho, H.-J., Choe, W.-S., Kim, H., Choi, J.O., Jeon, E.-S., Kim, M.-S., Kim, J.-J., Hwang, K.-K., Chae, S.C., Baek, S.H., Kang, S.-M., Choi, D.-J., Yoo, B.-S., Kim, K.H., Park, H.-Y., Cho, M.-C., Oh, B.-H.** Clinical characteristics & outcome of acute heart failure in Korea: Results from the Korean acute heart failure registry (KorAHF). // *Korean Circulation Journal*, 47, 2017, № 3, p. 341-353. ISSN 1738-5520. DOI 10.4070/kcj.2016.0419.
2296. **Lemachatti, N., Philippon, A.-L., Bloom, B., Hausfater, P., Riou, B., Ray, P., Freund, Y.** Temporal trends in nitrate utilization for acute heart failure in elderly emergency patients: A single-centre observational study. [Évolution temporelle de l'utilisation des dérivés chez les patients de plus de 75 ans admis aux urgences pour insuffisance cardiaque aiguë]. // *Archives of Cardiovascular Diseases*, 109, 2016, № 8/9, p. 449-456. ISSN 1875-2136. DOI 10.1016/j.acvd.2016.01.014.
2297. **Lenarda, A.D., Tano, G.D., Cipriani, M., Oliva, F., Imazio, M., Murrone, A., Caldarola, P., Iacoviello, M., Urbinati, S., Colivicchi, F., Gabrielli, D.** ANMCO Position paper: Double, triple or quadruple therapy for heart failure with reduced ejection fraction. Current evidence and new strategies. [Position paper ANMCO: Duplice, triplice o quadruplica terapia nello scompenso sistolico? Evidenze e nuove strategie]. // *Giornale Italiano di Cardiologia*, 22, 2021, № 10, p. 861-868. ISSN 1827-6806. DOI 10.1714/3666.36518.
2298. **Lerma, E., White, W.B., Bakris, G.** Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. // *Postgraduate Medicine*, 135, 2023, № 3, p. 224-233. ISSN 0032-5481. DOI 10.1080/00325481.2022.2060598.
2299. **Lescano, A., Sorasio, G., Soricetti, J., Arakaki, D., Coronel, L., Cáceres, L., Arazi, H.C., Benavidez, A., Prado, A.H., ALBERTO FERNANDEZ (ARGENIC TEAM).** Argentine registry of acute heart failure (Argen-ic). evaluation of a partial cohort at 30 days. [Registro argentino de insuficiencia cardíaca aguda (Argen-ic). evaluación de cohorte parcial a 30 días]. // *Revista Argentina de Cardiología*, 88, 2020, № 2, p. 118-124. ISSN 0034-7000. DOI 10.7775/rac.es.v88.i2.17201.



2300. **Leyva, F., Nisam, S., Auricchio, A.** 20 years of cardiac resynchronization therapy. // *Journal of the American College of Cardiology*, 64, 2014, № 10, p. 1047-1058. ISSN 0735-1097. DOI 10.1016/j.jacc.2014.06.1178.
2301. **Lin, C., Chau, T., Lin, C.-S., Shang, H.-S., Fang, W.-H., Lee, D.-J., Lee, C.-C., Tsai, S.-H., Wang, C.-H., Lin, S.-H.** Point-of-care artificial intelligence-enabled ECG for dyskalemia: a retrospective cohort analysis for accuracy and outcome prediction. // *npj Digital Medicine*, 5, 2022, № 1, art. no. 8. ISSN 2398-6352. DOI 10.1038/s41746-021-00550-0.
2302. **Linde, C., Bakhai, A., Furuland, H., Evans, M., McEwan, P., Ayoubkhani, D., Qin, L.** Real-World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. // *Journal of the American Heart Association*, 8, 2019, № 22, art. no. e012655. ISSN 2047-9980. DOI 10.1161/JAHA.119.012655.
2303. **Linde, C.M., Normand, C., Bogale, N., Auricchio, A., Sterlinski, M., Marinskis, G., Sticherling, C., Bulava, A., Pérez, Ó.C., Maass, A.H., Witte, K.K., Rekvava, R., Abdelali, S., Dickstein, K.** Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. // *European Journal of Heart Failure*, 20, 2018, № 10, p. 1457-1468. ISSN 1388-9842. DOI 10.1002/ejhf.1235.
2304. **Llubani, R., Vukadinović, D., Werner, C., Marx, N., Zewinger, S., Böhm, M.** Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. // *Current Heart Failure Reports*, 15, 2018, № 6, p. 390-397. ISSN 1546-9530. DOI 10.1007/s11897-018-0413-9.
2305. **Lohmann, M.** Chronic heart failure: Do not leave out patients who are difficult to treat! [Chronische herzinsuffizienz: schwer behandelbare patienten nicht außen vor lassen!]. // *Perfusion (Germany)*, 26, 2013, № 5, p. 162-163. ISSN 0935-0020.
2306. **Long, W., Liao, H., Liu, Q., Ning, Y., Wu, T., Kang, J., Liu, J., Xian, S., Yang, Z.** Effect of nitrate treatment on functional capacity and exercise time in patients with heart failure: a systematic review and meta-analysis. // *Journal of International Medical Research*, 48, 2020, № 8. ISSN 0300-0605. DOI 10.1177/0300060520939742.
2307. **Loukianov, M.M., Andreenko, E.Yu., Martsevich, S.Yu., Yakushin, S.S., Vorobyev, A.N., Pereverzeva, K.G., Zagrebelnyy, A.V., Okshina, E.Yu., Yakusevich, V.V., Yakusevich, V.V., Pozdnyakova, E.M., Gomova, T.A., Fedotova, E.E., Valiakhmetov, M.N., Mikhin, V.P., Maslennikova, Y.V., Klyashtorny, V.G., Kudryashov, E.V., Tatsii, J.E., Boytsov, S.A., Drapkina, O.M.** Patients with atrial fibrillation in clinical practice: Comorbidity, drug treatment and outcomes (Data from RECVASA registries). [Больные с фибрилляцией предсердий в клинической практике: коморбидность, медикаментозное лечение и исходы (данные регистров РЕКВАЗА)]. // *Rational Pharmacotherapy in Cardiology*, 16, 2021, № 6, p. 888-898. ISSN 1819-6446. DOI 10.20996/1819-6446-2020-12-01.
2308. **Loukianov, M.M., Martsevich, S.Y., Andreenko, E.Y., Yakushin, S.S., Vorobyev, A.N., Pereverzeva, K.G., Zagrebelnyy, A.V., Okshina, E.Y., Yakusevich, V.V., Yakusevich, V.V., Pozdnyakova, E.M., Gomova, T.A., Valiakhmetov, M.N., Mikhin, V.P., Maslennikova, Y.V., Belova, E.N., Klyashtorny, V.G., Kudryashov, E.V., Makoveeva, A.N., Tatsii, J.E., Boytsov, S.A., Drapkina, O.M.**



Combination of atrial fibrillation and coronary heart disease in patients in clinical practice: Comorbidities, pharmacotherapy and outcomes (data from the recvasa registries). // *Rational Pharmacotherapy in Cardiology*, 17, 2021, № 5, p. 702-711. ISSN 1819-6446. DOI 10.20996/1819-6446-2021-10-03.

2309. **Lund, L.H.** Optimizing outcomes after heart transplantation. // *European Journal of Heart Failure*, 20, 2018, № 2, p. 395-397. ISSN 1388-9842. DOI 10.1002/ejhf.1026.
2310. **Lund, L.H., Oldgren, J., James, S.** Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. // *Current Heart Failure Reports*, 14, 2017, № 2, p. 59-70. ISSN 1546-9530. DOI 10.1007/s11897-017-0325-0.
2311. **Lund, L.H., Pitt, B.** Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin–angiotensin–aldosterone system inhibitor use. // *European Journal of Heart Failure*, 20, 2018, № 5, p. 931-932. ISSN 1388-9842. DOI 10.1002/ejhf.1175.
2312. **Mahrer-Imhof, R., Østergaard, B., Brødsgaard, A., Konradsen, H., Svavarsdóttir, E.K., Dieperink, K.B., Imhof, L., García-Vivar, C., Luttik, M.-L.** Healthcare practices and interventions in Europe towards families of older patients with cardiovascular disease: A scoping review. // *Scandinavian Journal of Caring Sciences*, 36, 2022, № 2, p. 320-345. ISSN 0283-9318. DOI 10.1111/scs.13045.
2313. **Manea, M., Marcu, D., Stoian, A.P., Gaman, M.A., Gaman, A.M., Socea, B., Neagu, T.P., Stanescu, A.M.A., Bratu, O.G., Diaconu, C.C.** Heart failure with preserved ejection fraction and atrial fibrillation a review. // *Revista de Chimie*, 69, 2018, № 11, p. 3280-3284. ISSN 0034-7752. DOI 10.37358/rc.18.11.6730.
2314. **Marciszek, M., Paterek, A., Oknińska, M., Zambrowska, Z., Mackiewicz, U., Mączewski, M.** Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic? // *Heart Rhythm*, 18, 2021, № 7, p. 1230-1238. ISSN 1547-5271. DOI 10.1016/j.hrthm.2021.03.020.
2315. **Marques, M.D.C., Pires, R., Perdigão, M., Sousa, L., Fonseca, C., Pinho, L.G., Lopes, M.** Patient-centered care for patients with cardiometabolic diseases: An integrative review. // *Journal of Personalized Medicine*, 11, 2021, № 12, art. no. 1289. ISSN 2075-4426. DOI 10.3390/jpm11121289.
2316. **Martens, P., Verluyten, L., Van de Broek, H., Somers, F., Dauw, J., Dupont, M., Mullens, W.** Determinants of maximal dose titration of sacubitril/valsartan in clinical practice. // *Acta Cardiologica*, 76, 2021, № 1, p. 20-29. ISSN 0001-5385. DOI 10.1080/00015385.2019.1686226.
2317. **Martín-Fortea, M.P., Amores-Arriaga, B., Sánchez-Marteles, M., Ruiz-Laiglesia, F., Clemente-Roldán, E., Pérez-Calvo, J.I.** Results of implementing a programme to improve the quality of the contents in hospital discharge reports in cases of heart failure. [Resultados tras la implementación de un programa de mejora de la calidad del contenido de los informes de alta hospitalaria en insuficiencia cardíaca]. // *Revista de Calidad Asistencial*, 30, 2015, № 2, p. 64-71. ISSN 1134-282X. DOI 10.1016/j.cali.2014.12.008.

2318. **McCullough, P.A., Rahimi, G., Tecson, K.M.** Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction. // *Journal of the American College of Cardiology*, 77, 2021, № 9, p. 1222-1224. ISSN 0735-1097. DOI 10.1016/j.jacc.2021.01.007.
2319. **McMurray, J.J.J.V.** Improving outcomes in heart failure: A personal perspective†. // *European Heart Journal*, 36, 2015, № 48, p. 3467-3470. ISSN 0195-668X. DOI 10.1093/eurheartj/ehv565.
2320. **McMurray, J.J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K., Zile, M.R.** Angiotensin-neprilysin inhibition versus enalapril in heart failure. // *New England Journal of Medicine*, 371, 2014, № 11, p. 993-1004. ISSN 0028-4793. DOI 10.1056/NEJMoa1409077.
2321. **Minà, C., Ajello, L., Gesaro, G.D., Falletta, C., Clemenza, F.** Hyperkalemia in heart failure: Current treatment and new therapeutic perspectives. // *Reviews in Cardiovascular Medicine*, 21, 2020, № 2, p. 241-252. ISSN 1530-6550. DOI 10.31083/J.RCM.2020.02.8.
2322. **Miñana, G., Bosch, M.J., Núñez, E., Mollar, A., Santas, E., Valero, E., García-Blas, S., Pellicer, M., Bodí, V., Chorro, F.J., Sanchis, J., Núñez, J.** Length of stay and risk of very early readmission in acute heart failure. // *European Journal of Internal Medicine*, 42, 2017, p. 61-66. ISSN 0953-6205. DOI 10.1016/j.ejim.2017.04.003.
2323. **Miura, Y., Higuchi, S., Kohno, T., Shiraishi, Y., Kitamura, M., Nagatomo, Y., Takei, M., Nakano, S., Goda, A., Soejima, K., Kohsaka, S., Yoshikawa, T., on behalf of the West Tokyo Heart Failure (WET-HF) Registry Investigators.** Association of Potassium Level at Discharge with Long-Term Mortality in Hospitalized Patients with Heart Failure. // *Journal of Clinical Medicine*, 11, 2022, № 24, art. no. 7358. ISSN 2077-0383. DOI 10.3390/jcm11247358.
2324. **Moysidis, D.V., Kartas, A., Samaras, A., Papazoglou, A.S., Patsiou, V., Bekiari-dou, A., Baroutidou, A., Tsagkaris, C., Karagiannidis, E., Daios, S., Anastasiou, V., Tsalikakis, D., Efthimiadis, G., Ziakas, A., Tzikas, A., Giannakoulas, G.** Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial. // *Journal of Cardiovascular Pharmacology*, 81, 2023, № 3, p. 203-211. ISSN 0160-2446. DOI 10.1097/FJC.0000000000001390.
2325. **Munibari, A.-N., Al-Motarreb, A., Al-Sagheer, N., Hadi, H.A., Othman, A., Al-Wather, N., Hamoud, A., Alawlagy, M., Almehdar, S., Alhammadi, A., Al-mogayed, M., Caretta, G., Al Jabri, A., Agati, L.** Clinical characteristics and outcomes of Yemeni patients with acute heart failure aged 50 years or younger: Data from Gulf Acute Heart Failure Registry (Gulf CARE). // *International Journal of Cardiology*, 229, 2017, p. 91-95. ISSN 0167-5273. DOI 10.1016/j.ijcard.2016.11.222.
2326. **Nadar, S.** New classification for heart failure with mildly reduced ejection fraction: Greater clarity or more confusion? // *Sultan Qaboos University Medical Journal*, 17, 2017, № 1, p. e23-e26. ISSN 2075-051X. DOI 10.18295/squmj.2016.17.01.005.

2327. **Narita, K., Amiya, E., Hatano, M., Ishida, J., Maki, H., Minatsuki, S., Tsuji, M., Saito, A., Bujo, C., Ishii, S., Kakuda, N., Shimbo, M., Hosoya, Y., Endo, M., Kagami, Y., Imai, H., Itoda, Y., Ando, M., Shimada, S., Kinoshita, O., Ono, M., Komuro, I.** Differences in the prognoses of patients referred to an advanced heart failure center from hospitals with different bed volumes. // *Scientific Reports*, 10, 2020, № 1, art. no. 21071. ISSN 2045-2322. DOI 10.1038/s41598-020-78162-z.
2328. **Natale, E., Marsocci, A.** Decreasing heart rate in heart failure: Pros and cons. // *Journal of Cardiovascular Medicine*, 19, 2018, p. E96-E98. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000564.
2329. **Nordberg Backelin, C., Fu, M., Ljungman, C.** Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. // *ESC Heart Failure*, 7, 2020, № 3, p. 1049-1055. ISSN 2055-5822. DOI 10.1002/ehf2.12644.
2330. **Novosadova, M., Gianchetti, L., Takagi, K., Morishetty, P., Gaeta, L., Edwards, C., Davison, B.A., Picod, A., Mebazaa, A., Cotter, G.** Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire. // *ESC Heart Failure*, 10, 2023, № 4, p. 2236-2247. ISSN 2055-5822. DOI 10.1002/ehf2.14370.
2331. **Novotná, B., Koblížek, V., Kudela, O.** Heart failure and COPD - Review article. [Srdeční selhání a CHOPN - Přehledový článek]. // *Kardiologická Revue*, 16, 2014, № 5, p. 348-351. ISSN 1212-4540.
2332. **O'Brien, T., Park, M.-S., Youn, J.-C., Chung, E.S.** The past, present and future of cardiac resynchronization therapy. // *Korean Circulation Journal*, 49, 2019, № 5, p. 384-399. ISSN 1738-5520. DOI 10.4070/kcj.2019.0114.
2333. **Ogawa, K., Yamasaki, H., Aonuma, K., Otani, M., Hattori, A., Baba, M., Yoshida, K., Igarashi, M., Nishina, H., Suzuki, K., Nogami, A., Ieda, M.** Immediate pharmacotherapy intensification after cardiac resynchronization therapy: incidence, characteristics, and impact. // *ESC Heart Failure*, 2024. ISSN 2055-5822. DOI 10.1002/ehf2.14737.
2334. **Ohkuma, T., Harris, K., Cooper, M., Grobbee, D.E., Hamet, P., Harrap, S., Mancia, G., Marre, M., Patel, A., Rodgers, A., Williams, B., Woodward, M., Chalmers, J., ADVANCE Collaborative Group.** Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality Results from a Randomized Controlled Trial of ACE Inhibitors. // *Clinical Journal of the American Society of Nephrology*, 17, 2022, № 8, p. 1139-1149. ISSN 1555-9041. DOI 10.2215/CJN.00180122.
2335. **Onteddu, S.H., Wangchuk, G., Sharma, A.J., Mohan, J.C.** Acute decompensated heart failure in a North Indian community hospital: Demographics, clinical characteristics, comorbidities and adherence to therapy. // *Indian Heart Journal*, 72, 2020, № 1, p. 27-31. ISSN 0019-4832. DOI 10.1016/j.ihj.2020.03.004.
2336. **Ortiz, A., Ferro, C.J., Balafa, O., Burnier, M., Ekart, R., Halimi, J.-M., Kreutz, R., Mark, P.B., Persu, A., Rossignol, P., Ruilope, L.M., Schmieder, R.E., Valdivielso, J.M., Del Vecchio, L., Zoccali, C., Mallamaci, F., Sarafidis, P., for the European Renal and Cardiovascular Medicine (EURECA-m) Working Group**

- of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. // *Nephrology Dialysis Transplantation*, 38, 2023, № 1, p. 10-25. ISSN 0931-0509. DOI 10.1093/ndt/gfab167.
2337. **Ostojić, J., Pintarić, H.** Chronic obstructive pulmonary disease and heart failure: Closer than close. // *Acta Clinica Croatica*, 56, 2017, № 2, p. 269-276. ISSN 0353-9466. DOI 10.20471/acc.2017.56.02.10.
2338. **Oyanguren, J., García-Garrido, L., Nebot Margalef, M., Lekuona, I., Comin-Colet, J., Manito, N., Roure, J., Ruiz Rodriguez, P., Enjuanes, C., Latorre, P., Torcal Laguna, J., García-Gutiérrez, S., on behalf of the ETIFIC7 research group.** Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol. // *ESC Heart Failure*, 4, 2017, № 4, p. 507-519. ISSN 2055-5822. DOI 10.1002/ehf2.12152.
2339. **Öztekin, G.M.Y., Genç, A., Şahin, A., Çağırıcı, G., Arslan, Ş.** Effect of Bendopnea on Achievement Medical Treatment Target Doses in Heart Failure. // *Archives of Iranian Medicine*, 26, 2023, № 1, p. 36-42. ISSN 1029-2977. DOI 10.34172/aim.2023.06.
2340. **Packham, D.K., Kosiborod, M.** Potential New Agents for the Management of Hyperkalemia. // *American Journal of Cardiovascular Drugs*, 16, 2016, № 1, p. 19-31. ISSN 1175-3277. DOI 10.1007/s40256-015-0130-7.
2341. **Palmisano, P., Ammendola, E., D'Onofrio, A., Accogli, M., Calo, L., Ruocco, A., Rapacciuolo, A., Del Giorno, G., Bianchi, V., Malacrida, M., Valsecchi, S., Gronda, E.** Evaluation of synergistic effects of resynchronization therapy and a  $\beta$ -blocker up-titration strategy based on a predefined patient-management program: The RESTORE study. // *Clinical Cardiology*, 38, 2015, № 1, p. 2-7. ISSN 0160-9289. DOI 10.1002/clc.22352.
2342. **Paolillo, S., Carlomagno, G.** Mineralocorticoid receptor antagonists (MRAs): More attention required (to prescription)! // *Kardiologia Polska*, 76, 2018, № 9, p. 1301-1302. ISSN 0022-9032. DOI 10.5603/KP.2018.0182.
2343. **Parajuli, D.R., Shakib, S., Eng-Frost, J., McKinnon, R.A., Caughey, G.E., Whitehead, D.** Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. // *BMC Cardiovascular Disorders*, 21, 2021, № 1, art. no. 104. ISSN 1471-2261. DOI 10.1186/s12872-021-01868-z.
2344. **Pariona, M., Segura Saldaña, P.A., Padilla Reyes, M., Reyes Villanes, J.S., Jáuregui Contreras, M., Valenzuela-Rodríguez, G.** Epidemiological clinical characteristics of acute cardiac insufficiency in a tertiary hospital in Lima, Peru. [Características clínico epidemiológicas de la insuficiencia cardíaca aguda en un hospital terciario de Lima, Perú]. // *Revista Peruana de Medicina Experimental y Salud Pública*, 34, 2017, № 4, p. 655-659. ISSN 1726-4634. DOI 10.17843/rpmesp.2017.344.2890.

2345. **Park, H.-J., Jang, H.-J., Kim, T.-H., Kwon, S.W., Park, S.-D., Kong, M.G., Suh, J., Oh, P.C., Moon, J., Lee, K., Kang, W.C.** Assessment of optimal renin-angiotensin-system inhibition strategy in Asian patients with STEMI after primary myocardial revascularization. // *Reviews in Cardiovascular Medicine*, 23, 2022, № 1, art. no. 018. ISSN 1530-6550. DOI 10.31083/j.rcm2301018.
2346. **Park, J.J., Lee, S.-E., Cho, H.-J., Choi, J.-O., Yoo, B.-S., Kang, S.-M., Wang, H.-C., Lee, S., Choi, D.-J.** Real-World Usage of Sacubitril/ Valsartan in Korea: A Multi-Center, Retrospective Study. // *International Journal of Heart Failure*, 4, 2022, № 4, p. 193-204. ISSN 2636-154X. DOI 10.36628/ijhf.2022.0015.
2347. **Passos, L.C., Oliveira, M.G., Duraes, A.R., Trindade, T.M., Barbosa, A.C.C.** Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure. // *International Journal of Clinical Pharmacy*, 38, 2016, № 4, p. 802-807. ISSN 2210-7703. DOI 10.1007/s11096-016-0265-x.
2348. **Pellicori, P., Khan, M.J.I., Graham, F.J., Cleland, J.G.F.** New perspectives and future directions in the treatment of heart failure. // *Heart Failure Reviews*, 25, 2020, № 1, p. 147-159. ISSN 1382-4147. DOI 10.1007/s10741-019-09829-7.
2349. **Pellicori, P., Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., Zhang, J., Cleland, J.G.F., Clark, A.L.** What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? // *European Journal of Heart Failure*, 19, 2017, № 6, p. 768-778. ISSN 1388-9842. DOI 10.1002/ejhf.788.
2350. **Perera, R., Stevens, R., Aronson, J.K., Banerjee, A., Evans, J., Feakins, B.G., Fleming, S., Glasziou, P., Heneghan, C., Richard Hobbs, F.D., Jones, L., Kurtinecz, M., Lasserson, D.S., Locock, L., McLellan, J., Mihaylova, B., O'Callaghan, C.A., Oke, J.L., Pidduck, N., Plüddemann, A., Roberts, N., Schlackow, I., Shine, B., Simons, C.L., Taylor, C.J., Taylor, K.S., Verbakel, J.Y., Bankhead, C.** Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: A multi-method research programme. // *Programme Grants for Applied Research*, 9, 2021, art. no. 10. ISSN 2050-4322. DOI 10.3310/pgfar09100.
2351. **Petunina, N.A., Trukhin, I.V., Trukhina, L.V., Sizova, Z.M., Zakharova, V.L.** Heart failure and diabetes mellitus: Insight into comorbidity. [Сердечная недостаточность и сахарный диабет: взгляд на коморбидность]. // *Diabetes Mellitus*, 22, 2019, № 1, p. 79-87. ISSN 2072-0351. DOI 10.14341/DM9784.
2352. **Philippe, M., Henri, L., Roger, H.** Patisomer and medication optimisation in heart failure with reduced ejection fraction: a Swiss perspective. // *Swiss Medical Weekly*, 150, 2020, № 3940, art. no. w20362. ISSN 1424-7860. DOI 10.4414/SMW.2020.20362.
2353. **Piña, I.L., Yuan, J., Ackourey, G., Ventura, H.** Effect of patisomer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. // *Progress in Cardiovascular Diseases*, 63, 2020, № 5, p. 656-661. ISSN 0033-0620. DOI 10.1016/j.pcad.2020.09.007.
2354. **Pinto, G., Tondi, L., Gemma, M., De Marco, A., Silipigni, C., Spoladore, R., Margonato, A., Fragasso, G.** Real-Life Indications to Sacubitril/Valsartan Treatment in Patients with Chronic Systolic Heart Failure. // *Journal of Cardiovascular Pharmacology*, 73, 2019, № 5, p. 301-306. ISSN 0160-2446. DOI 10.1097/FJC.0000000000000665.



2355. **Pitt, B., Rossignol, P.** Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. // *Journal of the American Heart Association*, 6, 2017, № 12, art. no. e008054. ISSN 2047-9980. DOI 10.1161/JAHA.117.008054.
2356. **Psotka, M.A., Teerlink, J.R.** Ivabradine : Role in the chronic heart failure armamentarium. // *Circulation*, 133, 2016, № 21, p. 2066-2075. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.115.018094.
2357. **Raffaello, W.M., Henrina, J., Huang, I., Lim, M.A., Suciadi, L.P., Siswanto, B.B., Pranata, R.** Clinical Characteristics of De Novo Heart Failure and Acute De-compensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes. // *Cardiac Failure Review*, 7, 2021, art. no. e02. ISSN 2057-7540. DOI 10.15420/cfr.2020.20.
2358. **Rasenack, E., Maier, L.S., Unsöld, B.** Acute heart failure. What doctors in clinical practice need to know [Akute herzinsuffizienz. Was braucht man für die diagnose?]. // *Notfall und Rettungsmedizin*, 17, 2014, № 4, p. 287-292. ISSN 1434-6222. DOI 10.1007/s10049-013-1781-z.
2359. **Rashid, A.M., Khan, M.S., Fudim, M., DeWald, T.A., DeVore, A., Butler, J.** Management of Heart Failure With Reduced Ejection Fraction. // *Current Problems in Cardiology*, 48, 2023, № 5, art. no. 101596. ISSN 0146-2806. DOI 10.1016/j.cpcardi.2023.101596.
2360. **Rezaei, S.S., Rinner, C., Ratajczak, P., Grossmann, W., Gall, W., Wolzt, M.** Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD. // *Clinical Respiratory Journal*, 12, 2018, № 12, p. 2627-2634. ISSN 1752-6981. DOI 10.1111/crj.12968.
2361. **Rosano, G.M.C., Allen, L.A., Abdin, A., Lindenfeld, J., O'Meara, E., Lam, C.S.P., Lancellotti, P., Savarese, G., Gottlieb, S.S., Teerlink, J., Wintrich, J., Böhm, M.** Drug Layering in Heart Failure: Phenotype-Guided Initiation. // *JACC: Heart Failure*, 9, 2021, № 11, p. 775-783. ISSN 2213-1779. DOI 10.1016/j.jchf.2021.06.011.
2362. **Rosano, G.M.C., Spoletini, I., Vitale, C., Agewall, S.** Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. // *Cardiac Failure Review*, 5, 2019, № 3, p. 130-132. ISSN 2057-7540. DOI 10.15420/cfr.2019.8.2.
2363. **Rossignol, P., Williams, B., Mayo, M.R., Warren, S., Arthur, S., Ackourey, G., White, W.B., Agarwal, R.** Patisiran versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. // *European Journal of Heart Failure*, 22, 2020, № 8, p. 1462-1471. ISSN 1388-9842. DOI 10.1002/ejhf.1860.
2364. **Ruschitzka, F.** Understanding and treating heart failure: Looking to the future. // *Dialogues in Cardiovascular Medicine*, 21, 2016, № 1, p. 7-24. ISSN 1272-9949.
2365. **Ruwald, A.-C., Gislason, G.H., Vinther, M., Johansen, J.B., Nielsen, J.C., Petersen, H.H., Torp-Pedersen, C., Riahi, S., Jøns, C.** The use of guideline recom-

mended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers. // *Europace*, 20, 2018, № 2, p. 301-307. ISSN 1099-5129. DOI 10.1093/europace/euw408.

2366. **Saheb Sharif-Askari, N., Sulaiman, S.A.S., Saheb Sharif-Askari, F., Hussain, A.A.S., Al-Mulla, A.A.** Assessment of guideline adherence in hospitalised heart failure patients with systolic dysfunction in Dubai, United Arab Emirates. // *International Journal of Cardiology*, 172, 2014, № 3, p. e491-e493. ISSN 0167-5273. DOI 10.1016/j.ijcard.2014.01.002.
2367. **Sarafidis, P., Iatridi, F., Ferro, C., Alexandrou, M.-E., Fernandez-Fernandez, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., Cozzolino, M., Ortiz, A., on behalf of the ERBP board.** Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). // *Clinical Kidney Journal*, 16, 2023, № 11, p. 1885-1907. ISSN 2048-8505. DOI 10.1093/ckj/sfad139.
2368. **Savarese, G., Bodegard, J., Norhammar, A., Sartipy, P., Thuresson, M., Cowie, M.R., Fonarow, G.C., Vaduganathan, M., Coats, A.J.S.** Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). // *European Journal of Heart Failure*, 23, 2021, № 9, p. 1499-1511. ISSN 1388-9842. DOI 10.1002/ehjhf.2271.
2369. **Savarese, G., Lund, L.H.** Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges. // *European Journal of Heart Failure*, 20, 2018, № 2, p. 370-372. ISSN 1388-9842. DOI 10.1002/ehjhf.978.
2370. **Schmitt, A., Weidner, K., Rusnak, J., Ruka, M., Egner-Walter, S., Mashayekhi, K., Tajti, P., Ayoub, M., Akin, I., Behnes, M., Schupp, T.** Age-related outcomes in patients with cardiogenic shock stratified by etiology. // *Journal of Geriatric Cardiology*, 20, 2023, № 8, p. 555-566. ISSN 1671-5411. DOI 10.26599/1671-5411.2023.08.003.
2371. **Schrage, B., Lund, L.H., Benson, L., Dahlström, U., Shadman, R., Linde, C., Braunschweig, F., Levy, W.C., Savarese, G.** Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. // *European Journal of Heart Failure*, 24, 2022, № 7, p. 1212-1222. ISSN 1388-9842. DOI 10.1002/ehjhf.2530.
2372. **Schupp, T., Akin, I., Behnes, M.** Pharmacological treatment following myocardial infarction: How large is the gap between guideline recommendations and routine clinical care? // *Journal of the American Heart Association*, 10, 2021, № 14, art. no. e021799. ISSN 2047-9980. DOI 10.1161/JAHA.121.021799.
2373. **Schupp, T., Akin, I., Behnes, M.** Special Issue: Sudden Cardiac Death: Clinical Updates and Perspectives. // *Journal of Clinical Medicine*, 11, 2022, № 11, art. no. 3120. ISSN 2077-0383. DOI 10.3390/jcm11113120.
2374. **Schupp, T., Rusnak, J., Weidner, K., Bertsch, T., Mashayekhi, K., Tajti, P., Akin, I., Behnes, M.** Prognostic Impact of Different Types of Ventricular Tachyarrhythmias Stratified by Underlying Cardiac Disease. // *Journal of Personalized*

2375. **Schupp, T., Von Zworowsky, M., Reiser, L., Abumayyaleh, M., Weidner, K., Mashayekhi, K., Bertsch, T., Abba, M.L., Akin, I., Behnes, M.** Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias. // *Pharmacology*, 107, 2022, № 1, p. 35-45. ISSN 0031-7012. DOI 10.1159/000520310.
2376. **Schupp, T., Ziyadova, S., Reinhardt, J., Sag, Y.U., von Zworowsky, M., Reiser, L., Abumayyaleh, M., Weidner, K., Saleh, A., Mashayekhi, K., Bertsch, T., Abba, M.L., Akin, I., Behnes, M.** Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias. // *Heart and Vessels*, 37, 2022, № 7, p. 1213-1223. ISSN 0910-8327. DOI 10.1007/s00380-021-02018-3.
2377. **Sciatti, E., D'elia, E., Balestrieri, G., D'isa, S., Iacovoni, A., Senni, M.** In pursuit of balance: renin-angiotensin-aldosterone system inhibitors and hyperkalaemia treatment. // *European Heart Journal, Supplement*, 25, 2023, № SC, p. C301-C305. ISSN 1520-765X. DOI 10.1093/eurheartjsupp/suad053.
2378. **Scorcu, G., Pilleri, A.** Treatment of heart failure in the elderly: Which drugs are essential and which should be avoided. // *Monaldi Archives for Chest Disease*, 88, 2018, № 2, p. 1-4. ISSN 1122-0643. DOI 10.4081/monaldi.2018.948.
2379. **Senni, M., McMurray, J.J.V., Wachter, R., McIntyre, H.F., Anand, I.S., Duino, V., Sarkar, A., Shi, V., Charney, A.** Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. // *European Journal of Heart Failure*, 20, 2018, № 3, p. 491-500. ISSN 1388-9842. DOI 10.1002/ejhf.1054.
2380. **Senni, M., Sciatti, E., Bussalino, E., D'Elia, E., Ravera, M., Paoletti, E.** Practical patient care appraisals with use of new potassium binders in heart failure and chronic kidney diseases. // *Journal of Cardiovascular Medicine*, 24, 2023, № 11, p. 781-789. ISSN 1558-2027. DOI 10.2459/JCM.0000000000001555.
2381. **Sfairopoulos, D., Arseniou, A., Korantzopoulos, P.** Serum potassium and heart failure: association, causation, and clinical implications. // *Heart Failure Reviews*, 26, 2021, № 3, p. 479-486. ISSN 1382-4147. DOI 10.1007/s10741-020-10039-9.
2382. **Shacham, Y.** Medication titration in heart failure: Too high or too complex? // *Israel Medical Association Journal*, 22, 2020, № 8, p. 453-454. ISSN 1565-1088.
2383. **Shanbhag, D., Graham, I.D., Harlos, K., Haynes, R.B., Gabizon, I., Connolly, S.J., Van Spall, H.G.C.** Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: A systematic review. // *BMJ Open*, 8, 2018, № 3, art. no. e017765. ISSN 2044-6055. DOI 10.1136/bmjopen-2017-017765.
2384. **Sharma, A., Alvarez, P.J., Woods, S.D., Dai, D.** A model to predict risk of hyperkalemia in patients with chronic kidney disease using a large administrative claims database. // *ClinicoEconomics and Outcomes Research*, 12, 2020, p. 657-667. ISSN 1178-6981. DOI 10.2147/CEOR.S267063.

2385. **Shlyakhto, E.V., Belenkov, Y.N., Boytsov, S.A., Villevalde, S.V., Galyavich, A.S., Glezer, M.G., Zvartau, N.E., Kobalava, Z.D., Lopatin, Y.M., Mareev, V.Y., Tereshchenko, S.N., Fomin, I.V., Barbarash, O.L., Vinogradova, N.G., Duplyakov, D.V., Zhirov, I.V., Kosmacheva, E.D., Nevzorova, V.A., Reitblat, O.M., Solovieva, A.E., Zorina, E.A.** Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation "PRIORITET-CHF": initial characteristics and treatment of the first included patients. // *Russian Journal of Cardiology*, 28, 2023, № 10, art. no. 5593, p. 93-103. ISSN 1560-4071. DOI 10.15829/1560-4071-2023-5593.
2386. **Shoaib, A., Mamas, M.A., Ahmad, Q.S., McDonagh, T.M., Hardman, S.M.C., Rashid, M., Butler, R., Duckett, S., Satchithananda, D., Nolan, J., Dargie, H.J., Clark, A.L., Cleland, J.G.F.** Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. // *International Journal of Cardiology*, 285, 2019, p. 40-46. ISSN 0167-5273. DOI 10.1016/j.ijcard.2019.03.020.
2387. **Shumakov, D.V., Zybin, D.I., Popov, M.A., Dontsov, V.V., Agafonov, E.G.** Resynchronization therapy in end-stage heart failure. // *Russian Medical Inquiry*, 5, 2021, № 4, p. 206-211. ISSN 2587-6821. DOI 10.32364/2587-6821-2021-5-4-206-211.
2388. **Shuvy, M., von Bardeleben, R.S., Grasso, C., Raake, P., Lurz, P., Zamorano, J.L., Asch, F., Kar, S., Maisano, F., EXPAND Investigators.** Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study. // *ESC Heart Failure*, 10, 2023, № 2, p. 1122-1132. ISSN 2055-5822. DOI 10.1002/ehf2.14273.
2389. **Simpson, J., Benson, L., Jhund, P.S., Dahlström, U., McMurray, J.J.V., Lund, L.H.** "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. // *Cardiovascular Drugs and Therapy*, 2019. ISSN 0920-3206. DOI 10.1007/s10557-019-06873-1.
2390. **Sinner, G.J., Gupta, V.A., Seratnahaei, A., Charnigo, R.J., Darrat, Y.H., Elayi, S.C., Leung, S.W., Sorrell, V.L.** Atrioventricular dyssynchrony from empiric device settings is common in cardiac resynchronization therapy and adversely impacts left ventricular morphology and function. // *Echocardiography*, 34, 2017, № 4, p. 496-503. ISSN 0742-2822. DOI 10.1111/echo.13486.
2391. **Sitepu, A., Hamdani, K.** Adherence to the European Society of Cardiology guidelines for the treatment of chronic heart failure. // *IOP Conference Series: Earth and Environmental Science*, 125, 2018, № 1, art. no. 012117. ISSN 1755-1307. DOI 10.1088/1755-1315/125/1/012117.
2392. **Sitnikova, M.Yu., Lysnikova, E.A., Yurchenko, A.V., Trukshina, M.A., Libis, R.A., Kondratenko, V.Yu., Duplyakov, D.V., Khokhlunov, S.M., Shlyakhto, E.V.** Results of Russian hospital chronic heart failure registry in three subjects of Russianuion. // *Kardiologiya*, 55, 2015, № 10, p. 5-13. ISSN 0022-9040. DOI 10.18565/cardio.2015.10.5-13.
2393. **Skonieczny, B., Gajek, A., Strózik, P., Zawadzki, J., Adamowicz, J., Gajek, J., Ślawuta, A.** The optimal management of patient with permanent atrial fibrillation and heart failure with reduced ejection fraction – The permanent His-bundle pacing is a solution. A case report. // *Journal of Electrocardiology*, 51, 2018, № 6, p. 1141-1144. ISSN 0022-0736. DOI 10.1016/j.jelectrocard.2018.10.091.

2394. **Smeets, C.J.P., Storms, V., Vandervoort, P.M., Dreesen, P., Vranken, J., Houbrechts, M., Goris, H., Grieten, L., Dendale, P.** A novel intelligent two-way communication system for remote heart failure medication uptitration (the cardio-coach study): Randomized controlled feasibility trial. // *JMIR Cardio*, 2, 2018, № 1, art. no. e8. ISSN 2561-1011. DOI 10.2196/cardio.9153.
2395. **Spahillari, A.** Heart and Kidney Interactions in Acutely Decompensated Heart Failure: Harmony or Discord. // *Circulation: Heart Failure*, 16, 2023, № 3, p. E010386. ISSN 1941-3289. DOI 10.1161/CIRCHEARTFAILURE.122.010386.
2396. **Spencer, S., Wheeler-Jones, C., Elliott, J.** Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. // *Journal of Veterinary Pharmacology and Therapeutics*, 43, 2020, № 3, p. 243-267. ISSN 0140-7783. DOI 10.1111/jvp.12848.
2397. **Staszewsky, L., Cortesi, L., Tettamanti, M., Dal Bo, G.A., Fortino, I., Bortolotti, A., Merlino, L., Latini, R., Roncaglioni, M.C., Baviera, M.** Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. // *European Journal of Heart Failure*, 18, 2016, № 7, p. 840-848. ISSN 1388-9842. DOI 10.1002/ejhf.519.
2398. **Störk, S., Handrock, R., Jacob, J., Walker, J., Calado, F., Lahoz, R., Hupfer, S., Klebs, S.** Treatment of chronic heart failure in Germany: a retrospective database study. // *Clinical Research in Cardiology*, 106, 2017, № 11, p. 923-932. ISSN 1861-0684. DOI 10.1007/s00392-017-1138-6.
2399. **Störk, S., Handrock, R., Jacob, J., Walker, J., Calado, F., Lahoz, R., Hupfer, S., Klebs, S.** Epidemiology of heart failure in Germany: a retrospective database study. // *Clinical Research in Cardiology*, 106, 2017, № 11, p. 913-922. ISSN 1861-0684. DOI 10.1007/s00392-017-1137-7.
2400. **Sulaiman, K., Panduranga, P., Al-Zakwani, I., Alsheikh-Ali, A.A., Alhabib, K.F., Al-Suwaidi, J., Al-Mahmeed, W., Alfaleh, H., Elasar, A., Al-Motarreb, A., Ridha, M., Bulbanat, B., Al-Jarallah, M., Bazargani, N., Asaad, N., Amin, H.** Clinical characteristics, management, and outcomes of acute heart failure patients: Observations from the Gulf acute heart failure registry (Gulf CARE). // *European Journal of Heart Failure*, 17, 2015, № 4, p. 374-384. ISSN 1388-9842. DOI 10.1002/ejhf.245.
2401. **Sung, S.-H., Wang, T.-J., Cheng, H.-M., Yu, W.-C., Guo, C.-Y., Chiang, C.-E., Chen, C.-H.** Clinical Characteristics and Outcomes in the Very Elderly Patients Hospitalized for Acute Heart Failure: Importance of Pharmacologic Guideline Adherence. // *Scientific Reports*, 8, 2018, № 1, art. no. 14270. ISSN 2045-2322. DOI 10.1038/s41598-018-32684-9.
2402. **Swedberg, K.** The clinical practice of treating patients with chronic heart failure needs to be improved. // *European Journal of Heart Failure*, 23, 2021, № 9, p. 1512-1513. ISSN 1388-9842. DOI 10.1002/ejhf.2309.
2403. **Tamargo, J., Caballero, R., Delpón, E.** New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. // *Cardiovascular Drugs and Therapy*, 32, 2018, № 1, p. 99-119. ISSN 0920-3206. DOI 10.1007/s10557-017-6767-5.



2404. **Tamargo, J., Caballero, R., Delpón, E.** The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. // *Expert Opinion on Pharmacotherapy*, 22, 2021, № 10, p. 1319-1341. ISSN 1465-6566. DOI 10.1080/14656566.2021.1891223.
2405. **Tereshchenko, S.N., Zhiron, I.V., Petrukhina, A.A.** Clinical and demographic characteristics of an outpatient Russian population with chronic heart failure at the time of enrollment in the QUALIFY registry for evaluating consistency with clinical guidelines on drug therapy. [Клинико-демографические характеристики российской популяции амбулаторных пациентов с хронической сердечной недостаточностью на момент включения в регистр QUALIFY для оценки соблюдения клинических рекомендаций в отношении лекарственной терапии]. // *Kardiologiya*, 57, 2017, p. 324-330. ISSN 0022-9040. DOI 10.18087/cardio.2363.
2406. **Tondi, L., Fragasso, G., Spoladore, R., Pinto, G., Gemma, M., Slavich, M., Godino, C., Salerno, A., Montanaro, C., Margonato, A.** Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. // *Journal of Cardiovascular Medicine*, 19, 2018, № 7, p. 351-356. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000661.
2407. **Trevisan, M., de Deco, P., Xu, H., Evans, M., Lindholm, B., Bellocco, R., Barany, P., Jernberg, T., Lund, L.H., Carrero, J.J.** Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. // *European Journal of Heart Failure*, 20, 2018, № 8, p. 1217-1226. ISSN 1388-9842. DOI 10.1002/ejhf.1199.
2408. **Trevisan, M., Fu, E.L., Xu, Y., Savarese, G., Dekker, F.W., Lund, L.H., Clase, C.M., Sjölander, A., Carrero, J.J.** Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. // *European Journal of Heart Failure*, 23, 2021, № 10, p. 1698-1707. ISSN 1388-9842. DOI 10.1002/ejhf.2287.
2409. **Ural, D., Kandemir, A.Ş., Karaüzüm, K., Baydemir, C., Karaüzüm, İ.Y., Bozyel, S., Kozdağ, G., Ağır, A.A.** Effect of Oral Nitrates on All-Cause Mortality and Hospitalization in Heart Failure Patients with Reduced Ejection Fraction: A Propensity-Matched Analysis. // *Journal of Cardiac Failure*, 23, 2017, № 4, p. 286-292. ISSN 1071-9164. DOI 10.1016/j.cardfail.2017.02.006.
2410. **Urbanek, I., Kaczmarek, K., Cygankiewicz, I., Ptaszynski, P.** Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. // *Drug, Healthcare and Patient Safety*, 6, 2014, № 1, p. 47-54. ISSN 1179-1365. DOI 10.2147/DHPS.S43275.
2411. **Vaduganathan, M., Butler, J., Pitt, B., Gheorghiade, M.** Contemporary drug development in heart failure: Call for Hemodynamically neutral therapies. // *Circulation: Heart Failure*, 8, 2015, № 4, p. 826-831. ISSN 1941-3289. DOI 10.1161/CIRCHEARTFAILURE.115.002271.
2412. **Vaduganathan, M., Fonarow, G.C., Greene, S.J., Devore, A.D., Albert, N.M., Duffy, C.I., Hill, C.L., Patterson, J.H., Spertus, J.A., Thomas, L.E., Williams, F.B., Hernandez, A.F., Butler, J.** Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. // *Journal of Cardiac Failure*, 28, 2022, № 2, p. 191-201. ISSN 1071-9164. DOI 10.1016/j.cardfail.2021.08.008.

2413. **Valentova, M., Von Haehling, S.** An overview of recent developments in the treatment of heart failure: Update from the ESC Congress 2013. // *Expert Opinion on Investigational Drugs*, 23, 2014, № 4, p. 573-578. ISSN 1354-3784. DOI 10.1517/13543784.2014.881799.
2414. **van der Wal, H.H., Grote Beverborg, N., van Veldhuisen, D.J., Voors, A.A., van der Meer, P.** Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. // *Expert Opinion on Pharmacotherapy*, 17, 2016, № 11, p. 1527-1538. ISSN 1465-6566. DOI 10.1080/14656566.2016.1197201.
2415. **van der Wal, H.H., van Deursen, V.M., van der Meer, P., Voors, A.A.** Comorbidities in heart failure. // *Handbook of Experimental Pharmacology*, 243, 2017, p. 35-66. ISSN 0171-2004. DOI 10.1007/164\_2017\_27.
2416. **Veenis, J.F., Brunner-La Rocca, H.-P., Linssen, G.C.M., Smeele, F.J.J., Wouters, N.T.A.E., Westendorp, P.H.M., Rademaker, P.C., Hemels, M.E.W., Rienstra, M., Hoes, A.W., Brugs, J.J., CHECK-HF investigators.** Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry. // *International Journal of Cardiology*, 308, 2020, p. 60-66. ISSN 0167-5273. DOI 10.1016/j.ijcard.2020.03.001.
2417. **Ventura, H.O., Mehra, M.R.** Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again? // *European Journal of Heart Failure*, 20, 2018, № 3, p. 501-503. ISSN 1388-9842. DOI 10.1002/ejhf.1094.
2418. **Vergaro, G., Januzzi, J.L., Jr., Cohen Solal, A., Aimò, A., Arzilli, C., Zytw, L., Valleggi, A., Giannoni, A., Prontera, C., Barison, A., Poletti, R., Gabutti, A., Mammini, C., Passino, C., Emdin, M.** NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. // *International Journal of Cardiology*, 271, 2018, p. 324-330. ISSN 0167-5273. DOI 10.1016/j.ijcard.2018.04.006.
2419. **Vijayakumar, S., Butler, J., Bakris, G.L.** Barriers to guideline mandated renin-angiotensin inhibitor use: Focus on hyperkalaemia. // *European Heart Journal, Supplement*, 21, 2019, p. A20-A27. ISSN 1520-765X. DOI 10.1093/eurheartj/suy030.
2420. **Vinogradova, N.G., Polyakov, D.S., Fomin, I.V.** Analysis of mortality in patients with heart failure after decompensation during long-term follow-up in specialized medical care and in real clinical practice. [Анализ смертности у пациентов с ХСН после декомпенсации при длительном наблюдении в условиях специализированной медицинской помощи и в реальной клинической практике.] // *Kardiologiya*, 60, 2020, № 4, p. 91-100. ISSN 0022-9040. DOI 10.18087/cardio.2020.4.n1014.
2421. **Vinogradova, N.G., Polyakov, D.S., Fomin, I.V., Solovyova, E.V.** Stability of chronic heart failure from the position of a doctor and a patient: In search of contact points. [Стабильность хронической сердечной недостаточности с позиции врача и пациента: ищем точки соприкосновения.] // *Kardiologiya*, 59, 2019, p. 33-40. ISSN 0022-9040. DOI 10.18087/cardio.2667.
2422. **Vinogradova, N.G., Tjurin, A.A., Fomin, I.V., Polyakov, D.S., Ivanchenko, E.Yu., Vaisberg, A.R., Shcherbinina, E.V., Krylova, A.N.** Patients after acute de-

compensation of Heart Failure: adherence to self-monitoring and treatment depending on the mode of outpatient monitoring. [Пациенты после острой декомпенсации сердечной недостаточности: приверженность к самоконтролю и лечению в зависимости от условий амбулаторного наблюдения]. // *Kardiologiia*, 60, 2020, № 5, p. 25-34. ISSN 0022-9040. DOI 10.18087/cardio.2020.5.n1022.

2423. **Vinter, N., Jensen, M., Skjøth, F., Larsen, T.B., Frost, L., Johnsen, S.P.** Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. // *Basic and Clinical Pharmacology and Toxicology*, 127, 2020, № 1, p. 30-38. ISSN 1742-7835. DOI 10.1111/bcpt.13392.
2424. **Von Knobelsdorff-Brenkenhoff, F., Schulz-Menger, J.** Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. // *Journal of Cardiovascular Magnetic Resonance*, 18, 2016, № 1, art. no. 225. ISSN 1097-6647. DOI 10.1186/s12968-016-0225-6.
2425. **Vukadinović, D., Lavall, D., Vukadinović, A.N., Pitt, B., Wagenpfeil, S., Böhm, M.** True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. // *American Heart Journal*, 188, 2017, p. 99-108. ISSN 0002-8703. DOI 10.1016/j.ahj.2017.03.011.
2426. **Wachter, R., Fonseca, A.F., Balas, B., Kap, E., Engelhard, J., Schlienger, R., Klebs, S., Wirta, S.B., Kostev, K.** Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. // *European Journal of Heart Failure*, 21, 2019, № 5, p. 588-597. ISSN 1388-9842. DOI 10.1002/ejhf.1465.
2427. **Wachter, R., Klebs, S., Balas, B., Kap, E., Engelhard, J., Schlienger, R., Bruce Wirta, S., Fonseca, A.F.** Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany. // *ESC Heart Failure*, 7, 2020, № 5, p. 2318-2330. ISSN 2055-5822. DOI 10.1002/ehf2.12768.
2428. **Wang, A.Y.-M.** Optimally managing hyperkalemia in patients with cardiorenal syndrome. // *Nephrology Dialysis Transplantation*, 34, 2019, p. III36-III44. ISSN 0931-0509. DOI 10.1093/ndt/gfz225.
2429. **Westphal, J.G., Bekfani, T., Schulze, P.C.** What's new in heart failure therapy 2018? // *Interactive Cardiovascular and Thoracic Surgery*, 27, 2018, № 6, p. 921-930. ISSN 1569-9293. DOI 10.1093/icvts/ivy282.
2430. **Wright, P., Thomas, M.** Pathophysiology and management of heart failure. // *Clinical Pharmacist*, 10, 2018, № 12, art. no. 20205742. ISSN 1758-9061. DOI 10.1211/CP.2018.20205742.
2431. **Xie, Y., She, F., Zhang, P.** Application status of guideline-directed medical therapy in HFrEF patients and improvement strategies. [射血分数减低型心力衰竭的GDMT应用现状与改善策略]. // *Chinese Journal of Cardiology*, 51, 2023, № 9, p. 1001-1005. ISSN 0253-3758. DOI 10.3760/cma.j.cn112148-20221203-00960.
2432. **Yan, C.L., Gallo, R.A., Vasquez Martinez, M., Rivera Rodriguez, B., Trujillo, L., Thakkar Rivera, N., Hoffman, J.E.** Safety and Efficacy of Traditional Heart

Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure. // *American Journal of Cardiology*, 204, 2023, p. 360-365. ISSN 0002-9149. DOI 10.1016/j.amjcard.2023.07.140.

2433. **Yandrapalli, S., Andries, G., Biswas, M., Khera, S.** Profile of sacubitril/valsartan in the treatment of heart failure: Patient selection and perspectives. // *Vascular Health and Risk Management*, 13, 2017, p. 369-382. ISSN 1176-6344. DOI 10.2147/VHRM.S114784.
2434. **Yandrapalli, S., Jolly, G., Biswas, M., Rochlani, Y., Harikrishnan, P., Aronow, W.S., Lanier, G.M.** Newer hormonal pharmacotherapies for heart failure. // *Expert Review of Endocrinology and Metabolism*, 13, 2018, № 1, p. 35-49. ISSN 1744-6651. DOI 10.1080/17446651.2018.1406799.
2435. **Yang, X.-D., Shi, J.-X., Liao, W.-C., Cui, J.-Y., Jin, Z., Liu, D.-L., Chen, X.-L., Li, R., Wu, H., Luo, C., Chu, Q., Li, R., Wu, W., Qing, L.** Intervention of Compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome: A multi-center, randomized, double-blind, controlled trial. // *Medicine (United States)*, 101, 2022, № 50, p. E32311. ISSN 0025-7974. DOI 10.1097/MD.00000000000032311.
2436. **Yang, Y., Guo, S., Huang, Z., Deng, C., Chen, L., Zhou, G., Jian, Z., He, R., Huang, Z., Yao, Y., Lu, J., Hua, Z., Huang, Y.** Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation. // *Cardiology Research and Practice*, 2020, art. no. 3059864. ISSN 2090-8016. DOI 10.1155/2020/3059864.
2437. **Yassin, H.T., Saaed, H.K., Obeid, K.A.** Pharmacist collaborative care in heart failure management in Kirkuk city- Iraq. // *Systematic Reviews in Pharmacy*, 11, 2020, № 3, p. 309-319. ISSN 0975-8453. DOI 10.5530/srp.2020.3.36.
2438. **Yin, W.-H.** ARNI: A new paradigm for the treatment of heart failure in Taiwan? // *Acta Cardiologica Sinica*, 32, 2016, № 4, p. 397-399. ISSN 1011-6842. DOI 10.6515/ACS20160316A.
2439. **Yohannes, A.M., Chen, W., Moga, A.M., Leroi, I., Connolly, M.J.** Cognitive Impairment in Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. // *Journal of the American Medical Directors Association*, 18, 2017, № 5, p. 451.e1-451.e11. ISSN 1525-8610. DOI 10.1016/j.jamda.2017.01.014.
2440. **Yu, L.-Y., Liu, L.-Y., Tan, D.-H., Tian, H.-F., Zheng, P.** Torasemide-induced IgA vasculitis in a patient with heart failure. // *Journal of Geriatric Cardiology*, 20, 2023, № 7, p. 548-550. ISSN 1671-5411. DOI 10.26599/1671-5411.2023.07.004.
2441. **Yu, S.M., Lyasnikova, E.A., Yurchenko, A.V., Trukshina, M.A., Kuular, A.A., Galenko, V.L., Ovanov, S.G., Duplyakov, D.V., Shlyakhto, E.V.** Results of 3 years work of the Russian hospital register of chronic heart failure (Russian hoSpital Heart Failure Registry - RUS-HFR): Relationship between management and outcomes in patients with chronic heart failure. [Результаты 3 лет работы Российского госпитального регистра хронической сердечной недостаточности (Russian hoSpital Heart Failure Registry - RUS-HFR): взаимосвязь менеджмента и исходов у

больных хронической сердечной недостаточностью.] // *Kardiologiya*, 58, 2018, p. 9-19. ISSN 0022-9040. DOI 10.18087/cardio.2483.

2442. **Zhang, C., Cai, G.** Compliance and influencing factors of renin - angiotensin system inhibitors in the real - world application of chronic kidney disease. [肾素-血管紧张素系统抑制剂在慢性肾脏病中应用的依从性与影响因素]. // *Chinese Journal of Nephrology*, 36, 2020, № 10, p. 812-816. ISSN 1001-7097. DOI 10.3760/cma.j.cn441217-20200508-00143.
2443. **Zhang, Z., Wang, C., Tu, T., Lin, Q., Zhou, J., Huang, Y., Wu, K., Zhang, Z., Zuo, W., Liu, N., Xiao, Y., Liu, Q.** Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits. // *American Journal of Cardiovascular Drugs*, 2024. ISSN 1175-3277. DOI 10.1007/s40256-024-00646-4.
2444. **Zhao, D., Wei, W., Peng, D., Xiang, Z., Ayijiaken, K., Rong, S.** Worsening renal function and the plasma B-type natriuretic peptide in prognosis of patients with acute heart failure. [肾功能恶化程度和血浆 B 型利钠肽下降对急性心力衰竭患者预后的影响]. // *Clinical Medicine of China*, 39, 2023, № 4, p. 260-272. ISSN 1008-6315. DOI 10.3760/cma.j.cn101721-20221206-000573.
2445. **Zhu, T., Lei, M., Wang, Z., Zhang, R., Zhang, Y., Jin, W., Yu, C., Huang, C.L.H., Liu, D., Zheng, W., Liu, Y., Quan, X., Kong, L., Liang, S., Zhang, X.** A Comparative Study of Systolic and Diastolic Mechanical Synchrony in Canine, Primate, and Healthy and Failing Human Hearts. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 750067. ISSN 2297-055X. DOI 10.3389/fcvm.2021.750067.
2446. **Zugck, C., Martinka, P., Stöckl, G.** Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice. // *Advances in Therapy*, 31, 2014, № 9, p. 961-974. ISSN 0741-238X. DOI 10.1007/s12325-014-0147-3.
2447. **Zugck, C., Martinka, P., Stöckl, G., Tschöpe, C., Störk, S.** Is heart rate adequately controlled in chronic systolic heart failure patients in Germany? Results from a nationwide survey (INDICATE). [Ist die Herzfrequenz bei Herzinsuffizienz-Patienten in Deutschland ausreichend kontrolliert?: Ergebnisse einer nationalen Beobachtungsstudie (INDICATE)]. // *Deutsche Medizinische Wochenschrift*, 140, 2015, № 5, p. e48-e55. ISSN 0012-0472. DOI 10.1055/s-0041-100608.
2448. **Zugck, C., Störk, S., Stöckl, G., on behalf of the, RELIf-CHF study investigators.** Long-term treatment with ivabradine over 12 months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations. // *International Journal of Cardiology*, 240, 2017, p. 258-264. ISSN 0167-5273. DOI 10.1016/j.ijcard.2017.03.131.

## **2012**

Kichukov K., Dimitrov Ch., Nikolova L., **Petrov I.**, Tokmakova M. Non-Pharmacological Method in The treatment of Resistant Hypertension *Folia Medica*, 2012, volume 54, 5-11.



**Cited by:**

2449. **Dassanayake, S., Sole, G., Wilkins, G., Skinner, M.** Effect of exercise and physical activity on blood pressure in adults with resistant hypertension: a protocol for a systematic review. // *Physical Therapy Reviews*, 25, 2020, № 2, p. 128-134. ISSN 1083-3196. DOI 10.1080/10833196.2020.1728986.
2450. **Dassanayake, S., Sole, G., Wilkins, G., Skinner, M.** Exercise: a therapeutic modality to treat blood pressure in resistant hypertension. // *Physical Therapy Reviews*, 25, 2020, № 3, p. 149-158. ISSN 1083-3196. DOI 10.1080/10833196.2020.1733781.

Grozdinski L., **Petrov I.**, Iloska M., Chronic cerebrospinal venous insufficiency in amyotrophic lateral sclerosis. *Gazzetta Medica Italiana*, 2012, vol. 171, №5, 605-611.

**Cited by:**

2451. **Simka, M.** What is the relationship between chronic cerebrospinal venous insufficiency and multiple sclerosis? // *Reviews in Vascular Medicine*, 1, 2013, № 4, p. 66-70. ISSN 2212-0211. DOI 10.1016/j.rvm.2013.08.001.

**Petrov I.**, Grozdinski L. Kaninski G., Iliev N., Iloska m., Radev A. Safety Profile of Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency in Patient With Multiple Sclerosis. *Journal Endovascular Therapy*, 2011; 18, 314-323.

**Cited by:**

2452. **Arata, M., Debarge, P.** Transvascular autonomic modulation, initial assessment of safety. // *Acta Phlebologica*, 15, 2014, № 1, p. 19-23. ISSN 1593-232X.
2453. **Arata, M., Sternberg, Z.** Neuroendocrine Responses to Transvascular Autonomic Modulation: A Modified Balloon Angioplasty in Multiple Sclerosis Patients. // *Hormone and Metabolic Research*, 48, 2015, № 2, p. 123-129. ISSN 0018-5043. DOI 10.1055/s-0035-1547235.
2454. **Arata, M., Sternberg, Z.** Transvascular autonomic modulation: A modified balloon angioplasty technique for the treatment of autonomic dysfunction in multiple sclerosis patients. // *Journal of Endovascular Therapy*, 21, 2014, № 3, p. 417-428. ISSN 1526-6028. DOI 10.1583/13-4605MR.1.
2455. **Beggs, C.B., Giaquinta, A., Veroux, M., De Marco, E., Mociskyte, D., Veroux, P.** Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis. // *PLoS ONE*, 13, 2018, № 1, art. no. e0191534. ISSN 1932-6203. DOI 10.1371/journal.pone.0191534.
2456. **Chen, H., Wu, J., Dai, Y., Zhuang, H., Zhan, T., Guo, P.** Endovascular angioplasty in treatment of chronic cerebrospinal venous insufficiency. [腔内血管成形术治疗慢性脑脊髓静脉机能不全]. // *Chinese Journal of Interventional Imaging and Therapy*, 15, 2018, № 9, p. 526-529. ISSN 1672-8475. DOI 10.13929/j.1672-8475.201712047.

2457. **Ciciarello, F., Mandolesi, S., Galeandro, A.I., Marceca, A., Rossi, M., Fedele, F., Gesualdo, M., Cortese, F., Zito, A., Federico, F., Livrea, P., Trojano, M., Scicchitano, P., Ciccone, M.M.** Age-related vascular differences among patients suffering from multiple sclerosis. // *Current Neurovascular Research*, 11, 2014, № 1, p. 23-30. ISSN 1567-2026. DOI 10.2174/1567202610666131125000506.
2458. **Dake, M.D.** Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: History and Background. // *Techniques in Vascular and Interventional Radiology*, 15, 2012, № 2, p. 94-100. ISSN 1089-2516. DOI 10.1053/j.tvir.2012.02.002.
2459. **Dake, M.D., Zivadinov, R., Mark Haacke, E.** Chronic cerebrospinal venous insufficiency in multiple sclerosis: A historical perspective. // *Functional Neurology*, 26, 2011, № 4, p. 181-195. ISSN 0393-5264.
2460. **Denislic, M., Milosevic, Z., Zorc, M., Ravnik, I.Z.D., Mendiz, O.** Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: Possible improvement by venous angioplasty. Results of a prospective study. // *Phlebology*, 28, 2013, № 7, p. 353-360. ISSN 0268-3555. DOI 10.1258/phleb.2012.012065.
2461. **Diaconu, C.I., Conway, D., Fox, R.J., Rae-Grant, A.** Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: Controversy and reality. // *Current Treatment Options in Cardiovascular Medicine*, 14, 2012, № 2, p. 203-214. ISSN 1092-8464. DOI 10.1007/s11936-012-0168-7.
2462. **Doepp, F., Paul, F., Valdueza, J.M., Schreiber, S.J.** Is chronic cerebrospinal venous insufficiency a cause of multiple sclerosis? [Chronisch venöse Insuffizienz als Ursache der Multiplen Sklerose?] // *Aktuelle Neurologie*, 38, 2011, № 7, p. 332-338. ISSN 0302-4350. DOI 10.1055/s-0031-1287850.
2463. **Dolic, K., Siddiqui, A.H., Karmon, Y., Marr, K., Zivadinov, R.** The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants. // *BMC Medicine*, 11, 2013, № 1, art. no. 155. ISSN 1741-7015. DOI 10.1186/1741-7015-11-155.
2464. **Dolic, K., Zivadinov, R.** The role of diagnostic imaging techniques for detection of extracranial venous system abnormalities associated with central nervous system disorders. – In: *Neurovascular Imaging: From Basics to Advanced Concepts*, 2016, p. 953-979. ISBN 9781461490296; 9781461490289. DOI 10.1007/978-1-4614-9029-6\_12.
2465. **Ghezzi, A., Annovazzi, P., Amato, M.P., Capello, E., Cavalla, P., Cocco, E., Falcini, M., Gallo, A., Patti, F., Perini, P., Rodegher, M.E., Rovaris, M., Rottoli, M.R., Comi, G.** Adverse events after endovascular treatment of chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis. // *Multiple Sclerosis Journal*, 19, 2013, № 7, p. 961-963. ISSN 1352-4585. DOI 10.1177/1352458513475491.
2466. **Ghezzi, A., Annovazzi, P., Cocco, E., Coarelli, G., Lugaresi, A., Rovaris, M., Patti, F., Capello, E., Rodegher, M.E., Moiola, L., Malucchi, S., Salemi, G., De Rossi, N., Provinciali, L., Perini, P., Bergamaschi, R., Scarpini, E., Lus, G., Gallo, A., Tola, M.R., Amato, M.P., Rottoli, M.R., Bianchi, A., Comi, G.** Endovascular treatment of CCSVI in patients with multiple sclerosis: Clinical

outcome of 462 cases. // *Neurological Sciences*, 34, 2013, № 9, p. 1633-1637. ISSN 1590-1874. DOI 10.1007/s10072-013-1300-5.

2467. **Giaquinta, A., Beggs, C.B., Veroux, M., Cappellani, A., De Marco, E., Veroux, P.** Catheter venous angiography for the evaluation of cerebral venous outflow. // *Italian Journal of Vascular and Endovascular Surgery*, 25, 2018, № 3, p. 273-276. ISSN 1824-4777. DOI 10.23736/S1824-4777.18.01354-2.
2468. **Giaquinta, A., Beggs, C.B., Veroux, M., De Marco, E., Sanzone, A., Virgilio, C., Veroux, P.** Factors influencing the hemodynamic response to balloon angioplasty in the treatment of outflow anomalies of internal jugular veins. // *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, 5, 2017, № 6, p. 777-788. ISSN 2213-333X. DOI 10.1016/j.jvsv.2017.06.015.
2469. **Hampson, C.O., Soares, G.M., Jaffan, A.A.** Reported Outcomes After the Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency. // *Techniques in Vascular and Interventional Radiology*, 15, 2012, № 2, p. 144-149. ISSN 1089-2516. DOI 10.1053/j.tvir.2012.02.007.
2470. **Hoffer, E.K.** Interventional radiology in the treatment of chronic cerebrospinal venous insufficiency. // *Journal of Radiology Nursing*, 31, 2012, № 1, p. 3-12. ISSN 1546-0843. DOI 10.1016/j.jradnu.2011.10.003.
2471. ISSN 1051-0443. DOI 10.1016/j.jvir.2014.07.024.
2472. **Karmon, Y., Zivadinov, R., Weinstock-Guttman, B., Marr, K., Valnarov, V., Dolic, K., Kennedy, C.L., Hojnacki, D., Carl, E.M., Hagemeier, J., Hopkins, L.N., Levy, E.I., Siddiqui, A.H.** Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. // *Journal of Vascular and Interventional Radiology*, 24, 2013, № 10, p. 1487-1498.e1. ISSN 1051-0443. DOI 10.1016/j.jvir.2013.06.012.
2473. **Kazibudzuki, M., Latacz, P., Ludyga, T., Simka, M.** Efficacy and safety of cutting balloons for the treatment of obstructive lesions in the internal jugular veins. // *Journal of Cardiovascular Surgery*, 57, 2016, № 4, p. 514-518. ISSN 0021-9509.
2474. **Lugli, M., Morelli, M., Guerzoni, S., Maletti, O.** The hypothesis of pathophysiological correlation between chronic cerebrospinal venous insufficiency and multiple sclerosis: Rationale of treatment. // *Phlebology*, 27, 2012, Suppl. № 1, p. 178-186. ISSN 0268-3555. DOI 10.1258/phleb.2012.012S24.
2475. **Lupattelli, T., Bellagamba, G., Righi, E., Di Donna, V., Flaishman, I., Fazioli, R., Garaci, F., Onorati, P.** Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. // *Journal of Vascular Surgery*, 58, 2013, № 6, p. 1609-1618. ISSN 0741-5214. DOI 10.1016/j.jvs.2013.05.108.
2476. **Mayer, C.A., Ziemann, U.** CCSVI: Is blinding the key? // *European Journal of Vascular and Endovascular Surgery*, 43, 2012, № 1, p. 124-125. ISSN 1078-5884. DOI 10.1016/j.ejvs.2011.09.014.
2477. **McAuliffe, W., Kermode, A.G.** Mystery of chronic cerebrospinal venous insufficiency: Identical venographic and ultrasound findings in patients with MS and

controls. // *American Journal of Neuroradiology*, 34, 2013, № 7, p. 1370-1374. ISSN 0195-6108. DOI 10.3174/ajnr.A3390.

2478. **Mehrpour, M., Najimi, N., Fereshtehnejad, S.-M., Safa, F.N., Mirzaeizadeh, S., Motamed, M.R., Nabavi, M., Sahraeian, M.A.** Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: A case-control study from Iran. // *Perspectives in Medicine*, 2012, № 1-12, p. 375-380. ISSN 2211-968X. DOI 10.1016/j.permed.2012.02.037.
2479. **Morovic, S., Zamboni, P.** Ccsvg is associated with multiple sclerosis. // *Neurological Research*, 34, 2012, № 8, p. 770-779. ISSN 0161-6412. DOI 10.1179/1743132812Y.00000000035.
2480. **Napoli, V., Berchiolli, R., Carboncini, M.C., Sartucci, F., Marconi, M., Bocci, T., Perrone, O., Mannoni, N., Congestri, C., Benedetti, R., Morganti, R., Caramella, D., Cioni, R., Ferrari, M.** Percutaneous Venous Angioplasty in Patients with Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: A Randomized Wait List Control Study. // *Annals of Vascular Surgery*, 62, 2020, p. 275-286. ISSN 0890-5096. DOI 10.1016/j.avsg.2019.05.018.
2481. **Onida, S., Davies, A.H.** The chronic cerebrospinal venous insufficiency debate. // *European Journal of Vascular and Endovascular Surgery*, 48, 2014, № 1, p. 1-3. ISSN 1078-5884. DOI 10.1016/j.ejvs.2014.01.005.
2482. **Radak, D., Kolar, J., Sagic, D., Ilijevski, N., Tanaskovic, S., Aleksic, N., Marinkovic, J., Mitrasinovic, A., Radak, S., Babic, S., Matic, P., Vlajinac, H.** Percutaneous angioplasty of internal jugular and azygous veins in patients with chronic cerebrospinal venous insufficiency and multiple sclerosis: Early and mid-term results. // *Phlebology*, 29, 2014, № 6, p. 367-375. ISSN 0268-3555. DOI 10.1177/0268355513481766.
2483. **Radak, D., Tanaskovic, S., Antonic, Z., Kolar, J., Aleksic, N., Ilijevski, N.** Compressive syndrome of internal jugular veins in multiple sclerosis: Does it matter? // *Phlebology*, 29, 2014, № 2, p. 98-104. ISSN 0268-3555. DOI 10.1258/phleb.2012.012037
2484. **Reid, D.B.** Significance of the internal jugular vein in the treatment of cerebrovascular insufficiency. // *Journal of Endovascular Therapy*, 18, 2011, № 3, p. 324-325. ISSN 1526-6028. DOI 10.1583/11-3400C1.1.
2485. **Scerrati, A., Menegatti, E., Zamboni, M., Malagoni, A.M., Tessari, M., Galeotti, R., Zamboni, P.** Internal jugular vein thrombosis: Etiology, symptomatology, diagnosis and current treatment. // *Diagnostics*, 11, 2021, № 2, art. no. 378. ISSN 2075-4418. DOI 10.3390/diagnostics11020378.
2486. **Siddiqui, A.H., Zivadinov, R., Benedict, R.H.B., Karmon, Y., Yu, J., Hartney, M.L., Marr, K.L., Valnarov, V., Kennedy, C.L., Ramanathan, M., Ramasamy, D.P., Dolic, K., Hojnacki, D.W., Carl, E., Levy, E.I., Hopkins, L.N., Weinstock-Guttman, B.** Prospective randomized trial of venous angioplasty in MS (PREMiSe). // *Neurology*, 83, 2014, № 5, p. 441-449. ISSN 0028-3878. DOI 10.1212/WNL.0000000000000638.

2487. **Simka, M.** An overview of randomized controlled trials on endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients. // *Phlebologie*, 50, 2021, № 1, p. 76-80. ISSN 0939-978X. DOI 10.1055/a-1061-3205.
2488. **Simka, M.** Chronic cerebrospinal venous insufficiency: State of the art and research challenges. // *Phlebolympology*, 19, 2012, № 3, p. 105-160. ISSN 1286-0107.
2489. **Simka, M.** Safety of endovascular treatment for CCSVI and future perspectives. // *Journal of Endovascular Therapy*, 18, 2011, № 3, p. 326-327. ISSN 1526-6028. DOI 10.1583/11-3400C2.1.
2490. **Simka, M.** What is the relationship between chronic cerebrospinal venous insufficiency and multiple sclerosis? // *Reviews in Vascular Medicine*, 1, 2013, № 4, p. 66-70. ISSN 2212-0211. DOI 10.1016/j.rvm.2013.08.001.
2491. **Simka, M., Hubbard, D., Siddiqui, A.H., Dake, M.D., Sclafani, S.J.A., Al-Omari, M., Eisele, C.G., Haskal, Z.J., Ludyga, T., Milošević, Z.V., Sievert, H., Stehling, M.K., Zapf, S., Zorc, M.** Catheter venography for the assessment of internal jugular veins and azygous vein: Position statement by expert panel of the international society for neuro vascular disease. [Kathetervenenographie zur Beurteilung der Vena jugularis interna und der Vena azygos: Positionspapier von Experten der International Society for Neurovascular Diseases]. // *Vasa - Journal of Vascular Diseases*, 42, 2013, № 3, p. 168-176. ISSN 0301-1526. DOI 10.1024/0301-1526/a000265.
2492. **Simka, M., Ludyga, T., Latacz, P., Kazibudzki, M.** Diagnostic accuracy of current sonographic criteria for the detection of outflow abnormalities in the internal jugular veins. // *Phlebology*, 28, 2013, № 6, p. 285-292. ISSN 0268-3555. DOI 10.1258/phleb.2012.011125.
2493. **Simka, M., Ludyga, T., Latacz, P., Kazibudzki, M., Majewski, E., Zaniewski, M.** Chronic cerebrospinal venous insufficiency is unlikely to be a direct trigger of multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 2, 2013, № 4, p. 334-339. ISSN 2211-0348. DOI 10.1016/j.msard.2013.02.004.
2494. **Sternberg, Z.** Promoting sympathovagal balance in multiple sclerosis; pharmacological, non-pharmacological, and surgical strategies. // *Autoimmunity Reviews*, 15, 2016, № 2, p. 113-123. ISSN 1568-9972. DOI 10.1016/j.autrev.2015.04.012.
2495. **Sternberg, Z., Grewal, P., Cen, S., DeBarge-Igoe, F., Yu, J., Arata, M.** Blood pressure normalization post-jugular venous balloon angioplasty. // *Phlebology*, 30, 2015, № 4, p. 280-287. ISSN 0268-3555. DOI: 10.1177/0268355513512824.
2496. **Tsivgoulis, G., Faissner, S., Voumvourakis, K., Katsanos, A.H., Triantafyllou, N., Grigoriadis, N., Gold, R., Krogias, C.** "Liberation treatment" for chronic cerebrospinal venous insufficiency in multiple sclerosis: The truth will set you free. // *Brain and Behavior*, 5, 2015, № 1, p. 3-12. ISSN 2162-3279. DOI 10.1002/brb3.297.
2497. **Vachon, J.P., Siskin, G.P.** Jugular interventions for multiple sclerosis and chronic cerebrospinal venous insufficiency. – In: *Endovascular Interventions: A Case-Based Approach*, 2014, p. 979-991. ISBN 9781461473121; 9781461473114. DOI 10.1007/978-1-4614-7312-1\_78.



2498. **Valdúez, J.M., Doepp, F., Schreiber, S.J., Van Oosten, B.W., Schmierer, K., Paul, F., Wattjes, M.P.** What went wrong the flawed concept of cerebrospinal venous insufficiency. // *Journal of Cerebral Blood Flow and Metabolism*, 33, 2013, № 5, p. 657-668. ISSN 0271-678X. DOI 10.1038/jcbfm.2013.31.
2499. **Varatharajan, L., Lane, T.R.A., Thapar, A., Franklin, I.J., Davies, A.H.** Complications and safety of jugular and azygous angioplasty in CCSVI patients with multiple sclerosis. // *Interventional Cardiology (London)*, 4, 2012, № 4, p. 473-479. ISSN 1755-5302. DOI 10.2217/ica.12.35.
2500. **Zamboni, P., Bertolotto, A., Boldrini, P., Cenni, P., D'Alessandro, R., D'Amico, R., Del Sette, M., Galeotti, R., Galimberti, S., Liberati, A., Massacesi, L., Papini, D., Salvi, F., Simi, S., Stella, A., Tesio, L., Valsecchi, M.G., Filippini, G.** Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): Study protocol for a randomized controlled trial. // *Trials*, 13, 2012, art. no. 183. ISSN 1745-6215. DOI 10.1186/1745-6215-13-183.
2501. **Zamboni, P., Morović, S.** Influence of chronic cerebrospinal venous insufficiency on demyelinating diseases. // *Periodicum Biologorum*, 114, 2012, № 3, p. 387-392. ISSN 0031-5362.
2502. **Zamboni, P., Morovic, S., Menegatti, E., Viselner, G., Nicolaidis, A.N., Neuhardt, D., Griffin, M.B., Setacci, C., Cavezzi, A., Lee, B.B., Thibault, P., Andreozzi, G., Al-Omari, M., Bastianello, S., Beggs, C.B., Cecconi, P., Demarin, V., Franceschi, C., Galassi, A., Haacke, E.M., Lagace, A., Liasis, N., Ludyga, T., Lugli, M., Maleti, O., Mancini, M., Marinoni, M., Marr, K., McDonald, S., Morrison, N., Salvi, F., Sclafani, S., Scuderi, A., Shepherd, S., Simka, M., Stella, A., Zivadinov, R.** Screening for chronic cerebrospinal venous insufficiency (CCSVI) using ultrasound - Recommendations for a protocol. // *International Angiology*, 30, 2011, № 6, p. 571-597. ISSN 0392-9590.
2503. **Zaniewski, M., Simka, M.** Biophysics of venous return from the brain from the perspective of the pathophysiology of chronic cerebrospinal venous insufficiency. // *Reviews on Recent Clinical Trials*, 7, 2012, № 2, p. 88-92. ISSN 1574-8871. DOI 10.2174/157488712800100288.
2504. **Zhou, D., Ding, J.-Y., Ya, J.-Y., Pan, L.-Q., Yan, F., Yang, Q., Ding, Y.-C., Ji, X.-M., Meng, R.** Understanding jugular venous outflow disturbance. // *CNS Neuroscience and Therapeutics*, 24, 2018, № 6, p. 473-482. ISSN 1755-5930. DOI 10.1111/cns.12859.
2505. **Zivadinov, R., Bastianello, S., Dake, M.D., Ferral, H., Haacke, E.M., Haskal, Z.J., Hubbard, D., Liasis, N., Mandato, K., Sclafani, S., Siddiqui, A.H., Simka, M., Zamboni, P.** Recommendations for multimodal noninvasive and invasive screening for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency: A position statement of the international society for neurovascular disease. // *Journal of Vascular and Interventional Radiology*, 25, 2014, № 11, p. 1785-1794.e17.
2506. **Zivadinov, R., Chung, C.-P.** Potential involvement of the extracranial venous system in central nervous system disorders and aging. // *BMC Medicine*, 11, 2013, № 1, art. no. 260. ISSN 1741-7015. DOI 10.1186/1741-7015-11-260.

2507. **Zivadinov, R., Magnano, C., Galeotti, R., Schirda, C., Menegatti, E., Weinstock-Guttman, B., Marr, K., Bartolomei, I., Hagemeier, J., Maria Malagoni, A., Hojnacki, D., Kennedy, C., Carl, E., Beggs, C., Salvi, F., Zamboni, P.** Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: A case-control study. // *Journal of Vascular and Interventional Radiology*, 24, 2013, № 6, p. 829-838. ISSN 1051-0443. DOI 10.1016/j.jvir.2013.01.490.
2508. **Zivadinov, R., Ramanathan, M., Dolic, K., Marr, K., Karmon, Y., Siddiqui, A.H., Benedict, R.H.B., Weinstock-Guttman, B.** Chronic cerebrospinal venous insufficiency in multiple sclerosis: Diagnostic, pathogenetic, clinical and treatment perspectives. // *Expert Review of Neurotherapeutics*, 11, 2011, № 9, p. 1277-1294. ISSN 1473-7175. DOI 10.1586/ern.11.117.
2509. **Zivadinov, R., Weinstock-Guttman, B.** Role of venoplasty for treatment of multiple sclerosis: Value of open-label studies and surrogate treatment outcomes. // *Journal of Vascular and Interventional Radiology*, 23, 2012, № 10, p. 1308-1310. ISSN 1051-0443. DOI 10.1016/j.jvir.2012.08.009.

## **2011**

Nikolov D, Grigorova V, **Petrov I**, Ivanov V. Emergency surgical intervention after unsuccessful percutaneous transluminal angioplasty and stenting of aortic coarctation. *Interact Cardiovasc Thorac Surg*. 2011 Jul;13(1):98-100. DOI 10.1510/icvts.2010.265264. Epub 2011 Apr 27. PubMed PMID: 21525030.

### **Cited by:**

2510. **Faim, D.R.O., Silva, P.V., Francisco, A., Pires, A.** Transcatheter management of proximal stent migration in coarctation of the aorta. // *Annals of Pediatric Cardiology*, 15, 2022, № 2, p. 222-224. ISSN 0974-2069. DOI 10.4103/apc.apc\_191\_21.
2511. **Sachithanandan, A., Badmanaban, B.** Ecomment: Trans-pericardial extra-anatomic aortic bypass for coarctation of the aorta. // *Interactive Cardiovascular and Thoracic Surgery*, 13, 2011, № 1, p. 100. ISSN 1569-9293. DOI 10.1510/icvts.2010.265264A.
2512. **Sevta, P., Agarwal, S., Khante, V., Satsangi, D.K., Banerjee, A.** Dissection of thoraco-abdominal aorta following stenting for coarctation. // *Indian Journal of Thoracic and Cardiovascular Surgery*, 27, 2011, № 4, p. 188-189. ISSN 0970-9134. DOI 10.1007/s12055-011-0117-1.

## **2009**

**Petrov I.** Dimitrov Ch. Closing of a Right Ventricle Perforation With a Vascular Closure Device. *Catheterization Cardiovascular Interventions*, 2009, 74, 247-250.

### **Cited by:**

2513. **Acharya, D., Nagaraj, H., Misra, V.K.** Transcatheter closure of left ventricular pseudoaneurysm. // *Journal of Invasive Cardiology*, 24, 2012, № 6, p. E111-E114. ISSN 1042-3931.
2514. **Arı, H., Karakuş, A., Arı, S., Çamcı, S., Melek, M.** An alternative treatment for iatrogenic right ventricular puncture in primary percutaneous intervention. [Primer perkütan girişim sırasında iyatrojenik sağ ventrikül delinmesinin alternatif tedavisi]. // *Türk Kardiyoloji Dernegi Arsivi*, 45, 2017, № 7, p. 638-640. ISSN 1016-5169. DOI 10.5543/tkda.2017.72823.
2515. **Bakos, Z., Harnek, J., Jenkins, N., Johnson, T., Strange, J., Asimakopoulos, G., Baumbach, A., Kliger, C., Ruiz, C.E.** How should i treat an accidentally misplaced 8 Fr drainage catheter in the right ventricle? // *EuroIntervention*, 10, 2014, № 6. ISSN 1774-024X. DOI 10.4244/eijv10i61a131.
2516. **Barbash, I.M., Saikus, C.E., Ratnayaka, K., Faranesh, A.Z., Kocaturk, O., Wu, V., Bell, J.A., Schenke, W.H., Raman, V.K., Lederman, R.J.** Limitations of closing percutaneous transthoracic ventricular access ports using a commercial collagen vascular closure device. // *Catheterization and Cardiovascular Interventions*, 77, 2011, № 7, p. 1079-1085. ISSN 1522-1946. DOI 10.1002/ccd.22941.
2517. **Celik, M., Yilmaz, Y., Kahyaoglu, M., Kup, A., Bilen, Y., Zehir, R.** Right ventricular free wall perforation during pericardiocentesis, and an inappropriate device selection for percutaneous treatment. // *Journal of Cardiac Surgery*, 36, 2021, № 1, p. 336-338. ISSN 0886-0440. DOI 10.1111/jocs.15146.
2518. **Coughlan, J.J., Szirt, R., Pearson, I., Cosgrave, J.** Percutaneous closure of an iatrogenic right ventricular perforation with an angio-seal vascular closure device: A case report. // *European Heart Journal - Case Reports*, 4, 2020, № 5, p. 1-4. ISSN 2514-2119. DOI 10.1093/EHJCR/YTAA258.
2519. **Frenzel, F., Fries, P., Shayesteh-Kheslat, R., Buecker, A., Massmann, A.** Single Angio-Seal vascular closure device for transfemoral access exceeding 8F. // *Journal of Cardiology*, 76, 2020, № 2, p. 211-216. ISSN 0914-5087. DOI 10.1016/j.jjcc.2020.02.024.
2520. **Ghanem, R., Tabrizi, N.S., Shapeton, A.D., Musuku, S.R.** Iatrogenic Left Atrial Puncture Treated with a Septal Occluder Device. // *Journal of Cardiothoracic and Vascular Anesthesia*, 38, 2024, № 1, p. 239-242. ISSN 1053-0770. DOI 10.1053/j.jvca.2023.10.012.
2521. **Krishnasamy, V.P., Hagar, M.J., Scher, D.J., Sanogo, M.L., Gabriel, G.E., Sarin, S.N.** Vascular Closure Devices: Technical Tips, Complications, and Management. // *Techniques in Vascular and Interventional Radiology*, 18, 2015, № 2, p. 100-112. ISSN 1089-2516. DOI 10.1053/j.tvir.2015.04.008.
2522. **Maisch, B., Ristić, A.D., Pankuweit, S., Seferovic, P.** Percutaneous Therapy in Pericardial Diseases. // *Cardiology Clinics*, 35, 2017, № 4, p. 567-588. ISSN 0733-8651. DOI 10.1016/j.ccl.2017.07.010.
2523. **Mendes, G.S., De Araújo Gonçalves, P., Madeira, S., Oliveira, P.** Percutaneous closure of accidental left atrium puncture: A case report. // *European Heart Journal*

2524. **Patel, R., Muller-Hulsbeck, S., Morgan, R., Uberoi, R.** Vascular Closure Devices in Interventional Radiology Practice. // *CardioVascular and Interventional Radiology*, 38, 2015, № 4, p. 781-793. ISSN 0174-1551. DOI 10.1007/s00270-015-1116-1.
2525. **Picone, F., Contro, A., Nguyen, H.Q., Gasparini, C., Mansueto, G.** Management of Percutaneous Access to Portal Vein: A Initial Experience of Hemostasis by Vascular Closure Device (AngioSeal). // *CardioVascular and Interventional Radiology*, 46, 2023, № 10, p. 1422-1424. ISSN 0174-1551. DOI 10.1007/s00270-023-03522-x.
2526. **Pourdjabbar, A., Hibbert, B., Hendry, P., Labinaz, M.** Angio-Seal closure of an iatrogenic right ventricular perforation. // *Clinical Research in Cardiology*, 103, 2014, № 7, p. 577-579. ISSN 1861-0684. DOI 10.1007/s00392-014-0693-3.
2527. **Provaznik, Z., Holzamer, A., Camboni, D., Rupprecht, L., Resch, M., Wittmann, S., Schmid, C., Floerchinger, B.** Perforation of myocardial wall and great vessels after cardiovascular interventions-a 5-year analysis. // *Journal of Thoracic Disease*, 9, 2017, № 12, p. 5288-5294. ISSN 2072-1439. DOI 10.21037/jtd.2017.10.113.
2528. **Ratnayaka, K., Saikus, C.E., Faranesh, A.Z., Bell, J.A., Barbash, I.M., Kocaturk, O., Reyes, C.A., Sonmez, M., Schenke, W.H., Wright, V.J., Hansen, M.S., Slack, M.C., Lederman, R.J.** Closed-chest transthoracic magnetic resonance imaging-guided ventricular septal defect closure in swine. // *JACC: Cardiovascular Interventions*, 4, 2011, № 12, p. 1326-1334. ISSN 1936-8798. DOI 10.1016/j.jcin.2011.09.012.
2529. **Saxena, A., Karmakar, S., Narang, R.** Successful Percutaneous Device Closure of Right Ventricular Perforation During Pericardiocentesis. // *JACC: Cardiovascular Interventions*, 9, 2016, № 22, p. e221-e222. ISSN 1936-8798. DOI 10.1016/j.jcin.2016.09.031.
2530. **Vijayvergiya, R., Shrimanth, Y.S., Kasinadhuni, G., Singh, H., Sharma, A., Bhargav, A., Kaur, N.** Percutaneous suture based device closure of an inadvertent right ventricle perforation following pericardiocentesis. // *Anatolian Journal of Cardiology*, 25, 2021, № 11, p. 829-831. ISSN 2149-2263. DOI 10.5152/AnatolJCardiol.2021.49.
2531. **Vyas, R., El-Hajj, S.** Percutaneous Closure of an Apical Left Ventricular Pseudoaneurysm. // *Cardiovascular Revascularization Medicine*, 53, 2023, p. S159-S162. ISSN 1553-8389. DOI 10.1016/j.carrev.2022.07.012.
2532. **Zhao, Y., Lin, Y., Hong, Z., Lai, B., Lian, L., Chen, L., Xie, Q., Zhou, X., Wu, S.** Minimally invasive repair of iatrogenic right ventricular perforation guided by bedside contrast-enhanced ultrasound: A case report and literature review. // *Frontiers in Cardiovascular Medicine*, 9, 2022, art. no. 986904. ISSN 2297-055X. DOI 10.3389/fcvm.2022.986904.

Lenzen MJ, Scholte op Reimer WJ, Pedersen SS, Boersma E, Maier W, Widimsky P, Simoons ML, Mercado NF, Wijns W; **Euro Heart Survey on Coronary Revascularization**. The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation. *Heart*. 2007 Mar;93(3):339-44. DOI 10.1136/hrt.2005.086868. Epub 2006 Sep 15. PMID: 16980515; PMCID: PMC1861429.

#### Cited by:

2533. **Abbott, J., Hart, A., Morton, A.M., Dey, P., Conway, S.P., Webb, A.K.** Can health-related quality of life predict survival in adults with cystic fibrosis? // *American Journal of Respiratory and Critical Care Medicine*, 179, 2009, № 1, p. 54-58. ISSN 1073-449X. DOI 10.1164/rccm.200802-220OC.
2534. **Benzer, W., Philippi, A., Hoefer, S., Friedrich, O., Oldridge, N.** Health-related quality of life predicts unplanned rehospitalization following coronary revascularization. [Gesundheitsbezogene Lebensqualität als Prädiktor ungeplanter stationärer Wiederaufnahmen nach Koronarrevaskularisation]. // *Herz*, 41, 2016, № 2, p. 138-143. ISSN 0340-9937. DOI 10.1007/s00059-015-4351-y.
2535. **Biddiss, E., Brownsell, S., Hawley, M.S.** Predicting need for intervention in individuals with congestive heart failure using a home-based telecare system. // *Journal of Telemedicine and Telecare*, 15, 2009, № 5, p. 226-231. ISSN 1357-633X. DOI 10.1258/jtt.2009.081203.
2536. **Biering, K., Frydenberg, M., Hjollund, N.H.** Self-reported health following percutaneous coronary intervention: Results from a cohort followed for 3 years with multiple measurements. // *Clinical Epidemiology*, 6, 2014, p. 441-449. ISSN 1179-1349. DOI 10.2147/CLEP.S65476.
2537. **Biering, K., Nielsen, T.T., Rasmussen, K., Niemann, T., Hjollund, N.H.** Return to Work after Percutaneous Coronary Intervention: The Predictive Value of Self-Reported Health Compared to Clinical Measures. // *PLoS ONE*, 7, 2012, № 11, art. no. e49268. ISSN 1932-6203. DOI 10.1371/journal.pone.0049268.
2538. **Cavrini, G., Broccoli, S., Puccini, A., Zoli, M.** EQ-5D as a predictor of mortality and hospitalization in elderly people. // *Quality of Life Research*, 21, 2012, № 2, p. 269-280. ISSN 0962-9343. DOI 10.1007/s11136-011-9937-0.
2539. **Cavrini, G., Zamberletti, J., Zoli, M.** Could the EQ-5D be Used to Predict Mortality and Hospitalization Over a Long Term Period? // *Social Indicators Research*, 128, 2016, № 2, p. 813-834. ISSN 0303-8300. DOI 10.1007/s11205-015-1058-7.
2540. **Clarke, P.M., Hayes, A.J., Glasziou, P.G., Scott, R., Simes, J., Keech, A.C.** Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. // *Medical Care*, 47, 2009, № 1, p. 61-68. ISSN 0025-7079. DOI 10.1097/MLR.0b013e3181844855.
2541. **Conradie, A., Atherton, J., Chowdhury, E., Duong, M., Schwarz, N., Worthley, S., Eccleston, D.** Health-Related Quality of Life (HRQoL) and the Effect on Outcome in Patients Presenting with Coronary Artery Disease and Treated with



2542. **Du, X., Pi, Y., Dreyer, R.P., Li, J., Li, X., Downing, N.S., Li, L., Feng, F., Zhan, L., Zhang, H., Guan, W., Xu, X., Li, S.-X., Lin, Z., Masoudi, F.A., Spertus, J.A., Krumholz, H.M., Jiang, L., for the China PEACE Collaborative Group.** The china patient-centered evaluative assessment of cardiac events (PEACE) prospective study of percutaneous coronary intervention: Study design. // *Catheterization and Cardiovascular Interventions*, 88, 2016, № 7, p. E212-E221. ISSN 1522-1946. DOI 10.1002/ccd.26461.
2543. **Einvik, G., Ekeberg, Ø., Klemsdal, T.O., Sandvik, L., Hjerkin, E.M.** Physical distress is associated with cardiovascular events in a high risk population of elderly men. // *BMC Cardiovascular Disorders*, 9, 2009, art. no. 14. ISSN 1471-2261. DOI 10.1186/1471-2261-9-14.
2544. **El Baz, N., Middel, B., van Dijk, J.P., Wesselman, D.C.M., Boonstra, P.W., Reijneveld, S.A.** EuroSCORE predicts poor health-related physical functioning six month postcoronary artery bypass graft surgery. // *Journal of Cardiovascular Surgery*, 49, 2008, № 5, p. 663-672. ISSN 0021-9509.
2545. **Gijsberts, C.M., Den Ruijter, H.M.** Non-response to questionnaires independently predicts mortality of coronary angiography patients. // *International Journal of Cardiology*, 201, 2015, p. 168-170. ISSN 0167-5273. DOI 10.1016/j.ijcard.2015.06.150.
2546. **Glezer, M.G.** Effect of treatment with ivabradine on quality of life of patients with ischemic heart disease: Results of the LINCOR program. // *Kardiologiya*, 55, 2015, № 2, p. 4-9. ISSN 0022-9040. DOI 10.18565/cardio.2015.2.4-9.
2547. **Greco, A., Steca, P., Pozzi, R., Monzani, D., Malfatto, G., Parati, G.** The influence of illness severity on health satisfaction in patients with cardiovascular disease: The mediating role of illness perception and self-efficacy beliefs. // *Behavioral Medicine*, 41, 2015, № 1, p. 9-17. ISSN 0896-4289. DOI 10.1080/08964289.2013.855159.
2548. **Hedlund, Å., Kristofferzon, M.-L., Boman, E., Nilsson, A.** Are return to work beliefs, psychological well-being and perceived health related to return-to-work intentions among women on long-term sick leave for common mental disorders? A cross-sectional study based on the theory of planned behaviour. // *BMC Public Health*, 21, 2021, № 1, art. no. 535. ISSN 1471-2458. DOI 10.1186/s12889-021-10562-w.
2549. **Höfer, S., Benzer, W., Oldridge, N.** Change in health-related quality of life in patients with coronary artery disease predicts 4-year mortality. // *International Journal of Cardiology*, 174, 2014, № 1, p. 7-12. ISSN 0167-5273. DOI 10.1016/j.ijcard.2014.03.144.
2550. **Jerant, A., Tancredi, D.J., Franks, P.** Mortality prediction by quality-adjusted life year compatible health measures: Findings in a nationally representative US sample. // *Medical Care*, 49, 2011, № 5, p. 443-450. ISSN 0025-7079. DOI 10.1097/MLR.0b013e318206c231.

2551. **Khan, S.N., Dutka, D.P.** A systematic approach to refractory angina. // *Current Opinion in Supportive and Palliative Care*, 2, 2008, № 4, p. 247-251. ISSN 1751-4258. DOI 10.1097/SPC.0b013e32831a86c7.
2552. **Kuchi, Z.G., Zakerimoghadam, M., Esmaeili, M., Geraiely, B.** The effect of an empowerment program on the perceived risk and physical health of patients with coronary artery disease. // *Holistic Nursing Practice*, 34, 2020, № 3, p. 163-170. ISSN 0887-9311. DOI 10.1097/HNP.0000000000000370.
2553. **Matza, L.S., Stewart, K.D., Gandra, S.R., Delio, P.R., Fenster, B.E., Davies, E.W., Jordan, J.B., Lothgren, M., Feeny, D.H.** Acute and chronic impact of cardiovascular events on health state utilities Utilization, expenditure, economics and financing systems. // *BMC Health Services Research*, 15, 2015, № 1, art. no. 173. ISSN 1472-6963. DOI 10.1186/s12913-015-0772-9.
2554. **Möller, A., Sartipy, U.** Quality of life six months after lung cancer surgery is associated with long-term survival. // *Acta Oncologica*, 51, 2012, № 8, p. 1029-1035. ISSN 0284-186X. DOI 10.3109/0284186X.2012.689112.
2555. **Muangpaisan, W., Assantachai, P., Intalapaporn, S., Richardson, K., Brayne, C.** Health expectancies in the older Thai population. // *Archives of Gerontology and Geriatrics*, 53, 2011, № 1, p. 3-7. ISSN 0167-4943. DOI 10.1016/j.archger.2010.05.012.
2556. **Nevarez-Flores, A.G., Chappell, K.J., Morgan, V.A., Neil, A.L.** Health-Related Quality of Life Scores and Values as Predictors of Mortality: A Scoping Review. // *Journal of General Internal Medicine*, 38, 2023, № 15, p. 3389-3405. ISSN 0884-8734. DOI 10.1007/s11606-023-08380-4.
2557. **Nguyen, L.L., Henry, A.J.** Editorial: Health-related quality of life: A measure of process and outcome. // *Vascular Medicine*, 15, 2010, № 3, p. 233-234. ISSN 1358-863X. DOI 10.1177/1358863X10361636.
2558. **Ono, M., Serruys, P.W., Garg, S., Kawashima, H., Gao, C., Hara, H., Lunardi, M., Wang, R., O'Leary, N., Wykrzykowska, J.J., Piek, J.J., Mack, M.J., Holmes, D.R., Morice, M.-C., Kappetein, A.P., Thuijs, D.J.F.M., Noack, T., Mohr, F.W., Davierwala, P.M., Spertus, J.A., Cohen, D.J., Onuma, Y., for the SYNTAX Extended Survival Investigators.** Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization. // *Circulation*, 146, 2022, № 17, p. 1268-1280. ISSN 0009-7322. DOI 10.1161/CIRCULATIONAHA.121.057021.
2559. **Pan, C.-W., Liu, R.-J., Yang, X.-J., Ma, Q.-H., Xu, Y., Luo, N., Wang, P.** Could the EQ-5D-3L predict all-cause mortality in older Chinese? Evidence from a 5-year longitudinal study in eastern China. // *Quality of Life Research*, 30, 2021, № 10, p. 2887-2894. ISSN 0962-9343. DOI 10.1007/s11136-021-02883-5.
2560. **Prabhakaran, D., Chandrasekaran, A.M., Singh, K., Mohan, B., Chattopadhyay, K., Chadha, D.S., Negi, P.C., Bhat, P., Sadananda, K.S., Ajay, V.S., Singh, K., Praveen, P.A., Devarajan, R., Kondal, D., Soni, D., Mallinson, P., Manchanda, S.C., Madan, K., Hughes, A.D., Chathurvedi, N., Roberts, I., Ebrahim, S., Reddy, K.S., Tandon, N., Pocock, S., Roy, A., Kinra, S., Chand Manchanda, S., Bhatnagar, D., Chaturvedi, V., Perel, P., Poulter, N., Harikrishnan, S., Pandey, R.M., Banerjee, A., Gill, P., Chadha, D.S., Bardoloi,**

- N., Chand Negi, P., Asotra, S., Bhat, P., Nanjappa, M.C., Prasad, M.R., Sarma, R., Natrajan, K.U., Swaminathan, S., Tongia, R.K., Natarajan, S., Rao, B., Narasimhan, C., Abdullakutty, J., Mallya, S., Jain, A.R., Naik, S.R., Desai, N., Kumar, S., Patil, S., Patil, S., Chandra, S., Madappa, N.U., Yoga-CaRe Trial Investigators. Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial. // *Journal of the American College of Cardiology*, 75, 2020, № 13, p. 1551-1561. ISSN 0735-1097. DOI 10.1016/j.jacc.2020.01.050.
2561. Skodova, Z., Nagyova, I., Dijk, J.P., Sudzinova, A., Vargova, H., Rosenberger, J., Middel, B., Studencan, M., Reijneveld, S.A. Socioeconomic inequalities in quality of life and psychological outcomes among cardiac patients. // *International Journal of Public Health*, 54, 2009, № 4, p. 233-240. ISSN 1661-8556. DOI 10.1007/s00038-009-7086-9.
2562. Skodova, Z., Van Dijk, J.P., Nagyova, I., Rosenberger, J., Ondusova, D., Studencan, M., Reijneveld, S.A. Psychosocial factors of coronary heart disease and quality of life among Roma coronary patients: A study matched by socioeconomic position. // *International Journal of Public Health*, 55, 2010, № 5, p. 373-380. ISSN 1661-8556. DOI 10.1007/s00038-010-0153-4.
2563. Škodová, Z., van Dijk, J.P., Nagyová, I., Rosenberger, J., Ondušová, D., Middel, B., Reijneveld, S.A. Psychosocial predictors of change in quality of life in patients after coronary interventions. // *Heart and Lung: Journal of Acute and Critical Care*, 40, 2011, № 4, p. 331-339. ISSN 0147-9563. DOI 10.1016/j.hrtlng.2009.12.007.
2564. Smith, D.W., Davies, E.W., Wissinger, E., Huelin, R., Matza, L.S., Chung, K. A systematic literature review of cardiovascular event utilities. // *Expert Review of Pharmacoeconomics and Outcomes Research*, 13, 2013, № 6, p. 767-790. ISSN 1473-7167. DOI 10.1586/14737167.2013.841545.
2565. Soloveva, A., Gale, C.P., Han, N.T., Hurdus, B., Aktaa, S., Palin, V., Mebrahtu, T.F., Van Spall, H., Batra, G., Dondo, T.B., Bäck, M., Munyombwe, T. Associations of health-related quality of life with major adverse cardiovascular and cerebrovascular events for individuals with ischaemic heart disease: systematic review, meta-analysis and evidence mapping. // *Open Heart*, 10, 2023, № 2, art. no. e002452. ISSN 2398-595X. DOI 10.1136/openhrt-2023-002452.
2566. Steca, P., D'Addario, M., Magrin, M.E., Miglioretti, M., Monzani, D., Pancani, L., Sarini, M., Scignaro, M., Vecchio, L., Fattirolli, F., Giannattasio, C., Cesana, F., Riccobono, S.P., Greco, A. A type A and type D combined personality typology in essential hypertension and acute coronary syndrome patients: Associations with demographic, psychological, clinical, and lifestyle indicators. // *PLoS ONE*, 11, 2016, № 9, art. no. e0161840. ISSN 1932-6203. DOI 10.1371/journal.pone.0161840.
2567. Van Beek, M.H.C.T., Roest, A.M., Wardenaar, K.J., Van Balkom, A.J.L.M., Speckens, A.E.M., Oude Voshaar, R.C., Zuidersma, M. The Prognostic Effect of Physical Health Complaints With New Cardiac Events and Mortality in Patients With a Myocardial Infarction. // *Psychosomatics*, 58, 2017, № 2, p. 121-131. ISSN 0033-3182. DOI 10.1016/j.psych.2016.10.009.

Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, Bertrand ME, Mercado N, Boersma E; **EHS-CR Investigators**. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. *Eur Heart J*. 2006 Mar;27(6):671-8. DOI 10.1093/eurheartj/ehi731. Epub 2006 Jan 19. PMID: 16423872.

**Cited by:**

2568. **Abelin, A.P., De Quadros, A.S., Zanettini, M.T., Leboutte, F.C., Yordi, L.M., Cardoso, C.R., Moraes, C.A.R., La Hore, C.R., La Hoore Jr., C.R., Moura, M.R.S., Sarmento-Leite, R., Gottschall, C.A.M.** Twelve-year experience with coronary stenting in 5,284 patients. [Doze Anos de Experiência com Implante de Stents Coronários em 5.284 Pacientes]. // *Revista Brasileira de Cardiologia Invasiva*, 17, 2009, № 3, p. 346-351. ISSN 0104-1843.
2569. **Al-Khatib, S.M., Hellkamp, A., Bardy, G.H., Hammill, S., Hall, W.J., Mark, D.B., Anstrom, K.J., Curtis, J., Al-Khalidi, H., Curtis, L.H., Heidenreich, P., Peterson, E.D., Sanders, G., Clapp-Channing, N., Lee, K.L., Moss, A.J.** Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. // *JAMA*, 309, 2013, № 1, p. 55-62. ISSN 0098-7484. DOI 10.1001/jama.2012.157182.
2570. **Ariyaratne, T.V., Ademi, Z., Yap, C.-H., Billah, B., Rosenfeldt, F., Yan, B.P., Reid, C.M.** Prolonged effectiveness of coronary artery bypass surgery versus drug-eluting stents in diabetics with multi-vessel disease: An updated systematic review and meta-analysis. // *International Journal of Cardiology*, 176, 2014, № 2, p. 346-353. ISSN 0167-5273. DOI 10.1016/j.ijcard.2014.06.072.
2571. **Ascione, R., Angelini, G.** When and why should we employ the surgeon? Biological and clinical rationale for early reperfusion. // *Dialogues in Cardiovascular Medicine*, 11, 2006, № 4, p. 281-290. ISSN 1272-9949.
2572. **Atladottir, H.O., Modrau, I.S., Jakobsen, C.-J., Torp-Pedersen, C.T., Gissel, M.S., Nielsen, D.V.** Impact of perioperative course during cardiac surgery on outcomes in patients 80 years and older. // *Journal of Thoracic and Cardiovascular Surgery*, 162, 2021, № 5, p. 1568-1577. ISSN 0022-5223. DOI 10.1016/j.jtcvs.2020.03.005.
2573. **Banasiak, W., Wilkins, A., Pociupany, R., Ponikowski, P.** Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study. // *Kardiologia Polska*, 66, 2008, № 6, p. 642-649. ISSN 0022-9032.
2574. **Barra, S., Providência, R., Paiva, L., Caetano, F., Almeida, I., Gomes, P., Marques, A.L.** ACHTUNG-Rule: A new and improved model for prognostic assessment in myocardial infarction. // *European Heart Journal: Acute Cardiovascular Care*, 1, 2012, № 4, p. 320-336. ISSN 2048-8726. DOI 10.1177/2048872612466536.
2575. **Berghammer, M.C., Mattsson, E., Johansson, B., Moons, P., Dellborg, M.** Comparison of participants and non-participants in patient-reported outcome surveys: The case of Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart disease-International Study. // *Cardiology in the Young*, 27, 2017, № 3, p. 427-434. ISSN 1047-9511. DOI 10.1017/S1047951116000676.

2576. **Bernardi, G., Morocutti, G., Spedicato, L., Zanuttini, D.** The value of clinical wisdom in randomised studies, real-world registries and new hypotheses. // *Journal of Cardiovascular Medicine*, 8, 2007, № 5, p. 313-317. ISSN 1558-2027. DOI 10.2459/JCM.0b013e32813e4024.
2577. **Blann, A.D., Pisters, R., Lip, G.Y.H.** Net clinical benefit of edoxaban for stroke, mortality, and bleeding risk modeling projections for a European population. // *JACC: Clinical Electrophysiology*, 2, 2016, № 1, p. 47-54. ISSN 2405-500X. DOI 10.1016/j.jacep.2015.09.015.
2578. **Caldonazo, T., Kirov, H., Riedel, L.L., Gaudino, M., Doenst, T.** Comparing CABG and PCI across the globe based on current regional registry evidence. // *Scientific Reports*, 12, 2022, № 1, art. no. 22164. ISSN 2045-2322. DOI 10.1038/s41598-022-25853-4.
2579. **Chadow, D., Audisio, K., Perezgrovas-Olaria, R., Cancelli, G., Robinson, N.B., Rahouma, M., Soletti, G., Jr., Angiolillo, D.J., Metkus, T.S., Gaudino, M.F.L.** Differences Among Clinical Trials and Registries on Surgical and Percutaneous Coronary Interventions. // *Annals of Thoracic Surgery*, 115, 2023, № 1, p. 79-86. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2022.05.015.
2580. **Chueca González, E.M., Carrasco Chinchilla, F., López Benítez, J.L., Alonso Briales, J.H., Domínguez Franco, A.J., de Lemos Albadalejo, R., Melero Tejedor, J.M., Hernández García, J.M., Jiménez Navarro, M.** Coronary multivessel disease in the diabetic patient in the real life setting: Efficacy or effectiveness? [Enfermedad coronaria multivaso en el paciente diabético en la vida real: ¿eficacia o efectividad?]. // *REC: CardioClinics*, 54, 2019, № 2, p. 81-90. ISSN 2605-1532. DOI 10.1016/j.rccl.2019.01.022.
2581. **Cohen, M.G., Matthews, R., Maini, B., Dixon, S., Vetrovec, G., Wohns, D., Palacios, I., Popma, J., Ohman, E.M., Schreiber, T., O'Neill, W.W.** Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience. // *American Heart Journal*, 170, 2015, № 5, p. 872-879. ISSN 0002-8703. DOI 10.1016/j.ahj.2015.08.009.
2582. **Contini, G.A., Nicolini, F., Fortuna, D., Pacini, D., Gabbieri, D., Vignali, L., Valgimigli, M., Manari, A., Zussa, C., Guastaroba, P., De Palma, R., Grilli, R., Gherli, T.** Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. // *International Journal of Cardiology*, 168, 2013, № 2, p. 1028-1033. ISSN 0167-5273. DOI 10.1016/j.ijcard.2012.10.030.
2583. **Córdoba-Soriano, J.G., Gutiérrez-Díez, A., Del Blanco, B.G., Núñez, J., Amat-Santos, I.J., Oteo, J.F., Romaguera, R., Gallardo-López, A., Lozano Ruíz-Poveda, F., Baello, P., Aguar, P., Jerez-Valero, M., Jiménez-Díaz, V.A., Serra, B., Cascon, J.D., Morales-Ponce, F.J., Portero-Portaz, J.J., Melehi El Assali, D., Cerrato-García, P., Jiménez-Mazuecos, J.** Bioactive or Drug-Eluting Stents in 75 Years or Older Patients: The BIODS-75 Registry. // *Cardiovascular Revascularization Medicine*, 42, 2022, p. 114-120. ISSN 1553-8389. DOI 10.1016/j.carrev.2022.02.001.
2584. **Cremer, J.** Some comments from the surgical perspective on the SYNTAX discussion. [Einige anmerkungen aus chirurgischem blickwinkel zur SYNTAX-diskussion.] // *Zeitschrift für Herz-, Thorax- und Gefäßschirurgie*, 22, 2008, № 6, p. 342-345. ISSN 0930-9225. DOI 10.1007/s00398-008-0667-8.



2585. Czyż, Ł., Chmiel, J., Drabik, L., Mazurek, A., Kwiecień, E., Sikorska, M., Skubera, M., Zasada, W., Podolec, P., Musiałek, P. Eligible-and-enrolled vs. eligible-but-not-enrolled patients with chronic ischaemic heart failure in randomized clinical trials of myocardial regeneration. // *Postępy w Kardiologii Interwencyjnej*, 18, 2022, № 4, p. 407-415. ISSN 1734-9338. DOI 10.5114/AIC.2022.121133.
2586. Dai, J., Gong, J., Guo, R. Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of *Clostridium difficile* infection: a systematic review and meta-analysis. // *European Journal of Clinical Pharmacology*, 78, 2022, № 11, p. 1727-1737. ISSN 0031-6970. DOI 10.1007/s00228-022-03376-1.
2587. Danson, E.J.F., Sapontis, J., Kaura, A., Hill, J.M., Dworakowski, R., MacCarthy, P., Melikian, N., Webb, I., Shah, A., Byrne, J. Long-term outcomes in surgically ineligible patients managed with percutaneous coronary revascularization or medical therapy. // *Cardiovascular Intervention and Therapeutics*, 34, 2019, № 3, p. 249-259. ISSN 1868-4300. DOI 10.1007/s12928-018-0554-5.
2588. de la Torre Hernández, J.M. Debate: The role of percutaneous coronary intervention for left main disease after EXCEL and NOBEL trials. [Debate: Papel de la revascularización percutánea del tronco coronario izquierdo tras los ensayos EXCEL y NOBLE.] // *Revista Espanola de Cardiologia*, 74, 2021, № 8, p. 651-654. ISSN 0300-8932. DOI 10.1016/j.recesp.2020.12.012.
2589. de la Torre Hernández, J.M., Edelman, E.R. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. [De la investigación no clínica a los ensayos y registros clínicos: retos y oportunidades en la investigación biomédica]. // *Revista Espanola de Cardiologia*, 70, 2017, № 12, p. 1121-1133. ISSN 0300-8932. DOI 10.1016/j.recesp.2017.07.017.
2590. De Quadros, A.S., Lima, T.C., Rodrigues, A.P.D.R., Modkovski, T.B., Welter, D.I., Sarmiento-Leite, R., Gottschall, C.A.M. Quality of life and health status after percutaneous coronary intervention in stable angina patients. // *Catheterization and Cardiovascular Interventions*, 77, 2011, № 7, p. 954-960. ISSN 1522-1946. DOI 10.1002/ccd.22746.
2591. de Winter, R.W., Rahman, M.S., van Diemen, P.A., Schumacher, S.P., Jukema, R.A., Somsen, Y.B.O., van Rossum, A.C., Verouden, N.J., Danad, I., Delewi, R., Nap, A., Knaapen, P. Diagnostic and Management Strategies in Patients with Late Recurrent Angina after Coronary Artery Bypass Grafting. // *Current Cardiology Reports*, 24, 2022, № 10, p. 1309-1325. ISSN 1523-3782. DOI 10.1007/s11886-022-01746-w.
2592. Dekkers, O.M., Vandenbroucke, J.P. Generalizability of therapeutic trials. [Generaliseerbaarheid van therapeutisch onderzoek]. // *Nederlands Tijdschrift voor Geneeskunde*, 151, 2007, № 40, p. 2203-2206. ISSN 0028-2162.
2593. Domínguez-Franco, A.J., Jiménez-Navarro, M.F., Hernández-García, J.M., Alonso-Briales, J.H., Linde-Estrella, A.L., Pérez-González, O., Lervite-Martín, I., Olalla-Mercadé, E., De Teresa-Galván, E. Comparison of medium-term outcomes obtained with drug-eluting stents and coronary artery bypass grafts in an unselected population of diabetic patients with multivessel coronary disease. Propensity score analysis. [Comparación de los resultados clínicos a medio plazo de

los stents farmacoactivos frente a la cirugía de revascularización coronaria en una población no seleccionada de pacientes diabéticos con afección multivaso. Análisis mediante propensity score]. // *Revista Espanola de Cardiologia*, 62, 2009, № 5, p. 491-500. ISSN 0300-8932. DOI 10.1016/S0300-8932(09)71029-2.

2594. **Eikelboom, J.W., O'Donnell, M.** Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. // *JAMA*, 297, 2007, № 1, p. 91-92. ISSN 0098-7484. DOI 10.1001/jama.297.1.91.
2595. **Elbarouni, B., Goodman, S.G., Yan, R.T., Welsh, R.C., Kornder, J.M., DeYoung, J.P., Wong, G.C., Rose, B., Grondin, F.R., Gallo, R., Tan, M., Casanova, A., Eagle, K.A., Yan, A.T.** Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. // *American Heart Journal*, 158, 2009, № 3, p. 392-399. ISSN 0002-8703. DOI 10.1016/j.ahj.2009.06.010.
2596. **Elsner, D.** Stable coronary artery disease in hypertension: Diagnosis, medical therapy and revascularisation. [Stabile KHK und hypertonie: Diagnostik, medikamentöse therapie und revaskularisierungsstrategien.] // *Journal fur Hypertonie*, 12, 2008, № 3, p. 14-18. ISSN 1028-2327.
2597. **Elsner, D.** Therapy of chronic coronary artery disease: Medical treatment vs. bypass surgery vs. coronary intervention? [Therapie der stabilen koronaren herzkrankheit: Wann stent, wann medikamentös und wann operation?] // *Internist*, 47, 2006, № 12, p. 1251-1257. ISSN 0020-9554. DOI 10.1007/s00108-006-1733-5.
2598. **Faglia, E., Clerici, G., Caminiti, M., Quarantiello, A., Curci, V., Morabito, A.** Advantages of myocardial revascularization after admission for critical limb ischemia in diabetic patients with coronary artery disease: Data of a cohort of 564 consecutive patients. // *Journal of Cardiovascular Medicine*, 9, 2008, № 10, p. 1030-1036. ISSN 1558-2027. DOI 10.2459/JCM.0b013e328306f2da.
2599. **Foroutan, F., Guyatt, G., Zuk, V., Vandvik, P.O., Alba, A.C., Mustafa, R., Vernooij, R., Arevalo-Rodriguez, I., Munn, Z., Roshanov, P., Riley, R., Schandelmaier, S., Kuijpers, T., Siemieniuk, R., Canelo-Aybar, C., Schunemann, H., Iorio, A.** GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. // *Journal of Clinical Epidemiology*, 121, 2020, p. 62-70. ISSN 0895-4356. DOI 10.1016/j.jclinepi.2019.12.023.
2600. **Franzone, A., Heg, D., Räber, L., Valgimigli, M., Piccolo, R., Zanchin, T., Yamaji, K., Stortecky, S., Blöchliger, S., Hunziker, L., Praz, F., Jüni, P., Windecker, S., Pilgrim, T.** External validity of the "all-comers" design: insights from the BIOSCIENCE trial. // *Clinical Research in Cardiology*, 105, 2016, № 9, p. 744-754. ISSN 1861-0684. DOI 10.1007/s00392-016-0983-z.
2601. **Fried, T.R., O'Leary, J., Towle, V., Goldstein, M.K., Trentelange, M., Martin, D.K.** The effects of comorbidity on the benefits and harms of treatment for chronic disease: A systematic review. // *PLoS ONE*, 9, 2014, № 11, art. no. e112593. ISSN 1932-6203. DOI 10.1371/journal.pone.0112593.

2602. **Fried, T.R., Vaz Fragoso, C.A., Rabow, M.W.** Caring for the older person with chronic obstructive pulmonary disease. // *JAMA*, 308, 2012, № 12, p. 1254-1263. ISSN 0098-7484. DOI 10.1001/jama.2012.12422.
2603. **Ganyukov, V., Tarasov, R.** High risk percutaneous coronary interventions-significance of left ventricular assist device for clinical practice. // *Journal of Thoracic Disease*, 7, 2015, № 10, p. 1716-1718. ISSN 2072-1439. DOI 10.3978/j.issn.2072-1439.2015.10.57.
2604. **Golder, S., Loke, Y.K., Bland, M.** Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview. // *PLoS Medicine*, 8, 2011, № 5, art. no. e1001026. ISSN 1549-1277. DOI 10.1371/journal.pmed.1001026.
2605. **Goldman, B.S.** The life and hard times of a coronary surgeon. // *Canadian Journal of Cardiology*, 23, 2007, № 3, p. 183-188. ISSN 0828-282X. DOI 10.1016/S0828-282X(07)70741-9.
2606. **Goldstein, B.A., Navar, A.M., Pencina, M.J.** Risk prediction with electronic health records: The importance of model validation and clinical context. // *JAMA Cardiology*, 1, 2016, № 9, p. 976-977. ISSN 2380-6583. DOI 10.1001/jamacardio.2016.3826.
2607. **Grunkemeier, G.L., Jin, R., Wang, L., Starr, A.** Clinical Trials for Medical Devices. – In: *Biomaterials Science: An Introduction to Materials: Third Edition*, 2013, p. 1443-1458. ISBN 9780123746269. DOI 10.1016/B978-0-08-087780-8.00137-6.
2608. **Gupta, P., Sandy, L.C., Glorioso, T.J., Khanna, A., Khazanie, P., Allen, L.A., Peterson, P.N., Bull, S., Ho, P.J.M.** Secondary analysis of electronic opt-out consent in pragmatic research: A study design method to diversify clinical trials? // *American Heart Journal*, 261, 2023, p. 104-108. ISSN 0002-8703. DOI 10.1016/j.ahj.2023.03.010.
2609. **Hertting, K., Härle, T., Krause, K., Reimers, J., Boczor, S., Kuck, K.-H.** Stenting of unprotected left main stem stenosis: Results from a German single-centre registry. // *Experimental and Clinical Cardiology*, 13, 2008, № 1, p. 37-41. ISSN 1205-6626.
2610. **Iversen, A.Z.** On the use of abciximab in percutaneous coronary intervention. // *Danish Medical Bulletin*, 58, 2011, № 8. ISSN 1603-9629.
2611. **Iversen, A.Z., Galatius, S., Pedersen, S., Madsen, J.K., Jensen, J.S.** Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: An observational registry study. // *Drugs and Aging*, 28, 2011, № 5, p. 369-378. ISSN 1170-229X. DOI 10.2165/11587170-000000000-00000.
2612. **Iversen, A.Z., Pedersen, S.H., Joens, C., Mogelvang, R., Galatius, S., Galloe, A., Abildgaard, U., Hansen, P.R., Madsen, J.K., Jensen, J.S.** Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: Results from a high-volume, single-center registry. // *Journal of Invasive Cardiology*, 23, 2011, № 1, p. 21-26. ISSN 1042-3931.

2613. **Johannesen, K., Siverskog, J., Henriksson, M., Janzon, M., Lindahl, B., Grönqvist, E.** Implementation of Ticagrelor Reduced Mortality in Routine Clinical Care: Evidence From a Natural Experiment Including 109 995 Patients With Myocardial Infarction in Sweden. // *Journal of the American Heart Association*, 12, 2023, № 5, art. no. e027384. ISSN 2047-9980. DOI 10.1161/JAHA.122.027384.
2614. **Jung, A., Balzer, J., Braun, T., Luedtke, K.** Identification of tools used to assess the external validity of randomized controlled trials in reviews: a systematic review of measurement properties. // *BMC Medical Research Methodology*, 22, 2022, № 1, art. no. 100. ISSN 1471-2288. DOI 10.1186/s12874-022-01561-5.
2615. **Jung, A., Braun, T., Armijo-Olivo, S., Challoumas, D., Luedtke, K.** Consensus on the definition and assessment of external validity of randomized controlled trials: A Delphi study. // *Research Synthesis Methods*, 15, 2024, № 2, p. 288-302. ISSN 1759-2887. DOI 10.1002/jrsm.1688.
2616. **Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., Johnston, J.** A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. // *Trials*, 16, 2015, № 1, art. no. 495. ISSN 1745-6215. DOI 10.1186/s13063-015-1023-4.
2617. **Kimmelman, J., London, A.J.** The Structure of Clinical Translation: Efficiency, Information, and Ethics. // *Hastings Center Report*, 45, 2015, № 2, p. 27-39. ISSN 0093-0334. DOI 10.1002/hast.433.
2618. **Kinnaird, T., Butt, M., Abdul, F., Yazji, K., Hailan, A., Gallagher, S., Ossei-Gerning, N., Chase, A., Choudhury, A., Smith, D., Anderson, R.** Early clinical experience with a polymer-free biolimus A9 drug-coated stent in DES-type patients who are poor candidates for prolonged dual anti-platelet therapy. // *PLoS ONE*, 11, 2016, № 6, art. no. e0157812. ISSN 1932-6203. DOI 10.1371/journal.pone.0157812.
2619. **Kirtane, A.J., Moses, J.W.** Revascularization in Heart Failure: The Role of Percutaneous Coronary Intervention. // *Heart Failure Clinics*, 3, 2007, № 2, p. 229-235. ISSN 1551-7136. DOI 10.1016/j.hfc.2007.05.003.
2620. **Kobusiak-Prokopowicz, M., Mysiak, A.** Cardiogenic shock in acute coronary syndrome - The management of procedures. // *Advances in Clinical and Experimental Medicine*, 20, 2011, № 6, p. 661-665. ISSN 1230-025X.
2621. **Kraai, I.H., Vermeulen, K.M., Luttik, M.L.A., Hoekstra, T., Jaarsma, T., Hillege, H.L.** Preferences of heart failure patients in daily clinical practice: Quality of life or longevity? // *European Journal of Heart Failure*, 15, 2013, № 10, p. 1113-1121. ISSN 1388-9842. DOI 10.1093/eurjhf/hft071.
2622. **Kukreja, N., Onuma, Y., Garcia-Garcia, H.M., Daemen, J., van Domburg, R., Serruys, P.W.** The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents. // *JACC: Cardiovascular Interventions*, 2, 2009, № 6, p. 534-541. ISSN 1936-8798. DOI 10.1016/j.jcin.2009.04.003.
2623. **Kukreja, N., Onuma, Y., Garcia-Garcia, H.M., Daemen, J., van Domburg, R., Serruys, P.W.** Three-Year Survival Following Multivessel Percutaneous Coronary Intervention With Bare-Metal or Drug-Eluting Stents in Unselected Patients. //

2624. **Kukreja, N., Serruys, P.W.** When is percutaneous coronary intervention a better choice than coronary artery by-pass grafting? // *Polskie Archiwum Medycyny Wewnetrznej*, 118, 2008, № 3, p. 98-99. ISSN 0032-3772. DOI 10.20452/pamw.322.
2625. **Lattuca, B., Cayla, G.** Which strategy should be the global leader in antithrombotic therapy decision making in older patients? // *EuroIntervention*, 15, 2020, № 18, p. E1560-E1563. ISSN 1774-024X. DOI 10.4244/EIJV15I18A285.
2626. **Lavi, S., Ivanov, J., Appleby, C.E., Seidelin, P.H., Mackie, K., Schwartz, L., Džavik, V.** Selective use of embolic protection devices during saphenous vein grafts interventions: A single-center experience. // *Catheterization and Cardiovascular Interventions*, 75, 2010, № 7, p. 1037-1044. ISSN 1522-1946. DOI 10.1002/ccd.22392.
2627. **Limbruno, U., Picchi, A., Galli, S., Huber, K., Lipiecki, J., Bernstein, D., Deliargyris, E., Anthopoulos, P., Nienaber, C., Hamon, M.** Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry. // *Acute Cardiac Care*, 16, 2014, № 4, p. 127-131. ISSN 1748-2941. DOI 10.3109/17482941.2014.944542.
2628. **Lopez-Jimenez, F., Gersh, B.J.** Secondary prevention after coronary artery bypass grafting saves lives: A golden opportunity often wasted. // *European Heart Journal*, 41, 2020, № 17, p. 1662-1664. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz855.
2629. **López-Palop, R., Carrillo, P., Frutos, A., Cordero, A., Núñez, D., Toro, M., Bertomeu-Martínez, V.** Safety and Efficacy of Coronary Drug-Eluting Stents in Octogenarians. [Seguridad y eficacia del empleo de stents intracoronarios farmacoactivos en el paciente octogenario]. // *Revista Espanola de Cardiologia*, 62, 2009, № 11, p. 1250-1259. ISSN 0300-8932. DOI 10.1016/S0300-8932(09)73077-5.
2630. **Ludman, P.F.** The principles and practice of audit in coronary intervention. – In: *Practical Interventional Cardiology*, Third edition, 2017, p. 639-645. ISBN 9781498735100; 9781498735094. DOI 10.1201/9781315113753-47.
2631. **Lüscher, T.F.** The bumpy road to evidence: Why many research findings are lost in translation. // *European Heart Journal*, 34, 2013, № 43, p. 3329-3335. ISSN 0195-668X. DOI 10.1093/eurheartj/ehz396.
2632. **Lyseng-Williamson, K.A., Plosker, G.L.** Clopidogrel: A pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. // *PharmacoEconomics*, 24, 2006, № 7, p. 709-726. ISSN 1170-7690. DOI 10.2165/00019053-200624070-00009.
2633. **Mack, M.J.** Clinical trials versus registries in coronary revascularization: Which are more relevant? // *Current Opinion in Cardiology*, 22, 2007, № 6, p. 524-528. ISSN 0268-4705. DOI 10.1097/HCO.0b013e3282f078e3.
2634. **Malatestinic, W., Nordstrom, B., Wu, J.J., Goldblum, O., Solotkin, K., Lin, C.-Y., Kistler, K., Fraeman, K., Johnston, J., Hawley, L., Sicignano, N., Araujo, A.**



Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. // *Journal of Managed Care and Specialty Pharmacy*, 23, 2017, № 3, p. 370-381. ISSN 2376-0540. DOI 10.18553/jmcp.2017.16367.

2635. **Malkin, C.J., Prakash, R., Chew, D.P.** The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: Retrospective analysis study from the ACACIA registry. // *BMJ Open*, 2, 2012, № 1, art. no. 000540. ISSN 2044-6055. DOI 10.1136/bmjopen-2011-000540.
2636. **McPhail, S.M.** Multimorbidity in chronic disease: Impact on health care resources and costs. // *Risk Management and Healthcare Policy*, 9, 2016, p. 143-156. ISSN 1179-1594. DOI 10.2147/RMHP.S97248.
2637. **Ndrepepa, G., Neumann, F.-J., Menichelli, M., Bernlochner, I., Richardt, G., Wöhrle, J., Witzenbichler, B., Mayer, K., Cassese, S., Gewalt, S., Xhepa, E., Kufner, S., Sager, H.B., Joner, M., Ibrahim, T., Laugwitz, K.-L., Schunkert, H., Schüpke, S., Kastrati, A.** Assessment of impact of patient recruitment volume on risk profile, outcomes, and treatment effect in a randomized trial of ticagrelor versus prasugrel in acute coronary syndromes. // *Journal of the American Heart Association*, 10, 2021, № 22, art. no. e021418. ISSN 2047-9980. DOI 10.1161/JAHA.121.021418.
2638. **Nordon, C., Karcher, H., Groenwold, R.H.H., Ankarfeldt, M.Z., Pichler, F., Chevrou-Severac, H., Rossignol, M., Abbe, A., Abenhaim, L., on behalf of the GetReal consortium.** The "efficacy-effectiveness gap": Historical background and current conceptualization. // *Value in Health*, 19, 2016, № 1, p. 75-81. ISSN 1098-3015. DOI 10.1016/j.jval.2015.09.2938.
2639. **Nordon, C., Sanchez, B., Zhang, M., Wang, X., Hunt, P., Belger, M., Karcher, H., The GetReal Initiative.** Testing the "RCT augmentation" methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness. // *Contemporary Clinical Trials Communications*, 33, 2023, art. no. 101142. ISSN 2451-8654. DOI 10.1016/j.conctc.2023.101142.
2640. **Olivari, Z., Stritoni, P., Burelli, C., McMahon, L., Capodaglio, G., Fedeli, U., Avossa, F., De Servi, S., Favero, L.** Management and 5-year outcome of patients with coronary artery disease in different periods of stent technology. // *Journal of Cardiovascular Medicine*, 21, 2020, № 6, p. 444-452. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000955.
2641. **Osswald, B.R., Gegouskov, V., Badowski-Zyla, D., Tochtermann, U., Thomas, G., Hagl, S., Blackstone, E.H.** Overestimation of aortic valve replacement risk by EuroSCORE: Implications for percutaneous valve replacement. // *European Heart Journal*, 30, 2009, № 1, p. 74-80. ISSN 0195-668X. DOI 10.1093/eurheartj/ehn523.
2642. **Papageorgiou, S.N., Xavier, G.M., Cobourne, M.T.** Basic study design influences the results of orthodontic clinical investigations. // *Journal of Clinical Epidemiology*, 68, 2015, № 12, p. 1512-1522. ISSN 0895-4356. DOI 10.1016/j.jclinepi.2015.03.008.
2643. **Pedersen, S., Galatius, S., Mogelvang, R., Abildstrom, S.Z., Sorensen, R., Galloe, A., Abildgaard, U., Hansen, P., Davidsen, U., Iversen, A., Bech, J.,**

**Madsen, J.K., Jensen, J.S.** Long-term clinical outcome in STEMI patients treated with primary PCI and drug-eluting or bare-metal stents: Insights from a high-volume single-center registry. // *Journal of Invasive Cardiology*, 23, 2011, № 8, p. 328-333. ISSN 1042-3931.

2644. **Pino, R.C., Ferrero, L.L., Rojas, L.D.L., Nande, L.M.R., Veliz, A.G., Rodríguez, E.E.A.** Percutaneous coronary intervention in octogenarians. [Intervención coronaria percutánea en octogenarios]. // *Revista Cubana de Cardiología y Cirugía Cardiovascular*, 29, 2023, № 1, art. no. e1354. ISSN 1561-2937.
2645. **Politi, A., Martinoni, A., Klugmann, S., Zanini, R., Onofri, M., Guagliumi, G., Fiorentini, C., Lettieri, C., Belli, G., Piccaluga, E., De Cesare, N., D'Urbano, M., Etti, F., Repetto, A., Musumeci, G., Castiglioni, B., Colombo, P., Passamonti, E., Bramucci, E., Cattaneo, L., Ferrari, G., Repetto, S., Bartorelli, A., Pirelli, S., De Servi, S.** LombardIMA: A regional registry for coronary angioplasty in ST-elevation myocardial infarction. // *Journal of Cardiovascular Medicine*, 12, 2011, № 1, p. 43-50. ISSN 1558-2027. DOI 10.2459/JCM.0b013e328340334d.
2646. **Prasad, S.B., Ahmar, W., Malaiapan, Y., Meredith, I.T.** Drug-eluting Stents for the Treatment of Acute Myocardial Infarction: The View to the HORIZONS. // *Heart Lung and Circulation*, 19, 2010, № 1, p. 11-18. ISSN 1443-9506. DOI 10.1016/j.hlc.2009.05.707.
2647. **Pusca, S.V., Puskas, J.D.** Revascularization in Heart Failure: Coronary Bypass or Percutaneous Coronary Intervention? // *Heart Failure Clinics*, 3, 2007, № 2, p. 211-228. ISSN 1551-7136. DOI 10.1016/j.hfc.2007.05.002.
2648. **Quadros, A.S., Welter, D.I., Camozzatto, F.O., Chaves, Á., Mehta, R.H., Gottschall, C.A., Lopes, R.D.** Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. // *American Journal of Cardiology*, 107, 2011, № 5, p. 685-689. ISSN 0002-9149. DOI 10.1016/j.amjcard.2010.10.045.
2649. **Ramadan, A.S.E., Stefanidis, C., N'Gatchou, W., El Oumeiri, B., Jansens, J.-L., De Smet, J.-M., Antoine, M., De Cannière, D.** Five years follow-up after Y-graft arterial revascularization: On pump versus off pump; prospective clinical trial. // *Interactive Cardiovascular and Thoracic Surgery*, 10, 2010, № 3, p. 423-427. ISSN 1569-9293. DOI 10.1510/icvts.2009.206458.
2650. **Rastan, A.J., Boudriot, E., Falk, V., Kappetein, A.P., Borger, M.A., Serruys, P.W., Schuler, G., Mohr, F.W.** Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. // *European Journal of Cardio-thoracic Surgery*, 34, 2008, № 2, p. 376-383. ISSN 1010-7940. DOI 10.1016/j.ejcts.2008.04.029.
2651. **Routman, J.S., Willig, J.H., Westfall, A.O., Abrams, S.R., Varshney, M., Adusumilli, S., Allison, J.J., Savage, K.G., Saag, M.S., Mugavero, M.J.** Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. // *Clinical Infectious Diseases*, 50, 2010, № 4, p. 574-584. ISSN 1058-4838. DOI 10.1086/650004.
2652. **Schiano, P., Monségu, J.** Coronary angioplasty in octogenarians. [Angioplastie coronaire chez l'octogénaire]. // *Annales de Cardiologie et d'Angéiologie*, 57, 2008, № 6, p. 365-370. ISSN 0003-3928. DOI 10.1016/j.ancard.2008.09.009.

2653. **Sen, H., Tandjung, K., Basalus, M.W.Z., Löwik, M.M., Van Houwelingen, G.K., Stoel, M.G., Louwerenburg, H.W., De Man, F.H.A.F., Linssen, G.C.M., Nijhuis, R., Nienhuis, M.B., Verhorst, P.M.J., Van Der Palen, J., Von Birgelen, C.** Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE v drug-eluting stents. // *EuroIntervention*, 8, 2012, № 6, p. 664-671. ISSN 1774-024X. DOI 10.4244/EIJV8I6A104.
2654. **Sharma, A., Ezekowitz, J.A.** Similarities and differences in patient characteristics between heart failure registries versus clinical trials. // *Current Heart Failure Reports*, 10, 2013, № 4, p. 373-379. ISSN 1546-9530. DOI: 10.1007/s11897-013-0152-x.
2655. **Sleilaty, G., Achouh, P., Fabiani, J.-N.** Stenting or coronary artery bypass surgery for triple vessel disease? [Maladie coronaire tritronculaire : angioplastie/stent ou pontages aortocoronaires ? État actuel et revue de la littérature]. // *Annales de Cardiologie et d'Angéiologie*, 58, 2009, № 2, p. 104-112. ISSN 0003-3928. DOI 10.1016/j.ancard.2008.07.009.
2656. **Smilowitz, N.R., Carey, E.P., Shah, B., Hartigan, P.M., Plomondon, M.E., Maron, D.J., Maddox, T.M., Spertus, J.A., Mancini, G.B.J., Chaitman, B.R., Weintraub, W.S., Sedlis, S.P., Boden, W.E., COURAGE Trial Investigators and VA CART CL.** Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. // *American Journal of Cardiology*, 180, 2022, p. 1-9. ISSN 0002-9149. DOI 10.1016/j.amjcard.2022.06.049.
2657. **Smyth, B., Haber, A., Trongtrakul, K., Hawley, C., Perkovic, V., Woodward, M., Jardine, M.** Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis. // *JAMA Internal Medicine*, 179, 2019, № 10, p. 1316-1324. ISSN 2168-6106. DOI 10.1001/jamainternmed.2019.1501.
2658. **Streiner, D.L.** Commentary #1: Adaptive randomization. // *Journal of Clinical Psychopharmacology*, 34, 2014, № 1, p. 7-8. ISSN 0271-0749. DOI 10.1097/JCP.0000000000000083.
2659. **Sungkanuparph, S.** Mortality rates in HIV-infected patients with second failure of antiretroviral therapy are still high: A lesson from NA-ACCORD. // *Expert Review of Anti-Infective Therapy*, 8, 2010, № 4, p. 371-373. ISSN 1478-7210. DOI 10.1586/eri.10.18.
2660. **Trabattoni, D., Teruzzi, G., Montorsi, P., Fabbicchi, F., Gili, S., Calligaris, G., Grancini, L., Galli, S., Ravagnani, P., Bartorelli, A.** Comparison of the Effectiveness of Percutaneous Intervention of the Left-Main Coronary Artery With Everolimus-Eluting Stents in Women -Vs- Men. // *American Journal of Cardiology*, 124, 2019, № 9, p. 1357-1362. ISSN 0002-9149. DOI 10.1016/j.amjcard.2019.07.060.
2661. **Travieso, A., Salinas, P.** Complete revascularization and diabetes in the real world: observational data as a necessary addition to clinical trials. [Revascularización completa y diabetes en el mundo real: datos observacionales como complemento necesario de los ensayos clínicos]. // *REC: Interventional Cardiology*, 4, 2022, № 4, p. 267-268. ISSN 2604-7306. DOI 10.24875/RECICE.M22000327.

2662. **Uthamalingam, S., Ahmado, I., Selvaraj, V., Dewey, R., Flynn, J.** Long term outcomes in octogenarians undergoing percutaneous coronary intervention: Comparison of bare metal versus drug eluting stent. // *International Journal of Cardiology*, 179, 2015, p. 385-389. ISSN 0167-5273. DOI 10.1016/j.ijcard.2014.11.012.
2663. **Veerasamy, M., Edwards, R., Ford, G., Kirkwood, T., Newton, J., Jones, D., Kunadian, V.** Acute coronary syndrome among older patients: A review. // *Cardiology in Review*, 23, 2015, № 1, p. 26-32. ISSN 1061-5377. DOI 10.1097/CRD.000000000000016.
2664. **Visser, J.J., Van Sambeek, M.R.H.M., Hamza, T.H., Hunink, M.G.M., Bosch, J.L.** Ruptured abdominal aortic aneurysms: Endovascular repair versus open surgery - Systematic review. // *Radiology*, 245, 2007, № 1, p. 122-129. ISSN 0033-8419. DOI 10.1148/radiol.2451061204.
2665. **Visser, J.J., Williams, M., Kievit, J., Bosch, J.L.** Prediction of 30-day mortality after endovascular repair or open surgery in patients with ruptured abdominal aortic aneurysms. // *Journal of Vascular Surgery*, 49, 2009, № 5, p. 1093-1099. ISSN 0741-5214. DOI 10.1016/j.jvs.2008.12.027.
2666. **Von Birgelen, C., Van Der Heijden, L.C., Basalus, M.W.Z., Kok, M.M., Sen, H., Louwerenburg, H.W., Van Houwelingen, K.G., Stoel, M.G., De Man, F.H.A.F., Linssen, G.C.M., Tandjung, K., Doggen, C.J.M., Van Der Palen, J., Löwik, M.M.** Five-year outcome after implantation of zotarolimus- and everolimus-eluting stents in randomized trial participants and nonenrolled eligible patients: A secondary analysis of a randomized clinical trial. // *JAMA Cardiology*, 2, 2017, № 3, p. 268-276. ISSN 2380-6583. DOI 10.1001/jamacardio.2016.5190.
2667. **Xu, R., Wu, F., Lan, J., Duan, P.** Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis. // *Expert Review of Hematology*, 14, 2021, № 5, p. 493-502. ISSN 1747-4086. DOI 10.1080/17474086.2021.1920012.
2668. **Zhao, D., Yao, C.** Pragmatic Clinical Studies: An Emerging Clinical Research Discipline for Improving Evidence-Based Practice of Cardiovascular Diseases in Asia. // *Korean Circulation Journal*, 52, 2022, № 6, p. 401-413. ISSN 1738-5520. DOI 10.4070/KCJ.2022.0100.
2669. **Zingone, B.** Stenting the coronaries and bypassing the evidence in patients with multivessel coronary artery disease: Time to set the record straight. // *Journal of Cardiovascular Medicine*, 8, 2007, № 5, p. 362-370. ISSN 1558-2027. DOI 10.2459/JCM.0b013e32807fb088.

## **2005**

Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle E, Widimsky P, de Jaegere P, Scholte op Reimer WJ, Mercado N, Wijns W; European Society of Cardiology. Management and outcome of patients with established coronary artery disease: **the Euro Heart Survey** on coronary revascularization. *Eur Heart J*. 2005 Jun;26(12):1169-79. DOI 10.1093/eurheartj/ehi238. Epub 2005 Mar 31. PMID: 15802360.

**Cited by:**

2670. **AlHabib, K.F., Sulaiman, K., Al-Motarreb, A., Almahmeed, W., Asaad, N., Amin, H., Hersi, A., Al-Saif, S., AlNemer, K., Al-Lawati, J., Al-Sagheer, N.Q., AlBustani, N., Al Suwaidie, J.** Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2). // *Annals of Saudi Medicine*, 32, 2012, № 1, p. 9-18. ISSN 0256-4947. DOI 10.5144/0256-4947.2012.9.
2671. **Arbel, Y., Qiu, F., Bennell, M.C., Austin, P.C., Roifman, I., Rezai, M.R., Tu, J.V., Ko, D.T., Wijeyesundera, H.C.** Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study. // *American Heart Journal*, 175, 2016, p. 153-159. ISSN 0002-8703. DOI 10.1016/j.ahj.2016.02.014.
2672. **Aronow, H.D., Strawderman, R.L., Moscucci, M., Cowen, M.E.** Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. // *International Journal of Cardiology*, 153, 2011, № 3, p. 262-266. ISSN 0167-5273. DOI 10.1016/j.ijcard.2010.08.017.
2673. **Bakalli, A., Bekteshi, T., Sejdiu, B.** Physicians' acquaintance with a new procedure results in higher patient referral: Experience of Kosovo in coronary angiography. // *Heart International*, 7, 2012, № 1, art. no. e6, p. 32-35. ISSN 1826-1868. DOI 10.4081/hi.2012.e6.
2674. **Banasiak, W., Wilkins, A., Pociupany, R., Ponikowski, P.** Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study. // *Kardiologia Polska*, 66, 2008, № 6, p. 642-649. ISSN 0022-9032.
2675. **Barlis, P., Tanigawa, J., Kaplan, S., Di Mario, C.** Complex coronary interventions: Unprotected left main and bifurcation lesions. // *Journal of Interventional Cardiology*, 19, 2006, № 6, p. 510-524. ISSN 0896-4327. DOI 10.1111/j.1540-8183.2006.00203.x.
2676. **Barlis, P., Wong, M.C.G., Clark, D.J.** Stenting of Unprotected Left Main Coronary Artery Stenosis. // *Heart Lung and Circulation*, 16, 2007, Suppl. № 3, p. S34-S38. ISSN 1443-9506. DOI 10.1016/j.hlc.2007.04.003.
2677. **Bauer, T., Hamm, C.** Antiplatelet therapy in acute coronary syndrome: Prehospital phase: nothing, aspirin or what? [Akutes Koronarsyndrom und antithrombozytäre Therapie: Prähospital Phase: nichts, ASS oder?]. // *Herz*, 39, 2014, № 7, p. 803-807. ISSN 0340-9937. DOI 10.1007/s00059-014-4157-3.
2678. **Bauer, T., Zahn, R.** Modern treatment in acute coronary syndrome. [Moderne Therapie des akuten Koronarsyndroms]. // *Deutsche Medizinische Wochenschrift*, 137, 2012, № 14, p. 722-725. ISSN 0012-0472. DOI 10.1055/s-0031-1299012.
2679. **Bruguera-Cortada, J., García-García, C.** The antianginal effects of ivabradine. Its mechanism of action differentiates it from other antianginal drugs. [Eficacia antianginosa de la ivabradina. Mecanismos de acción diferenciales con otros



fármacos antianginosos]. // *Revista Espanola de Cardiologia Suplementos*, 7, 2007, № D, p. 46D-52D. ISSN 1131-3587.

2680. **Camm, A.J.** How does pure heart rate lowering impact on cardiac tolerability? // *European Heart Journal, Supplement*, 8, 2006, № D, p. D9-D15. ISSN 1520-765X. DOI 10.1093/eurheartj/sul019.
2681. **Cao, D., Chandiramani, R., Chiarito, M., Claessen, B.E., Mehran, R.** Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: A 40-year journey. // *European Heart Journal*, 42, 2021, № 4, p. 339-351. ISSN 0195-668X. DOI 10.1093/eurheartj/ehaa824.
2682. **Carrió, M.L., Ventura, J.L., Javierre, C., Rodríguez-Castro, D., Farrero, E., Torrado, H., Badia, M.B., Granados, J.** Does post-cardiac surgery magnesium supplementation improve outcome? // *Magnesium Research*, 25, 2012, № 4, p. 159-167. ISSN 0953-1424. DOI 10.1684/mrh.2012.0324.
2683. **Caruba, T., Chevreul, K., Zarca, K., Cadier, B., Juillière, Y., Dubourg, O., Sabatier, B., Danchin, N.** Annual cost of stable coronary artery disease in France: A modeling study. // *Archives of Cardiovascular Diseases*, 108, 2015, № 11, p. 576-588. ISSN 1875-2136. DOI 10.1016/j.acvd.2015.06.006.
2684. **Chen, S.-L., Ye, F., Zhang, J.-J., Lin, S., Tian, N.-L., Liu, Z.-Z., Qian, X.-S., Ding, S.-Q.** Comparison of a five-year clinical outcome between Chinese women and men with de novo coronary disease treated with implantation of a drug-eluting stent: A three-center, prospective, registry study. // *Chinese Medical Journal*, 125, 2012, № 1, p. 7-11. ISSN 0366-6999. DOI 10.3760/cma.j.issn.0366-6999.2012.01.002.
2685. **Corbett, R.H.** Ethical issues, justification, referral criteria for budget limited and high-dose procedures. // *Radiation Protection Dosimetry*, 130, 2008, № 2, p. 125-132. ISSN 0144-8420. DOI 10.1093/rpd/ncn089.
2686. **Crea, F., Greco, C.** Tradotto da guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of Non-ST-Segment elevation acute coronary syndromes of the European society of cardiology. [Linee guida per la diagnosi e il trattamento delle sindromi coronariche acute senza sopraslivellamento del tratto ST: Task Force per la Diagnosi e il Trattamento delle Sindromi Coronariche acute senza sopraslivellamento del tratto ST della società Europea di cardiologia]. // *Giornale Italiano di Cardiologia*, 8, 2007, № 10, p. 599-675. ISSN 1827-6806. DOI 10.34.3455/1111.
2687. **Cuneo, A., Tebbe, U.** The management of chronic total coronary occlusions. // *Minerva Cardioangiologica*, 56, 2008, № 5, p. 527-541. ISSN 0026-4725.
2688. **Daul, C., Lopez-Hernandez, J., Wolf, D., Karcher, G., Ethévenot, G.** 3-D multimodal cardiac data superimposition using 2-D image registration and 3-D reconstruction from multiple views. // *Image and Vision Computing*, 27, 2009, № 6, p. 790-802. ISSN 0262-8856. DOI 10.1016/j.imavis.2008.08.009.
2689. **De Paula, L.J.C., Lemos, P.A., Medeiros, C.R., Marin-Neto, J.A., Figueiredo, G.L., Polanczyk, C.A., Wainstein, M.V., Ribeiro, A.L.P., Lodi-Junqueira, L., Oliveira, F.R.A., Sarmiento-Leite, R., Mattos, L.A., Cantarelli, M.J.C., De Brito**

- Jr., F.S., Carvalho, A.C.C., Barbosa, M.R.** Construction and validation of an integrated percutaneous coronary intervention data system in Brazil (ICP-BR Registry): Clinical profile of the first 1,249 patients included. [Construção e validação de um sistema integrado de dados de intervenção coronária percutânea no Brasil (Registro ICP-BR): Perfil clínico dos primeiros 1.249 pacientes incluídos]. // *Revista Brasileira de Cardiologia Invasiva*, 18, 2010, № 3. ISSN 0104-1843.
2690. **Dimitriadis, K., Iliakis, P., Pyrpuris, N., Beneki, E., Tsioufis, P., Aznaouridis, K., Aggeli, K., Tsioufis, K.** Coronary sinus narrowing therapy: A “Reducer” for angina and beyond. // *Cardiovascular Revascularization Medicine*, 57, 2023, p. 96-105. ISSN 1553-8389. DOI 10.1016/j.carrev.2023.07.008.
2691. **Dörr, R.** Acute coronary syndrome - A challenge for the cooperation between outpatient and inpatient care. [Akutes koronarsyndrom - Eine herausforderung für die kooperation zwischen ambulanter und stationärer versorgung]. // *Herz*, 33, 2008, № 6, p. 395-401. ISSN 0340-9937. DOI 10.1007/s00059-008-3163-8.
2692. **Ducrocq, G., Bhatt, D.L., Labreuche, J., Corbalan, R., Porath, A., Gao, R., Panchenko, E., Liao, C.S., Ikeda, Y., Goto, S., Amarenco, P., Steg, P.G.** Geographic differences in outcomes in outpatients with established atherothrombotic disease: Results from the REACH Registry. // *European Journal of Preventive Cardiology*, 21, 2014, № 12, p. 1509-1516. ISSN 2047-4873. DOI 10.1177/2047487313501278.
2693. **Duggal, B., Subramanian, J., Duggal, M., Singh, P., Rajivlochan, M., Saunik, S., Desiraju, K., Avhad, A., Ram, U., Sen, S., Agrawal, A.** Survival outcomes post percutaneous coronary intervention: Why the hype about stent type? Lessons from a healthcare system in India. // *PLoS ONE*, 13, 2018, № 5, art. no. e0196830. ISSN 1932-6203. DOI 10.1371/journal.pone.0196830.
2694. **Ebbing, M., Bleie, Ø., Ueland, P.M., Nordrehaug, J.E., Nilsen, D.W., Vollset, S.E., Refsum, H., Ringdal Pedersen, E.K., Nygård, O.** Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. // *JAMA*, 300, 2008, № 7, p. 795-804. ISSN 0098-7484. DOI 10.1001/jama.300.7.795.
2695. **Eberli, F.R., Roffi, M.** Treatment after drug-eluting stent placement. [Nachbehandlung nach medikamentös beschichteten stents]. // *Herz*, 32, 2007, № 4, p. 301-306. ISSN 0340-9937. DOI 10.1007/s00059-007-3008-x.
2696. **El-Gamel, A., Chan, B.** Full Metal Jacket Endarterectomy of Left Anterior Descending Coronary Artery is Safe With Good Midterm Outcomes. // *Heart Lung and Circulation*, 30, 2021, № 4, p. 605-611. ISSN 1443-9506. DOI 10.1016/j.hlc.2020.08.007.
2697. **Escaned, J.** Secondary coronary revascularisation: An emerging issue. // *EuroIntervention*, 5, 2009, Suppl. № D, p. D6-D13. ISSN 1774-024X.
2698. **Escaned, J.** Secondary revascularization after CABG surgery. // *Nature Reviews Cardiology*, 9, 2012, № 9, p. 540-549. ISSN 1759-5002. DOI 10.1038/nrcardio.2012.100.
2699. **Falcone, C., Geroldi, D., Buzzi, M.P., Emanuele, E., Yilmaz, Y., Fontana, J.M., Vignali, L., Boiocchi, C., Sbarsi, I., Cuccia, M.** The -374T/A RAGE Polymorphism

Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease. // *Archives of Medical Research*, 39, 2008, № 3, p. 320-325. ISSN 0188-4409. DOI 10.1016/j.arcmed.2007.11.003.

2700. **Ferraro, S., Santagostino, M., Marano, G., Colli, E., Vendramin, C., Maffé, S., Rossi, L., Galvani, M., Panteghini, M., Bongo, A.S.** The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: A cautionary message. // *Scandinavian Journal of Clinical and Laboratory Investigation*, 72, 2012, № 5, p. 355-362. ISSN 0036-5513. DOI 10.3109/00365513.2012.671491.
2701. **García Tejada, J., González-Trevilla, A.A.** Stents and thrombosis. [Stents y trombosis]. // *Medicina Clínica*, 130, 2008, № 5, p. 175-176. ISSN 0025-7753. DOI 10.1157/13116322.
2702. **Gayed, M., Yadak, N., Qamhia, W., Daralammouri, Y., Ohlow, M.-A.** Comorbidities and complications in nonagenarians undergoing coronary angiography and intervention: Tertiary center analysis. // *International Heart Journal*, 58, 2017, № 2, p. 180-184. ISSN 1349-2365. DOI 10.1536/ihj.16-083.
2703. **Genders, T.S.S., Meijboom, W.B., Meijs, M.F.L., Schuijf, J.D., Mollet, N.R., Weustink, A.C., Pugliese, F., Bax, J.J., Cramer, M.J., Krestin, G.P., De Feyter, P.J., Hunink, M.G.M.** CT coronary angiography in patients suspected of having coronary artery disease: Decision making from various perspectives in the face of uncertainty. // *Radiology*, 253, 2009, № 3, p. 734-744. ISSN 0033-8419. DOI 10.1148/radiol.2533090507.
2704. **Geovanini, G.R., Gowdak, L.H.W., Pereira, A.C., De Jesus Danzi-Soares, N., Dourado, L.O.C., Poppi, N.T., Cesar, L.A.M., Drager, L.F., Lorenzi-Filho, G.** OSA and depression are common and independently associated with refractory angina in patients with coronary artery disease. // *Chest*, 146, 2014, № 1, p. 73-80. ISSN 0012-3692. DOI 10.1378/chest.13-2885.
2705. **Goeree, R., Blackhouse, G., Bowen, J.M., O'Reilly, D., Sutherland, S., Hopkins, R., Chow, B., Freeman, M., Provost, Y., Dennie, C., Cohen, E., Marcuzzi, D., Iwanochko, R., Moody, A., Paul, N., Parker, J.D.** Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. // *Expert Review of Pharmacoeconomics and Outcomes Research*, 13, 2013, № 5, p. 675-690. ISSN 1473-7167. DOI 10.1586/14737167.2013.838079.
2706. **Gonsorčík, J., Pella, D.** Heart rate reduction by ivabradine - Benefit for angina pectoris and chronic heart failure management. [Redukcia srdcovej frekvencie ivabradínom - Prínos pre manažment stabilnej angíny pectoris a chronického srdcového zlyhávania]. // *Kardiologia*, 17, 2008, № 3, p. 122-129. ISSN 1210-0048.
2707. **Gravning, J., Ueland, T., Mørkrid, L., Endresen, K., Aaberge, L., Kjekshus, J.** Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris. // *Scandinavian Cardiovascular Journal*, 42, 2008, № 3, p. 214-221. ISSN 1401-7431. DOI 10.1080/14017430801932824.

2708. **Green, A., Alton, E.** Cardiac repair clinical trials. – In: *Advances in Tissue Engineering*, 2008, p. 695-731. ISBN 9781848161832; 9781848161825. DOI 10.1142/9781848161832\_0033.
2709. **Gudnason, T., Gudnadottir, G.S., Lagerqvist, B., Eyjolfsson, K., Nilsson, T., Thorgeirsson, G., Thorgeirsson, G., Andersen, K., James, S.** Comparison of interventional cardiology in two European countries: A nationwide internet based registry study. // *International Journal of Cardiology*, 168, 2013, № 2, p. 1237-1242. ISSN 0167-5273. DOI 10.1016/j.ijcard.2012.11.054.
2710. **Hájek, P.** Timing and selection of the type of revascularization procedure in acute coronary syndrome without ST-segment elevation with multivessel coronary artery disease. [Načasování a výběr způsobu revaskularizace při akutním koronárním syndromu bez elevací úseku ST s vícečetným postižením věnčitých tepen]. // *Cor et Vasa*, 52, 2010, № 7/8, p. 447-452. ISSN 0010-8650. DOI 10.33678/cor.2010.119.
2711. **Hamm, C.W., Elsaesser, A.** Indications in acute coronary syndromes without st elevation (NSTEMI-ACS). – In: *Interventional Cardiology: Principles and Practice*, 2011, p. 232-241. ISBN 9781405178877. DOI 10.1002/9781444319446.ch15.
2712. **Hammoudeh, A.J., Alhaddad, I.A., Khader, Y., Tabbalat, R., Al-Mousa, E., Saleh, A., Jarrah, M., Nammas, A., Izraiq, M.** Cardiovascular risk factors in Middle Eastern patients undergoing percutaneous coronary intervention: Results from the first Jordanian percutaneous coronary intervention study. // *Journal of the Saudi Heart Association*, 29, 2017, № 3, p. 195-202. ISSN 1016-7315. DOI 10.1016/j.jsha.2016.10.002.
2713. **Hammoudeh, A.J., Kharabsheh, H., Khader, Y., Tabbalat, R., Alhaddad, I., Nammas, A., Izraiq, M., Mousa, E.A., Saleh, A.** Adherence to clinical practice guidelines and use of secondary cardiovascular prevention medications in Middle Eastern patients undergoing percutaneous coronary intervention: Results from the first Jordanian PCI Registry (JOPCR1). // *Jordan Medical Journal*, 53, 2019, № 3, p. 127-137. ISSN 0446-9283.
2714. **Hao, F., Zhang, H.-J., Zhu, J., Kuang, H., Yu, Q., Bai, M., Mu, J.** Association between vaspin level and coronary artery disease in patients with type 2 diabetes. // *Diabetes Research and Clinical Practice*, 113, 2016, p. 26-32. ISSN 0168-8227. DOI 10.1016/j.diabres.2015.12.001.
2715. **Henry, T.D., Satran, D., Hodges, J.S., Johnson, R.K., Poulouse, A.K., Campbell, A.R., Garberich, R.F., Bart, B.A., Olson, R.E., Boisjolie, C.R., Harvey, K.L., Arndt, T.L., Traverse, J.H.** Long-term survival in patients with refractory angina. // *European Heart Journal*, 34, 2013, № 34, p. 2683-2688. ISSN 0195-668X. DOI 10.1093/eurheartj/eh165.
2716. **Hilliard, A.A., From, A.M., Lennon, R.J., Singh, M., Lerman, A., Gersh, B.J., Holmes Jr., D.R., Rihal, C.S., Prasad, A.** Percutaneous Revascularization for Stable Coronary Artery Disease. Temporal Trends and Impact of Drug-Eluting Stents. // *JACC: Cardiovascular Interventions*, 3, 2010, № 2, p. 172-179. ISSN 1936-8798. DOI 10.1016/j.jcin.2009.11.013.
2717. **Hochholzer, W., Buettner, H.J., Trenk, D., Breidhardt, T., Noveanu, M., Laule, K., Christ, M., Schindler, C., Neumann, F.-J., Mueller, C.** Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting as Primary Revascularization

in Patients With Acute Coronary Syndrome. // *American Journal of Cardiology*, 102, 2008, № 2, p. 173-179. ISSN 0002-9149. DOI 10.1016/j.amjcard.2008.03.033.

2718. **Isik, T., Ayhan, E., Uyarel, H., Akkaya, E., Ergelen, M., Cicek, G., Vuruskan, E., Kurt, M., Tanboga, I.H., Eren, M.** Circadian, weekly, and seasonal variation in early stent thrombosis patients who previously underwent primary percutaneous intervention with st elevation myocardial infarction. // *Clinical and Applied Thrombosis/Hemostasis*, 19, 2013, № 6, p. 679-684. ISSN 1076-0296. DOI 10.1177/1076029612445918.
2719. **Ivanov, A.G., Kharkov, E.I., Tsybulskaya, N.Yu., Yaskevich, R.A., Davydov, E.L., Baron, I.I.** Gender-age features of the state of the coronary arteries in people with first-time angina pectoris. // *Clinical Review for General Practice*, 3, 2022, № 5, p. 10-15. ISSN 2713-2552. DOI 10.47407/kr2022.3.5.00157.
2720. **Jang, J.-S., Choi, K.-N., Jin, H.-Y., Seo, J.-S., Yang, T.-H., Kim, D.-K., Kim, D.-S., Urm, S.-H., Chun, J.H., Kang, S.-J., Park, D.-W., Lee, S.-W., Kim, Y.-H., Lee, C.W., Park, S.-W., Park, S.-J.** Meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease. // *American Journal of Cardiology*, 110, 2012, № 10, p. 1411-1418. ISSN 0002-9149. DOI 10.1016/j.amjcard.2012.06.051.
2721. **Jankowski, P., Kawecka-Jaszcz, K., Czarnecka, D., Bryniarski, L., Brzozowska-Kiszka, M., Kić-Wilk, B., Dymek, G., Kopacz, E., Królikowski, T., Dudek, D.** Gender does not influence event-free survival in patients with ischaemic heart disease undergoing non-emergency coronary angiography. A single centre analysis. // *Kardiologia Polska*, 65, 2007, № 5, p. 475-484. ISSN 0022-9032.
2722. **Jarrah, M., Hammoudeh, A., Okkeh, O., Khader, Y., Gharaibeh, S., Nasser, L., Rasheed, A., Al-Hindi, A., Mohealdeh, M., Kharabsheh, H., Abunimeh, H., Hijjeh, E., Tashman, L., Omar, D., Kufoof, N., on behalf of the First Jordanian PCI Registry Investigators Group.** Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. results from the first Jordanian PCR (PCR1). // *Anatolian Journal of Cardiology*, 17, 2017, № 6, p. 445-451. ISSN 2149-2263. DOI 10.14744/AnatolJCardiol.2017.7530.
2723. **Jarrah, M., Hammoudeh, A.J., Khader, Y., Tabbalat, R., Al-Mousa, E., Okkeh, O., Alhaddad, I.A., Tawalbeh, L.I., Hweidi, I.M.** Reality of obesity paradox: Results of percutaneous coronary intervention in Middle Eastern patients. // *Journal of International Medical Research*, 46, 2018, № 4, p. 1595-1605. ISSN 0300-0605. DOI 10.1177/0300060518757354.
2724. **Jarrah, M.I., Hammoudeh, A.J., Al-Natour, D.B., Khader, Y.S., Tabbalat, R.A., Alhaddad, I.A., Kullab, S.M.** Gender differences in risk profile and outcome of Middle Eastern patients undergoing percutaneous coronary intervention. // *Saudi Medical Journal*, 38, 2017, № 2, p. 149-155. ISSN 0379-5284. DOI 10.15537/smj.2017.2.16301.
2725. **Jau, P., Jacob, T., Lecorff, G., Bouvier, J.-L., Novella, P., Bechet, V., Pelet, V.** Myocardial perfusion SPECT in stable angina. [Place de la scintigraphie myocardique dans l'angor stable]. // *Medecine Nucleaire*, 34, 2010, № 3, p. 178-183. ISSN 0928-1258. DOI 10.1016/j.mednuc.2010.01.005.



2726. **Jaworski, R., Jankowska, E.A., Ponikowski, P., Banasiak, W.** Costs of management of patients with coronary artery disease in Poland: The multicenter RECENT study. // *Polskie Archiwum Medycyny Wewnętrznej*, 122, 2012, № 12, p. 599-607. ISSN 0032-3772. DOI 10.20452/pamw.1533.
2727. **Katritsis, D.G., Ioannidis, J.P.A.** PCI for stable coronary disease [1]. // *New England Journal of Medicine*, 357, 2007, № 4, p. 414-418. ISSN 0028-4793. DOI 10.1056/NEJMc071317.
2728. **Kerl, J.M., Schoepf, U.J., Vogl, T.J., Ackermann, H., Vogt, S., Costello, P., Herzog, C.** In vitro evaluation of metallic coronary artery stents with 64-MDCT using an ECG-Gated cardiac phantom: Relationship between in-stent visualization, stent type, and heart rate. // *American Journal of Roentgenology*, 194, 2010, № 3, p. W256-W262. ISSN 0361-803X. DOI 10.2214/AJR.09.2318.
2729. **Khalifa, A.A., Cornily, J.-C., David, C.H., Choplain, J.-N., Le Gal, G., Barra, J.A., Bezou, E.** Medium-term survival of diffuse coronary artery disease patients following coronary artery reconstruction with the internal thoracic artery. // *Cardiology*, 120, 2012, № 4, p. 192-199. ISSN 0008-6312. DOI 10.1159/000335068.
2730. **Khan, M.F., Wesarg, S., Gurung, J., Dogan, S., Maataoui, A., Brehmer, B., Herzog, C., Ackermann, H., Aßmus, B., Vogl, T.J.** Facilitating coronary artery evaluation in MDCT using a 3D automatic vessel segmentation tool. // *European Radiology*, 16, 2006, № 8, p. 1789-1795. ISSN 0938-7994. DOI 10.1007/s00330-006-0159-8.
2731. **Khan, S.N., Dutka, D.P.** A systematic approach to refractory angina. // *Current Opinion in Supportive and Palliative Care*, 2, 2008, № 4, p. 247-251. ISSN 1751-4258. DOI 10.1097/SPC.0b013e32831a86c7.
2732. **Khare, R.K., Courtney, D.M., Powell, E.S., Venkatesh, A.K., Lee, T.A.** Sixty-four-slice computed tomography of the coronary arteries: Cost-effectiveness analysis of patients presenting to the emergency department with low-risk chest pain. // *Academic Emergency Medicine*, 15, 2008, № 7, p. 623-632. ISSN 1069-6563. DOI 10.1111/j.1553-2712.2008.00161.x.
2733. **Kim, J.-H., Lee, S.H., Joo, H.-C., Yoo, K.-J., Youn, Y.-N.** Repeated Target Vessel Revascularization After Coronary Artery Bypass for In-Stent Restenosis. // *Annals of Thoracic Surgery*, 104, 2017, № 4, p. 1332-1339. ISSN 0003-4975. DOI 10.1016/j.athoracsur.2017.03.034.
2734. **Kim, W., Kim, Y.-J., Lee, W.-J., Lee, S.-H., Hong, G.-R., Park, J.-S., Shin, D.-G., Shim, B.-S., Cho, Y.-K., Kim, H.-S., Nam, C.-W., Hur, S.-H., Kim, Y.-N., Kim, K.-B., Yang, T.-H., Kim, D.-K., Kim, S.-M., Kim, D.-I., Kim, D.-S.** Lesion location: Its impacts on the procedural and postprocedural outcomes of unprotected left main coronary stenting. // *Korean Circulation Journal*, 37, 2007, № 9, p. 419-424. ISSN 1738-5520. DOI 10.4070/kcj.2007.37.9.419.
2735. **Kim, W., Park, J.-S., Lee, S.-H., Hong, G.-R., Shin, D.-G., Kim, Y.-J., Shim, B.-S., Cho, Y.-K., Kim, H.-S., Nam, C.-W., Hur, S.-H., Kim, Y.-N., Kim, K.-B., Seol, S.-H., Yang, T.-H., Kim, D.-K., Kim, S.-M., Kim, D.-I., Kim, D.-S.** Risk factors associated with hemodynamic instability during stent implantation in unprotected left main lesions without routine IABP: Identification of the high risk patients. //

2736. **Kocher, A.A., Schlechta, B., Gasparovicova, A., Wolner, E., Bonaros, N., Laufer, G.** Stem cells and cardiac regeneration. // *Transplant International*, 20, 2007, № 9, p. 731-746. ISSN 0934-0874. DOI 10.1111/j.1432-2277.2007.00493.x.
2737. **Kofler, B., Mueller, E.E., Eder, W., Stanger, O., Maier, R., Weger, M., Haas, A., Winker, R., Schmut, O., Paulweber, B., Iglseder, B., Renner, W., Wiesbauer, M., Aigner, I., Santic, D., Zimmermann, F.A., Mayr, J.A., Sperl, W.** Mitochondrial DNA haplogroup T is associated with coronary artery disease and diabetic retinopathy: A case control study. // *BMC Medical Genetics*, 10, 2009, art. no. 35. ISSN 1471-2350. DOI 10.1186/1471-2350-10-35.
2738. **Koziński, M., Sukiennik, A., Sinkiewicz, W., Kochman, W., Kubica, J.** Drug-eluting stent-associated thrombosis: Clinical relevance of impaired vessel-wall healing. [Zakrzepica w stentach uwalniających leki. Kliniczne znaczenie zaburzonego gojenia się ściany naczynia]. // *Postepy Higieny i Medycyny Doswiadczalnej*, 62, 2008, p. 185-205. ISSN 0032-5449.
2739. **Kupferwasser, L.I., Lee, M.S., Schapira, J.N., Makkar, R.R.** Percutaneous coronary intervention in unprotected left main disease: A status report. // *Minerva Cardioangiologica*, 54, 2006, № 5, p. 633-641. ISSN 0026-4725.
2740. **Lima Filho, M.D.O., De Figueiredo, G.L., Haddad, J.L., Schmidt, A., Lima, N.K.D.C.** Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention. [Tratamento clínico adjuvante no paciente diabético submetido à intervenção coronariana percutânea]. // *Arquivos Brasileiros de Endocrinologia e Metabologia*, 51, 2007, № 2, p. 334-344. ISSN 0004-2730. DOI 10.1590/s0004-27302007000200025.
2741. **Liu, C., Yan, H.-B., Zhao, H.-J., Song, L., Zheng, B., Chi, Y.-P., Wang, S.-P., Wang, J., Peng, H.-Y., Wu, Z.** Associated factors with repeat coronary angioplasty during the drug eluting stent era: A high volume center investigation. // *Chinese Medical Journal*, 126, 2013, № 3, p. 446-449. ISSN 0366-6999. DOI 10.3760/cma.j.issn.0366-6999.20113185.
2742. **Madeira, S., Brízido, C., Raposo, L., Brito, J., Vale, N., Leal, S., Gonçalves, P.D.A., Gabriel, H.M., Teles, R.C., Almeida, M.** Non-pharmacological treatment of refractory angina: The coronary sinus reducer, the new kid on the block. [Tratamento não farmacológico da angina refratária. Dispositivo de redução do seio coronário, uma nova alternativa terapêutica]. // *Revista Portuguesa de Cardiologia*, 40, 2021, № 5, p. 371-382. ISSN 0870-2551. DOI 10.1016/j.repc.2020.09.005.
2743. **Martínez-Ríos, M.A., Méndez-Ortíz, A., Gaspar, J., Barragán-García, R., Fernández-de-la-Reguera, G., González-Quesada, C.J.** Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy. // *Archivos de Cardiologia de Mexico*, 78, 2008, № 4, p. 407-412. ISSN 1405-9940.
2744. **Motovska, Z.** Management of antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing non-cardiac surgery. // *Drugs*, 71, 2011, № 14, p. 1797-1806. ISSN 0012-6667. DOI 10.2165/11594260-000000000-00000.

2745. **Mukherjee, D.** Optimizing management of patients with coronary artery disease: How do we get there? // *European Heart Journal*, 26, 2005, № 12, p. 1147-1149. ISSN 0195-668X. DOI 10.1093/eurheartj/ehi247.
2746. **Musumeci, G., Baroni, M., Rossini, R.** GP IIb/IIIa inhibitors for STEMI: Still the gold standard or an old survivor? // *Current Vascular Pharmacology*, 10, 2012, № 4, p. 443-447. ISSN 1570-1611. DOI 10.2174/157016112800812737.
2747. **Navas Lobato, M.A., Martín Reyes, R., Peinado Peinado, R., Lurueña Lobo, P., Roldán Rabadán, I., López Sendón, J.L.** Clinical characteristics, epidemiology and prognosis of acute coronary syndrome without ST-segment elevation and angiographically normal coronary arteries. [Características clínicas, epidemiología y pronóstico del síndrome coronario agudo sin elevación del segmento ST con coronarias sanas]. // *Medicina Clínica*, 131, 2008, № 17, p. 653-655. ISSN 0025-7753. DOI 10.1157/13128723.
2748. **Neglia, D., Rimoldi, O., Kaufmann, P.A., Camici, P.G.** Radionuclide PET and PET/CT in coronary artery disease. // *Current Pharmaceutical Design*, 14, 2008, № 18, p. 1798-1814. ISSN 1381-6128. DOI 10.2174/138161208784746662.
2749. **Neužil, P., Pavlíčková, P.** Analysis of the BARI 2D study - Revascularization and the use of anti-diabetic drugs in patients with Type 2 diabetes and coronary heart disease. [Analýza studie BARI 2D - Strategie revaskularizační a antidiabetické léčby nemocných s DM 2. typu a ICHS]. // *Praktický Lekar*, 90, 2010, № 1, p. 34-39. ISSN 0032-6739.
2750. **Niccoli, G., Sgueglia, G.A., Cosentino, N., Piro, M., Toma, A., Cataneo, L., Fracassi, F., Porto, I., Leone, A.M., Burzotta, F., Trani, C., Crea, F.** Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease. // *European Journal of Preventive Cardiology*, 19, 2012, № 5, p. 914-926. ISSN 2047-4873. DOI 10.1177/1741826711420001.
2751. **Ohlow, M.-A., Hassan, A., Lotze, U., Lauer, B.** Cardiac catheterisation in nonagenarians: Single center experience. // *Journal of Geriatric Cardiology*, 9, 2012, № 2, p. 148-152. ISSN 1671-5411. DOI 10.3724/SP.J.1263.2012.01042.
2752. **Ohlow, M.-A., Secknus, M.-A., Von Korn, H., Göttel, C., Wagner, A., Yu, J., Farah, A., Lauer, B.** Characteristics, clinical presentation and outcome of nonogenarians with acute coronary syndrome. [Patienten älter als 90 Jahre mit akutem koronarsyndrom: Charakteristika, klinische präsentation und outcome]. // *Notarzt*, 24, 2008, № 6, p. 203-206. ISSN 0177-2309. DOI: 10.1055/s-2008-1067533.
2753. **Ohlow, M.-A., Secknus, M.-A., Von Korn, H., Wagner, A., Yu, J., Lauer, B.** Contemporary outcome of cardiac catheterization in nonogenarians. // *Journal of the American Geriatrics Society*, 56, 2008, № 9, p. 1764-1766. ISSN 0002-8614. DOI 10.1111/j.1532-5415.2008.01809.x.
2754. **Olivari, Z., Stritoni, P., Burelli, C., McMahon, L., Capodaglio, G., Fedeli, U., Avossa, F., De Servi, S., Favero, L.** Management and 5-year outcome of patients with coronary artery disease in different periods of stent technology. // *Journal of Cardiovascular Medicine*, 21, 2020, № 6, p. 444-452. ISSN 1558-2027. DOI 10.2459/JCM.0000000000000955.

2755. **O'Mahony, C., Rothman, M., Mathur, A.** A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. // *Interventional Cardiology*, 6, 2014, № 5, p. 453-462. ISSN 1755-5302. DOI 10.2217/ica.14.47.
2756. **Onuma, Y., Kukreja, N., Daemen, J., Garcia-Garcia, H.M., Gonzalo, N., Cheng, J.M., van Twisk, P.H., van Domburg, R., Serruys, P.W.** Impact of Sex on 3-Year Outcome After Percutaneous Coronary Intervention Using Bare-Metal and Drug-Eluting Stents in Previously Untreated Coronary Artery Disease. Insights From the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. // *JACC: Cardiovascular Interventions*, 2, 2009, № 7, p. 603-610. ISSN 1936-8798. DOI 10.1016/j.jcin.2009.03.016.
2757. **Opie, L.H., Commerford, P.J., Gersh, B.J.** Controversies in Cardiology 1: Controversies in stable coronary artery disease. // *Lancet*, 367, 2006, № 9504, p. 69-78. ISSN 0140-6736. DOI 10.1016/S0140-6736(06)67927-0.
2758. **Pahlajani, D., Kaul, U., Mishra, A., Mullasari, A., Sawhney, J.P.S., Dargad, R., Mehta, K., Brar, S., Radhakrishnan, R., McMahon, D., Ibrahim, S., Sachanandani, H., Sinha, N.** Medical management and diagnostic testing among stable angina patients in India: The STable Angina obseRvational (STAR) registry. // *Journal of Association of Physicians of India*, 63, 2015, p. 20-26. ISSN 0004-5772.
2759. **Pavlícková, L., Neužil, P.** BARI 2D - Where has it taken us to and what the future has in store for us. [BARI 2D - Kam nás dovedla a co bude dál]. // *Cor et Vasa*, 52, 2010, № 3, p. 168-175. ISSN 0010-8650. DOI 10.33678/cor.2010.044.
2760. **Pendyala, L., Goodchild, T., Gadesam, R.R., Chen, J., Robinson, K., Chronos, N., Gou, D.** Cellular cardiomyoplasty and cardiac regeneration. // *Current Cardiology Reviews*, 4, 2008, № 2, p. 72-80. ISSN 1573-403X. DOI 10.2174/157340308784245748.
2761. **Pérez-Vizcayno, M.J., Hernández-Antolín, R.A., Alfonso, F., De Lucas, C.B., Escaned, J., Jiménez, P., Fernández-Ortiz, A., Fernández, C., Macaya, C.** Changes in percutaneous coronary intervention over the last 20 years: Demographic, epidemiologic and clinical characteristics, techniques, and outcomes. [Evolución en los últimos 20 años en el perfil demográfico, epidemiológico y clínico, técnica y resultados de los procedimientos coronarios percutáneos]. // *Revista Espanola de Cardiologia*, 60, 2007, № 9, p. 932-942. ISSN 0300-8932. DOI 10.1157/13109646.
2762. **Philippe, F.** Ischemic heart disease: Focus on pharmacological treatment in 2008. [Cardiopathie ischémique: Le point sur le traitement pharmacologique en 2008]. // *Medecine des Maladies Metaboliques*, 2, 2008, № 3, p. 241-247. ISSN 1957-2557. DOI 10.1016/S1957-2557(08)71666-3.
2763. **Porto, I., Dato, I., Todaro, D., Calabrese, M., Rigattieri, S., Leone, A.M., Niccoli, G., Burzotta, F., Trani, C., Crea, F.** Comparison of two- and three-dimensional quantitative coronary angiography to intravascular ultrasound in the assessment of intermediate left main stenosis. // *American Journal of Cardiology*, 109, 2012, № 11, p. 1600-1607. ISSN 0002-9149. DOI 10.1016/j.amjcard.2012.01.386.
2764. **Puehler, T., Haneya, A., Philipp, A., Zausig, Y.A., Kobuch, R., Diez, C., Birnbaum, D.E., Schmid, C.** Minimized extracorporeal circulation system in coronary artery bypass surgery: A 10-year single-center experience with 2243

patients. // *European Journal of Cardio-thoracic Surgery*, 39, 2011, № 4, p. 459-464. ISSN 1010-7940. DOI: 10.1016/j.ejcts.2010.08.006.

2765. **Puymirat, E., Blanchard, D., Perier, M.-C., Piadonataccio, M., Gilard, M., Lefèvre, T., Mulak, G., Le Breton, H., Danchin, N., Spaulding, C., Jouven, X.** Study design and baseline characteristics of the national observational study of diagnostic and interventional cardiac catheterization by the french society of cardiology. // *American Journal of Cardiology*, 112, 2013, № 3, p. 336-342. ISSN 0002-9149. DOI 10.1016/j.amjcard.2013.03.030.
2766. **Radhakrishnan, K., Galvin, S.D., El-Gamel, A.** Outcomes of long left coronary endarterectomy in patients with diffuse coronary artery disease. // *Vessel Plus*, 3, 2019, art. no. A76. ISSN 2574-1209. DOI 10.20517/2574-1209.2019.23.
2767. **Rodrigo, S.F., Mann, I., van Ramshorst, J., Beeres, S.L., Zwaginga, J.J., Fibbe, W.E., Bax, J.J., Schali, M.J., Atsma, D.E.** Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long-term results. // *Journal of Interventional Cardiology*, 30, 2017, № 5, p. 440-447. ISSN 0896-4327. DOI 10.1111/joic.12408.
2768. **Rodríguez-Leor, O., de la Torre-Hernández, J.M., García-Camarero, T., López-Palop, R., del Blanco, B.G., Carrillo, X., Portero-Portaz, J.J., Jiménez-Kockar, M., Gómez-Lara, J., Ojeda, S., Alfonso, F., Brugaletta, S., del Viejo, A.P., Linares, J.A., Fernández-Cisnal, A., Vaquerizo, B., Fernández-Salinas, F., Díaz-Fernández, J.F., Rama-Merchán, J.C., Molina, E., Muñoz-García, É., Morales, F., Trillo, R., Tellería, M., Rondán, J., Avanzas, P., Moreu, J., Baz-Alonso, J.A., Hernández, F., Escaned, J., Sanchis, J., Lozano, F., Toledano, B., Puigfel, M., Sádaba, M., de Prado, A.P.** Rationale and design of the Concordance study between FFR and iFR for the assessment of lesions in the left main coronary artery. The ILITRO-EPIC-07 Trial. [Justificación y diseño del estudio Concordancia entre RFF e iFR en lesiones del tronco común. Estudio iLITRO-EPIC-07]. // *REC: Interventional Cardiology*, 4, 2022, № 1, p. 19-26. ISSN 2604-7306. DOI 10.24875/RECICE.M21000227.
2769. **Roura-Ferrer, G., Gómez-Hospital, J.A., Cequier, A.** Secondary revascularization after coronary surgery. // *Minerva Cardioangiologica*, 59, 2011, № 1, p. 61-74. ISSN 0026-4725.
2770. **Rowinska, Z., Koepfel, T.A., Sanati, M., Schelzig, H., Jankowski, J., Weber, C., Zerneck, A., Liehn, E.A.** Role of the CX3C chemokine receptor CX3CR1 in the pathogenesis of atherosclerosis after aortic transplantation. // *PLoS ONE*, 12, 2017, № 2, art. no. e0170644. ISSN 1932-6203. DOI 10.1371/journal.pone.0170644.
2771. **Sánchez González, C., Roa Garrido, J., en representacion del Grupo de Trabajo en Hemodinamica de la Sociedad Andaluza de Cardiología, Equipo de Investigadores del Estudio RETRATO.** Current treatment of unprotected left main coronary artery disease: Situation in Andalusia and justification for the RETRATO Study. [Tratamiento actual de la enfermedad del tronco común de la coronaria izquierda no protegido. Situación en Andalucía y justificación del estudio RETRATO]. // *CardiCore*, 51, 2016, № 2, p. 76-80. ISSN 1889-898X. DOI 10.1016/j.carcor.2013.11.002.
2772. **Seraphim, A., Knott, K.D., Augusto, J.B., Menacho, K., Tyebally, S., Dowsing, B., Bhattacharyya, S., Menezes, L.J., Jones, D.A., Uppal, R., Moon, J.C.,**



- Manisty, C.** Non-invasive Ischaemia Testing in Patients With Prior Coronary Artery Bypass Graft Surgery: Technical Challenges, Limitations, and Future Directions. // *Frontiers in Cardiovascular Medicine*, 8, 2021, art. no. 795195. ISSN 2297-055X. DOI 10.3389/fcvm.2021.795195.
2773. **Shiryaev, A.A., Akchurin, R.S., Vlasova, E.E., Vasiliev, V.P., Galyautdinov, D.M., Kurbanov, S.K., Zaikovskii, V.Y.** Annual outcomes of coronary artery bypass grafting in patients with diffuse lesion of coronary arteries. // *Kardiologiya i Serdechno-Sosudistaya Khirurgiya*, 14, 2021, № 5, p. 413-419. ISSN 1996-6385. DOI 10.17116/KARDIO202114051413.
2774. **Sibai, A.M., Tohme, R.A., Saade, G.A., Ghanem, G., Alam, S.** The appropriateness of use of coronary angiography in Lebanon: Implications for health policy. // *Health Policy and Planning*, 23, 2008, № 3, p. 210-217. ISSN 0268-1080. DOI 10.1093/heapol/czn005.
2775. **Simoons, M.L., Windecker, S.** Chronic stable coronary artery disease: Drugs vs. revascularization. // *European Heart Journal*, 31, 2010, № 5, p. 530-541. ISSN 0195-668X. DOI 10.1093/eurheartj/ehp605.
2776. **Simsek, C., Pedersen, S.S., van Gestel, Y.R.B.M., Erdman, R.A.M., Daemen, J., Serruys, P.W., van Domburg, R.T.** Feelings of being disabled as a prognostic factor for mortality in the drug-eluting stent era. // *Journal of Psychosomatic Research*, 67, 2009, № 1, p. 85-91. ISSN 0022-3999. DOI 10.1016/j.jpsychores.2008.10.011.
2777. **Simsekyilmaz, S., Liehn, E.A., Weinandy, S., Schreiber, F., Megens, R.T.A., Theelen, W., Smeets, R., Jockenhövel, S., Gries, T., Möller, M., Klee, D., Weber, C., Zerneck, A.** Targeting in-stent-stenosis with RGD- and CXCL1-coated mini-stents in mice. // *PLoS ONE*, 11, 2016, № 5, art. no. e0155829. ISSN 1932-6203. DOI 10.1371/journal.pone.0155829.
2778. **Sokolov, M.Yu., Danylchuk, I.V., Besh, D.I., Klantsa, A.I., Kolesnyk, V.O., Rafalyuk, O.I., Salo, V.M., Salo, S.V., Sorokhtey, L.V., Furkalo, S.M.** Registry of percutaneous coronary interventions: changes over recent years (2010–2022). // *Ukrainian Journal of Cardiology*, 31, 2024, № 1, p. 7-33. ISSN 1608-635X. DOI 10.31928/2664-4479-2024.1.733.
2779. **Stramba-Badiale, M.** Women and research on cardiovascular diseases in Europe: A report from the European Heart Health Strategy (EuroHeart) project. // *European Heart Journal*, 31, 2010, № 14, p. 1677-1681+1681a-1681d. ISSN 0195-668X. DOI 10.1093/eurheartj/ehq094.
2780. **Szekely, L., György, M., Juhász, B., Szabó, J.Z., Szudi, L., Paulovich, E., Lonkay, E., Horkay, F.** Heart surgery among octogenarians fiction or reality. [Szívmu tetek nyolcvanéves életkor felett Ábránd vagy valóság]. // *Lege Artis Medicinae*, 20, 2010, № 2, p. 105-111. ISSN 0866-4811.
2781. **Tanigawa, J., Sutaria, N., Goktekin, O., Di Mario, C.** Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era. // *Journal of Interventional Cardiology*, 18, 2005, № 6, p. 455-465. ISSN 0896-4327. DOI 10.1111/j.1540-8183.2005.00086.x.
2782. **Tobis, J., Azarbal, B., Slavin, L.** Assessment of Intermediate Severity Coronary Lesions in the Catheterization Laboratory. // *Journal of the American College of*

2783. **Träff, E., Venetsanos, D., Alpkvist, K., Sederholm Lawesson, S., Skibniewski, M., Zwackman, S., Alfredsson, J.** Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography. // *Cardiology (Switzerland)*, 147, 2022, № 5/6, p. 486-496. ISSN 0008-6312. DOI 10.1159/000527459.
2784. **Valgimigli, M., Minarelli, M.** Triple antiplatelet therapy in acute coronary syndromes. // *Drugs*, 71, 2011, № 13, p. 1703-1719. ISSN 0012-6667. DOI 10.2165/11594100-000000000-00000.
2785. **Wasilewski, J., Poloński, L., Lekston, A., Osadnik, T., Reguła, R., Bujak, K., Kurek, A.** Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center. // *Trials*, 16, 2015, № 1, art. no. 411. ISSN 1745-6215. DOI 10.1186/s13063-015-0934-4.
2786. **Widimský, J., Vaněk, P., Jurán, F., Lánská, V.** Current status of cardiovascular pharmacotherapy in patients after myocardial infarction and/or revascularization in the Czech Republic in 2005. Developments seen during the past 5 and 10 years. [Stav kardiologické farmakoterapie u nemocných po infarktu myokardu a/nebo revaskularizaci myokardu v roce 2005 v České republice. Vývoj za 5 a 10 let]. // *Cor et Vasa*, 48, 2006, № 4, p. 135-141. ISSN 0010-8650. DOI 10.33678/cor.2006.046.
2787. **Wienbergen, H., Schwaab, B., Bjarnason-Wehrens, B., Guha, M., Laszlo, R., Burgstahler, C., von Haehling, S., Halle, M., Zahn, R., Hambrecht, R.** Physician support for outpatient cardiac rehabilitation groups: Position paper of the German Cardiac Society (DGK) in cooperation with the German Society for Prevention and Rehabilitation of Cardiovascular Diseases (DGPR). [Ärztliche Betreuung von ambulanten Herzgruppen: Positionspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK) in Kooperation mit der Deutschen Gesellschaft für Prävention und Rehabilitation von Herz-Kreislaufkrankungen (DGPR)]. // *Kardiologie*, 15, 2021, № 1, p. 11-18. ISSN 1864-9718. DOI 10.1007/s12181-020-00433-w.
2788. **Wills, B., Monsalve, G., Álvarez, D., Amaya, W., Moyano, J., Buitrago, A.F.** Spinal neurostimulator for the treatment of refractory cardiac angina. [Neuroestimulador espinal para el tratamiento de la angina cardiaca refractaria]. // *Revista Colombiana de Cardiología*, 22, 2015, № 6, p. 312-317. ISSN 0120-5633. DOI 10.1016/j.rccar.2015.06.011.
2789. **Witberg, G., Plakht, Y., Bental, T., Feldman, B.S., Leventer-Roberts, M., Levi, A., Gabay, H., Balicer, R., Gerber, Y., Kornowski, R.** Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease. // *PLoS ONE*, 14, 2019, № 2, art. no. e0209661. ISSN 1932-6203. DOI 10.1371/journal.pone.0209661.
2790. **Wu, X.-M., Liu, C.-P., Lin, W.-C., Kao, H.-L.** Long-term outcome of percutaneous coronary intervention for unprotected left main coronary artery disease. //

2791. **Yao, Y., Shao, C., Li, X., Wang, Z., Zuo, C., Yan, Y., Qianzhou, L.** A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction. // *Clinical Epidemiology*, 14, 2022, p. 911-923. ISSN 1179-1349. DOI 10.2147/CLEP.S370004.
2792. **Yap, C.-H., Yan, B.P., Akowuah, E., Dinh, D.T., Smith, J.A., Shardey, G.C., Tatoulis, J., Skillington, P.D., Newcomb, A., Mohajeri, M., Pick, A., Seevanayagam, S., Reid, C.M.** Does Prior Percutaneous Coronary Intervention Adversely Affect Early and Mid-Term Survival After Coronary Artery Surgery? // *JACC: Cardiovascular Interventions*, 2, 2009, № 8, p. 758-764. ISSN 1936-8798. DOI 10.1016/j.jcin.2009.04.018.
2793. **Zembala, M.O., Bello, R.A., Michler, R.E.** Tissue engineering of the heart. – In: *Biomedical Engineering Principles Of The Bionic Man* (Second Edition), 2023, p. 287-328. ISBN 9789811259180; 9789811259197. DOI 10.1142/9789811259197\_0009.
2794. **Zeren, G., Erer, H.B., Kiriş, T., Şahin, O., Aksu, H., Köprülü, D., Güvenç, T.S., Erdoğan, G., Sayar, N., Günaydin, Z.Y., Eren, M.** Relation of heart-type fatty acid-binding protein with the degree and extent of atherosclerosis in patients with non-ST elevation acute coronary syndrome. [ST segment yükselmesiz akut koroner sendromlu hastalarda kalp tipi yağ asidi bağlayıcı proteinin koroner arter hastalığının yaygınlık ve ciddiyeti ile ilişkisi]. // *Türk Kardiyoloji Dernegi Arsivi*, 41, 2013, № 7, p. 610-616. ISSN 1016-5169. DOI 10.5543/tkda.2013.26974.
2795. **Zhang, H.J., Sun, C.H., Kuang, H.Y., Jiang, X.Y., Liu, H.L., Hua, W.F., Liu, Z.J., Zhou, H., Sui, H., Qi, R.** 12(S)-hydroxyeicosatetraenoic acid levels link to coronary artery disease in Type 2 diabetic patients. // *Journal of Endocrinological Investigation*, 36, 2013, № 6, p. 385-389. ISSN 0391-4097. DOI 10.3275/8654.
2796. **Zhang, L., Qiao, B., Han, Y.-L., Li, Y., Xu, K., Zhang, Q.-Y., Yang, L.-X., Liu, H.-L., Xu, B., Gao, R.-L.** Gender difference on five-year outcomes of EXCEL biodegradable polymer-coated sirolimus-eluting stents implantation: Results from the CREATE study. // *Chinese Medical Journal*, 126, 2013, № 6, p. 1039-1045. ISSN 0366-6999. DOI 10.3760/cma.j.issn.0366-6999.20123430.
2797. **Zheng, S., Zheng, Z., Hou, J., Hu, S.** Comparison between drug-eluting stents and coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of two randomized trials and thirteen observational studies. // *Cardiology*, 118, 2011, № 1, p. 22-32. ISSN 0008-6312. DOI 10.1159/000324169.
2798. **Zhu, L., Chen, T., Ye, W., Wang, J.-Y., Zhou, J.-P., Li, Z.-Y., Li, C.-C.** Circulating miR-182-5p and miR-5187-5p as biomarkers for the diagnosis of unprotected left main coronary artery disease. // *Journal of Thoracic Disease*, 11, 2019, № 5, p. 1799-1808. ISSN 2072-1439. DOI 10.21037/jtd.2019.05.24.

**Petrov I., Nedevska M., Chilingirova N., Simeonov P., Kratunkov P., Stoinova V., Nikolov D., Konteva M., Tzarianski G., Tshirkov Al.** Endovascular Repair of Dissecting Thoracic Aortic Aneurysm in a Patient With Turner Syndrome. // *Journal Endovascular Therapy*, 2006; 13, 693-696.

**Cited by:**

2799. **Durai, R., Ellul, J.P.M.** Delayed dysphagia after endovascular repair of thoracic aortic aneurysm. // *Annals of Vascular Surgery*, 24, 2010, № 8, p. 1158-1159. ISSN 0890-5096. DOI 10.1016/j.avsg.2010.07.009.
2800. **Grimaldi, S., Milito, P., Lovece, A., Asti, E., Secchi, F., Bonavina, L.** Dysphagia aortica. // *European Surgery - Acta Chirurgica Austriaca*, 54, 2022, № 5, p. 228-239. ISSN 1682-8631. DOI 10.1007/s10353-021-00741-9.
2801. **Hamidian-Jahromi, A., Carroll, J.D., Doucet, L.D., Zhang, W.W.** Hybrid repair of ruptured type B aortic dissection extending into an aberrant right subclavian artery in a patient with turner's syndrome. // *Annals of Vascular Surgery*, 27, 2013, № 8, p. 1182.e1-1182.e4. ISSN 0890-5096. DOI 10.1016/j.avsg.2013.04.007.
2802. **Kin, H., Okabayashi, H., Nakajima, T., Takahashi, K.** Aortic dissecting aneurysm with a bicuspid aortic valve in Turner's syndrome: Report of a case. // *Surgery Today*, 37, 2007, № 8, p. 667-670. ISSN 0941-1291. DOI 10.1007/s00595-006-3462-8.
2803. **Murayama, T., Funabashi, N., Uehara, M., Takaoka, H., Komuro, I.** New classification of aortic dissection during the cardiac cycle as pulsating type and static type evaluated by electrocardiogram-gated multislice CT. // *International Journal of Cardiology*, 142, 2010, № 2, p. 177-186. ISSN 0167-5273. DOI 10.1016/j.ijcard.2008.12.194.
2804. **Yuan, S.-M.** Cardiovascular dysphagia - Anatomical and clinical implications. // *Folia Morphologica (Poland)*, 73, 2014, № 2, p. 113-121. ISSN 0015-5659. DOI 10.5603/FM.2014.0026.
2805. **Yuan, S.-M., Jing, H.** Cardiovascular disorders of Turner's syndrome: A review. // *Balkan Journal of Medical Genetics*, 13, 2010, № 2, p. 3-9. ISSN 1311-0160. DOI 10.2478/v10034-010-0011-y.



**РЕПУБЛИКА БЪЛГАРИЯ**

Национален център за  
информация и документация

класификация на информацията:  
ниво 1, TLP-GREEN



**НАЦИД**

Per №: 94-12-31 / 12.04.2024

Дата: 27.05.2024

## **СПРАВКА**

**ЗА IMPACT FACTOR /WEB OF SCIENCE/ И SCIMAGO JOURNAL RANK  
/SCOPUS/ НА СПИСАНИЯТА, В КОИТО СА НАМЕРЕНИ СТАТИИ С  
ЦИТИРАНИЯ НА ПУБЛИКАЦИИ НА ИВО СПАСОВ ПЕТРОВ**

<b>№</b>	<b>Заглавие</b>	<b>Година</b>	<b>ISSN</b>	<b>IF</b>	<b>SJR</b>
1	Acta Cardiologica/2024*	2023	0001-5385		0.341
2	Acta Cardiologica/2024*	2022	0001-5385	1.6	
3	American Heart Journal/2024*	2023	0002-8703		2.109
4	American Heart Journal/2024*	2022	0002-8703	4.8	
5	American Journal of Cardiology/2024*	2023	0002-9149		0.950
6	American Journal of Cardiology/2024*	2022	0002-9149	2.8	
7	American Journal of Cardiovascular Drugs/2024*	2023	1175-3277		0.790
8	American Journal of Cardiovascular Drugs/2024*	2022	1175-3277	3.0	
9	American Journal of Preventive Cardiology/2024*	2023	2666-6677		1.611
10	American Journal of Preventive Cardiology/2024*	2022	2666-6677	4.1	
11	Annals of Vascular Surgery/2024*	2023	0890-5096		0.616
12	Annals of Vascular Surgery/2024*	2022	0890-5096	1.5	



13	Annual Review of Pharmacology and Toxicology/2024*	2023	0362-1642		3.957
14	Annual Review of Pharmacology and Toxicology/2024*	2022	0362-1642	12.5	
15	Archives of Physical Medicine and Rehabilitation/2024*	2023	0003-9993		1.091
16	Archives of Physical Medicine and Rehabilitation/2024*	2022	0003-9993	4.3	
17	AsiaIntervention	2023	2426-3958	-	0.262
18	Atherosclerosis/2024*	2023	0021-9150		1.461
19	Atherosclerosis/2024*	2022	0021-9150	5.3	
20	BMC Cardiovascular Disorders/2024*	2023	1471-2261		0.646
21	BMC Cardiovascular Disorders/2024*	2022	1471-2261	2.1	
22	BMJ Open/2024*	2023	2044-6055		0.971
23	BMJ Open/2024*	2022	2044-6055	2.9	
24	British Journal of General Practice/2024*	2023	0960-1643		1.092
25	British Journal of General Practice/2024*	2022	0960-1643	5.9	
26	Canadian Journal of Cardiology/2024*	2023	0828-282X		1.666
27	Canadian Journal of Cardiology/2024*	2022	0828-282X	7.2	
28	Cardiology in Review/2024*	2023	1061-5377		0.598
29	Cardiology in Review/2024*	2022	1061-5377	2.1	
30	Cardiovascular Revascularization Medicine/2024*	2023	1553-8389		0.493
31	Cardiovascular Revascularization Medicine/2024*	2022	1553-8389	1.7	
32	Chest/2024*	2023	0012-3692		2.123
33	Chest/2024*	2022	0012-3692	10.1	
34	Chinese General Practice/2024*	2023	1007-9572	-	0.156
35	Circulation/2024*	2023	0009-7322		8.415
36	Circulation/2024*	2022	0009-7322	37.8	
37	Clinica e Investigacion en Arteriosclerosis/2024*	2023	0214-9168		0.424
38	Clinica e Investigacion en Arteriosclerosis/2024*	2022	0214-9168	1.6	
39	Clinical and Applied Thrombosis/Hemostasis/2024*	2023	1076-0296		0.633
40	Clinical and Applied Thrombosis/Hemostasis/2024*	2022	1076-0296	2.9	
41	Clinical Cardiology/2024*	2023	0160-9289		0.878
42	Clinical Cardiology/2024*	2022	0160-9289	2.7	
43	Clinical eHealth/2024*	2023	2588-9141	-	1.122
44	Clinical Rehabilitation/2024*	2023	0269-2155		0.949

45	Clinical Rehabilitation/2024*	2022	0269-2155	3.0	
46	CNS & Neurological Disorders-Drug Targets/2024*	2023	1871-5273		0.620
47	CNS & Neurological Disorders-Drug Targets/2024*	2022	1871-5273	3.0	
48	Current Atherosclerosis Reports/2024*	2023	1523-3804		1.582
49	Current Atherosclerosis Reports/2024*	2022	1523-3804	5.8	
50	Current Cardiology Reports/2024*	2023	1523-3782		1.011
51	Current Cardiology Reports/2024*	2022	1523-3782	3.7	
52	Current Issues in Molecular Biology/2024*	2023	1467-3037		0.675
53	Current Issues in Molecular Biology/2024*	2022	1467-3037	3.1	
54	Current Problems in Cardiology/2024*	2023	0146-2806		0.934
55	Current Problems in Cardiology/2024*	2022	0146-2806	4.2	
56	Diabetes Care/2024*	2023	0149-5992		5.694
57	Diabetes Care/2024*	2022	0149-5992	16.2	
58	Drug Safety/2024*	2023	0114-5916		1.204
59	Drug Safety/2024*	2022	0114-5916	4.2	
60	ESC heart failure/2024*	2023	2055-5822		1.425
61	ESC heart failure/2024*	2022	2055-5822	3.8	
62	European Heart Journal - Cardiovascular Pharmacotherapy/2024*	2023	2055-6837		1.507
63	European Heart Journal - Cardiovascular Pharmacotherapy/2024*	2022	2055-6837	7.1	
64	European Heart Journal Open/2024*	2023	2752-4191	-	1.397
65	European Heart Journal/2024*	2023	0195-668X		4.091
66	European Heart Journal/2024*	2022	0195-668X	39.3	
67	European Heart Journal-Case Reports/2024*	2023	2514-2119		0.312
68	European Heart Journal-Case Reports/2024*	2022	2514-2119	1.0	
69	Expert Opinion on Drug Safety/2024*	2023	1474-0338		0.905
70	Expert Opinion on Drug Safety/2024*	2022	1474-0338	3.1	
71	Frontiers in Cardiovascular Medicine/2024*	2023	2297-055X		0.863
72	Frontiers in Cardiovascular Medicine/2024*	2022	2297-055X	3.6	
73	Giornale Italiano di Cardiologia/2024*	2023	1827-6806		0.195
74	Giornale Italiano di Cardiologia/2024*	2022	1827-6806	0.5	
75	Heart and Lung/2024*	2023	0147-9563		0.733
76	Heart and Lung/2024*	2022	0147-9563	2.8	
77	Herz/2024*	2023	0340-9937		0.396



78	Herz/2024*	2022	0340-9937	1.7	
79	International Journal of Cardiology/2024*	2023	0167-5273		1.126
80	International Journal of Cardiology/2024*	2022	0167-5273	3.5	
81	International Journal of Nutrition, Pharmacology, Neurological Diseases/2024*	2023	2231-0738	-	0.147
82	Interventional Neuroradiology/2024*	2023	1591-0199		0.543
83	Interventional Neuroradiology/2024*	2022	1591-0199	1.7	
84	JAMA Cardiology/2024*	2023	2380-6583		6.231
85	JAMA Cardiology/2024*	2022	2380-6583	24.0	
86	JAMA network open/2024*	2023	2574-3805		3.478
87	JAMA network open/2024*	2022	2574-3805	13.8	
88	Journal of Cardiology/2024*	2023	0914-5087		0.810
89	Journal of Cardiology/2024*	2022	0914-5087	2.5	
90	Journal of Cardiothoracic and Vascular Anesthesia/2024*	2023	1053-0770		0.744
91	Journal of Cardiothoracic and Vascular Anesthesia/2024*	2022	1053-0770	2.8	
92	Journal of Cardiovascular Development and Disease/2024*	2023	2308-3425		0.621
93	Journal of Cardiovascular Development and Disease/2024*	2022	2308-3425	2.4	
94	Journal of Clinical Medicine/2024*	2023	2077-0383		0.882
95	Journal of Clinical Medicine/2024*	2022	2077-0383	3.9	
96	Journal of Geriatric Cardiology/2024*	2023	1671-5411		0.509
97	Journal of Geriatric Cardiology/2024*	2022	1671-5411	2.5	
98	Journal of NeuroInterventional Surgery/2024*	2023	1759-8478		1.659
99	Journal of NeuroInterventional Surgery/2024*	2022	1759-8478	4.9	
100	Journal of Pharmacy Practice/2024*	2023	0897-1900		0.380
101	Journal of Pharmacy Practice/2024*	2022	0897-1900	1.3	
102	Journal of Public Health/2024*	2023	1741-3842		0.981
103	Journal of Public Health/2024*	2022	1741-3842	4.7	
104	Journal of the American College of Cardiology/2024*	2023	0735-1097		8.762
105	Journal of the American College of Cardiology/2024*	2022	0735-1097	24.4	
106	Journal of the American Heart Association/2024*	2023	2047-9980		2.126
107	Journal of the American Heart Association/2024*	2022	2047-9980	5.4	

108	Journal of the Society for Cardiovascular Angiography and Interventions/2024*	2023	2772-9303	-	0.562
109	Journal of Thoracic and Cardiovascular Surgery/2024*	2023	0022-5223		1.744
110	Journal of Thoracic and Cardiovascular Surgery/2024*	2022	0022-5223	6.0	
111	Journal of Thrombosis and Thrombolysis/2024*	2023	0929-5305		0.744
112	Journal of Thrombosis and Thrombolysis/2024*	2022	0929-5305	4.0	
113	Journal of Vascular Access/2024*	2023	1129-7298		0.463
114	Journal of Vascular Access/2024*	2022	1129-7298	1.9	
115	Lancet/2024*	2023	0140-6736		12.113
116	Lancet/2024*	2022	0140-6737	168.9	
117	Medical Clinics of North America/2024*	2023	0025-7125		1.409
118	Medical Clinics of North America/2024*	2022	0025-7125	5.9	
119	Medical Letter on Drugs and Therapeutics/2024*	2023	0025-732X		0.239
120	Medical Letter on Drugs and Therapeutics/2024*	2022	0025-732X	1.9	
121	Medicine (United States)/2024*	2023	0025-7974		0.441
122	Medicine (United States)/2024*	2022	0025-7974	1.6	
123	Polish Archives of Internal Medicine/2024*	2023	0032-3772		0.539
124	Polish Archives of Internal Medicine/2024*	2022	0032-3772	4.8	
125	Revista Espanola de Cardiologia/2024*	2023	0300-8932		0.593
126	Revista Espanola de Cardiologia/2024*	2022	0300-8932	5.9	
127	Revista Portuguesa de Cardiologia/2024*	2023	0870-2551		0.333
128	Revista Portuguesa de Cardiologia/2024*	2022	0870-2551	1.8	
129	Stroke/2024*	2023	0039-2499		2.450
130	Stroke/2024*	2022	0039-2499	8.4	
131	Acta Cardiologica Sinica	2023	1011-6842		0.411
132	Acta Cardiologica Sinica/2023*	2022	1011-6843	1.9	
133	Acta Cardiologica	2023	0001-5385		0.341
134	Acta Cardiologica/2023*	2022	0001-5385	1.6	
135	Advanced Science	2023	2198-3844		3.914
136	Advanced Science/2023*	2022	2198-3844	15.1	
137	American Heart Journal	2023	0002-8703		2.109
138	American Heart Journal/2023*	2022	0002-8703	4.8	
139	American Journal of Cardiology	2023	0002-9149		0.950



140	American Journal of Cardiology/2023*	2022	0002-9149	2.8	
141	American Journal of Cardiovascular Drugs	2023	1175-3277		0.790
142	American Journal of Cardiovascular Drugs/2023*	2022	1175-3277	3.0	
143	Annales de Cardiologie et d'Angéiologie	2023	0003-3928	-	0.200
144	Annals of Medicine	2023	0785-3890		1.306
145	Annals of Medicine/2023*	2022	0785-3890	4.4	
146	Annals of Thoracic Surgery	2023	0003-4975		1.203
147	Annals of Thoracic Surgery/2023*	2022	0003-4975	4.6	
148	Antioxidants and Redox Signaling	2023	1523-0864		1.708
149	Antioxidants and Redox Signaling/2023*	2022	1523-0864	6.6	
150	Arteriosclerosis, Thrombosis, and Vascular Biology	2023	1079-5642		2.582
151	Arteriosclerosis, Thrombosis, and Vascular Biology/2023*	2022	1079-5642	8.7	
152	ARYA Atherosclerosis	2023	1735-3955		0.201
153	ARYA Atherosclerosis/2023*	2022	1735-3955	0.6	
154	Atherosclerosis	2023	0021-9150		1.461
155	Atherosclerosis/2023*	2022	0021-9150	5.3	
156	Biomedical and Environmental Sciences	2023	0895-3988		0.403
157	Biomedical and Environmental Sciences/2023*	2022	0895-3988	3.5	
158	Biomedicines	2023	2227-9059		0.962
159	Biomedicines/2023*	2022	2227-9059	4.7	
160	BioTech	2023	2673-6284	-	0.558
161	Blood Coagulation and Fibrinolysis	2023	0957-5235		0.361
162	Blood Coagulation and Fibrinolysis/2023*	2022	0957-5235	1.1	
163	BMC Cardiovascular Disorders	2023	1471-2261		0.646
164	BMC Cardiovascular Disorders/2023*	2022	1471-2261	2.1	
165	BMC Medical Ethics	2023	1472-6939		0.975
166	BMC Medical Ethics/2023*	2022	1472-6939	2.7	
167	BMC Medicine	2023	1741-7015		2.711
168	BMC Medicine/2023*	2022	1741-7015	9.3	
169	Bulgarian Cardiology	2023	1310-7488	-	0.113
170	Cardiology Letters	2023	1338-3655	-	0.111
171	Cardiology	2023	0008-6312		0.547
172	Cardiology/2023*	2022	0008-6312	1.9	
173	Cardiovascular Diabetology	2023	1475-2840		2.621
174	Cardiovascular Diabetology/2023*	2022	1475-2840	9.3	
175	Cardiovascular Drugs and Therapy	2023	0920-3206		0.973



176	Cardiovascular Drugs and Therapy/2023*	2022	0920-3206	3.4	
177	Cardiovascular Intervention and Therapeutics	2023	1868-4300		0.822
178	Cardiovascular Intervention and Therapeutics/2023*	2022	1868-4300	3.2	
179	Cardiovascular Research	2023	0008-6363		2.809
180	Cardiovascular Research/2023*	2022	0008-6363	10.9	
181	Cardiovascular Revascularization Medicine	2023	1553-8389		0.493
182	Cardiovascular Revascularization Medicine/2023*	2022	1553-8389	1.7	
183	Cardiovascular Therapeutics	2023	1755-5914		0.769
184	Cardiovascular Therapeutics/2023*	2022	1755-5914	3.1	
185	Cardiovascular Therapy and Prevention (Russian Federation)	2023	1728-8800	-	0.212
186	Catheterization and Cardiovascular Interventions	2023	1522-1946		0.948
187	Catheterization and Cardiovascular Interventions/2023*	2022	1522-1947	2.3	
188	Chinese General Practice	2023	1007-9572	-	0.156
189	Chinese Journal of Cardiology	2023	0253-3758	-	0.176
190	Circulation Journal	2023	1346-9843		1.140
191	Circulation Journal/2023*	2022	1346-9843	3.3	
192	Circulation	2023	0009-7322		8.415
193	Circulation/2023*	2022	0009-7322	37.8	
194	Circulation: Cardiovascular Interventions	2023	1941-7640		2.242
195	Circulation: Cardiovascular Interventions/2023*	2022	1941-7640	5.6	
196	CJC Open	2023	2589-790X	-	0.646
197	Clinical and Applied Thrombosis/Hemostasis	2023	1076-0296		0.633
198	Clinical and Applied Thrombosis/Hemostasis/2023*	2022	1076-0296	2.9	
199	Clinical and Experimental Pharmacology and Physiology/2023*	2023	0305-1870		0.610
200	Clinical and Experimental Pharmacology and Physiology/2023*	2022	0305-1871	2.9	
201	Clinical Cardiology	2023	0160-9289		0.878
202	Clinical Cardiology/2023*	2022	0160-9289	2.7	
203	Clinical Radiology	2023	0009-9260		0.603
204	Clinical Radiology/2023*	2022	0009-9260	2.6	
205	Clinical Research in Cardiology	2023	1861-0684		1.416

206	Clinical Research in Cardiology/2023*	2022	1861-0684	5.0	
207	Cochrane Database of Systematic Reviews	2023	1469-493X		1.408
208	Cochrane Database of Systematic Reviews/2023*	2022	1469-493X	8.4	
209	Coronary Artery Disease	2023	0954-6928		0.384
210	Coronary Artery Disease/2023*	2022	0954-6928	1.8	
211	Current Atherosclerosis Reports	2023	1523-3804		1.582
212	Current Atherosclerosis Reports/2023*	2022	1523-3804	5.8	
213	Current Cardiology Reports	2023	1523-3782		1.011
214	Current Cardiology Reports/2023*	2022	1523-3782	3.7	
215	Current Cardiology Reviews	2023	1573-403X		0.608
216	Current Cardiology Reviews/2023*	2022	1573-403X	1.9	
217	Current Opinion in Lipidology	2023	0957-9672		1.232
218	Current Opinion in Lipidology/2023*	2022	0957-9672	4.4	
219	Current Pediatric Reviews	2023	1573-3963		0.601
220	Current Pediatric Reviews/2023*	2022	1573-3963	2.0	
221	Current Pharmaceutical Design	2023	1381-6128		0.586
222	Current Pharmaceutical Design/2023*	2022	1381-6128	3.1	
223	Current Problems in Cardiology	2023	0146-2806		0.934
224	Current Problems in Cardiology/2023*	2022	0146-2806	4.2	
225	Current Treatment Options in Cardiovascular Medicine	2023	1092-8464		0.395
226	Current Treatment Options in Cardiovascular Medicine/2023*	2022	1092-8464	0.8	
227	CVIR Endovascular	2023	2520-8934		0.360
228	CVIR Endovascular/2023*	2022	2520-8934	1.2	
229	Diabetes Therapy	2023	1869-6953		0.938
230	Diabetes Therapy/2023*	2022	1869-6953	3.8	
231	Diabetes, Obesity and Metabolism	2023	1462-8902		2.079
232	Diabetes, Obesity and Metabolism/2023*	2022	1462-8902	5.8	
233	Diagnostics	2023	2075-4418		0.667
234	Diagnostics/2023*	2022	2075-4418	3.6	
235	Digital Health	2023	2055-2076		0.767
236	Digital Health/2023*	2022	2055-2076	3.9	
237	Echocardiography	2023	0742-2822		0.384
238	Echocardiography/2023*	2022	0742-2822	1.5	
239	eClinicalMedicine	2023	2589-5370		3.522
240	eClinicalMedicine/2023*	2022	2589-5370	15.1	
241	Egyptian Heart Journal	2023	1110-2608		0.377
242	Egyptian Heart Journal/2023*	2022	1110-2608	1.1	
243	Engineering	2023	2095-8099		1.646
244	Engineering/2023*	2022	2095-8099	12.8	



245	ESC heart failure	2023	2055-5822		1.425
246	ESC heart failure/2023*	2022	2055-5822	3.8	
247	EuroIntervention	2023	1774-024X		2.266
248	EuroIntervention/2023*	2022	1774-024X	6.2	
249	Europace	2023	1099-5129		2.895
250	Europace/2023*	2022	1099-5130	6.1	
251	European Cardiology Review	2023	1758-3756		0.814
252	European Cardiology Review/2023*	2022	1758-3756	3.0	
253	European Heart Journal - Cardiovascular Pharmacotherapy	2023	2055-6837		1.507
254	European Heart Journal - Cardiovascular Pharmacotherapy/2023*	2022	2055-6837	7.1	
255	European Heart Journal, Supplement	2023	1520-765X		0.477
256	European Heart Journal, Supplement/2023*	2022	1520-765X	1.6	
257	European heart journal. Quality of care & clinical outcomes	2023	2058-5225		2.206
258	European heart journal. Quality of care & clinical outcomes/2023*	2022	2058-5225	5.2	
259	European Heart Journal	2023	0195-668X		4.091
260	European Heart Journal/2023*	2022	0195-668X	39.3	
261	European Journal of Clinical Pharmacology	2023	0031-6970		0.727
262	European Journal of Clinical Pharmacology/2023*	2022	0031-6970	2.9	
263	European Journal of Internal Medicine	2023	0953-6205		1.100
264	European Journal of Internal Medicine/2023*	2022	0953-6205	8.0	
265	European Journal of Medicinal Chemistry	2023	0223-5234		1.151
266	European Journal of Medicinal Chemistry/2023*	2022	0223-5234	6.7	
267	European Journal of Translational Myology	2023	2037-7452		0.445
268	European Journal of Translational Myology/2023*	2022	2037-7452	2.2	
269	European Review for Medical and Pharmacological Sciences	2023	1128-3602		0.580
270	European Review for Medical and Pharmacological Sciences/2023*	2022	1128-3602	3.3	
271	Expert Opinion on Pharmacotherapy	2023	1465-6566		0.687
272	Expert Opinion on Pharmacotherapy/2023*	2022	1465-6566	3.2	

273	Expert Review of Cardiovascular Therapy	2023	1477-9072		0.635
274	Expert Review of Cardiovascular Therapy/2023*	2022	1477-9072	2.0	
275	Frontiers in Cardiovascular Medicine	2023	2297-055X		0.863
276	Frontiers in Cardiovascular Medicine/2023*	2022	2297-055X	3.6	
277	Frontiers in Nutrition	2023	2296-861X		0.828
278	Frontiers in Nutrition/2023*	2022	2296-861X	5.0	
279	Frontiers in Public Health	2023	2296-2565		0.895
280	Frontiers in Public Health/2023*	2022	2296-2565	5.2	
281	Future Cardiology	2023	1479-6678		0.412
282	Future Cardiology/2023*	2022	1479-6678	1.7	
283	Genes	2023	2073-4425		0.817
284	Genes/2023*	2022	2073-4425	3.5	
285	Giornale Italiano di Cardiologia	2023	1827-6806		0.195
286	Giornale Italiano di Cardiologia/2023*	2022	1827-6806	0.5	
287	Healthcare	2023	2227-9032		0.606
288	Healthcare/2023*	2022	2227-9032	2.8	
289	Heart and Vessels	2023	0910-8327		0.574
290	Heart and Vessels/2023*	2022	0910-8327	1.5	
291	Heart Failure Reviews	2023	1382-4147		1.208
292	Heart Failure Reviews/2023*	2022	1382-4147	4.6	
293	Heart	2023	1355-6037		1.736
294	Heart/2023*	2022	1355-6037	5.7	
295	Heliyon	2023	2405-8440		0.617
296	Heliyon/2023*	2022	2405-8440	4.0	
297	Hellenic Journal of Cardiology	2023	1109-9666		0.606
298	Hellenic Journal of Cardiology/2023*	2022	1109-9666	4.1	
299	Indian Heart Journal	2023	0019-4832		0.377
300	Indian Heart Journal/2023*	2022	0019-4832	1.5	
301	International Journal of Cardiology	2023	0167-5273		1.126
302	International Journal of Cardiology/2023*	2022	0167-5273	3.5	
303	International Journal of Clinical Practice	2023	1368-5031		0.634
304	International Journal of Clinical Practice/2023*	2022	1368-5031	2.6	
305	International Journal of Environmental Research and Public Health	2023	1661-7827	-	0.808
306	International Journal of Molecular Sciences	2023	1661-6596		1.179
307	International Journal of Molecular Sciences/2023*	2022	1661-6596	5.6	



308	International Journal of Stroke	2023	1747-4930		1.800
309	International Journal of Stroke/2023*	2022	1747-4930	6.7	
310	Interventional Cardiology: Reviews, Research, Resources	2023	1756-1477	-	0.855
311	JACC: Asia	2023	2772-3747	-	1.204
312	JACC: Cardiovascular Interventions	2023	1936-8798		2.886
313	JACC: Cardiovascular Interventions/2023*	2022	1936-8798	11.3	
314	JAMA Pediatrics	2023	2168-6203		5.494
315	JAMA Pediatrics/2023*	2022	2168-6203	26.1	
316	Journal of Cardiology	2023	0914-5087		0.810
317	Journal of Cardiology/2023*	2022	0914-5087	2.5	
318	Journal of Cardiovascular Development and Disease	2023	2308-3425		0.621
319	Journal of Cardiovascular Development and Disease/2023*	2022	2308-3425	2.4	
320	Journal of Cardiovascular Medicine	2023	1558-2027		0.544
321	Journal of Cardiovascular Medicine/2023*	2022	1558-2028	3.0	
322	Journal of Cardiovascular Pharmacology	2023	0160-2446		0.610
323	Journal of Cardiovascular Pharmacology/2023*	2022	0160-2446	3.0	
324	Journal of Client-Centered Nursing Care	2023	2476-4124	-	0.229
325	Journal of Clinical and Translational Science	2023	2059-8661		0.669
326	Journal of Clinical and Translational Science/2023*	2022	2059-8661	2.6	
327	Journal of Clinical Lipidology	2023	1933-2874		1.048
328	Journal of Clinical Lipidology/2023*	2022	1933-2874	4.4	
329	Journal of Clinical Medicine	2023	2077-0383		0.882
330	Journal of Clinical Medicine/2023*	2022	2077-0383	3.9	
331	Journal of Clinical Nursing	2023	0962-1067		1.235
332	Journal of Clinical Nursing/2023*	2022	0962-1067	4.2	
333	Journal of Geriatric Cardiology	2023	1671-5411		0.509
334	Journal of Geriatric Cardiology/2023*	2022	1671-5411	2.5	
335	Journal of Inflammation Research	2023	1178-7031		1.047
336	Journal of Inflammation Research/2023*	2022	1178-7031	4.5	
337	Journal of Internal Medicine	2023	0954-6820		2.895
338	Journal of Internal Medicine/2023*	2022	0954-6820	11.1	
339	Journal of Interventional Cardiac Electrophysiology	2023	1383-875X		0.767



340	Journal of Interventional Cardiac Electrophysiology/2023*	2022	1383-875X	1.8	
341	Journal of Multidisciplinary Healthcare	2023	1178-2390		0.682
342	Journal of Multidisciplinary Healthcare/2023*	2022	1178-2390	3.3	
343	Journal of NeuroInterventional Surgery	2023	1759-8478		1.659
344	Journal of NeuroInterventional Surgery/2023*	2022	1759-8478	4.9	
345	Journal of Personalized Medicine	2023	2075-4426		0.736
346	Journal of Personalized Medicine/2023*	2022	2075-4426	3.4	
347	Journal of Psychiatric Research	2023	0022-3956		1.553
348	Journal of Psychiatric Research/2023*	2022	0022-3956	4.8	
349	Journal of Science in Sport and Exercise	2023	2096-6709	-	0.387
350	Journal of Telemedicine and Telecare	2023	1357-633X		1.056
351	Journal of Telemedicine and Telecare/2023*	2022	1357-633X	4.7	
352	Journal of the American College of Cardiology	2023	0735-1097		8.762
353	Journal of the American College of Cardiology/2023*	2022	0735-1097	24.4	
354	Journal of the American Heart Association	2023	2047-9980		2.126
355	Journal of the American Heart Association/2023*	2022	2047-9980	5.4	
356	Journal of the College of Physicians and Surgeons--Pakistan : JCPSP	2023	1022-386X		0.247
357	Journal of the College of Physicians and Surgeons--Pakistan : JCPSP/2023*	2022	1022-386X	1.0	
358	Journal of the Neurological Sciences	2023	0022-510X		1.042
359	Journal of the Neurological Sciences/2023*	2022	0022-510X	4.4	
360	Journal of the Society for Cardiovascular Angiography and Interventions	2023	2772-9303	-	0.562
361	Journal of Thoracic and Cardiovascular Surgery/2023*	2023	0022-5223		1.744
362	Journal of Thoracic and Cardiovascular Surgery/2023*	2022	0022-5223	6.0	
363	Journal of Thrombosis and Thrombolysis	2023	0929-5305		0.744
364	Journal of Thrombosis and Thrombolysis/2023*	2022	0929-5305	4.0	
365	Journal of Vascular and Interventional Radiology	2023	1051-0443		0.767

366	Journal of Vascular and Interventional Radiology/2023*	2022	1051-0443	2.9	
367	Journal of Vascular Surgery Cases Innovations and Techniques	2023	2468-4287		0.238
368	Journal of Vascular Surgery Cases Innovations and Techniques/2023*	2022	2468-4287	0.7	
369	Journal of Vascular Surgery	2023	0741-5214		1.936
370	Journal of Vascular Surgery/2023*	2022	0741-5214	4.3	
371	Kardiologiya i Serdechno-Sosudistaya Khirurgiya	2023	1996-6385	-	0.230
372	Kardiologiya	2023	0022-9040		0.205
373	Kardiologiya/2023*	2022	0022-9040	0.5	
374	Kidney360	2023	2641-7650		0.835
375	Kidney360/2023*	2022	2641-7650	2.7	
376	Lancet Regional Health - Europe	2023	2666-7762		4.955
377	Lancet Regional Health - Europe/2023*	2022	2666-7762	20.9	
378	Life	2023	2075-1729		0.713
379	Life/2023*	2022	2075-1729	3.2	
380	Medicina (Lithuania)	2023	1010-660X		0.593
381	Medicina (Lithuania)/2023*	2022	1010-660X	2.6	
382	Medsitsinskiy Sovet	2023	2079-701X	-	0.144
383	Minerva Cardiology and Angiology	2023	2724-5683		0.304
384	Minerva Cardiology and Angiology/2023*	2022	2724-5683	1.6	
385	Molecular Biology Reports	2023	0301-4851		0.649
386	Molecular Biology Reports/2023*	2022	0301-4851	2.8	
387	National Medical Journal of China	2023	0376-2491	-	0.175
388	Nature Reviews Cardiology	2023	1759-5002		8.408
389	Nature Reviews Cardiology/2023*	2022	1759-5002	49.6	
390	Nephrology Dialysis Transplantation	2023	0931-0509		1.414
391	Nephrology Dialysis Transplantation/2023*	2022	0931-0509	6.1	
392	Open Heart	2023	2053-3624		1.043
393	Open Heart/2023*	2022	2053-3624	2.7	
394	Pakistan Heart Journal	2023	0048-2706		0.126
395	Pakistan Heart Journal/2023*	2022	0048-2706	0.1	
396	Pathogens	2023	2076-0817		0.843
397	Pathogens/2023*	2022	2076-0817	3.7	
398	Perfusion	2023	0267-6591		0.433
399	Perfusion/2023*	2022	0267-6591	1.2	
400	Pharmaceuticals	2023	1424-8247		0.845
401	Pharmaceuticals/2023*	2022	1424-8247	4.6	
402	Pharmaceutics	2023	1999-4923		0.892
403	Pharmaceutics/2023*	2022	1999-4923	5.4	



404	Pharmacogenomics and Personalized Medicine	2023	1178-7066		0.508
405	Pharmacogenomics and Personalized Medicine/2023*	2022	1178-7066	1.9	
406	Pharmacology	2023	0031-7012		0.679
407	Pharmacology/2023*	2022	0031-7012	3.1	
408	Pharmacy Practice-Granada	2023	1885-642X		0.570
409	Pharmacy Practice-Granada/2023*	2022	1885-642X	2.5	
410	Physical Therapy	2023	0031-9023		1.193
411	Physical Therapy/2023*	2022	0031-9023	3.8	
412	Platelets	2023	0953-7104		0.816
413	Platelets/2023*	2022	0953-7104	3.3	
414	PLoS ONE	2023	1932-6203		0.839
415	PLoS ONE/2023*	2022	1932-6203	3.7	
416	Polish Archives of Internal Medicine	2023	0032-3772		0.539
417	Polish Archives of Internal Medicine/2023*	2022	0032-3772	4.8	
418	Postepy w Kardiologii Interwencyjnej	2023	1734-9338		0.242
419	Postepy w Kardiologii Interwencyjnej/2023*	2022	1734-9338	1.3	
420	Pulmonary Circulation	2023	2045-8932		0.761
421	Pulmonary Circulation/2023*	2022	2045-8932	2.6	
422	REC: CardioClinics	2023	2605-1532	-	0.158
423	REC: Interventional Cardiology	2023	2604-7306		0.238
424	REC: Interventional Cardiology/2023*	2022	2604-7306	1.4	
425	Retos	2023	1579-1726		0.383
426	Retos/2023*	2022	1579-1726	1.3	
427	Review of Clinical Pharmacology and Pharmacokinetics, International Edition	2023	1011-6583	-	0.150
428	Reviews in Cardiovascular Medicine	2023	1530-6550		0.518
429	Reviews in Cardiovascular Medicine/2023*	2022	1530-6550	2.7	
430	Revista Brasileira de Epidemiologia	2023	1415-790X	-	0.579
431	Revista de la Federacion Argentina de Cardiologia	2023	0326-646X		0.110
432	Revista de la Federacion Argentina de Cardiologia/2023*	2022	0326-646X	0.1	
433	Revista Espanola de Cardiologia	2023	0300-8932		0.593
434	Revista Espanola de Cardiologia/2023*	2022	0300-8932	5.9	
435	Scientific Reports	2023	2045-2322		0.900
436	Scientific Reports/2023*	2022	2045-2322	4.6	
437	Seminars in Thrombosis and Hemostasis	2023	0094-6176		0.801

438	Seminars in Thrombosis and Hemostasis/2023*	2022	0094-6177	5.7	
439	Sibirskij Zurnal Kliniceskoj i Eksperimental'noj Mediciny	2023	2713-2927	-	0.132
440	Stroke and Vascular Neurology	2023	2059-8688		1.857
441	Stroke and Vascular Neurology/2023*	2022	2059-8688	5.9	
442	Techniques in Vascular and Interventional Radiology	2023	1089-2516		0.434
443	Techniques in Vascular and Interventional Radiology/2023*	2022	1089-2516	1.7	
444	Thrombosis and Haemostasis	2023	0340-6245		1.248
445	Thrombosis and Haemostasis/2023*	2022	0340-6245	6.7	
446	Thrombosis Research	2023	0049-3848		1.098
447	Thrombosis Research/2023*	2023	0049-3848	7.5	
448	Trials	2023	1745-6215		0.812
449	Trials/2023*	2022	1745-6215	2.5	
450	Ukrainian Journal of Nephrology and Dialysis	2023	2304-0238	-	0.167
451	Yale Journal of Biology and Medicine	2023	0044-0086		0.729
452	Yale Journal of Biology and Medicine/2023*	2022	0044-0086	2.7	
453	ACS Applied Bio Materials	2022	2576-6422	4.7	0.855
454	Acta Cardiologica	2022	0001-5385	1.6	0.355
455	Advances in Therapy	2022	0741-238X	3.8	1.076
456	American Heart Journal	2022	0002-8703	4.8	2.155
457	American Journal of Cardiology	2022	0002-9149	2.8	1.132
458	American Journal of Cardiovascular Drugs	2022	1175-3277	3.0	0.841
459	American Journal of Emergency Medicine	2022	0735-6757	3.6	0.880
460	American Journal of Neuroradiology	2022	0195-6108	3.5	1.167
461	Annals of Palliative Medicine	2022	2224-5820	-	0.375
462	Annals of Thoracic Surgery	2022	0003-4975	4.6	1.276
463	Archives of Cardiovascular Diseases	2022	1875-2136	3.0	0.676
464	Archives of Medical Science	2022	1734-1922	3.9	0.799
465	Arquivos Brasileiros de Cardiologia	2022	0066-782X	2.6	0.359
466	Arteriosclerosis, Thrombosis, and Vascular Biology	2022	1079-5642	8.7	2.798
467	Atherosclerosis	2022	0021-9150	5.3	1.375
468	Basic and Clinical Pharmacology and Toxicology	2022	1742-7835	3.1	0.681
469	Biomedicine and Pharmacotherapy	2022	0753-3322	7.5	1.366
470	Blood Advances	2022	2473-9529	7.6	3.070
471	BMC Cardiovascular Disorders	2022	1471-2261	2.1	0.601



472	<b>BMC Sports Science Medicine and Rehabilitation</b>	2022	2052-1847	1.9	0.471
473	<b>BMJ Case Reports</b>	2022	1757-790X	0.9	0.261
474	<b>BMJ Open</b>	2022	2044-6055	2.9	1.059
475	<b>British Journal of Clinical Pharmacology</b>	2022	0306-5251	3.4	0.941
476	<b>Canadian Journal of Cardiology</b>	2022	0828-282X	7.2	1.482
477	<b>Canadian Pharmacists Journal</b>	2022	1715-1635	1.5	0.362
478	<b>Cancers</b>	2022	2072-6694	5.2	1.312
479	<b>Cardiology</b>	2022	0008-6312	1.9	0.486
480	<b>Cardiovascular and Hematological Agents in Medicinal Chemistry</b>	2022	1871-5257	-	0.268
481	<b>Cardiovascular Diabetology</b>	2022	1475-2840	9.3	2.361
482	<b>Cardiovascular Drugs and Therapy</b>	2022	0920-3206	3.4	0.913
483	<b>Cardiovascular Intervention and Therapeutics</b>	2022	1868-4300	3.2	0.832
484	<b>Cardiovascular Research</b>	2022	0008-6363	10.9	2.481
485	<b>Cardiovascular Revascularization Medicine</b>	2022	1553-8389	1.7	0.504
486	<b>Cardiovascular Therapy and Prevention (Russian Federation)</b>	2022	1728-8800	-	0.209
487	<b>Catheterization and Cardiovascular Interventions</b>	2022	1522-1948	2.3	0.964
488	<b>Cells</b>	2022	2073-4409	6.0	1.537
489	<b>Cellular and Molecular Biology</b>	2022	0145-5680	1.6	0.297
490	<b>Chest</b>	2022	0012-3692	10.1	2.322
491	<b>Children</b>	2022	2227-9067	2.4	0.504
492	<b>Chinese Journal of Cardiology</b>	2022	0253-3758	-	0.206
493	<b>Chinese Journal of General Practitioners</b>	2022	1671-7368	-	0.144
494	<b>Circulation</b>	2022	0009-7322	37.8	7.800
495	<b>Circulation Journal</b>	2022	1346-9843	3.3	1.044
496	<b>Circulation: Cardiovascular Interventions</b>	2022	1941-7640	5.6	2.296
497	<b>CJC Open</b>	2022	2589-790X	-	0.642
498	<b>Cleveland Clinic Journal of Medicine</b>	2022	0891-1150	6.1	0.496
499	<b>Clinical and Experimental Surgery</b>	2022	2308-1198	-	0.120
500	<b>Clinical Cardiology</b>	2022	0160-9289	2.7	0.806
501	<b>Clinical Pharmacology and Therapeutics</b>	2022	0009-9236	6.7	1.643
502	<b>Clinical Research in Cardiology</b>	2022	1861-0684	5.0	1.461
503	<b>CMAJ</b>	2022	0820-3946	17.4	1.716
504	<b>Cochrane Database of Systematic Reviews</b>	2022	1469-493X	8.4	1.476



505	Complex Issues of Cardiovascular Diseases	2022	2306-1278	-	0.154
506	Coronary Artery Disease	2022	0954-6928	1.8	0.419
507	Current Atherosclerosis Reports	2022	1523-3804	5.8	1.467
508	Current Cardiology Reports	2022	1523-3782	3.7	0.863
509	Current Pharmaceutical Design	2022	1381-6128	3.1	0.580
510	Current Problems in Cardiology	2022	0146-2806	4.2	0.906
511	Current Vascular Pharmacology	2022	1570-1611	4.5	0.917
512	Diabetes Care	2022	0149-5992	16.2	6.008
513	Drug Design, Development and Therapy	2022	1177-8881	4.8	0.887
514	Egyptian Heart Journal	2022	1110-2608	1.1	0.300
515	ESC heart failure	2022	2055-5822	3.8	0.899
516	EuroIntervention	2022	1774-024X	6.2	1.624
517	Europace	2022	1099-5131	6.1	1.899
518	European Heart Journal	2022	0195-668X	39.3	3.450
519	European Heart Journal - Cardiovascular Pharmacotherapy	2022	2055-6837	7.1	1.641
520	European Heart Journal, Supplement	2022	1520-765X	1.6	0.460
521	European heart journal. Quality of care & clinical outcomes	2022	2058-5225	5.2	2.090
522	European Heart Journal-Case Reports	2022	2514-2119	1.0	0.289
523	European Journal of Anaesthesiology	2022	0265-0215	3.6	0.846
524	European Journal of Clinical Pharmacology	2022	0031-6970	2.9	0.723
525	European Journal of Preventive Cardiology	2022	2047-4873	8.3	1.582
526	European Review for Medical and Pharmacological Sciences	2022	1128-3602	3.3	0.634
527	Expert Opinion on Drug Delivery	2022	1742-5247	6.6	1.018
528	Expert Review of Cardiovascular Therapy	2022	1477-9072	2.0	0.593
529	Fiziolohichnyi zhurnal	2022	2522-9028	-	0.120
530	Frontiers in Bioengineering and Biotechnology	2022	2296-4185	5.7	0.930
531	Frontiers in Cardiovascular Medicine	2022	2297-055X	3.6	1.391
532	Frontiers in Endocrinology	2022	1664-2392	5.2	1.278
533	Frontiers in Genetics	2022	1664-8021	3.7	1.000
534	Frontiers in Medicine	2022	2296-858X	3.9	0.926
535	Frontiers in Nutrition	2022	2296-861X	5.0	0.875
536	Frontiers in Pharmacology	2022	1663-9812	5.6	1.064
537	Future Cardiology	2022	1479-6678	1.7	0.399
538	Giornale Italiano di Cardiologia	2022	1827-6806	0.5	0.167

539	Global & Regional Health Technology Assessment	2022	2284-2403	0.5	-
540	Haematologica	2022	0390-6078	10.1	2.557
541	Hamostaseologie	2022	0720-9355	3.2	0.664
542	Healthcare	2022	2227-9032	2.8	0.550
543	Heart	2022	1355-6037	5.7	1.877
544	Heart and Vessels	2022	0910-8327	1.5	0.567
545	Heart Failure Reviews	2022	1382-4147	4.6	1.249
546	Heart Lung and Circulation	2022	1443-9506	2.6	0.722
547	HemaSphere	2022	2572-9241	9.1	1.145
548	Herz	2022	0340-9937	1.7	0.371
549	High Blood Pressure and Cardiovascular Prevention	2022	1120-9879	3.0	0.720
550	Indian Heart Journal	2022	0019-4832	1.5	0.438
551	International Journal of Artificial Organs	2022	0391-3988	1.7	0.386
552	International Journal of Cardiology	2022	0167-5273	3.5	1.122
553	International Journal of Environmental Research and Public Health	2022	1661-7827	-	0.828
554	International Journal of General Medicine	2022	1178-7074	2.3	0.521
555	International Journal of Molecular Sciences	2022	1661-6596	5.6	1.154
556	Intervencni a Akutni Kardiologie	2022	1213-807X	-	0.112
557	JACC: Asia	2022	2772-3748	-	0.915
558	JACC: Cardiovascular Interventions	2022	1936-8798	11.3	2.909
559	JAMA Cardiology	2022	2380-6583	24.0	7.371
560	JAMA network open	2022	2574-3805	13.8	4.108
561	JMV-Journal de Medecine Vasculaire	2022	2542-4513	-	0.286
562	Journal of Arrhythmia	2022	1880-4276	2.0	0.541
563	Journal of Atherosclerosis and Thrombosis	2022	1340-3478	4.4	1.017
564	Journal of Cardiology	2022	0914-5087	2.5	0.734
565	Journal of Cardiovascular Development and Disease	2022	2308-3425	2.4	0.725
566	Journal of Cardiovascular Electrophysiology	2022	1045-3873	2.7	0.969
567	Journal of Cardiovascular Medicine	2022	1558-2029	3.0	0.493
568	Journal of Cardiovascular Pharmacology	2022	0160-2446	3.0	0.641
569	Journal of Clinical Endocrinology and Metabolism	2022	0021-972X	5.8	1.776
570	Journal of Clinical Medicine	2022	2077-0383	3.9	0.935
571	Journal of Clinical Medicine Research	2022	1918-3003	-	0.586



572	Journal of Drug Delivery Science and Technology	2022	1773-2247	5.0	0.688
573	Journal of Hospital Medicine	2022	1553-5592	3.4	0.936
574	Journal of Interventional Cardiology	2022	0896-4327	2.1	0.609
575	Journal of Lipid and Atherosclerosis	2022	2287-2892	-	1.027
576	Journal of Personalized Medicine	2022	2075-4426	3.4	0.665
577	Journal of the American College of Cardiology	2022	0735-1097	24.4	8.343
578	Journal of the American Heart Association	2022	2047-9980	5.4	2.079
579	Journal of the Association of Physicians of India	2022	0004-5772	-	0.184
580	Journal of the Chinese Medical Association	2022	1726-4901	3.0	0.590
581	Journal of Thoracic and Cardiovascular Surgery	2022	0022-5223	6.0	1.876
582	Journal of Thrombosis and Thrombolysis	2022	0929-5305	4.0	0.862
583	Kardiologia Polska	2022	0022-9032	3.3	0.400
584	Kardiologiya	2022	0022-9040	0.5	0.214
585	Korean Journal of Internal Medicine	2022	1226-3303	2.4	0.649
586	Kuwait Medical Journal	2022	1607-8047	0.1	0.104
587	Lancet	2022	0140-6738	168.9	14.607
588	Latin American Journal of Pharmacy	2022	0326-2383	0.2	0.126
589	Life	2022	2075-1729	3.2	0.634
590	Medicina	2022	0025-7680	0.8	0.245
591	Medicina (Lithuania)	2022	1010-660X	2.6	0.590
592	Medicine (United States)	2022	0025-7974	1.6	0.460
593	Minerva Cardiology and Angiology	2022	2724-5683	1.6	0.236
594	Nephrology Dialysis Transplantation	2022	0931-0509	6.1	1.460
595	Netherlands Heart Journal	2022	1568-5888	2.0	0.728
596	Neurohospitalist	2022	1941-8744	1.0	0.326
597	Open Heart	2022	2053-3624	2.7	0.823
598	PACE - Pacing and Clinical Electrophysiology	2022	0147-8389	1.8	0.645
599	Pharmaceutics	2022	1999-4923	5.4	0.795
600	Pharmacogenomics	2022	1462-2416	2.1	0.435
601	Pharmacogenomics and Personalized Medicine	2022	1178-7066	1.9	0.469
602	Pharmacological Research	2022	1043-6618	9.3	1.784
603	Pharmacology	2022	0031-7012	3.1	0.551
604	Pharmacy Practice-Granada	2022	1885-642X	2.5	0.496
605	Platelets	2022	0953-7104	3.3	0.905
606	PLoS ONE	2022	1932-6203	3.7	0.839

607	Polish Archives of Internal Medicine	2022	0032-3772	4.8	0.512
608	Postepy w Kardiologii Interwencyjnej	2022	1734-9338	1.3	0.308
609	REC: CardioClinics	2022	2605-1533	-	0.138
610	REC: Interventional Cardiology	2022	2604-7306	1.4	0.209
611	Research and Practice in Thrombosis and Haemostasis	2022	2475-0379	4.6	1.320
612	Reviews in Cardiovascular Medicine	2022	1530-6550	2.7	0.575
613	Revista de la Federacion Argentina de Cardiologia	2022	0326-646X	0.1	0.106
614	Revista Espanola de Cardiologia	2022	0300-8932	5.9	0.463
615	Scandinavian Cardiovascular Journal	2022	1401-7431	2.2	0.539
616	Scientific Reports	2022	2045-2322	4.6	0.973
617	Stroke	2022	0039-2499	8.4	2.746
618	Supportive Care in Cancer	2022	0941-4355	3.1	0.984
619	Tagliche Praxis	2022	0494-464X	-	0.100
620	Terapevticheskii Arkhiv	2022	0040-3660	0.3	0.167
621	Thrombosis and Haemostasis	2022	0340-6245	6.7	1.565
622	Thrombosis Journal	2022	1477-9560	3.1	0.699
623	Thrombosis Research	2022	0049-3848	7.5	1.487
624	Turk Kardiyoloji Dernegi Arsivi	2022	1016-5169	0.8	0.221
625	US Cardiology Review	2022	1758-3896	-	0.200
626	World Journal of Cardiology	2022	1949-8462	1.9	0.415
627	World Journal of Clinical Cases	2022	2307-8960	1.1	-
628	Acta Cardiologica	2021	0001-5385	1.738	0.387
629	Acta Cardiologica Sinica	2021	1011-6844	1.800	0.388
630	Advances in Therapy	2021	0741-238X	4.070	1.032
631	Aging	2021	1945-4589	5.955	1.212
632	American Heart Journal	2021	0002-8703	5.099	2.564
633	American Journal of Cardiology	2021	0002-9149	3.133	1.115
634	American Journal of Cardiovascular Drugs	2021	1175-3277	3.290	1.010
635	Anaesthesia and Intensive Care	2021	0310-057X	1.512	0.408
636	Anatolian Journal of Cardiology	2021	2149-2263	1.475	0.354
637	Angewandte Chemie - International Edition	2021	1433-7851	16.823	5.126
638	Annales de Cardiologie et d'Angiologie	2021	0003-3928	-	0.166
639	Annals of Thoracic Surgery	2021	0003-4975	5.113	1.104
640	Archives of Cardiovascular Diseases	2021	1875-2136	3.196	0.818
641	Arquivos Brasileiros de Cardiologia	2021	0066-782X	2.667	0.325
642	Atherosclerosis	2021	0021-9150	6.851	1.399
643	Biomedicine and Pharmacotherapy	2021	0753-3322	7.419	1.194
644	BMC Cardiovascular Disorders	2021	1471-2261	2.174	0.675
645	BMC Sports Science Medicine and Rehabilitation	2021	2052-1847	2.367	0.512



646	BMJ Case Reports	2021	1757-790X	-	0.230
647	BMJ Open	2021	2044-6055	3.007	0.982
648	Canadian Journal of Cardiology	2021	0828-282X	6.617	1.328
649	Canadian Pharmacists Journal	2021	1715-1635	-	0.468
650	Cancers	2021	2072-6694	6.575	1.349
651	Cardiology	2021	0008-6312	2.342	0.524
652	Cardiology in Review	2021	1061-5377	3.109	0.622
653	Cardiovascular and Hematological Agents in Medicinal Chemistry	2021	1871-5257	-	0.409
654	Cardiovascular Diabetology	2021	1475-2840	8.949	2.449
655	Cardiovascular Drugs and Therapy	2021	0920-3206	3.947	0.860
656	Cardiovascular Intervention and Therapeutics	2021	1868-4300	-	0.874
657	Cardiovascular Journal of Africa	2021	1995-1892	0.802	0.297
658	Cardiovascular Revascularization Medicine	2021	1553-8389	-	0.486
659	Catheterization and Cardiovascular Interventions	2021	1522-1949	2.585	1.088
660	Chinese General Practice	2021	1007-9572	-	0.142
661	Chinese Journal of Cardiology	2021	0253-3758	-	0.221
662	Circulation	2021	0009-7322	39.922	8.281
663	Circulation Journal	2021	1346-9843	3.350	0.926
664	Circulation: Cardiovascular Interventions	2021	1941-7640	7.514	3.047
665	Circulation: Cardiovascular Quality and Outcomes	2021	1941-7713	8.271	2.520
666	CJC Open	2021	2589-790X	-	0.590
667	Cleveland Clinic Journal of Medicine	2021	0891-1150	6.522	0.500
668	Clinical Pharmacology and Therapeutics	2021	0009-9236	7.051	1.689
669	Clinical Research in Cardiology	2021	1861-0684	6.138	1.772
670	Clinical Transplantation	2021	0902-0063	3.456	0.901
671	Cochrane Database of Systematic Reviews	2021	1469-493X	11.874	1.412
672	Contemporary Clinical Trials	2021	1551-7144	2.261	0.867
673	Coronary Artery Disease	2021	0954-6928	1.717	0.395
674	Critical Reviews in Biomedical Engineering	2021	0278-940X	-	0.258
675	Current Cardiology Reports	2021	1523-3782	3.955	0.916
676	Current Cardiology Reviews	2021	1573-403X	-	0.551
677	Current Opinion in Cardiology	2021	0268-4705	2.108	0.649
678	Current Problems in Cardiology	2021	0146-2806	16.464	2.016
679	Deutsche Medizinische Wochenschrift	2021	0012-0472	0.653	0.171
680	Diabetes Care	2021	0149-5992	17.155	6.528



681	Diabetes Therapy	2021	1869-6953	3.605	0.902
682	Diagnostics	2021	2075-4418	3.992	0.658
683	EJVES Vascular Forum	2021	2666-688X	-	0.254
684	Endoscopy	2021	0013-726X	10.437	1.468
685	ESC heart failure	2021	2055-5822	3.612	0.797
686	EuroIntervention	2021	1774-024X	7.728	1.682
687	Europace	2021	1099-5132	5.486	1.957
688	European Cardiology Review	2021	1758-3756	-	0.959
689	European Heart Journal	2021	0195-668X	35.855	4.118
690	European Heart Journal - Cardiovascular Pharmacotherapy	2021	2055-6837	11.177	1.662
691	European Heart Journal, Supplement	2021	1520-765X	1.624	0.464
692	European Heart Journal-Case Reports	2021	2514-2119	-	0.276
693	European Journal of Cardio-thoracic Surgery	2021	1010-7940	4.534	1.143
694	European Journal of Clinical Pharmacology	2021	0031-6970	3.064	0.732
695	European Journal of Epidemiology	2021	0393-2990	12.442	3.920
696	European Journal of Preventive Cardiology	2021	2047-4873	8.526	1.689
697	Expert Opinion on Drug Safety	2021	1474-0338	4.011	0.882
698	Expert Opinion on Pharmacotherapy	2021	1465-6566	4.103	0.735
699	Expert Review of Cardiovascular Therapy	2021	1477-9072	-	0.661
700	Frontiers in Bioengineering and Biotechnology	2021	2296-4185	6.064	0.925
701	Frontiers in Cardiovascular Medicine	2021	2297-055X	5.848	1.443
702	Frontiers in Neurology	2021	1664-2295	4.086	1.027
703	Frontiers in Pharmacology	2021	1663-9812	5.988	1.143
704	Future Cardiology	2021	1479-6678	-	0.338
705	Giornale Italiano di Cardiologia	2021	1827-6806	-	0.173
706	Gut	2021	0017-5749	31.795	7.885
707	Haemophilia	2021	1351-8216	4.268	1.449
708	Healthcare	2021	2227-9032	3.160	0.529
709	Heart	2021	1355-6037	7.369	2.146
710	Heart Failure Reviews	2021	1382-4147	4.654	1.143
711	Heart International	2021	2036-2579	-	0.183
712	Heart Lung and Circulation	2021	1443-9506	2.838	0.735
713	Heart Surgery Forum	2021	1098-3511	0.699	0.215
714	Herz	2021	0340-9937	1.740	0.360
715	IJC Heart and Vasculature	2021	2352-9067	-	0.803
716	Indian Heart Journal	2021	0019-4832	-	0.430
717	International Journal of Cardiology	2021	0167-5273	4.039	1.195

718	International Journal of Clinical Practice	2021	1368-5031	3.149	0.646
719	International Journal of Environmental Research and Public Health	2021	1661-7827	4.614	0.814
720	International Journal of Molecular Sciences	2021	1661-6596	6.208	1.176
721	Interventional Cardiology: Reviews, Research, Resources	2021	1756-1478	-	1.047
722	JACC: Cardiovascular Interventions	2021	1936-8798	11.075	3.595
723	JACC: Case Reports	2021	2666-0849	-	0.196
724	JAMA - Journal of the American Medical Association	2021	0098-7484	157.375	6.076
725	Journal Européen des Urgences et de Réanimation	2021	2211-4238	-	0.102
726	Journal of Cardiac Surgery	2021	0886-0440	1.778	0.385
727	Journal of Cardiology	2021	0914-5087	3.115	0.860
728	Journal of Cardiothoracic and Vascular Anesthesia	2021	1053-0770	2.894	0.582
729	Journal of Cardiovascular Electrophysiology	2021	1045-3873	2.942	1.019
730	Journal of Cardiovascular Pharmacology	2021	0160-2446	3.271	0.694
731	Journal of Cardiovascular Pharmacology and Therapeutics	2021	1074-2484	2.807	0.685
732	Journal of Cardiovascular Surgery	2021	0021-9509	1.595	0.575
733	Journal of Clinical Medicine	2021	2077-0383	4.964	1.040
734	Journal of Diabetes and its Complications	2021	1056-8727	3.219	1.057
735	Journal of Diabetes Investigation	2021	2040-1116	3.681	0.932
736	Journal of Geriatric Cardiology	2021	1671-5411	3.189	0.704
737	Journal of Internal Medicine	2021	0954-6820	11.1	3.193
738	Journal of Internal Medicine of Taiwan	2021	1016-7390	-	0.105
739	Journal of Interventional Cardiology	2021	0896-4327	1.783	0.683
740	Journal of Invasive Cardiology	2021	1042-3931	1.711	0.572
741	Journal of Nephrology	2021	1121-8428	4.406	1.087
742	Journal of Personalized Medicine	2021	2075-4426	3.508	0.757
743	Journal of the American College of Cardiology	2021	0735-1097	27.206	9.756
744	Journal of the American Heart Association	2021	2047-9980	6.107	2.237
745	Journal of the Medical Association of Thailand	2021	0125-2208	-	0.150
746	Journal of Thoracic and Cardiovascular Surgery	2021	0022-5223	6.439	1.389



747	Journal of Thrombosis and Thrombolysis	2021	0929-5305	5.221	0.974
748	Journal of Vascular Surgery	2021	0741-5214	4.860	1.799
749	Kaohsiung Journal of Medical Sciences	2021	1607-551X	2.996	0.568
750	Kardiologe	2021	1864-9718	-	0.171
751	Kardiologiya	2021	0022-9040	0.513	0.170
752	Kardiologiya i Serdechno-Sosudistaya Khirurgiya	2021	1996-6385	-	0.144
753	Korean Journal of Internal Medicine	2021	1226-3303	3.165	0.731
754	Lancet	2021	0140-6739	202.731	15.652
755	Life	2021	2075-1729	3.253	0.588
756	Medical Principles and Practice	2021	1011-7571	2.132	0.459
757	Medicina (Lithuania)	2021	1010-660X	2.948	0.536
758	Medicine (United States)	2021	0025-7974	1.817	0.470
759	Minerva Medica	2021	0026-4806	5.580	0.570
760	Nature Reviews Cardiology	2021	1759-5002	49.421	6.721
761	Netherlands Heart Journal	2021	1568-5888	2.888	0.753
762	New England Journal of Medicine	2021	0028-4793	176.082	24.907
763	Nutrition, Metabolism and Cardiovascular Diseases	2021	0939-4753	4.666	1.013
764	Open Heart	2021	2053-3624	-	0.911
765	Platelets	2021	0953-7104	4.236	0.869
766	PLoS ONE	2021	1932-6203	3.752	0.852
767	Polish Archives of Internal Medicine	2021	0032-3772	5.218	0.520
768	Progress in Cardiovascular Diseases	2021	0033-0620	11.278	2.029
769	Purinergic Signalling	2021	1573-9538	3.950	0.738
770	Research and Practice in Thrombosis and Haemostasis	2021	2475-0379	5.953	1.817
771	Reviews in Cardiovascular Medicine	2021	1530-6550	4.430	0.590
772	Revista Espanola de Cardiologia	2021	0300-8932	7.050	0.407
773	Revista Portuguesa de Cardiologia	2021	0870-2551	1.651	0.239
774	Scientific Reports	2021	2045-2322	4.997	1.005
775	Seminars in Neurology	2021	0271-8235	3.212	1.075
776	Seminars in Thrombosis and Hemostasis	2021	0094-6178	6.415	1.195
777	Stroke	2021	0039-2499	10.170	3.245
778	Structural Heart	2021	2474-8706	-	0.214
779	Thrombosis and Haemostasis	2021	0340-6245	6.830	1.745
780	Thrombosis Journal	2021	1477-9560	5.509	1.038
781	Thrombosis Research	2021	0049-3848	10.409	1.678
782	World Journal of Cardiology	2021	1949-8462	-	0.346
783	Acta Cardiologica Sinica	2020	1011-6845	2.672	0.551
784	Advances in Therapy	2020	0741-238X	3.847	1.097
785	Aging	2020	1945-4589	5.682	1.473
786	American Heart Journal	2020	0002-8703	4.749	2.925

787	American Journal of Cardiology	2020	0002-9149	2.778	1.394
788	American Journal of Cardiovascular Drugs	2020	1175-3277	3.571	1.063
789	Anatolian Journal of Cardiology	2020	2149-2263	1.596	0.364
790	Anesthesia and Analgesia	2020	0003-2999	5.178	1.404
791	Animals	2020	2076-2615	2.752	0.584
792	Annals of Vascular Surgery	2020	0890-5096	1.466	0.635
793	Archives of Cardiovascular Diseases	2020	1875-2136	2.340	0.768
794	Archives of Medical Science	2020	1734-1922	3.318	1.000
795	Basic and Clinical Pharmacology and Toxicology	2020	1742-7835	4.084	0.805
796	Biomedicine and Pharmacotherapy	2020	0753-3322	6.530	1.323
797	BMJ Open	2020	2044-6055	2.692	1.132
798	Canadian Journal of Cardiology	2020	0828-282X	5.352	1.395
799	Cardiology Clinics	2020	0733-8651	2.213	0.897
800	Cardiovascular Drugs and Therapy	2020	0920-3206	3.727	1.108
801	Cardiovascular Intervention and Therapeutics	2020	1868-4300	-	0.524
802	Cardiovascular Revascularization Medicine	2020	1553-8389	-	0.476
803	Cardiovascular Therapeutics	2020	1755-5914	3.023	0.818
804	Catheterization and Cardiovascular Interventions	2020	1522-1950	2.692	0.988
805	Chinese Journal of Cardiology	2020	0253-3758	-	0.163
806	Circulation	2020	0009-7322	29.690	7.795
807	Circulation Journal	2020	1346-9843	2.993	0.949
808	Circulation: Cardiovascular Interventions	2020	1941-7640	6.546	2.621
809	CJC Open	2020	2589-790X	-	0.241
810	Cleveland Clinic Journal of Medicine	2020	0891-1150	2.321	0.359
811	Clinical Cardiology	2020	0160-9289	2.882	1.263
812	Clinical Drug Investigation	2020	1173-2563	2.859	0.739
813	Clinical Pharmacology and Therapeutics	2020	0009-9236	6.889	1.941
814	Clinical Research in Cardiology	2020	1861-0684	5.460	1.838
815	Clinical Therapeutics	2020	0149-2918	3.396	0.925
816	Clinical Transplantation	2020	0902-0063	2.863	0.918
817	Coronary Artery Disease	2020	0954-6928	1.439	0.504
818	Current Cardiology Reports	2020	1523-3782	2.931	0.941
819	Current Opinion in Cardiology	2020	0268-4705	2.161	0.826
820	Current Pharmaceutical Design	2020	1381-6128	3.116	0.690
821	Current Problems in Cardiology	2020	0146-2806	5.200	0.634
822	Current Vascular Pharmacology	2020	1570-1611	2.719	0.806
823	Diabetes Therapy	2020	1869-6953	2.945	0.907



824	Diabetic Medicine	2020	0742-3071	4.359	1.474
825	Drug Development Research	2020	0272-4391	4.360	0.582
826	Egyptian Heart Journal	2020	1110-2608	-	0.212
827	ESC heart failure	2020	2055-5822	4.411	0.787
828	EuroIntervention	2020	1774-024X	6.534	1.592
829	Europace	2020	1099-5133	5.214	2.119
830	European Cardiology Review	2020	1758-3756	-	0.864
831	European Heart Journal	2020	0195-668X	29.983	4.336
832	European Heart Journal - Cardiovascular Pharmacotherapy	2020	2055-6837	6.617	1.895
833	European Heart Journal, Supplement	2020	1520-765X	1.803	0.389
834	European Heart Journal-Case Reports	2020	2514-2119	-	0.256
835	European Journal of Cardio-thoracic Surgery	2020	1010-7941	4.191	1.303
836	European Journal of Internal Medicine	2020	0953-6205	4.624	0.894
837	European Journal of Preventive Cardiology	2020	2047-4873	7.804	1.669
838	Expert Opinion on Pharmacotherapy	2020	1465-6566	3.889	0.873
839	Expert Review of Cardiovascular Therapy	2020	1477-9072	-	0.809
840	Frontiers in Bioengineering and Biotechnology	2020	2296-4185	5.890	1.081
841	Frontiers in Cardiovascular Medicine	2020	2297-055X	6.050	1.711
842	Frontiers in Pharmacology	2020	1663-9812	5.811	1.384
843	Future Cardiology	2020	1479-6678	-	0.392
844	Giornale Italiano di Cardiologia	2020	1827-6806	-	0.182
845	Heart	2020	1355-6037	5.994	2.184
846	Heart Failure Reviews	2020	1382-4147	4.214	1.353
847	Heart International	2020	2036-2579	-	0.183
848	Heart Lung and Circulation	2020	1443-9506	2.975	0.770
849	Herz	2020	0340-9937	1.443	0.374
850	Hypertension	2020	0194-911X	10.190	2.986
851	IJC Heart and Vasculature	2020	2352-9067	-	0.813
852	Indian Heart Journal	2020	0019-4832	-	0.548
853	International Journal of Cardiology	2020	0167-5273	4.164	1.406
854	Intervencni a Akutni Kardiologie	2020	1213-807X	-	0.100
855	Interventional Cardiology Clinics	2020	2211-7458	-	0.591
856	JACC: Cardiovascular Interventions	2020	1936-8798	11.195	3.108
857	JAMA - Journal of the American Medical Association	2020	0098-7484	56.274	4.688
858	JAMA Cardiology	2020	2380-6583	14.676	6.108
859	JAMA network open	2020	2574-3805	8.485	3.278
860	Journal of Arrhythmia	2020	1880-4276	-	0.463
861	Journal of Cardiology	2020	0914-5087	3.159	1.058

862	Journal of Cardiovascular Medicine	2020	1558-2030	2.160	0.458
863	Journal of Cardiovascular Pharmacology	2020	0160-2446	3.105	0.762
864	Journal of Cardiovascular Pharmacology and Therapeutics	2020	1074-2484	2.457	0.787
865	Journal of Clinical Medicine	2020	2077-0383	4.242	-
866	Journal of Gastroenterology and Hepatology (Australia)	2020	0815-9319	4.029	1.214
867	Journal of Geriatric Cardiology	2020	1671-5411	3.327	0.949
868	Journal of the American College of Cardiology	2020	0735-1097	24.093	10.315
869	Journal of the American Heart Association	2020	2047-9980	5.501	2.494
870	Journal of Thrombosis and Thrombolysis	2020	0929-5305	2.300	0.708
871	Kardiologe	2020	1864-9718	-	0.136
872	Kardiologiya	2020	0022-9040	0.395	0.159
873	Klinikarzt	2020	0341-2350	-	0.113
874	Lancet	2020	0140-6740	79.323	13.103
875	Life Sciences	2020	0024-3205	5.037	1.131
876	Medicina (Lithuania)	2020	1010-660X	2.430	0.530
877	Medicine (United States)	2020	0025-7974	1.889	0.590
878	Minerva Cardioangiologica	2020	0026-4725	1.347	0.259
879	Minerva Medica	2020	0026-4806	4.806	0.625
880	Nature Reviews Cardiology	2020	1759-5002	32.430	5.495
881	Netherlands Heart Journal	2020	1568-5888	2.380	0.578
882	New England Journal of Medicine	2020	0028-4793	91.253	19.889
883	Open Heart	2020	2053-3624	-	1.050
884	Pharmacogenomics and Personalized Medicine	2020	1178-7066	3.912	0.845
885	Pharmacological Research	2020	1043-6618	7.658	1.850
886	Platelets	2020	0953-7104	3.862	0.939
887	PLoS ONE	2020	1932-6203	3.240	0.990
888	Postępy w Kardiologii Interwencyjnej	2020	1734-9338	1.426	0.344
889	Progress in Cardiovascular Diseases	2020	0033-0620	8.194	1.929
890	REC: CardioClinics	2020	2605-1534	-	0.114
891	Reviews in Cardiovascular Medicine	2020	1530-6550	2.930	0.555
892	Revista Espanola de Cardiologia	2020	0300-8932	4.753	0.455
893	Revista Portuguesa de Cardiologia	2020	0870-2551	1.374	0.266
894	Seminars in Thrombosis and Hemostasis	2020	0094-6179	4.180	1.116
895	Therapeutic Advances in Cardiovascular Disease	2020	1753-9447	-	1.164
896	Thrombosis and Haemostasis	2020	0340-6245	5.723	1.970
897	Thrombosis Research	2020	0049-3848	3.944	1.184



898	<b>Trials</b>	<b>2020</b>	<b>1745-6215</b>	<b>2.279</b>	<b>1.067</b>
899	<b>Turk Kardiyoloji Dernegi Arsivi</b>	<b>2020</b>	<b>1016-5169</b>	<b>-</b>	<b>0.200</b>
900	<b>Visceral Medicine</b>	<b>2020</b>	<b>2297-4725</b>	<b>1.960</b>	<b>0.598</b>
901	<b>ACS Omega</b>	<b>2019</b>	<b>2470-1343</b>	<b>2.870</b>	<b>0.767</b>
902	<b>Acta Cardiologica Sinica</b>	<b>2019</b>	<b>1011-6846</b>	<b>-</b>	<b>0.565</b>
903	<b>Advances in Therapy</b>	<b>2019</b>	<b>0741-238X</b>	<b>3.871</b>	<b>0.979</b>
904	<b>American Heart Journal</b>	<b>2019</b>	<b>0002-8703</b>	<b>4.153</b>	<b>2.902</b>
905	<b>American Journal of Cardiology</b>	<b>2019</b>	<b>0002-9149</b>	<b>2.570</b>	<b>1.479</b>
906	<b>Annales de Cardiologie et d'Angiologie</b>	<b>2019</b>	<b>0003-3928</b>	<b>-</b>	<b>0.236</b>
907	<b>Annals of Thoracic Surgery</b>	<b>2019</b>	<b>0003-4975</b>	<b>3.639</b>	<b>1.293</b>
908	<b>Archives of Cardiovascular Diseases</b>	<b>2019</b>	<b>1875-2136</b>	<b>2.434</b>	<b>0.940</b>
909	<b>Archives of Cardiovascular Diseases Supplements</b>	<b>2019</b>	<b>1878-6480</b>	<b>-</b>	<b>0.108</b>
910	<b>Arquivos Brasileiros de Cardiologia</b>	<b>2019</b>	<b>0066-782X</b>	<b>1.450</b>	<b>0.370</b>
911	<b>Canadian Pharmacists Journal</b>	<b>2019</b>	<b>1715-1635</b>	<b>-</b>	<b>0.534</b>
912	<b>Cardiovascular Diabetology</b>	<b>2019</b>	<b>1475-2840</b>	<b>7.332</b>	<b>2.172</b>
913	<b>Cardiovascular Drugs and Therapy</b>	<b>2019</b>	<b>0920-3206</b>	<b>4.069</b>	<b>1.360</b>
914	<b>Cardiovascular Intervention and Therapeutics</b>	<b>2019</b>	<b>1868-4300</b>	<b>-</b>	<b>0.442</b>
915	<b>Cardiovascular Research</b>	<b>2019</b>	<b>0008-6363</b>	<b>8.168</b>	<b>2.684</b>
916	<b>Cardiovascular Revascularization Medicine</b>	<b>2019</b>	<b>1553-8389</b>	<b>-</b>	<b>0.523</b>
917	<b>Cardiovascular Therapy and Prevention (Russian Federation)</b>	<b>2019</b>	<b>1728-8800</b>	<b>-</b>	<b>0.256</b>
918	<b>Catheterization and Cardiovascular Interventions</b>	<b>2019</b>	<b>1522-1951</b>	<b>2.044</b>	<b>0.918</b>
919	<b>Chinese Journal of Cardiology</b>	<b>2019</b>	<b>0253-3758</b>	<b>-</b>	<b>0.136</b>
920	<b>Circulation</b>	<b>2019</b>	<b>0009-7322</b>	<b>23.603</b>	<b>7.446</b>
921	<b>Circulation Journal</b>	<b>2019</b>	<b>1346-9843</b>	<b>2.540</b>	<b>1.084</b>
922	<b>Circulation: Cardiovascular Interventions</b>	<b>2019</b>	<b>1941-7640</b>	<b>5.493</b>	<b>2.737</b>
923	<b>Clinical Cardiology</b>	<b>2019</b>	<b>0160-9289</b>	<b>2.248</b>	<b>1.263</b>
924	<b>Coronary Artery Disease</b>	<b>2019</b>	<b>0954-6928</b>	<b>1.335</b>	<b>0.524</b>
925	<b>Current Opinion in Cardiology</b>	<b>2019</b>	<b>0268-4705</b>	<b>2.149</b>	<b>0.820</b>
926	<b>Current Treatment Options in Cardiovascular Medicine</b>	<b>2019</b>	<b>1092-8464</b>	<b>-</b>	<b>0.676</b>
927	<b>Deutsche Medizinische Wochenschrift</b>	<b>2019</b>	<b>0012-0472</b>	<b>0.569</b>	<b>0.176</b>
928	<b>Diabetes Therapy</b>	<b>2019</b>	<b>1869-6953</b>	<b>3.179</b>	<b>1.120</b>
929	<b>ERJ Open Research</b>	<b>2019</b>	<b>2312-0541</b>	<b>-</b>	<b>1.204</b>
930	<b>ESC heart failure</b>	<b>2019</b>	<b>2055-5822</b>	<b>3.902</b>	<b>0.640</b>
931	<b>European Heart Journal</b>	<b>2019</b>	<b>0195-668X</b>	<b>22.673</b>	<b>5.883</b>
932	<b>European Heart Journal - Cardiovascular Pharmacotherapy</b>	<b>2019</b>	<b>2055-6837</b>	<b>6.696</b>	<b>1.725</b>
933	<b>European Heart Journal, Supplement</b>	<b>2019</b>	<b>1520-765X</b>	<b>1.655</b>	<b>0.468</b>

934	European Journal of Cardio-thoracic Surgery	2019	1010-7942	3.486	1.475
935	European Journal of Internal Medicine	2019	0953-6205	4.329	1.017
936	European Journal of Preventive Cardiology	2019	2047-4873	5.864	1.459
937	Expert Opinion on Drug Safety	2019	1474-0338	3.383	0.975
938	Expert Review of Cardiovascular Therapy	2019	1477-9072	-	0.595
939	Frontiers in Cardiovascular Medicine	2019	2297-055X	3.915	1.197
940	Future Cardiology	2019	1479-6678	-	0.475
941	Giornale Italiano di Cardiologia	2019	1827-6806	-	0.183
942	Heart	2019	1355-6037	5.213	2.229
943	Heart Failure Reviews	2019	1382-4147	3.538	1.454
944	Heart International	2019	2036-2579	-	0.474
945	Herz	2019	0340-9937	1.033	0.317
946	IJC Heart and Vasculature	2019	2352-9067	-	0.810
947	International Journal of Cardiology	2019	0167-5273	3.229	1.082
948	International Journal of Molecular Sciences	2019	1661-6596	4.556	1.317
949	JACC: Cardiovascular Interventions	2019	1936-8798	8.432	3.083
950	JAMA - Journal of the American Medical Association	2019	0098-7484	45.540	5.913
951	Journal of Cardiology	2019	0914-5087	2.246	0.888
952	Journal of Cardiovascular Electrophysiology	2019	1045-3873	2.424	1.337
953	Journal of Cardiovascular Pharmacology	2019	0160-2446	2.598	0.800
954	Journal of Clinical Medicine	2019	2077-0383	3.303	-
955	Journal of Geriatric Cardiology	2019	1671-5411	2.491	0.696
956	Journal of Nephrology	2019	1121-8428	3.484	1.114
957	Journal of the American College of Cardiology	2019	0735-1097	20.589	9.989
958	Journal of the American Heart Association	2019	2047-9980	4.605	2.382
959	Journal of Thoracic and Cardiovascular Surgery	2019	0022-5223	4.451	1.608
960	Journal of Thoracic Disease	2019	2072-1439	2.046	0.572
961	Journal of Thrombosis and Thrombolysis	2019	0929-5305	2.054	0.838
962	Kardiologia Polska	2019	0022-9032	1.874	0.473
963	Kardiologiya	2019	0022-9040	0.264	0.133
964	Lancet	2019	0140-6741	60.390	14.554
965	Medicina (Lithuania)	2019	1010-660X	1.205	0.404
966	Nature Reviews Cardiology	2019	1759-5002	20.260	4.395
967	Nephrology Dialysis Transplantation	2019	0931-0509	4.531	1.857



968	New England Journal of Medicine	2019	0028-4793	74.699	18.291
969	Platelets	2019	0953-7104	3.378	0.901
970	PLoS ONE	2019	1932-6203	2.740	1.023
971	REC: CardioClinics	2019	2605-1535	-	0.104
972	Revista Espanola de Cardiologia	2019	0300-8932	4.642	0.473
973	Seminars in Thrombosis and Hemostasis	2019	0094-6180	2.892	1.049
974	Stroke	2019	0039-2499	7.190	3.097
975	Therapeutic Advances in Cardiovascular Disease	2019	1753-9447	-	0.599
976	Thrombosis Research	2019	0049-3848	2.869	1.035
977	Aging	2018	1945-4589	5.515	2.307
978	American Heart Journal	2018	0002-8703	4.023	2.711
979	Arteriosclerosis, Thrombosis, and Vascular Biology	2018	1079-5642	6.618	2.771
980	BMJ Open	2018	2044-6055	2.376	1.321
981	Cardiology Letters	2018	1338-3655	-	0.107
982	Cardiovascular Drugs and Therapy	2018	0920-3206	4.181	1.338
983	Cardiovascular Journal of Africa	2018	1995-1892	1.410	0.698
984	Cells	2018	2073-4409	5.656	-
985	Circulation	2018	0009-7322	23.054	8.613
986	Circulation Journal	2018	1346-9843	3.025	1.329
987	Circulation: Cardiovascular Interventions	2018	1941-7640	6.088	3.196
988	Clinical Pharmacology and Therapeutics	2018	0009-9236	6.336	1.842
989	Clinical Research in Cardiology	2018	1861-0684	4.907	2.206
990	Current Hypertension Reports	2018	1522-6417	3.606	1.202
991	Current Pharmaceutical Design	2018	1381-6128	2.412	0.703
992	Current Vascular Pharmacology	2018	1570-1611	2.583	0.605
993	Deutsche Medizinische Wochenschrift	2018	0012-0472	0.635	0.183
994	Drug Design, Development and Therapy	2018	1177-8881	3.208	0.986
995	ESC heart failure	2018	2055-5822	3.407	0.711
996	Europace	2018	1099-5134	5.047	2.612
997	European Heart Journal	2018	0195-668X	24.889	6.788
998	European Journal of Internal Medicine	2018	0953-6205	3.660	1.076
999	Expert Review of Cardiovascular Therapy	2018	1477-9072	-	0.823
1000	Frontiers in Public Health	2018	2296-2565	2.031	0.629
1001	Future Cardiology	2018	1479-6678	-	0.419
1002	Herz	2018	0340-9937	0.995	0.357
1003	IJC Heart and Vasculature	2018	2352-9067	-	0.488
1004	International Journal of Cardiology	2018	0167-5273	3.471	0.990

1005	International Journal of Molecular Sciences	2018	1661-6596	4.183	1.312
1006	Intervencni a Akutni Kardiologie	2018	1213-807X	-	0.105
1007	Interventional Cardiology: Reviews, Research, Resources	2018	1756-1477	-	0.161
1008	Journal of Cardiovascular Medicine	2018	1558-2031	1.427	0.473
1009	Journal of Cardiovascular Pharmacology and Therapeutics	2018	1074-2484	2.570	0.877
1010	Journal of Invasive Cardiology	2018	1042-3932	1.363	0.651
1011	Journal of the American Heart Association	2018	2047-9980	4.660	2.517
1012	Journal of Vascular Surgery	2018	0741-5214	3.243	1.757
1013	Kardiologia Polska	2018	0022-9032	1.674	0.396
1014	Kardiologiya	2018	0022-9040	0.377	0.136
1015	Lancet	2018	0140-6742	59.102	15.871
1016	Nature Reviews Cardiology	2018	1759-5002	17.420	4.882
1017	Netherlands Heart Journal	2018	1568-5888	1.972	0.605
1018	New England Journal of Medicine	2018	0028-4793	70.670	19.524
1019	Platelets	2018	0953-7104	3.106	0.959
1020	PLoS ONE	2018	1932-6203	2.776	1.100
1021	Revista Espanola de Cardiologia	2018	0300-8932	5.078	0.579
1022	Scientific Reports	2018	2045-2322	4.011	1.414
1023	American Heart Journal	2017	0002-8703	4.171	3.267
1024	Anatolian Journal of Cardiology	2017	2149-2263	1.271	0.248
1025	Annals of Thoracic Surgery	2017	0003-4975	3.780	1.294
1026	BMC Cardiovascular Disorders	2017	1471-2261	1.812	0.909
1027	BMJ Open	2017	2044-6055	2.413	1.372
1028	Cardiology Clinics	2017	0733-8651	1.420	0.806
1029	Clinical Research in Cardiology	2017	1861-0684	4.455	2.237
1030	Coronary Artery Disease	2017	0954-6928	1.705	0.705
1031	Echocardiography	2017	0742-2822	1.197	0.570
1032	European Heart Journal	2017	0195-668X	23.425	9.315
1033	European Journal of Internal Medicine	2017	0953-6205	3.282	1.087
1034	Frontiers in Pharmacology	2017	1663-9812	3.831	1.587
1035	Future Cardiology	2017	1479-6678	-	0.483
1036	Herz	2017	0340-9937	0.936	0.322
1037	International Journal of Cardiology	2017	0167-5273	4.034	1.200
1038	JAMA Cardiology	2017	2380-6583	10.133	5.551
1039	Journal of Cardiovascular Medicine	2017	1558-2032	1.824	0.599
1040	Journal of Interventional Cardiology	2017	0896-4327	1.728	0.846
1041	Journal of the American College of Cardiology	2017	0735-1097	16.834	11.061
1042	Journal of the American Heart Association	2017	2047-9980	4.450	2.674



1043	Journal of Thoracic Disease	2017	2072-1439	1.804	0.701
1044	Journal of Vascular Surgery	2017	0741-5214	3.294	2.308
1045	Kardiologia Polska	2017	0022-9032	1.213	0.402
1046	Kardiologiya	2017	0022-9040	0.210	0.138
1047	Minerva Cardioangiologica	2017	0026-4725	0.571	0.273
1048	PLoS ONE	2017	1932-6203	2.766	1.164
1049	Revista Espanola de Cardiologia	2017	0300-8932	5.166	0.553
1050	Therapeutic Advances in Cardiovascular Disease	2017	1753-9447	-	0.535
1051	Turk Kardiyoloji Dernegi Arsivi	2017	1016-5169	-	0.199
1052	Acta Cardiologica Sinica	2016	1011-6847	0.342	0.180
1053	American Heart Journal	2016	0002-8703	4.436	3.195
1054	American Journal of Cardiology	2016	0002-9149	3.398	2.089
1055	American Journal of Cardiovascular Drugs	2016	1175-3277	2.768	0.927
1056	Archives of Cardiovascular Diseases	2016	1875-2136	2.331	1.129
1057	Cardiovascular Diabetology	2016	1475-2840	4.752	1.984
1058	Cardiovascular Revascularization Medicine	2016	1553-8389	-	0.569
1059	Catheterization and Cardiovascular Interventions	2016	1522-1952	2.602	1.434
1060	Circulation	2016	0009-7322	19.309	8.835
1061	Clinical Research in Cardiology	2016	1861-0684	4.760	2.031
1062	Coronary Artery Disease	2016	0954-6928	1.823	0.731
1063	European Heart Journal	2016	0195-668X	20.212	7.285
1064	Expert Opinion on Pharmacotherapy	2016	1465-6566	3.894	1.014
1065	Expert Review of Cardiovascular Therapy	2016	1477-9072	-	0.557
1066	Heart Failure Reviews	2016	1382-4147	3.481	1.696
1067	Herz	2016	0340-9937	0.776	0.283
1068	International Journal of Cardiology	2016	0167-5273	6.189	1.603
1069	JACC: Cardiovascular Interventions	2016	1936-8798	8.841	5.813
1070	Journal of Cardiovascular Surgery	2016	0021-9509	2.179	0.706
1071	Journal of Geriatric Cardiology	2016	1671-5411	1.806	0.759
1072	Journal of Telemedicine and Telecare	2016	1357-633X	2.008	0.691
1073	Journal of the American College of Cardiology	2016	0735-1097	19.896	12.020
1074	Kardiologiya	2016	0022-9040	0.189	0.137
1075	Minerva Cardioangiologica	2016	0026-4725	0.695	0.299
1076	Netherlands Heart Journal	2016	1568-5888	1.894	0.526
1077	Perfusion	2016	0267-6591	1.134	0.477
1078	PLoS ONE	2016	1932-6203	2.806	1.236
1079	Postepy w Kardiologii Interwencyjnej	2016	1734-9338	0.917	0.332
1080	Revista Espanola de Cardiologia	2016	0300-8932	4.485	0.710

1081	Thrombosis and Haemostasis	2016	0340-6245	5.627	2.148
1082	Acta Cardiologica	2015	0001-5385	0.600	0.326
1083	American Heart Journal	2015	0002-8703	4.332	3.308
1084	Annual Review of Pharmacology and Toxicology	2015	0362-1642	14.769	8.547
1085	Archives of Cardiovascular Diseases	2015	1875-2136	2.271	1.110
1086	Atherosclerosis	2015	0021-9150	3.942	1.878
1087	BMC Cardiovascular Disorders	2015	1471-2261	1.916	1.035
1088	Cardiology in Review	2015	1061-5377	2.590	1.016
1089	Cardiovascular Revascularization Medicine	2015	1553-8389	-	0.591
1090	Catheterization and Cardiovascular Interventions	2015	1522-1953	2.181	1.388
1091	Circulation: Cardiovascular Interventions	2015	1941-7640	5.706	4.204
1092	Clinica e Investigacion en Arteriosclerosis	2015	0214-9168	-	0.204
1093	Clinical Cardiology	2015	0160-9289	2.431	1.342
1094	Current Opinion in Cardiology	2015	0268-4705	2.158	1.060
1095	Current Vascular Pharmacology	2015	1570-1611	2.374	0.897
1096	Deutsche Medizinische Wochenschrift	2015	0012-0472	0.503	0.162
1097	European Heart Journal	2015	0195-668X	15.064	7.264
1098	Giornale Italiano di Cardiologia	2015	1827-6806	-	0.206
1099	International Journal of Cardiology	2015	0167-5273	4.638	1.540
1100	Intervencni a Akutni Kardiologie	2015	1213-807X	-	0.104
1101	JACC: Cardiovascular Interventions	2015	1936-8798	7.630	5.278
1102	Journal of the Association of Physicians of India	2015	0004-5772	-	0.248
1103	Journal of Thoracic Disease	2015	2072-1439	1.649	0.660
1104	Kardiologia Polska	2015	0022-9032	0.878	0.319
1105	Kardiologiya	2015	0022-9040	0.176	0.140
1106	Lancet	2015	0140-6743	44.002	14.974
1107	Revista Espanola de Cardiologia	2015	0300-8932	4.596	0.721
1108	Techniques in Vascular and Interventional Radiology	2015	1089-2516	-	0.513
1109	Thrombosis and Haemostasis	2015	0340-6245	5.255	2.113
1110	Trials	2015	1745-6215	1.859	1.235
1111	Advances in Therapy	2014	0741-238X	2.272	0.851
1112	Anesthesia and Analgesia	2014	0003-2999	3.472	1.743
1113	Chest	2014	0012-3692	7.483	3.169
1114	Clinical Research in Cardiology	2014	1861-0684	4.560	2.087
1115	Deutsche Medizinische Wochenschrift	2014	0012-0472	0.542	0.172
1116	EuroIntervention	2014	1774-024X	3.769	2.151
1117	European Heart Journal	2014	0195-668X	15.203	6.807



1118	European Heart Journal, Supplement	2014	1520-765X	1.000	0.417
1119	European Journal of Preventive Cardiology	2014	2047-4873	3.319	1.647
1120	Expert Review of Cardiovascular Therapy	2014	1477-9072	-	0.644
1121	Heart	2014	1355-6037	5.595	3.168
1122	Heart Failure Reviews	2014	1382-4147	3.787	1.678
1123	Herz	2014	0340-9937	0.690	0.339
1124	International Journal of Cardiology	2014	0167-5273	4.036	1.353
1125	Journal of the American College of Cardiology	2014	0735-1097	16.503	9.915
1126	Journal of Vascular and Interventional Radiology	2014	1051-0443	2.9	1.109
1127	Kardiologiya	2014	0022-9040	0.117	0.127
1128	Netherlands Heart Journal	2014	1568-5888	1.837	0.558
1129	New England Journal of Medicine	2014	0028-4793	55.873	16.259
1130	PLoS ONE	2014	1932-6203	3.234	1.559
1131	Revista Espanola de Cardiologia	2014	0300-8932	3.792	0.708
1132	American Journal of Cardiology	2013	0002-9149	3.425	2.313
1133	American Journal of Neuroradiology	2013	0195-6108	3.675	1.823
1134	Annals of Vascular Surgery	2013	0890-5096	1.029	0.657
1135	BMC Medicine	2013	1741-7015	7.276	2.964
1136	Clinical and Applied Thrombosis/Hemostasis	2013	1076-0296	1.575	0.471
1137	European Heart Journal	2013	0195-668X	14.723	6.997
1138	International Journal of Cardiology	2013	0167-5273	6.175	0.936
1139	JAMA - Journal of the American Medical Association	2013	0098-7484	30.387	6.506
1140	Journal of Vascular and Interventional Radiology	2013	1051-0443	2.149	1.106
1141	Journal of Vascular Surgery	2013	0741-5214	2.980	2.079
1142	Nature Reviews Cardiology	2013	1759-5002	10.154	2.355
1143	Turk Kardiyoloji Dernegi Arsivi	2013	1016-5169	-	0.185
1144	American Journal of Cardiology	2012	0002-9149	3.209	2.362
1145	BMJ Open	2012	2044-6055	1.583	0.495
1146	Cardiology	2012	0008-6312	1.519	0.717
1147	Current Treatment Options in Cardiovascular Medicine	2012	1092-8464	-	0.423
1148	Current Vascular Pharmacology	2012	1570-1611	2.821	0.975
1149	Deutsche Medizinische Wochenschrift	2012	0012-0472	0.653	0.185
1150	EuroIntervention	2012	1774-024X	3.173	1.962
1151	European Journal of Preventive Cardiology	2012	2047-4873	-	1.802
1152	Heart International	2012	2036-2579	-	0.180

1153	JAMA - Journal of the American Medical Association	2012	0098-7484	29.978	6.288
1154	Journal of Geriatric Cardiology	2012	1671-5411	-	0.112
1155	Journal of Invasive Cardiology	2012	1042-3933	1.569	0.614
1156	Journal of Vascular and Interventional Radiology	2012	1051-0443	2.002	1.197
1157	Nature Reviews Cardiology	2012	1759-5002	10.400	2.028
1158	PLoS ONE	2012	1932-6203	3.730	1.982
1159	Polish Archives of Internal Medicine	2012	0032-3772	1.833	0.467
1160	Techniques in Vascular and Interventional Radiology	2012	1089-2516	-	0.333
1161	Trials	2012	1745-6215	2.206	1.483
1162	American Journal of Cardiology	2011	0002-9149	3.368	2.386
1163	Cardiology	2011	0008-6312	1.705	0.906
1164	Catheterization and Cardiovascular Interventions	2011	1522-1954	2.290	1.714
1165	European Journal of Cardio-thoracic Surgery	2011	1010-7943	2.550	1.449
1166	Heart and Lung	2011	0147-9563	1.318	0.525
1167	International Journal of Cardiology	2011	0167-5273	7.078	0.869
1168	JACC: Cardiovascular Interventions	2011	1936-8798	6.800	5.888
1169	Journal of Cardiovascular Medicine	2011	1558-2033	1.510	0.580
1170	Journal of Invasive Cardiology	2011	1042-3934	1.841	0.664
1171	Minerva Cardioangiologica	2011	0026-4725	-	0.275
1172	Annals of Vascular Surgery	2010	0890-5096	1.332	0.679
1173	Catheterization and Cardiovascular Interventions	2010	1522-1955	2.398	1.465
1174	European Heart Journal	2010	0195-668X	10.052	4.785
1175	Heart Lung and Circulation	2010	1443-9506	1.330	0.536
1176	International Journal of Cardiology	2010	0167-5273	6.802	0.912
1177	JACC: Cardiovascular Interventions	2010	1936-8798	5.862	3.979
1178	American Heart Journal	2009	0002-8703	4.357	3.257
1179	American Journal of Cardiology	2009	0002-9149	3.575	2.454
1180	Annales de Cardiologie et d'Angéiologie	2009	0003-3928	0.212	0.180
1181	BMC Cardiovascular Disorders	2009	1471-2261	-	0.943
1182	EuroIntervention	2009	1774-024X	-	0.962
1183	European Heart Journal	2009	0195-668X	9.800	5.153
1184	JACC: Cardiovascular Interventions	2009	1936-8798	-	4.447
1185	Journal of Telemedicine and Telecare	2009	1357-633X	0.921	0.521
1186	Journal of Vascular Surgery	2009	0741-5214	3.517	2.520
1187	Revista Espanola de Cardiologia	2009	0300-8932	2.746	0.429
1188	American Journal of Cardiology	2008	0002-9149	3.905	2.342
1189	Annales de Cardiologie et d'Angéiologie	2008	0003-3928	-	0.178
1190	Current Cardiology Reviews	2008	1573-403X	-	0.235




1191	Current Pharmaceutical Design	2008	1381-6128	4.399	1.642
1192	European Journal of Cardio-thoracic Surgery	2008	1010-7944	2.181	1.170
1193	Herz	2008	0340-9937	0.510	0.291
1194	JAMA - Journal of the American Medical Association	2008	0098-7484	31.718	7.024
1195	Journal of Cardiovascular Medicine	2008	1558-2034	-	0.320
1196	Journal of Cardiovascular Surgery	2008	0021-9509	1.542	0.751
1197	Kardiologia Polska	2008	0022-9032	-	0.210
1198	Minerva Cardioangiologica	2008	0026-4725	-	0.328
1199	Polish Archives of Internal Medicine	2008	0032-3772	-	0.135
1200	Scandinavian Cardiovascular Journal	2008	1401-7431	0.908	0.572
1201	Canadian Journal of Cardiology	2007	0828-282X	1.422	0.824
1202	Current Opinion in Cardiology	2007	0268-4705	2.504	1.420
1203	Giornale Italiano di Cardiologia	2007	1827-6806	-	0.176
1204	Heart Lung and Circulation	2007	1443-9506	-	0.407
1205	Herz	2007	0340-9937	0.405	0.289
1206	JAMA - Journal of the American Medical Association	2007	0098-7484	25.547	7.013
1207	Journal of Cardiovascular Medicine	2007	1558-2035	-	0.478
1208	Journal of the American College of Cardiology	2007	0735-1097	11.054	7.987
1209	New England Journal of Medicine	2007	0028-4793	52.589	10.481
1210	European Heart Journal, Supplement	2006	1520-765X	1.506	0.388
1211	Journal of Interventional Cardiology	2006	0896-4327	-	1.046
1212	Lancet	2006	0140-6744	25.800	5.311
1213	Minerva Cardioangiologica	2006	0026-4725	-	0.285
1214	European Heart Journal	2005	0195-668X	7.341	3.865
1215	Journal of Interventional Cardiology	2005	0896-4327	-	0.783

\*за публикации от 2023 и 2024 г. са посочени IF за 2022 г. и SJR за 2023 г.

**КРАСИМИРА ИЛИЕВА**

Директор на дирекция

„Научно-техническа и педагогическа библиотека”





**РЕПУБЛИКА БЪЛГАРИЯ**

Национален център за  
информация и документация

класификация на информацията:  
ниво 1, TLP-GREEN



**НАЦИД**

Per №: 94-06-47

Дата: 27.05.2024

## **СПРАВКА**

**ЗА IMPACT FACTOR /WEB OF SCIENCE/ И SCIMAGO JOURNAL RANK  
/SCOPUS/ НА СПИСАНИЯТА, В КОИТО СА ПУБЛИКАЦИИТЕ  
НА ИВО СПАСОВ ПЕТРОВ**

№	Заглавие	Година	ISSN	IF	SJR
1	Cardiovascular Revascularization Medicine	2023	1553-8389		0.493
2	Cardiovascular Revascularization Medicine/2023*	2022	1553-8389	1.7	
3	International Journal of Cardiology	2023	0167-5273		1.126
4	International Journal of Cardiology/2023*	2022	0167-5273	3.5	
5	Journal of Cardiovascular Pharmacology and Therapeutics	2023	1074-2484		0.696
6	Journal of Cardiovascular Pharmacology and Therapeutics/2023*	2022	1074-2484	2.6	



7	Panminerva Medica	2023	0031-0808		0.282
8	Panminerva Medica/2023*	2022	0031-0808	4.3	
9	Reviews in Cardiovascular Medicine	2023	1530-6550		0.518
10	Reviews in Cardiovascular Medicine/2023*	2022	1530-6550	2.7	
11	Catheterization and Cardiovascular Interventions	2022	1522-1946	2.3	0.964
12	Cor et Vasa	2022	0010-8650	0.2	0.130
13	EuroIntervention	2022	1774-024X	6.2	1.624
14	European Heart Journal-Case Reports	2022	2514-2119	1.0	0.289
15	European Journal of Physical and Rehabilitation Medicine	2022	1973-9087	4.5	1.019
16	European Journal of Translational Myology	2022	2037-7452	2.2	0.397
17	Health Policy and Technology	2022	2211-8837	6.0	1.071
18	JACC: Cardiovascular Interventions	2022	1936-8798	11.3	2.909
19	Journal of the American College of Cardiology	2022	0735-1097	6.278	3.758
20	Reviews in Cardiovascular Medicine	2022	1530-6550	2.7	0.575
21	Advances in Therapy	2021	0741-238X	4.070	1.032
22	BMJ Case Reports	2021	1757-790X	-	0.230
23	Circulation-Cardiovascular Interventions	2021	1941-7640	7.514	3.047
24	Circulation-Cardiovascular Quality and Outcomes	2021	1941-7713	8.271	2.520
25	European Heart Journal	2021	0195-668X	35.855	4.118
26	Interdisciplinary Neurosurgery: Advanced Techniques and Case Management	2021	2214-7519	-	0.182
27	JACC: Cardiovascular Interventions	2021	1936-8798	11.075	3.595
28	JACC: Case Reports	2021	2666-0849	-	0.196
29	Journal of the American College of Cardiology	2021	0735-1097	27.206	9.756
30	Lancet	2021	0140-6736	202.731	15.652
31	Reviews in Cardiovascular Medicine	2021	1530-6550	4.430	0.590
32	Atherosclerosis	2020	1879-1484	5.162	1.554
33	Cardiovascular Revascularization Medicine	2020	1553-8389	-	0.476
34	Clinical Research in Cardiology	2020	1861-0684	5.460	1.838
35	Cor et Vasa	2020	0010-8650	0.177	0.177
36	European Heart Journal	2020	0195-668X	29.983	4.336
37	European Heart Journal - Cardiovascular Pharmacotherapy	2020	2055-6837	6.617	1.895
38	European Heart Journal Cardiovascular Imaging	2020	2047-2404	6.875	2.576
39	European Journal of Physical and Rehabilitation Medicine	2020	1973-9087	2.874	0.926

40	New England Journal of Medicine	2020	0028-4793	91.253	19.889
41	Series on Biomechanics	2020	1313-2458	-	0.196
42	BMJ Open	2019	2044-6055	2.496	1.247
43	Cardiovascular Revascularization Medicine	2019	1553-8389	-	0.523
44	Clinical Cardiology	2019	0160-9289	2.248	1.263
45	European Journal of Preventive Cardiology	2019	2047-4873	5.864	1.459
46	International Journal of Cardiology	2019	0167-5273	3.229	1.082
47	Journal of Hypertension	2019	0263-6352	4.171	1.365
48	Journal of the American College of Cardiology	2019	0735-1097	20.589	9.989
49	Lancet	2019	0140-6736	60.390	14.554
50	Methodist DeBakey cardiovascular journal	2019	1947-6108	-	0.332
51	New England Journal of Medicine	2019	0028-4793	74.699	18.291
52	Cardiovascular Revascularization Medicine	2018	1553-8389	-	0.631
53	Cor et Vasa	2018	0010-8650	0.162	0.162
54	International Journal of Cardiology	2018	0167-5273	3.471	0.990
55	JACC: Cardiovascular Interventions	2018	1936-8798	9.544	3.113
56	Journal of Hypertension	2018	0263-6352	4.209	1.649
57	Journal of the American College of Cardiology	2018	0735-1097	18.639	9.280
58	Lancet	2018	0140-6736	59.102	15.871
59	Atherosclerosis	2017	1879-1484	4.467	1.967
60	Cor et Vasa	2017	0010-8650	0.150	0.150
61	Journal of the American College of Cardiology	2017	0735-1097	16.834	11.061
62	Journal of Vascular Surgery	2017	0741-5214	3.294	2.308
63	Cor et Vasa	2016	0010-8650	0.173	0.173
64	European Heart Journal	2016	0195-668X	20.212	7.285
65	European Heart Journal	2014	0195-668X	15.203	6.807
66	Nutrition	2014	0899-9007	2.926	1.135
67	European Journal of Heart Failure	2013	1388-9842	6.577	4.362
68	Heart	2013	1355-6037	6.023	2.795
69	JAMA - Journal of the American Medical Association	2013	0098-7484	30.387	6.506
70	Folia Medica	2012	0204-8043	-	0.144
71	Gazzetta Medica Italiana Archivio per le Scienze Mediche	2012	0393-3660	-	0.151
72	Interactive Cardiovascular and Thoracic Surgery	2011	1569-9285	-	0.553
73	International Journal of Cardiology	2011	0167-5273	7.078	0.869
74	Journal of Endovascular Therapy	2011	1526-6028	2.856	1.762
75	Catheterization and Cardiovascular Interventions	2009	1522-1946	2.363	1.519




76	EuroIntervention	2009	1774-024X	-	0.962
77	Heart	2007	1355-6037	4.141	1.381
78	Rentgenologiya i Radiologiya	2007	0486-400X	-	0.105
79	European Heart Journal	2006	0195-668X	7.286	4.879
80	Journal of Endovascular Therapy	2006	1526-6028	2.135	1.421
81	European Heart Journal	2005	0195-668X	7.341	3.865
82	Rentgenologiya i Radiologiya	2004	0486-400X	-	0.100
83	American Journal of Cardiology	2003	1879-1913	3.059	1.767
84	Rentgenologiya i Radiologiya	2003	0486-400X	-	0.101
85	Rentgenologiya i Radiologiya	2002	0486-400X	-	0.101

\*за публикации от 2023 и 2024 г. са посочени IF за 2022 г. и SJR за 2023 г.

**КРАСИМИРА ИЛИЕВА**

*Директор на дирекция*

*„Научно-техническа и педагогическа библиотека“*



14.08.2024